ORPHAcode,Preferred term,Typology,PrevalenceType,ValMoy,PrevalenceClass,PrevalenceQualification,PrevalenceGeographic,PrevalenceValidationStatus,Source
166024,Multiple epiphyseal dysplasia-macrocephaly-facial dysmorphism syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,11389160[PMID]_9689990[PMID]_ [EXPERT]
166024,Multiple epiphyseal dysplasia-macrocephaly-facial dysmorphism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11389160[PMID]_9689990[PMID]
58,Alexander disease,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,Japan,Validated,21533827[PMID]_[EXPERT]
58,Alexander disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
166032,Multiple epiphyseal dysplasia-miniepiphyses syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,15523498[PMID]
166032,Multiple epiphyseal dysplasia-miniepiphyses syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15523498[PMID]
61,Alpha-mannosidosis,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2005[INST]
61,Alpha-mannosidosis,Disease,Prevalence at birth,0.09,<1 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
61,Alpha-mannosidosis,Disease,Prevalence at birth,0.13,1-9 / 1 000 000,Value and class,Norway,Not yet validated,7900112[PMID]
61,Alpha-mannosidosis,Disease,Prevalence at birth,0.09,<1 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
61,Alpha-mannosidosis,Disease,Prevalence at birth,0.12,1-9 / 1 000 000,Value and class,Portugal,Validated,14685153[PMID]
61,Alpha-mannosidosis,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
61,Alpha-mannosidosis,Disease,Prevalence at birth,0.07,<1 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
166029,Multiple epiphyseal dysplasia-severe proximal femoral dysplasia syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,15523498[PMID]
166029,Multiple epiphyseal dysplasia-severe proximal femoral dysplasia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15523498[PMID]
166038,"Metaphyseal chondrodysplasia, Kaitila type",Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,6979929[PMID]
166038,"Metaphyseal chondrodysplasia, Kaitila type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6979929[PMID]
93,Aspartylglucosaminuria,Disease,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
93,Aspartylglucosaminuria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93,Aspartylglucosaminuria,Disease,Prevalence at birth,0.62,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
93,Aspartylglucosaminuria,Disease,Prevalence at birth,3.35,1-9 / 100 000,Value and class,Finland,Validated,27906067[PMID]
166035,Brachydactyly-short stature-retinitis pigmentosa syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,7252997[PMID]_28285769[PMID]
166035,Brachydactyly-short stature-retinitis pigmentosa syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7252997[PMID]_28285769[PMID]
585,Multiple sulfatase deficiency,Disease,Cases/families,154.0,,Case(s),Worldwide,Validated,36980153[PMID]_37732042[PMID]_ORPHANET
585,Multiple sulfatase deficiency,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Worldwide,Validated,33144036[PMID]
118,Beta-mannosidosis,Disease,Prevalence at birth,0.14,1-9 / 1 000 000,Value and class,Europe,Validated,14685153[PMID]_10480370[PMID]_20490927[PMID]
118,Beta-mannosidosis,Disease,Prevalence at birth,0.16,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
118,Beta-mannosidosis,Disease,Prevalence at birth,0.13,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
118,Beta-mannosidosis,Disease,Prevalence at birth,0.12,1-9 / 1 000 000,Value and class,Portugal,Validated,14685153[PMID]
118,Beta-mannosidosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
141,Canavan disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
141,Canavan disease,Disease,Annual incidence,7.0,1-9 / 100 000,Value and class,Specific population,Validated,20301412[PMID]_ORPHANET
141,Canavan disease,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
166063,Pontocerebellar hypoplasia type 4,Malformation syndrome,Cases/families,10.0,,Family(ies),Worldwide,Validated,[EXPERT]
166063,Pontocerebellar hypoplasia type 4,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20952379[PMID]
166078,Von Willebrand disease type 1,Clinical subtype,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
166073,Pontocerebellar hypoplasia type 6,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,25809939[PMID]
166073,Pontocerebellar hypoplasia type 6,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25809939[PMID]
213,Cystinosis,Disease,Prevalence at birth,0.75,1-9 / 1 000 000,Value and class,Worldwide,Validated,12110740[PMID]_18008091[PMID]_11562417[PMID]
213,Cystinosis,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
213,Cystinosis,Disease,Prevalence at birth,0.31,1-9 / 1 000 000,Value and class,France,Validated,1018302[PMID]
213,Cystinosis,Disease,Prevalence at birth,0.59,1-9 / 1 000 000,Value and class,Germany,Validated,3921756[PMID]
213,Cystinosis,Disease,Prevalence at birth,2.1,1-9 / 100 000,Value and class,United Kingdom,Validated,9610798[PMID]
213,Cystinosis,Disease,Prevalence at birth,0.52,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
213,Cystinosis,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2014[INST]
213,Cystinosis,Disease,Prevalence at birth,0.87,1-9 / 1 000 000,Value and class,Denmark,Validated,975942[PMID]_27102039[PMID]
213,Cystinosis,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]_27102039[PMID]
213,Cystinosis,Disease,Prevalence at birth,1.6,1-9 / 100 000,Value and class,Specific population,Validated,1937486[PMID]_25274184[PMID]
166084,Von Willebrand disease type 2A,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
333,Farber disease,Disease,Cases/families,96.0,,Case(s),Worldwide,Validated,29048419[PMID]
333,Farber disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29048419[PMID]
166081,Von Willebrand disease type 2,Clinical subtype,Point prevalence,0.935,1-9 / 1 000 000,Class only,Worldwide,Validated,PMID: 30306084
349,Fucosidosis,Disease,Cases/families,161.0,,Case(s),Worldwide,Validated,36082656[PMID]
349,Fucosidosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,36082656[PMID]_ORPHANET
349,Fucosidosis,Disease,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
349,Fucosidosis,Disease,Prevalence at birth,0.63,1-9 / 1 000 000,Value and class,Cuba,Validated,27706744[PMID]
166090,Von Willebrand disease type 2M,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,0.8,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,0.17,1-9 / 1 000 000,Value and class,Portugal,Validated,14685153[PMID]
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,0.83,1-9 / 1 000 000,Value and class,Italy,Validated,11953730[PMID]
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,2.25,1-9 / 100 000,Value and class,Netherlands,Validated,10480370[PMID]_10482961[PMID]
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,0.37,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,11.5,1-5 / 10 000,Value and class,Austria,Validated,22133539[PMID]
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,2.5,1-9 / 100 000,Value and class,United States,Validated,9738873[PMID]
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,0.68,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,2.0,1-9 / 100 000,Value and class,China,Validated,3106710[PMID]
365,Glycogen storage disease due to acid maltase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,0.72,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,2.3,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]
365,Glycogen storage disease due to acid maltase deficiency,Disease,Prevalence at birth,4.8,1-9 / 100 000,Value and class,Specific population,Validated,33239050[PMID]
365,Glycogen storage disease due to acid maltase deficiency,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
166087,Von Willebrand disease type 2B,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
366,Glycogen storage disease due to glycogen debranching enzyme deficiency,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,United States,Validated,9412782[PMID]
366,Glycogen storage disease due to glycogen debranching enzyme deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
166093,Von Willebrand disease type 2N,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
368,Glycogen storage disease due to muscle glycogen phosphorylase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.1865,1-9 / 1 000 000,Value and class,Worldwide,Validated,30306084[PMID]_33780098[PMID]_ORPHANET
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.037,<1 / 1 000 000,Value and class,Austria,Validated,PMID: 6609712
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.24,<1 / 1 000 000,Value and class,Finland,Validated,PMID: 6609712
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.016,<1 / 1 000 000,Value and class,France,Validated,PMID: 6609712
166096,Von Willebrand disease type 3,Clinical subtype,Prevalence at birth,0.044,<1 / 1 000 000,Value and class,Greece,Validated,PMID: 6609712
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.16,<1 / 1 000 000,Value and class,Israel,Validated,PMID: 6609712
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.055,<1 / 1 000 000,Value and class,Italy,Validated,PMID: 6609712
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.037,<1 / 1 000 000,Value and class,Netherlands,Validated,PMID: 6609712
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.25,1-9 / 1 000 000,Value and class,Norway,Validated,PMID: 6609712
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.022,<1 / 1 000 000,Value and class,Portugal,Validated,PMID: 6609712
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.011,<1 / 1 000 000,Value and class,Spain,Validated,PMID: 6609712
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.312,1-9 / 1 000 000,Value and class,Sweden,Validated,PMID: 6609712
166096,Von Willebrand disease type 3,Clinical subtype,Point prevalence,0.027,<1 / 1 000 000,Value and class,United Kingdom,Validated,PMID: 6609712
367,Glycogen storage disease due to glycogen branching enzyme deficiency,Disease,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,23285490[PMID]
367,Glycogen storage disease due to glycogen branching enzyme deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
371,Glycogen storage disease due to muscle phosphofructokinase deficiency,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,18421897[PMID]
371,Glycogen storage disease due to muscle phosphofructokinase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18421897[PMID]
166105,FASTKD2-related infantile mitochondrial encephalomyopathy,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,18771761[PMID]_28499982[PMID]
166105,FASTKD2-related infantile mitochondrial encephalomyopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18771761[PMID]_28499982[PMID]
369,Glycogen storage disease due to liver glycogen phosphorylase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
369,Glycogen storage disease due to liver glycogen phosphorylase deficiency,Disease,Prevalence at birth,2.3,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]
369,Glycogen storage disease due to liver glycogen phosphorylase deficiency,Disease,Prevalence at birth,4.8,1-9 / 100 000,Value and class,Specific population,Validated,33239050[PMID]
447,Paroxysmal nocturnal hemoglobinuria,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,United Kingdom,Validated,34060690[PMID]
447,Paroxysmal nocturnal hemoglobinuria,Disease,Point prevalence,3.81,1-9 / 100 000,Value and class,United Kingdom,Validated,34060690[PMID]
447,Paroxysmal nocturnal hemoglobinuria,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2016[INST]
166108,Birk-Barel syndrome,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,18678320[PMID]
166108,Birk-Barel syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18678320[PMID]
166113,Bazex syndrome,Disease,Cases/families,145.0,,Case(s),Worldwide,Validated,18775590[PMID]
166113,Bazex syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18775590[PMID]
535,Rare cutaneous lupus erythematosus,Clinical group,Point prevalence,50.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2007[INST]
535,Rare cutaneous lupus erythematosus,Clinical group,Annual incidence,4.3,1-9 / 100 000,Value and class,United States,Validated,19289752[PMID]
535,Rare cutaneous lupus erythematosus,Clinical group,Point prevalence,73.0,6-9 / 10 000,Value and class,United States,Validated,19289752[PMID]
535,Rare cutaneous lupus erythematosus,Clinical group,Annual incidence,4.0,1-9 / 100 000,Value and class,Sweden,Validated,21574972[PMID]
166119,Isolated osteopoikilosis,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Worldwide,Validated,31129707[PMID]
166119,Isolated osteopoikilosis,Disease,Annual incidence,2.0,1-9 / 100 000,Value and class,Worldwide,Validated,31129707[PMID]
487,Krabbe disease,Disease,Prevalence at birth,0.327,1-9 / 1 000 000,Value and class,United States,Validated,22991292[PMID]_26795590[PMID]
487,Krabbe disease,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
487,Krabbe disease,Disease,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Worldwide,Validated,[EXPERT]
487,Krabbe disease,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Not yet validated,20301416[PMID]
487,Krabbe disease,Disease,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,France,Validated,[EXPERT]
487,Krabbe disease,Disease,Prevalence at birth,0.71,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
487,Krabbe disease,Disease,Prevalence at birth,1.35,1-9 / 100 000,Value and class,Netherlands,Validated,10480370[PMID]
487,Krabbe disease,Disease,Prevalence at birth,1.21,1-9 / 100 000,Value and class,Portugal,Validated,14685153[PMID]
487,Krabbe disease,Disease,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,Germany,Validated,9286459[PMID]
487,Krabbe disease,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Turkey,Validated,20490927[PMID]
487,Krabbe disease,Disease,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
487,Krabbe disease,Disease,Prevalence at birth,1.9,1-9 / 100 000,Value and class,Sweden,Validated,5409293[PMID]
166260,Dentinogenesis imperfecta type 2,Clinical subtype,Point prevalence,14.6,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
166265,Dentinogenesis imperfecta type 3,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.16,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.23,1-9 / 1 000 000,Value and class,Germany,Validated,16435194[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.15,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.42,1-9 / 1 000 000,Value and class,Portugal,Validated,14685153[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.23,1-9 / 1 000 000,Value and class,Sweden,Validated,18681890[PMID]_25274184[PMID]
583,Mucopolysaccharidosis type 6,Disease,Point prevalence,3.3,1-9 / 100 000,Value and class,Sweden,Validated,18681890[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.07,<1 / 1 000 000,Value and class,Norway,Validated,18681890[PMID]
583,Mucopolysaccharidosis type 6,Disease,Point prevalence,2.2,1-9 / 100 000,Value and class,Norway,Validated,18681890[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.05,<1 / 1 000 000,Value and class,Denmark,Validated,18681890[PMID]
583,Mucopolysaccharidosis type 6,Disease,Point prevalence,3.7,1-9 / 100 000,Value and class,Denmark,Validated,18681890[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.05,<1 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.37,1-9 / 1 000 000,Value and class,Australia,Validated,16600651[PMID]_14608657[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Canada,Validated,10617747[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.14,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,19396827[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.27,1-9 / 1 000 000,Value and class,Estonia,Validated,22480138[PMID]
583,Mucopolysaccharidosis type 6,Disease,Point prevalence,0.059,<1 / 1 000 000,Value and class,Colombia,Validated,22550061[PMID]
583,Mucopolysaccharidosis type 6,Disease,Point prevalence,0.16,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2001[INST]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,2.3,1-9 / 100 000,Value and class,Turkey,Validated,16435194[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.0132,<1 / 1 000 000,Value and class,Poland,Validated,25472774[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,7.85,1-9 / 100 000,Value and class,Saudi Arabia,Validated,20622343[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.28,1-9 / 1 000 000,Value and class,Brazil,Validated,PMID: 31926052
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.03,<1 / 1 000 000,Value and class,Japan,Validated,28595941[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.11,1-9 / 1 000 000,Value and class,Switzerland,Validated,28595941[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Tunisia,Validated,20209839[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.019,<1 / 1 000 000,Value and class,"Korea, Republic of",Validated,25364648[PMID]
583,Mucopolysaccharidosis type 6,Disease,Prevalence at birth,0.04,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
583,Mucopolysaccharidosis type 6,Disease,Point prevalence,0.011,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
166272,Odontochondrodysplasia,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,18241073[PMID]
166272,Odontochondrodysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18241073[PMID]
576,Mucolipidosis type II,Disease,Prevalence at birth,0.34,1-9 / 1 000 000,Value and class,Europe,Validated,10480370[PMID]_14685153[PMID]_ 25274184[PMID]_ORPHANET
576,Mucolipidosis type II,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
576,Mucolipidosis type II,Disease,Prevalence at birth,0.81,1-9 / 1 000 000,Value and class,Portugal,Validated,14685153[PMID]
576,Mucolipidosis type II,Disease,Prevalence at birth,0.16,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
576,Mucolipidosis type II,Disease,Prevalence at birth,16.2,1-5 / 10 000,Value and class,Specific population,Validated,18190596[PMID]_1937486[PMID]
576,Mucolipidosis type II,Disease,Prevalence at birth,0.05,<1 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
166277,Wormian bone-multiple fractures-dentinogenesis imperfecta-skeletal dysplasia,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,10544232[PMID]
166277,Wormian bone-multiple fractures-dentinogenesis imperfecta-skeletal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10544232[PMID]
812,Sialidosis type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
812,Sialidosis type 1,Disease,Prevalence at birth,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
166282,Familial sick sinus syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,ORPHANET
166282,Familial sick sinus syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
578,Mucolipidosis type IV,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
578,Mucolipidosis type IV,Disease,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
578,Mucolipidosis type IV,Disease,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Specific population,Validated,20159435[PMID]_16287144[PMID]_16645217[PMID]
166286,Porokeratotic eccrine ostial and dermal duct nevus,Disease,Cases/families,45.0,,Case(s),Worldwide,Validated,21393947[PMID]
166286,Porokeratotic eccrine ostial and dermal duct nevus,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21393947[PMID]
577,Mucolipidosis type III,Disease,Annual incidence,0.985,1-9 / 1 000 000,Value and class,Europe,Validated,10480370[PMID]_ 14685153[PMID]_ ORPHANET
577,Mucolipidosis type III,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
577,Mucolipidosis type III,Disease,Annual incidence,1.68,1-9 / 1 000 000,Value and class,Portugal,Validated,14685153[PMID]
577,Mucolipidosis type III,Disease,Point prevalence,29.55,1-5 / 10 000,Value and class,Europe,Validated,ORPHANET
577,Mucolipidosis type III,Disease,Point prevalence,2.4,1-9 / 100 000,Value and class,Netherlands,Validated,ORPHANET
577,Mucolipidosis type III,Disease,Point prevalence,50.4,1-5 / 10 000,Value and class,Portugal,Validated,ORPHANET
166291,Dirofilariasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
166308,Benign infantile focal epilepsy with midline spikes and waves during sleep,Disease,Cases/families,36.0,,Case(s),Worldwide,Validated,20822975[PMID]
166308,Benign infantile focal epilepsy with midline spikes and waves during sleep,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20822975[PMID]
166305,Benign infantile seizures associated with mild gastroenteritis,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,24125788[PMID]
166305,Benign infantile seizures associated with mild gastroenteritis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24125788[PMID]
2912,Poliomyelitis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2912,Poliomyelitis,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
796,Sandhoff disease,Disease,Prevalence at birth,1.49,1-9 / 100 000,Value and class,Portugal,Validated,14685153[PMID]
796,Sandhoff disease,Disease,Prevalence at birth,0.34,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
796,Sandhoff disease,Disease,Prevalence at birth,0.19,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
796,Sandhoff disease,Disease,Prevalence at birth,0.26,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
796,Sandhoff disease,Disease,Prevalence at birth,0.95,1-9 / 1 000 000,Value and class,Turkey,Validated,15275696[PMID]
796,Sandhoff disease,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,United States,Validated,2955697[PMID]
796,Sandhoff disease,Disease,Prevalence at birth,0.67,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
796,Sandhoff disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
796,Sandhoff disease,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
801,Scleroderma,Clinical group,Annual incidence,1.41,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
801,Scleroderma,Clinical group,Point prevalence,42.0,1-5 / 10 000,Value and class,Worldwide,Validated,[EXPERT]
801,Scleroderma,Clinical group,Annual incidence,1.5,1-9 / 100 000,Value and class,Australia,Validated,11456035[PMID]
801,Scleroderma,Clinical group,Point prevalence,23.0,1-5 / 10 000,Value and class,Australia,Validated,11456035[PMID]
801,Scleroderma,Clinical group,Point prevalence,469.0,>1 / 1000,Value and class,Specific population,Validated,8702445[PMID]
461,Recessive X-linked ichthyosis,Disease,Annual incidence,15.0,1-5 / 10 000,Value and class,Europe,Validated,ORPHANET
461,Recessive X-linked ichthyosis,Disease,Point prevalence,16.6,1-5 / 10 000,Value and class,Europe,Validated,ORPHANET
461,Recessive X-linked ichthyosis,Disease,Annual incidence,9.9,1-9 / 100 000,Value and class,Italy,Not yet validated,12920363[PMID]_ORPHANET
584,Mucopolysaccharidosis type 7,Disease,Point prevalence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
584,Mucopolysaccharidosis type 7,Disease,Prevalence at birth,0.24,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
584,Mucopolysaccharidosis type 7,Disease,Prevalence at birth,0.02,<1 / 1 000 000,Value and class,Brazil,Validated,PMID: 31926052
584,Mucopolysaccharidosis type 7,Disease,Prevalence at birth,0.02,<1 / 1 000 000,Value and class,Czech Republic,Validated,25060283[PMID]
584,Mucopolysaccharidosis type 7,Disease,Prevalence at birth,0.02,<1 / 1 000 000,Value and class,Japan,Validated,28595941[PMID]
584,Mucopolysaccharidosis type 7,Disease,Prevalence at birth,0.038,<1 / 1 000 000,Value and class,Switzerland,Validated,28595941[PMID]
584,Mucopolysaccharidosis type 7,Disease,Prevalence at birth,0.047,<1 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
584,Mucopolysaccharidosis type 7,Disease,Point prevalence,0.007,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
584,Mucopolysaccharidosis type 7,Disease,Prevalence at birth,0.027,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
584,Mucopolysaccharidosis type 7,Disease,Prevalence at birth,0.29,1-9 / 1 000 000,Value and class,Canada,Validated,28595941[PMID]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,5.5,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 1985-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,7.5,1-9 / 100 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 1985-2009[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,7.9,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,10.5,1-5 / 10 000,Value and class,Bulgaria,Validated,EUROCAT European surveillance of congenital anomalies 1996-1999[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,3.6,1-9 / 100 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 1983-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,10.4,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,7.1,1-9 / 100 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,8.0,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 1987-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,3.2,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 1998-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,7.1,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,3.4,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 1986-2009[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,14.0,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 1981-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,4.2,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 1999-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,3.6,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 1999-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,2.8,1-9 / 100 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 1990-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,2.8,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 1980-2009[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,22.4,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 1989-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,10.1,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 1980-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,2.3,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2005-2010[REG]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,70.0,6-9 / 10 000,Value and class,Japan,Not yet validated,ISBN:444897208[OTHER]
881,Turner syndrome,Malformation syndrome,Prevalence at birth,42.5,1-5 / 10 000,Value and class,Singapore,Validated,19551311[PMID]
881,Turner syndrome,Malformation syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
95,Friedreich ataxia,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,20301458[PMID]_23859338[PMID]
95,Friedreich ataxia,Disease,Point prevalence,2.3,1-9 / 100 000,Value and class,France,Validated,9207112 [PMID]_23859338[PMID]
95,Friedreich ataxia,Disease,Prevalence at birth,2.8,1-9 / 100 000,Value and class,Italy,Validated,2225525[PMID]_7793232[PMID]
95,Friedreich ataxia,Disease,Point prevalence,1.1,1-9 / 100 000,Value and class,Italy,Validated,2225525[PMID]_7793232[PMID]
95,Friedreich ataxia,Disease,Prevalence at birth,6.2,1-9 / 100 000,Value and class,Spain,Validated,2043954[PMID]_7898602[PMID]
95,Friedreich ataxia,Disease,Point prevalence,4.3,1-9 / 100 000,Value and class,Spain,Not yet validated,2043954[PMID]_7898602[PMID]
95,Friedreich ataxia,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Finland,Validated,11810294[PMID]
95,Friedreich ataxia,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,Finland,Validated,11810294[PMID]_23859338[PMID]
95,Friedreich ataxia,Disease,Point prevalence,0.7,1-9 / 1 000 000,Value and class,Denmark,Not yet validated,2096315[PMID]
95,Friedreich ataxia,Disease,Point prevalence,0.9,1-9 / 1 000 000,Value and class,Portugal,Validated,23609960[PMID]
95,Friedreich ataxia,Disease,Point prevalence,1.8,1-9 / 100 000,Value and class,United Kingdom,Validated,19347027[PMID]
95,Friedreich ataxia,Disease,Point prevalence,0.9,1-9 / 1 000 000,Value and class,Greece,Validated,24209901[PMID]
95,Friedreich ataxia,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Norway,Validated,1126051[PMID]
95,Friedreich ataxia,Disease,Point prevalence,2.1,1-9 / 100 000,Value and class,Germany,Validated,9187683[PMID]_23859338[PMID]
95,Friedreich ataxia,Disease,Point prevalence,0.24,1-9 / 1 000 000,Value and class,Sweden,Validated,11810294[PMID]_23859338[PMID]
95,Friedreich ataxia,Disease,Point prevalence,0.27,1-9 / 1 000 000,Value and class,Czech Republic,Validated,15726025[PMID]_23859338[PMID]
95,Friedreich ataxia,Disease,Point prevalence,3.03,1-9 / 100 000,Value and class,Russian Federation,Validated,15559155[PMID]_23859338[PMID]
848,Beta-thalassemia,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
848,Beta-thalassemia,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,France,Validated,[EXPERT]
848,Beta-thalassemia,Disease,Annual incidence,10.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
848,Beta-thalassemia,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
846,Alpha-thalassemia,Disease,Prevalence at birth,0.0,Unknown,Class only,Europe,Validated,ORPHANET
846,Alpha-thalassemia,Disease,Prevalence at birth,10.3,1-5 / 10 000,Value and class,United States,Validated,19061217[PMID]_22766612[PMID]
846,Alpha-thalassemia,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,25390741[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,19.3912,1-5 / 10 000,Value and class,Europe,Validated,ORPHANET
586,Cystic fibrosis,Disease,Point prevalence,11.1319,1-5 / 10 000,Value and class,Europe,Validated,ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,28.5714,1-5 / 10 000,Value and class,Austria,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,8.39,1-9 / 100 000,Value and class,Austria,Validated,18442953[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,35.0877,1-5 / 10 000,Value and class,Belgium,Validated,30335254[PMID]
586,Cystic fibrosis,Disease,Point prevalence,20.1429,1-5 / 10 000,Value and class,Belgium,Validated,30335254[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,40.0,1-5 / 10 000,Value and class,Bulgaria,Validated,18442953 [PMID]
586,Cystic fibrosis,Disease,Point prevalence,2.26,1-9 / 100 000,Value and class,Bulgaria,Validated,18442953 [PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,12.6358,1-5 / 10 000,Value and class,Cyprus,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,3.35,1-9 / 100 000,Value and class,Cyprus,Validated,18442953[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,15.29,1-5 / 10 000,Value and class,Czech Republic,Validated,31241292[PMID]
586,Cystic fibrosis,Disease,Point prevalence,8.7775,1-9 / 100 000,Value and class,Czech Republic,Validated,31241292[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,17.41,1-5 / 10 000,Value and class,Denmark,Validated,31682332[PMID]
586,Cystic fibrosis,Disease,Point prevalence,9.9946,1-9 / 100 000,Value and class,Denmark,Validated,31682332[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,22.2222,1-5 / 10 000,Value and class,Estonia,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,6.18,1-9 / 100 000,Value and class,Estonia,Validated,18442953[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Finland,Validated,16051530[PMID]_18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,1.1027,1-9 / 100 000,Value and class,Finland,Validated,18442953[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,21.15,1-5 / 10 000,Value and class,France,Validated,25122143[PMID]
586,Cystic fibrosis,Disease,Point prevalence,12.1416,1-5 / 10 000,Value and class,France,Validated,25122143[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,19.5017,1-5 / 10 000,Value and class,Germany,Validated,25914230[PMID]
586,Cystic fibrosis,Disease,Point prevalence,11.1954,1-5 / 10 000,Value and class,Germany,Validated,25914230[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,28.5714,1-5 / 10 000,Value and class,Greece,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,5.21,1-9 / 100 000,Value and class,Greece,Validated,18442953[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,0.0,Unknown,Class only,Hungary,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,4.09,1-9 / 100 000,Value and class,Hungary,Validated,18442953[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,36.36,1-5 / 10 000,Value and class,Ireland,Validated,32483343[PMID]
586,Cystic fibrosis,Disease,Point prevalence,20.8733,1-5 / 10 000,Value and class,Ireland,Validated,32483343[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,17.809,1-5 / 10 000,Value and class,Italy,Validated,31005549[PMID]
586,Cystic fibrosis,Disease,Point prevalence,10.2236,1-5 / 10 000,Value and class,Italy,Validated,31005549[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,0.0,Unknown,Class only,Latvia,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,1.04,1-9 / 100 000,Value and class,Latvia,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Prevalence at birth,0.0,Unknown,Class only,Lithuania,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,1.3,1-9 / 100 000,Value and class,Lithuania,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Prevalence at birth,0.0,Unknown,Class only,Luxembourg,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,4.31,1-9 / 100 000,Value and class,Luxembourg,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Prevalence at birth,0.0,Unknown,Class only,Malta,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,5.79,1-9 / 100 000,Value and class,Malta,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Prevalence at birth,16.58,1-5 / 10 000,Value and class,Netherlands,Validated,30146269[PMID]
586,Cystic fibrosis,Disease,Point prevalence,9.5181,1-9 / 100 000,Value and class,Netherlands,Validated,30146269[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,11.5474,1-5 / 10 000,Value and class,Norway,Validated,26795017[PMID]
586,Cystic fibrosis,Disease,Point prevalence,6.629,1-9 / 100 000,Value and class,Norway,Validated,26795017[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,17.4881,1-5 / 10 000,Value and class,Poland,Validated,22892530[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Point prevalence,10.0394,1-5 / 10 000,Value and class,Poland,Validated,22892530[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,12.549,1-5 / 10 000,Value and class,Portugal,Validated,33072945[PMID]
586,Cystic fibrosis,Disease,Point prevalence,7.204,1-9 / 100 000,Value and class,Portugal,Validated,33072945[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,48.6381,1-5 / 10 000,Value and class,Romania,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,1.06,1-9 / 100 000,Value and class,Romania,Validated,18442953[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,9.7119,1-9 / 100 000,Value and class,Russian Federation,Validated,ECFS Neonatal Screening Working Group
586,Cystic fibrosis,Disease,Point prevalence,5.5753,1-9 / 100 000,Value and class,Russian Federation,Validated,ECFS Neonatal Screening Working Group
586,Cystic fibrosis,Disease,Prevalence at birth,15.38,1-5 / 10 000,Value and class,Slovakia,Validated,28544683[PMID]
586,Cystic fibrosis,Disease,Point prevalence,8.8292,1-9 / 100 000,Value and class,Slovakia,Validated,28544683[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,33.3333,1-5 / 10 000,Value and class,Slovenia,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,3.28,1-9 / 100 000,Value and class,Slovenia,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Prevalence at birth,16.5048,1-5 / 10 000,Value and class,Spain,Validated,25680858[PMID]
586,Cystic fibrosis,Disease,Point prevalence,9.4749,1-9 / 100 000,Value and class,Spain,Validated,25680858[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,17.9285,1-5 / 10 000,Value and class,Sweden,Validated,12243313[PMID]_18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,10.2922,1-5 / 10 000,Value and class,Sweden,Validated,12243313[PMID]_18442953[PMID]_ORPHANET
586,Cystic fibrosis,Disease,Prevalence at birth,41.9991,1-5 / 10 000,Value and class,United Kingdom,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Point prevalence,13.7,1-5 / 10 000,Value and class,United Kingdom,Validated,18442953[PMID]
586,Cystic fibrosis,Disease,Annual incidence,13.1995,1-5 / 10 000,Value and class,Brazil,Validated,35209917[PMID]
586,Cystic fibrosis,Disease,Point prevalence,0.7786,1-9 / 1 000 000,Value and class,China,Validated,35313924[PMID]
262,Duchenne and Becker muscular dystrophy,Clinical group,Point prevalence,0.23,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
262,Duchenne and Becker muscular dystrophy,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
262,Duchenne and Becker muscular dystrophy,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,United States,Validated,25687144[PMID]
261,Emery-Dreifuss muscular dystrophy,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
550,MELAS,Disease,Point prevalence,0.18,1-9 / 1 000 000,Value and class,Japan,Validated,21443929[PMID]
550,MELAS,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
550,MELAS,Disease,Point prevalence,0.6,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
550,MELAS,Disease,Point prevalence,1.63,1-9 / 100 000,Value and class,Finland,Validated,9371917[PMID]
550,MELAS,Disease,Point prevalence,236.0,>1 / 1000,Value and class,Specific population,Validated,17300999[PMID]
269,Facioscapulohumeral dystrophy,Disease,Point prevalence,4.5,1-9 / 100 000,Value and class,Europe,Validated,19320656[PMID]_22217918[PMID]_19767415[PMID]_[EXPERT]_ORPHANET
269,Facioscapulohumeral dystrophy,Disease,Point prevalence,4.4,1-9 / 100 000,Value and class,Italy,Validated,19320656[PMID]
269,Facioscapulohumeral dystrophy,Disease,Point prevalence,3.95,1-9 / 100 000,Value and class,United Kingdom,Validated,19767415[PMID]
269,Facioscapulohumeral dystrophy,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Japan,Validated,1745328[PMID]
269,Facioscapulohumeral dystrophy,Disease,Point prevalence,12.0,1-5 / 10 000,Value and class,Netherlands,Validated,25122204[PMID]
269,Facioscapulohumeral dystrophy,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Netherlands,Validated,25122204[PMID]
480,Kearns-Sayre syndrome,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_17886296[PMID]
480,Kearns-Sayre syndrome,Disease,Point prevalence,0.8,1-9 / 1 000 000,Value and class,Finland,Validated,15781811[PMID]
480,Kearns-Sayre syndrome,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,United Kingdom,Validated,17886296[PMID]
480,Kearns-Sayre syndrome,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Israel,Validated,33239050[PMID]
593,Myofibrillar myopathy,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
551,MERRF,Disease,Prevalence at birth,0.494,1-9 / 1 000 000,Value and class,Sweden,Validated,11261513[PMID]
551,MERRF,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
597,Central core disease,Disease,Point prevalence,0.4,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
597,Central core disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
607,Nemaline myopathy,Clinical group,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET_15221447[PMID]
607,Nemaline myopathy,Clinical group,Point prevalence,0.2,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
163746,Peripheral demyelinating neuropathy-central dysmyelinating leukodystrophy-Waardenburg syndrome-Hirschsprung disease,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,Dr Véronique PINGAULT[EXPERT]
163746,Peripheral demyelinating neuropathy-central dysmyelinating leukodystrophy-Waardenburg syndrome-Hirschsprung disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
684,Paramyotonia congenita of Von Eulenburg,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
684,Paramyotonia congenita of Von Eulenburg,Disease,Point prevalence,0.17,1-9 / 1 000 000,Value and class,United Kingdom,Validated,23516313[PMID]
684,Paramyotonia congenita of Von Eulenburg,Disease,Point prevalence,0.94,1-9 / 1 000 000,Value and class,Netherlands,Validated,29606556[PMID]
684,Paramyotonia congenita of Von Eulenburg,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET_23516313[PMID]_29606556[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
273,Steinert myotonic dystrophy,Disease,Point prevalence,12.5,1-5 / 10 000,Value and class,Worldwide,Not yet validated,ISBN:702021520[OTHER]_21364698[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,10.4,1-5 / 10 000,Value and class,United Kingdom,Validated,19767415[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,7.9,1-9 / 100 000,Value and class,Iceland,Validated,16264243[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,5.3,1-9 / 100 000,Value and class,Serbia,Validated,16713671[PMID]_21364698[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,9.13,1-9 / 100 000,Value and class,Japan,Validated,1745328[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,0.46,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,12902623[PMID]_21364698[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,14.3,1-5 / 10 000,Value and class,South Africa,Validated,3992413[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,76.3,6-9 / 10 000,Value and class,Specific population,Validated,4973215[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,210.5,>1 / 1000,Value and class,Specific population,Validated,2924205[PMID]_21364698[PMID]
273,Steinert myotonic dystrophy,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,Serbia,Validated,16713671[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,9.31,1-9 / 100 000,Value and class,Italy,Validated,11359466[PMID]_21364698[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,11.95,1-5 / 10 000,Value and class,Ireland,Validated,14960839[PMID]_21364698[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Specific population,Validated,12784291[PMID]_21364698[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,5.7,1-9 / 100 000,Value and class,Specific population,Validated,12784291[PMID]_21364698[PMID]
273,Steinert myotonic dystrophy,Disease,Point prevalence,18.1,1-5 / 10 000,Value and class,Croatia,Validated,9088385[PMID]_21364698[PMID]
163937,"X-linked intellectual disability, Najm type",Disease,Cases/families,35.0,,Family(ies),Worldwide,Validated,ORPHANET
163937,"X-linked intellectual disability, Najm type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
163934,Atopic keratoconjunctivitis,Disease,Point prevalence,15.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2009[INST]
614,Thomsen and Becker disease,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,1822774[PMID]
614,Thomsen and Becker disease,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET
614,Thomsen and Becker disease,Disease,Point prevalence,7.3,1-9 / 100 000,Value and class,Finland,Validated,9598722[PMID]
614,Thomsen and Becker disease,Disease,Point prevalence,0.9,1-9 / 1 000 000,Value and class,Italy,Validated,7161034[PMID]
614,Thomsen and Becker disease,Disease,Point prevalence,0.52,1-9 / 1 000 000,Value and class,United Kingdom,Validated,23516313[PMID]
614,Thomsen and Becker disease,Disease,Point prevalence,0.75,1-9 / 1 000 000,Value and class,Netherlands,Validated,29606556[PMID]
163921,Posttransplant acute limbic encephalitis,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
163966,"X-linked dominant chondrodysplasia, Chassaing-Lacombe type",Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,16001442[PMID]_[EXPERT]
163966,"X-linked dominant chondrodysplasia, Chassaing-Lacombe type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
163971,"X-linked intellectual disability, Cilliers type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17369115[PMID]
163971,"X-linked intellectual disability, Cilliers type",Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,17369115[PMID]
163976,"X-linked intellectual disability, Van Esch type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16053905[PMID]
163976,"X-linked intellectual disability, Van Esch type",Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,16053905[PMID]
163979,X-linked intellectual disability-craniofacioskeletal syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17853486[PMID]
163979,X-linked intellectual disability-craniofacioskeletal syndrome,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,17853486[PMID]
163956,"X-linked intellectual disability, Nascimento type",Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,20412111[PMID]
163956,"X-linked intellectual disability, Nascimento type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20412111[PMID]
163961,X-linked cerebral-cerebellar-coloboma syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15887274[PMID]
163961,X-linked cerebral-cerebellar-coloboma syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,15887274[PMID]
324,Fabry disease,Disease,Prevalence at birth,6.66,1-9 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET
324,Fabry disease,Disease,Prevalence at birth,6.96,1-9 / 1 000 000,Value and class,Australia,Validated,35024668[PMID]
324,Fabry disease,Disease,Prevalence at birth,0.21,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
324,Fabry disease,Disease,Prevalence at birth,0.12,1-9 / 1 000 000,Value and class,Portugal,Validated,14685153[PMID]
324,Fabry disease,Disease,Prevalence at birth,0.52,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
324,Fabry disease,Disease,Prevalence at birth,0.015,<1 / 1 000 000,Value and class,Turkey,Validated,15275696[PMID]
324,Fabry disease,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,United Kingdom,Validated,11732485[PMID]
324,Fabry disease,Disease,Prevalence at birth,0.25,1-9 / 1 000 000,Value and class,Japan,Validated,22790789[PMID]
324,Fabry disease,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
324,Fabry disease,Disease,Prevalence at birth,1.11,1-9 / 100 000,Value and class,Sweden,Validated,25274184[PMID]
324,Fabry disease,Disease,Point prevalence,0.118,1-9 / 1 000 000,Value and class,China,Validated,34103049[PMID]
163985,Hyperekplexia-epilepsy syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,30078784[PMID]
163985,Hyperekplexia-epilepsy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30078784[PMID]
778,Rett syndrome,Disease,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Europe,Not yet validated,12378695[PMID]_21878110[PMID]
778,Rett syndrome,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2019[INST]
778,Rett syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,France,Not yet validated,16647997[PMID]_ORPHANET
778,Rett syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,ORPHANET
778,Rett syndrome,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Sweden,Not yet validated,3571139[PMID]_ORPHANET
778,Rett syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Japan,Not yet validated,2803793[PMID]
778,Rett syndrome,Disease,Prevalence at birth,0.0,1-9 / 100 000,Class only,United States,Not yet validated,2063900[PMID]
778,Rett syndrome,Disease,Point prevalence,1.6,1-9 / 100 000,Value and class,United Kingdom,Validated,National Congenital Anomaly and Rare Disease Registration Service 2017[INST]_3087206[PMID]
778,Rett syndrome,Disease,Prevalence at birth,3.05,1-9 / 100 000,Value and class,Australia,Not yet validated,21587099[PMID]_ORPHANET
778,Rett syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Australia,Not yet validated,21587099[PMID]
778,Rett syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Hong Kong,Not yet validated,18174559[PMID]
72,Angelman syndrome,Malformation syndrome,Point prevalence,7.5,1-9 / 100 000,Value and class,Worldwide,Validated,20301323[PMID]_21587322[PMID]_[EXPERT]_ORPHANET
72,Angelman syndrome,Malformation syndrome,Prevalence at birth,1.3,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
72,Angelman syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2009[REG]
72,Angelman syndrome,Malformation syndrome,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Australia,Validated,16492624[PMID]
72,Angelman syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Australia,Not yet validated,16492624[PMID]
72,Angelman syndrome,Malformation syndrome,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Spain,Validated,12373673[PMID]
72,Angelman syndrome,Malformation syndrome,Point prevalence,8.3,1-9 / 100 000,Value and class,Spain,Validated,12373673[PMID]
72,Angelman syndrome,Malformation syndrome,Prevalence at birth,1.8,1-9 / 100 000,Value and class,Estonia,Validated,16906556[PMID]
72,Angelman syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Estonia,Not yet validated,16906556[PMID]
72,Angelman syndrome,Malformation syndrome,Point prevalence,10.0,1-5 / 10 000,Value and class,Denmark,Validated,7573182[PMID]
72,Angelman syndrome,Malformation syndrome,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Denmark,Validated,23913711[PMID]
72,Angelman syndrome,Malformation syndrome,Point prevalence,4.0,1-9 / 100 000,Value and class,United Kingdom,Validated,21152085[PMID]
307,Juvenile myoclonic epilepsy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1941,Juvenile absence epilepsy,Disease,Annual incidence,7.5,1-9 / 100 000,Value and class,Europe,Validated,8275976[PMID]_ORPHANET
1941,Juvenile absence epilepsy,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_Dr Gabrielle Rudolf[EXPERT]
892,Von Hippel-Lindau disease,Disease,Prevalence at birth,2.3,1-9 / 100 000,Value and class,United Kingdom,Validated,20082463[PMID]_[EXPERT]
892,Von Hippel-Lindau disease,Disease,Point prevalence,1.1,1-9 / 100 000,Value and class,United Kingdom,Validated,20082463[PMID]_[EXPERT]
892,Von Hippel-Lindau disease,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
892,Von Hippel-Lindau disease,Disease,Point prevalence,2.13,1-9 / 100 000,Value and class,Denmark,Validated,27966541[PMID]
892,Von Hippel-Lindau disease,Disease,Prevalence at birth,3.66,1-9 / 100 000,Value and class,Denmark,Validated,27966541[PMID]
731,Autosomal recessive polycystic kidney disease,Disease,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Germany,Validated,[EXPERT]_9511976[PMID]
731,Autosomal recessive polycystic kidney disease,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
138,CHARGE syndrome,Malformation syndrome,Prevalence at birth,3.5,1-9 / 100 000,Value and class,Canada,Validated,15637722[PMID]
138,CHARGE syndrome,Malformation syndrome,Prevalence at birth,6.5,1-9 / 100 000,Value and class,Worldwide,Not yet validated,16959034[PMID]
138,CHARGE syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
138,CHARGE syndrome,Malformation syndrome,Point prevalence,9.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2019[INST]
558,Marfan syndrome,Disease,Annual incidence,25.0,1-5 / 10 000,Value and class,Europe,Not yet validated,16325700[PMID]_ORPHANET
558,Marfan syndrome,Disease,Point prevalence,15.0,1-5 / 10 000,Value and class,Worldwide,Not yet validated,20301510[PMID]
558,Marfan syndrome,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
558,Marfan syndrome,Disease,Prevalence at birth,10.2,1-5 / 10 000,Value and class,United Kingdom,Validated,8151638[PMID]
558,Marfan syndrome,Disease,Point prevalence,7.0,1-9 / 100 000,Value and class,United Kingdom,Validated,8151638[PMID]
558,Marfan syndrome,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,United States,Validated,3788757[PMID]
165805,Familial mesial temporal lobe epilepsy with febrile seizures,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,21922598[PMID]
165805,Familial mesial temporal lobe epilepsy with febrile seizures,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21922598[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,2.2,1-9 / 100 000,Value and class,Europe,Validated,19710046[PMID]_[EXPERT]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,5.2,1-9 / 100 000,Value and class,Europe,Validated,19192301[PMID]_[EXPERT]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,3.85,1-9 / 100 000,Value and class,Worldwide,Not yet validated,21665992[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,1.35,1-9 / 100 000,Value and class,Worldwide,Not yet validated,21665992[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,1.06,1-9 / 100 000,Value and class,United Kingdom,Validated,17898523[PMID]_17219036[PMID]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,4.9,1-9 / 100 000,Value and class,United Kingdom,Validated,17898523[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,2.1,1-9 / 100 000,Value and class,Ireland,Validated,10025778[PMID]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,4.7,1-9 / 100 000,Value and class,Ireland,Validated,10025778[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,2.4,1-9 / 100 000,Value and class,Finland,Validated,6601351[PMID]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,6.4,1-9 / 100 000,Value and class,Finland,Validated,6601351[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,2.0,1-9 / 100 000,Value and class,Canada,Not yet validated,3762972[PMID]_19494548[PMID]_ ORPHANET
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,4.9,1-9 / 100 000,Value and class,Canada,Validated,3762972[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,1.46,1-9 / 100 000,Value and class,United States,Validated,25298019[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,1.37,1-9 / 100 000,Value and class,Uruguay,Validated,18334826[PMID]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,1.9,1-9 / 100 000,Value and class,Uruguay,Validated,18334826[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,1.4,1-9 / 100 000,Value and class,Denmark,Validated,2786160[PMID]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,3.1,1-9 / 100 000,Value and class,Denmark,Validated,2786160[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,3.0,1-9 / 100 000,Value and class,Italy,Validated,19237701[PMID]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,7.9,1-9 / 100 000,Value and class,Italy,Not yet validated,19237701[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,2.0,1-9 / 100 000,Value and class,France,Validated,19452307[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,1.4,1-9 / 100 000,Value and class,Spain,Validated,23286747[PMID]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,5.4,1-9 / 100 000,Value and class,Spain,Validated,23286747[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,2.2,1-9 / 100 000,Value and class,Norway,Validated,21860251[PMID]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Norway,Validated,21860251[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,0.51,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,DOI:10.1016/j.jfma.2013.01.008[OTHER]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,1.97,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,DOI:10.1016/j.jfma.2013.01.008[OTHER]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,2.6,1-9 / 100 000,Value and class,Faroe Islands,Validated,22034926[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,0.42,1-9 / 1 000 000,Value and class,"Iran, Islamic Republic of",Validated,20214678[PMID]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,1.57,1-9 / 100 000,Value and class,"Iran, Islamic Republic of",Validated,20214678[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,2.5,1-9 / 100 000,Value and class,Specific population,Validated,23052600[PMID]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,10.8,1-5 / 10 000,Value and class,Specific population,Validated,23052600[PMID]
803,Amyotrophic lateral sclerosis,Disease,Annual incidence,1.4,1-9 / 100 000,Value and class,Specific population,Validated,22409362[PMID]
803,Amyotrophic lateral sclerosis,Disease,Point prevalence,6.0,1-9 / 100 000,Value and class,Specific population,Validated,22409362[PMID]
100,Ataxia-telangiectasia,Disease,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Norway,Validated,19339254[PMID]
100,Ataxia-telangiectasia,Disease,Point prevalence,0.4,1-9 / 1 000 000,Value and class,Norway,Validated,19339254[PMID]
100,Ataxia-telangiectasia,Disease,Prevalence at birth,1.7,1-9 / 100 000,Value and class,United States,Validated,20301790[PMID]_21569628[PMID]
100,Ataxia-telangiectasia,Disease,Point prevalence,0.49,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET_19339254[PMID]_23609960[PMID]_19440741[PMID]_1512613[PMID]
100,Ataxia-telangiectasia,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Portugal,Validated,23609960[PMID]
100,Ataxia-telangiectasia,Disease,Point prevalence,0.25,1-9 / 1 000 000,Value and class,France,Validated,19440741[PMID]
100,Ataxia-telangiectasia,Disease,Point prevalence,0.25,1-9 / 1 000 000,Value and class,United Kingdom,Not yet validated,Ataxia Telangiectasia Society 2014[OTHER]
100,Ataxia-telangiectasia,Disease,Point prevalence,1.19,1-9 / 100 000,Value and class,Italy,Validated,1512613[PMID]
733,Familial adenomatous polyposis,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,ORPHANET
733,Familial adenomatous polyposis,Disease,Point prevalence,6.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2011[INST]
733,Familial adenomatous polyposis,Disease,Annual incidence,19.0,1-5 / 10 000,Value and class,Denmark,Validated,12692062[PMID]
733,Familial adenomatous polyposis,Disease,Point prevalence,4.65,1-9 / 100 000,Value and class,Denmark,Validated,12692062[PMID]
733,Familial adenomatous polyposis,Disease,Annual incidence,8.6,1-9 / 100 000,Value and class,Sweden,Validated,10636071[PMID]
733,Familial adenomatous polyposis,Disease,Point prevalence,3.2,1-9 / 100 000,Value and class,Sweden,Validated,10636071[PMID]
733,Familial adenomatous polyposis,Disease,Annual incidence,15.8,1-5 / 10 000,Value and class,Finland,Validated,1314763[PMID]
733,Familial adenomatous polyposis,Disease,Point prevalence,2.63,1-9 / 100 000,Value and class,Finland,Validated,1314763[PMID]
733,Familial adenomatous polyposis,Disease,Prevalence at birth,11.6,1-5 / 10 000,Value and class,United Kingdom,Validated,20082463[PMID]
733,Familial adenomatous polyposis,Disease,Point prevalence,5.3,1-9 / 100 000,Value and class,United Kingdom,Validated,20082463[PMID]
733,Familial adenomatous polyposis,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,Australia,Validated,2556632[PMID]
733,Familial adenomatous polyposis,Disease,Point prevalence,2.8,1-9 / 100 000,Value and class,Australia,Validated,2556632[PMID]
399,Huntington disease,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Greece,Validated,21166788[PMID]
399,Huntington disease,Disease,Annual incidence,0.38,1-9 / 1 000 000,Value and class,Worldwide,Validated,22692795[PMID]
399,Huntington disease,Disease,Point prevalence,2.7,1-9 / 100 000,Value and class,Worldwide,Validated,22692795[PMID]
399,Huntington disease,Disease,Point prevalence,12.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2019[INST]
399,Huntington disease,Disease,Point prevalence,10.6,1-5 / 10 000,Value and class,Ireland,Validated,20880124[PMID]
399,Huntington disease,Disease,Annual incidence,0.61,1-9 / 1 000 000,Value and class,United Kingdom,Not yet validated,22133668[PMID]_ORPHANET
399,Huntington disease,Disease,Point prevalence,5.4,1-9 / 100 000,Value and class,United Kingdom,Not yet validated,22133668[PMID]_21088431[PMID]_7994530[PMID]_9231935[PMID]
399,Huntington disease,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,Italy,Validated,2151397[PMID]
399,Huntington disease,Disease,Point prevalence,6.35,1-9 / 100 000,Value and class,Italy,Not yet validated,2151397[PMID]_25689972[PMID]
399,Huntington disease,Disease,Annual incidence,0.69,1-9 / 1 000 000,Value and class,Canada,Validated,11595021[PMID]
399,Huntington disease,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,United States,Validated,8018043[PMID]
399,Huntington disease,Disease,Point prevalence,1.9,1-9 / 100 000,Value and class,United States,Validated,8018043[PMID]
399,Huntington disease,Disease,Point prevalence,0.65,1-9 / 1 000 000,Value and class,Japan,Validated,8700304[PMID]
399,Huntington disease,Disease,Annual incidence,0.65,1-9 / 1 000 000,Value and class,Australia,Validated,11008591[PMID]
399,Huntington disease,Disease,Point prevalence,6.3,1-9 / 100 000,Value and class,Australia,Validated,11008591[PMID]
399,Huntington disease,Disease,Annual incidence,0.046,<1 / 1 000 000,Value and class,China,Validated,7586664[PMID]
399,Huntington disease,Disease,Point prevalence,0.37,1-9 / 1 000 000,Value and class,China,Validated,7586664[PMID]
399,Huntington disease,Disease,Point prevalence,5.2,1-9 / 100 000,Value and class,Slovenia,Validated,18976322[PMID]
399,Huntington disease,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,7586664[PMID]
399,Huntington disease,Disease,Point prevalence,0.42,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,7586664[PMID]
399,Huntington disease,Disease,Annual incidence,0.14,1-9 / 1 000 000,Value and class,Iceland,Validated,22722209[PMID]
399,Huntington disease,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Iceland,Validated,22722209[PMID]
399,Huntington disease,Disease,Point prevalence,6.7,1-9 / 100 000,Value and class,Norway,Validated,2938203[PMID]
399,Huntington disease,Disease,Point prevalence,4.7,1-9 / 100 000,Value and class,Sweden,Validated,22722209[PMID]
399,Huntington disease,Disease,Annual incidence,0.33,1-9 / 1 000 000,Value and class,Greece,Validated,21166788[PMID]
399,Huntington disease,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Finland,Validated,2889026[PMID]
399,Huntington disease,Disease,Point prevalence,21.0,1-5 / 10 000,Value and class,Egypt,Validated,7969703[PMID]
399,Huntington disease,Disease,Point prevalence,4.64,1-9 / 100 000,Value and class,Cyprus,Validated,29105741[PMID]
399,Huntington disease,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Cyprus,Validated,29105741[PMID]
399,Huntington disease,Disease,Point prevalence,5.8,1-9 / 100 000,Value and class,Denmark,Validated,28155235[PMID]
399,Huntington disease,Disease,Point prevalence,4.94,1-9 / 100 000,Value and class,Spain,Validated,33568143[PMID]
399,Huntington disease,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,Spain,Validated,33568143[PMID]
501,Lafora disease,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,France,Validated,[EXPERT]
501,Lafora disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
501,Lafora disease,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,25217339[PMID]
501,Lafora disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25217339[PMID]
870,Down syndrome,Malformation syndrome,Prevalence at birth,95.0,6-9 / 10 000,Value and class,Worldwide,Validated,World Health Organization[INST]
870,Down syndrome,Malformation syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Worldwide,Validated,World Health Organization[INST]
870,Down syndrome,Malformation syndrome,Prevalence at birth,101.0,>1 / 1000,Value and class,Europe,Validated,33130823[PMID]
870,Down syndrome,Malformation syndrome,Point prevalence,57.0,1-5 / 10 000,Value and class,Europe,Validated,33130823[PMID]
870,Down syndrome,Malformation syndrome,Prevalence at birth,63.7,6-9 / 10 000,Value and class,France,Validated,Institut de Veille Sanitaire 2011[INST]
870,Down syndrome,Malformation syndrome,Prevalence at birth,98.3,6-9 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,70.0,6-9 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,74.0,6-9 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,91.2,6-9 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,110.0,>1 / 1000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,69.0,6-9 / 10 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,38.0,1-5 / 10 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,91.6,6-9 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,98.0,6-9 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,66.0,6-9 / 10 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,59.0,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,44.0,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,75.0,6-9 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,235.0,>1 / 1000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,100.0,>1 / 1000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
870,Down syndrome,Malformation syndrome,Prevalence at birth,174.0,>1 / 1000,Value and class,Japan,Validated,18412274[PMID]
870,Down syndrome,Malformation syndrome,Point prevalence,66.0,6-9 / 10 000,Value and class,United Kingdom,Validated,23321618[PMID]
870,Down syndrome,Malformation syndrome,Prevalence at birth,126.0,>1 / 1000,Value and class,United States,Validated,25822844[PMID]
870,Down syndrome,Malformation syndrome,Prevalence at birth,130.0,>1 / 1000,Value and class,South Africa,Validated,9373864[PMID]
512,Metachromatic leukodystrophy,Disease,Prevalence at birth,1.47,1-9 / 100 000,Value and class,Europe,Validated,21496291[PMID]_[EXPERT]_European Medicines Agency 2010[INST]
512,Metachromatic leukodystrophy,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,21496291[PMID]_[EXPERT]_European Medicines Agency 2010[INST]
512,Metachromatic leukodystrophy,Disease,Prevalence at birth,1.42,1-9 / 100 000,Value and class,Netherlands,Validated,10480370[PMID]
512,Metachromatic leukodystrophy,Disease,Prevalence at birth,1.85,1-9 / 100 000,Value and class,Portugal,Validated,14685153[PMID]
512,Metachromatic leukodystrophy,Disease,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,Germany,Validated,9286459[PMID]
512,Metachromatic leukodystrophy,Disease,Prevalence at birth,1.43,1-9 / 100 000,Value and class,Turkey,Validated,20490927[PMID]
512,Metachromatic leukodystrophy,Disease,Prevalence at birth,1.09,1-9 / 100 000,Value and class,Australia,Validated,9918480[PMID]
512,Metachromatic leukodystrophy,Disease,Prevalence at birth,0.69,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
512,Metachromatic leukodystrophy,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Poland,Validated,21695197[PMID]
512,Metachromatic leukodystrophy,Disease,Prevalence at birth,2.5,1-9 / 100 000,Value and class,United States,Validated,19380076[PMID]
512,Metachromatic leukodystrophy,Disease,Prevalence at birth,0.0,1-9 / 100 000,Class only,Worldwide,Validated,ORPHANET_21695197[PMID]_20490927[PMID]_19380076[PMID]_9918480[PMID]_9286459[PMID]_14685153[PMID]_10480370[PMID]
512,Metachromatic leukodystrophy,Disease,Prevalence at birth,1.73,1-9 / 100 000,Value and class,Sweden,Validated,25274184[PMID]
567,22q11.2 deletion syndrome,Malformation syndrome,Prevalence at birth,9.6,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
567,22q11.2 deletion syndrome,Malformation syndrome,Prevalence at birth,10.3,1-5 / 10 000,Value and class,France,Not yet validated,8863171[PMID]
567,22q11.2 deletion syndrome,Malformation syndrome,Prevalence at birth,37.5,1-5 / 10 000,Value and class,Worldwide,Not yet validated,21570089[PMID]_ORPHANET
567,22q11.2 deletion syndrome,Malformation syndrome,Prevalence at birth,16.8,1-5 / 10 000,Value and class,United States,Validated,12837874[PMID]
567,22q11.2 deletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
567,22q11.2 deletion syndrome,Malformation syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,European Medicines Agency 2019[INST]
166016,"Multiple epiphyseal dysplasia, Lowry type",Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,8723087[PMID]
166016,"Multiple epiphyseal dysplasia, Lowry type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8723087[PMID]
232,Sickle cell anemia,Disease,Prevalence at birth,42.0,1-5 / 10 000,Value and class,France,Validated,Institut de Veille Sanitaire 2010[INST]
232,Sickle cell anemia,Disease,Prevalence at birth,25.0,1-5 / 10 000,Value and class,Germany,Validated,24398797[PMID]
232,Sickle cell anemia,Disease,Point prevalence,30.0,1-5 / 10 000,Value and class,United States,Validated,20331952[PMID]_Center for Diseases Control and Prevention[INST]
232,Sickle cell anemia,Disease,Prevalence at birth,47.5,1-5 / 10 000,Value and class,Belgium,Validated,10321364[PMID]
232,Sickle cell anemia,Disease,Prevalence at birth,41.7,1-5 / 10 000,Value and class,United Kingdom,Not yet validated,Sickle Cell Society 2008[OTHER]
232,Sickle cell anemia,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2019[INST]
232,Sickle cell anemia,Disease,Prevalence at birth,32.8,1-5 / 10 000,Value and class,United States,Validated,17183567[PMID]
232,Sickle cell anemia,Disease,Prevalence at birth,344.8,>1 / 1000,Value and class,Guadeloupe,Not yet validated,Institut de Veille Sanitaire 2015[INST]
232,Sickle cell anemia,Disease,Prevalence at birth,248.75,>1 / 1000,Value and class,Martinique,Not yet validated,Institut de Veille Sanitaire 2015[INST]
232,Sickle cell anemia,Disease,Prevalence at birth,467.3,>1 / 1000,Value and class,Guyana,Not yet validated,Institut de Veille Sanitaire 2015[INST]
232,Sickle cell anemia,Disease,Prevalence at birth,20.15,1-5 / 10 000,Value and class,Reunion,Not yet validated,Institut de Veille Sanitaire 2015[INST]
232,Sickle cell anemia,Disease,Annual incidence,21.6262,1-5 / 10 000,Value and class,Brazil,Validated,35209917[PMID]
536,Systemic lupus erythematosus,Disease,Point prevalence,47.0,1-5 / 10 000,Value and class,France,Validated,25172239[PMID]_28968809[PMID]
536,Systemic lupus erythematosus,Disease,Point prevalence,64.2,6-9 / 10 000,Value and class,Martinique,Validated,11859691[PMID]_28968809[PMID]
536,Systemic lupus erythematosus,Disease,Point prevalence,14.7,1-5 / 10 000,Value and class,New Zealand,Validated,6929995[PMID]_28968809[PMID]
536,Systemic lupus erythematosus,Disease,Point prevalence,20.6,1-5 / 10 000,Value and class,"Korea, Republic of",Validated,24322455[PMID]_28968809[PMID]
536,Systemic lupus erythematosus,Disease,Point prevalence,53.6,1-5 / 10 000,Value and class,United States,Validated,15333286[PMID]_28968809[PMID]
536,Systemic lupus erythematosus,Disease,Point prevalence,37.0,1-5 / 10 000,Value and class,"Taiwan, Province of China",Validated,22899470[PMID]_28968809[PMID]
536,Systemic lupus erythematosus,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,ORPHANET
536,Systemic lupus erythematosus,Disease,Point prevalence,28.0,1-5 / 10 000,Value and class,Finland,Validated,4001877[PMID]_28968809[PMID]
536,Systemic lupus erythematosus,Disease,Annual incidence,5.14,1-9 / 100 000,Value and class,Worldwide,Validated,36241363[PMID]
536,Systemic lupus erythematosus,Disease,Point prevalence,43.7,1-5 / 10 000,Value and class,Worldwide,Validated,36241363[PMID]
536,Systemic lupus erythematosus,Disease,Annual incidence,81.84,6-9 / 10 000,Value and class,Poland,Validated,36241363[PMID]
534,Oculocerebrorenal syndrome of Lowe,Malformation syndrome,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,16722554[PMID]
534,Oculocerebrorenal syndrome of Lowe,Malformation syndrome,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,16722554[PMID]_[EXPERT]
534,Oculocerebrorenal syndrome of Lowe,Malformation syndrome,Point prevalence,0.2,1-9 / 1 000 000,Value and class,United Kingdom,Validated,21152085[PMID]
790,Retinoblastoma,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Prevalence at birth,4.6,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,19373260[PMID]
790,Retinoblastoma,Disease,Prevalence at birth,5.9,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,24692122[PMID]
790,Retinoblastoma,Disease,Lifetime Prevalence,1.05,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Prevalence at birth,6.0,1-9 / 100 000,Value and class,Worldwide,Validated,22414599[PMID]_19704035[PMID]_ [EXPERT]
790,Retinoblastoma,Disease,Prevalence at birth,5.05,1-9 / 100 000,Value and class,Japan,Validated,1513060[PMID]
790,Retinoblastoma,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
790,Retinoblastoma,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.073,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.035,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.053,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.033,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.071,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.045,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.094,<1 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.071,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.038,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.047,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.042,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.038,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.048,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.039,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.071,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
790,Retinoblastoma,Disease,Annual incidence,0.107,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
652,Multiple endocrine neoplasia type 1,Disease,Point prevalence,3.3,1-9 / 100 000,Value and class,Europe,Validated,20301710[PMID]_17014705[PMID]_ [EXPERT]
908,Fragile X syndrome,Malformation syndrome,Point prevalence,32.5,1-5 / 10 000,Value and class,Worldwide,Validated,18413371[PMID]_[EXPERT]_ ORPHANET
908,Fragile X syndrome,Malformation syndrome,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
908,Fragile X syndrome,Malformation syndrome,Prevalence at birth,9.7,1-9 / 100 000,Value and class,United States,Validated,19804849[PMID]_23765048[PMID]
908,Fragile X syndrome,Malformation syndrome,Prevalence at birth,1.3,1-9 / 100 000,Value and class,France,Validated,22925539[PMID]
908,Fragile X syndrome,Malformation syndrome,Prevalence at birth,19.0,1-5 / 10 000,Value and class,Spain,Validated,19460941[PMID]
908,Fragile X syndrome,Malformation syndrome,Prevalence at birth,16.11,1-5 / 10 000,Value and class,Canada,Validated,19863547[PMID]
908,Fragile X syndrome,Malformation syndrome,Prevalence at birth,2.4,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
3099,Rheumatic fever,Disease,Annual incidence,5.0,1-9 / 100 000,Value and class,Europe,Validated,21386976[PMID]_[EXPERT]
3099,Rheumatic fever,Disease,Annual incidence,12.5,1-5 / 10 000,Value and class,Canada,Validated,21386976[PMID]_[EXPERT]_ ORPHANET
3099,Rheumatic fever,Disease,Annual incidence,12.5,1-5 / 10 000,Value and class,Spain,Validated,21386976[PMID]_[EXPERT]_ ORPHANET
3099,Rheumatic fever,Disease,Annual incidence,100.0,>1 / 1000,Value and class,Australia,Validated,21386976[PMID]_[EXPERT]
3099,Rheumatic fever,Disease,Annual incidence,30.0,1-5 / 10 000,Value and class,India,Validated,21386976[PMID]_[EXPERT]_ ORPHANET
3099,Rheumatic fever,Disease,Annual incidence,100.0,>1 / 1000,Value and class,Mexico,Validated,21386976[PMID]_[EXPERT]
3099,Rheumatic fever,Disease,Annual incidence,5.0,1-9 / 100 000,Value and class,Latin America,Validated,21386976[PMID]_[EXPERT]
3099,Rheumatic fever,Disease,Annual incidence,7.6,1-9 / 100 000,Value and class,New Zealand,Validated,23254495[PMID]_21386976[PMID]_ [EXPERT]
3099,Rheumatic fever,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
739,Prader-Willi syndrome,Disease,Prevalence at birth,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,ORPHANET
739,Prader-Willi syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,ORPHANET
739,Prader-Willi syndrome,Disease,Prevalence at birth,3.1,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
739,Prader-Willi syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
739,Prader-Willi syndrome,Disease,Prevalence at birth,3.7,1-9 / 100 000,Value and class,Belgium,Validated,14679397[PMID]
739,Prader-Willi syndrome,Disease,Point prevalence,1.3,1-9 / 100 000,Value and class,Belgium,Validated,14679397[PMID]
739,Prader-Willi syndrome,Disease,Prevalence at birth,3.4,1-9 / 100 000,Value and class,United Kingdom,Validated,11732491[PMID]
739,Prader-Willi syndrome,Disease,Point prevalence,1.9,1-9 / 100 000,Value and class,United Kingdom,Validated,11732491[PMID]
739,Prader-Willi syndrome,Disease,Prevalence at birth,6.6,1-9 / 100 000,Value and class,Japan,Validated,8579217[PMID]
739,Prader-Willi syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Japan,Validated,8579217[PMID]
739,Prader-Willi syndrome,Disease,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Australia,Validated,12598399[PMID]
739,Prader-Willi syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Australia,Validated,12598399[PMID]
739,Prader-Willi syndrome,Disease,Prevalence at birth,6.2,1-9 / 100 000,Value and class,United States,Validated,2240051[PMID]
739,Prader-Willi syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,United States,Validated,2240051[PMID]
739,Prader-Willi syndrome,Disease,Prevalence at birth,4.76,1-9 / 100 000,Value and class,France,Validated,28659150[PMID]
739,Prader-Willi syndrome,Disease,Point prevalence,0.229,1-9 / 1 000 000,Value and class,China,Validated,34103049[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Not yet validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.22,1-9 / 1 000 000,Value and class,Worldwide,Validated,[EXPERT]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.18,1-9 / 1 000 000,Value and class,France,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.21,1-9 / 1 000 000,Value and class,Italy,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.08,<1 / 1 000 000,Value and class,United Kingdom,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.06,<1 / 1 000 000,Value and class,Spain,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.03,<1 / 1 000 000,Value and class,Germany,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.09,<1 / 1 000 000,Value and class,Poland,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.13,1-9 / 1 000 000,Value and class,Croatia,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.16,1-9 / 1 000 000,Value and class,Hungary,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.25,1-9 / 1 000 000,Value and class,North Macedonia,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Slovenia,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.09,<1 / 1 000 000,Value and class,Serbia,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.04,<1 / 1 000 000,Value and class,Ukraine,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.06,<1 / 1 000 000,Value and class,Belarus,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.03,<1 / 1 000 000,Value and class,Romania,Validated,19419768[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Prevalence at birth,0.26,1-9 / 1 000 000,Value and class,United States,Validated,16862044[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.07,<1 / 1 000 000,Value and class,United States,Validated,16862044[PMID]
47,X-linked agammaglobulinemia,Clinical subtype,Point prevalence,0.11,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,22787376[PMID]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.31,1-9 / 1 000 000,Value and class,Sweden,Validated,18681890[PMID]_25274184[PMID]
580,Mucopolysaccharidosis type 2,Disease,Point prevalence,9.1,1-9 / 100 000,Value and class,Denmark,Validated,18681890[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.43,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.71,1-9 / 1 000 000,Value and class,Ireland,Validated,9439667[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,1.07,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,19396827[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.74,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,2.16,1-9 / 100 000,Value and class,Estonia,Validated,22480138[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Canada,Validated,10617747[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2018 [INST]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,1.09,1-9 / 100 000,Value and class,Portugal,Validated,14685153[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.64,1-9 / 1 000 000,Value and class,Germany,Validated,16435194[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,1.21,1-9 / 100 000,Value and class,Italy,Validated,11953730[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.67,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Point prevalence,6.5,1-9 / 100 000,Value and class,Sweden,Validated,18681890[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.13,1-9 / 1 000 000,Value and class,Norway,Validated,18681890[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Point prevalence,4.4,1-9 / 100 000,Value and class,Norway,Validated,18681890[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.27,1-9 / 1 000 000,Value and class,Denmark,Validated,18681890[PMID]_[EXPERT]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.68,1-9 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.46,1-9 / 1 000 000,Value and class,Poland,Validated,25472774[PMID]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.84,1-9 / 1 000 000,Value and class,Japan,Validated,28595941[PMID]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.46,1-9 / 1 000 000,Value and class,Switzerland,Validated,28595941[PMID]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.74,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,25364648[PMID]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.29,1-9 / 1 000 000,Value and class,Tunisia,Validated,20209839[PMID]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.26,1-9 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
580,Mucopolysaccharidosis type 2,Disease,Prevalence at birth,0.37,1-9 / 1 000 000,Value and class,Brazil,Validated,PMID: 31926052
580,Mucopolysaccharidosis type 2,Disease,Point prevalence,0.07,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.69,1-9 / 1 000 000,Value and class,Germany,Validated,16435194[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,1.33,1-9 / 100 000,Value and class,Portugal,Validated,14685153[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,1.19,1-9 / 100 000,Value and class,Netherlands,Validated,10480370[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.67,1-9 / 1 000 000,Value and class,Sweden,Validated,18681890[PMID]_25274184[PMID]
579,Mucopolysaccharidosis type 1,Disease,Point prevalence,8.7,1-9 / 100 000,Value and class,Sweden,Validated,18681890[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,1.85,1-9 / 100 000,Value and class,Norway,Validated,18681890[PMID]
579,Mucopolysaccharidosis type 1,Disease,Point prevalence,31.0,1-5 / 10 000,Value and class,Norway,Validated,18681890[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.54,1-9 / 1 000 000,Value and class,Denmark,Validated,18681890[PMID]
579,Mucopolysaccharidosis type 1,Disease,Point prevalence,7.4,1-9 / 100 000,Value and class,Denmark,Validated,18681890[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,3.8,1-9 / 100 000,Value and class,Ireland,Validated,18463126[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,1.07,1-9 / 100 000,Value and class,United Kingdom,Validated,18796143[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.63,1-9 / 1 000 000,Value and class,Tunisia,Validated,20209839[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.11,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,19396827[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.58,1-9 / 1 000 000,Value and class,Canada,Validated,10617747[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,1.14,1-9 / 100 000,Value and class,Australia,Validated,9918480[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.72,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
579,Mucopolysaccharidosis type 1,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.82,1-9 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.22,1-9 / 1 000 000,Value and class,Poland,Validated,25472774[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.23,1-9 / 1 000 000,Value and class,Japan,Validated,28595941[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.19,1-9 / 1 000 000,Value and class,Switzerland,Validated,28595941[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,3.62,1-9 / 100 000,Value and class,Saudi Arabia,Validated,20622343[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.21,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,25364648[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.24,1-9 / 1 000 000,Value and class,Brazil,Validated,PMID: 31926052
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,0.34,1-9 / 1 000 000,Value and class,United States,Validated,DOI: https://doi.org/10.1016/j.ymgme.2016.11.285[OTHER]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]
579,Mucopolysaccharidosis type 1,Disease,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Specific population,Validated,33239050[PMID]
905,Wilson disease,Disease,Prevalence at birth,2.25,1-9 / 100 000,Value and class,Worldwide,Validated,31449670[PMID]
905,Wilson disease,Disease,Point prevalence,6.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
905,Wilson disease,Disease,Point prevalence,2.02,1-9 / 100 000,Value and class,Worldwide,Validated,31449670[PMID]
905,Wilson disease,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,France,Validated,28648494[PMID]
905,Wilson disease,Disease,Prevalence at birth,0.94,1-9 / 1 000 000,Value and class,Italy,Validated,11953730[PMID]
905,Wilson disease,Disease,Prevalence at birth,3.0,1-5 / 10 000,Value and class,Japan,Validated,7338703[PMID]_17276780 [PMID]
905,Wilson disease,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,China,Validated,20301685[PMID]
905,Wilson disease,Disease,Prevalence at birth,13.5,1-5 / 10 000,Value and class,Specific population,Validated,11953730[PMID]
905,Wilson disease,Disease,Point prevalence,37.04,1-5 / 10 000,Value and class,Specific population,Validated,23486543[PMID]
905,Wilson disease,Disease,Prevalence at birth,1.37,1-9 / 100 000,Value and class,Ireland,Validated,8459248[PMID]
905,Wilson disease,Disease,Prevalence at birth,2.9,1-9 / 100 000,Value and class,Germany,Validated,542546[PMID]_17276780[PMID]
905,Wilson disease,Disease,Annual incidence,0.016,1-9 / 1 000 000,Value and class,Finland,Validated,32618023[PMID]
905,Wilson disease,Disease,Point prevalence,0.45,1-9 / 1 000 000,Value and class,Finland,Validated,32618023[PMID]
792,X-linked retinoschisis,Malformation syndrome,Point prevalence,5.0,1-9 / 100 000,Value and class,Denmark,Not yet validated,17172462[PMID]_ORPHANET
792,X-linked retinoschisis,Malformation syndrome,Point prevalence,5.0,1-9 / 100 000,Value and class,Netherlands,Not yet validated,17172462[PMID]_ORPHANET
792,X-linked retinoschisis,Malformation syndrome,Point prevalence,5.0,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
792,X-linked retinoschisis,Malformation syndrome,Point prevalence,3.6,1-9 / 100 000,Value and class,France,Validated,1918822[PMID]
792,X-linked retinoschisis,Malformation syndrome,Point prevalence,4.5,1-9 / 100 000,Value and class,Europe,Validated,17172462[PMID]_1918822[PMID]_ ORPHANET
163525,Subacute cutaneous lupus erythematosus,Disease,Annual incidence,0.63,1-9 / 1 000 000,Value and class,United States,Validated,19289752[PMID]
163525,Subacute cutaneous lupus erythematosus,Disease,Point prevalence,1.4805,1-9 / 100 000,Value and class,United States,Validated,32141953[PMID]_35359921[PMID]_ORPHANET
827,Stargardt disease,Disease,Point prevalence,13.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
906,Wiskott-Aldrich syndrome,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
906,Wiskott-Aldrich syndrome,Disease,Point prevalence,0.18,1-9 / 1 000 000,Value and class,France,Validated,[EXPERT]
906,Wiskott-Aldrich syndrome,Disease,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Switzerland,Validated,3065352[PMID]
906,Wiskott-Aldrich syndrome,Disease,Point prevalence,0.55,1-9 / 1 000 000,Value and class,Norway,Not yet validated,11202238[PMID]_ORPHANET
906,Wiskott-Aldrich syndrome,Disease,Point prevalence,0.07,<1 / 1 000 000,Value and class,Australia,Validated,9314356[PMID]
906,Wiskott-Aldrich syndrome,Disease,Point prevalence,0.03,<1 / 1 000 000,Value and class,"Korea, Republic of",Validated,22787376[PMID]
906,Wiskott-Aldrich syndrome,Disease,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,United States,Validated,7381651[PMID]
906,Wiskott-Aldrich syndrome,Disease,Point prevalence,0.0278,<1 / 1 000 000,Value and class,China,Validated,34103049[PMID]
904,Williams syndrome,Malformation syndrome,Prevalence at birth,13.3,1-5 / 10 000,Value and class,Norway,Validated,12088082[PMID]
904,Williams syndrome,Malformation syndrome,Prevalence at birth,4.2,1-9 / 100 000,Value and class,Hong Kong,Validated,14967851[PMID]
904,Williams syndrome,Malformation syndrome,Point prevalence,13.3,1-5 / 10 000,Value and class,Norway,Validated,12088082[PMID]_ORPHANET
904,Williams syndrome,Malformation syndrome,Point prevalence,4.2,1-9 / 100 000,Value and class,Hong Kong,Validated,14967851[PMID]_ORPHANET
280,Wolf-Hirschhorn syndrome,Malformation syndrome,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Europe,Validated,11480768[PMID]_[EXPERT]
280,Wolf-Hirschhorn syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,11480768[PMID]_[EXPERT]
15,Achondroplasia,Disease,Prevalence at birth,4.73,1-9 / 100 000,Value and class,Worldwide,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,3.62,1-9 / 100 000,Value and class,Europe,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,5.645,1-9 / 100 000,Value and class,France,Validated,32803853[PMID]_ORPHANET
15,Achondroplasia,Disease,Prevalence at birth,3.7,1-9 / 100 000,Value and class,Italy,Validated,3071354[PMID]_[EXPERT]
15,Achondroplasia,Disease,Prevalence at birth,4.195,1-9 / 100 000,Value and class,Sweden,Validated,32803853[PMID]_[ORPHANET]
15,Achondroplasia,Disease,Prevalence at birth,2.6466,1-9 / 100 000,Value and class,Spain,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,2.37,1-9 / 100 000,Value and class,Denmark,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,3.2,1-9 / 100 000,Value and class,Latin America,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,3.8,1-9 / 100 000,Value and class,Australia,Validated,458831[PMID]_[EXPERT]
15,Achondroplasia,Disease,Prevalence at birth,3.63,1-9 / 100 000,Value and class,Switzerland,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,3.7877,1-9 / 100 000,Value and class,United Kingdom,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,6.0,1-9 / 100 000,Value and class,Ukraine,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,79.05,6-9 / 10 000,Value and class,Iraq,Validated,32803853[PMID]_ORPHANET
15,Achondroplasia,Disease,Prevalence at birth,36.73,1-5 / 10 000,Value and class,"Iran, Islamic Republic of",Validated,32803853[PMID]_ORPHANET
15,Achondroplasia,Disease,Prevalence at birth,12.92,1-5 / 10 000,Value and class,Kuwait,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,25.87,1-5 / 10 000,Value and class,Lebanon,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,48.14,1-5 / 10 000,Value and class,Saudi Arabia,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,10.51,1-5 / 10 000,Value and class,United Arab Emirates,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,16.53,1-5 / 10 000,Value and class,Cameroon,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,4.0,1-9 / 100 000,Value and class,North America,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,4.42,1-9 / 100 000,Value and class,Cuba,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,6.75,1-9 / 100 000,Value and class,Mexico,Validated,32803853[PMID]_ORPHANET
15,Achondroplasia,Disease,Prevalence at birth,4.75,1-9 / 100 000,Value and class,Argentina,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,14.25,1-5 / 10 000,Value and class,Venezuela,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,4.76,1-9 / 100 000,Value and class,Germany,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,6.35,1-9 / 100 000,Value and class,Malta,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,3.01,1-9 / 100 000,Value and class,Netherlands,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,2.39,1-9 / 100 000,Value and class,Norway,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,4.47,1-9 / 100 000,Value and class,Poland,Validated,32803853[PMID]
15,Achondroplasia,Disease,Prevalence at birth,18.11,1-5 / 10 000,Value and class,Nigeria,Validated,32803853[PMID]_ORPHANET
15,Achondroplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,32803853[PMID]_ORPHANET
96,Ataxia with vitamin E deficiency,Disease,Point prevalence,0.33,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
101,Dentatorubral pallidoluysian atrophy,Disease,Point prevalence,0.48,1-9 / 1 000 000,Value and class,Japan,Validated,18418674[PMID]_[EXPERT]
101,Dentatorubral pallidoluysian atrophy,Disease,Point prevalence,0.71,1-9 / 1 000 000,Value and class,United Kingdom,Not yet validated,17965145[PMID]
101,Dentatorubral pallidoluysian atrophy,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
783,Rubinstein-Taybi syndrome,Malformation syndrome,Prevalence at birth,0.9,1-9 / 1 000 000,Value and class,Netherlands,Validated,2118773[PMID]
783,Rubinstein-Taybi syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Netherlands,Validated,2118773[PMID]
783,Rubinstein-Taybi syndrome,Malformation syndrome,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
783,Rubinstein-Taybi syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET
163649,Spondyloepiphyseal dysplasia-craniosynostosis-cleft palate-cataracts-intellectual disability syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,9557884[PMID]
163649,Spondyloepiphyseal dysplasia-craniosynostosis-cleft palate-cataracts-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9557884[PMID]
631,Non-acquired isolated growth hormone deficiency,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,22851490[PMID]
276,T-B+ severe combined immunodeficiency due to gamma chain deficiency,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
163654,Spondyloepiphyseal dysplasia-brachydactyly-speech disorder syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,17515304[PMID]
163654,Spondyloepiphyseal dysplasia-brachydactyly-speech disorder syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17515304[PMID]
481,Kennedy disease,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,Italy,Validated,11949733[PMID]_[EXPERT]
481,Kennedy disease,Disease,Prevalence at birth,1.6,1-9 / 100 000,Value and class,Italy,Validated,11949733[PMID]_[EXPERT]
481,Kennedy disease,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Italy,Validated,11949733[PMID]_[EXPERT]
481,Kennedy disease,Disease,Point prevalence,7.6,1-9 / 100 000,Value and class,Finland,Validated,9724012[PMID]
481,Kennedy disease,Disease,Point prevalence,3.8,1-9 / 100 000,Value and class,Europe,Validated,9724012[PMID]_11949733[PMID]_ORPHANET
664,Ornithine transcarbamylase deficiency,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
664,Ornithine transcarbamylase deficiency,Disease,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Italy,Validated,11953730[PMID]
664,Ornithine transcarbamylase deficiency,Disease,Prevalence at birth,1.29,1-9 / 100 000,Value and class,Australia,Validated,15050980[PMID]
664,Ornithine transcarbamylase deficiency,Disease,Prevalence at birth,1.6,1-9 / 100 000,Value and class,Finland,Validated,18616627[PMID]
664,Ornithine transcarbamylase deficiency,Disease,Prevalence at birth,0.88,1-9 / 1 000 000,Value and class,Canada,Validated,12788994[PMID]_10617747[PMID]_ORPHANET_[EXPERT]
664,Ornithine transcarbamylase deficiency,Disease,Prevalence at birth,1.77,1-9 / 100 000,Value and class,United States,Validated,23972786[PMID]
664,Ornithine transcarbamylase deficiency,Disease,Prevalence at birth,1.77,1-9 / 100 000,Value and class,Worldwide,Validated,23972786[PMID]_[EXPERT]
163668,"Spondyloepiphyseal dysplasia, MacDermot type",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,3681905[PMID]
163668,"Spondyloepiphyseal dysplasia, MacDermot type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3681905[PMID]
163662,"Spondyloepiphyseal dysplasia, Reardon type",Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,7747755[PMID]
163662,"Spondyloepiphyseal dysplasia, Reardon type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7747755[PMID]
394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,10328723[PMID]
394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Point prevalence,1.65,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2001[INST]
394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Ireland,Validated,9587032[PMID]
394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Prevalence at birth,0.77,1-9 / 1 000 000,Value and class,Germany,Validated,9587032[PMID]
394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Prevalence at birth,15.6,1-5 / 10 000,Value and class,Norway,Validated,15192637[PMID]
394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Denmark,Validated,10328723[PMID]
394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Australia,Validated,646432[PMID]
394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Prevalence at birth,55.5,1-5 / 10 000,Value and class,Qatar,Validated,19914636[PMID]
394,Homocystinuria due to cystathionine beta-synthase deficiency,Disease,Prevalence at birth,0.11,1-9 / 1 000 000,Value and class,Japan,Validated,9587032[PMID]
163665,"Spondyloepiphyseal dysplasia tarda, Kohn type",Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,3612708[PMID]
163665,"Spondyloepiphyseal dysplasia tarda, Kohn type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3612708[PMID]
508,Leprechaunism,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
508,Leprechaunism,Malformation syndrome,Prevalence at birth,0.0,<1 / 1 000 000,Class only,Europe,Validated,9128805[PMID]
436,Hypophosphatasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]_21488855[PMID]
436,Hypophosphatasia,Disease,Point prevalence,0.0208,<1 / 1 000 000,Value and class,China,Validated,34103049[PMID]
163596,Hb Bart's hydrops fetalis,Clinical subtype,Prevalence at birth,275.0,>1 / 1000,Value and class,South East Asia,Validated,19459517[PMID]_2351917[PMID]_ [EXPERT]
163596,Hb Bart's hydrops fetalis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
163596,Hb Bart's hydrops fetalis,Clinical subtype,Prevalence at birth,7.6,1-9 / 100 000,Value and class,United States,Validated,21167500[PMID]
429,Hypochondroplasia,Disease,Prevalence at birth,3.0303,1-9 / 100 000,Value and class,Worldwide,Validated,20301650[PMID]_33051983[PMID]
429,Hypochondroplasia,Disease,Point prevalence,3.0303,1-9 / 100 000,Value and class,Worldwide,Validated,20301650[PMID]_33051983[PMID]
437,Hypophosphatemic rickets,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
104,Leber hereditary optic neuropathy,Disease,Point prevalence,2.6,1-9 / 100 000,Value and class,Netherlands,Validated,16564802[PMID]
104,Leber hereditary optic neuropathy,Disease,Point prevalence,4.3,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
104,Leber hereditary optic neuropathy,Disease,Point prevalence,2.3,1-9 / 100 000,Value and class,Europe,Validated,21928272[PMID]
104,Leber hereditary optic neuropathy,Disease,Point prevalence,3.22,1-9 / 100 000,Value and class,United Kingdom,Not yet validated,12518276[PMID]
104,Leber hereditary optic neuropathy,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Finland,Validated,17406640[PMID]
104,Leber hereditary optic neuropathy,Disease,Point prevalence,1.85,1-9 / 100 000,Value and class,Denmark,Validated,27007794[PMID]
104,Leber hereditary optic neuropathy,Disease,Point prevalence,1.9743,1-9 / 100 000,Value and class,Japan,Validated,35987635[PMID]_ORPHANET
2182,Hydrocephalus with stenosis of the aqueduct of Sylvius,Clinical subtype,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Worldwide,Not yet validated,22344793[PMID]_20301657[PMID]
2182,Hydrocephalus with stenosis of the aqueduct of Sylvius,Clinical subtype,Point prevalence,1.7,1-9 / 100 000,Value and class,Worldwide,Not yet validated,22344793[PMID]_20301657[PMID]
163634,Maffucci syndrome,Disease,Cases/families,250.0,,Case(s),Worldwide,Validated,ORPHANET
163634,Maffucci syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
636,Neurofibromatosis type 1,Disease,Point prevalence,21.0,1-5 / 10 000,Value and class,United Kingdom,Validated,20082463[PMID]_2511318[PMID]
636,Neurofibromatosis type 1,Disease,Point prevalence,24.46,1-5 / 10 000,Value and class,Finland,Validated,29215653[PMID]
636,Neurofibromatosis type 1,Disease,Point prevalence,47.5,1-5 / 10 000,Value and class,New Zealand,Validated,2518509[PMID]
636,Neurofibromatosis type 1,Disease,Point prevalence,21.3,1-5 / 10 000,Value and class,Europe,Validated,10991696[PMID]_20082463[PMID]_2511318[PMID]_6807042[PMID]_ORPHANET
636,Neurofibromatosis type 1,Disease,Prevalence at birth,36.65,1-5 / 10 000,Value and class,United States,Validated,ISBN:039800370X[OTHER]_ORPHANET
636,Neurofibromatosis type 1,Disease,Prevalence at birth,36.9,1-5 / 10 000,Value and class,United Kingdom,Validated,20082463[PMID]
636,Neurofibromatosis type 1,Disease,Prevalence at birth,33.3,1-5 / 10 000,Value and class,Worldwide,Validated,20301288[PMID]
636,Neurofibromatosis type 1,Disease,Prevalence at birth,50.0,1-5 / 10 000,Value and class,Finland,Validated,25354145[PMID]
636,Neurofibromatosis type 1,Disease,Point prevalence,6.7,1-9 / 100 000,Value and class,Canada,Validated,1685193[PMID]
636,Neurofibromatosis type 1,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Sweden,Validated,6807042[PMID]
163703,Febrile infection-related epilepsy syndrome,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Germany,Validated,PMID: 22911482
163703,Febrile infection-related epilepsy syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Germany,Validated,28898171[PMID]_ORPHANET
649,Norrie disease,Malformation syndrome,Cases/families,400.0,,Case(s),Worldwide,Validated,16052165[PMID]
649,Norrie disease,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
163727,Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,10072049[PMID]
163727,Rolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10072049[PMID]
163684,Leukoencephalopathy-dystonia-motor neuropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,16685654[PMID]
163684,Leukoencephalopathy-dystonia-motor neuropathy syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,ORPHANET_16685654[PMID]
163681,CNTNAP2-related developmental and epileptic encephalopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
163681,CNTNAP2-related developmental and epileptic encephalopathy,Disease,Cases/families,28.0,,Case(s),Worldwide,,
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.46,1-9 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Worldwide,Validated,[EXPERT]
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,United States,Validated,10844935[PMID]
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,United States,Not yet validated,10844935[PMID]
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.75,1-9 / 1 000 000,Value and class,United Kingdom,Validated,18410635[PMID]
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,United Kingdom,Validated,18410635[PMID]
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.57,1-9 / 1 000 000,Value and class,France,Validated,20700078[PMID]
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,France,Validated,20700078[PMID]
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.22,1-9 / 1 000 000,Value and class,Sweden,Validated,8645957[PMID]
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Sweden,Validated,8645957[PMID]
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Italy,Validated,18037347[PMID]
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Italy,Validated,18037347[PMID]
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Denmark,Validated,18708296[PMID]
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Denmark,Validated,18708296[PMID]
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.48,1-9 / 1 000 000,Value and class,Netherlands,Validated,18708296[PMID]
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Netherlands,Validated,18708296[PMID]
379,Chronic granulomatous disease,Disease,Point prevalence,0.08,<1 / 1 000 000,Value and class,Australia,Validated,9314356[PMID]
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.35,1-9 / 1 000 000,Value and class,Japan,Validated,10530081[PMID]
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Japan,Validated,10530081[PMID]
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.34,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,22787376[PMID]
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,"Korea, Republic of",Validated,22787376[PMID]
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.99,1-9 / 1 000 000,Value and class,Latin America,Validated,17191150[PMID]_ORPHANET
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Latin America,Validated,17191150[PMID]_ORPHANET
379,Chronic granulomatous disease,Disease,Prevalence at birth,0.53,1-9 / 1 000 000,Value and class,Israel,Validated,18708296[PMID]
379,Chronic granulomatous disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Israel,Validated,18708296[PMID]
16,Blue cone monochromatism,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,ISBN:9780521004398[OTHER]_[EXPERT]
16,Blue cone monochromatism,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,ISBN:9780521004398[OTHER]_[EXPERT]
644,NARP syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET
637,Full NF2-related schwannomatosis,Disease,Point prevalence,1.7,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
637,Full NF2-related schwannomatosis,Disease,Prevalence at birth,3.0,1-9 / 100 000,Value and class,United Kingdom,Validated,20082463[PMID]
637,Full NF2-related schwannomatosis,Disease,Point prevalence,1.78,1-9 / 100 000,Value and class,United Kingdom,Validated,20082463[PMID]
637,Full NF2-related schwannomatosis,Disease,Prevalence at birth,2.56,1-9 / 100 000,Value and class,Finland,Validated,25354145[PMID]
163696,Action myoclonus-renal failure syndrome,Disease,Cases/families,38.0,,Case(s),Worldwide,Validated,26677510[PMID]
163696,Action myoclonus-renal failure syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26677510[PMID]
181,X-linked hypohidrotic ectodermal dysplasia,Etiological subtype,Prevalence at birth,0.75,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
181,X-linked hypohidrotic ectodermal dysplasia,Etiological subtype,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,[EXPERT]_ORPHANET
181,X-linked hypohidrotic ectodermal dysplasia,Etiological subtype,Point prevalence,12.7,1-5 / 10 000,Value and class,Denmark,Not yet validated,23416623[PMID]_ORPHANET
163693,2p21 microdeletion syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,11524703[PMID]
163693,2p21 microdeletion syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11524703[PMID]
163690,Hypotonia-cystinuria syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
163690,Hypotonia-cystinuria syndrome,Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,23794250[PMID]
337,Fibrodysplasia ossificans progressiva,Disease,Point prevalence,0.05,<1 / 1 000 000,Value and class,Worldwide,Validated,22133093[PMID]_[EXPERT]
337,Fibrodysplasia ossificans progressiva,Disease,Point prevalence,0.061,<1 / 1 000 000,Value and class,United Kingdom,Validated,7069743[PMID]
337,Fibrodysplasia ossificans progressiva,Disease,Prevalence at birth,0.087,<1 / 1 000 000,Value and class,Spain,Validated,22796417[PMID]
337,Fibrodysplasia ossificans progressiva,Disease,Point prevalence,0.036,<1 / 1 000 000,Value and class,Spain,Validated,22796417[PMID]
337,Fibrodysplasia ossificans progressiva,Disease,Point prevalence,0.078,<1 / 1 000 000,Value and class,Europe,Validated,ORPHANET_22796417[PMID]_28666455[PMID]_7069743[PMID]
337,Fibrodysplasia ossificans progressiva,Disease,Point prevalence,0.136,1-9 / 1 000 000,Value and class,France,Validated,28666455[PMID]
337,Fibrodysplasia ossificans progressiva,Disease,Point prevalence,0.085,<1 / 1 000 000,Value and class,United States,Validated,34353327[PMID]
377,Gorlin syndrome,Malformation syndrome,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
377,Gorlin syndrome,Malformation syndrome,Prevalence at birth,5.3,1-9 / 100 000,Value and class,United Kingdom,Validated,20082463[PMID]
377,Gorlin syndrome,Malformation syndrome,Point prevalence,3.2,1-9 / 100 000,Value and class,United Kingdom,Validated,20082463[PMID]
377,Gorlin syndrome,Malformation syndrome,Point prevalence,0.39,1-9 / 1 000 000,Value and class,Italy,Validated,10066029[PMID]
377,Gorlin syndrome,Malformation syndrome,Point prevalence,0.61,1-9 / 1 000 000,Value and class,Australia,Validated,8042673[PMID]
377,Gorlin syndrome,Malformation syndrome,Point prevalence,0.007,<1 / 1 000 000,Value and class,"Korea, Republic of",Validated,15183409[PMID]
377,Gorlin syndrome,Malformation syndrome,Point prevalence,1.1,1-9 / 100 000,Value and class,Worldwide,Validated,24403894[PMID]_[EXPERT]
648,Noonan syndrome,Malformation syndrome,Prevalence at birth,70.0,6-9 / 10 000,Value and class,United States,Validated,3895929[PMID]_ORPHANET
648,Noonan syndrome,Malformation syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Worldwide,Validated,European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability[EXPERT]
281,Monosomy 5p syndrome,Malformation syndrome,Prevalence at birth,7.0,1-9 / 100 000,Value and class,Japan,Validated,2092586[PMID]
281,Monosomy 5p syndrome,Malformation syndrome,Prevalence at birth,2.22,1-9 / 100 000,Value and class,Denmark,Validated,365706[PMID]
281,Monosomy 5p syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
752,"46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency",Disease,Prevalence at birth,0.68,1-9 / 1 000 000,Value and class,Netherlands,Validated,10599740[PMID]
752,"46,XY difference of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency",Disease,Point prevalence,0.68,1-9 / 1 000 000,Value and class,Netherlands,Validated,ORPHANET
214,Cystinuria,Disease,Prevalence at birth,50.0,1-5 / 10 000,Value and class,United Kingdom,Validated,19096983[PMID]
214,Cystinuria,Disease,Prevalence at birth,8.0,1-9 / 100 000,Value and class,Canada,Validated,19096983[PMID]
214,Cystinuria,Disease,Prevalence at birth,5.5,1-9 / 100 000,Value and class,Japan,Validated,19096983[PMID]
214,Cystinuria,Disease,Point prevalence,40.0,1-5 / 10 000,Value and class,Specific population,Validated,[EXPERT]
214,Cystinuria,Disease,Point prevalence,14.0,1-5 / 10 000,Value and class,Worldwide,Validated,22480232[PMID]_[EXPERT]
214,Cystinuria,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Sweden,Validated,[EXPERT]
214,Cystinuria,Disease,Prevalence at birth,25.0,1-5 / 10 000,Value and class,Australia,Validated,19096983[PMID]
214,Cystinuria,Disease,Prevalence at birth,5.9,1-9 / 100 000,Value and class,United States,Validated,19096983[PMID]
214,Cystinuria,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
510,Lesch-Nyhan syndrome,Disease,Prevalence at birth,0.43,1-9 / 1 000 000,Value and class,Italy,Validated,11953730[PMID]
510,Lesch-Nyhan syndrome,Disease,Prevalence at birth,0.34,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
510,Lesch-Nyhan syndrome,Disease,Prevalence at birth,0.42,1-9 / 1 000 000,Value and class,Spain,Validated,18067674[PMID]
510,Lesch-Nyhan syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Spain,Not yet validated,18067674[PMID]
510,Lesch-Nyhan syndrome,Disease,Prevalence at birth,0.18,1-9 / 1 000 000,Value and class,Canada,Validated,4558815[PMID]
510,Lesch-Nyhan syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Canada,Not yet validated,4558815[PMID]
510,Lesch-Nyhan syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Italy,Validated,11953730[PMID]
510,Lesch-Nyhan syndrome,Disease,Prevalence at birth,0.18,1-9 / 1 000 000,Value and class,United Kingdom,Not yet validated,21152085[PMID]_21126241[PMID]
510,Lesch-Nyhan syndrome,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,United Kingdom,Validated,21152085[PMID]_21126241[PMID]
510,Lesch-Nyhan syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
524,Li-Fraumeni syndrome,Disease,Point prevalence,7.0,1-9 / 100 000,Value and class,United Kingdom,Validated,23939697[PMID]
524,Li-Fraumeni syndrome,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,United States,Validated,19556618[PMID]
524,Li-Fraumeni syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_30335319[PMID]
699,Pearson syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,33837965[PMID]_36820126[PMID]_ORPHANET
699,Pearson syndrome,Disease,Cases/families,194.0,,Case(s),Worldwide,Validated,33837965[PMID]_36820126[PMID]_ORPHANET
640,Hereditary neuropathy with liability to pressure palsies,Malformation syndrome,Point prevalence,3.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_24646194[PMID]
640,Hereditary neuropathy with liability to pressure palsies,Malformation syndrome,Point prevalence,16.0,1-5 / 10 000,Value and class,Finland,Validated,9447611[PMID]
60,Alpha-1-antitrypsin deficiency,Disease,Point prevalence,47.5,1-5 / 10 000,Value and class,Ireland,Validated,21752289[PMID]
60,Alpha-1-antitrypsin deficiency,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2016[INST]
60,Alpha-1-antitrypsin deficiency,Disease,Point prevalence,25.0,1-5 / 10 000,Value and class,Germany,Validated,18855308[PMID]
60,Alpha-1-antitrypsin deficiency,Disease,Prevalence at birth,17.0,1-5 / 10 000,Value and class,United States,Validated,10954251[PMID]_18565211[PMID]
60,Alpha-1-antitrypsin deficiency,Disease,Point prevalence,33.0,1-5 / 10 000,Value and class,Specific population,Validated,18565211[PMID]
60,Alpha-1-antitrypsin deficiency,Disease,Prevalence at birth,63.5,6-9 / 10 000,Value and class,Sweden,Validated,1083485[PMID]_18565211[PMID]
895,Waardenburg syndrome type 2,Clinical subtype,Cases/families,3.0,,Family(ies),Worldwide,Validated,9158138[PMID]_19938076[PMID]
895,Waardenburg syndrome type 2,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,9158138[PMID]_19938076[PMID]
896,Waardenburg syndrome type 3,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_Dr Véronique PINGAULT[EXPERT]
857,Townes-Brocks syndrome,Malformation syndrome,Prevalence at birth,0.42,1-9 / 1 000 000,Value and class,Spain,Validated,10083645[PMID]
857,Townes-Brocks syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
894,Waardenburg syndrome type 1,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
894,Waardenburg syndrome type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_Dr Véronique PINGAULT[EXPERT]
682,Hyperkalemic periodic paralysis,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,20301669[PMID]_[EXPERT]
682,Hyperkalemic periodic paralysis,Disease,Point prevalence,0.17,1-9 / 1 000 000,Value and class,United Kingdom,Validated,23516313[PMID]
682,Hyperkalemic periodic paralysis,Disease,Point prevalence,0.06,<1 / 1 000 000,Value and class,Netherlands,Validated,29606556[PMID]
800,Schwartz-Jampel syndrome,Disease,Cases/families,129.0,,Case(s),Worldwide,Validated,26436077[PMID]
800,Schwartz-Jampel syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26436077[PMID]
628,Diastrophic dysplasia,Disease,Point prevalence,1.2,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
628,Diastrophic dysplasia,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
628,Diastrophic dysplasia,Disease,Point prevalence,3.03,1-9 / 100 000,Value and class,Finland,Validated,1948373[PMID]
673,Malaria,Disease,Annual incidence,73.0,6-9 / 10 000,Value and class,Worldwide,Not yet validated,ORPHANET
673,Malaria,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency2015[INST]
673,Malaria,Disease,Annual incidence,12.0,1-5 / 10 000,Value and class,France,Not yet validated,ORPHANET
673,Malaria,Disease,Annual incidence,1.2,1-9 / 100 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,1.62,1-9 / 100 000,Value and class,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.75,1-9 / 1 000 000,Value and class,Iceland,Validated,European Centre for Disease prevention and Control 2016-2017[INST]
673,Malaria,Disease,Annual incidence,0.8,1-9 / 1 000 000,Value and class,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,2.1,1-9 / 100 000,Value and class,Belgium,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
673,Malaria,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.52,1-9 / 1 000 000,Value and class,Cyprus,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.32,1-9 / 1 000 000,Value and class,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,Estonia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.74,1-9 / 1 000 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.68,1-9 / 1 000 000,Value and class,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.14,1-9 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,1.7,1-9 / 100 000,Value and class,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.18,1-9 / 1 000 000,Value and class,Latvia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.84,1-9 / 1 000 000,Value and class,Luxembourg,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,1.54,1-9 / 100 000,Value and class,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,1.84,1-9 / 100 000,Value and class,Netherlands,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,Poland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,1.44,1-9 / 100 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,0.28,1-9 / 1 000 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,1.5,1-9 / 100 000,Value and class,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,1.88,1-9 / 100 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,2.38,1-9 / 100 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
673,Malaria,Disease,Annual incidence,1.62,1-9 / 100 000,Value and class,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
681,Hypokalemic periodic paralysis,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,20301512[PMID]_[EXPERT]
681,Hypokalemic periodic paralysis,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,United Kingdom,Validated,23516313[PMID]
681,Hypokalemic periodic paralysis,Disease,Point prevalence,0.53,1-9 / 1 000 000,Value and class,Netherlands,Validated,29606556[PMID]
126,Blepharophimosis-ptosis-epicanthus inversus syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
107,BOR syndrome,Malformation syndrome,Point prevalence,2.5,1-9 / 100 000,Value and class,Canada,Validated,7468659[PMID]_[EXPERT]
107,BOR syndrome,Malformation syndrome,Point prevalence,2.5,1-9 / 100 000,Value and class,Worldwide,Validated,7468659[PMID]_ORPHANET
774,Hereditary hemorrhagic telangiectasia,Disease,Point prevalence,16.0,1-5 / 10 000,Value and class,Europe,Validated,30111344[PMID]_[EXPERT]_European Medicines Agency 2018[INST]
774,Hereditary hemorrhagic telangiectasia,Disease,Point prevalence,43.5,1-5 / 10 000,Value and class,France,Validated,12157905[PMID]
774,Hereditary hemorrhagic telangiectasia,Disease,Point prevalence,2.5,1-9 / 100 000,Value and class,United Kingdom,Validated,1518020[PMID]
774,Hereditary hemorrhagic telangiectasia,Disease,Point prevalence,15.6,1-5 / 10 000,Value and class,Denmark,Validated,10095814[PMID]
774,Hereditary hemorrhagic telangiectasia,Disease,Point prevalence,16.25,1-5 / 10 000,Value and class,Japan,Validated,11793473[PMID]_ORPHANET
774,Hereditary hemorrhagic telangiectasia,Disease,Point prevalence,6.1,1-9 / 100 000,Value and class,United States,Validated,7802026[PMID]
774,Hereditary hemorrhagic telangiectasia,Disease,Point prevalence,19.4,1-5 / 10 000,Value and class,Specific population,Validated,8242961[PMID]
794,Saethre-Chotzen syndrome,Malformation syndrome,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Europe,Validated,15923834[PMID]_8988166[PMID]_[EXPERT]
794,Saethre-Chotzen syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,15923834[PMID]_[EXPERT]
794,Saethre-Chotzen syndrome,Malformation syndrome,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Australia,Validated,34626670[PMID]
710,Pfeiffer syndrome,Malformation syndrome,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,16740155[PMID]_[EXPERT]
710,Pfeiffer syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
710,Pfeiffer syndrome,Malformation syndrome,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Australia,Validated,34626670[PMID]
2869,Peutz-Jeghers syndrome,Disease,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Worldwide,Not yet validated,20301443[PMID]
2869,Peutz-Jeghers syndrome,Disease,Point prevalence,0.4,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
2869,Peutz-Jeghers syndrome,Disease,Prevalence at birth,0.65,1-9 / 1 000 000,Value and class,Uruguay,Validated,24260271[PMID]
893,WAGR syndrome,Malformation syndrome,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Worldwide,Validated,20301534[PMID]
893,WAGR syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
912,Zellweger syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
912,Zellweger syndrome,Disease,Point prevalence,8.2,1-9 / 100 000,Value and class,Specific population,Validated,22894767[PMID]_[EXPERT]
912,Zellweger syndrome,Disease,Prevalence at birth,4.6,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]
912,Zellweger syndrome,Disease,Prevalence at birth,8.2,1-9 / 100 000,Value and class,Specific population,Validated,33239050[PMID]
50,Aicardi syndrome,Disease,Prevalence at birth,1.07,1-9 / 100 000,Value and class,Netherlands,Validated,18182643[PMID]
50,Aicardi syndrome,Disease,Prevalence at birth,0.95,1-9 / 1 000 000,Value and class,United States,Validated,18182643[PMID]
50,Aicardi syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,United States,Not yet validated,18182643[PMID]
50,Aicardi syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
53,Albers-Schönberg osteopetrosis,Malformation syndrome,Point prevalence,1.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,20301306[PMID]
53,Albers-Schönberg osteopetrosis,Malformation syndrome,Point prevalence,5.5,1-9 / 100 000,Value and class,Denmark,Validated,3829443[PMID]
53,Albers-Schönberg osteopetrosis,Malformation syndrome,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Brazil,Validated,14496532[PMID]
53,Albers-Schönberg osteopetrosis,Malformation syndrome,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
14,Abetalipoproteinemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30358967[PMID]
14,Abetalipoproteinemia,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,30358967[PMID]
52,Alagille syndrome,Malformation syndrome,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Australia,Validated,559475[PMID]_[EXPERT]
52,Alagille syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Australia,Validated,559475[PMID]_[EXPERT]
52,Alagille syndrome,Malformation syndrome,Prevalence at birth,0.8,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
52,Alagille syndrome,Malformation syndrome,Prevalence at birth,2.7,1-9 / 100 000,Value and class,United States,Not yet validated,14684686[PMID]
52,Alagille syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
167,Chédiak-Higashi syndrome,Disease,Cases/families,500.0,,Case(s),Worldwide,Validated,23541537[PMID]_10527680[PMID]_18043242[PMID]
167,Chédiak-Higashi syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
195,Cat-eye syndrome,Malformation syndrome,Prevalence at birth,1.35,1-9 / 100 000,Value and class,Europe,Validated,17001329[PMID]_Dr Catherine TURLEAU[EXPERT]
195,Cat-eye syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_Dr Catherine TURLEAU[EXPERT]
207,Crouzon syndrome,Malformation syndrome,Prevalence at birth,0.9,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
207,Crouzon syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
207,Crouzon syndrome,Malformation syndrome,Point prevalence,1.65,1-9 / 100 000,Value and class,Canada,Validated,1633640[PMID]
207,Crouzon syndrome,Malformation syndrome,Prevalence at birth,2.6,1-9 / 100 000,Value and class,Australia,Validated,34626670[PMID]
205,Crigler-Najjar syndrome,Disease,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
205,Crigler-Najjar syndrome,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2014[INST]
160148,Cap polyposis,Disease,Cases/families,67.0,,Case(s),Worldwide,Validated,24949613[PMID]
160148,Cap polyposis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24949613[PMID]
201,Cowden syndrome,Disease,Point prevalence,0.45,1-9 / 1 000 000,Value and class,Netherlands,Validated,10234502[PMID]
201,Cowden syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,10234502[PMID]_35422633[PMID]_ORPHANET
192,Coffin-Lowry syndrome,Malformation syndrome,Point prevalence,1.5,1-9 / 100 000,Value and class,Worldwide,Not yet validated,19888300[PMID]
192,Coffin-Lowry syndrome,Malformation syndrome,Point prevalence,1.5,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET
2442,X-linked lymphoproliferative disease,Clinical group,Point prevalence,0.05,<1 / 1 000 000,Value and class,Europe,Validated,20301580[PMID]_[EXPERT]
2442,X-linked lymphoproliferative disease,Clinical group,Point prevalence,0.0347,<1 / 1 000 000,Value and class,China,Validated,34103049[PMID]
169802,Severe hemophilia A,Clinical subtype,Point prevalence,2.8,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
562,McCune-Albright syndrome,Disease,Point prevalence,0.55,1-9 / 1 000 000,Value and class,Europe,Validated,18489744[PMID]_[EXPERT]
565,Menkes disease,Disease,Prevalence at birth,0.33,1-9 / 1 000 000,Value and class,Europe,Not yet validated,1999344[PMID]
565,Menkes disease,Disease,Prevalence at birth,0.28,1-9 / 1 000 000,Value and class,Japan,Validated,15902550[PMID]
565,Menkes disease,Disease,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Australia,Validated,15902550[PMID]
565,Menkes disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2443,Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies,Category,Point prevalence,9.0,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
474,Jeune syndrome,Malformation syndrome,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
474,Jeune syndrome,Malformation syndrome,Prevalence at birth,0.89,1-9 / 1 000 000,Value and class,Australia,Not yet validated,931421[PMID]_ORPHANET
474,Jeune syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
540,Familial hemophagocytic lymphohistiocytosis,Disease,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Sweden,Validated,9561910[PMID]_[EXPERT]
540,Familial hemophagocytic lymphohistiocytosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
540,Familial hemophagocytic lymphohistiocytosis,Disease,Annual incidence,0.104,1-9 / 1 000 000,Value and class,China,Validated,34344437[PMID]
568,"Microphthalmia, Lenz type",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
564,Meckel syndrome,Malformation syndrome,Prevalence at birth,1.3,1-9 / 100 000,Value and class,France,Validated,22925539[PMID]
564,Meckel syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,France,Validated,22925539[PMID]
564,Meckel syndrome,Malformation syndrome,Prevalence at birth,11.0,1-5 / 10 000,Value and class,Finland,Validated,6486168[PMID]_[EXPERT]
564,Meckel syndrome,Malformation syndrome,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
564,Meckel syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,[EXPERT]
564,Meckel syndrome,Malformation syndrome,Prevalence at birth,2.6,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 1990-2011[REG]_25182137[PMID]
289,Ellis Van Creveld syndrome,Malformation syndrome,Prevalence at birth,500.0,>1 / 1000,Value and class,Specific population,Validated,10700162[PMID]
289,Ellis Van Creveld syndrome,Malformation syndrome,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
289,Ellis Van Creveld syndrome,Malformation syndrome,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Worldwide,Not yet validated,ISBN:9780313387135[OTHER]_ORPHANET
289,Ellis Van Creveld syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
258,Laminin subunit alpha 2-related congenital muscular dystrophy,Malformation syndrome,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
258,Laminin subunit alpha 2-related congenital muscular dystrophy,Malformation syndrome,Point prevalence,0.6,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
1247,Schistosomiasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,18445419[PMID]
1247,Schistosomiasis,Disease,Point prevalence,0.0,>1 / 1000,Class only,Africa,Not yet validated,ORPHANET
112,Bartter syndrome,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
112,Bartter syndrome,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Sweden,Validated,3421146[PMID]
112,Bartter syndrome,Disease,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Kuwait,Validated,10365582[PMID]
112,Bartter syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1646,Chromosome Y microdeletion syndrome,Malformation syndrome,Point prevalence,20.8,1-5 / 10 000,Value and class,Worldwide,Validated,ORPHANET_20301513[PMID]
1646,Chromosome Y microdeletion syndrome,Malformation syndrome,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
169464,Primary CD59 deficiency,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,23149847[PMID]_16631367[PMID]
169464,Primary CD59 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
99,Autosomal dominant cerebellar ataxia,Category,Point prevalence,2.7,1-9 / 100 000,Value and class,Worldwide,Validated,24603320[PMID]
99,Autosomal dominant cerebellar ataxia,Category,Point prevalence,3.0,1-9 / 100 000,Value and class,Netherlands,Validated,11889231[PMID]
99,Autosomal dominant cerebellar ataxia,Category,Point prevalence,0.9,1-9 / 1 000 000,Value and class,Italy,Validated,7793232[PMID]
99,Autosomal dominant cerebellar ataxia,Category,Point prevalence,5.6,1-9 / 100 000,Value and class,Portugal,Validated,23609960[PMID]
99,Autosomal dominant cerebellar ataxia,Category,Point prevalence,5.6,1-9 / 100 000,Value and class,Europe,Validated,23609960[PMID]
99,Autosomal dominant cerebellar ataxia,Category,Point prevalence,12.6,1-5 / 10 000,Value and class,Japan,Validated,19169038[PMID]
116,Beckwith-Wiedemann syndrome,Malformation syndrome,Prevalence at birth,3.5,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
116,Beckwith-Wiedemann syndrome,Malformation syndrome,Prevalence at birth,1.3,1-9 / 100 000,Value and class,Spain,Validated,10199027[PMID]
116,Beckwith-Wiedemann syndrome,Malformation syndrome,Prevalence at birth,5.25,1-9 / 100 000,Value and class,Japan,Validated,2092586[PMID]_7424972[PMID]_ORPHANET
116,Beckwith-Wiedemann syndrome,Malformation syndrome,Prevalence at birth,7.4,1-9 / 100 000,Value and class,Jamaica,Validated,5434588[PMID]
116,Beckwith-Wiedemann syndrome,Malformation syndrome,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Italy,Validated,23918458[PMID]
116,Beckwith-Wiedemann syndrome,Malformation syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
87,Apert syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
87,Apert syndrome,Malformation syndrome,Prevalence at birth,0.0,1-9 / 100 000,Class only,Worldwide,Validated,ORPHANET
87,Apert syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,ORPHANET
87,Apert syndrome,Malformation syndrome,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Spain,Validated,10666902[PMID]
87,Apert syndrome,Malformation syndrome,Point prevalence,1.1,1-9 / 100 000,Value and class,Spain,Validated,10666902[PMID]
87,Apert syndrome,Malformation syndrome,Prevalence at birth,1.2,1-9 / 100 000,Value and class,United States,Validated,9375719[PMID]
87,Apert syndrome,Malformation syndrome,Point prevalence,1.2,1-9 / 100 000,Value and class,United States,Validated,9375719[PMID]
87,Apert syndrome,Malformation syndrome,Prevalence at birth,1.47,1-9 / 100 000,Value and class,Canada,Validated,1303629[PMID]_1602157[PMID]
87,Apert syndrome,Malformation syndrome,Point prevalence,1.47,1-9 / 100 000,Value and class,Canada,Validated,1303629[PMID]_1602157[PMID]
87,Apert syndrome,Malformation syndrome,Prevalence at birth,1.6,1-9 / 100 000,Value and class,Australia,Validated,34626670[PMID]
97,Familial paroxysmal ataxia,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,United States,Not yet validated,20301674[PMID]
97,Familial paroxysmal ataxia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
313,Lamellar ichthyosis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,9887377[PMID]_22000705[PMID]_ORPHANET
313,Lamellar ichthyosis,Disease,Point prevalence,0.35,1-9 / 1 000 000,Value and class,Spain,Validated,22000705[PMID]
313,Lamellar ichthyosis,Disease,Point prevalence,1.1,1-9 / 100 000,Value and class,Norway,Validated,9887377[PMID]
169799,Mild hemophilia B,Clinical subtype,Point prevalence,0.6,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
169796,Moderate hemophilia B,Clinical subtype,Point prevalence,0.6,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
169793,Severe hemophilia B,Clinical subtype,Point prevalence,0.8,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
1000,Ocular albinism with late-onset sensorineural deafness,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,6542750[PMID]_10330347[PMID]
1000,Ocular albinism with late-onset sensorineural deafness,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10330347[PMID]
999,Ermine phenotype,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,3055988[PMID]_19449401[PMID]
999,Ermine phenotype,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3055988[PMID]_19449401[PMID]
171430,Severe congenital nemaline myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
171433,Intermediate nemaline myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
171436,Typical nemaline myopathy,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
171439,Childhood-onset nemaline myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
55,Oculocutaneous albinism,Clinical group,Point prevalence,5.9,1-9 / 100 000,Value and class,Worldwide,Validated,17980020[PMID]_[EXPERT]
55,Oculocutaneous albinism,Clinical group,Prevalence at birth,3.9,1-9 / 100 000,Value and class,Denmark,Validated,19060277[PMID]
55,Oculocutaneous albinism,Clinical group,Point prevalence,45.0,1-5 / 10 000,Value and class,South Africa,Validated,17620156[PMID]
171442,Adult-onset nemaline myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
171607,X-linked spastic paraplegia type 34,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,1084423[PMID]
171607,X-linked spastic paraplegia type 34,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1084423[PMID]
2771,Bruck syndrome,Malformation syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,25238597[PMID]
2771,Bruck syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25238597[PMID]
171612,Autosomal dominant spastic paraplegia type 37,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,17605047[PMID]
171612,Autosomal dominant spastic paraplegia type 37,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17605047[PMID]
171617,Autosomal dominant spastic paraplegia type 38,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,18401025[PMID]
171617,Autosomal dominant spastic paraplegia type 38,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18401025[PMID]
1349,Mitochondrial DNA-related cardiomyopathy and hearing loss,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,8651277[PMID]
1349,Mitochondrial DNA-related cardiomyopathy and hearing loss,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8651277[PMID]
171622,Autosomal recessive spastic paraplegia type 32,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,17515546[PMID]
171622,Autosomal recessive spastic paraplegia type 32,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17515546[PMID]
171629,Autosomal recessive spastic paraplegia type 35,Disease,Cases/families,38.0,,Case(s),Worldwide,Validated,24359114[PMID]
171629,Autosomal recessive spastic paraplegia type 35,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24359114[PMID]
861,Treacher-Collins syndrome,Malformation syndrome,Prevalence at birth,0.63,1-9 / 1 000 000,Value and class,France,Validated,22925539[PMID]
861,Treacher-Collins syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,France,Validated,22925539[PMID]
861,Treacher-Collins syndrome,Malformation syndrome,Prevalence at birth,6.9,1-9 / 100 000,Value and class,Japan,Validated,7424972[PMID]
861,Treacher-Collins syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Japan,Not yet validated,7424972[PMID]
861,Treacher-Collins syndrome,Malformation syndrome,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Europe,Validated,6024864[PMID]_14198411[PMID]_21131976[PMID]_[EXPERT]
861,Treacher-Collins syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,6024864[PMID]_14198411[PMID]_ [EXPERT]
308,Progressive myoclonic epilepsy type 1,Disease,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Finland,Validated,20301321[PMID]
308,Progressive myoclonic epilepsy type 1,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Finland,Validated,20301321[PMID]
1991,Cleft lip with or without cleft palate,Clinical group,Prevalence at birth,0.0,6-9 / 10 000,Class only,Worldwide,Validated,20507242[PMID]
1991,Cleft lip with or without cleft palate,Clinical group,Prevalence at birth,190.5,>1 / 1000,Value and class,Japan,Validated,22374000[PMID]
1991,Cleft lip with or without cleft palate,Clinical group,Prevalence at birth,77.5,6-9 / 10 000,Value and class,United States,Validated,22374000[PMID]
199,Cornelia de Lange syndrome,Malformation syndrome,Prevalence at birth,1.24,1-9 / 100 000,Value and class,Europe,Validated,18074387[PMID]
199,Cornelia de Lange syndrome,Malformation syndrome,Prevalence at birth,0.65,1-9 / 1 000 000,Value and class,France,Validated,22925539[PMID]
199,Cornelia de Lange syndrome,Malformation syndrome,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Denmark,Validated,961413[PMID]
2162,Holoprosencephaly,Malformation syndrome,Prevalence at birth,13.4,1-5 / 10 000,Value and class,Europe,Validated,20104599[PMID]_[EXPERT]_EUROCAT European surveillance of congenital anomalies[REG]
2162,Holoprosencephaly,Malformation syndrome,Prevalence at birth,5.5,1-9 / 100 000,Value and class,United States,Not yet validated,9409876[PMID]_ORPHANET
2162,Holoprosencephaly,Malformation syndrome,Prevalence at birth,21.6,1-5 / 10 000,Value and class,Latin America,Validated,17987642[PMID]
2162,Holoprosencephaly,Malformation syndrome,Prevalence at birth,15.0,1-5 / 10 000,Value and class,United Kingdom,Not yet validated,11349198[PMID]_17286306[PMID]_8818944[PMID]_ORPHANET
2162,Holoprosencephaly,Malformation syndrome,Prevalence at birth,60.6,6-9 / 10 000,Value and class,"Taiwan, Province of China",Validated,15844779[PMID]
2162,Holoprosencephaly,Malformation syndrome,Prevalence at birth,502.0,>1 / 1000,Value and class,Japan,Validated,15329827[PMID]
2162,Holoprosencephaly,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2162,Holoprosencephaly,Malformation syndrome,Prevalence at birth,10.9,1-5 / 10 000,Value and class,Specific population,Validated,10703035[PMID]
930,Idiopathic achalasia,Disease,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,23871090[PMID]
930,Idiopathic achalasia,Disease,Point prevalence,8.0,1-9 / 100 000,Value and class,Worldwide,Validated,11319059[PMID]
930,Idiopathic achalasia,Disease,Point prevalence,10.82,1-5 / 10 000,Value and class,Canada,Validated,20465592[PMID]
930,Idiopathic achalasia,Disease,Point prevalence,6.29,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,24753707[PMID]
930,Idiopathic achalasia,Disease,Point prevalence,13.5,1-5 / 10 000,Value and class,Ireland,Validated,3423207[PMID]
930,Idiopathic achalasia,Disease,Point prevalence,8.7,1-9 / 100 000,Value and class,Iceland,Validated,17420933[PMID]
930,Idiopathic achalasia,Disease,Point prevalence,1.8,1-9 / 100 000,Value and class,Singapore,Validated,10482430[PMID]
930,Idiopathic achalasia,Disease,Annual incidence,1.59,1-9 / 100 000,Value and class,Italy,Validated,21116729[PMID]
930,Idiopathic achalasia,Disease,Annual incidence,0.73,1-9 / 1 000 000,Value and class,Iceland,Validated,17420933[PMID]
930,Idiopathic achalasia,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Singapore,Validated,10482430[PMID]
930,Idiopathic achalasia,Disease,Annual incidence,0.39,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,24753707[PMID]
930,Idiopathic achalasia,Disease,Annual incidence,1.63,1-9 / 100 000,Value and class,Canada,Validated,20465592[PMID]
930,Idiopathic achalasia,Disease,Annual incidence,0.77,1-9 / 1 000 000,Value and class,Worldwide,Validated,11319059[PMID]
998,Albinism-deafness syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,14469778[PMID]
998,Albinism-deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14469778[PMID]
1727,22q11.2 duplication syndrome,Malformation syndrome,Cases/families,216.0,,Case(s),Worldwide,Validated,36735193[PMID]
1727,22q11.2 duplication syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,36735193[PMID]_ORPHANET
169079,Cernunnos-XLF deficiency,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,[EXPERT]
169079,Cernunnos-XLF deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1715,Trisomy 18p syndrome,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,26042156[PMID]
1715,Trisomy 18p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26042156[PMID]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,16.7,1-5 / 10 000,Value and class,Worldwide,Not yet validated,23088440[PMID]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,9.8,1-9 / 100 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2007[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,4.4,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,25.3,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,4.1,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,11.4,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,11.2,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,10.4,1-9 / 100 000,Value and class,Europe,Validated,22713804[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2009[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2009[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,5.8,1-9 / 100 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,8.9,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,5.8,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,48.2,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,4.4,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,9.5,1-9 / 100 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,1.9,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,24.6,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,13.0,1-5 / 10 000,Value and class,United Kingdom,Validated,20384468 [PMID]_ORPHANET
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,6.5,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,14.6,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,38.8,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,18.0,1-5 / 10 000,Value and class,Japan,Validated,2092586[PMID]
3380,Trisomy 18 syndrome,Malformation syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Japan,Validated,2092586[PMID]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,19.1,1-5 / 10 000,Value and class,United States,Not yet validated,ORPHANET_18348276[PMID]_20878909[PMID]
3380,Trisomy 18 syndrome,Malformation syndrome,Prevalence at birth,12.6,1-5 / 10 000,Value and class,Specific population,Validated,10627940[PMID]
168984,CLAPO syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,18798326[PMID]
168984,CLAPO syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18798326[PMID]
168999,Malignant melanoma of the mucosa,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,Europe,Validated,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
168999,Malignant melanoma of the mucosa,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
168999,Malignant melanoma of the mucosa,Disease,Lifetime Prevalence,1.5,1-9 / 100 000,Value and class,Europe,Validated,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
168999,Malignant melanoma of the mucosa,Disease,Annual incidence,0.32,1-9 / 1 000 000,Value and class,Belgium,Validated,Belgium Cancer registry[INST]
168999,Malignant melanoma of the mucosa,Disease,Annual incidence,0.23,1-9 / 1 000 000,Value and class,United States,Validated,National Cancer Institute[INST]_24272143[PMID]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,3.7,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2009[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,2.9,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,4.8,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2007[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,7.2,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,24.1,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,4.8,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,5.0,1-9 / 100 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,3.3,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,18.0,1-5 / 10 000,Value and class,Japan,Validated,2092586[PMID]_7424972[PMID]
3378,Trisomy 13 syndrome,Malformation syndrome,Point prevalence,15.9,1-5 / 10 000,Value and class,Japan,Not yet validated,2092586[PMID]_7424972[PMID]_ ORPHANET
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,12.6,1-5 / 10 000,Value and class,United States,Validated,20878909[PMID]_Center for Diseases Control and Prevention[INST]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,1.9,1-9 / 100 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,9.8,1-9 / 100 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,11.4,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,5.2,1-9 / 100 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Prevalence at birth,13.2,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2007[REG]
3378,Trisomy 13 syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
169100,Immunodeficiency due to CD25 deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,17196245[PMID]_9096364[PMID]
169100,Immunodeficiency due to CD25 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17196245[PMID]_9096364[PMID]
169105,Good syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20149753[PMID]
169105,Good syndrome,Disease,Cases/families,241.0,,Case(s),Worldwide,Validated,20149753[PMID]
169090,Combined immunodeficiency due to CRAC channel dysfunction,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
169090,Combined immunodeficiency due to CRAC channel dysfunction,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
236,Trisomy 9p syndrome,Malformation syndrome,Cases/families,150.0,,Case(s),Worldwide,Validated,25526829[PMID]
236,Trisomy 9p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25526829[PMID]
169095,Severe combined immunodeficiency due to FOXN1 deficiency,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,28077132[PMID]
169095,Severe combined immunodeficiency due to FOXN1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28077132[PMID]
169085,Susceptibility to respiratory infections associated with CD8alpha chain mutation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
168829,Primary peritoneal carcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
168816,Peritoneal inclusion cyst,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,[EXPERT]
168816,Peritoneal inclusion cyst,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
753,"46,XY difference of sex development due to 5-alpha-reductase 2 deficiency",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
868,Triose phosphate-isomerase deficiency,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,10916682[PMID]_[EXPERT]
868,Triose phosphate-isomerase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
168811,Malignant peritoneal mesothelioma,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,France,Validated,[EXPERT]
168811,Malignant peritoneal mesothelioma,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,European Medicines Agency 2016[INST]
168811,Malignant peritoneal mesothelioma,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Italy,Validated,[EXPERT]
218,Darier disease,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,United Kingdom,Validated,1390140[PMID]_11841374[PMID]
218,Darier disease,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Denmark,Validated,13835928[PMID]
218,Darier disease,Disease,Point prevalence,3.8,1-9 / 100 000,Value and class,Slovenia,Validated,16001099[PMID]
218,Darier disease,Disease,Point prevalence,3.4,1-9 / 100 000,Value and class,Europe,Validated,1390140[PMID]_11841374[PMID]_16001099[PMID]
218,Darier disease,Disease,Annual incidence,0.31,1-9 / 1 000 000,Value and class,Singapore,Validated,15727640[PMID]
168796,"Heart-hand syndrome, Slovenian type",Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,15996213[PMID]_27723096[PMID]
168796,"Heart-hand syndrome, Slovenian type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15996213[PMID]_27723096[PMID]
1465,Coffin-Siris syndrome,Malformation syndrome,Cases/families,190.0,,Case(s),Worldwide,Validated,22711679[PMID]_11170086[PMID]_23906836[PMID]_24092917[PMID]_23929686[PMID]
1465,Coffin-Siris syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
168782,Childhood disintegrative disorder,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
1642,Distal deletion 9p syndrome,Malformation syndrome,Cases/families,89.0,,Case(s),Worldwide,Validated,23824832[PMID]_24330994[PMID]
1642,Distal deletion 9p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23824832[PMID]_24330994[PMID]
168966,Composite lymphoma,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
168960,Refractory anemia with excess blasts in transformation,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
8,"47,XYY syndrome",Malformation syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Denmark,Not yet validated,20509956[PMID]
8,"47,XYY syndrome",Malformation syndrome,Prevalence at birth,50.0,1-5 / 10 000,Value and class,Europe,Not yet validated,22893477[PMID]
8,"47,XYY syndrome",Malformation syndrome,Prevalence at birth,14.1,1-5 / 10 000,Value and class,Denmark,Validated,20509956[PMID]
8,"47,XYY syndrome",Malformation syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,22893477[PMID]
168956,Hypereosinophilic syndrome,Clinical group,Annual incidence,0.027,<1 / 1 000 000,Value and class,United States,Validated,20639012[PMID]
168956,Hypereosinophilic syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
168956,Hypereosinophilic syndrome,Clinical group,Point prevalence,3.3,1-9 / 100 000,Value and class,United States,Validated,20639012[PMID]_[EXPERT]
168956,Hypereosinophilic syndrome,Clinical group,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1600,Monosomy 18q syndrome,Malformation syndrome,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Worldwide,Not yet validated,21977138[PMID]_1614460[PMID]
1600,Monosomy 18q syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1598,Monosomy 18p syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_[EXPERT]
1598,Monosomy 18p syndrome,Disease,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Europe,Validated,18284672[PMID]_[EXPERT]
2773,Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7515752[PMID]
2773,Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7515752[PMID]
2772,Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,728577[PMID]
2772,Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_728577[PMID]
2609,Isolated complex I deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_15190193[PMID]_20818732[PMID]
626,Large/giant congenital melanocytic nevus,Disease,Point prevalence,2.75,1-9 / 100 000,Value and class,Europe,Validated,21139903[PMID]_[EXPERT]_ ORPHANET
773,Refsum disease,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,20301527[PMID]_[EXPERT]
773,Refsum disease,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,ISBN 13:9789350901885[OTHER]_[EXPERT]
11,Pentasomy X syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
169154,T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency,Disease,Prevalence at birth,0.15,1-9 / 1 000 000,Value and class,Worldwide,Validated,14726805[PMID]
169154,T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
169154,T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency,Disease,Prevalence at birth,0.04,<1 / 1 000 000,Value and class,Chile,Validated,33861827[PMID]_ORPHANET
370,Glycogen storage disease due to phosphorylase kinase deficiency,Clinical group,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
370,Glycogen storage disease due to phosphorylase kinase deficiency,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
370,Glycogen storage disease due to phosphorylase kinase deficiency,Clinical group,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Israel,Validated,33239050[PMID]
370,Glycogen storage disease due to phosphorylase kinase deficiency,Clinical group,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Specific population,Validated,33239050[PMID]
169160,T-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zeta,Disease,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
169160,T-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zeta,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
385,Neurodegeneration with brain iron accumulation,Clinical group,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_European Medicines Agency 2018[INST]
169157,T-B+ severe combined immunodeficiency due to CD45 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9068311[PMID]_10700239[PMID]_22689986[PMID]
169157,T-B+ severe combined immunodeficiency due to CD45 deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,9068311[PMID]_10700239[PMID]_22689986[PMID]
1947,"Progressive epilepsy-intellectual disability syndrome, Finnish type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
352,Galactosemia,Category,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET
352,Galactosemia,Category,Annual incidence,2.1,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
352,Galactosemia,Category,Prevalence at birth,1.3,1-9 / 100 000,Value and class,United States,Validated,22766612[PMID]
352,Galactosemia,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
596,X-linked centronuclear myopathy,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,France,Validated,18817572[PMID]_[EXPERT]
596,X-linked centronuclear myopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
596,X-linked centronuclear myopathy,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
610,Bethlem muscular dystrophy,Disease,Point prevalence,0.77,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
610,Bethlem muscular dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
169186,Autosomal recessive centronuclear myopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
464,Incontinentia pigmenti,Malformation syndrome,Prevalence at birth,0.62,1-9 / 1 000 000,Value and class,United States,Validated,[EXPERT]_Texas Birth Defect Registry[REG]
464,Incontinentia pigmenti,Malformation syndrome,Prevalence at birth,1.2,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
464,Incontinentia pigmenti,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
3307,Tetrasomy 18p syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
169189,Autosomal dominant centronuclear myopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
44,Neonatal adrenoleukodystrophy,Disease,Prevalence at birth,1.2,1-9 / 100 000,Value and class,Italy,Validated,11953730[PMID]
44,Neonatal adrenoleukodystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
56,Alkaptonuria,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Worldwide,Validated,[EXPERT]
56,Alkaptonuria,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2003[INST]
56,Alkaptonuria,Disease,Prevalence at birth,0.15,1-9 / 1 000 000,Value and class,France,Validated,21927854[PMID]
56,Alkaptonuria,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,France,Not yet validated,21927854[PMID]
56,Alkaptonuria,Disease,Prevalence at birth,0.25,1-9 / 1 000 000,Value and class,United States,Not yet validated,20301627[PMID]
56,Alkaptonuria,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,United States,Not yet validated,20301627[PMID]
56,Alkaptonuria,Disease,Prevalence at birth,5.3,1-9 / 100 000,Value and class,Slovakia,Validated,12051967[PMID]
56,Alkaptonuria,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Slovakia,Validated,12051967[PMID]
963,Acromegaly,Disease,Annual incidence,0.47,1-9 / 1 000 000,Value and class,Worldwide,Validated,17893253[PMID]_26792654[PMID]_ORPHANET_[EXPERT]
963,Acromegaly,Disease,Point prevalence,3.6,1-9 / 100 000,Value and class,Spain,Validated,15476442[PMID]
963,Acromegaly,Disease,Point prevalence,9.7,1-9 / 100 000,Value and class,Italy,Validated,20621957[PMID]
963,Acromegaly,Disease,Point prevalence,8.6,1-9 / 100 000,Value and class,United Kingdom,Validated,19650784[PMID]
963,Acromegaly,Disease,Annual incidence,0.19,1-9 / 1 000 000,Value and class,Belgium,Validated,17893253[PMID]
963,Acromegaly,Disease,Point prevalence,12.0,1-5 / 10 000,Value and class,Belgium,Validated,[EXPERT]_17893253[PMID]
963,Acromegaly,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Ireland,Validated,2349750[PMID]
963,Acromegaly,Disease,Point prevalence,6.3,1-9 / 100 000,Value and class,Ireland,Validated,2349750[PMID]
963,Acromegaly,Disease,Annual incidence,0.34,1-9 / 1 000 000,Value and class,Finland,Validated,20534753[PMID]
963,Acromegaly,Disease,Annual incidence,0.39,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,22909047[PMID]
963,Acromegaly,Disease,Point prevalence,2.79,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,22909047[PMID]
963,Acromegaly,Disease,Annual incidence,0.77,1-9 / 1 000 000,Value and class,Iceland,Validated,25893613[PMID]
963,Acromegaly,Disease,Point prevalence,13.4,1-5 / 10 000,Value and class,Iceland,Validated,25893613[PMID]
963,Acromegaly,Disease,Point prevalence,7.8,1-9 / 100 000,Value and class,United States,Validated,26792654[PMID]
963,Acromegaly,Disease,Annual incidence,1.1,1-9 / 100 000,Value and class,United States,Validated,26792654[PMID]
963,Acromegaly,Disease,Point prevalence,8.5,1-9 / 100 000,Value and class,Denmark,Validated,27280374[PMID]
963,Acromegaly,Disease,Annual incidence,0.31,1-9 / 1 000 000,Value and class,Malta,Validated,23239049[PMID]
963,Acromegaly,Disease,Point prevalence,12.5,1-5 / 10 000,Value and class,Malta,Validated,23239049[PMID]
963,Acromegaly,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,Sweden,Validated,25084775[PMID]
963,Acromegaly,Disease,Annual incidence,0.38,1-9 / 1 000 000,Value and class,Denmark,Validated,27280374[PMID]
963,Acromegaly,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
1059,Blue rubber bleb nevus,Malformation syndrome,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
1059,Blue rubber bleb nevus,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1006,Alopecia antibody deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,978318[PMID]
1006,Alopecia antibody deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_978318[PMID]
1046,Lethal hemolytic anemia-genital anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7726230[PMID]
1046,Lethal hemolytic anemia-genital anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7726230[PMID]
22,Succinic semialdehyde dehydrogenase deficiency,Disease,Cases/families,450.0,,Case(s),Worldwide,Validated,20301374[PMID]
22,Succinic semialdehyde dehydrogenase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301374[PMID]
29,Mevalonic aciduria,Clinical subtype,Cases/families,30.0,,Case(s),Worldwide,Validated,16722536[PMID]
29,Mevalonic aciduria,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
245,Nager syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,ISBN:1437725562[OTHER]
245,Nager syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_ISBN:1437725562[OTHER]
245,Nager syndrome,Malformation syndrome,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Finland,Validated,17119427[PMID]
30,Hereditary orotic aciduria,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,25757096[PMID]
30,Hereditary orotic aciduria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25757096[PMID]
36,Acrocallosal syndrome,Malformation syndrome,Cases/families,38.0,,Case(s),Worldwide,Validated,22696705[PMID]
36,Acrocallosal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22696705[PMID]
915,Aarskog-Scott syndrome,Malformation syndrome,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
915,Aarskog-Scott syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2614,Nail-patella syndrome,Malformation syndrome,Point prevalence,2.2,1-9 / 100 000,Value and class,United Kingdom,Validated,10972657[PMID]
2614,Nail-patella syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Validated,10972657[PMID]_16825280[PMID]
2614,Nail-patella syndrome,Malformation syndrome,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
2614,Nail-patella syndrome,Malformation syndrome,Point prevalence,1.0,1-9 / 100 000,Value and class,Australia,Validated,16825280[PMID]
33,Isovaleric acidemia,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
33,Isovaleric acidemia,Disease,Prevalence at birth,1.55,1-9 / 100 000,Value and class,Germany,Not yet validated,12777559[PMID]_21335445[PMID]
33,Isovaleric acidemia,Disease,Prevalence at birth,0.28,1-9 / 1 000 000,Value and class,Australia,Validated,12788994[PMID]
33,Isovaleric acidemia,Disease,Prevalence at birth,0.63,1-9 / 1 000 000,Value and class,Italy,Validated,18956250[PMID]
33,Isovaleric acidemia,Disease,Prevalence at birth,0.53,1-9 / 1 000 000,Value and class,United States,Not yet validated,16601872[PMID]_16735252[PMID]_ ORPHANET
819,Smith-Magenis syndrome,Malformation syndrome,Prevalence at birth,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,17468296[PMID]
819,Smith-Magenis syndrome,Malformation syndrome,Point prevalence,4.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,17468296[PMID]
819,Smith-Magenis syndrome,Malformation syndrome,Point prevalence,5.35,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
819,Smith-Magenis syndrome,Malformation syndrome,Prevalence at birth,0.0,1-9 / 100 000,Class only,United States,Not yet validated,1746552[PMID]_16354942[PMID]
819,Smith-Magenis syndrome,Malformation syndrome,Point prevalence,5.35,1-9 / 100 000,Value and class,United States,Not yet validated,1746552[PMID]_16354942[PMID]_ ORPHANET
3085,Retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,8456839[PMID]_1251844[PMID]
3085,Retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8456839[PMID]_1251844[PMID]
9,Tetrasomy X syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,23494840[PMID]
9,Tetrasomy X syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23494840[PMID]
168615,Hereditary persistence of alpha-fetoprotein,Biological anomaly,Cases/families,19.0,,Family(ies),Worldwide,Validated,21116028[PMID]
168615,Hereditary persistence of alpha-fetoprotein,Biological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21116028[PMID]
168612,Congenital deficiency in alpha-fetoprotein,Biological anomaly,Cases/families,22.0,,Case(s),Worldwide,Validated,18854864[PMID]
168612,Congenital deficiency in alpha-fetoprotein,Biological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18854864[PMID]
1442,Ring chromosome 18 syndrome,Malformation syndrome,Cases/families,70.0,,Case(s),Worldwide,Validated,21333764[PMID]
1442,Ring chromosome 18 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
168621,"Dysplasia of head of femur, Meyer type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1452,Cleidocranial dysplasia,Malformation syndrome,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Worldwide,Validated,[EXPERT]
1452,Cleidocranial dysplasia,Malformation syndrome,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
1452,Cleidocranial dysplasia,Malformation syndrome,Prevalence at birth,1.2,1-9 / 100 000,Value and class,United States,Validated,22461456[PMID]_[EXPERT]
168624,"Familial scaphocephaly syndrome, McGillivray type",Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,16061565[PMID]
168624,"Familial scaphocephaly syndrome, McGillivray type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16061565[PMID]
193,Cohen syndrome,Malformation syndrome,Cases/families,200.0,,Case(s),Worldwide,Validated,[EXPERT]_20301655[PMID]
193,Cohen syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301655[PMID]
1488,Cooper-Jabs syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3572627[PMID]
1488,Cooper-Jabs syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3572627[PMID]
200,Isolated corpus callosum agenesis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,United States,Validated,ORPHANET
200,Isolated corpus callosum agenesis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Hungary,Validated,ORPHANET
200,Isolated corpus callosum agenesis,Morphological anomaly,Prevalence at birth,1.37,1-9 / 100 000,Value and class,United States,Validated,18642362[PMID]
200,Isolated corpus callosum agenesis,Morphological anomaly,Prevalence at birth,3.2,1-9 / 100 000,Value and class,Hungary,Validated,ORPHANET_21555052[PMID]
1334,Chronic mucocutaneous candidiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
168583,Hereditary North American Indian childhood cirrhosis,Clinical subtype,Cases/families,36.0,,Case(s),Worldwide,Validated,ORPHANET
168583,Hereditary North American Indian childhood cirrhosis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1369,Congenital cataract-hypertrophic cardiomyopathy-mitochondrial myopathy syndrome,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,22284826[PMID]
1369,Congenital cataract-hypertrophic cardiomyopathy-mitochondrial myopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
168577,Hereditary cryohydrocytosis with reduced stomatin,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,22492876[PMID]
168577,Hereditary cryohydrocytosis with reduced stomatin,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22492876[PMID]
168593,Sudden infant death-dysgenesis of the testes syndrome,Malformation syndrome,Cases/families,21.0,,Case(s),Worldwide,Validated,15273283[PMID]
168593,Sudden infant death-dysgenesis of the testes syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15273283[PMID]
1406,Charlie M syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_940017[PMID]
1406,Charlie M syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,940017[PMID]
168588,Hyperandrogenism due to cortisone reductase deficiency,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,ORPHANET
168588,Hyperandrogenism due to cortisone reductase deficiency,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1414,Cholestasis-lymphedema syndrome,Disease,Cases/families,47.0,,Case(s),Worldwide,Validated,25039919[PMID]
1414,Cholestasis-lymphedema syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25039919[PMID]
168598,Methionine adenosyltransferase I/III deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,8770875[PMID]
168598,Methionine adenosyltransferase I/III deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8770875[PMID]
168606,Seborrhea-like dermatitis with psoriasiform elements,Disease,Cases/families,44.0,,Case(s),Worldwide,Validated,ORPHANET
168606,Seborrhea-like dermatitis with psoriasiform elements,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
168549,Axial spondylometaphyseal dysplasia,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,26974433[PMID]
168549,Axial spondylometaphyseal dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26974433[PMID]
168552,Spondylometaphyseal dysplasia-bowed forearms-facial dysmorphism syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,12503112[PMID]
168552,Spondylometaphyseal dysplasia-bowed forearms-facial dysmorphism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12503112[PMID]
1154,Arthrogryposis-oculomotor limitation-electroretinal anomalies syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
168555,"Spondylometaphyseal dysplasia, A4 type",Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,9637426[PMID]_15517830[PMID]
168555,"Spondylometaphyseal dysplasia, A4 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9637426[PMID]_15517830[PMID]
168558,"46,XY difference of sex development-adrenal insufficiency due to CYP11A1 deficiency",Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,21880796[PMID]
168558,"46,XY difference of sex development-adrenal insufficiency due to CYP11A1 deficiency",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21880796[PMID]
168563,"46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome",Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,22209139[PMID]
168563,"46,XY gonadal dysgenesis-motor and sensory neuropathy syndrome",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22209139[PMID]
124,Diamond-Blackfan anemia,Disease,Prevalence at birth,0.67,1-9 / 1 000 000,Value and class,Europe,Validated,20824457[PMID]_[EXPERT]
124,Diamond-Blackfan anemia,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,United Kingdom,Validated,8826887[PMID]
124,Diamond-Blackfan anemia,Disease,Prevalence at birth,0.65,1-9 / 1 000 000,Value and class,Italy,Validated,10192448[PMID]
124,Diamond-Blackfan anemia,Disease,Prevalence at birth,0.75,1-9 / 1 000 000,Value and class,United States,Validated,18671700[PMID]
124,Diamond-Blackfan anemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
124,Diamond-Blackfan anemia,Disease,Point prevalence,0.194,1-9 / 1 000 000,Value and class,China,Validated,34103049[PMID]
168566,Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,25037205[PMID]
168566,Fatal mitochondrial disease due to combined oxidative phosphorylation defect type 3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25037205[PMID]
1310,Caffey disease,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1310,Caffey disease,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]_22855962[PMID]
168569,H syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,24172204[PMID]
168569,H syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24172204[PMID]
168572,Native American myopathy,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
125,Bloom syndrome,Disease,Prevalence at birth,2.08,1-9 / 100 000,Value and class,Specific population,Validated,10464606[PMID]_9758720[PMID]_10464671[PMID]
125,Bloom syndrome,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,20301572[PMID]
125,Bloom syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
90,Argininemia,Disease,Prevalence at birth,0.04,<1 / 1 000 000,Value and class,Finland,Validated,18616627[PMID]
90,Argininemia,Disease,Prevalence at birth,0.27,1-9 / 1 000 000,Value and class,United States,Validated,8794176[PMID]
90,Argininemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2016[INST]
168443,Spondyloepimetaphyseal dysplasia-hypotrichosis syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,2363424[PMID]
168443,Spondyloepimetaphyseal dysplasia-hypotrichosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2363424[PMID]
1065,Aniridia-cerebellar ataxia-intellectual disability syndrome,Malformation syndrome,Cases/families,22.0,,Family(ies),Worldwide,Validated,27108797[PMID]
1065,Aniridia-cerebellar ataxia-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27108797[PMID]
168451,Spondyloepimetaphyseal dysplasia-abnormal dentition syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,9018411[PMID]
168451,Spondyloepimetaphyseal dysplasia-abnormal dentition syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9018411[PMID]
168454,"Spondyloepimetaphyseal dysplasia, Geneviève type",Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,27213289[PMID]
168454,"Spondyloepimetaphyseal dysplasia, Geneviève type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27213289[PMID]
1146,Distal arthrogryposis type 1,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1143,Neurogenic arthrogryposis multiplex congenita,Disease,Prevalence at birth,4.3,1-9 / 100 000,Value and class,Europe,Not yet validated,23050160[PMID]_22005589[PMID]
1143,Neurogenic arthrogryposis multiplex congenita,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
168544,"Spondylometaphyseal dysplasia, Golden type",Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,Golden 1977[AUTHOR]
168544,"Spondylometaphyseal dysplasia, Golden type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1147,Sheldon-Hall syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
246,Postaxial acrofacial dysostosis,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
246,Postaxial acrofacial dysostosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1770,XY type gonadal dysgenesis-associated anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,6158563[PMID]
1770,XY type gonadal dysgenesis-associated anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6158563[PMID]
1775,Dyskeratosis congenita,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
1764,Familial dysautonomia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
1764,Familial dysautonomia,Disease,Prevalence at birth,18.5,1-5 / 10 000,Value and class,Specific population,Validated,27317387[PMID]_3652488[PMID]_4322121[PMID]_ORPHANET
235,Dubowitz syndrome,Malformation syndrome,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
235,Dubowitz syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
239,Dyggve-Melchior-Clausen disease,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
239,Dyggve-Melchior-Clausen disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
1672,Diencephalic syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
833,Encephalopathy due to sulfite oxidase deficiency,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
833,Encephalopathy due to sulfite oxidase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
167714,Unclassified acute myeloid leukemia,Category,Annual incidence,0.49,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
167635,Scleromyxedema,Disease,Cases/families,250.0,,Case(s),Worldwide,Validated,25814746[PMID]
167635,Scleromyxedema,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25814746[PMID]
765,Pyruvate dehydrogenase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
765,Pyruvate dehydrogenase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2015[INST]
395,Homocystinuria due to methylene tetrahydrofolate reductase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
408,Isolated glycerol kinase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
148,Multiple carboxylase deficiency,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
147,Carbamoyl-phosphate synthetase 1 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
147,Carbamoyl-phosphate synthetase 1 deficiency,Disease,Prevalence at birth,0.19,1-9 / 1 000 000,Value and class,Finland,Validated,18616627[PMID]
147,Carbamoyl-phosphate synthetase 1 deficiency,Disease,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Worldwide,Validated,20142522[PMID]_[EXPERT]
147,Carbamoyl-phosphate synthetase 1 deficiency,Disease,Prevalence at birth,0.077,<1 / 1 000 000,Value and class,United States,Validated,23972786[PMID]
147,Carbamoyl-phosphate synthetase 1 deficiency,Disease,Prevalence at birth,0.125,1-9 / 1 000 000,Value and class,Japan,Validated,2063931[PMID]
23,Argininosuccinic aciduria,Disease,Prevalence at birth,0.46,1-9 / 1 000 000,Value and class,United States,Validated,23972786[PMID]
23,Argininosuccinic aciduria,Disease,Prevalence at birth,0.69,1-9 / 1 000 000,Value and class,Finland,Validated,18616627[PMID]
23,Argininosuccinic aciduria,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2019[INST]_[EXPERT]
23,Argininosuccinic aciduria,Disease,Prevalence at birth,1.05,1-9 / 100 000,Value and class,Austria,Validated,20236848[PMID]
45,Adenosine monophosphate deaminase deficiency,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
45,Adenosine monophosphate deaminase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
226,Dihydropteridine reductase deficiency,Clinical subtype,Cases/families,150.0,,Case(s),Worldwide,Validated,14705166[PMID]
226,Dihydropteridine reductase deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
217,Isolated Dandy-Walker malformation,Morphological anomaly,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
217,Isolated Dandy-Walker malformation,Morphological anomaly,Point prevalence,2.1,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
1556,Cutis marmorata telangiectatica congenita,Malformation syndrome,Cases/families,300.0,,Case(s),Worldwide,Validated,ORPHANET
1556,Cutis marmorata telangiectatica congenita,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1538,Craniosynostosis-Dandy-Walker malformation-hydrocephalus syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,8266990[PMID]
1538,Craniosynostosis-Dandy-Walker malformation-hydrocephalus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8266990[PMID]
1496,Corpus callosum agenesis-neuronopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,20301546[PMID]
1496,Corpus callosum agenesis-neuronopathy syndrome,Disease,Point prevalence,47.0,1-5 / 10 000,Value and class,Specific population,Validated,20301546[PMID]
417,Neonatal severe primary hyperparathyroidism,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2233,Hypogonadism-mitral valve prolapse-intellectual disability syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,2502012[PMID]
2233,Hypogonadism-mitral valve prolapse-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2502012[PMID]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,18.0,1-5 / 10 000,Value and class,Worldwide,Not yet validated,27409588[PMID]_30661430[PMID]_2339046[PMID]_ORPHANET
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,16.2,1-5 / 10 000,Value and class,United States,Validated,2339046[PMID]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,15.1,1-5 / 10 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,49.1,1-5 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,29.1,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,56.8,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,21.3,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,11.8,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,23.8,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,19.9,1-5 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,18.1,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,9.9,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,49.8,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,5.8,1-9 / 100 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,16.4,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,9.2,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,5.5,1-9 / 100 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,12.5,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,16.6,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,22.3,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,1.9,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,8.0,1-9 / 100 000,Value and class,China,Validated,27409588[PMID]
2248,Hypoplastic left heart syndrome,Morphological anomaly,Prevalence at birth,11.6,1-5 / 10 000,Value and class,Sweden,Validated,30661430[PMID]
446,Neonatal hemochromatosis,Disease,Cases/families,35.0,,Case(s),Worldwide,Validated,21247995[PMID]_16237701[PMID]
446,Neonatal hemochromatosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2135,Cutaneous mastocytosis-deafness-microtia syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,19764024[PMID]
2135,Cutaneous mastocytosis-deafness-microtia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19764024[PMID]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,30.0,1-5 / 10 000,Value and class,Worldwide,Validated,8982563[PMID]_[EXPERT]_ ORPHANET
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,21.2,1-5 / 10 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,39.3,1-5 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,14.6,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,11.4,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,19.8,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,23.6,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,5.9,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,23.2,1-5 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,21.7,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,22.6,1-5 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,49.8,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,29.2,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,22.9,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,8.2,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,18.9,1-5 / 10 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,9.4,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,38.9,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,19.7,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,22.3,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Prevalence at birth,33.0,1-5 / 10 000,Value and class,United States,Validated,1290156[PMID]
2140,Congenital diaphragmatic hernia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2185,Congenital hydrocephalus,Malformation syndrome,Prevalence at birth,59.0,6-9 / 10 000,Value and class,United States,Validated,21763944[PMID]
2185,Congenital hydrocephalus,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2185,Congenital hydrocephalus,Malformation syndrome,Prevalence at birth,46.5,1-5 / 10 000,Value and class,Europe,Validated,19410489[PMID]
2116,Hartnup disease,Disease,Point prevalence,4.2,1-9 / 100 000,Value and class,Worldwide,Validated,ISBN:79130356[OTHER]_[EXPERT]
2116,Hartnup disease,Disease,Prevalence at birth,3.3,1-9 / 100 000,Value and class,Australia,Validated,ISBN:79130356[OTHER]
2116,Hartnup disease,Disease,Prevalence at birth,3.85,1-9 / 100 000,Value and class,United States,Validated,ISBN:79130356[OTHER]_17555458[PMID]
2116,Hartnup disease,Disease,Prevalence at birth,1.9,1-9 / 100 000,Value and class,Specific population,Validated,ISBN:79130356[OTHER]
2116,Hartnup disease,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,United Kingdom,Validated,909480[PMID]
2118,Hawkinsinuria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2118,Hawkinsinuria,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,11073718[PMID]
351,Galactosialidosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
351,Galactosialidosis,Disease,Prevalence at birth,0.14,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
351,Galactosialidosis,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,23915561[PMID]
2020,Congenital fiber-type disproportion myopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
2053,Freeman-Sheldon syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2053,Freeman-Sheldon syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,19309503[PMID]_[EXPERT]_23277889[PMID]
295,Fetal parvovirus syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1933,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria",Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,2738799[PMID]
1933,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2738799[PMID]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Point prevalence,1.25,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,3.5,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,7.8,1-9 / 100 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,19.5,1-5 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,3.1,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2007[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,16.5,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2005[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,18.2,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2005[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,11.6,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,3.6,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,4.1,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,24.1,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,5.7,1-9 / 100 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,27.2,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2006[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,3.5,1-9 / 100 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,6.5,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,4.7,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,20138303[PMID]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,6.0,1-9 / 100 000,Value and class,United States,Not yet validated,21465650[PMID]_19818453[PMID]_18657826[PMID]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,6.6,1-9 / 100 000,Value and class,Specific population,Validated,15535817[PMID]
1880,Ebstein malformation of the tricuspid valve,Morphological anomaly,Prevalence at birth,9.8,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
255,Dopa-responsive dystonia,Clinical group,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET
255,Dopa-responsive dystonia,Clinical group,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Worldwide,Validated,8420194[PMID]_19533203[PMID]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,1.6,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,9.8,1-9 / 100 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,5.8,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,14.8,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,8.1,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2006[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,1.6,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,13.2,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2007[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,1.9,1-9 / 100 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Point prevalence,6800.0,>1 / 1000,Value and class,South Africa,Validated,17127017[PMID]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,13.6,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,1.2,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Prevalence at birth,80.8,6-9 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1915,Fetal alcohol syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1885,Isolated ectopia lentis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1885,Isolated ectopia lentis,Malformation syndrome,Cases/families,90.0,,Case(s),Worldwide,Validated,[EXPERT]
1851,Multicystic dysplastic kidney,Morphological anomaly,Prevalence at birth,23.26,1-5 / 10 000,Value and class,Worldwide,Validated,19171687[PMID]
1851,Multicystic dysplastic kidney,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
660,Omphalocele,Morphological anomaly,Prevalence at birth,11.7,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,19.6,1-5 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,14.6,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,10.9,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,19.8,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,13.6,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,11.6,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,6.6,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,25.3,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,11.0,1-5 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,48.2,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,22.9,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,11.2,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,12.1,1-5 / 10 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,6.9,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,12.3,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,11.6,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,16.2,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
660,Omphalocele,Morphological anomaly,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Czech Republic,Validated,23116348[PMID]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Czech Republic,Not yet validated,23116348[PMID]
660,Omphalocele,Morphological anomaly,Prevalence at birth,6.3,1-9 / 100 000,Value and class,Japan,Validated,10646777[PMID]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Japan,Not yet validated,10646777[PMID]
660,Omphalocele,Morphological anomaly,Prevalence at birth,15.2,1-5 / 10 000,Value and class,China,Validated,15498248[PMID]
660,Omphalocele,Morphological anomaly,Prevalence at birth,18.6,1-5 / 10 000,Value and class,United States,Validated,Center for Diseases Control and Prevention 2010[INST]
660,Omphalocele,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,United States,Validated,Center for Diseases Control and Prevention 2010[INST]
635,Neuroblastoma,Disease,Point prevalence,11.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
635,Neuroblastoma,Disease,Prevalence at birth,5.8,1-9 / 100 000,Value and class,Europe,Not yet validated,16919772[PMID]
635,Neuroblastoma,Disease,Prevalence at birth,2.5,1-9 / 100 000,Value and class,United States,Validated,21108439[PMID]
635,Neuroblastoma,Disease,Prevalence at birth,14.0,1-5 / 10 000,Value and class,Germany,Validated,11932471[PMID]
635,Neuroblastoma,Disease,Annual incidence,1.26,1-9 / 100 000,Value and class,Worldwide,Not yet validated,22796286[PMID]
2612,Linear nevus sebaceus syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
2635,Metatropic dysplasia,Disease,Cases/families,81.0,,Case(s),Worldwide,Validated,ORPHANET_24223250[PMID]
2635,Metatropic dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2635,Metatropic dysplasia,Disease,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
2655,Thanatophoric dysplasia,Disease,Prevalence at birth,3.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
2655,Thanatophoric dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2655,Thanatophoric dysplasia,Disease,Prevalence at birth,2.8,1-9 / 100 000,Value and class,France,Validated,2785882[PMID]
2655,Thanatophoric dysplasia,Disease,Prevalence at birth,3.5,1-9 / 100 000,Value and class,Italy,Validated,3071354[PMID]
2655,Thanatophoric dysplasia,Disease,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Sweden,Validated,8449630[PMID]
2655,Thanatophoric dysplasia,Disease,Prevalence at birth,3.8,1-9 / 100 000,Value and class,Denmark,Validated,2783977[PMID]
2655,Thanatophoric dysplasia,Disease,Prevalence at birth,8.0,1-9 / 100 000,Value and class,Ireland,Validated,22375084[PMID]
2655,Thanatophoric dysplasia,Disease,Prevalence at birth,4.7,1-9 / 100 000,Value and class,Latin America,Validated,22407836[PMID]
2655,Thanatophoric dysplasia,Disease,Prevalence at birth,4.3,1-9 / 100 000,Value and class,United States,Validated,22461456[PMID]
606,Proximal myotonic myopathy,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Germany,Validated,12921797[PMID]_12970845[PMID]
606,Proximal myotonic myopathy,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
606,Proximal myotonic myopathy,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Finland,Validated,16684600[PMID]_22995693[PMID]
606,Proximal myotonic myopathy,Disease,Point prevalence,0.17,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
705,Pendred syndrome,Malformation syndrome,Point prevalence,7.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
2801,Juvenile Paget disease,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
2801,Juvenile Paget disease,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
884,Tetrasomy 12p syndrome,Malformation syndrome,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
884,Tetrasomy 12p syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
2785,Osteopetrosis with renal tubular acidosis,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
2785,Osteopetrosis with renal tubular acidosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2744,Horizontal gaze palsy with progressive scoliosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2746,Opsismodysplasia,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,23273569[PMID]
2746,Opsismodysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2971,Peroxisomal acyl-CoA oxidase deficiency,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,ORPHANET
2971,Peroxisomal acyl-CoA oxidase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2970,Prune belly syndrome,Malformation syndrome,Prevalence at birth,2.4,1-9 / 100 000,Value and class,Italy,Validated,22506933[PMID]_ORPHANET
2970,Prune belly syndrome,Malformation syndrome,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,United Kingdom,Not yet validated,8876090[PMID]_ORPHANET
2970,Prune belly syndrome,Malformation syndrome,Prevalence at birth,3.42,1-9 / 100 000,Value and class,Canada,Validated,6454342[PMID]
2970,Prune belly syndrome,Malformation syndrome,Prevalence at birth,3.8,1-9 / 100 000,Value and class,United States,Validated,20381841[PMID]
2970,Prune belly syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
744,Proteus syndrome,Malformation syndrome,Prevalence at birth,0.0,<1 / 1 000 000,Class only,Europe,Validated,21793738[PMID]_[EXPERT]
744,Proteus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,21793738[PMID]_[EXPERT]_European Medicines Agency 2018[INST]
2903,Familial spontaneous pneumothorax,Disease,Point prevalence,54.64,1-5 / 10 000,Value and class,Finland,Validated,22643181[PMID]_21364698[PMID]
2901,Neuralgic amyotrophy,Disease,Annual incidence,1.64,1-9 / 100 000,Value and class,United States,Validated,2996415[PMID]_[EXPERT]
2901,Neuralgic amyotrophy,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,[EXPERT]
2901,Neuralgic amyotrophy,Disease,Annual incidence,3.0,1-9 / 100 000,Value and class,United Kingdom,Validated,10733998[PMID]
2901,Neuralgic amyotrophy,Disease,Lifetime Prevalence,30.0,1-5 / 10 000,Value and class,United Kingdom,Validated,10733998[PMID]
718,Isolated Pierre Robin sequence,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,United Kingdom,Not yet validated,6626822[PMID]
718,Isolated Pierre Robin sequence,Malformation syndrome,Prevalence at birth,8.0,1-9 / 100 000,Value and class,France,Validated,22925539[PMID]
718,Isolated Pierre Robin sequence,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,France,Validated,22925539[PMID]
718,Isolated Pierre Robin sequence,Malformation syndrome,Prevalence at birth,12.4,1-5 / 10 000,Value and class,Germany,Validated,24433508[PMID]
718,Isolated Pierre Robin sequence,Malformation syndrome,Prevalence at birth,3.5,1-9 / 100 000,Value and class,Denmark,Validated,14697070[PMID]
718,Isolated Pierre Robin sequence,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Denmark,Not yet validated,14697070[PMID]
718,Isolated Pierre Robin sequence,Malformation syndrome,Prevalence at birth,4.5,1-9 / 100 000,Value and class,Sweden,Validated,8897214[PMID]
718,Isolated Pierre Robin sequence,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Sweden,Not yet validated,8897214[PMID]
718,Isolated Pierre Robin sequence,Malformation syndrome,Prevalence at birth,5.9,1-9 / 100 000,Value and class,United Kingdom,Validated,6626822[PMID]
718,Isolated Pierre Robin sequence,Malformation syndrome,Prevalence at birth,7.9,1-9 / 100 000,Value and class,United States,Not yet validated,ORPHANET
718,Isolated Pierre Robin sequence,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,United States,Not yet validated,ORPHANET
718,Isolated Pierre Robin sequence,Malformation syndrome,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
718,Isolated Pierre Robin sequence,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
718,Isolated Pierre Robin sequence,Malformation syndrome,Prevalence at birth,6.4,1-9 / 100 000,Value and class,Netherlands,Validated,25994858[PMID]
718,Isolated Pierre Robin sequence,Malformation syndrome,Prevalence at birth,18.8,1-5 / 10 000,Value and class,Australia,Validated,34626670[PMID]
290,Congenital rubella syndrome,Disease,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Worldwide,Validated,[EXPERT]_World Health Organization 2005[INST]
290,Congenital rubella syndrome,Disease,Prevalence at birth,0.29,1-9 / 1 000 000,Value and class,France,Validated,22178098[PMID]
290,Congenital rubella syndrome,Disease,Prevalence at birth,0.24,1-9 / 1 000 000,Value and class,Germany,Validated,22178098[PMID]
290,Congenital rubella syndrome,Disease,Prevalence at birth,0.8,1-9 / 1 000 000,Value and class,Italy,Validated,22178098[PMID]
290,Congenital rubella syndrome,Disease,Prevalence at birth,0.64,1-9 / 1 000 000,Value and class,Netherlands,Validated,22178098[PMID]
290,Congenital rubella syndrome,Disease,Prevalence at birth,0.27,1-9 / 1 000 000,Value and class,Austria,Validated,22178098[PMID]
290,Congenital rubella syndrome,Disease,Prevalence at birth,2.18,1-9 / 100 000,Value and class,Romania,Validated,22178098[PMID]
290,Congenital rubella syndrome,Disease,Prevalence at birth,0.22,1-9 / 1 000 000,Value and class,Spain,Validated,22178098[PMID]
290,Congenital rubella syndrome,Disease,Prevalence at birth,0.02,<1 / 1 000 000,Value and class,Turkey,Validated,22178098[PMID]
290,Congenital rubella syndrome,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,Europe,Not yet validated,22178098[PMID]
290,Congenital rubella syndrome,Disease,Prevalence at birth,0.35,1-9 / 1 000 000,Value and class,Europe,Not yet validated,22178098[PMID]
290,Congenital rubella syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3071,Costello syndrome,Malformation syndrome,Cases/families,300.0,,Case(s),Worldwide,Validated,20301680[PMID]
3071,Costello syndrome,Malformation syndrome,Point prevalence,0.08,<1 / 1 000 000,Value and class,Japan,Validated,22495831[PMID]
3071,Costello syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
763,Pycnodysostosis,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,21569238[PMID]
763,Pycnodysostosis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,[EXPERT]
2983,Difference of sex development-intellectual disability syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,2098045[PMID]_8031539[PMID]
2983,Difference of sex development-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2098045[PMID]_8031539[PMID]
2301,Congenital short bowel syndrome,Morphological anomaly,Cases/families,43.0,,Case(s),Worldwide,Validated,21042453[PMID]_22155368[PMID]_27352967[PMID]
2301,Congenital short bowel syndrome,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21042453[PMID]_22155368[PMID]
469,Hereditary fructose intolerance,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
469,Hereditary fructose intolerance,Disease,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Switzerland,Validated,15880727[PMID]
469,Hereditary fructose intolerance,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Switzerland,Validated,15880727[PMID]
469,Hereditary fructose intolerance,Disease,Prevalence at birth,5.0,1-9 / 100 000,Value and class,United Kingdom,Not yet validated,12042775[PMID]_15880727[PMID]_8933337[PMID]
469,Hereditary fructose intolerance,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,United Kingdom,Not yet validated,12042775[PMID]_15880727[PMID]_8933337[PMID]
469,Hereditary fructose intolerance,Disease,Prevalence at birth,3.8,1-9 / 100 000,Value and class,Germany,Validated,15880727[PMID]
469,Hereditary fructose intolerance,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Germany,Validated,15880727[PMID]
469,Hereditary fructose intolerance,Disease,Prevalence at birth,0.0,1-9 / 100 000,Class only,Poland,Not yet validated,16406649[PMID]
469,Hereditary fructose intolerance,Disease,Point prevalence,3.2,1-9 / 100 000,Value and class,Poland,Validated,16406649[PMID]
469,Hereditary fructose intolerance,Disease,Point prevalence,7.5,1-9 / 100 000,Value and class,Finland,Not yet validated,14565820[PMID]_ORPHANET
469,Hereditary fructose intolerance,Disease,Point prevalence,0.753,1-9 / 1 000 000,Value and class,United States,Validated,20033295[PMID]_36028839[PMID]
469,Hereditary fructose intolerance,Disease,Point prevalence,0.38,1-9 / 1 000 000,Value and class,Specific population,Validated,36028839[PMID]
469,Hereditary fructose intolerance,Disease,Point prevalence,0.1981,1-9 / 1 000 000,Value and class,China,Validated,36028839[PMID]
2308,Jacobsen syndrome,Malformation syndrome,Prevalence at birth,1.5,1-9 / 100 000,Value and class,United States,Validated,[EXPERT]_19267933[PMID]
2308,Jacobsen syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
2318,Joubert syndrome with oculorenal defect,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2318,Joubert syndrome with oculorenal defect,Malformation syndrome,Cases/families,17.0,,Case(s),Worldwide,Validated,23845172[PMID]
2253,Foveal hypoplasia-presenile cataract syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,ORPHANET
2253,Foveal hypoplasia-presenile cataract syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2300,Multiple intestinal atresia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,29437734[PMID]_ORPHANET
2300,Multiple intestinal atresia,Morphological anomaly,Prevalence at birth,4.05,1-9 / 100 000,Value and class,Worldwide,Validated,29437734[PMID]_ORPHANET
180226,Embryonal carcinoma,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
502,Trichorhinophalangeal syndrome type 2,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26269715[PMID]
502,Trichorhinophalangeal syndrome type 2,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,26269715[PMID]
180229,Polyembryoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2370,Larsen-like osseous dysplasia-short stature syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,12784294[PMID]_1916762[PMID]
2370,Larsen-like osseous dysplasia-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ 12784294[PMID]_1916762[PMID]
477,KID syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ISBN:0723436657[OTHER]
477,KID syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ISBN:0723436657[OTHER]
2346,Angioosteohypertrophic syndrome,Clinical group,Prevalence at birth,0.8,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2346,Angioosteohypertrophic syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
506,Leigh syndrome,Disease,Prevalence at birth,2.8,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
506,Leigh syndrome,Disease,Annual incidence,1.3,1-9 / 100 000,Value and class,Australia,Validated,8602753[PMID]
506,Leigh syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
506,Leigh syndrome,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2011[INST]
2414,Congenital pulmonary lymphangiectasia,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ISBN:019974808X[OTHER]
2414,Congenital pulmonary lymphangiectasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
180234,Mixed germ cell tumor,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2377,Laurence-Moon syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2374,Isolated congenital laryngeal web,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,33194889[PMID]_ORPHANET
180242,Malignant tumor of fallopian tubes,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2009[INST]
180242,Malignant tumor of fallopian tubes,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,United Kingdom,Validated,16263546[PMID]
180242,Malignant tumor of fallopian tubes,Disease,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Denmark,Validated,2706135[PMID]
180242,Malignant tumor of fallopian tubes,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,United States,Validated,18027113[PMID]
2466,MASA syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
180275,Paget disease of the nipple,Disease,Annual incidence,0.51,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.065,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.096,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.179,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.433,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.235,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.192,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.287,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.434,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.29,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.682,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.487,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.421,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.254,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.215,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.345,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.709,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.209,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.21,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.457,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.415,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.394,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.335,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
180275,Paget disease of the nipple,Disease,Annual incidence,0.637,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
560,Marshall syndrome,Malformation syndrome,Cases/families,17.0,,Case(s),Worldwide,Validated,17236192[PMID]_19449424[PMID]
560,Marshall syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17236192[PMID]_19449424[PMID]
570,Moebius syndrome,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,ORPHANET
570,Moebius syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
570,Moebius syndrome,Disease,Prevalence at birth,2.12,1-9 / 100 000,Value and class,Netherlands,Validated,12913192[PMID]
570,Moebius syndrome,Disease,Point prevalence,0.27,1-9 / 1 000 000,Value and class,Italy,Validated,33827605[PMID]
570,Moebius syndrome,Disease,Prevalence at birth,0.06,<1 / 1 000 000,Value and class,Italy,Validated,33827605[PMID]
1505,Short rib-polydactyly syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,8.2,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,2.9,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,17.7,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,5.9,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,7.2,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,17.1,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,4.9,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,3.8,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,12.3,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,18.1,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Prevalence at birth,3.2,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2444,Congenital pulmonary airway malformation,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
612,Potassium-aggravated myotonia,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,6.0,1-9 / 100 000,Value and class,France,Validated,11641035[PMID]_17616847[PMID]_[EXPERT]_Haute Autorité de Santé 2010[INST]
716,Phenylketonuria,Disease,Point prevalence,10.99,1-5 / 10 000,Value and class,France,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,11.4,1-5 / 10 000,Value and class,Europe,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Point prevalence,11.5079,1-5 / 10 000,Value and class,Europe,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,3.4,1-9 / 100 000,Value and class,United Kingdom,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,United Kingdom,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,22.0,1-5 / 10 000,Value and class,Ireland,Validated,9254847[PMID]_[EXPERT]
716,Phenylketonuria,Disease,Point prevalence,22.0,1-5 / 10 000,Value and class,Ireland,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Finland,Validated,8825928[PMID]_[EXPERT]
716,Phenylketonuria,Disease,Point prevalence,0.8928,1-9 / 1 000 000,Value and class,Finland,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,5.577,1-9 / 100 000,Value and class,United States,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,United States,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,9.8,1-9 / 100 000,Value and class,Latin America,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Point prevalence,3.5999,1-9 / 100 000,Value and class,Latin America,Validated,32668217[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,5.5,1-9 / 100 000,Value and class,Brazil,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Brazil,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,2.266,1-9 / 100 000,Value and class,Australia,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Point prevalence,8.89,1-9 / 100 000,Value and class,Australia,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,11.9,1-5 / 10 000,Value and class,Iceland,Validated,21659675[PMID]
716,Phenylketonuria,Disease,Point prevalence,11.9,1-5 / 10 000,Value and class,Iceland,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,1.16,1-9 / 100 000,Value and class,Japan,Not yet validated,6468444[PMID]_20971365[PMID]_ ORPHANET
716,Phenylketonuria,Disease,Point prevalence,0.8,1-9 / 1 000 000,Value and class,Japan,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,4.412,1-9 / 100 000,Value and class,China,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Point prevalence,6.2798,1-9 / 100 000,Value and class,China,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,2.68,1-9 / 100 000,Value and class,Thailand,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,0.4399,1-9 / 1 000 000,Value and class,Thailand,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,9.95,1-9 / 100 000,Value and class,Turkey,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Point prevalence,14.99,1-5 / 10 000,Value and class,Turkey,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,7.6,1-9 / 100 000,Value and class,United Arab Emirates,Validated,34082800[PMID]
716,Phenylketonuria,Disease,Point prevalence,6.89,1-9 / 100 000,Value and class,United Arab Emirates,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Jordan,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,2.6,1-9 / 100 000,Value and class,Jordan,Validated,DOI:10.1007/978-3-642-05080-0_11[OTHER]
716,Phenylketonuria,Disease,Point prevalence,5.4644,1-9 / 100 000,Value and class,India,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,2.439,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,0.862,1-9 / 1 000 000,Value and class,Philippines,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,1.2,1-9 / 100 000,Value and class,Singapore,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,1.6999,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,4.5,1-9 / 100 000,Value and class,Bahrain,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,"Iran, Islamic Republic of",Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,6.9998,1-9 / 100 000,Value and class,Iraq,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,15.603,1-5 / 10 000,Value and class,Israel,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,7.02,1-9 / 100 000,Value and class,Saudi Arabia,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Egypt,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,13.0005,1-5 / 10 000,Value and class,Tunisia,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,17.349,1-5 / 10 000,Value and class,Austria,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,13.0005,1-5 / 10 000,Value and class,Belarus,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Bosnia and Herzegovina,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,3.746,1-9 / 100 000,Value and class,Bulgaria,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,12.0004,1-5 / 10 000,Value and class,Croatia,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,7.6923,1-9 / 100 000,Value and class,Cyprus,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,19.1534,1-5 / 10 000,Value and class,Czech Republic,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,7.4437,1-9 / 100 000,Value and class,Denmark,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,13.9997,1-5 / 10 000,Value and class,Estonia,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,18.6567,1-5 / 10 000,Value and class,Germany,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,9.5969,1-9 / 100 000,Value and class,Greece,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,11.1111,1-5 / 10 000,Value and class,Hungary,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,25.0,1-5 / 10 000,Value and class,Italy,Validated,32668217[PMID]`
716,Phenylketonuria,Disease,Point prevalence,12.2399,1-5 / 10 000,Value and class,Latvia,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,10.7526,1-5 / 10 000,Value and class,Lithuania,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,13.5998,1-5 / 10 000,Value and class,"Moldova, Republic of",Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,8.661,1-9 / 100 000,Value and class,Netherlands,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,8.7282,1-9 / 100 000,Value and class,Norway,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,12.3051,1-5 / 10 000,Value and class,Poland,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,8.0,1-9 / 100 000,Value and class,Portugal,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Romania,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,12.9634,1-5 / 10 000,Value and class,Russian Federation,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,8.13,1-9 / 100 000,Value and class,Serbia,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,17.3822,1-5 / 10 000,Value and class,Slovakia,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,4.9,1-9 / 100 000,Value and class,Slovenia,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Point prevalence,9.8366,1-9 / 100 000,Value and class,Spain,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,7.8858,1-9 / 100 000,Value and class,Sweden,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,12.5,1-5 / 10 000,Value and class,Switzerland,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,14.0016,1-5 / 10 000,Value and class,Ukraine,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,6.6666,1-9 / 100 000,Value and class,Canada,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,6.2798,1-9 / 100 000,Value and class,New Caledonia,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,6.2798,1-9 / 100 000,Value and class,New Zealand,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,6.3633,1-9 / 100 000,Value and class,Argentina,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,5.1999,1-9 / 100 000,Value and class,Chile,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,2.0333,1-9 / 100 000,Value and class,Costa rica,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,3.5999,1-9 / 100 000,Value and class,Mexico,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,2.129,1-9 / 100 000,Value and class,Peru,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Cuba,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Point prevalence,4.1366,1-9 / 100 000,Value and class,Worldwide,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,13.34,1-5 / 10 000,Value and class,India,Validated,32668217[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,22.7,1-5 / 10 000,Value and class,Pakistan,Validated,32668217[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,6.8,1-9 / 100 000,Value and class,Saudi Arabia,Validated,34082800[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,8.75,1-9 / 100 000,Value and class,Austria,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,16.6,1-5 / 10 000,Value and class,Estonia,Validated,34082800[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,9.316,1-9 / 100 000,Value and class,Germany,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,4.25,1-9 / 100 000,Value and class,Greece,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,8.5,1-9 / 100 000,Value and class,Hungary,Validated,34082800[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,7.933,1-9 / 100 000,Value and class,Italy,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,24.6,1-5 / 10 000,Value and class,North Macedonia,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,7.85,1-9 / 100 000,Value and class,Poland,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,6.0,1-9 / 100 000,Value and class,Portugal,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,16.9,1-5 / 10 000,Value and class,Slovakia,Validated,34082800[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,6.6,1-9 / 100 000,Value and class,Spain,Validated,34082800[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,7.55,1-9 / 100 000,Value and class,Chile,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,7.271,1-9 / 100 000,Value and class,"Iran, Islamic Republic of",Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,5.5,1-9 / 100 000,Value and class,Canada,Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,5.1,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,34082800[PMID]
716,Phenylketonuria,Disease,Prevalence at birth,1.433,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,34082800[PMID]_ORPHANET
716,Phenylketonuria,Disease,Prevalence at birth,6.4,1-9 / 100 000,Value and class,Worldwide,Validated,34082800[PMID]
287,Classical Ehlers-Danlos syndrome,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Worldwide,Validated,20301422[PMID]_20847697[PMID]_[EXPERT]
1020,Early-onset autosomal dominant Alzheimer disease,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
63,Alport syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,[EXPERT]
63,Alport syndrome,Disease,Prevalence at birth,1.9,1-9 / 100 000,Value and class,Finland,Validated,8955456[PMID]
54,X-linked recessive ocular albinism,Disease,Prevalence at birth,0.58,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
54,X-linked recessive ocular albinism,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,[EXPERT]_ORPHANET
54,X-linked recessive ocular albinism,Disease,Prevalence at birth,0.84,1-9 / 1 000 000,Value and class,Denmark,Validated,9887374[PMID]_[EXPERT]
54,X-linked recessive ocular albinism,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Denmark,Validated,9887374[PMID]_[EXPERT]
54,X-linked recessive ocular albinism,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,United States,Validated,20301517[PMID]
54,X-linked recessive ocular albinism,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,United States,Not yet validated,20301517[PMID]
154,Familial isolated dilated cardiomyopathy,Disease,Annual incidence,2.91,1-9 / 100 000,Value and class,Europe,Validated,16839424[PMID]_[EXPERT]_ ORPHANET
154,Familial isolated dilated cardiomyopathy,Disease,Point prevalence,17.5,1-5 / 10 000,Value and class,Europe,Validated,16839424[PMID]_[EXPERT]_ ORPHANET
154,Familial isolated dilated cardiomyopathy,Disease,Annual incidence,6.0,1-9 / 100 000,Value and class,United States,Validated,2766509[PMID]
84,Fanconi anemia,Malformation syndrome,Point prevalence,3.3,1-9 / 100 000,Value and class,Specific population,Validated,7492758[PMID]
84,Fanconi anemia,Malformation syndrome,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,20824457[PMID]_European Medicines Agency 2018[INST]
84,Fanconi anemia,Malformation syndrome,Prevalence at birth,0.62,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
84,Fanconi anemia,Malformation syndrome,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Israel,Validated,20435624[PMID]
84,Fanconi anemia,Malformation syndrome,Point prevalence,2.5,1-9 / 100 000,Value and class,Specific population,Validated,11344308[PMID]
84,Fanconi anemia,Malformation syndrome,Point prevalence,2.5,1-9 / 100 000,Value and class,Specific population,Validated,15522956[PMID]
84,Fanconi anemia,Malformation syndrome,Point prevalence,0.111,1-9 / 1 000 000,Value and class,China,Validated,34103049[PMID]
70,Proximal spinal muscular atrophy,Disease,Annual incidence,2.6,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
70,Proximal spinal muscular atrophy,Disease,Prevalence at birth,20.0,1-5 / 10 000,Value and class,Europe,Not yet validated,23107878[PMID]
70,Proximal spinal muscular atrophy,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
69,Amyloidosis,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
69,Amyloidosis,Category,Point prevalence,1.91,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,28877709[PMID]
191,Cockayne syndrome,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
191,Cockayne syndrome,Disease,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
191,Cockayne syndrome,Disease,Prevalence at birth,0.09,<1 / 1 000 000,Value and class,Germany,Validated,18329345[PMID]
191,Cockayne syndrome,Disease,Prevalence at birth,0.18,1-9 / 1 000 000,Value and class,France,Validated,18329345[PMID]
191,Cockayne syndrome,Disease,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Italy,Validated,18329345[PMID]
191,Cockayne syndrome,Disease,Prevalence at birth,0.45,1-9 / 1 000 000,Value and class,Netherlands,Validated,18329345[PMID]
191,Cockayne syndrome,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,United Kingdom,Validated,18329345[PMID]
191,Cockayne syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Point prevalence,25.0,1-5 / 10 000,Value and class,Europe,Not yet validated,21820100[PMID]_20301532[PMID]_ ORPHANET
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Point prevalence,15.95,1-5 / 10 000,Value and class,United Kingdom,Not yet validated,21984771[PMID]_8026104[PMID]_ ORPHANET
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Point prevalence,61.0,6-9 / 10 000,Value and class,Norway,Not yet validated,20482598[PMID]_4430158[PMID]_ ORPHANET
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Point prevalence,28.2,1-5 / 10 000,Value and class,Spain,Validated,3472423[PMID]
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Point prevalence,17.5,1-5 / 10 000,Value and class,Italy,Validated,12207152[PMID]
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Point prevalence,19.55,1-5 / 10 000,Value and class,Sweden,Not yet validated,6576612[PMID]_8333247[PMID]_ ORPHANET
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Point prevalence,6.1,1-9 / 100 000,Value and class,Denmark,Validated,2096315[PMID]
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Point prevalence,12.0,1-5 / 10 000,Value and class,Iceland,Validated,19893324[PMID]
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Point prevalence,10.8,1-5 / 10 000,Value and class,Japan,Validated,12207153[PMID]
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Point prevalence,16.0,1-5 / 10 000,Value and class,Cyprus,Validated,20571287[PMID]
166,Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy,Category,Point prevalence,9.7,1-9 / 100 000,Value and class,Serbia,Validated,21546779[PMID]
834,Free sialic acid storage disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16584062[PMID]
834,Free sialic acid storage disease,Disease,Cases/families,130.0,,Case(s),Worldwide,Validated,16584062[PMID]
799,Schizencephaly,Disease,Prevalence at birth,1.48,1-9 / 100 000,Value and class,United Kingdom,Validated,21647999[PMID]
799,Schizencephaly,Disease,Prevalence at birth,1.54,1-9 / 100 000,Value and class,United States,Validated,16059942[PMID]
799,Schizencephaly,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
799,Schizencephaly,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Japan,Validated,26545857[PMID]
3151,Multiple sclerosis-ichthyosis-factor VIII deficiency syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,8336172[PMID]
3151,Multiple sclerosis-ichthyosis-factor VIII deficiency syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8336172[PMID]
178566,Mycosis fungoides and variants,Clinical group,Annual incidence,0.59,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET
178566,Mycosis fungoides and variants,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
813,Silver-Russell syndrome,Disease,Annual incidence,15.5,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
813,Silver-Russell syndrome,Disease,Prevalence at birth,0.0,1-9 / 100 000,Class only,United Kingdom,Not yet validated,16128241[PMID]
813,Silver-Russell syndrome,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,United Kingdom,Validated,16128241[PMID]
813,Silver-Russell syndrome,Disease,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
813,Silver-Russell syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,0.98,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Point prevalence,0.01,<1 / 1 000 000,Value and class,Worldwide,Not yet validated,ORPHANET
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,0.71,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
3169,Sirenomelia,Malformation syndrome,Point prevalence,0.009,<1 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,1.04,1-9 / 100 000,Value and class,France,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,0.62,1-9 / 1 000 000,Value and class,Italy,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,0.64,1-9 / 1 000 000,Value and class,Spain,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,0.54,1-9 / 1 000 000,Value and class,Netherlands,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Finland,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,0.31,1-9 / 1 000 000,Value and class,Slovakia,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,0.33,1-9 / 1 000 000,Value and class,Hungary,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,0.74,1-9 / 1 000 000,Value and class,United States,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,1.6,1-9 / 100 000,Value and class,Canada,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,0.83,1-9 / 1 000 000,Value and class,China,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,0.79,1-9 / 1 000 000,Value and class,Australia,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,2.36,1-9 / 100 000,Value and class,Mexico,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,1.36,1-9 / 100 000,Value and class,Latin America,Validated,22002878[PMID]
3169,Sirenomelia,Malformation syndrome,Prevalence at birth,12.0,1-5 / 10 000,Value and class,Colombia,Validated,22030798[PMID]
3169,Sirenomelia,Malformation syndrome,Point prevalence,0.98,1-9 / 1 000 000,Value and class,Brazil,Validated,35209917[PMID]
816,Sjögren-Larsson syndrome,Disease,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,Sweden,Validated,7273467[PMID]
816,Sjögren-Larsson syndrome,Disease,Point prevalence,16.0,1-5 / 10 000,Value and class,"Taiwan, Province of China",Validated,22899470[PMID]
816,Sjögren-Larsson syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
821,Sotos syndrome,Disease,Prevalence at birth,7.1,1-9 / 100 000,Value and class,Worldwide,Not yet validated,20301652[PMID]
821,Sotos syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,20301652[PMID]
821,Sotos syndrome,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
821,Sotos syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2005-2010[REG]
3173,Infantile spasms-broad thumbs syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,2335044[PMID]
3173,Infantile spasms-broad thumbs syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2335044[PMID]
3204,Stormorken-Sjaastad-Langslet syndrome,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,25044882[PMID]_25577287[PMID]
3204,Stormorken-Sjaastad-Langslet syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25044882[PMID]_25577287[PMID]
3205,Sturge-Weber syndrome,Malformation syndrome,Prevalence at birth,3.5,1-9 / 100 000,Value and class,Europe,Validated,24275166[PMID]
3205,Sturge-Weber syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
3320,Thrombocytopenia-absent radius syndrome,Malformation syndrome,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
3320,Thrombocytopenia-absent radius syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3346,Tracheal agenesis,Morphological anomaly,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET
3346,Tracheal agenesis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
858,Congenital toxoplasmosis,Disease,Prevalence at birth,33.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
858,Congenital toxoplasmosis,Disease,Prevalence at birth,30.0,1-5 / 10 000,Value and class,France,Validated,20587361[PMID]
858,Congenital toxoplasmosis,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Greece,Validated,23173875[PMID]
858,Congenital toxoplasmosis,Disease,Prevalence at birth,2.2,1-9 / 100 000,Value and class,United Kingdom,Validated,16547084[PMID]
858,Congenital toxoplasmosis,Disease,Prevalence at birth,7.3,1-9 / 100 000,Value and class,Sweden,Validated,11561964[PMID]
858,Congenital toxoplasmosis,Disease,Prevalence at birth,30.0,1-5 / 10 000,Value and class,Denmark,Validated,10359408[PMID]
858,Congenital toxoplasmosis,Disease,Prevalence at birth,50.0,1-5 / 10 000,Value and class,Switzerland,Validated,7597405[PMID]
858,Congenital toxoplasmosis,Disease,Prevalence at birth,130.0,>1 / 1000,Value and class,Germany,Validated,23173875[PMID]
858,Congenital toxoplasmosis,Disease,Prevalence at birth,113.0,>1 / 1000,Value and class,Poland,Validated,11326012[PMID]
858,Congenital toxoplasmosis,Disease,Prevalence at birth,40.0,1-5 / 10 000,Value and class,Brazil,Validated,22974376[PMID]
858,Congenital toxoplasmosis,Disease,Prevalence at birth,138.0,>1 / 1000,Value and class,Italy,Validated,19430667[PMID]
858,Congenital toxoplasmosis,Disease,Prevalence at birth,55.0,1-5 / 10 000,Value and class,United States,Validated,Center for Diseases Control and Prevention[INST]_ORPHANET
858,Congenital toxoplasmosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
858,Congenital toxoplasmosis,Disease,Prevalence at birth,640.0,>1 / 1000,Value and class,"Iran, Islamic Republic of",Validated,31096746[PMID]
887,VACTERL/VATER association,Malformation syndrome,Prevalence at birth,6.25,1-9 / 100 000,Value and class,Europe,Validated,21846383[PMID]_[EXPERT]_ ORPHANET
887,VACTERL/VATER association,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
291,Congenital varicella syndrome,Disease,Cases/families,130.0,,Case(s),Worldwide,Validated,26965725[PMID]
291,Congenital varicella syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26965725[PMID]
909,Cerebrotendinous xanthomatosis,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Specific population,Validated,16157755[PMID]_[EXPERT]
909,Cerebrotendinous xanthomatosis,Disease,Point prevalence,0.056,<1 / 1 000 000,Value and class,Spain,Validated,21645175[PMID]
909,Cerebrotendinous xanthomatosis,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,United States,Validated,16157755[PMID]
909,Cerebrotendinous xanthomatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3447,Weaver syndrome,Malformation syndrome,Cases/families,48.0,,Case(s),Worldwide,Validated,24214728[PMID]
3447,Weaver syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24214728[PMID]
1422,Chondrodysplasia-difference of sex development syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1342874[PMID]
1422,Chondrodysplasia-difference of sex development syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1342874[PMID]
178478,Infant botulism,Clinical subtype,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
178478,Infant botulism,Clinical subtype,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_Center for Diseases Control and Prevention[INST]_ ORPHANET
178478,Infant botulism,Clinical subtype,Prevalence at birth,2.1,1-9 / 100 000,Value and class,United States,Validated,[EXPERT]
178478,Infant botulism,Clinical subtype,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Argentina,Validated,[EXPERT]
178478,Infant botulism,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
178481,Intestinal botulism,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
178475,Wound botulism,Etiological subtype,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_Center for Diseases Control and Prevention[INST]_ ORPHANET
178475,Wound botulism,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
178461,X-linked myopathy with postural muscle atrophy,Disease,Cases/families,7.0,,Family(ies),Worldwide,Validated,19687455[PMID]
178461,X-linked myopathy with postural muscle atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19687455[PMID]
178464,Hereditary myopathy with early respiratory failure,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,10407851[PMID]_10053013[PMID]_2376753[PMID]
178464,Hereditary myopathy with early respiratory failure,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10407851[PMID]_10053013[PMID]_2376753[PMID]
178396,Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,19483159[PMID]
178396,Hemorrhagic disease due to alpha-1-antitrypsin Pittsburgh mutation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19483159[PMID]
178400,Distal myopathy with anterior tibial onset,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,11198284[PMID]
178400,Distal myopathy with anterior tibial onset,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11198284[PMID]
178382,Congenital vertical talus,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
178389,Osteopetrosis-hypogammaglobulinemia syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,18606301[PMID]
178389,Osteopetrosis-hypogammaglobulinemia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18606301[PMID]
62,Alpha-sarcoglycan-related limb-girdle muscular dystrophy R3,Disease,Point prevalence,0.07,<1 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
62,Alpha-sarcoglycan-related limb-girdle muscular dystrophy R3,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
178364,Syndromic microphthalmia type 5,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
178364,Syndromic microphthalmia type 5,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
715,Glycogen storage disease due to muscle phosphorylase kinase deficiency,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,[EXPERT]
715,Glycogen storage disease due to muscle phosphorylase kinase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
178377,Osteosclerosis-developmental delay-craniosynostosis syndrome,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,15940380[PMID]
178377,Osteosclerosis-developmental delay-craniosynostosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15940380[PMID]
348,"Fructose-1,6-bisphosphatase deficiency",Disease,Prevalence at birth,0.67,1-9 / 1 000 000,Value and class,Italy,Validated,11953730[PMID]
348,"Fructose-1,6-bisphosphatase deficiency",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
178345,Aromatase excess syndrome,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,24716396[PMID]
178345,Aromatase excess syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24716396[PMID]
178355,Smith-McCort dysplasia,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,23042644[PMID]_28127940[PMID]
178355,Smith-McCort dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28127940[PMID]
178338,UV-sensitive syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,19329487[PMID]_7264357[PMID]_9777763[PMID]_22466610[PMID]
178338,UV-sensitive syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19329487[PMID]_7264357[PMID]_9777763[PMID]_22466610[PMID]
3137,Alpha-N-acetylgalactosaminidase deficiency,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
3137,Alpha-N-acetylgalactosaminidase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
117,Behçet disease,Disease,Annual incidence,0.66,1-9 / 1 000 000,Value and class,Spain,Validated,10743812[PMID]
117,Behçet disease,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,Italy,Validated,17266063[PMID]
117,Behçet disease,Disease,Point prevalence,5.2,1-9 / 100 000,Value and class,United States,Validated,19405011[PMID]
117,Behçet disease,Disease,Annual incidence,0.58,1-9 / 1 000 000,Value and class,"Iran, Islamic Republic of",Validated,21199472[PMID]
117,Behçet disease,Disease,Point prevalence,7.1,1-9 / 100 000,Value and class,France,Validated,19035493[PMID]
117,Behçet disease,Disease,Point prevalence,3.8,1-9 / 100 000,Value and class,Italy,Validated,17266063[PMID]
117,Behçet disease,Disease,Point prevalence,11.1,1-5 / 10 000,Value and class,United Kingdom,Validated,36068543[PMID]
117,Behçet disease,Disease,Point prevalence,1.2,1-9 / 100 000,Value and class,Sweden,Validated,7904097[PMID]
117,Behçet disease,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Portugal,Validated,10519357[PMID]
117,Behçet disease,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Japan,Validated,19035493[PMID]_[EXPERT]
117,Behçet disease,Disease,Point prevalence,225.0,>1 / 1000,Value and class,Turkey,Validated,19035493[PMID]_[EXPERT]
117,Behçet disease,Disease,Point prevalence,16.7,1-5 / 10 000,Value and class,"Iran, Islamic Republic of",Validated,10519357[PMID]
117,Behçet disease,Disease,Point prevalence,15.2,1-5 / 10 000,Value and class,Israel,Validated,16897122[PMID]
117,Behçet disease,Disease,Point prevalence,1.4,1-9 / 100 000,Value and class,"Taiwan, Province of China",Not yet validated,22899470[PMID]
117,Behçet disease,Disease,Annual incidence,0.8,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,22899470[PMID]
117,Behçet disease,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Saudi Arabia,Validated,10519357[PMID]
117,Behçet disease,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
117,Behçet disease,Disease,Annual incidence,1.51,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,32770715[PMID]
732,Polymyositis,Disease,Annual incidence,0.585,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET
732,Polymyositis,Disease,Point prevalence,7.1,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
732,Polymyositis,Disease,Annual incidence,0.75,1-9 / 1 000 000,Value and class,Argentina,Validated,23965482[PMID]
732,Polymyositis,Disease,Point prevalence,7.2,1-9 / 100 000,Value and class,Argentina,Validated,23965482[PMID]
732,Polymyositis,Disease,Annual incidence,0.41,1-9 / 1 000 000,Value and class,Australia,Validated,23981756[PMID]
732,Polymyositis,Disease,Point prevalence,7.2,1-9 / 100 000,Value and class,Australia,Validated,23981756[PMID]
732,Polymyositis,Disease,Annual incidence,0.39,1-9 / 1 000 000,Value and class,Spain,Validated,18053482[PMID]
732,Polymyositis,Disease,Annual incidence,0.76,1-9 / 1 000 000,Value and class,Sweden,Validated,9137324[PMID]
221,Dermatomyositis,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Australia,Validated,23981756[PMID]
221,Dermatomyositis,Disease,Point prevalence,1.97,1-9 / 100 000,Value and class,Australia,Validated,23981756[PMID]
221,Dermatomyositis,Disease,Annual incidence,0.32,1-9 / 1 000 000,Value and class,Argentina,Validated,23965482[PMID]
221,Dermatomyositis,Disease,Point prevalence,10.2,1-5 / 10 000,Value and class,Argentina,Validated,23965482[PMID]
221,Dermatomyositis,Disease,Annual incidence,0.49,1-9 / 1 000 000,Value and class,Spain,Validated,18053482[PMID]
221,Dermatomyositis,Disease,Annual incidence,1.1,1-9 / 100 000,Value and class,United States,Validated,34549549[PMID]
221,Dermatomyositis,Disease,Point prevalence,13.0,1-5 / 10 000,Value and class,United States,Validated,34549549[PMID]
221,Dermatomyositis,Disease,Point prevalence,4.9172,1-9 / 100 000,Value and class,Norway,Validated,24695011[PMID]_ORPHANET
221,Dermatomyositis,Disease,Annual incidence,0.32,1-9 / 1 000 000,Value and class,Sweden,Validated,28160487[PMID]
221,Dermatomyositis,Disease,Point prevalence,3.8,1-9 / 100 000,Value and class,Sweden,Validated,28160487[PMID]
221,Dermatomyositis,Disease,Annual incidence,3.5,1-9 / 100 000,Value and class,Germany,Validated,36581896[PMID]
221,Dermatomyositis,Disease,Point prevalence,11.3,1-5 / 10 000,Value and class,Germany,Validated,36581896[PMID]
221,Dermatomyositis,Disease,Annual incidence,0.9704,1-9 / 100 000,Value and class,Worldwide,Validated,36581896[PMID]_ORPHANET
221,Dermatomyositis,Disease,Point prevalence,7.5312,1-9 / 100 000,Value and class,Worldwide,Validated,36581896[PMID]_ORPHANET
598,Multiminicore myopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.125,1-9 / 1 000 000,Value and class,Australia,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.0937,<1 / 1 000 000,Value and class,Australia,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.152,1-9 / 1 000 000,Value and class,Austria,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.114,1-9 / 1 000 000,Value and class,Austria,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.117,1-9 / 1 000 000,Value and class,Belgium,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.087,<1 / 1 000 000,Value and class,Belgium,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.105,1-9 / 1 000 000,Value and class,Canada,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.078,<1 / 1 000 000,Value and class,Canada,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Czech Republic,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.09,<1 / 1 000 000,Value and class,Czech Republic,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.104,1-9 / 1 000 000,Value and class,Cyprus,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.078,<1 / 1 000 000,Value and class,Cyprus,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.147,1-9 / 1 000 000,Value and class,Denmark,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.11,1-9 / 1 000 000,Value and class,Denmark,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.032,<1 / 1 000 000,Value and class,Estonia,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.024,<1 / 1 000 000,Value and class,Estonia,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.141,1-9 / 1 000 000,Value and class,Finland,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.105,1-9 / 1 000 000,Value and class,Finland,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,France,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.12,1-9 / 1 000 000,Value and class,France,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.133,1-9 / 1 000 000,Value and class,Germany,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.099,<1 / 1 000 000,Value and class,Germany,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.062,<1 / 1 000 000,Value and class,Greece,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.0465,<1 / 1 000 000,Value and class,Greece,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.0107,1-9 / 1 000 000,Value and class,Hungary,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.08,<1 / 1 000 000,Value and class,Hungary,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.142,1-9 / 1 000 000,Value and class,Italy,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.1065,1-9 / 1 000 000,Value and class,Italy,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.123,1-9 / 1 000 000,Value and class,Netherlands,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.092,<1 / 1 000 000,Value and class,Netherlands,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.102,1-9 / 1 000 000,Value and class,Norway,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.0765,<1 / 1 000 000,Value and class,Norway,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.0086,<1 / 1 000 000,Value and class,Slovakia,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.0645,<1 / 1 000 000,Value and class,Slovakia,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.146,1-9 / 1 000 000,Value and class,Slovenia,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.1095,1-9 / 1 000 000,Value and class,Slovenia,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.128,1-9 / 1 000 000,Value and class,Spain,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.096,<1 / 1 000 000,Value and class,Spain,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.142,1-9 / 1 000 000,Value and class,Sweden,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.1065,1-9 / 1 000 000,Value and class,Sweden,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.173,1-9 / 1 000 000,Value and class,Switzerland,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.129,1-9 / 1 000 000,Value and class,Switzerland,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.055,<1 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.041,<1 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.124,1-9 / 1 000 000,Value and class,United Kingdom,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.093,<1 / 1 000 000,Value and class,United Kingdom,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.122,1-9 / 1 000 000,Value and class,United States,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.0915,<1 / 1 000 000,Value and class,United States,Validated,31876504[PMID]
204,Sporadic Creutzfeldt-Jakob disease,Disease,Point prevalence,0.088,<1 / 1 000 000,Value and class,Worldwide,Validated,31876504[PMID]_ 32344417[PMID]_ORPHANET
204,Sporadic Creutzfeldt-Jakob disease,Disease,Annual incidence,0.118,1-9 / 1 000 000,Value and class,Worldwide,Validated,31876504[PMID]
178517,Localized pagetoid reticulosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
178512,Folliculotropic mycosis fungoides,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
178509,Perry syndrome,Disease,Cases/families,53.0,,Case(s),Worldwide,Validated,[EXPERT]
178509,Perry syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
178506,"Brain calcification, Rajab type",Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,19161147[PMID]
178506,"Brain calcification, Rajab type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19161147[PMID]
611,Inclusion body myositis,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
611,Inclusion body myositis,Disease,Annual incidence,2.5,1-9 / 1 000 000,Value and class,Sweden,Validated,35596584[PMID]
611,Inclusion body myositis,Disease,Point prevalence,0.49,1-9 / 1 000 000,Value and class,Netherlands,Validated,11087787[PMID]
611,Inclusion body myositis,Disease,Point prevalence,1.2,1-9 / 100 000,Value and class,Australia,Not yet validated,10842277[PMID]_18815046[PMID]_ ORPHANET
611,Inclusion body myositis,Disease,Point prevalence,1.1,1-9 / 100 000,Value and class,United States,Validated,11552086[PMID]
611,Inclusion body myositis,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Turkey,Validated,21842592[PMID]
611,Inclusion body myositis,Disease,Point prevalence,3.2,1-9 / 100 000,Value and class,Sweden,Validated,35596584[PMID]
178487,Adult intestinal botulism,Clinical subtype,Cases/families,19.0,,Case(s),Worldwide,Validated,[EXPERT]
178487,Adult intestinal botulism,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
177926,Bleeding disorder in hemophilia A carriers,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.21,1-9 / 1 000 000,Value and class,Brazil,Validated,PMID: 31926052
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.87,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,1.57,1-9 / 100 000,Value and class,Germany,Validated,16435194[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.84,1-9 / 1 000 000,Value and class,Portugal,Validated,14685153[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,1.89,1-9 / 100 000,Value and class,Netherlands,Validated,10480370[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,1.42,1-9 / 100 000,Value and class,Australia,Validated,9918480[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.91,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.84,1-9 / 1 000 000,Value and class,Sweden,Validated,18681890[PMID]_25274184[PMID]
581,Mucopolysaccharidosis type 3,Disease,Point prevalence,1.63,1-9 / 100 000,Value and class,Sweden,Validated,18681890[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.27,1-9 / 1 000 000,Value and class,Norway,Validated,18681890[PMID]
581,Mucopolysaccharidosis type 3,Disease,Point prevalence,0.88,1-9 / 1 000 000,Value and class,Norway,Validated,18681890[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.43,1-9 / 1 000 000,Value and class,Denmark,Validated,18681890[PMID]
581,Mucopolysaccharidosis type 3,Disease,Point prevalence,0.92,1-9 / 1 000 000,Value and class,Denmark,Validated,18681890[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.36,1-9 / 1 000 000,Value and class,Ireland,Validated,9439667[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.29,1-9 / 1 000 000,Value and class,Canada,Validated,10617747[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.39,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,19396827[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Tunisia,Validated,20209839[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
581,Mucopolysaccharidosis type 3,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.86,1-9 / 1 000 000,Value and class,Poland,Validated,25472774[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.26,1-9 / 1 000 000,Value and class,Japan,Validated,28595941[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Switzerland,Validated,28595941[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,1.8,1-9 / 100 000,Value and class,Saudi Arabia,Validated,20622343[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.25,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,25364648[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,1.62,1-9 / 100 000,Value and class,Estonia,Validated,22480138[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,2.4,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]_ORPHANET
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,4.8,1-9 / 100 000,Value and class,Specific population,Validated,33239050[PMID]_ORPHANET
581,Mucopolysaccharidosis type 3,Disease,Point prevalence,0.071,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
581,Mucopolysaccharidosis type 3,Disease,Prevalence at birth,0.26,1-9 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
177929,Bleeding disorder in hemophilia B carriers,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
685,Hereditary spastic paraplegia,Clinical group,Point prevalence,4.8,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET_2043954[PMID]_19339254[PMID]_19039240[PMID]_23609960[PMID]_1512613[PMID]
685,Hereditary spastic paraplegia,Clinical group,Point prevalence,9.6,1-9 / 100 000,Value and class,Spain,Validated,2043954[PMID]_24603320[PMID]
685,Hereditary spastic paraplegia,Clinical group,Point prevalence,4.1,1-9 / 100 000,Value and class,Portugal,Validated,23609960[PMID]_24603320[PMID]
685,Hereditary spastic paraplegia,Clinical group,Point prevalence,1.3,1-9 / 100 000,Value and class,Sweden,Not yet validated,ORPHANET
685,Hereditary spastic paraplegia,Clinical group,Point prevalence,4.2,1-9 / 100 000,Value and class,Worldwide,Validated,ORPHANET_24603320[PMID]
685,Hereditary spastic paraplegia,Clinical group,Point prevalence,5.75,1-9 / 100 000,Value and class,Tunisia,Validated,19438933[PMID]_24603320[PMID]
685,Hereditary spastic paraplegia,Clinical group,Point prevalence,7.4,1-9 / 100 000,Value and class,Norway,Validated,19339254[PMID]_24603320[PMID]
685,Hereditary spastic paraplegia,Clinical group,Point prevalence,2.7,1-9 / 100 000,Value and class,Italy,Validated,1512613[PMID]_3759416[PMID]_7793232[PMID]
685,Hereditary spastic paraplegia,Clinical group,Point prevalence,4.4,1-9 / 100 000,Value and class,Estonia,Validated,19039240[PMID]_24603320[PMID]
685,Hereditary spastic paraplegia,Clinical group,Point prevalence,2.1,1-9 / 100 000,Value and class,Libyan Arab Jamahiriya,Validated,4075075[PMID]_24603320[PMID]
666,Osteogenesis imperfecta,Disease,Point prevalence,8.06,1-5 / 10 000,Value and class,Worldwide,Validated,31769437[PMID]_25944380[PMID]_24715559[PMID]
666,Osteogenesis imperfecta,Disease,Prevalence at birth,6.4,1-9 / 100 000,Value and class,France,Validated,2785882[PMID]
666,Osteogenesis imperfecta,Disease,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Latin America,Validated,3746832[PMID]
666,Osteogenesis imperfecta,Disease,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Ireland,Validated,22375084[PMID]
666,Osteogenesis imperfecta,Disease,Prevalence at birth,6.95,1-9 / 100 000,Value and class,United States,Validated,22461456[PMID]_24715559[PMID]
666,Osteogenesis imperfecta,Disease,Prevalence at birth,7.4,1-9 / 100 000,Value and class,Sweden,Validated,25944380[PMID]
666,Osteogenesis imperfecta,Disease,Point prevalence,0.375,1-9 / 1 000 000,Value and class,China,Validated,34103049[PMID]
178029,Arginine vasopressin deficiency,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
423,Malignant hyperthermia of anesthesia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
418,Congenital adrenal hyperplasia,Clinical group,Annual incidence,13.35,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
418,Congenital adrenal hyperplasia,Clinical group,Point prevalence,10.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,6.7,1-9 / 100 000,Value and class,Europe,Not yet validated,15964450[PMID]_15554889[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,8.6,1-9 / 100 000,Value and class,France,Validated,10079883[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,6.65,1-9 / 100 000,Value and class,Italy,Not yet validated,8784357[PMID]_15818055[PMID]_ ORPHANET
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,12.8,1-5 / 10 000,Value and class,Germany,Validated,20148377[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,10.2,1-5 / 10 000,Value and class,Sweden,Validated,9521977[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,5.6,1-9 / 100 000,Value and class,United Kingdom,Not yet validated,22241917[PMID]_3259306[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,7.65,1-9 / 100 000,Value and class,Netherlands,Not yet validated,15554889[PMID]_11731654[PMID]_ ORPHANET
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Belgium,Validated,15554889[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,9.3,1-9 / 100 000,Value and class,Switzerland,Validated,12213856[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,5.35,1-9 / 100 000,Value and class,Japan,Not yet validated,23330248[PMID]_ORPHANET
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,6.9,1-9 / 100 000,Value and class,New Zealand,Validated,3259306[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,6.3,1-9 / 100 000,Value and class,Cuba,Validated,23481450[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,6.7,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,12517042[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,38.8,1-5 / 10 000,Value and class,India,Validated,15053381[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,4.8,1-9 / 100 000,Value and class,United States,Not yet validated,21641615[PMID]_15964450[PMID]_22766612[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Point prevalence,1.36,1-9 / 100 000,Value and class,China,Validated,34103049[PMID]
418,Congenital adrenal hyperplasia,Clinical group,Prevalence at birth,7.98,1-9 / 100 000,Value and class,Czech Republic,Validated,31241292[PMID]
216,Neuronal ceroid lipofuscinosis,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
216,Neuronal ceroid lipofuscinosis,Clinical group,Point prevalence,0.12,1-9 / 1 000 000,Value and class,Italy,Validated,23374165[PMID]
216,Neuronal ceroid lipofuscinosis,Clinical group,Annual incidence,0.98,1-9 / 1 000 000,Value and class,Italy,Validated,23374165[PMID]
216,Neuronal ceroid lipofuscinosis,Clinical group,Prevalence at birth,0.56,1-9 / 1 000 000,Value and class,Italy,Validated,7668318[PMID]
216,Neuronal ceroid lipofuscinosis,Clinical group,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Norway,Validated,17092455[PMID]
216,Neuronal ceroid lipofuscinosis,Clinical group,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
364,Glycogen storage disease due to glucose-6-phosphatase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
364,Glycogen storage disease due to glucose-6-phosphatase deficiency,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,21599942[PMID]_[EXPERT]
355,Gaucher disease,Disease,Annual incidence,1.7,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
355,Gaucher disease,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
355,Gaucher disease,Disease,Prevalence at birth,1.3,1-9 / 100 000,Value and class,Worldwide,Not yet validated,23046562[PMID]
355,Gaucher disease,Disease,Point prevalence,0.67,1-9 / 1 000 000,Value and class,Spain,Validated,22429443[PMID]
355,Gaucher disease,Disease,Prevalence at birth,5.7,1-9 / 100 000,Value and class,Austria,Validated,22133539[PMID]
355,Gaucher disease,Disease,Annual incidence,2.6,1-9 / 100 000,Value and class,France,Validated,23046562[PMID]
355,Gaucher disease,Disease,Prevalence at birth,2.0,1-9 / 100 000,Value and class,France,Validated,23046562[PMID]
355,Gaucher disease,Disease,Point prevalence,0.74,1-9 / 1 000 000,Value and class,France,Validated,23046562[PMID]
355,Gaucher disease,Disease,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Australia,Validated,9918480[PMID]
355,Gaucher disease,Disease,Prevalence at birth,1.13,1-9 / 100 000,Value and class,Czech Republic,Validated,20490927[PMID]
355,Gaucher disease,Disease,Prevalence at birth,1.35,1-9 / 100 000,Value and class,Portugal,Validated,14685153[PMID]
355,Gaucher disease,Disease,Prevalence at birth,1.16,1-9 / 100 000,Value and class,Netherlands,Validated,10480370[PMID]
355,Gaucher disease,Disease,Prevalence at birth,7.5,1-9 / 100 000,Value and class,Hungary,Validated,23430949[PMID]
355,Gaucher disease,Disease,Prevalence at birth,0.45,1-9 / 1 000 000,Value and class,Turkey,Validated,15275696[PMID]
355,Gaucher disease,Disease,Prevalence at birth,2.11,1-9 / 100 000,Value and class,Sweden,Validated,25274184[PMID]
355,Gaucher disease,Disease,Point prevalence,0.224,1-9 / 1 000 000,Value and class,China,Validated,34103049[PMID]
388,Hirschsprung disease,Disease,Prevalence at birth,13.2,1-5 / 10 000,Value and class,Europe,Validated,25066220[PMID]_Eurocat
388,Hirschsprung disease,Disease,Prevalence at birth,21.0,1-5 / 10 000,Value and class,United States,Validated,27702942[PMID]
388,Hirschsprung disease,Disease,Point prevalence,13.2,1-5 / 10 000,Value and class,Europe,Validated,25066220[PMID]_ORPHANET
388,Hirschsprung disease,Disease,Point prevalence,15.0,1-5 / 10 000,Value and class,Worldwide,Validated,31644668[PMID]_27702942[PMID]_ORPHANET
388,Hirschsprung disease,Disease,Prevalence at birth,22.0,1-5 / 10 000,Value and class,"Taiwan, Province of China",Validated,27118113[PMID]
388,Hirschsprung disease,Disease,Prevalence at birth,15.0,1-5 / 10 000,Value and class,Worldwide,Validated,31644668[PMID]_27702942[PMID]
177107,Syndromic hypothyroidism,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
448,Hemophilia,Clinical group,Annual incidence,6.25,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
448,Hemophilia,Clinical group,Point prevalence,7.7,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
448,Hemophilia,Clinical group,Point prevalence,6.46,1-9 / 100 000,Value and class,China,Validated,34103049[PMID]
304,Epidermolysis bullosa simplex,Clinical group,Point prevalence,0.656,1-9 / 1 000 000,Value and class,Worldwide,Validated,20566927[PMID]_ 25201089[PMID]_ 33095945[PMID]
304,Epidermolysis bullosa simplex,Clinical group,Point prevalence,0.58,1-9 / 1 000 000,Value and class,Australia,Validated,20566927[PMID]
304,Epidermolysis bullosa simplex,Clinical group,Point prevalence,1.19,1-9 / 100 000,Value and class,Netherlands,Validated,33095945[PMID]
304,Epidermolysis bullosa simplex,Clinical group,Point prevalence,0.197,1-9 / 1 000 000,Value and class,Romania,Validated,25201089[PMID]
354,GM1 gangliosidosis,Disease,Prevalence at birth,0.75,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET
354,GM1 gangliosidosis,Disease,Prevalence at birth,27.0,1-5 / 10 000,Value and class,Malta,Validated,9323577[PMID]_[EXPERT]
354,GM1 gangliosidosis,Disease,Prevalence at birth,5.9,1-9 / 100 000,Value and class,Brazil,Validated,10517258[PMID]_[EXPERT]
354,GM1 gangliosidosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
354,GM1 gangliosidosis,Disease,Prevalence at birth,0.34,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
178320,Acute lung injury,Particular clinical situation in a disease or syndrome,Annual incidence,25.0,1-5 / 10 000,Value and class,Europe,Not yet validated,15659944[PMID]_15166842[PMID]
178320,Acute lung injury,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,European Medicines Agency 2012[INST]
178320,Acute lung injury,Particular clinical situation in a disease or syndrome,Annual incidence,25.0,1-5 / 10 000,Value and class,Australia,Not yet validated,15659944[PMID]_15166842[PMID]
178320,Acute lung injury,Particular clinical situation in a disease or syndrome,Annual incidence,65.0,6-9 / 10 000,Value and class,United States,Not yet validated,15659944[PMID]_20073554[PMID]_9468178[PMID]
178333,Åland Islands eye disease,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,17525176[PMID]
178333,Åland Islands eye disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
760,Purine nucleoside phosphorylase deficiency,Disease,Cases/families,72.0,,Case(s),Worldwide,Validated,30885031[PMID]
760,Purine nucleoside phosphorylase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET_30885031[PMID]
270,Oculopharyngeal muscular dystrophy,Disease,Point prevalence,167.0,>1 / 1000,Value and class,Specific population,Validated,9392014[PMID]
270,Oculopharyngeal muscular dystrophy,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,France,Validated,9392013[PMID]_2204987[PMID]
270,Oculopharyngeal muscular dystrophy,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET
270,Oculopharyngeal muscular dystrophy,Disease,Point prevalence,100.0,>1 / 1000,Value and class,Specific population,Validated,7795598[PMID]
178303,8q22.1 microdeletion syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,22821852[PMID]
178303,8q22.1 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
244,Primary ciliary dyskinesia,Disease,Point prevalence,44.0,1-5 / 10 000,Value and class,Pakistan,Validated,19720631[PMID]
244,Primary ciliary dyskinesia,Disease,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Europe,Validated,23871404[PMID]
178307,Reticulate acropigmentation of Kitamura,Disease,Cases/families,130.0,,Case(s),Worldwide,Validated,23666529[PMID]
178307,Reticulate acropigmentation of Kitamura,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
589,Myasthenia gravis,Disease,Annual incidence,1.7,1-9 / 100 000,Value and class,Europe,Validated,20130418[PMID]_[EXPERT]_ ORPHANET
589,Myasthenia gravis,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,17986328[PMID]_[EXPERT]_European Medicines Agency 2018[INST]
589,Myasthenia gravis,Disease,Point prevalence,7.77,1-9 / 100 000,Value and class,Worldwide,Validated,20565885[PMID]
589,Myasthenia gravis,Disease,Annual incidence,0.9,1-9 / 1 000 000,Value and class,United States,Validated,8909435[PMID]
589,Myasthenia gravis,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Canada,Validated,14664466[PMID]
589,Myasthenia gravis,Disease,Annual incidence,2.1,1-9 / 100 000,Value and class,Spain,Validated,12654975[PMID]
589,Myasthenia gravis,Disease,Lifetime Prevalence,40.0,1-5 / 10 000,Value and class,United Kingdom,Validated,10733998[PMID]
589,Myasthenia gravis,Disease,Annual incidence,1.11,1-9 / 100 000,Value and class,United Kingdom,Validated,9771771[PMID]
589,Myasthenia gravis,Disease,Point prevalence,15.0,1-5 / 10 000,Value and class,United Kingdom,Validated,9771771[PMID]
589,Myasthenia gravis,Disease,Annual incidence,1.33,1-9 / 100 000,Value and class,Serbia,Validated,23363926[PMID]
589,Myasthenia gravis,Disease,Point prevalence,17.0,1-5 / 10 000,Value and class,United States,Validated,8909435[PMID]
589,Myasthenia gravis,Disease,Point prevalence,31.8,1-5 / 10 000,Value and class,Serbia,Validated,23363926[PMID]
589,Myasthenia gravis,Disease,Annual incidence,1.94,1-9 / 100 000,Value and class,Italy,Validated,21757957[PMID]_20623298[PMID]_ ORPHANET
589,Myasthenia gravis,Disease,Point prevalence,15.7,1-5 / 10 000,Value and class,Austria,Validated,23129486[PMID]
589,Myasthenia gravis,Disease,Annual incidence,2.5,1-9 / 100 000,Value and class,Australia,Validated,22469211[PMID]
589,Myasthenia gravis,Disease,Point prevalence,18.5,1-5 / 10 000,Value and class,Italy,Validated,21757957[PMID]_22377708[PMID]_ ORPHANET
589,Myasthenia gravis,Disease,Annual incidence,2.1,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,20523074[PMID]
589,Myasthenia gravis,Disease,Point prevalence,11.7,1-5 / 10 000,Value and class,Australia,Validated,22469211[PMID]
589,Myasthenia gravis,Disease,Annual incidence,0.74,1-9 / 1 000 000,Value and class,Greece,Validated,11511710[PMID]
589,Myasthenia gravis,Disease,Point prevalence,14.0,1-5 / 10 000,Value and class,"Taiwan, Province of China",Validated,20523074[PMID]
589,Myasthenia gravis,Disease,Annual incidence,0.65,1-9 / 1 000 000,Value and class,Croatia,Validated,9705586[PMID]
589,Myasthenia gravis,Disease,Point prevalence,7.8,1-9 / 100 000,Value and class,Estonia,Validated,14638881[PMID]
589,Myasthenia gravis,Disease,Point prevalence,7.1,1-9 / 100 000,Value and class,Greece,Validated,11511710[PMID]
589,Myasthenia gravis,Disease,Point prevalence,9.9,1-9 / 100 000,Value and class,Croatia,Validated,9705586[PMID]
589,Myasthenia gravis,Disease,Point prevalence,3.2,1-9 / 100 000,Value and class,Egypt,Validated,20948236[PMID]
589,Myasthenia gravis,Disease,Annual incidence,0.53,1-9 / 1 000 000,Value and class,Worldwide,Validated,20565885[PMID]
805,Tuberous sclerosis complex,Disease,Point prevalence,1.58,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,34344419[PMID]
805,Tuberous sclerosis complex,Disease,Prevalence at birth,5.62,1-9 / 100 000,Value and class,Germany,Validated,30016967[PMID]
805,Tuberous sclerosis complex,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Validated,ORPHANET
805,Tuberous sclerosis complex,Disease,Point prevalence,3.87,1-9 / 100 000,Value and class,Hong Kong,Validated,32988393[PMID]
805,Tuberous sclerosis complex,Disease,Point prevalence,5.38,1-9 / 100 000,Value and class,Sweden,Validated,29078087[PMID]
805,Tuberous sclerosis complex,Disease,Prevalence at birth,4.45,1-9 / 100 000,Value and class,United Kingdom,Validated,16700943[PMID]_18456692[PMID]
886,Usher syndrome,Disease,Point prevalence,4.53,1-9 / 100 000,Class only,Worldwide,Validated,15178965[PMID]_ORPHANET
886,Usher syndrome,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Denmark,Validated,9212179[PMID]
886,Usher syndrome,Disease,Point prevalence,6.2,1-9 / 100 000,Value and class,Germany,Validated,12107518[PMID]
886,Usher syndrome,Disease,Point prevalence,6.2,1-9 / 100 000,Value and class,United Kingdom,Validated,9135408[PMID]
886,Usher syndrome,Disease,Point prevalence,3.6,1-9 / 100 000,Value and class,Norway,Validated,3594933[PMID]
886,Usher syndrome,Disease,Point prevalence,4.2,1-9 / 100 000,Value and class,Spain,Validated,15178965[PMID]
886,Usher syndrome,Disease,Point prevalence,3.5,1-9 / 100 000,Value and class,Finland,Validated,5516287[PMID]
886,Usher syndrome,Disease,Point prevalence,4.4,1-9 / 100 000,Value and class,United States,Validated,6885960[PMID]
886,Usher syndrome,Disease,Point prevalence,3.2,1-9 / 100 000,Value and class,Colombia,Validated,1756603[PMID]
886,Usher syndrome,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Specific population,Validated,14569126[PMID]
3440,Waardenburg syndrome,Disease,Prevalence at birth,0.37,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
3440,Waardenburg syndrome,Disease,Point prevalence,1.74,1-9 / 100 000,Value and class,United States,Not yet validated,9279758[PMID]_ORPHANET
3440,Waardenburg syndrome,Disease,Prevalence at birth,2.4,1-9 / 100 000,Value and class,Netherlands,Validated,9279758[PMID]
3440,Waardenburg syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Netherlands,Not yet validated,9279758[PMID]
3440,Waardenburg syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
702,Pelizaeus-Merzbacher disease,Disease,Point prevalence,0.25,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
702,Pelizaeus-Merzbacher disease,Disease,Point prevalence,0.35,1-9 / 1 000 000,Value and class,United States,Not yet validated,20301361[PMID]_ORPHANET
702,Pelizaeus-Merzbacher disease,Disease,Prevalence at birth,0.13,1-9 / 1 000 000,Value and class,Germany,Validated,9286459[PMID]
738,Porphyria,Clinical group,Point prevalence,5.25,1-9 / 100 000,Value and class,Worldwide,Not yet validated,15652607[PMID]_ORPHANET
738,Porphyria,Clinical group,Lifetime Prevalence,0.7,1-9 / 1 000 000,Value and class,Japan,Validated,15239394[PMID]
738,Porphyria,Clinical group,Annual incidence,0.52,1-9 / 1 000 000,Value and class,Denmark,Validated,27139922[PMID]
768,Familial long QT syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
791,Retinitis pigmentosa,Disease,Point prevalence,30.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
791,Retinitis pigmentosa,Disease,Point prevalence,26.7,1-5 / 10 000,Value and class,Worldwide,Validated,[EXPERT]
791,Retinitis pigmentosa,Disease,Point prevalence,25.4,1-5 / 10 000,Value and class,Denmark,Validated,11921605[PMID]
791,Retinitis pigmentosa,Disease,Point prevalence,22.5,1-5 / 10 000,Value and class,Norway,Validated,3594933[PMID]
791,Retinitis pigmentosa,Disease,Point prevalence,21.0,1-5 / 10 000,Value and class,United States,Validated,6702974[PMID]
791,Retinitis pigmentosa,Disease,Point prevalence,20.5,1-5 / 10 000,Value and class,United Kingdom,Validated,6512829[PMID]
791,Retinitis pigmentosa,Disease,Point prevalence,26.4,1-5 / 10 000,Value and class,China,Validated,3500313[PMID]
791,Retinitis pigmentosa,Disease,Point prevalence,16.7,1-5 / 10 000,Value and class,Slovenia,Validated,1395082[PMID]
791,Retinitis pigmentosa,Disease,Point prevalence,11.09,1-5 / 10 000,Value and class,"Korea, Republic of",Validated,28130043[PMID]
375,Anti-glomerular basement membrane disease,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
375,Anti-glomerular basement membrane disease,Disease,Annual incidence,0.179,1-9 / 1 000 000,Value and class,New Zealand,Validated,22032242[PMID]
375,Anti-glomerular basement membrane disease,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,China,Validated,15056270[PMID]
375,Anti-glomerular basement membrane disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
375,Anti-glomerular basement membrane disease,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2018 [INST]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Point prevalence,1.56,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET_25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,Sweden,Validated,19797309[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Point prevalence,1.13,1-9 / 100 000,Value and class,France,Validated,20039171[PMID]_25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Point prevalence,1.4,1-9 / 100 000,Value and class,Sweden,Validated,17553910[PMID]_25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,United Kingdom,Validated,21798892[PMID]_25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Point prevalence,1.3,1-9 / 100 000,Value and class,Norway,Validated,9805179[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,Spain,Validated,11156552[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Point prevalence,2.23,1-9 / 100 000,Value and class,Australia,Validated,18771432[PMID]_25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Annual incidence,0.18,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET_19797309[PMID]_18565978[PMID]_11156552[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Worldwide,Validated,18771432[PMID]_9805179[PMID]_17553910[PMID]_14872461[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Norway,Validated,11760724[PMID]_25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,Germany,Validated,15696553[PMID]_25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Lithuania,Validated,15647446[PMID]_25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,France,Validated,20039171[PMID]_25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Turkey,Validated,25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Peru,Validated,25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Point prevalence,2.4,1-9 / 100 000,Value and class,Germany,Validated,24425780[PMID]_25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Point prevalence,1.78,1-9 / 100 000,Value and class,Japan,Validated,24289197[PMID]_25805746[PMID]
183,Eosinophilic granulomatosis with polyangiitis,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,United States,Validated,28881446[PMID]
1164,Allergic bronchopulmonary aspergillosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2406,Locked-in syndrome,Clinical syndrome,Cases/families,33.0,,Case(s),Worldwide,Validated,ORPHANET
2406,Locked-in syndrome,Clinical syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
509,Leptospirosis,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
509,Leptospirosis,Disease,Annual incidence,0.92,1-9 / 1 000 000,Value and class,France,Validated,23337900[PMID]
509,Leptospirosis,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Austria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Belgium,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.18,1-9 / 1 000 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,1.13,1-9 / 100 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2013-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Czech Republic,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Denmark,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,Estonia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Greece,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.36,1-9 / 1 000 000,Value and class,Ireland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.14,1-9 / 1 000 000,Value and class,Latvia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Luxembourg,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.42,1-9 / 1 000 000,Value and class,Malta,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.36,1-9 / 1 000 000,Value and class,Netherlands,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.38,1-9 / 1 000 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.38,1-9 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.52,1-9 / 1 000 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
509,Leptospirosis,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
761,Immunoglobulin A vasculitis,Disease,Annual incidence,55.9,6-9 / 10 000,Value and class,"Korea, Republic of",Validated,36263029[PMID]
761,Immunoglobulin A vasculitis,Disease,Annual incidence,30.0,1-5 / 10 000,Value and class,France,Validated,36263029[PMID]
761,Immunoglobulin A vasculitis,Disease,Annual incidence,6.79,1-9 / 100 000,Value and class,Croatia,Validated,36263029[PMID]
761,Immunoglobulin A vasculitis,Disease,Annual incidence,13.0,1-5 / 10 000,Value and class,United Kingdom,Validated,36263029[PMID]
761,Immunoglobulin A vasculitis,Disease,Annual incidence,6.1,1-9 / 100 000,Value and class,Netherlands,Validated,36263029[PMID]
761,Immunoglobulin A vasculitis,Disease,Annual incidence,17.55,1-5 / 10 000,Value and class,Sweden,Validated,36263029[PMID]
761,Immunoglobulin A vasculitis,Disease,Annual incidence,12.9,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,36263029[PMID]
761,Immunoglobulin A vasculitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,36263029[PMID]_ORPHANET
2131,Alternating hemiplegia of childhood,Disease,Prevalence at birth,0.94,1-9 / 1 000 000,Value and class,Denmark,Validated,24100174[PMID]
2131,Alternating hemiplegia of childhood,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,5.2,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_21493798[PMID]
171901,Primary cutaneous T-cell lymphoma,Category,Point prevalence,24.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.09,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.097,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.02,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.577,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.539,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.158,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.341,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.185,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.326,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.767,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.647,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.323,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.431,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.355,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.273,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.225,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.594,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.231,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.441,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,0.197,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,1.163,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171901,Primary cutaneous T-cell lymphoma,Category,Annual incidence,1.57,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
713,Glycogen storage disease due to phosphoglycerate kinase 1 deficiency,Disease,Cases/families,30.0,,Family(ies),Worldwide,Validated,[EXPERT]
713,Glycogen storage disease due to phosphoglycerate kinase 1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
171915,B-cell non-Hodgkin lymphoma,Category,Annual incidence,17.45,1-5 / 10 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
57,Glycogen storage disease due to aldolase A deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
249,Fibrous dysplasia of bone,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2334,Autosomal dominant keratitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
171918,T-cell non-Hodgkin lymphoma,Category,Annual incidence,0.99,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
171929,Trisomy 10p syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
171929,Trisomy 10p syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
187,Citrullinemia,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
46,Adenylosuccinate lyase deficiency,Disease,Cases/families,56.0,,Case(s),Worldwide,Validated,18830228[PMID]
46,Adenylosuccinate lyase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
442,Congenital hypothyroidism,Category,Prevalence at birth,38.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,[EXPERT]
442,Congenital hypothyroidism,Category,Prevalence at birth,10.0,1-5 / 10 000,Value and class,France,Validated,15807875[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,France,Not yet validated,15807875[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,57.0,6-9 / 10 000,Value and class,United Kingdom,Not yet validated,10102157[PMID]_21048833[PMID]_16595645[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,United Kingdom,Not yet validated,10102157[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,45.5,1-5 / 10 000,Value and class,Italy,Validated,23025761[PMID]_23426615[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,57.0,6-9 / 10 000,Value and class,Greece,Validated,20591982[PMID]_23426615[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,55.5,1-5 / 10 000,Value and class,Cyprus,Validated,15921174[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,15.5,1-5 / 10 000,Value and class,Latvia,Validated,11400783[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Latvia,Not yet validated,11400783[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,49.1,1-5 / 10 000,Value and class,China,Validated,23430943[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,China,Not yet validated,23430943[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,30.2,1-5 / 10 000,Value and class,Germany,Validated,16318620[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Germany,Not yet validated,16318620[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,29.4,1-5 / 10 000,Value and class,Denmark,Validated,9782755[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,25.0,1-5 / 10 000,Value and class,Poland,Validated,12762638[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Poland,Not yet validated,12762638[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,35.0,1-5 / 10 000,Value and class,Estonia,Validated,9575454[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Estonia,Not yet validated,9575454[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,54.8,1-5 / 10 000,Value and class,Lebanon,Validated,17146215[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,150.0,>1 / 1000,Value and class,"Iran, Islamic Republic of",Validated,23060475[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,73.35,6-9 / 10 000,Value and class,Brazil,Not yet validated,23033178[PMID]_22911283[PMID]_ ORPHANET
442,Congenital hypothyroidism,Category,Prevalence at birth,43.0,1-5 / 10 000,Value and class,Turkey,Validated,15857333[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Turkey,Not yet validated,15857333[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,35.4,1-5 / 10 000,Value and class,Australia,Validated,12031004[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Australia,Not yet validated,12031004[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,63.7,6-9 / 10 000,Value and class,United Arab Emirates,Validated,15751925[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,76.9,6-9 / 10 000,Value and class,Bangladesh,Validated,15906726[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,62.5,6-9 / 10 000,Value and class,Pakistan,Validated,19904471[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,50.2,1-5 / 10 000,Value and class,"Taiwan, Province of China",Validated,23291568[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,43.0,1-5 / 10 000,Value and class,Mexico,Validated,18782254[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Mexico,Not yet validated,18782254[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,25.3,1-5 / 10 000,Value and class,Bosnia and Herzegovina,Validated,18668261[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Bosnia and Herzegovina,Not yet validated,18668261[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,33.7,1-5 / 10 000,Value and class,Bahrain,Validated,20432804[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Bahrain,Not yet validated,20432804[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,36.0,1-5 / 10 000,Value and class,New Zealand,Validated,22723332[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,New Zealand,Not yet validated,22723332[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,16.0,1-5 / 10 000,Value and class,Thailand,Validated,11400774[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Thailand,Not yet validated,11400774[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,0.0,1-5 / 10 000,Class only,United States,Not yet validated,17512233[PMID]_16509526[PMID]
442,Congenital hypothyroidism,Category,Point prevalence,44.0,1-5 / 10 000,Value and class,United States,Not yet validated,17512233[PMID]_16509526[PMID]_ ORPHANET
442,Congenital hypothyroidism,Category,Prevalence at birth,37.3,1-5 / 10 000,Value and class,Specific population,Validated,21632812[PMID]
442,Congenital hypothyroidism,Category,Annual incidence,97.0873,6-9 / 10 000,Value and class,Brazil,Validated,35209917[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,34.76,1-5 / 10 000,Value and class,Czech Republic,Validated,31241292[PMID]
442,Congenital hypothyroidism,Category,Prevalence at birth,45.0,1-5 / 10 000,Value and class,Ireland,Validated,30242075[PMID]
43,X-linked adrenoleukodystrophy,Disease,Prevalence at birth,0.8,1-9 / 1 000 000,Value and class,Israel,Validated,33239050[PMID]
43,X-linked adrenoleukodystrophy,Disease,Point prevalence,0.8,1-9 / 1 000 000,Value and class,Norway,Validated,23419472[PMID]
43,X-linked adrenoleukodystrophy,Disease,Prevalence at birth,2.0639,1-5 / 10 000,Value and class,United States,Validated,31074578[PMID]
3166,Sialuria,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,11486897[PMID]
3166,Sialuria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11486897[PMID]
2882,Sitosterolemia,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,18441155[PMID]
2882,Sitosterolemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18441155[PMID]
810,Shigellosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
810,Shigellosis,Disease,Annual incidence,1.68,1-9 / 100 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.78,1-9 / 1 000 000,Value and class,Austria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,8.18,1-9 / 100 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.33,1-9 / 1 000 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2012-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Cyprus,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,1.6,1-9 / 100 000,Value and class,Czech Republic,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,2.08,1-9 / 100 000,Value and class,Denmark,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,1.38,1-9 / 100 000,Value and class,Estonia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,1.82,1-9 / 100 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,2.54,1-9 / 100 000,Value and class,France,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.7,1-9 / 1 000 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.74,1-9 / 1 000 000,Value and class,Greece,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.38,1-9 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,1.12,1-9 / 100 000,Value and class,Ireland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.34,1-9 / 1 000 000,Value and class,Latvia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,1.12,1-9 / 100 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,2.6,1-9 / 100 000,Value and class,Luxembourg,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.34,1-9 / 1 000 000,Value and class,Malta,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,2.4,1-9 / 100 000,Value and class,Netherlands,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Poland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,1.18,1-9 / 100 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,6.1,1-9 / 100 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,1.02,1-9 / 100 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.44,1-9 / 1 000 000,Value and class,Spain,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,3.68,1-9 / 100 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,3.32,1-9 / 100 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Iceland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
810,Shigellosis,Disease,Annual incidence,2.06,1-9 / 100 000,Value and class,Norway,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
3165,Eosinophilic fasciitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3165,Eosinophilic fasciitis,Disease,Point prevalence,1.4,1-9 / 100 000,Value and class,France,Validated,29526049[PMID]
2420,Primary pulmonary lymphoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
727,Microscopic polyangiitis,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
727,Microscopic polyangiitis,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,Germany,Validated,15696553[PMID]_25805746[PMID]
727,Microscopic polyangiitis,Disease,Point prevalence,4.2843,1-9 / 100 000,Value and class,Worldwide,Validated,25805746[PMID]_ORPHANET
727,Microscopic polyangiitis,Disease,Annual incidence,1.16,1-9 / 100 000,Value and class,Spain,Validated,11156552[PMID]
727,Microscopic polyangiitis,Disease,Point prevalence,9.4,1-9 / 100 000,Value and class,Sweden,Validated,17553910[PMID]
727,Microscopic polyangiitis,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Australia,Validated,18771432[PMID]
727,Microscopic polyangiitis,Disease,Point prevalence,2.5,1-9 / 100 000,Value and class,France,Validated,14872461[PMID]
727,Microscopic polyangiitis,Disease,Annual incidence,0.27,1-9 / 1 000 000,Value and class,Norway,Validated,11760724[PMID]
727,Microscopic polyangiitis,Disease,Point prevalence,3.7,1-9 / 100 000,Value and class,New Zealand,Validated,16368729[PMID]
727,Microscopic polyangiitis,Disease,Annual incidence,0.74,1-9 / 1 000 000,Value and class,United Kingdom,Not yet validated,11156552[PMID]_22258386[PMID]_10693883[PMID]_ORPHANET
727,Microscopic polyangiitis,Disease,Point prevalence,6.3,1-9 / 100 000,Value and class,United Kingdom,Validated,22258386[PMID]_25805746[PMID]
727,Microscopic polyangiitis,Disease,Point prevalence,2.8,1-9 / 100 000,Value and class,Germany,Validated,24425780[PMID]_25805746[PMID]
727,Microscopic polyangiitis,Disease,Point prevalence,3.91,1-9 / 100 000,Value and class,Australia,Validated,18771432[PMID]_25805746[PMID]
727,Microscopic polyangiitis,Disease,Point prevalence,1.38,1-9 / 100 000,Value and class,Japan,Validated,17699321[PMID]_25805746[PMID]
727,Microscopic polyangiitis,Disease,Annual incidence,2.4,1-9 / 100 000,Value and class,Kuwait,Validated,9306338[PMID]_25805746[PMID]
727,Microscopic polyangiitis,Disease,Annual incidence,1.82,1-9 / 100 000,Value and class,Japan,Validated,21798892[PMID]_25805746[PMID]
727,Microscopic polyangiitis,Disease,Annual incidence,0.71,1-9 / 1 000 000,Value and class,Canada,Validated,23838025[PMID]_25805746[PMID]
727,Microscopic polyangiitis,Disease,Annual incidence,1.02,1-9 / 100 000,Value and class,Greece,Validated,19604432[PMID]_25805746[PMID]
727,Microscopic polyangiitis,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Lithuania,Validated,15647446[PMID]_25805746[PMID]
727,Microscopic polyangiitis,Disease,Annual incidence,1.01,1-9 / 100 000,Value and class,Sweden,Validated,19797309[PMID]_25805746[PMID]
727,Microscopic polyangiitis,Disease,Annual incidence,1.6,1-9 / 100 000,Value and class,United States,Validated,28881446[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,0.85,1-9 / 1 000 000,Value and class,Europe,Validated,16859601[PMID]
900,Granulomatosis with polyangiitis,Disease,Point prevalence,9.0,1-9 / 100 000,Value and class,Europe,Validated,16859601[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,United Kingdom,Validated,10693883[PMID]_11156552[PMID]_22258386[PMID]_19790134[PMID]
900,Granulomatosis with polyangiitis,Disease,Point prevalence,16.0,1-5 / 10 000,Value and class,Sweden,Validated,17553910[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,0.86,1-9 / 1 000 000,Value and class,Germany,Validated,15696553[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Point prevalence,2.37,1-9 / 100 000,Value and class,France,Validated,14872461[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,1.19,1-9 / 100 000,Value and class,Sweden,Validated,16960922[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,0.49,1-9 / 1 000 000,Value and class,Spain,Validated,11156552[PMID]
900,Granulomatosis with polyangiitis,Disease,Point prevalence,9.51,1-9 / 100 000,Value and class,Norway,Validated,11083271[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Norway,Validated,11760724[PMID]_11083271[PMID]_ ORPHANET
900,Granulomatosis with polyangiitis,Disease,Point prevalence,9.5,1-9 / 100 000,Value and class,Australia,Validated,18771432[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Point prevalence,9.35,1-9 / 100 000,Value and class,New Zealand,Validated,16368729[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,0.93,1-9 / 1 000 000,Value and class,Finland,Validated,18799060[PMID]
900,Granulomatosis with polyangiitis,Disease,Point prevalence,2.6,1-9 / 100 000,Value and class,United States,Validated,8546743[PMID]
900,Granulomatosis with polyangiitis,Disease,Point prevalence,1.94,1-9 / 100 000,Value and class,China,Validated,26989646[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,0.21,1-9 / 1 000 000,Value and class,Lithuania,Validated,15647446[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,0.66,1-9 / 1 000 000,Value and class,Greece,Validated,19604432[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,Italy,Validated,24932888[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,0.46,1-9 / 1 000 000,Value and class,Canada,Validated,23838025[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,0.21,1-9 / 1 000 000,Value and class,Japan,Validated,21798892[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,24560699[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Point prevalence,0.23,1-9 / 1 000 000,Value and class,Japan,Validated,17699321[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Point prevalence,3.43,1-9 / 100 000,Value and class,Italy,Validated,24932888[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Denmark,Validated,17582741[PMID]_25805746[PMID]
900,Granulomatosis with polyangiitis,Disease,Annual incidence,1.3,1-9 / 100 000,Value and class,United States,Validated,28881446[PMID]
863,Trichinellosis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
863,Trichinellosis,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
863,Trichinellosis,Disease,Annual incidence,0.48,1-9 / 1 000 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
863,Trichinellosis,Disease,Annual incidence,0.067,<1 / 1 000 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2013-2015[INST]
863,Trichinellosis,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Estonia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
863,Trichinellosis,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
863,Trichinellosis,Disease,Annual incidence,1.06,1-9 / 100 000,Value and class,Latvia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
863,Trichinellosis,Disease,Annual incidence,0.6,1-9 / 1 000 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
863,Trichinellosis,Disease,Annual incidence,0.64,1-9 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
863,Trichinellosis,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
134,Beta-ketothiolase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
134,Beta-ketothiolase deficiency,Disease,Prevalence at birth,0.72,1-9 / 1 000 000,Value and class,Australia,Validated,10626578[PMID]_[EXPERT]
134,Beta-ketothiolase deficiency,Disease,Prevalence at birth,0.43,1-9 / 1 000 000,Value and class,United States,Validated,21669895[PMID]_[EXPERT]
134,Beta-ketothiolase deficiency,Disease,Prevalence at birth,0.98,1-9 / 1 000 000,Value and class,China,Validated,31156707[PMID]_[EXPERT]
134,Beta-ketothiolase deficiency,Disease,Prevalence at birth,0.53,1-9 / 1 000 000,Value and class,Viet Nam,Validated,28220263[PMID]_[EXPERT]
171700,Diffuse panbronchiolitis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
171703,Microcephaly-polymicrogyria-corpus callosum agenesis syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,17353897[PMID]
171703,Microcephaly-polymicrogyria-corpus callosum agenesis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17353897[PMID]
171706,Short stature-delayed bone age due to thyroid hormone metabolism deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
171719,Cutis laxa-Marfanoid syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1864606[PMID]
171719,Cutis laxa-Marfanoid syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,1864606[PMID]
1163,Aspergillosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3467,Hereditary xanthinuria,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,ORPHANET
3467,Hereditary xanthinuria,Disease,Annual incidence,9.05,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
3467,Hereditary xanthinuria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
171673,Limbal stem cell deficiency,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
511,Maple syrup urine disease,Disease,Prevalence at birth,0.67,1-9 / 1 000 000,Value and class,Worldwide,Validated,[EXPERT]
511,Maple syrup urine disease,Disease,Prevalence at birth,0.78,1-9 / 1 000 000,Value and class,United States,Validated,20307994[PMID]
511,Maple syrup urine disease,Disease,Prevalence at birth,0.79,1-9 / 1 000 000,Value and class,Italy,Validated,11953730[PMID]
511,Maple syrup urine disease,Disease,Prevalence at birth,7.3,1-9 / 100 000,Value and class,Tunisia,Validated,22481200[PMID]
511,Maple syrup urine disease,Disease,Prevalence at birth,0.19,1-9 / 1 000 000,Value and class,Japan,Validated,6468444[PMID]
511,Maple syrup urine disease,Disease,Prevalence at birth,1.15,1-9 / 100 000,Value and class,Portugal,Validated,20466570[PMID]
511,Maple syrup urine disease,Disease,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,Australia,Validated,12788994[PMID]
511,Maple syrup urine disease,Disease,Prevalence at birth,0.86,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,2056791[PMID]
511,Maple syrup urine disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2018[INST]
511,Maple syrup urine disease,Disease,Prevalence at birth,4.8,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]
511,Maple syrup urine disease,Disease,Prevalence at birth,10.2,1-5 / 10 000,Value and class,Specific population,Validated,33239050[PMID]
511,Maple syrup urine disease,Disease,Point prevalence,0.396,1-9 / 1 000 000,Value and class,China,Validated,34103049[PMID]
511,Maple syrup urine disease,Disease,Prevalence at birth,0.34,1-9 / 1 000 000,Value and class,Czech Republic,Validated,31241292[PMID]
171680,Lissencephaly due to TUBA1A mutation,Malformation syndrome,Cases/families,15.0,,Case(s),Worldwide,Validated,ORPHANET
171680,Lissencephaly due to TUBA1A mutation,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
32,Glutathione synthetase deficiency,Disease,Cases/families,70.0,,Case(s),Worldwide,Validated,26984560[PMID]
32,Glutathione synthetase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26984560[PMID]
26,Methylmalonic acidemia with homocystinuria,Disease,Cases/families,500.0,,Case(s),Worldwide,Validated,16714133[PMID]_[EXPERT]
26,Methylmalonic acidemia with homocystinuria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
171863,Autosomal dominant spastic paraplegia type 42,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,19061983[PMID]
171863,Autosomal dominant spastic paraplegia type 42,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19061983[PMID]
171871,Renal pseudohypoaldosteronism type 1,Clinical subtype,Prevalence at birth,1.51,1-9 / 100 000,Value and class,United Kingdom,Validated,PMID: 24616761
322,Exstrophy-epispadias complex,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
171866,"Spondyloepimetaphyseal dysplasia, aggrecan type",Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,19110214[PMID]
171866,"Spondyloepimetaphyseal dysplasia, aggrecan type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19110214[PMID]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,16.9,1-5 / 10 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010-2016[REG]_[EXPERT]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,29.4,1-5 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,14.6,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,22.7,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,21.3,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,17.7,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,41.6,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,6.2,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,18.1,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,9.9,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,25.8,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2006[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,17.5,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,36.0,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,11.6,1-5 / 10 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,11.0,1-5 / 10 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,5.6,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,12.3,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,36.3,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2368,Gastroschisis,Morphological anomaly,Prevalence at birth,9.5,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2368,Gastroschisis,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,ORPHANET_[EXPERT]
171881,Cap myopathy,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,25079567[PMID]
171881,Cap myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25079567[PMID]
2512,Autosomal recessive primary microcephaly,Etiological subtype,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Specific population,Validated,21668957[PMID]
2512,Autosomal recessive primary microcephaly,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2512,Autosomal recessive primary microcephaly,Etiological subtype,Annual incidence,1.0,1-9 / 100 000,Value and class,Pakistan,Validated,21668957[PMID]
171876,Generalized pseudohypoaldosteronism type 1,Clinical subtype,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,United Kingdom,Validated,PMID: 24616761
795,Rare form of salmonellosis,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
797,Sarcoidosis,Disease,Point prevalence,60.0,6-9 / 10 000,Value and class,United States,Validated,2750915[PMID]_[EXPERT]
797,Sarcoidosis,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Worldwide,Validated,[EXPERT]_ORPHANET_DOI:10.1016/B978-0-323-54429-0.00001-X[OTHER]
797,Sarcoidosis,Disease,Point prevalence,48.1,1-5 / 10 000,Value and class,Ireland,Validated,[EXPERT]_DOI:10.1016/B978-0-323-54429-0.00001-X[OTHER]
797,Sarcoidosis,Disease,Annual incidence,3.3,1-9 / 100 000,Value and class,Croatia,Validated,21906764[PMID]
797,Sarcoidosis,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2007[INST]_DOI:10.1016/B978-0-323-54429-0.00001-X[OTHER]
797,Sarcoidosis,Disease,Annual incidence,5.0,1-9 / 100 000,Value and class,United Kingdom,Validated,16844727[PMID]
797,Sarcoidosis,Disease,Point prevalence,30.2,1-5 / 10 000,Value and class,France,Validated,28775045 [PMID]_[EXPERT]
797,Sarcoidosis,Disease,Annual incidence,4.5,1-9 / 100 000,Value and class,Spain,Validated,21546016[PMID]
797,Sarcoidosis,Disease,Point prevalence,28.2,1-5 / 10 000,Value and class,Finland,Validated,7617979[PMID]
797,Sarcoidosis,Disease,Annual incidence,4.68,1-9 / 100 000,Value and class,Denmark,Validated,18983653[PMID]
797,Sarcoidosis,Disease,Annual incidence,7.0,1-9 / 100 000,Value and class,Switzerland,Validated,19897550[PMID]
797,Sarcoidosis,Disease,Point prevalence,0.0,6-9 / 10 000,Class only,Switzerland,Validated,DOI:10.1016/B978-0-323-54429-0.00001-X[OTHER]_[EXPERT]
797,Sarcoidosis,Disease,Annual incidence,1.07,1-9 / 100 000,Value and class,Greece,Validated,19345567[PMID]
797,Sarcoidosis,Disease,Point prevalence,5.89,1-9 / 100 000,Value and class,Greece,Validated,19345567[PMID]
797,Sarcoidosis,Disease,Annual incidence,3.84,1-9 / 100 000,Value and class,Iceland,Validated,17277405[PMID]
797,Sarcoidosis,Disease,Annual incidence,4.0,1-9 / 100 000,Value and class,Czech Republic,Validated,7809493[PMID]
797,Sarcoidosis,Disease,Point prevalence,63.0,6-9 / 10 000,Value and class,Czech Republic,Validated,7809493[PMID]
797,Sarcoidosis,Disease,Annual incidence,5.35,1-9 / 100 000,Value and class,Australia,Validated,17535377[PMID]_ORPHANET_[EXPERT]
797,Sarcoidosis,Disease,Annual incidence,1.01,1-9 / 100 000,Value and class,Japan,Validated,17959635[PMID]
797,Sarcoidosis,Disease,Point prevalence,3.7,1-9 / 100 000,Value and class,Japan,Validated,7617979[PMID]
797,Sarcoidosis,Disease,Annual incidence,0.125,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,11436538[PMID]
797,Sarcoidosis,Disease,Annual incidence,0.56,1-9 / 1 000 000,Value and class,Singapore,Validated,17539838[PMID]
797,Sarcoidosis,Disease,Point prevalence,49.0,1-5 / 10 000,Value and class,Italy,Validated,28475583[PMID]
797,Sarcoidosis,Disease,Annual incidence,4.9,1-9 / 100 000,Value and class,France,Validated,28775045 [PMID]_[EXPERT]
797,Sarcoidosis,Disease,Point prevalence,160.0,>1 / 1000,Value and class,Sweden,Validated,27471207[PMID]
797,Sarcoidosis,Disease,Annual incidence,11.5,1-5 / 10 000,Value and class,Sweden,Validated,27471207[PMID]
797,Sarcoidosis,Disease,Point prevalence,2.17,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,27786368 [PMID]
797,Sarcoidosis,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Portugal,Validated,5884467[PMID]
797,Sarcoidosis,Disease,Point prevalence,26.7,1-5 / 10 000,Value and class,Norway,Validated,5884453[PMID]
797,Sarcoidosis,Disease,Annual incidence,14.4,1-5 / 10 000,Value and class,Norway,Validated,5884453[PMID]
797,Sarcoidosis,Disease,Point prevalence,10.5,1-5 / 10 000,Value and class,Canada,Validated,5884470[PMID]
797,Sarcoidosis,Disease,Point prevalence,21.0,1-5 / 10 000,Value and class,Guadeloupe,Validated,24962008[PMID]
797,Sarcoidosis,Disease,Annual incidence,2.3,1-9 / 100 000,Value and class,Guadeloupe,Validated,24962008[PMID]
797,Sarcoidosis,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Uruguay,Validated,5884475[PMID]
92,Juvenile idiopathic arthritis,Clinical group,Annual incidence,13.0,1-5 / 10 000,Value and class,Czech Republic,Validated,17181917[PMID]
92,Juvenile idiopathic arthritis,Clinical group,Annual incidence,1.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
92,Juvenile idiopathic arthritis,Clinical group,Point prevalence,4.7,1-9 / 100 000,Value and class,France,Validated,Haute Autorité de Santé 2009[INST]_ORPHANET_16821272[PMID]
92,Juvenile idiopathic arthritis,Clinical group,Point prevalence,8.9,1-9 / 100 000,Value and class,United States,Not yet validated,23588938[PMID]_ORPHANET
92,Juvenile idiopathic arthritis,Clinical group,Point prevalence,21.0,1-5 / 10 000,Value and class,Czech Republic,Not yet validated,17181917[PMID]_ORPHANET
92,Juvenile idiopathic arthritis,Clinical group,Point prevalence,20.5,1-5 / 10 000,Value and class,Worldwide,Validated,24210707[PMID]
92,Juvenile idiopathic arthritis,Clinical group,Point prevalence,74.6,6-9 / 10 000,Value and class,Specific population,Validated,31150159[PMID]
92,Juvenile idiopathic arthritis,Clinical group,Annual incidence,7.8,1-9 / 100 000,Value and class,Worldwide,Validated,24210707[PMID]
171829,6q16 microdeletion syndrome,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,24038875[PMID]
171829,6q16 microdeletion syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,9.0,1-9 / 100 000,Value and class,Europe,Validated,229330959[PMID]
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,9.0,1-9 / 100 000,Value and class,Spain,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,11.0,1-5 / 10 000,Value and class,Ireland,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Portugal,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,14.5,1-5 / 10 000,Value and class,Italy,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,22.0,1-5 / 10 000,Value and class,Reunion,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,9.0,1-9 / 100 000,Value and class,Switzerland,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Austria,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,14.0,1-5 / 10 000,Value and class,Germany,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,19.0,1-5 / 10 000,Value and class,Denmark,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,12.0,1-5 / 10 000,Value and class,Malta,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,18.0,1-5 / 10 000,Value and class,France,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,18.0,1-5 / 10 000,Value and class,United Kingdom,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Prevalence at birth,15.0,1-5 / 10 000,Value and class,Belgium,Validated,2293309[PMID]_EUROCAT
1201,Small bowel atresia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
171844,Blindness-scoliosis-arachnodactyly syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,18990988[PMID]
171844,Blindness-scoliosis-arachnodactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18990988[PMID]
171839,Craniosynostosis-hydrocephalus-Arnold-Chiari malformation type I-radioulnar synostosis syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,19022412[PMID]
171839,Craniosynostosis-hydrocephalus-Arnold-Chiari malformation type I-radioulnar synostosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19022412[PMID]
1202,Larynx atresia,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,24.3,1-5 / 10 000,Value and class,Europe,Validated,22247246[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1199,Esophageal atresia,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,22247246[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,19.5,1-5 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,17.5,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,11.4,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,42.5,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,11.8,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,23.8,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,26.6,1-5 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,10.8,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,18.4,1-5 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,24.9,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,17.1,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,34.4,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,9.7,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,18.9,1-5 / 10 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,15.7,1-5 / 10 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,25.1,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,22.4,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,22.3,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1199,Esophageal atresia,Morphological anomaly,Prevalence at birth,21.0,1-5 / 10 000,Value and class,United States,Validated,8013895[PMID]_15826889[PMID]
171851,MEDNIK syndrome,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,23423674[PMID]
171851,MEDNIK syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23423674[PMID]
171848,Polyneuropathy-hearing loss-ataxia-retinitis pigmentosa-cataract syndrome,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,23490117[PMID]
171848,Polyneuropathy-hearing loss-ataxia-retinitis pigmentosa-cataract syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1304,Brucellosis,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,France,Validated,27717526[PMID]_European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,1.13,1-9 / 100 000,Value and class,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,Luxembourg,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1304,Brucellosis,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
1304,Brucellosis,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
1304,Brucellosis,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
1304,Brucellosis,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
1304,Brucellosis,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Netherlands,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
1304,Brucellosis,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Poland,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
1304,Brucellosis,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Belgium,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
1304,Brucellosis,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
1304,Brucellosis,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
1304,Brucellosis,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
1304,Brucellosis,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2013-2016[INST]
173,Cholera,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,World Health Organization 2011[INST]
173,Cholera,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,United States,Validated,World Health Organization 2011[INST]
173,Cholera,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
173,Cholera,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
173,Cholera,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
173,Cholera,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
173,Cholera,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Belgium,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
173,Cholera,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
173,Cholera,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
173,Cholera,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,France,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
173,Cholera,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
173,Cholera,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
173,Cholera,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,34.0,1-5 / 10 000,Value and class,Worldwide,Validated,22078432[PMID]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,29.3,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,39.3,1-5 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,40.8,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,11.4,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,39.7,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,13.8,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,11.9,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,34.3,1-5 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,14.5,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,26.8,1-5 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,48.2,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,29.2,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,31.1,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,16.2,1-5 / 10 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,23.7,1-5 / 10 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,63.0,6-9 / 10 000,Value and class,"Taiwan, Province of China",Validated,20138303[PMID]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,11.9,1-5 / 10 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,25.1,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,32.0,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,25.4,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,47.0,1-5 / 10 000,Value and class,United States,Validated,18657826[PMID]
3303,Tetralogy of Fallot,Malformation syndrome,Prevalence at birth,40.0,1-5 / 10 000,Value and class,China,Validated,23350618[PMID]
3303,Tetralogy of Fallot,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3303,Tetralogy of Fallot,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
200418,Immunodeficiency with factor I anomaly,Disease,Cases/families,35.0,,Family(ies),Worldwide,Validated,22710145[PMID]
200418,Immunodeficiency with factor I anomaly,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
730,Autosomal dominant polycystic kidney disease,Disease,Point prevalence,39.6,1-5 / 10 000,Value and class,Europe,Validated,27325254[PMID]_European Medicines Agency 2018[INST]
486,Autosomal dominant severe congenital neutropenia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,5.5625,1-9 / 100 000,Value and class,Europe,Validated,31270117[PMID]
1209,Tricuspid atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,5.9,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2012[REG]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,9.0,1-9 / 100 000,Value and class,France,Validated,31270117[PMID]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Germany,Validated,31270117[PMID]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,10.5,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,6.5,1-9 / 100 000,Value and class,Italy,Validated,31270117[PMID]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Netherlands,Validated,31270117[PMID]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,3.3,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,1.9,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,11.1,1-5 / 10 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,12.6,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,5.0,1-9 / 100 000,Value and class,United Kingdom,Validated,31270117[PMID]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,9.7,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,4.6,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,20138303[PMID]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,8.0,1-9 / 100 000,Value and class,Malta,Validated,31270117[PMID]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,6.0,1-9 / 100 000,Value and class,Czech Republic,Validated,31270117[PMID]
1209,Tricuspid atresia,Morphological anomaly,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Slovakia,Validated,31270117[PMID]
98,Autosomal recessive spastic ataxia of Charlevoix-Saguenay,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301432[PMID]
98,Autosomal recessive spastic ataxia of Charlevoix-Saguenay,Disease,Prevalence at birth,51.76,6-9 / 10 000,Value and class,Specific population,Validated,8472930[PMID]
1478,Interatrial communication,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
330,Congenital factor XII deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1959,Evans syndrome,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
284,Alveolar echinococcosis,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,Europe,Validated,23301116[PMID]_ORPHANET
284,Alveolar echinococcosis,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,Switzerland,Validated,17553227[PMID]
284,Alveolar echinococcosis,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Poland,Validated,23301116[PMID]
284,Alveolar echinococcosis,Disease,Annual incidence,2.8,1-9 / 100 000,Value and class,Austria,Validated,23628138[PMID]
284,Alveolar echinococcosis,Disease,Annual incidence,0.026,<1 / 1 000 000,Value and class,France,Validated,FrancEchino[REG]_Institut de Veille Sanitaire 2010[INST]
284,Alveolar echinococcosis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
1177,Early-onset cerebellar ataxia with retained tendon reflexes,Disease,Prevalence at birth,2.08,1-9 / 100 000,Value and class,Italy,Validated,8330454[PMID]
1177,Early-onset cerebellar ataxia with retained tendon reflexes,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Italy,Validated,8330454[PMID]
1177,Early-onset cerebellar ataxia with retained tendon reflexes,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET
828,Stickler syndrome,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
828,Stickler syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
828,Stickler syndrome,Disease,Prevalence at birth,0.65,1-9 / 1 000 000,Value and class,France,Validated,22925539[PMID]
828,Stickler syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,France,Validated,22925539[PMID]
828,Stickler syndrome,Disease,Prevalence at birth,12.2,1-5 / 10 000,Value and class,Worldwide,Not yet validated,20301479[PMID]
1431,Paroxysmal dyskinesia,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
293,Congenital herpes simplex virus infection,Disease,Annual incidence,6.6,1-9 / 100 000,Value and class,Sweden,Not yet validated,ORPHANET
293,Congenital herpes simplex virus infection,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
293,Congenital herpes simplex virus infection,Disease,Annual incidence,1.6,1-9 / 100 000,Value and class,United Kingdom,Not yet validated,ORPHANET
199340,"Muscular dystrophy, Selcen type",Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,22734908[PMID]
199340,"Muscular dystrophy, Selcen type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
199337,Pancreatic insufficiency-anemia-hyperostosis syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,19268275[PMID]
199337,Pancreatic insufficiency-anemia-hyperostosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19268275[PMID]
234,Dubin-Johnson syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
199348,Thiamine-responsive encephalopathy,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,19387023[PMID]
199348,Thiamine-responsive encephalopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19387023[PMID]
3287,Takayasu arteritis,Disease,Annual incidence,0.084,<1 / 1 000 000,Value and class,Europe,Validated,ORPHANET_27159262[PMID]
3287,Takayasu arteritis,Disease,Point prevalence,1.34,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET_27159262[PMID]
3287,Takayasu arteritis,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,United Kingdom,Validated,ORPHANET_19542212[PMID]
3287,Takayasu arteritis,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Japan,Validated,9119531[PMID]
3287,Takayasu arteritis,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Sweden,Validated,ORPHANET_6133485[PMID]_25774057[PMID]
3287,Takayasu arteritis,Disease,Point prevalence,0.98,1-9 / 1 000 000,Value and class,Sweden,Validated,ORPHANET_6133485[PMID]_25774057[PMID]
3287,Takayasu arteritis,Disease,Point prevalence,0.47,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19542212[PMID]
3287,Takayasu arteritis,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Denmark,Validated,21385546[PMID]
3287,Takayasu arteritis,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,ORPHANET
3287,Takayasu arteritis,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,Germany,Not yet validated,15696553[PMID]_ORPHANET
3287,Takayasu arteritis,Disease,Point prevalence,0.78,1-9 / 1 000 000,Value and class,Kuwait,Validated,7563255[PMID]
3287,Takayasu arteritis,Disease,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Japan,Not yet validated,1360971[PMID]_ORPHANET
3287,Takayasu arteritis,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Lithuania,Validated,15647446[PMID]
3287,Takayasu arteritis,Disease,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Kuwait,Validated,7563255[PMID]
3287,Takayasu arteritis,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,United States,Validated,2858047[PMID]
3287,Takayasu arteritis,Disease,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Norway,Validated,27159262[PMID]
3287,Takayasu arteritis,Disease,Point prevalence,2.56,1-9 / 100 000,Value and class,Norway,Validated,27159262[PMID]
3287,Takayasu arteritis,Disease,Point prevalence,2.82,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,28283361[PMID]
3287,Takayasu arteritis,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,28283361[PMID]
3287,Takayasu arteritis,Disease,Point prevalence,0.46,1-9 / 1 000 000,Value and class,Poland,Validated,30260188[PMID]
3287,Takayasu arteritis,Disease,Annual incidence,0.092,<1 / 1 000 000,Value and class,Poland,Validated,30260188[PMID
199343,EAST syndrome,Disease,Cases/families,26.0,,Case(s),Worldwide,Validated,27500072[PMID]
199343,EAST syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27500072[PMID]
2800,Extramammary Paget disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
199326,"Isolated autosomal dominant hypomagnesemia, Glaudemans type",Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,19307729[PMID]
199326,"Isolated autosomal dominant hypomagnesemia, Glaudemans type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1928,Congenital lobar emphysema,Morphological anomaly,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Worldwide,Validated,24068262[PMID]
1928,Congenital lobar emphysema,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Validated,24068262[PMID]_ORPHANET_[EXPERT]
199332,Endocrine-cerebro-osteodysplasia syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,19185282[PMID]_27069622[PMID]
199332,Endocrine-cerebro-osteodysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19185282[PMID]_27069622[PMID]
199329,"Congenital myopathy, Paradas type",Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,19084402[PMID]
199329,"Congenital myopathy, Paradas type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19084402[PMID]
3463,Wolfram syndrome,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,United Kingdom,Validated,7490992[PMID]
3463,Wolfram syndrome,Disease,Point prevalence,0.12,1-9 / 1 000 000,Value and class,India,Validated,21726277[PMID]
3463,Wolfram syndrome,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET_7490992[PMID]_21726277[PMID]_25211237[PMID]
3463,Wolfram syndrome,Disease,Point prevalence,1.83,1-9 / 100 000,Value and class,Specific population,Validated,24497219[PMID]
3463,Wolfram syndrome,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,Japan,Validated,25211237[PMID]
3463,Wolfram syndrome,Disease,Point prevalence,0.62,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
549,Legionnaires disease,Disease,Annual incidence,1.4,1-9 / 100 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,2.5,1-9 / 100 000,Value and class,France,Validated,21109475[PMID]
549,Legionnaires disease,Disease,Annual incidence,1.82,1-9 / 100 000,Value and class,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,1.38,1-9 / 100 000,Value and class,Belgium,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.8,1-9 / 1 000 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2014-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.42,1-9 / 1 000 000,Value and class,Cyprus,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,1.24,1-9 / 100 000,Value and class,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,3.18,1-9 / 100 000,Value and class,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.84,1-9 / 1 000 000,Value and class,Estonia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.32,1-9 / 1 000 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,1.18,1-9 / 100 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.83,1-9 / 1 000 000,Value and class,Iceland,Validated,European Centre for Disease prevention and Control 2014-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.28,1-9 / 1 000 000,Value and class,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,2.72,1-9 / 100 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,1.5,1-9 / 100 000,Value and class,Latvia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.28,1-9 / 1 000 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,1.02,1-9 / 100 000,Value and class,Luxembourg,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,1.88,1-9 / 100 000,Value and class,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,2.48,1-9 / 100 000,Value and class,Netherlands,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.96,1-9 / 1 000 000,Value and class,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Poland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,2.42,1-9 / 100 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,4.38,1-9 / 100 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,2.16,1-9 / 100 000,Value and class,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,1.52,1-9 / 100 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.62,1-9 / 1 000 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
549,Legionnaires disease,Disease,Annual incidence,5.4,1-9 / 100 000,Value and class,New Zealand,Validated,31294928[PMID]
704,Pemphigus vulgaris,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,France,Validated,7829889[PMID]
704,Pemphigus vulgaris,Disease,Point prevalence,18.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
704,Pemphigus vulgaris,Disease,Annual incidence,0.7,1-9 / 1 000 000,Value and class,United Kingdom,Validated,18614511[PMID]
704,Pemphigus vulgaris,Disease,Annual incidence,0.076,<1 / 1 000 000,Value and class,Finland,Validated,6187153[PMID]
704,Pemphigus vulgaris,Disease,Annual incidence,0.47,1-9 / 1 000 000,Value and class,Bulgaria,Validated,10692058[PMID]
704,Pemphigus vulgaris,Disease,Annual incidence,0.42,1-9 / 1 000 000,Value and class,United States,Validated,7416755[PMID]
704,Pemphigus vulgaris,Disease,Annual incidence,0.25,1-9 / 1 000 000,Value and class,Tunisia,Validated,7829889[PMID]
704,Pemphigus vulgaris,Disease,Point prevalence,9.482,1-9 / 100 000,Value and class,Germany,Validated,27456755[PMID]
199354,Cerebral autosomal recessive arteriopathy-subcortical infarcts-leukoencephalopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
199351,Adult-onset dystonia-parkinsonism,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,18570303[PMID]_20938027[PMID]
199351,Adult-onset dystonia-parkinsonism,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
356,Gerstmann-Straussler-Scheinker syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
356,Gerstmann-Straussler-Scheinker syndrome,Disease,Annual incidence,0.0055,<1 / 1 000 000,Value and class,Worldwide,Validated,16903147[PMID]
268316,Complication in hemodialysis,Particular clinical situation in a disease or syndrome,Annual incidence,13.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2011[INST]
268316,Complication in hemodialysis,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
268162,Intermediate maple syrup urine disease,Clinical subtype,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
268162,Intermediate maple syrup urine disease,Clinical subtype,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2832,Short tarsus-absence of lower eyelashes syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,7889642[PMID]
2832,Short tarsus-absence of lower eyelashes syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7889642[PMID]
268145,Classic maple syrup urine disease,Clinical subtype,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
268145,Classic maple syrup urine disease,Clinical subtype,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
268184,Thiamine-responsive maple syrup urine disease,Clinical subtype,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
268184,Thiamine-responsive maple syrup urine disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
2833,Stiff skin syndrome,Disease,Cases/families,54.0,,Case(s),Worldwide,Validated,27846975[PMID]_26944597[PMID]
2833,Stiff skin syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27846975[PMID]_26944597[PMID]
199293,Congenital microgastria,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28361011[PMID]
3452,Whipple disease,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,[EXPERT]
3452,Whipple disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3452,Whipple disease,Disease,Point prevalence,0.29,1-9 / 1 000 000,Value and class,Italy,Validated,25804189[PMID]
3452,Whipple disease,Disease,Point prevalence,0.98,1-9 / 1 000 000,Value and class,United States,Validated,30488239[PMID]
2962,De Barsy syndrome,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,ORPHANET
2962,De Barsy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2972,Non-eruption of teeth-maxillary hypoplasia-genu valgum syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,975598[PMID]
2972,Non-eruption of teeth-maxillary hypoplasia-genu valgum syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2102,GTP cyclohydrolase I deficiency,Clinical subtype,Cases/families,16.0,,Case(s),Worldwide,Validated,ORPHANET
2102,GTP cyclohydrolase I deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2976,"Pseudoleprechaunism syndrome, Patterson type",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7277424 [PMID]
2976,"Pseudoleprechaunism syndrome, Patterson type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7277424 [PMID][PMID]
3002,Immune thrombocytopenia,Disease,Point prevalence,25.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2007[INST]
3002,Immune thrombocytopenia,Disease,Point prevalence,9.5,1-9 / 100 000,Value and class,United States,Validated,19200301[PMID]
3002,Immune thrombocytopenia,Disease,Annual incidence,3.9,1-9 / 100 000,Value and class,United Kingdom,Validated,19245432[PMID]
3002,Immune thrombocytopenia,Disease,Annual incidence,6.75,1-9 / 100 000,Value and class,Europe,Not yet validated,ISBN:70703868[OTHER]_ORPHANET
3002,Immune thrombocytopenia,Disease,Annual incidence,2.68,1-9 / 100 000,Value and class,Denmark,Validated,10419881[PMID]
3002,Immune thrombocytopenia,Disease,Point prevalence,45.0,1-5 / 10 000,Value and class,Denmark,Validated,20066507[PMID]
3002,Immune thrombocytopenia,Disease,Annual incidence,2.9,1-9 / 100 000,Value and class,France,Validated,25305203[PMID]
199267,Infantile digital fibromatosis,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,23157779[PMID]
199267,Infantile digital fibromatosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2946,Brachydactyly-long thumb syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,7246605[PMID]
2946,Brachydactyly-long thumb syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7246605[PMID]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Europe,Validated,16053904[PMID]_EUROCAT European surveillance of congenital anomalies 2009-2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,4.5,1-9 / 100 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,5.8,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,5.7,1-9 / 100 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,10.8,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,3.2,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,1.2,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,19.0,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,9.7,1-9 / 100 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,13.6,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,24.1,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,1.2,1-9 / 100 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Prevalence at birth,3.2,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1848,"Renal agenesis, bilateral",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
2951,Absent thumb-short stature-immunodeficiency syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,728551[PMID]
2951,Absent thumb-short stature-immunodeficiency syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_728551[PMID]
3020,Ramsay Hunt syndrome,Disease,Annual incidence,5.0,1-9 / 100 000,Value and class,United States,Validated,23763077[PMID]_24799517[PMID]
3020,Ramsay Hunt syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
264978,Drug or radiation exposure-related interstitial lung disease,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2956,Acrodysplasia scoliosis,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,6335370[PMID]
2956,Acrodysplasia scoliosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6335370[PMID]
1675,Dihydropyrimidine dehydrogenase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
189427,Cushing syndrome due to bilateral macronodular adrenocortical disease,Disease,Point prevalence,0.08,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
976,Adenine phosphoribosyltransferase deficiency,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Specific population,Validated,[EXPERT]
976,Adenine phosphoribosyltransferase deficiency,Disease,Point prevalence,3.7,1-9 / 100 000,Value and class,Japan,Validated,[EXPERT]
976,Adenine phosphoribosyltransferase deficiency,Disease,Point prevalence,6.7,1-9 / 100 000,Value and class,Iceland,Validated,[EXPERT]
976,Adenine phosphoribosyltransferase deficiency,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
2958,X-linked intellectual disability-dysmorphism-cerebral atrophy syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,3121220[PMID]
2958,X-linked intellectual disability-dysmorphism-cerebral atrophy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3121220[PMID]
415,Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25874378[PMID]
415,Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2013[INST]
415,Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome,Disease,Cases/families,111.0,,Case(s),Worldwide,Validated,25874378[PMID]
415,Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome,Disease,Prevalence at birth,0.0,<1 / 1 000 000,Class only,United States,Validated,23972786[PMID]
13,6-pyruvoyl-tetrahydropterin synthase deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,30853107[PMID]_32456656[PMID]_ORPHANET
13,6-pyruvoyl-tetrahydropterin synthase deficiency,Clinical subtype,Prevalence at birth,0.0,<1 / 1 000 000,Class only,Europe,Validated,30853107[PMID]_32456656[PMID]
13,6-pyruvoyl-tetrahydropterin synthase deficiency,Clinical subtype,Prevalence at birth,0.0854,<1 / 1 000 000,Value and class,Brazil,Validated,28801146[PMID]
13,6-pyruvoyl-tetrahydropterin synthase deficiency,Clinical subtype,Prevalence at birth,0.3094,1-9 / 1 000 000,Value and class,China,Validated,33980295[PMID]
13,6-pyruvoyl-tetrahydropterin synthase deficiency,Clinical subtype,Prevalence at birth,2.5258,1-9 / 100 000,Value and class,Hong Kong,Validated,24803483[PMID]_24992243[PMID]
2935,Crossed polysyndactyly,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,8042663[PMID]_20127219 [PMID]
2935,Crossed polysyndactyly,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8042663[PMID]_20127219 [PMID]
2934,Polysyndactyly-cardiac malformation syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,12749069[PMID]_19400539[PMID]
2934,Polysyndactyly-cardiac malformation syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12749069[PMID]_19400539[PMID]
2941,Porencephaly-cerebellar hypoplasia-internal malformations syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8737647[PMID]
2941,Porencephaly-cerebellar hypoplasia-internal malformations syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8737647[PMID]
2940,Porencephaly,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2940,Porencephaly,Disease,Prevalence at birth,3.5,1-9 / 100 000,Value and class,United States,Validated,18383510[PMID]
2940,Porencephaly,Disease,Prevalence at birth,5.2,1-9 / 100 000,Value and class,Japan,Validated,26545857[PMID]
2896,Pitt-Hopkins syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET_[EXPERT]_30677142[PMID]
2896,Pitt-Hopkins syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2900,Leri pleonosteosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2905,POEMS syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
2905,POEMS syndrome,Disease,Point prevalence,0.33,1-9 / 1 000 000,Value and class,Japan,Validated,22338030[PMID]
2134,Atypical hemolytic uremic syndrome,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,United States,Validated,15168377[PMID]_21902819[PMID]
2134,Atypical hemolytic uremic syndrome,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
2134,Atypical hemolytic uremic syndrome,Disease,Point prevalence,0.0278,<1 / 1 000 000,Value and class,China,Validated,34103049[PMID]
2911,Poland syndrome,Malformation syndrome,Prevalence at birth,3.1,1-9 / 100 000,Value and class,Canada,Validated,205132[PMID]
2911,Poland syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Canada,Not yet validated,205132[PMID]
2911,Poland syndrome,Malformation syndrome,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
2911,Poland syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
1934,Early infantile epileptic encephalopathy,Clinical syndrome,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Japan,Validated,19828294[PMID]
1934,Early infantile epileptic encephalopathy,Clinical syndrome,Prevalence at birth,2.0,1-9 / 100 000,Value and class,United Kingdom,Validated,23252366[PMID]_[EXPERT]
1934,Early infantile epileptic encephalopathy,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
845,Tay-Sachs disease,Disease,Prevalence at birth,27.8,1-5 / 10 000,Value and class,Specific population,Validated,20301397[PMID]
845,Tay-Sachs disease,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Specific population,Not yet validated,ORPHANET
845,Tay-Sachs disease,Disease,Prevalence at birth,0.31,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET
845,Tay-Sachs disease,Disease,Prevalence at birth,3.13,1-9 / 100 000,Value and class,Portugal,Validated,14685153[PMID]
845,Tay-Sachs disease,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
845,Tay-Sachs disease,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
845,Tay-Sachs disease,Disease,Prevalence at birth,0.28,1-9 / 1 000 000,Value and class,Worldwide,Validated,ISBN:0870684507[OTHER]
845,Tay-Sachs disease,Disease,Prevalence at birth,0.41,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
845,Tay-Sachs disease,Disease,Prevalence at birth,0.29,1-9 / 1 000 000,Value and class,Canada,Validated,10617747[PMID]
845,Tay-Sachs disease,Disease,Prevalence at birth,0.74,1-9 / 1 000 000,Value and class,United Arab Emirates,Validated,23430803[PMID]
845,Tay-Sachs disease,Disease,Prevalence at birth,0.23,1-9 / 1 000 000,Value and class,Turkey,Validated,15275696[PMID]
845,Tay-Sachs disease,Disease,Prevalence at birth,0.48,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
845,Tay-Sachs disease,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
845,Tay-Sachs disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1942,Myoclonic-astatic epilepsy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2921,Preaxial polydactyly-colobomata-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3441111[PMID]
2921,Preaxial polydactyly-colobomata-intellectual disability syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3441111[PMID]
3451,Infantile epileptic spasms syndrome,Clinical syndrome,Point prevalence,6.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2017[INST]
3451,Infantile epileptic spasms syndrome,Clinical syndrome,Prevalence at birth,3.5,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET_11701251[PMID]_8082625[PMID]_7555969[PMID]
3451,Infantile epileptic spasms syndrome,Clinical syndrome,Prevalence at birth,3.7,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]_ORPHANET
3451,Infantile epileptic spasms syndrome,Clinical syndrome,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Finland,Validated,11701251[PMID]_8082625[PMID]
3451,Infantile epileptic spasms syndrome,Clinical syndrome,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Iceland,Validated,11701251[PMID]_8082625[PMID]
3451,Infantile epileptic spasms syndrome,Clinical syndrome,Prevalence at birth,4.5,1-9 / 100 000,Value and class,Sweden,Validated,7555969[PMID]
3451,Infantile epileptic spasms syndrome,Clinical syndrome,Prevalence at birth,2.9,1-9 / 100 000,Value and class,United States,Validated,10368073[PMID]
3451,Infantile epileptic spasms syndrome,Clinical syndrome,Prevalence at birth,31.0,1-5 / 10 000,Value and class,Singapore,Validated,11701260[PMID]
3451,Infantile epileptic spasms syndrome,Clinical syndrome,Prevalence at birth,25.0,1-5 / 10 000,Value and class,"Korea, Republic of",Validated,11701256[PMID]
3451,Infantile epileptic spasms syndrome,Clinical syndrome,Prevalence at birth,3.25,1-9 / 100 000,Value and class,Japan,Not yet validated,11701258[PMID]_17633081[PMID]_ORPHANET
3299,Tetanus,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,France,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.024,<1 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.044,<1 / 1 000 000,Value and class,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.028,<1 / 1 000 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.032,<1 / 1 000 000,Value and class,Estonia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.036,<1 / 1 000 000,Value and class,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.024,<1 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.076,<1 / 1 000 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Netherlands,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.032,<1 / 1 000 000,Value and class,Poland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.032,<1 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.118,1-9 / 1 000 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3299,Tetanus,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
275786,Drug- or toxin-induced pulmonary arterial hypertension,Clinical group,Point prevalence,0.0,1-9 / 1 000 000,Class only,France,Validated,16456139[PMID]_ORPHANET
275791,Pulmonary arterial hypertension associated with another disease,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3369,Trigonocephaly-short stature-developmental delay syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,6168197[PMID]
3369,Trigonocephaly-short stature-developmental delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6168197[PMID]
3386,American trypanosomiasis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,21944556[PMID]
3386,American trypanosomiasis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,France,Not yet validated,21944556[PMID]
3386,American trypanosomiasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Germany,Not yet validated,21944556[PMID]
3386,American trypanosomiasis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Italy,Not yet validated,21944556[PMID]
3386,American trypanosomiasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Netherlands,Not yet validated,21944556[PMID]
3386,American trypanosomiasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Portugal,Not yet validated,21944556[PMID]
3386,American trypanosomiasis,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Spain,Not yet validated,21944556[PMID]
3386,American trypanosomiasis,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Switzerland,Not yet validated,21944556[PMID]
3386,American trypanosomiasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,United Kingdom,Not yet validated,21944556[PMID]
3386,American trypanosomiasis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Belgium,Not yet validated,21944556[PMID]
3386,American trypanosomiasis,Disease,Point prevalence,95.0,6-9 / 10 000,Value and class,United States,Validated,19640226[PMID]_Center for Diseases Control and Prevention [INST]
3363,Trichomegaly-retina pigmentary degeneration-dwarfism syndrome,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,25480986[PMID]
3363,Trichomegaly-retina pigmentary degeneration-dwarfism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25480986[PMID]
275761,Lysosomal acid lipase deficiency,Disease,Prevalence at birth,0.27,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
275761,Lysosomal acid lipase deficiency,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
3366,Non-syndromic metopic craniosynostosis,Morphological anomaly,Prevalence at birth,6.7,1-9 / 100 000,Value and class,Europe,Not yet validated,21931569[PMID]_19326483[PMID]
3366,Non-syndromic metopic craniosynostosis,Morphological anomaly,Point prevalence,10.2979,1-5 / 10 000,Value and class,Europe,Validated,ORPHANET
3365,Trigonocephaly-broad thumbs syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1271432[PMID]
3365,Trigonocephaly-broad thumbs syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1271432[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.07,<1 / 1 000 000,Value and class,Sweden,Validated,28595941[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.76,1-9 / 1 000 000,Value and class,Norway,Validated,18681890[PMID]
582,Mucopolysaccharidosis type 4,Disease,Point prevalence,24.2,1-5 / 10 000,Value and class,Norway,Validated,18681890[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.48,1-9 / 1 000 000,Value and class,Denmark,Validated,18681890[PMID]
582,Mucopolysaccharidosis type 4,Disease,Point prevalence,31.0,1-5 / 10 000,Value and class,Denmark,Validated,18681890[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.73,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.45,1-9 / 1 000 000,Value and class,Tunisia,Validated,20209839[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.33,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,19396827[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.45,1-9 / 1 000 000,Value and class,Europe,Validated,28595941[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.36,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.14,1-9 / 1 000 000,Value and class,Poland,Validated,25472774[PMID]
582,Mucopolysaccharidosis type 4,Disease,Point prevalence,27.6,1-5 / 10 000,Value and class,Europe,Validated,18681890[PMID]_ORPHANET
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.15,1-9 / 1 000 000,Value and class,Japan,Validated,28595941[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Switzerland,Validated,28595941[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,3.62,1-9 / 100 000,Value and class,Saudi Arabia,Validated,20622343[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.13,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,25364648[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.14,1-9 / 1 000 000,Value and class,Brazil,Validated,31926052[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,Portugal,Validated,14685153[PMID]
582,Mucopolysaccharidosis type 4,Disease,Point prevalence,0.038,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.14,1-9 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
582,Mucopolysaccharidosis type 4,Disease,Prevalence at birth,0.07,<1 / 1 000 000,Value and class,Worldwide,Validated,28595941[PMID]
3361,Trichodysplasia-xeroderma syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,3608221[PMID]
3361,Trichodysplasia-xeroderma syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3608221[PMID]
3408,Upington disease,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,5316541[PMID]
3408,Upington disease,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5316541[PMID]
3409,Urban-Rogers-Meyer syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,758422[PMID]_3239569[PMID]
3409,Urban-Rogers-Meyer syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_758422[PMID]_3239569[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,2.57,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
186,Primary biliary cholangitis,Disease,Point prevalence,21.05,1-5 / 10 000,Value and class,Worldwide,Validated,[EXPERT]_22245904[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,3.0,1-9 / 100 000,Value and class,Worldwide,Validated,22245904[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,25.0,1-5 / 10 000,Value and class,Europe,Validated,17873609[PMID]_22562114[PMID]_24387641[PMID]_17918011[PMID]_22961000[PMID]_10421645[PMID]_9279616[PMID]_20347176[PMID]_24502439[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,0.9,1-9 / 1 000 000,Value and class,France,Validated,20347176[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,1.7,1-9 / 100 000,Value and class,Spain,Validated,17873609[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,19.5,1-5 / 10 000,Value and class,Spain,Validated,17873609[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,2.5,1-9 / 100 000,Value and class,Iceland,Validated,22562114[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,38.3,1-5 / 10 000,Value and class,Iceland,Validated,22562114[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,1.1,1-9 / 100 000,Value and class,Netherlands,Validated,24387641[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,13.2,1-5 / 10 000,Value and class,Netherlands,Validated,24387641[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,1.7,1-9 / 100 000,Value and class,Denmark,Validated,17918011[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,12.0,1-5 / 10 000,Value and class,Denmark,Validated,17918011[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,1.7,1-9 / 100 000,Value and class,Finland,Validated,17918011[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,18.0,1-5 / 10 000,Value and class,Finland,Validated,17918011[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,25.0,1-5 / 10 000,Value and class,United Kingdom,Validated,22961000[PMID]_9279616[PMID]_10421645[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,4.5,1-9 / 100 000,Value and class,United States,Validated,11113084[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,40.2,1-5 / 10 000,Value and class,United States,Validated,11113084[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,3.0,1-9 / 100 000,Value and class,Canada,Validated,19821525[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,22.7,1-5 / 10 000,Value and class,Canada,Validated,19821525[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,5.1,1-9 / 100 000,Value and class,Australia,Validated,15300579[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,5.5,1-9 / 100 000,Value and class,Israel,Validated,16308995[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,4.9,1-9 / 100 000,Value and class,China,Validated,20815889[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Brunei Darussalam,Validated,21134832[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,2.6,1-9 / 100 000,Value and class,Brunei Darussalam,Validated,21134832[PMID]
186,Primary biliary cholangitis,Disease,Point prevalence,36.5,1-5 / 10 000,Value and class,Greece,Validated,24502439[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,2.1,1-9 / 100 000,Value and class,Greece,Validated,24502439[PMID]
186,Primary biliary cholangitis,Disease,Annual incidence,2.3,1-9 / 100 000,Value and class,United Kingdom,Validated,10421645[PMID]_9279616[PMID]
397,Giant cell arteritis,Disease,Point prevalence,8.9,1-9 / 100 000,Value and class,Germany,Validated,11136884[PMID]
397,Giant cell arteritis,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,United States,Validated,6626279[PMID]
397,Giant cell arteritis,Disease,Annual incidence,2.8,1-9 / 100 000,Value and class,Italy,Validated,2003856[PMID]
397,Giant cell arteritis,Disease,Annual incidence,7.7,1-9 / 100 000,Value and class,Sweden,Validated,10587547[PMID]
397,Giant cell arteritis,Disease,Annual incidence,11.2,1-5 / 10 000,Value and class,United Kingdom,Validated,25132663[PMID]
397,Giant cell arteritis,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,ORPHANET
397,Giant cell arteritis,Disease,Point prevalence,30.4,1-5 / 10 000,Value and class,Italy,Validated,27214746[PMID]
397,Giant cell arteritis,Disease,Annual incidence,16.8,1-5 / 10 000,Value and class,Norway,Validated,31909871[PMID]
2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Point prevalence,3.7,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Annual incidence,0.36,1-9 / 1 000 000,Value and class,Italy,Validated,17494979[PMID]
2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Point prevalence,2.6,1-9 / 100 000,Value and class,United Kingdom,Not yet validated,23679015[PMID]_10209187[PMID]_19260065[PMID]
2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Point prevalence,3.86,1-9 / 100 000,Value and class,Italy,Validated,17494979[PMID]
2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Point prevalence,7.7,1-9 / 100 000,Value and class,Norway,Validated,11284994[PMID]
2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Point prevalence,12.0,1-5 / 10 000,Value and class,Egypt,Validated,23146298[PMID]
2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Annual incidence,0.48,1-9 / 1 000 000,Value and class,Japan,Validated,18223015[PMID]
2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Point prevalence,1.61,1-9 / 100 000,Value and class,Japan,Validated,18223015[PMID]
2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Australia,Validated,10589544[PMID]
2932,Chronic inflammatory demyelinating polyneuropathy,Disease,Point prevalence,1.9,1-9 / 100 000,Value and class,Australia,Validated,10589544[PMID]
2398,Multiple symmetric lipomatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2398,Multiple symmetric lipomatosis,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Italy,Validated,[EXPERT]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,4.3,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,4.8,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,5.8,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,9.8,1-9 / 100 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,5.8,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,5.5,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,3.6,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,2.8,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,5.8,1-9 / 100 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,3.3,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,1.9,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,12.6,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,7.7,1-9 / 100 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3384,Common arterial trunk,Morphological anomaly,Prevalence at birth,6.4,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
3384,Common arterial trunk,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3198,Stiff person spectrum disorder,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,21921002[PMID]_ORPHANET
3198,Stiff person spectrum disorder,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,United Kingdom,Validated,21921002[PMID]
3198,Stiff person spectrum disorder,Disease,Point prevalence,0.09,<1 / 1 000 000,Value and class,"Tanzania, United Republic of",Validated,26316197[PMID]
275944,Hemolytic disease of the newborn with Kell alloimmunization,Disease,Annual incidence,116.0,>1 / 1000,Value and class,United Kingdom,Validated,2081378[PMID]
275944,Hemolytic disease of the newborn with Kell alloimmunization,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3388,Neural tube defect,Category,Prevalence at birth,55.0,6-9 / 10 000,Value and class,United States,Validated,Center for Diseases Control and Prevention 2004[INST]_26108864[PMID]
3388,Neural tube defect,Category,Prevalence at birth,91.05,6-9 / 10 000,Value and class,Europe,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
3388,Neural tube defect,Category,Prevalence at birth,88.75,6-9 / 10 000,Value and class,Belgium,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
3388,Neural tube defect,Category,Prevalence at birth,76.8,6-9 / 10 000,Value and class,Austria,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2009[REG]
3388,Neural tube defect,Category,Prevalence at birth,74.7,6-9 / 10 000,Value and class,Czech Republic,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 2000-2009[REG]
3388,Neural tube defect,Category,Prevalence at birth,47.9,1-5 / 10 000,Value and class,Croatia,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG]
3388,Neural tube defect,Category,Prevalence at birth,109.6,>1 / 1000,Value and class,Denmark,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
3388,Neural tube defect,Category,Prevalence at birth,86.7,6-9 / 10 000,Value and class,Finland,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1993-2010[REG]
3388,Neural tube defect,Category,Prevalence at birth,120.2,>1 / 1000,Value and class,France,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
3388,Neural tube defect,Category,Prevalence at birth,138.25,>1 / 1000,Value and class,Germany,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
3388,Neural tube defect,Category,Prevalence at birth,67.2,6-9 / 10 000,Value and class,Hungary,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1998-2010[REG]
3388,Neural tube defect,Category,Prevalence at birth,87.4,6-9 / 10 000,Value and class,Ireland,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
3388,Neural tube defect,Category,Prevalence at birth,54.65,1-5 / 10 000,Value and class,Italy,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
3388,Neural tube defect,Category,Prevalence at birth,109.5,>1 / 1000,Value and class,Malta,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG]
3388,Neural tube defect,Category,Prevalence at birth,84.2,6-9 / 10 000,Value and class,Netherlands,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
3388,Neural tube defect,Category,Prevalence at birth,92.7,6-9 / 10 000,Value and class,Norway,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1999-2011[REG]
3388,Neural tube defect,Category,Prevalence at birth,92.5,6-9 / 10 000,Value and class,Poland,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1999-2010[REG]
3388,Neural tube defect,Category,Prevalence at birth,47.3,1-5 / 10 000,Value and class,Portugal,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG]
3388,Neural tube defect,Category,Prevalence at birth,98.5,6-9 / 10 000,Value and class,Spain,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2010[REG]
3388,Neural tube defect,Category,Prevalence at birth,101.7,>1 / 1000,Value and class,Switzerland,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
3388,Neural tube defect,Category,Prevalence at birth,115.5,>1 / 1000,Value and class,United Kingdom,Validated,26601850[PMID]_EUROCAT European surveillance of congenital anomalies 1991-2011[REG]
3388,Neural tube defect,Category,Prevalence at birth,1387.0,>1 / 1000,Value and class,China,Validated,16575897[PMID]
3388,Neural tube defect,Category,Prevalence at birth,31.0,1-5 / 10 000,Value and class,Brazil,Validated,23990401[PMID]
1723,Mosaic trisomy 2 syndrome,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,23276565[PMID]
1723,Mosaic trisomy 2 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23276565[PMID]
275828,Pulmonary arterial hypertension associated with chronic hemolytic anemia,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1724,Mosaic trisomy 20 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_23548241[PMID]
1747,Mosaic trisomy 7 syndrome,Malformation syndrome,Cases/families,31.0,,Case(s),Worldwide,Validated,28099615[PMID]_21056320[PMID]
1747,Mosaic trisomy 7 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28099615[PMID]_21056320[PMID]
3329,Tibial aplasia-ectrodactyly syndrome,Malformation syndrome,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
3328,Absent tibia-polydactyly-arachnoid cyst syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,8592337[PMID]
3328,Absent tibia-polydactyly-arachnoid cyst syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8592337[PMID]
3327,Thyrocerebrorenal syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,728567[PMID]
3327,Thyrocerebrorenal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_728567[PMID]
3326,Thymic-renal-anal-lung dysplasia,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,2260572[PMID]
3326,Thymic-renal-anal-lung dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2260572[PMID]
3322,Hoyeraal-Hreidarsson syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3322,Hoyeraal-Hreidarsson syndrome,Disease,Cases/families,33.0,,Case(s),Worldwide,Validated,23453664[PMID]_23453664[PMID]_23329068[PMID]
3317,Thoracolaryngopelvic dysplasia,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
3317,Thoracolaryngopelvic dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3316,Thomas syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,8456859[PMID]_8882777[PMID]
3316,Thomas syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8456859[PMID]_8882777[PMID]
3314,"Thiemann disease, familial form",Disease,Cases/families,33.0,,Case(s),Worldwide,Validated,31248428[PMID]
3314,"Thiemann disease, familial form",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_31248428[PMID]
3355,Trichoodontoonychial dysplasia,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,6859125[PMID]
3355,Trichoodontoonychial dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6859125[PMID]
275555,Preeclampsia,Disease,Point prevalence,45.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2011[INST]
275543,L1 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1489,Whooping cough,Disease,Annual incidence,8.9,1-9 / 100 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,9.76,1-9 / 100 000,Value and class,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,10.08,1-5 / 10 000,Value and class,Belgium,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,1.08,1-9 / 100 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,0.88,1-9 / 1 000 000,Value and class,Cyprus,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,10.7,1-5 / 10 000,Value and class,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,19.16,1-5 / 10 000,Value and class,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,4.66,1-9 / 100 000,Value and class,Estonia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,5.1,1-9 / 100 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,15.4,1-5 / 10 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,0.38,1-9 / 1 000 000,Value and class,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,2.34,1-9 / 100 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,5.3,1-9 / 100 000,Value and class,Iceland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,3.58,1-9 / 100 000,Value and class,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,1.2,1-9 / 100 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,8.48,1-9 / 100 000,Value and class,Latvia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,2.22,1-9 / 100 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,2.14,1-9 / 100 000,Value and class,Luxembourg,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,0.52,1-9 / 1 000 000,Value and class,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,31.72,1-5 / 10 000,Value and class,Netherlands,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,47.24,1-5 / 10 000,Value and class,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,10.6,1-5 / 10 000,Value and class,Poland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,2.1,1-9 / 100 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,0.42,1-9 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,10.5,1-5 / 10 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,9.5,1-9 / 100 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,8.3,1-9 / 100 000,Value and class,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,6.2,1-9 / 100 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1489,Whooping cough,Disease,Annual incidence,8.5,1-9 / 100 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
2764,Osteochondritis dissecans,Disease,Point prevalence,35.0,1-5 / 10 000,Value and class,Europe,Not yet validated,16958015[PMID]
3389,Tuberculosis,Clinical group,Annual incidence,4.0,1-9 / 100 000,Value and class,Greece,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,5.0,1-9 / 100 000,Value and class,Iceland,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,6.0,1-9 / 100 000,Value and class,Israel,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,15.0,1-5 / 10 000,Value and class,Spain,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,24.0,1-5 / 10 000,Value and class,Portugal,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,8.0,1-9 / 100 000,Value and class,Belgium,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,4.0,1-9 / 100 000,Value and class,Austria,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,90.0,6-9 / 10 000,Value and class,Algeria,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,23.0,1-5 / 10 000,Value and class,Poland,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,42.0,1-5 / 10 000,Value and class,Latvia,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,59.0,1-5 / 10 000,Value and class,Lithuania,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,49.0,1-5 / 10 000,Value and class,Bosnia and Herzegovina,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,17.0,1-5 / 10 000,Value and class,Croatia,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,101.0,>1 / 1000,Value and class,Romania,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,97.0,6-9 / 10 000,Value and class,Russian Federation,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,139.0,>1 / 1000,Value and class,Worldwide,Validated,21420560[PMID]
3389,Tuberculosis,Clinical group,Point prevalence,16.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
3389,Tuberculosis,Clinical group,Annual incidence,3.4,1-9 / 100 000,Value and class,United States,Validated,Centers for Disease Control and Prevention 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,20.0,1-5 / 10 000,Value and class,Japan,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,6.0,1-9 / 100 000,Value and class,Australia,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,4.0,1-9 / 100 000,Value and class,France,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,8.0,1-9 / 100 000,Value and class,Finland,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,18.0,1-5 / 10 000,Value and class,Hungary,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,181.0,>1 / 1000,Value and class,India,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,7.0,1-9 / 100 000,Value and class,Netherlands,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,14.0,1-5 / 10 000,Value and class,United Kingdom,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,6.0,1-9 / 100 000,Value and class,Norway,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,7.0,1-9 / 100 000,Value and class,Sweden,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,75.0,6-9 / 10 000,Value and class,China,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,47.0,1-5 / 10 000,Value and class,Latin America,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,993.0,>1 / 1000,Value and class,South Africa,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,7.1,1-9 / 100 000,Value and class,Denmark,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,6.0,1-9 / 100 000,Value and class,Czech Republic,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,5.0,1-9 / 100 000,Value and class,Germany,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,10.7,1-5 / 10 000,Value and class,Ireland,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,3.0,1-9 / 100 000,Value and class,Italy,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,25.0,1-5 / 10 000,Value and class,Estonia,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,24.0,1-5 / 10 000,Value and class,Turkey,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,89.0,6-9 / 10 000,Value and class,Ukraine,Validated,World Health Organization 2011[INST]
3389,Tuberculosis,Clinical group,Annual incidence,9.0,1-9 / 100 000,Value and class,Europe,Validated,World Health Organization 2011[INST]
1679,Diphtheria,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
279943,Hereditary neutrophilia,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,19620628[PMID]
279943,Hereditary neutrophilia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19620628[PMID]
279934,"Mitochondrial DNA depletion syndrome, hepatocerebral form due to DGUOK deficiency",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
279934,"Mitochondrial DNA depletion syndrome, hepatocerebral form due to DGUOK deficiency",Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,29137425[PMID]_[EXPERT]
3152,Sclerosteosis,Malformation syndrome,Cases/families,80.0,,Case(s),Worldwide,Validated,20301406[PMID]
3152,Sclerosteosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301406[PMID]
280142,Severe combined immunodeficiency due to LCK deficiency,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,9664084[PMID]_22985903[PMID]
280142,Severe combined immunodeficiency due to LCK deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3164,"Omphalocele syndrome, Shprintzen-Goldberg type",Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,16411191[PMID]
3164,"Omphalocele syndrome, Shprintzen-Goldberg type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16411191[PMID]
3168,Sillence syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,671485[PMID]
3168,Sillence syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280133,Complement component 3 deficiency,Disease,Cases/families,27.0,,Case(s),Worldwide,Validated,21664996[PMID]
280133,Complement component 3 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21664996[PMID]
2103,Guillain-Barré syndrome,Clinical group,Annual incidence,1.45,1-9 / 100 000,Value and class,Worldwide,Validated,19088488[PMID]_[EXPERT]_ ORPHANET
2103,Guillain-Barré syndrome,Clinical group,Annual incidence,1.72,1-9 / 100 000,Value and class,United States,Validated,22846726[PMID]
2103,Guillain-Barré syndrome,Clinical group,Point prevalence,3.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_European Medicines Agency 2007[INST]_ ORPHANET
2103,Guillain-Barré syndrome,Clinical group,Point prevalence,25.0,1-5 / 10 000,Value and class,Denmark,Validated,20066507[PMID]
2103,Guillain-Barré syndrome,Clinical group,Annual incidence,1.4,1-9 / 100 000,Value and class,Europe,Not yet validated,22694000[PMID]_ORPHANET
2103,Guillain-Barré syndrome,Clinical group,Point prevalence,12.0,1-5 / 10 000,Value and class,Egypt,Validated,23146298[PMID]
2103,Guillain-Barré syndrome,Clinical group,Annual incidence,2.42,1-9 / 100 000,Value and class,France,Validated,27991707[PMID]
3156,Senior-Loken syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Worldwide,Validated,33109693[PMID]
183669,Agammaglobulinemia,Category,Point prevalence,0.13,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
183669,Agammaglobulinemia,Category,Point prevalence,0.287,1-9 / 1 000 000,Value and class,France,Validated,22288591[PMID]
183669,Agammaglobulinemia,Category,Point prevalence,0.134,1-9 / 1 000 000,Value and class,Spain,Validated,22288591[PMID]
183669,Agammaglobulinemia,Category,Point prevalence,0.192,1-9 / 1 000 000,Value and class,Netherlands,Validated,22288591[PMID]
183669,Agammaglobulinemia,Category,Point prevalence,0.045,<1 / 1 000 000,Value and class,Turkey,Validated,22288591[PMID]
183669,Agammaglobulinemia,Category,Point prevalence,0.094,<1 / 1 000 000,Value and class,United Kingdom,Validated,22288591[PMID]
183669,Agammaglobulinemia,Category,Point prevalence,0.205,1-9 / 1 000 000,Value and class,Italy,Validated,22288591[PMID]
183669,Agammaglobulinemia,Category,Point prevalence,0.077,<1 / 1 000 000,Value and class,Germany,Validated,22288591[PMID]
183669,Agammaglobulinemia,Category,Point prevalence,0.071,<1 / 1 000 000,Value and class,Poland,Validated,22288591[PMID]
3180,Spondylocamptodactyly syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,8591666[PMID]
3180,Spondylocamptodactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8591666[PMID]
280210,"Pelizaeus-Merzbacher disease, connatal form",Clinical subtype,Point prevalence,0.03,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
280219,"Pelizaeus-Merzbacher disease, classic form",Clinical subtype,Point prevalence,0.17,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
280200,Microform holoprosencephaly,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
183678,Hermansky-Pudlak syndrome due to AP-3 deficiency,Clinical subtype,Cases/families,40.0,,Case(s),Worldwide,Validated,29580292[PMID]
183678,Hermansky-Pudlak syndrome due to AP-3 deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29580292[PMID]
449,Hepatoblastoma,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.019,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.042,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.046,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.031,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.021,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.022,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.031,<1 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.033,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.023,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.032,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.025,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.032,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
449,Hepatoblastoma,Disease,Annual incidence,0.028,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
280234,Null syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1855,Spondyloenchondrodysplasia,Malformation syndrome,Cases/families,36.0,,Case(s),Worldwide,Validated,16470600[PMID]
1855,Spondyloenchondrodysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16470600[PMID]
280224,"Pelizaeus-Merzbacher disease, transitional form",Clinical subtype,Point prevalence,0.03,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
1797,Autosomal dominant spondylocostal dysostosis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
280229,Pelizaeus-Merzbacher disease in female carriers,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
276580,Autosomal dominant hyperinsulinism due to Kir6.2 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
533,Listeriosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
533,Listeriosis,Disease,Annual incidence,0.43,1-9 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.337,1-9 / 1 000 000,Value and class,Worldwide,Validated,25241232[PMID]
533,Listeriosis,Disease,Annual incidence,0.31,1-9 / 1 000 000,Value and class,United States,Validated,17243053[PMID]_CDC Centers for disease Control and prevention 1996-2003[INST]
533,Listeriosis,Disease,Annual incidence,0.48,1-9 / 1 000 000,Value and class,Austria,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,1.07,1-9 / 100 000,Value and class,Belgium,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Cyprus,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.36,1-9 / 1 000 000,Value and class,Czech Republic,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.98,1-9 / 1 000 000,Value and class,Denmark,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Estonia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,1.1,1-9 / 100 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.57,1-9 / 1 000 000,Value and class,France,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.68,1-9 / 1 000 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Greece,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.28,1-9 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.29,1-9 / 1 000 000,Value and class,Ireland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.28,1-9 / 1 000 000,Value and class,Latvia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.25,1-9 / 1 000 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Luxembourg,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.38,1-9 / 1 000 000,Value and class,Malta,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.47,1-9 / 1 000 000,Value and class,Netherlands,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.23,1-9 / 1 000 000,Value and class,Poland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.29,1-9 / 1 000 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2015-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.31,1-9 / 1 000 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.67,1-9 / 1 000 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.9,1-9 / 1 000 000,Value and class,Spain,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
533,Listeriosis,Disease,Annual incidence,0.92,1-9 / 1 000 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.56,1-9 / 1 000 000,Value and class,Iceland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
533,Listeriosis,Disease,Annual incidence,0.46,1-9 / 1 000 000,Value and class,Norway,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
3268,Radioulnar synostosis-microcephaly-scoliosis syndrome,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,20635354[PMID]
3268,Radioulnar synostosis-microcephaly-scoliosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20635354[PMID]
683,Progressive supranuclear palsy,Disease,Annual incidence,0.65,1-9 / 100 000,Value and class,Worldwide,Validated,11487180[PMID]_9371909[PMID]_4792160[PMID]_3405368[PMID]_6333204[PMID]_3386818[PMID]_[EXPERT]
683,Progressive supranuclear palsy,Disease,Point prevalence,5.26,1-9 / 100 000,Value and class,Worldwide,Validated,PMID: 27037234  ; 34220661; ORPHANET
683,Progressive supranuclear palsy,Disease,Point prevalence,14.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
683,Progressive supranuclear palsy,Disease,Point prevalence,1.39,1-9 / 100 000,Value and class,United States,Validated,3386818[PMID]
683,Progressive supranuclear palsy,Disease,Point prevalence,3.2,1-9 / 100 000,Value and class,Italy,Validated,9613728[PMID]
683,Progressive supranuclear palsy,Disease,Point prevalence,14.0,1-5 / 10 000,Value and class,Guadeloupe,Validated,11912113[PMID]
683,Progressive supranuclear palsy,Disease,Point prevalence,3.75,1-9 / 100 000,Value and class,United Kingdom,Validated,21088431[PMID]_10577638[PMID]_11408338[PMID]_ORPHANET
683,Progressive supranuclear palsy,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Libyan Arab Jamahiriya,Validated,3405368[PMID]
683,Progressive supranuclear palsy,Disease,Annual incidence,0.63,1-9 / 1 000 000,Value and class,United States,Validated,6333204[PMID]_9371909[PMID]_3386818[PMID]
683,Progressive supranuclear palsy,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Australia,Validated,4792160[PMID]
677,Pancreatoblastoma,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,16080945[PMID]
677,Pancreatoblastoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
677,Pancreatoblastoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
677,Pancreatoblastoma,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
677,Pancreatoblastoma,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
677,Pancreatoblastoma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
677,Pancreatoblastoma,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
677,Pancreatoblastoma,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
677,Pancreatoblastoma,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
677,Pancreatoblastoma,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
677,Pancreatoblastoma,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
677,Pancreatoblastoma,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
677,Pancreatoblastoma,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
183660,Severe combined immunodeficiency,Clinical group,Prevalence at birth,1.65,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
183660,Severe combined immunodeficiency,Clinical group,Prevalence at birth,1.6,1-9 / 100 000,Value and class,France,Validated,22288591[PMID]
183660,Severe combined immunodeficiency,Clinical group,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Greece,Validated,21732012[PMID]
183660,Severe combined immunodeficiency,Clinical group,Prevalence at birth,1.75,1-9 / 100 000,Value and class,Australia,Not yet validated,18221464[PMID]_9314356[PMID]_ ORPHANET
183660,Severe combined immunodeficiency,Clinical group,Prevalence at birth,1.28,1-9 / 100 000,Value and class,Chile,Validated,17191150[PMID]
183660,Severe combined immunodeficiency,Clinical group,Prevalence at birth,3.79,1-9 / 100 000,Value and class,Costa rica,Validated,17191150[PMID]
183660,Severe combined immunodeficiency,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
183660,Severe combined immunodeficiency,Clinical group,Prevalence at birth,1.72,1-9 / 100 000,Value and class,United States,Validated,25138334[PMID]
183660,Severe combined immunodeficiency,Clinical group,Prevalence at birth,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,ORPHANET
279894,Toxic maculopathy due to antimalarial drugs,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
808,Seckel syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,20301772[PMID]
808,Seckel syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25284118[PMID]
808,Seckel syndrome,Malformation syndrome,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
844,Lown-Ganong-Levine syndrome,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,836114[PMID]
844,Lown-Ganong-Levine syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_836114[PMID]
3304,Fallot complex-intellectual disability-growth delay syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,8010348[PMID]_15578610[PMID]
3304,Fallot complex-intellectual disability-growth delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8010348[PMID]_15578610[PMID]
676,Hereditary chronic pancreatitis,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,France,Validated,18755888[PMID]
676,Hereditary chronic pancreatitis,Disease,Point prevalence,0.57,1-9 / 1 000 000,Value and class,Denmark,Validated,20502448[PMID]
676,Hereditary chronic pancreatitis,Disease,Point prevalence,0.43,1-9 / 1 000 000,Value and class,Europe,Validated,18755888[PMID]_20502448[PMID]
276198,Spinocerebellar ataxia type 36,Disease,Cases/families,100.0,,Family(ies),Worldwide,Validated,25101480[PMID]
276198,Spinocerebellar ataxia type 36,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25101480[PMID]
634,Netherton syndrome,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
634,Netherton syndrome,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
140,Campomelic dysplasia,Malformation syndrome,Point prevalence,3.0E-4,<1 / 1 000 000,Value and class,Worldwide,Validated,[https://www.ncbi.nlm.nih.gov/books/NBK1760/]_ORPHANET
140,Campomelic dysplasia,Malformation syndrome,Prevalence at birth,1.875,1-9 / 100 000,Value and class,Worldwide,,[https://www.ncbi.nlm.nih.gov/books/NBK1760/]_ORPHANET
3224,Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,15887301[PMID]
3224,Deafness-genital anomalies-metacarpal and metatarsal synostosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15887301[PMID]
276174,Idiopathic recurrent stupor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
642,Hereditary sensory and autonomic neuropathy type 4,Disease,Point prevalence,0.14,1-9 / 1 000 000,Value and class,Japan,Validated,23495212[PMID]
642,Hereditary sensory and autonomic neuropathy type 4,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
627,Nance-Horan syndrome,Malformation syndrome,Cases/families,196.0,,Case(s),Worldwide,Validated,27616609[PMID]
627,Nance-Horan syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27616609[PMID]
3230,Deafness-oligodontia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_646726[PMID]_485932[PMID]_9720683[PMID]
3230,Deafness-oligodontia syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,646726[PMID]_485932[PMID]_9720683[PMID]
326,Congenital factor V deficiency,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET_19598066[PMID]
276244,Machado-Joseph disease type 3,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,23994570[PMID]
650,LCAT deficiency,Disease,Cases/families,125.0,,Case(s),Worldwide,Validated,ORPHANET
650,LCAT deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3235,Progressive deafness with stapes fixation,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3236,Conductive deafness-ptosis-skeletal anomalies syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,728561[PMID]
3236,Conductive deafness-ptosis-skeletal anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_728561[PMID]
342,Familial Mediterranean fever,Disease,Point prevalence,175.0,>1 / 1000,Value and class,Turkey,Not yet validated,9858443[PMID]_15515780[PMID]_15643295[PMID]
342,Familial Mediterranean fever,Disease,Point prevalence,200.0,>1 / 1000,Value and class,Armenia,Validated,18403822[PMID]
342,Familial Mediterranean fever,Disease,Point prevalence,2.5,1-9 / 100 000,Value and class,Sweden,Validated,23194659[PMID]
342,Familial Mediterranean fever,Disease,Point prevalence,0.23,1-9 / 1 000 000,Value and class,Japan,Not yet validated,23111802[PMID]_ORPHANET
342,Familial Mediterranean fever,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
342,Familial Mediterranean fever,Disease,Annual incidence,14.0,1-5 / 10 000,Value and class,Specific population,Not yet validated,ORPHANET
3241,Deafness-craniofacial syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3690878[PMID]
3241,Deafness-craniofacial syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3690878[PMID]
754,Androgen insensitivity syndrome,Clinical group,Prevalence at birth,1.01,1-9 / 100 000,Value and class,Netherlands,Validated,11549642[PMID]
754,Androgen insensitivity syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
754,Androgen insensitivity syndrome,Clinical group,Prevalence at birth,4.1,1-9 / 100 000,Value and class,Denmark,Validated,27603905[PMID]
754,Androgen insensitivity syndrome,Clinical group,Annual incidence,0.04,<1 / 1 000 000,Value and class,Denmark,Validated,27603905[PMID]
253,Spondyloepiphyseal dysplasia and spondyloepimetaphyseal dysplasia,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
327,Congenital factor VII deficiency,Disease,Point prevalence,0.33,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
3238,Cardiospondylocarpofacial syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,5901343[PMID]_20186786[PMID]
3238,Cardiospondylocarpofacial syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5901343[PMID]_20186786[PMID]
373,Simpson-Golabi-Behmel syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
373,Simpson-Golabi-Behmel syndrome,Malformation syndrome,Cases/families,250.0,,Case(s),Worldwide,Validated,25238977[PMID]_[EXPERT]
3246,Symphalangism with multiple anomalies of hands and feet,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,6272576[PMID]
3246,Symphalangism with multiple anomalies of hands and feet,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6272576[PMID]
574,21q deletion syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
574,21q deletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3242,Renpenning syndrome,Malformation syndrome,Cases/families,64.0,,Case(s),Worldwide,Validated,20950397[PMID]_16493439[PMID]_17033686[PMID]_11950858[PMID]_[EXPERT]
3242,Renpenning syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
146,Differentiated thyroid carcinoma,Disease,Annual incidence,5.25,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]_ORPHANET
146,Differentiated thyroid carcinoma,Disease,Annual incidence,2.0,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
146,Differentiated thyroid carcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1331,Familial prostate cancer,Disease,Annual incidence,9.4,1-9 / 100 000,Value and class,United States,Validated,[EXPERT]_National Cancer Institute 2006-2010[INST]_ ORPHANET
3250,Proximal symphalangism,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3248,Isolated distal symphalangism,Morphological anomaly,Cases/families,8.0,,Family(ies),Worldwide,Validated,3436086[PMID]_2061594[PMID]
3248,Isolated distal symphalangism,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3436086[PMID]_2061594[PMID]
276422,10q22.3q23.3 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
276429,Hypnic headache,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1446,Ring chromosome 22 syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,ISBN:978-3-8055-9280-2[OTHER]
1446,Ring chromosome 22 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ISBN:978-3-8055-9280-2[OTHER]
276556,Hyperinsulinism due to UCP2 deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,19065272[PMID]
276556,Hyperinsulinism due to UCP2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
276432,Ogden syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,21700266[PMID]
276432,Ogden syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
475,Joubert syndrome,Malformation syndrome,Point prevalence,0.47,1-9 / 1 000 000,Value and class,Italy,Validated,31969461[PMID]
475,Joubert syndrome,Malformation syndrome,Prevalence at birth,1.6666,1-9 / 100 000,Value and class,Worldwide,Validated,35860112[PMID]
475,Joubert syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,35860112[PMID]_ORPHANET
475,Joubert syndrome,Malformation syndrome,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Spain,Validated,34308544[PMID]
276435,Lower motor neuron syndrome with late-adult onset,Disease,Cases/families,55.0,,Case(s),Worldwide,Validated,25428574[PMID]
276435,Lower motor neuron syndrome with late-adult onset,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25428574[PMID]
911,Combined immunodeficiency due to ZAP70 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
113,Bazex-Dupré-Christol syndrome,Disease,Cases/families,143.0,,Case(s),Worldwide,Validated,ORPHANET
113,Bazex-Dupré-Christol syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
746,Mitochondrial trifunctional protein deficiency,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET_22000755[PMID]
746,Mitochondrial trifunctional protein deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_22000755[PMID
746,Mitochondrial trifunctional protein deficiency,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
943,Malonic aciduria,Disease,Cases/families,34.0,,Case(s),Worldwide,Validated,23177061[PMID]
943,Malonic aciduria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
621,Hereditary methemoglobinemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2089,Glycogen storage disease due to hepatic glycogen synthase deficiency,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,12072888[PMID]
2089,Glycogen storage disease due to hepatic glycogen synthase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
412,Dysbetalipoproteinemia,Disease,Point prevalence,7.8,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
412,Dysbetalipoproteinemia,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Worldwide,Validated,21354122[PMID]_24314366[PMID]
743,Severe hereditary thrombophilia due to congenital protein S deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,Pr Jenny GOUDEMAND [EXPERT]
743,Severe hereditary thrombophilia due to congenital protein S deficiency,Disease,Prevalence at birth,0.0,Unknown,Class only,Europe,Validated,Pr Jenny GOUDEMAND [EXPERT]
182130,Tumor of endocrine glands,Category,Annual incidence,3.75,1-9 / 100 000,Value and class,Europe,Not yet validated,22361014[PMID]
182130,Tumor of endocrine glands,Category,Point prevalence,64.0,6-9 / 10 000,Value and class,Europe,Not yet validated,22361014[PMID]
528,Congenital generalized lipodystrophy,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
528,Congenital generalized lipodystrophy,Disease,Point prevalence,0.01,<1 / 1 000 000,Value and class,United States,Validated,16722806[PMID]
528,Congenital generalized lipodystrophy,Disease,Point prevalence,0.86,1-9 / 1 000 000,Value and class,Peru,Validated,32201678[PMID]
528,Congenital generalized lipodystrophy,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Norway,Validated,https://www.ncbi.nlm.nih.gov/books/NBK1212/
528,Congenital generalized lipodystrophy,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Lebanon,Validated,https://www.ncbi.nlm.nih.gov/books/NBK1212/
528,Congenital generalized lipodystrophy,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Portugal,Validated,https://www.ncbi.nlm.nih.gov/books/NBK1212/
528,Congenital generalized lipodystrophy,Disease,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Oman,Validated,15767751[PMID]
528,Congenital generalized lipodystrophy,Disease,Point prevalence,0.6812,1-9 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET
528,Congenital generalized lipodystrophy,Disease,Point prevalence,0.05,<1 / 1 000 000,Value and class,Turkey,Validated,27144933[PMID]
528,Congenital generalized lipodystrophy,Disease,Point prevalence,3.23,1-9 / 100 000,Value and class,Brazil,Validated,35209917[PMID]
275,Severe combined immunodeficiency due to DCLRE1C deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
182090,Pulmonary arterial hypertension,Category,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]_16456139[PMID]_17360728[PMID]
182090,Pulmonary arterial hypertension,Category,Point prevalence,1.6,1-9 / 100 000,Value and class,Spain,Validated,22362843[PMID]
182090,Pulmonary arterial hypertension,Category,Annual incidence,0.37,1-9 / 1 000 000,Value and class,Spain,Validated,22362843[PMID]
182090,Pulmonary arterial hypertension,Category,Point prevalence,1.5,1-9 / 100 000,Value and class,France,Validated,16456139[PMID]
182090,Pulmonary arterial hypertension,Category,Annual incidence,0.24,1-9 / 1 000 000,Value and class,France,Validated,16456139[PMID]
182090,Pulmonary arterial hypertension,Category,Point prevalence,1.09,1-9 / 100 000,Value and class,United States,Validated,21793646[PMID]
182090,Pulmonary arterial hypertension,Category,Annual incidence,1.07,1-9 / 100 000,Value and class,Czech Republic,Validated,24629043[PMID]
182090,Pulmonary arterial hypertension,Category,Point prevalence,2.24,1-9 / 100 000,Value and class,Czech Republic,Validated,24629043[PMID]
182090,Pulmonary arterial hypertension,Category,Point prevalence,1.55,1-9 / 100 000,Value and class,Switzerland,Validated,18587690[PMID]
182090,Pulmonary arterial hypertension,Category,Annual incidence,0.35,1-9 / 1 000 000,Value and class,Switzerland,Validated,18587690[PMID]
182090,Pulmonary arterial hypertension,Category,Annual incidence,0.72,1-9 / 1 000 000,Value and class,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
182090,Pulmonary arterial hypertension,Category,Point prevalence,5.2,1-9 / 100 000,Value and class,United Kingdom,Validated,17360728[PMID]
182095,Interstitial lung disease,Category,Annual incidence,4.1,1-9 / 100 000,Value and class,Denmark,Validated,24636811[PMID]
182095,Interstitial lung disease,Category,Annual incidence,5.4,1-9 / 100 000,Value and class,Europe,Not yet validated,24636811[PMID]
182095,Interstitial lung disease,Category,Annual incidence,7.6,1-9 / 100 000,Value and class,Spain,Validated,15127977[PMID]
182095,Interstitial lung disease,Category,Annual incidence,4.63,1-9 / 100 000,Value and class,Greece,Validated,19345567[PMID]
182095,Interstitial lung disease,Category,Point prevalence,17.3,1-5 / 10 000,Value and class,Greece,Validated,19345567[PMID]
184,Cherubism,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
184,Cherubism,Malformation syndrome,Cases/families,300.0,,Case(s),Worldwide,Validated,[EXPERT]
1047,Sideroblastic anemia,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
71,Chylomicron retention disease,Disease,Cases/families,55.0,,Case(s),Worldwide,Validated,ORPHANET
71,Chylomicron retention disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
182067,Glial tumor,Clinical group,Annual incidence,5.26,1-9 / 100 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2004[REG]_24193082[PMID]
182067,Glial tumor,Clinical group,Point prevalence,26.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
182067,Glial tumor,Clinical group,Annual incidence,5.7,1-9 / 100 000,Value and class,Greece,Validated,19494549[PMID]
182067,Glial tumor,Clinical group,Annual incidence,6.2,1-9 / 100 000,Value and class,Croatia,Validated,15103760[PMID]
182067,Glial tumor,Clinical group,Annual incidence,5.35,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1949,Self-limited neonatal epilepsy,Disease,Cases/families,100.0,,Family(ies),Worldwide,Validated,[EXPERT]_20437616[PMID]_24375629[PMID]
1949,Self-limited neonatal epilepsy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
189,Hidrotic ectodermal dysplasia,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
1473,Uveal coloboma-cleft lip and palate-intellectual disability,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,24462371[PMID]
1473,Uveal coloboma-cleft lip and palate-intellectual disability,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
820,Sneddon syndrome,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
820,Sneddon syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
182050,MYH9-related disease,Disease,Point prevalence,0.29,1-9 / 1 000 000,Value and class,Italy,Validated,20301740[PMID]
182050,MYH9-related disease,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,20301740[PMID]_[EXPERT]
1945,Self-limited epilepsy with centrotemporal spikes,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1945,Self-limited epilepsy with centrotemporal spikes,Disease,Annual incidence,20.0,1-5 / 10 000,Value and class,Sweden,Validated,16638642[PMID]
709,Peters plus syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,20301637[PMID]
709,Peters plus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301637[PMID]
776,Lujan-Fryns syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
902,Werner syndrome,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
902,Werner syndrome,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,United States,Validated,10484259[PMID]
902,Werner syndrome,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Japan,Validated,10347997[PMID]_[EXPERT]
902,Werner syndrome,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Specific population,Validated,17478382[PMID]_[EXPERT]
20,3-hydroxy-3-methylglutaric aciduria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,19177531[PMID]_[EXPERT]
20,3-hydroxy-3-methylglutaric aciduria,Disease,Prevalence at birth,0.8,1-9 / 1 000 000,Value and class,Portugal,Validated,[EXPERT]
20,3-hydroxy-3-methylglutaric aciduria,Disease,Prevalence at birth,0.0,<1 / 1 000 000,Class only,United States,Validated,22766612[PMID]
20,3-hydroxy-3-methylglutaric aciduria,Disease,Prevalence at birth,0.0,<1 / 1 000 000,Class only,China,Validated,19036343[PMID]_29039164[PMID]
712,Hemolytic anemia due to glucophosphate isomerase deficiency,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
712,Hemolytic anemia due to glucophosphate isomerase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
871,Familial progressive cardiac conduction defect,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
871,Familial progressive cardiac conduction defect,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1597,Distal deletion 17q syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1590,Distal deletion 13q syndrome,Malformation syndrome,Cases/families,150.0,,Case(s),Worldwide,Validated,24433316[PMID]
1590,Distal deletion 13q syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24433316[PMID]
1587,Monosomy 13q14 syndrome,Malformation syndrome,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1587,Monosomy 13q14 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1621,3q13 microdeletion syndrome,Malformation syndrome,Cases/families,42.0,,Case(s),Worldwide,Validated,24650298[PMID]
1621,3q13 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24650298[PMID]
1620,Distal deletion 3p syndrome,Malformation syndrome,Cases/families,34.0,,Case(s),Worldwide,Validated,ISBN-10:0781730635[OTHER]
1620,Distal deletion 3p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ISBN-10:0781730635[OTHER]
1627,Deletion 5q35 syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,11562936[PMID]_[EXPERT]
1627,Deletion 5q35 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1699,Trisomy 12p syndrome,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,16502429[PMID]
1699,Trisomy 12p syndrome,Malformation syndrome,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,8723118[PMID]
1699,Trisomy 12p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,8723118[PMID]_ORPHANET
500,Noonan syndrome with multiple lentigines,Malformation syndrome,Cases/families,296.0,,Case(s),Worldwide,Validated,21500339[PMID]
500,Noonan syndrome with multiple lentigines,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_21500339[PMID]
507,Leishmaniasis,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
507,Leishmaniasis,Disease,Annual incidence,25.0,1-5 / 10 000,Value and class,Worldwide,Validated,World Health Organization[INST]_ORPHANET
206546,Symptomatic form of muscular dystrophy of Duchenne and Becker in female carriers,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
233,Duane retraction syndrome,Malformation syndrome,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Not yet validated,ISBN:3642022014[OTHER]
657,Congenital isolated hyperinsulinism,Clinical group,Prevalence at birth,2.24,1-9 / 100 000,Value and class,Czech Republic,Validated,26431509[PMID]
657,Congenital isolated hyperinsulinism,Clinical group,Prevalence at birth,5.25,1-9 / 100 000,Value and class,Japan,Validated,31742894[PMID]
657,Congenital isolated hyperinsulinism,Clinical group,Prevalence at birth,3.52,1-9 / 100 000,Value and class,United Kingdom,Validated,32027664[PMID]
657,Congenital isolated hyperinsulinism,Clinical group,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Netherlands,Validated,14518075[PMID]
657,Congenital isolated hyperinsulinism,Clinical group,Prevalence at birth,40.0,1-5 / 10 000,Value and class,Saudi Arabia,Validated,21967988[PMID]
657,Congenital isolated hyperinsulinism,Clinical group,Prevalence at birth,3.67,1-9 / 100 000,Value and class,Worldwide,Validated,ORPHANET
657,Congenital isolated hyperinsulinism,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
657,Congenital isolated hyperinsulinism,Clinical group,Point prevalence,23.2,1-5 / 10 000,Value and class,China,Validated,34103049[PMID]
2495,Meningioma,Disease,Annual incidence,4.15,1-9 / 100 000,Value and class,Germany,Validated,25249493[PMID]
2495,Meningioma,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
2495,Meningioma,Disease,Annual incidence,8.14,1-9 / 100 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
1123,Caudal appendage-deafness syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7894739[PMID]
1123,Caudal appendage-deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7894739[PMID]
206564,POMGNT1-related limb-girdle muscular dystrophy R15,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,18195152[PMID]_22419172[PMID]
206564,POMGNT1-related limb-girdle muscular dystrophy R15,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18195152[PMID]_22419172[PMID]
206559,POMT2-related limb-girdle muscular dystrophy R14,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17923109[PMID]
206559,POMT2-related limb-girdle muscular dystrophy R14,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,17923109[PMID]
206572,Overlap myositis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
2014,Cleft palate,Clinical group,Prevalence at birth,53.6,1-5 / 10 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,19.6,1-5 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,40.8,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,56.8,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,127.6,>1 / 1000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,>1 / 1000,Class only,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,25.5,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,47.5,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,67.5,6-9 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,6-9 / 10 000,Class only,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,54.2,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,39.6,1-5 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,74.7,6-9 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,6-9 / 10 000,Class only,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,11.7,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,65.4,6-9 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,6-9 / 10 000,Class only,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,36.5,1-5 / 10 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,14.2,1-5 / 10 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,30.7,1-5 / 10 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,25.1,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,60.2,6-9 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,6-9 / 10 000,Class only,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,57.2,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
2014,Cleft palate,Clinical group,Prevalence at birth,101.2,>1 / 1000,Value and class,Australia,Validated,23371924[PMID]
2014,Cleft palate,Clinical group,Point prevalence,0.0,>1 / 1000,Class only,Australia,Not yet validated,23371924[PMID]
2014,Cleft palate,Clinical group,Prevalence at birth,52.0,1-5 / 10 000,Value and class,Chile,Validated,11372296[PMID]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Chile,Not yet validated,11372296[PMID]
2014,Cleft palate,Clinical group,Prevalence at birth,27.0,1-5 / 10 000,Value and class,Sudan,Validated,15854114[PMID]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Sudan,Not yet validated,15854114[PMID]
2014,Cleft palate,Clinical group,Prevalence at birth,26.0,1-5 / 10 000,Value and class,"Iran, Islamic Republic of",Validated,20648890[PMID]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,"Iran, Islamic Republic of",Not yet validated,20648890[PMID]
2014,Cleft palate,Clinical group,Prevalence at birth,27.0,1-5 / 10 000,Value and class,Mexico,Validated,8442867[PMID]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Mexico,Not yet validated,8442867[PMID]
2014,Cleft palate,Clinical group,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Bolivia,Validated,14989684[PMID]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Bolivia,Not yet validated,14989684[PMID]
2014,Cleft palate,Clinical group,Prevalence at birth,68.0,6-9 / 10 000,Value and class,Specific population,Validated,15516165[PMID]
2014,Cleft palate,Clinical group,Point prevalence,0.0,6-9 / 10 000,Class only,Specific population,Validated,15516165[PMID]
2014,Cleft palate,Clinical group,Prevalence at birth,40.0,1-5 / 10 000,Value and class,"Taiwan, Province of China",Validated,23555592[PMID]
2014,Cleft palate,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,"Taiwan, Province of China",Not yet validated,23555592[PMID]
822,Hereditary spherocytosis,Disease,Point prevalence,50.0,1-5 / 10 000,Value and class,Germany,Validated,1554800[PMID]
822,Hereditary spherocytosis,Disease,Prevalence at birth,20.0,1-5 / 10 000,Value and class,United States,Validated,14476391[PMID]
822,Hereditary spherocytosis,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,[EXPERT]_1554800[PMID]
910,Xeroderma pigmentosum,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,United States,Validated,[EXPERT]
910,Xeroderma pigmentosum,Disease,Point prevalence,4.5,1-9 / 100 000,Value and class,Japan,Validated,16905156[PMID]
910,Xeroderma pigmentosum,Disease,Prevalence at birth,0.23,1-9 / 1 000 000,Value and class,Europe,Not yet validated,18329345[PMID]
910,Xeroderma pigmentosum,Disease,Prevalence at birth,0.19,1-9 / 1 000 000,Value and class,United Kingdom,Validated,18329345[PMID]
910,Xeroderma pigmentosum,Disease,Prevalence at birth,0.41,1-9 / 1 000 000,Value and class,Netherlands,Validated,18329345[PMID]
910,Xeroderma pigmentosum,Disease,Prevalence at birth,0.16,1-9 / 1 000 000,Value and class,Italy,Validated,18329345[PMID]
910,Xeroderma pigmentosum,Disease,Prevalence at birth,0.34,1-9 / 1 000 000,Value and class,France,Validated,18329345[PMID]
910,Xeroderma pigmentosum,Disease,Prevalence at birth,0.18,1-9 / 1 000 000,Value and class,Germany,Validated,18329345[PMID]
910,Xeroderma pigmentosum,Disease,Annual incidence,1.75,1-9 / 100 000,Value and class,Libyan Arab Jamahiriya,Not yet validated,10440281[PMID]
777,X-linked non-syndromic intellectual disability,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
766,Hemolytic anemia due to red cell pyruvate kinase deficiency,Disease,Point prevalence,5.1,1-9 / 100 000,Value and class,Specific population,Validated,10828047[PMID]
766,Hemolytic anemia due to red cell pyruvate kinase deficiency,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2014[INST]
766,Hemolytic anemia due to red cell pyruvate kinase deficiency,Disease,Point prevalence,0.96,1-9 / 1 000 000,Value and class,Specific population,Validated,1511997[PMID]
1358,Carey-Fineman-Ziter syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,27232676[PMID]
1358,Carey-Fineman-Ziter syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27232676[PMID]
206973,Congenital myotonia,Clinical group,Point prevalence,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,1822774[PMID]_20301529[PMID]
206594,Subacute inflammatory demyelinating polyneuropathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
206599,Isolated asymptomatic elevation of creatine phosphokinase,Biological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3206,Stüve-Wiedemann syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19207241[PMID]
3206,Stüve-Wiedemann syndrome,Malformation syndrome,Cases/families,56.0,,Case(s),Worldwide,Validated,19207241[PMID]
3206,Stüve-Wiedemann syndrome,Malformation syndrome,Prevalence at birth,20.0,1-5 / 10 000,Value and class,United Arab Emirates,Validated,21337444[PMID]
206583,Adult polyglucosan body disease,Clinical subtype,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
206583,Adult polyglucosan body disease,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
65,Leber congenital amaurosis,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,European Medicines Agency 2015[INST]
65,Leber congenital amaurosis,Disease,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Worldwide,Not yet validated,20301475[PMID]
65,Leber congenital amaurosis,Disease,Point prevalence,1.23,1-9 / 100 000,Value and class,United States,Validated,17964524[PMID]
65,Leber congenital amaurosis,Disease,Point prevalence,2.5,1-9 / 100 000,Value and class,Worldwide,Validated,ORPHANET_[EXPERT]_20301475[PMID]
321,Multiple osteochondromas,Disease,Point prevalence,100.0,>1 / 1000,Value and class,Specific population,Validated,13754517[PMID]
321,Multiple osteochondromas,Disease,Point prevalence,0.9,1-9 / 1 000 000,Value and class,United Kingdom,Validated,6417335[PMID]
321,Multiple osteochondromas,Disease,Point prevalence,1.35,1-9 / 100 000,Value and class,Netherlands,Validated,1856833[PMID]
321,Multiple osteochondromas,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
321,Multiple osteochondromas,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,United States,Validated,8027127[PMID]
144,Lynch syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
206647,Myotonic dystrophy,Clinical group,Point prevalence,189.0,>1 / 1000,Value and class,Specific population,Validated,2330114[PMID]
206647,Myotonic dystrophy,Clinical group,Point prevalence,6.7,1-9 / 100 000,Value and class,Worldwide,Validated,ORPHANET_25532075[PMID]
206647,Myotonic dystrophy,Clinical group,Point prevalence,8.78,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET_25532075[PMID]
206647,Myotonic dystrophy,Clinical group,Point prevalence,2.1,1-9 / 100 000,Value and class,Italy,Validated,25532075[PMID]
206647,Myotonic dystrophy,Clinical group,Point prevalence,5.5,1-9 / 100 000,Value and class,Japan,Validated,25532075[PMID]
206647,Myotonic dystrophy,Clinical group,Point prevalence,8.4,1-9 / 100 000,Value and class,Ireland,Validated,8845721[PMID]
206647,Myotonic dystrophy,Clinical group,Point prevalence,13.3,1-5 / 10 000,Value and class,Croatia,Validated,9088385[PMID]_25532075[PMID]
206647,Myotonic dystrophy,Clinical group,Point prevalence,11.6,1-5 / 10 000,Value and class,New Zealand,Validated,16964297[PMID]_25532075[PMID]
206647,Myotonic dystrophy,Clinical group,Point prevalence,20.0,1-5 / 10 000,Value and class,Finland,Validated,21364698[PMID]
206647,Myotonic dystrophy,Clinical group,Point prevalence,1.22,1-9 / 100 000,Value and class,Norway,Validated,3263224[PMID]
206647,Myotonic dystrophy,Clinical group,Point prevalence,10.9,1-5 / 10 000,Value and class,Spain,Validated,1369611[PMID]_25532075[PMID]
206647,Myotonic dystrophy,Clinical group,Point prevalence,2.0,1-9 / 100 000,Value and class,United States,Validated,6333203[PMID]_25532075[PMID]
110,Bardet-Biedl syndrome,Disease,Point prevalence,7.4,1-9 / 100 000,Value and class,Specific population,Validated,2591073[PMID]
110,Bardet-Biedl syndrome,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
110,Bardet-Biedl syndrome,Disease,Point prevalence,0.64,1-9 / 1 000 000,Value and class,Tunisia,Validated,22109794[PMID]
110,Bardet-Biedl syndrome,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,United States,Validated,20949666[PMID]
2326,Kallmann syndrome-heart disease syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,8322819[PMID]
2326,Kallmann syndrome-heart disease syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8322819[PMID]
1130,Arachnodactyly-intellectual disability-dysmorphism syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,8357568[PMID]_7794564[PMID]
1130,Arachnodactyly-intellectual disability-dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8357568[PMID]_7794564[PMID]
133,Chronic beryllium disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1552,Currarino syndrome,Malformation syndrome,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
1450,Ring chromosome 8 syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,15337475[PMID]_ISBN 10:3110116073[OTHER]
1450,Ring chromosome 8 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ISBN 10:3110116073[OTHER]_15337475[PMID]
1448,Ring chromosome 6 syndrome,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,23398904[PMID]
1448,Ring chromosome 6 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23398904[PMID]
1580,Distal deletion 10p syndrome,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2062,Progressive non-infectious anterior vertebral fusion,Malformation syndrome,Cases/families,67.0,,Case(s),Worldwide,Validated,25485486[PMID]_28235247[PMID]
2062,Progressive non-infectious anterior vertebral fusion,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,25485486[PMID]_28235247[PMID]_ORPHANET
172,Progressive familial intrahepatic cholestasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2427,Macrocephaly-short stature-paraplegia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8471221[PMID]
2427,Macrocephaly-short stature-paraplegia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8471221[PMID]
1444,Ring chromosome 20 syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
1444,Ring chromosome 20 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2349,Muscular pseudohypertrophy-hypothyroidism syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1438,Ring chromosome 10 syndrome,Malformation syndrome,Cases/families,16.0,,Case(s),Worldwide,Validated,23247912[PMID]
1438,Ring chromosome 10 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2183,Hydrocephalus-obesity-hypogonadism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,4039476[PMID]
2183,Hydrocephalus-obesity-hypogonadism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4039476[PMID]
1114,Aplasia cutis congenita,Malformation syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Worldwide,Validated,12596124[PMID]_[EXPERT]
1114,Aplasia cutis congenita,Malformation syndrome,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Worldwide,Validated,5910871[PMID]_12596124[PMID]_[EXPERT]
1114,Aplasia cutis congenita,Malformation syndrome,Prevalence at birth,7.69,1-9 / 100 000,Value and class,Denmark,Validated,25430571[PMID]
209004,Axonal polyneuropathy associated with IgG/IgM/IgA monoclonal gammopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
209004,Axonal polyneuropathy associated with IgG/IgM/IgA monoclonal gammopathy,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3176,Spina bifida-hypospadias syndrome,Malformation syndrome,Point prevalence,6.1,1-9 / 100 000,Value and class,Spain,Validated,7977461[PMID]_37868647[PMID]_ORPHANET
3176,Spina bifida-hypospadias syndrome,Malformation syndrome,Prevalence at birth,6.1,1-9 / 100 000,Value and class,Spain,Validated,7977461[PMID]
2184,Hydrocephaly-low insertion umbilicus syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8305966[PMID]
2184,Hydrocephaly-low insertion umbilicus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8305966[PMID]
1711,Mosaic trisomy 17 syndrome,Malformation syndrome,Cases/families,31.0,,Case(s),Worldwide,Validated,27751421[PMID]
1711,Mosaic trisomy 17 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27751421[PMID]
1272,Aymé-Gripp syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,19396831[PMID]_19251507[PMID]_25865493[PMID]_28482824[PMID]
1272,Aymé-Gripp syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28482824[PMID]
1692,Mosaic trisomy 1 syndrome,Malformation syndrome,Cases/families,1.0,,Case(s),Worldwide,Validated,8835327[PMID]
1692,Mosaic trisomy 1 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8835327[PMID]
1485,"Arthrogryposis-hyperkeratosis syndrome, lethal form",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8213913[PMID]
1485,"Arthrogryposis-hyperkeratosis syndrome, lethal form",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8213913[PMID]
1706,Mosaic trisomy 15 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25736076[PMID]
1134,Isolated arrhinia,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
1134,Isolated arrhinia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
920,Ablepharon macrostomia syndrome,Malformation syndrome,Cases/families,16.0,,Case(s),Worldwide,Validated,27196381[PMID]
920,Ablepharon macrostomia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27196381[PMID]
2204,"Dysplastic cortical hyperostosis, Kozlowski-Tsuruta type",Clinical subtype,Cases/families,2.0,,Case(s),Worldwide,Validated,12401992[PMID]
2204,"Dysplastic cortical hyperostosis, Kozlowski-Tsuruta type",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12401992[PMID]
2963,"Progeroid syndrome, Petty type",Malformation syndrome,Cases/families,1.0,,Case(s),Worldwide,Validated,2309786[PMID]
2963,"Progeroid syndrome, Petty type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2309786[PMID]
2619,"Brachydactylous dwarfism, Mseleni type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
929,Achalasia-microcephaly syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,3048841[PMID]_2591072[PMID]
929,Achalasia-microcephaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3048841[PMID]_2591072[PMID]
869,Triple A syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,14723589[PMID]_[EXPERT]
869,Triple A syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1415,Hardikar syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,22243360[PMID]
1415,Hardikar syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22243360[PMID]
922,Familial nasal acilia,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,4002006[PMID]_8813877[PMID]
922,Familial nasal acilia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4002006[PMID]_8813877[PMID]
209341,DYNC1H1-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID]
209341,DYNC1H1-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Etiological subtype,Cases/families,37.0,,Case(s),Worldwide,Validated,20697106[PMID]_22459677[PMID]_22847149[PMID]
27,Vitamin B12-unresponsive methylmalonic acidemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
209981,IRIDA syndrome,Disease,Cases/families,75.0,,Case(s),Worldwide,Validated,28491880[PMID]
209981,IRIDA syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28491880[PMID]
31,Oxoglutaric aciduria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1459,Celiac disease-epilepsy-cerebral calcification syndrome,Disease,Cases/families,170.0,,Case(s),Worldwide,Validated,ORPHANET
1459,Celiac disease-epilepsy-cerebral calcification syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
932,Achondrogenesis,Disease,Prevalence at birth,2.8,1-9 / 100 000,Value and class,France,Validated,2785882[PMID]
932,Achondrogenesis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
210136,Pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,19401489[PMID]
210136,Pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19401489[PMID]
2582,Myalgia-eosinophilia syndrome associated with tryptophan,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_21702023[PMID]
950,Acrodysostosis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
950,Acrodysostosis,Malformation syndrome,Cases/families,80.0,,Case(s),Worldwide,Validated,[EXPERT]
210128,Urocanic aciduria,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,19304569[PMID]
210128,Urocanic aciduria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19304569[PMID]
945,Acalvaria,Malformation syndrome,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Europe,Validated,[EXPERT]
945,Acalvaria,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
209959,Phacoanaphylactic uveitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
958,Acro-renal-mandibular syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,25075450[PMID]
958,Acro-renal-mandibular syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25075450[PMID]
209951,Autosomal spastic paraplegia type 18,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,16636240[PMID]_23109145[PMID]_21796390[PMID]
209951,Autosomal spastic paraplegia type 18,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16636240[PMID]_23109145[PMID]_21796390[PMID]
952,"Acrofacial dysostosis, Weyers type",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
209973,Benign nocturnal alternating hemiplegia of childhood,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,23820111[PMID]
209973,Benign nocturnal alternating hemiplegia of childhood,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23820111[PMID]
1738,Trisomy 4p syndrome,Malformation syndrome,Cases/families,85.0,,Case(s),Worldwide,Validated,12239731[PMID]
1738,Trisomy 4p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12239731[PMID]
209970,Episodic ataxia type 7,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,ORPHANET_17502476[PMID]
209970,Episodic ataxia type 7,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1745,Distal duplication 6p syndrome,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,ORPHANET
1745,Distal duplication 6p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
209908,Isolated childhood apraxia of speech,Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,ORPHANET
209908,Isolated childhood apraxia of speech,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1762,Proximal Xq28 duplication syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET_EXPERT
1762,Proximal Xq28 duplication syndrome,Malformation syndrome,Prevalence at birth,0.65,1-9 / 1 000 000,Value and class,Australia,Validated,30756435[PMID]
1762,Proximal Xq28 duplication syndrome,Malformation syndrome,Annual incidence,0.07,<1 / 1 000 000,Value and class,Australia,Validated,30756435[PMID]
209902,Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,ORPHANET
209902,Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1876,Oculogastrointestinal muscular dystrophy,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,3366929[PMID]
1876,Oculogastrointestinal muscular dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
209943,IRVAN syndrome,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
209943,IRVAN syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1946,Amelocerebrohypohidrotic syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1951,Epilepsy-telangiectasia syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,627106[PMID]
1951,Epilepsy-telangiectasia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_627106[PMID]
209916,Extraskeletal myxoid chondrosarcoma,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
2604,Familial visceral myopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
209370,Severe neonatal-onset encephalopathy with microcephaly,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
209370,Severe neonatal-onset encephalopathy with microcephaly,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2597,Mitochondrial myopathy-lactic acidosis-deafness syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,4725145[PMID]
2597,Mitochondrial myopathy-lactic acidosis-deafness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4725145[PMID]
210571,Dystonia 16,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,18420150[PMID]_22842711[PMID]_25142429[PMID]
210571,Dystonia 16,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18420150[PMID]_22842711[PMID]_25142429[PMID]
1078,Thumb stiffness-brachydactyly-intellectual disability syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,6631421[PMID]_2363441[PMID]
1078,Thumb stiffness-brachydactyly-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6631421[PMID]_2363441[PMID]
1077,Dental ankylosis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1074,Ankyloblepharon filiforme adnatum-imperforate anus syndrome,Clinical subtype,Cases/families,3.0,,Family(ies),Worldwide,Validated,8135297[PMID]
1074,Ankyloblepharon filiforme adnatum-imperforate anus syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8135297[PMID]
1072,Ankyloblepharon filiforme adnatum-cleft palate syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1071,Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1069,Aniridia-absent patella syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,1218204[PMID]
1069,Aniridia-absent patella syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1218204[PMID]
1068,Aniridia-intellectual disability syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,4422267[PMID]
1068,Aniridia-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4422267[PMID]
1067,Aniridia-ptosis-intellectual disability-familial obesity syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3091805[PMID]
1067,Aniridia-ptosis-intellectual disability-familial obesity syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3091805[PMID]
1064,Aniridia-renal agenesis-psychomotor retardation syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,4419812[PMID]
1064,Aniridia-renal agenesis-psychomotor retardation syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4419812[PMID]
1062,Hereditary neurocutaneous malformation,Disease,Cases/families,9.0,,Family(ies),Worldwide,Validated,537017[PMID]_3342546[PMID]_7189031[PMID]_998575[PMID]_14186663[PMID]_8929507[PMID]
1062,Hereditary neurocutaneous malformation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3342546[PMID]
210548,Macrocephaly-intellectual disability-autism syndrome,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,ORPHANET
210548,Macrocephaly-intellectual disability-autism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1052,Mosaic variegated aneuploidy syndrome,Malformation syndrome,Cases/families,41.0,,Case(s),Worldwide,Validated,16059936[PMID]_[EXPERT]
1052,Mosaic variegated aneuploidy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3283,His bundle tachycardia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
210163,"Congenital lethal myopathy, Compton-North type",Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,19026398[PMID]
210163,"Congenital lethal myopathy, Compton-North type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19026398[PMID]
1037,Arthrogryposis multiplex congenita,Clinical group,Prevalence at birth,5.7,1-9 / 100 000,Value and class,Europe,Validated,22005589[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1037,Arthrogryposis multiplex congenita,Clinical group,Prevalence at birth,8.3,1-9 / 100 000,Value and class,Australia,Validated,9928642[PMID]
1037,Arthrogryposis multiplex congenita,Clinical group,Prevalence at birth,0.0,1-5 / 10 000,Class only,Canada,Not yet validated,21157886[PMID]
1037,Arthrogryposis multiplex congenita,Clinical group,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
210144,"Lethal polymalformative syndrome, Boissel type",Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,26378117[PMID]_19559399[PMID]
210144,"Lethal polymalformative syndrome, Boissel type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26378117[PMID]_19559399[PMID]
1125,"Ocular motor apraxia, Cogan type",Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
1125,"Ocular motor apraxia, Cogan type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
67,Amoebiasis due to Entamoeba histolytica,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1120,Lung agenesis-heart defect-thumb anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25487726[PMID]_26513515[PMID]
1120,Lung agenesis-heart defect-thumb anomalies syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,25487726[PMID]_26513515[PMID]
2023,Undifferentiated pleomorphic sarcoma,Disease,Annual incidence,0.9,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
2023,Undifferentiated pleomorphic sarcoma,Disease,Annual incidence,0.9,1-9 / 1 000 000,Value and class,United States,Validated,National Cancer institute[INST]_17013893[PMID]
2023,Undifferentiated pleomorphic sarcoma,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
416,Primary hyperoxaluria,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Germany,Validated,15961947[PMID]
416,Primary hyperoxaluria,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15961947[PMID]
416,Primary hyperoxaluria,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,19225556[PMID]
1117,Aplasia cutis-myopia syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,3395567[PMID]_8741916[PMID]
1117,Aplasia cutis-myopia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3395567[PMID]_8741916[PMID]
1110,Aortic arch anomaly-facial dysmorphism-intellectual disability syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,5696314[PMID]
1110,Aortic arch anomaly-facial dysmorphism-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5696314[PMID]
1113,Aphalangy-syndactyly-microcephaly syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,19449409[PMID]
1113,Aphalangy-syndactyly-microcephaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19449409[PMID]
1112,Aphalangy-hemivertebrae-urogenital-intestinal dysgenesis syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,2282714[PMID]
1112,Aphalangy-hemivertebrae-urogenital-intestinal dysgenesis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2282714[PMID]
1106,Microphthalmia with limb anomalies,Malformation syndrome,Cases/families,35.0,,Family(ies),Worldwide,Validated,21750680[PMID]_21194680[PMID]
1106,Microphthalmia with limb anomalies,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
83,Antley-Bixler syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,[EXPERT]_ORPHANET
1104,Anophthalmia plus syndrome,Malformation syndrome,Cases/families,17.0,,Case(s),Worldwide,Validated,24341146[PMID]_25804017[PMID]
1104,Anophthalmia plus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24341146[PMID]_25804017[PMID]
1063,Tufted angioma,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,25365496[PMID]
1063,Tufted angioma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25365496[PMID]
991,PAGOD syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,8291549[PMID]
991,PAGOD syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8291549[PMID]
211067,Episodic ataxia type 5,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,ORPHANET_16100538[PMID]
211067,Episodic ataxia type 5,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
989,Hypoglossia-hypodactyly syndrome,Malformation syndrome,Cases/families,47.0,,Case(s),Worldwide,Validated,23431477[PMID]
989,Hypoglossia-hypodactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23431477[PMID]
211062,Hereditary episodic ataxia,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,ORPHANET
51,Aicardi-Goutières syndrome,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
51,Aicardi-Goutières syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301648[PMID]
2583,Mycetoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1685,Distomatosis,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
978,ADULT syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,Pr MANOUVRIER-HANU Sylvie[EXPERT]
978,ADULT syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27469932[PMID]_22607287[PMID]_21078104[PMID]_16114047[PMID]_16724007[PMID]
1902,Ehrlichiosis,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
1902,Ehrlichiosis,Disease,Annual incidence,0.25,1-9 / 1 000 000,Value and class,United States,Validated,Center for Diseases Control and Prevention[INST]
1902,Ehrlichiosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
983,Testicular regression syndrome,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
655,Nephronophthisis,Disease,Prevalence at birth,1.25,1-9 / 100 000,Value and class,Finland,Validated,10196704[PMID]
655,Nephronophthisis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,[EXPERT]
971,Acrorenal syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
971,Acrorenal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2122,Kaposiform hemangioendothelioma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
969,Acromicric dysplasia,Malformation syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,[EXPERT]
969,Acromicric dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
974,Adams-Oliver syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_28160419[PMID]
974,Adams-Oliver syndrome,Malformation syndrome,Cases/families,398.0,,Case(s),Worldwide,Validated,28160419[PMID]
973,"Isolated absence/hypoplasia of fingers excluding thumb, unilateral",Morphological anomaly,Cases/families,2.0,,Family(ies),Worldwide,Validated,3725479[PMID]
973,"Isolated absence/hypoplasia of fingers excluding thumb, unilateral",Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3725479[PMID]
959,Acro-renal-ocular syndrome,Malformation syndrome,Cases/families,20.0,,Family(ies),Worldwide,Validated,ORPHANET
959,Acro-renal-ocular syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
407,Glycine encephalopathy,Disease,Point prevalence,0.17,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2002[INST]
407,Glycine encephalopathy,Disease,Prevalence at birth,1.8,1-9 / 100 000,Value and class,Finland,Validated,20301531[PMID]
407,Glycine encephalopathy,Disease,Prevalence at birth,1.59,1-9 / 100 000,Value and class,Canada,Validated,10617747[PMID]
407,Glycine encephalopathy,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Saudi Arabia,Validated,20622343[PMID]
407,Glycine encephalopathy,Disease,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Portugal,Validated,22532538[PMID]
407,Glycine encephalopathy,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,Portugal,Validated,22532538[PMID]
407,Glycine encephalopathy,Disease,Prevalence at birth,3.8,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]
407,Glycine encephalopathy,Disease,Prevalence at birth,8.0,1-9 / 100 000,Value and class,Specific population,Validated,33239050[PMID]
139414,Congenital panfollicular nevus,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,26822169[PMID]
139414,Congenital panfollicular nevus,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26822169[PMID]
663,Mitochondrial DNA-related progressive external ophthalmoplegia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
137,Congenital disorder of glycosylation,Category,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET
137,Congenital disorder of glycosylation,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
220,Denys-Drash syndrome,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,[EXPERT]
220,Denys-Drash syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
1031,Enamel-renal syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,21212699[PMID]
1031,Enamel-renal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
139423,Idiopathic acute transverse myelitis,Clinical subtype,Annual incidence,0.25,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
139423,Idiopathic acute transverse myelitis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
85,Congenital dyserythropoietic anemia,Clinical group,Prevalence at birth,0.16,1-9 / 1 000 000,Value and class,Europe,Not yet validated,20824457[PMID]
85,Congenital dyserythropoietic anemia,Clinical group,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,20824457[PMID]
85,Congenital dyserythropoietic anemia,Clinical group,Cases/families,740.0,,Case(s),Worldwide,Validated,20665989[PMID]
85,Congenital dyserythropoietic anemia,Clinical group,Point prevalence,0.0,1-9 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1035,Beta-mercaptolactate cysteine disulfiduria,Biological anomaly,Cases/families,1.0,,Case(s),Worldwide,Validated,4973015[PMID]
1035,Beta-mercaptolactate cysteine disulfiduria,Biological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4973015[PMID]
139436,Multicentric reticulohistiocytosis,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
139436,Multicentric reticulohistiocytosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1021,Amaurosis-hypertrichosis syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,2769722[PMID]
1021,Amaurosis-hypertrichosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2769722[PMID]
177,Rhizomelic chondrodysplasia punctata,Disease,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Europe,Validated,34229749[PMID]
177,Rhizomelic chondrodysplasia punctata,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,United States,Validated,34229749[PMID]
177,Rhizomelic chondrodysplasia punctata,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,34229749[PMID]_ORPHANET
1023,"Congenital generalized hypertrichosis, Ambras type",Clinical subtype,Cases/families,40.0,,Case(s),Worldwide,Validated,ORPHANET
1023,"Congenital generalized hypertrichosis, Ambras type",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
618,Familial melanoma,Disease,Annual incidence,1.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
618,Familial melanoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
359,Pediatric-onset glaucoma of genetic origin,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
213500,Ovarian cancer,Category,Point prevalence,49.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
701,Alopecia universalis,Disease,Point prevalence,25.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2006[INST]
1010,Autosomal dominant palmoplantar keratoderma and congenital alopecia,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
1010,Autosomal dominant palmoplantar keratoderma and congenital alopecia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
213512,Malignant mixed Müllerian tumor of the ovary,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1003,Scalp defects-postaxial polydactyly syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,4029956[PMID]_468253[PMID]
1003,Scalp defects-postaxial polydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4029956[PMID]_468253[PMID]
1005,Alopecia-contractures-dwarfism-intellectual disability syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,6250998[PMID]_7158638[PMID]_10861681[PMID]
1005,Alopecia-contractures-dwarfism-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6250998[PMID]_7158638[PMID]_10861681[PMID]
1253,Ascher syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,8994475[PMID]
1253,Ascher syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1252,Blepharonasofacial malformation syndrome,Malformation syndrome,Cases/families,3.0,,Family(ies),Worldwide,Validated,10631920[PMID]
1252,Blepharonasofacial malformation syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10631920[PMID]
1248,Maxillonasal dysplasia,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
175,Cartilage-hair hypoplasia,Disease,Point prevalence,150.0,>1 / 1000,Value and class,Specific population,Validated,22420014[PMID]
175,Cartilage-hair hypoplasia,Disease,Prevalence at birth,4.34,1-9 / 100 000,Value and class,Finland,Validated,1404295[PMID]
175,Cartilage-hair hypoplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
209,Cutis laxa,Clinical group,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
209,Cutis laxa,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1259,Blepharoptosis-myopia-ectopia lentis syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,6978128[PMID]
1259,Blepharoptosis-myopia-ectopia lentis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6978128[PMID]
1261,Bonnemann-Meinecke-Reich syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,2654691[PMID]_1941968[PMID]
1261,Bonnemann-Meinecke-Reich syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2654691[PMID]_1941968[PMID]
1234,Bartsocas-Papas syndrome,Malformation syndrome,Cases/families,24.0,,Case(s),Worldwide,Validated,ORPHANET
1234,Bartsocas-Papas syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1234,Bartsocas-Papas syndrome,Malformation syndrome,Prevalence at birth,0.15,1-9 / 1 000 000,Value and class,Spain,Validated,1867261[PMID]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.038,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.095,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.024,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.068,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.024,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.077,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.075,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.031,<1 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.039,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.019,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.044,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.054,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.064,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.053,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213557,Salivary gland type cancer of the breast,Disease,Annual incidence,0.323,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
114,Auriculoosteodysplasia,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,6065451[PMID]
114,Auriculoosteodysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6065451[PMID]
115,Congenital contractural arachnodactyly,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1236,Severe microbrachycephaly-intellectual disability-athetoid cerebral palsy syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1609828[PMID]
1236,Severe microbrachycephaly-intellectual disability-athetoid cerebral palsy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1609828[PMID]
137622,Intractable diarrhea-choanal atresia-eye anomalies syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,17786112[PMID]
137622,Intractable diarrhea-choanal atresia-eye anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17786112[PMID]
1292,Brachymorphism-onychodysplasia-dysphalangism syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,5567413[PMID]_8445623[PMID]
1292,Brachymorphism-onychodysplasia-dysphalangism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5567413[PMID]_8445623[PMID]
137628,Cardiac anomalies-heterotaxy syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,17938964[PMID]
137628,Cardiac anomalies-heterotaxy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17938964[PMID]
3188,Congenital pulmonary veins atresia or stenosis,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
137625,Glycogen storage disease due to muscle and heart glycogen synthase deficiency,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,17928598[PMID]_19699667[PMID]
137625,Glycogen storage disease due to muscle and heart glycogen synthase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17928598[PMID]_19699667[PMID]
1299,Branchioskeletogenital syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,5141271[PMID]_9843000[PMID]_20949527[PMID]
1299,Branchioskeletogenital syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5141271[PMID]_9843000[PMID]_20949527[PMID]
1300,Autosomal dominant popliteal pterygium syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1300,Autosomal dominant popliteal pterygium syndrome,Malformation syndrome,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET_[EXPERT]
137667,Capillary malformation-arteriovenous malformation,Malformation syndrome,Cases/families,261.0,,Case(s),Worldwide,Validated,24038909[PMID]
137667,Capillary malformation-arteriovenous malformation,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
137634,Overgrowth-macrocephaly-facial dysmorphism syndrome,Malformation syndrome,Cases/families,6.0,,Family(ies),Worldwide,Validated,17632510[PMID]
137634,Overgrowth-macrocephaly-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17632510[PMID]
1295,Brachytelephalangy-dysmorphism-Kallmann syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3728571[PMID]
1295,Brachytelephalangy-dysmorphism-Kallmann syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3728571[PMID]
137631,"Lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome",Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,17937424[PMID]
137631,"Lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17937424[PMID]
1296,Lambert syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,2352262[PMID]
1296,Lambert syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2352262[PMID]
1297,Branchio-oculo-facial syndrome,Malformation syndrome,Cases/families,150.0,,Case(s),Worldwide,Validated,21634087[PMID]
1297,Branchio-oculo-facial syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21634087[PMID]
185,Scimitar syndrome,Malformation syndrome,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
185,Scimitar syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,27.2,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,19.6,1-5 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,29.1,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,14.6,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,59.5,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,63.6,6-9 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,63.1,6-9 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,3.6,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,26.1,1-5 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,48.2,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,6.3,1-9 / 100 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,35.3,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,11.4,1-5 / 10 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,23.7,1-5 / 10 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,25.7,1-5 / 10 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,98.4,6-9 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,42.5,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,19.4,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Prevalence at birth,0.0,1-5 / 10 000,Class only,Europe,Validated,ORPHANET
3189,Congenital pulmonary valvar stenosis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
1464,Univentricular heart,Morphological anomaly,Prevalence at birth,7.5,1-9 / 100 000,Value and class,Worldwide,Validated,23705101[PMID]
1464,Univentricular heart,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1278,Brachydactyly-preaxial hallux varus syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,5082920[PMID]
1278,Brachydactyly-preaxial hallux varus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5082920[PMID]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.039,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.044,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.083,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.031,<1 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.045,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.034,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.019,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.039,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.056,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.041,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.117,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.177,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.139,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.113,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.173,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.228,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213716,Squamous cell carcinoma of the corpus uteri,Disease,Annual incidence,0.106,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1178,Ataxia-tapetoretinal degeneration syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1572,Common variable immunodeficiency,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Specific population,Validated,[EXPERT]
1572,Common variable immunodeficiency,Disease,Annual incidence,2.3,1-9 / 100 000,Value and class,Netherlands,Validated,22288591[PMID]
1572,Common variable immunodeficiency,Disease,Point prevalence,0.98,1-9 / 1 000 000,Value and class,France,Validated,22288591[PMID]
1572,Common variable immunodeficiency,Disease,Point prevalence,0.66,1-9 / 1 000 000,Value and class,Spain,Validated,22288591[PMID]
1572,Common variable immunodeficiency,Disease,Point prevalence,0.87,1-9 / 1 000 000,Value and class,Netherlands,Validated,22288591[PMID]
1572,Common variable immunodeficiency,Disease,Point prevalence,0.6,1-9 / 1 000 000,Value and class,United Kingdom,Validated,22288591[PMID]
1572,Common variable immunodeficiency,Disease,Point prevalence,0.72,1-9 / 1 000 000,Value and class,Italy,Validated,22288591[PMID]
1572,Common variable immunodeficiency,Disease,Point prevalence,0.52,1-9 / 1 000 000,Value and class,Germany,Validated,22288591[PMID]
1572,Common variable immunodeficiency,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Turkey,Validated,22288591[PMID]
1572,Common variable immunodeficiency,Disease,Point prevalence,0.073,<1 / 1 000 000,Value and class,Poland,Validated,22288591[PMID]
1572,Common variable immunodeficiency,Disease,Point prevalence,0.77,1-9 / 1 000 000,Value and class,Australia,Validated,9314356[PMID]
1572,Common variable immunodeficiency,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
3261,Autoimmune lymphoproliferative syndrome,Disease,Cases/families,500.0,,Case(s),Worldwide,Validated,20538792[PMID]
3261,Autoimmune lymphoproliferative syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20538792[PMID]
1133,AREDYLD syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,6638067[PMID]_1488989[PMID]
1133,AREDYLD syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6638067[PMID]_1488989[PMID]
137675,Histiocytoid cardiomyopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,25921236[PMID]_ORPHANET
137675,Histiocytoid cardiomyopathy,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,25921236[PMID]
1131,X-linked mandibulofacial dysostosis,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,4039890[PMID]_8465866[PMID]_12002155[PMID]
1131,X-linked mandibulofacial dysostosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4039890[PMID]_8465866[PMID]_12002155[PMID]
137678,Spondyloepiphyseal dysplasia with metatarsal shortening,Disease,Cases/families,13.0,,Family(ies),Worldwide,Validated,30363003[PMID]_19764028[PMID]_[EXPERT]
137678,Spondyloepiphyseal dysplasia with metatarsal shortening,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30363003[PMID]
137698,Cytomegalovirus disease in patients with impaired cell mediated immunity deemed at risk,Particular clinical situation in a disease or syndrome,Point prevalence,25.5,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]_ORPHANET
137754,Aminoacylase 1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29653693[PMID]
137754,Aminoacylase 1 deficiency,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,29653693[PMID]
1145,Infantile-onset X-linked spinal muscular atrophy,Disease,Cases/families,14.0,,Family(ies),Worldwide,Validated,20301739[PMID]
1145,Infantile-onset X-linked spinal muscular atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301739[PMID]
137776,Lethal congenital contracture syndrome type 2,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,12548738[PMID]
137776,Lethal congenital contracture syndrome type 2,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12548738[PMID]
1150,Arthrogryposis multiplex congenita-whistling face syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
1150,Arthrogryposis multiplex congenita-whistling face syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1149,Kuskokwim syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23712425[PMID]
1149,Kuskokwim syndrome,Malformation syndrome,Cases/families,8.0,,Family(ies),Worldwide,Validated,23712425[PMID]
137807,Primary cutaneous amyloidosis,Clinical group,Point prevalence,9.8,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,21070198[PMID]
137807,Primary cutaneous amyloidosis,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1159,Progressive pseudorheumatoid dysplasia,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
137783,Lethal congenital contracture syndrome type 3,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,17701898[PMID]_22610851[PMID]
137783,Lethal congenital contracture syndrome type 3,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17701898[PMID]_22610851[PMID]
1214,Progressive hemifacial atrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1214,Progressive hemifacial atrophy,Disease,Point prevalence,0.143,1-9 / 1 000 000,Value and class,United States,Validated,12963760[PMID]_[EXPERT]
213812,Primitive neuroectodermal tumor of the cervix uteri,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21962148[PMID]
138044,Rare disease with Pierre Robin syndrome,Category,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Not yet validated,24433508[PMID]
138044,Rare disease with Pierre Robin syndrome,Category,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
1221,Cheilitis glandularis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1221,Cheilitis glandularis,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
213807,Leiomyosarcoma of the cervix uteri,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23519508[PMID]
1226,Bamforth-Lazarus syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,[EXPERT]
1226,Bamforth-Lazarus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3082,Intellectual disability-polydactyly-uncombable hair syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,9028447[PMID]
3082,Intellectual disability-polydactyly-uncombable hair syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9028447[PMID]
1184,Ataxia-photosensitivity-short stature syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,6620277[PMID]
1184,Ataxia-photosensitivity-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6620277[PMID]
3269,Isolated radio-ulnar synostosis,Morphological anomaly,Cases/families,350.0,,Case(s),Worldwide,Validated,22802806[PMID]
3269,Isolated radio-ulnar synostosis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_22802806[PMID]
137888,Auriculocondylar syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
137888,Auriculocondylar syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,22560091[PMID]_23315542[PMID]
3309,Tetrasomy 5p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25424187[PMID]
137898,Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome,Disease,Cases/families,127.0,,Case(s),Worldwide,Validated,24566671[PMID]
137898,Leukoencephalopathy with brain stem and spinal cord involvement-high lactate syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1188,Ataxia-deafness-intellectual disability syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,4728186[PMID]_3470627[PMID]_8411058[PMID]
1188,Ataxia-deafness-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4728186[PMID]_3470627[PMID]_8411058[PMID]
1187,Lethal ataxia with deafness and optic atrophy,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,27256512[PMID]
1187,Lethal ataxia with deafness and optic atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27256512[PMID]
1190,Atelosteogenesis type I,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
466,Fatal familial insomnia,Disease,Cases/families,27.0,,Case(s),Worldwide,Validated,ORPHANET
466,Fatal familial insomnia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2834,Wrinkly skin syndrome,Clinical subtype,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
2834,Wrinkly skin syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
268173,Intermittent maple syrup urine disease,Clinical subtype,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
268173,Intermittent maple syrup urine disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
2969,Proteus-like syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
199282,Harlequin syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,28018464[PMID]
199282,Harlequin syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28018464[PMID]
199285,Hereditary hypercarotenemia and vitamin A deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2331,Kawasaki disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
750,Pseudoachondroplasia,Disease,Point prevalence,3.3,1-9 / 100 000,Value and class,Worldwide,Not yet validated,20301660[PMID]
2975,"46,XX difference of sex development-skeletal anomalies syndrome",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,5042791[PMID]
2975,"46,XX difference of sex development-skeletal anomalies syndrome",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5042791[PMID]
2980,Acrootoocular syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2978,Chronic intestinal pseudoobstruction,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2040,Congenital respiratory-biliary fistula,Morphological anomaly,Cases/families,35.0,,Case(s),Worldwide,Validated,21516501[PMID]_19586763[PMID]
2040,Congenital respiratory-biliary fistula,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
199318,15q13.3 microdeletion syndrome,Malformation syndrome,Cases/families,246.0,,Case(s),Worldwide,Validated,25077648[PMID]_[EXPERT]
199318,15q13.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2357,Bronchogenic cyst,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
274,Bernard-Soulier syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,17109744[PMID]_24051937[PMID]
274,Bernard-Soulier syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17109744[PMID]
1195,Congenital atransferrinemia,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,19696475[PMID]_23888904[PMID]
1195,Congenital atransferrinemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
199302,Isolated cleft lip,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,Pr Marie-Paule VAZQUEZ_Dr Eva GALLIANI[EXPERT]
199306,Cleft lip/palate,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,Pr Marie-Paule VAZQUEZ_Dr Eva GALLIANI[EXPERT]
199306,Cleft lip/palate,Morphological anomaly,Prevalence at birth,56.0,1-5 / 10 000,Value and class,United States,Validated,25399767[PMID]
199306,Cleft lip/palate,Morphological anomaly,Prevalence at birth,98.0,6-9 / 10 000,Value and class,France,Validated,1842671[PMID]
199306,Cleft lip/palate,Morphological anomaly,Prevalence at birth,80.0,6-9 / 10 000,Value and class,Worldwide,Validated,22374000[PMID]
926,Acatalasemia,Disease,Point prevalence,3.2,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
2947,Triphalangeal thumbs-brachyectrodactyly syndrome,Malformation syndrome,Cases/families,4.0,,Family(ies),Worldwide,Validated,7438506[PMID]_3568429[PMID]_8946115[PMID]
2947,Triphalangeal thumbs-brachyectrodactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7438506[PMID]_3568429[PMID]_8946115[PMID]
1531,Craniosynostosis,Category,Prevalence at birth,24.3,1-5 / 10 000,Value and class,Europe,Not yet validated,EUROCAT European surveillance of congenital anomalies 2012[REG]
1531,Craniosynostosis,Category,Prevalence at birth,47.6,1-5 / 10 000,Value and class,France,Validated,7762595[PMID]
1531,Craniosynostosis,Category,Prevalence at birth,49.4,1-5 / 10 000,Value and class,Australia,Validated,34626670[PMID]
1531,Craniosynostosis,Category,Prevalence at birth,43.0,1-5 / 10 000,Value and class,United States,Validated,18344207[PMID]
1531,Craniosynostosis,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2952,"Adducted thumbs-arthrogryposis syndrome, Christian type",Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,6662143[PMID]
2952,"Adducted thumbs-arthrogryposis syndrome, Christian type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6662143[PMID]
740,Hutchinson-Gilford progeria syndrome,Disease,Prevalence at birth,0.025,<1 / 1 000 000,Value and class,Worldwide,Validated,[EXPERT]
740,Hutchinson-Gilford progeria syndrome,Disease,Point prevalence,0.005,<1 / 1 000 000,Value and class,Worldwide,Validated,[EXPERT]
2959,Progeria-short stature-pigmented nevi syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,29718885[PMID]
2959,Progeria-short stature-pigmented nevi syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29718885[PMID]
2957,Guttmacher syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8484413[PMID]
2957,Guttmacher syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,8484413[PMID]
3129,Sarcosinemia,Disease,Prevalence at birth,0.28,1-9 / 1 000 000,Value and class,United States,Validated,6207480[PMID]
3129,Sarcosinemia,Disease,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Worldwide,Validated,ORPHANET
3129,Sarcosinemia,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Validated,ORPHANET
3129,Sarcosinemia,Disease,Prevalence at birth,2.3,1-9 / 100 000,Value and class,Specific population,Validated,ISBN:79092543[OTHER]
2924,Isolated polycystic liver disease,Malformation syndrome,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
2926,Digital extensor muscle aplasia-polyneuropathy,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3459358[PMID]
2926,Digital extensor muscle aplasia-polyneuropathy,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3459358[PMID]
2928,Polyneuropathy-intellectual disability-acromicria-premature menopause syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,5117105[PMID]
2928,Polyneuropathy-intellectual disability-acromicria-premature menopause syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5117105[PMID]
2930,Cronkhite-Canada syndrome,Disease,Cases/families,500.0,,Case(s),Worldwide,Validated,25004941[PMID]
2930,Cronkhite-Canada syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25004941[PMID]
2494,Ménétrier disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
171,Primary sclerosing cholangitis,Disease,Annual incidence,0.77,1-9 / 1 000 000,Value and class,Europe,Validated,21351115[PMID]_[EXPERT]
171,Primary sclerosing cholangitis,Disease,Point prevalence,7.84,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET_9489916[PMID]_18433916[PMID]_23775876[PMID]_7890895[PMID]_20683956[PMID]
171,Primary sclerosing cholangitis,Disease,Point prevalence,8.1,1-9 / 100 000,Value and class,Worldwide,Validated,22245904[PMID]
171,Primary sclerosing cholangitis,Disease,Annual incidence,0.65,1-9 / 1 000 000,Value and class,Worldwide,Validated,22245904[PMID]
171,Primary sclerosing cholangitis,Disease,Annual incidence,0.77,1-9 / 1 000 000,Value and class,United States,Not yet validated,14598252[PMID]_21351115[PMID]
171,Primary sclerosing cholangitis,Disease,Point prevalence,8.81,1-9 / 100 000,Value and class,United States,Not yet validated,14598252[PMID]_ORPHANET
171,Primary sclerosing cholangitis,Disease,Annual incidence,1.3,1-9 / 100 000,Value and class,Norway,Validated,9489916[PMID]
171,Primary sclerosing cholangitis,Disease,Point prevalence,8.5,1-9 / 100 000,Value and class,Norway,Validated,9489916[PMID]
171,Primary sclerosing cholangitis,Disease,Annual incidence,1.22,1-9 / 100 000,Value and class,Sweden,Validated,22098097[PMID]
171,Primary sclerosing cholangitis,Disease,Point prevalence,16.2,1-5 / 10 000,Value and class,Sweden,Validated,20683956[PMID]
171,Primary sclerosing cholangitis,Disease,Annual incidence,0.66,1-9 / 1 000 000,Value and class,United Kingdom,Not yet validated,18433916[PMID]_15188211[PMID]_ ORPHANET
171,Primary sclerosing cholangitis,Disease,Point prevalence,8.28,1-9 / 100 000,Value and class,United Kingdom,Not yet validated,18433916[PMID]_15188211[PMID]_ ORPHANET
171,Primary sclerosing cholangitis,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Netherlands,Validated,23775876[PMID]
171,Primary sclerosing cholangitis,Disease,Point prevalence,6.0,1-9 / 100 000,Value and class,Netherlands,Validated,23775876[PMID]
171,Primary sclerosing cholangitis,Disease,Annual incidence,0.9,1-9 / 1 000 000,Value and class,Canada,Validated,17313496[PMID]
171,Primary sclerosing cholangitis,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,Spain,Validated,7890895[PMID]
171,Primary sclerosing cholangitis,Disease,Point prevalence,0.22,1-9 / 1 000 000,Value and class,Spain,Validated,7890895[PMID]
171,Primary sclerosing cholangitis,Disease,Point prevalence,1.3,1-9 / 100 000,Value and class,Singapore,Validated,12164967[PMID]_22245904[PMID]
199247,Corticosteroid-binding globulin deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
199241,Pulmonary capillary hemangiomatosis,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,24493495[PMID]
199241,Pulmonary capillary hemangiomatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24493495[PMID]
2907,Hereditary acrokeratotic poikiloderma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4253719[PMID]_7015974[PMID]
2907,Hereditary acrokeratotic poikiloderma,Disease,Cases/families,41.0,,Case(s),Worldwide,Validated,4253719[PMID]_7015974[PMID]
17,Fatal infantile lactic acidosis with methylmalonic aciduria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3006,Pyridoxine-dependent epilepsy,Disease,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
3006,Pyridoxine-dependent epilepsy,Disease,Prevalence at birth,0.13,1-9 / 1 000 000,Value and class,United Kingdom,Validated,10519720[PMID]
3006,Pyridoxine-dependent epilepsy,Disease,Prevalence at birth,0.25,1-9 / 1 000 000,Value and class,Netherlands,Validated,16159904[PMID]
3006,Pyridoxine-dependent epilepsy,Disease,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Germany,Not yet validated,10356240[PMID]_ORPHANET
3006,Pyridoxine-dependent epilepsy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
780,Rhabdomyosarcoma,Disease,Annual incidence,0.59,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
780,Rhabdomyosarcoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3111,Rotor syndrome,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
3111,Rotor syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2382,Lennox-Gastaut syndrome,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
2382,Lennox-Gastaut syndrome,Disease,Point prevalence,15.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]_European Medicines Agency 2004[INST]
2806,Subacute sclerosing leukoencephalitis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2806,Subacute sclerosing leukoencephalitis,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,United States,Validated,[EXPERT]_22277189[PMID]
2806,Subacute sclerosing leukoencephalitis,Disease,Annual incidence,2.0,1-9 / 100 000,Value and class,India,Validated,[EXPERT]
2467,Systemic mastocytosis,Clinical group,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Italy,Validated,8645532[PMID]
2467,Systemic mastocytosis,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Worldwide,Validated,[EXPERT]_ORPHANET
2467,Systemic mastocytosis,Clinical group,Annual incidence,0.9,1-9 / 1 000 000,Value and class,Denmark,Validated,24761987[PMID]
2467,Systemic mastocytosis,Clinical group,Point prevalence,9.6,1-9 / 100 000,Value and class,Denmark,Validated,24761987[PMID]
2467,Systemic mastocytosis,Clinical group,Annual incidence,0.6,1-9 / 1 000 000,Value and class,Europe,Validated,24761987[PMID]_8645532[PMID]
2467,Systemic mastocytosis,Clinical group,Point prevalence,13.0,1-5 / 10 000,Value and class,Netherlands,Validated,23219169[PMID]
2467,Systemic mastocytosis,Clinical group,Point prevalence,11.3,1-5 / 10 000,Value and class,Europe,Validated,23219169[PMID]_24761987[PMID]
264580,Glycogen storage disease due to liver phosphorylase kinase deficiency,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
264580,Glycogen storage disease due to liver phosphorylase kinase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2916,Postaxial polydactyly-dental and vertebral anomalies syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,187745[PMID]
2916,Postaxial polydactyly-dental and vertebral anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_187745[PMID]
2917,Polydactyly-myopia syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,3802559[PMID]
2917,Polydactyly-myopia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3802559[PMID]
2919,Orofaciodigital syndrome type 5,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,7150858[PMID]_23972372[PMID]
2919,Orofaciodigital syndrome type 5,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7150858[PMID]_23972372[PMID]
264675,Hereditary pulmonary alveolar proteinosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20622029[PMID]
2920,Oliver syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,16278897[PMID]
2920,Oliver syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16278897[PMID]
264691,Isolated pulmonary capillaritis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1943,Early-onset progressive encephalopathy with migrant continuous myoclonus,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,8737801[PMID]
1943,Early-onset progressive encephalopathy with migrant continuous myoclonus,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8737801[PMID]
264688,Congenital chylothorax,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
264688,Congenital chylothorax,Disease,Prevalence at birth,4.17,1-9 / 100 000,Value and class,Germany,Validated,25480460[PMID]
3374,Unilateral ocular duplication,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17558850[PMID]
275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Point prevalence,0.17,1-9 / 1 000 000,Value and class,France,Validated,16456139[PMID]
275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Annual incidence,0.026,<1 / 1 000 000,Value and class,France,Validated,16456139[PMID]
275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Point prevalence,0.95,1-9 / 1 000 000,Value and class,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Annual incidence,0.2,1-9 / 1 000 000,Value and class,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Spain,Validated,22362843[PMID]
275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Point prevalence,0.46,1-9 / 1 000 000,Value and class,Czech Republic,Validated,24629043[PMID]
275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Czech Republic,Validated,24629043[PMID]
275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Netherlands,Validated,24794056[PMID]
275803,Pulmonary arterial hypertension associated with congenital heart disease,Clinical group,Point prevalence,0.57,1-9 / 1 000 000,Value and class,Europe,Validated,22362843[PMID]_16456139[PMID]_24629043[PMID]_21885399[PMID]_17360728[PMID]
275808,Pulmonary arterial hypertension associated with HIV infection,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
275813,Pulmonary arterial hypertension associated with portal hypertension,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3377,Trismus-pseudocamptodactyly syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
275823,Pulmonary arterial hypertension associated with schistosomiasis,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3368,Trigonocephaly-bifid nose-acral anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2063891[PMID]
3368,Trigonocephaly-bifid nose-acral anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2063891[PMID]
275777,Heritable pulmonary arterial hypertension,Etiological subtype,Point prevalence,0.08,<1 / 1 000 000,Value and class,Europe,Validated,16456139[PMID]_ORPHANET
275777,Heritable pulmonary arterial hypertension,Etiological subtype,Point prevalence,0.08,<1 / 1 000 000,Value and class,France,Validated,16456139[PMID]_ORPHANET
275777,Heritable pulmonary arterial hypertension,Etiological subtype,Point prevalence,0.8,1-9 / 1 000 000,Value and class,Czech Republic,Validated,24629043[PMID]_ORPHANET
2302,Asbestos intoxication,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
770,Rabies,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,[EXPERT]
770,Rabies,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,United States,Not yet validated,22699971[PMID]
770,Rabies,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Centre for Disease prevention and Control 2017[INST]
275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Point prevalence,0.23,1-9 / 1 000 000,Value and class,France,Validated,16456139[PMID]
275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Annual incidence,0.036,<1 / 1 000 000,Value and class,France,Validated,16456139[PMID]
275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Point prevalence,0.25,1-9 / 1 000 000,Value and class,Spain,Validated,22362843[PMID]
275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Point prevalence,1.25,1-9 / 100 000,Value and class,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Annual incidence,0.25,1-9 / 1 000 000,Value and class,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Point prevalence,0.25,1-9 / 1 000 000,Value and class,Czech Republic,Validated,24629043[PMID]
275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Czech Republic,Validated,24629043[PMID]
275798,Pulmonary arterial hypertension associated with connective tissue disease,Clinical group,Point prevalence,0.25,1-9 / 1 000 000,Value and class,Europe,Validated,24629043[PMID]_22362843[PMID]_16456139[PMID]_21885399[PMID]_17360728[PMID]
267,Calpain-3-related limb-girdle muscular dystrophy R1,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2006[INST]
267,Calpain-3-related limb-girdle muscular dystrophy R1,Disease,Point prevalence,0.6,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
267,Calpain-3-related limb-girdle muscular dystrophy R1,Disease,Point prevalence,4.8,1-9 / 100 000,Value and class,Reunion,Validated,8624690[PMID]
267,Calpain-3-related limb-girdle muscular dystrophy R1,Disease,Point prevalence,1.65,1-9 / 100 000,Value and class,Italy,Not yet validated,ORPHANET_15725583[PMID]_16141003[PMID]
1329,Complete atrioventricular septal defect,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1329,Complete atrioventricular septal defect,Morphological anomaly,Prevalence at birth,20.0,1-5 / 10 000,Value and class,Europe,Validated,16722604[PMID]_[EXPERT]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Point prevalence,0.0,1-9 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Point prevalence,0.59,1-9 / 1 000 000,Value and class,France,Validated,16456139[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Annual incidence,0.1,1-9 / 1 000 000,Value and class,France,Validated,16456139[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Point prevalence,0.56,1-9 / 1 000 000,Value and class,Spain,Validated,22362843[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Spain,Validated,22362843[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Point prevalence,1.4,1-9 / 100 000,Value and class,Czech Republic,Validated,24629043[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Annual incidence,0.62,1-9 / 1 000 000,Value and class,Czech Republic,Validated,24629043[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Point prevalence,0.86,1-9 / 1 000 000,Value and class,Switzerland,Validated,18587690[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Switzerland,Validated,18587690[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Annual incidence,0.25,1-9 / 1 000 000,Value and class,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Point prevalence,1.7,1-9 / 100 000,Value and class,United Kingdom,Validated,21885399[PMID]_17360728[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Annual incidence,0.11,1-9 / 1 000 000,Value and class,United States,Validated,20558556[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Annual incidence,0.17,1-9 / 1 000 000,Value and class,Belgium,Validated,8692238[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Annual incidence,0.14,1-9 / 1 000 000,Value and class,Israel,Validated,11399707[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Point prevalence,0.8,1-9 / 1 000 000,Value and class,Israel,Validated,11399707[PMID]
275766,Idiopathic pulmonary arterial hypertension,Etiological subtype,Point prevalence,1.1,1-9 / 100 000,Value and class,Europe,Validated,16456139[PMID]_22362843[PMID]_18587690[PMID]_21885399[PMID]_17360728[PMID]_24629043[PMID]
2137,Autoimmune hepatitis,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
2137,Autoimmune hepatitis,Disease,Annual incidence,1.2,1-9 / 100 000,Value and class,Worldwide,Not yet validated,ORPHANET_24326217[PMID]
2137,Autoimmune hepatitis,Disease,Point prevalence,23.5,1-5 / 10 000,Value and class,Worldwide,Not yet validated,ORPHANET_24326217[PMID]
2137,Autoimmune hepatitis,Disease,Annual incidence,0.75,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
2137,Autoimmune hepatitis,Disease,Annual incidence,1.9,1-9 / 100 000,Value and class,Norway,Validated,9489916[PMID]
2137,Autoimmune hepatitis,Disease,Point prevalence,16.9,1-5 / 10 000,Value and class,Norway,Validated,9489916[PMID]
2137,Autoimmune hepatitis,Disease,Annual incidence,0.85,1-9 / 1 000 000,Value and class,Sweden,Validated,18609163[PMID]
2137,Autoimmune hepatitis,Disease,Point prevalence,24.5,1-5 / 10 000,Value and class,New Zealand,Validated,20880179[PMID]
2137,Autoimmune hepatitis,Disease,Annual incidence,0.95,1-9 / 1 000 000,Value and class,Spain,Validated,15056409[PMID]_20163033[PMID]_ORPHANET
2137,Autoimmune hepatitis,Disease,Point prevalence,11.6,1-5 / 10 000,Value and class,Spain,Validated,15056409[PMID]
2137,Autoimmune hepatitis,Disease,Point prevalence,10.7,1-5 / 10 000,Value and class,Sweden,Validated,18609163[PMID]
2137,Autoimmune hepatitis,Disease,Annual incidence,0.67,1-9 / 1 000 000,Value and class,Israel,Validated,23815477[PMID]
2137,Autoimmune hepatitis,Disease,Point prevalence,11.0,1-5 / 10 000,Value and class,Israel,Validated,23815477[PMID]
2137,Autoimmune hepatitis,Disease,Annual incidence,1.68,1-9 / 100 000,Value and class,Denmark,Validated,24326217[PMID]
2137,Autoimmune hepatitis,Disease,Point prevalence,23.9,1-5 / 10 000,Value and class,Denmark,Validated,24326217[PMID]
2137,Autoimmune hepatitis,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Singapore,Validated,11851837[PMID]
2137,Autoimmune hepatitis,Disease,Point prevalence,42.9,1-5 / 10 000,Value and class,Specific population,Validated,12358264[PMID]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.73,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.85,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.986,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.809,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.737,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.98,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.817,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.864,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.937,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.899,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.99,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.657,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.919,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.906,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.786,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,0.906,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,1.121,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,1.026,1-9 / 100 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,1.261,1-9 / 100 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,1.113,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,1.127,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,1.093,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,1.227,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276145,Malignant epithelial tumor of salivary glands,Disease,Annual incidence,1.213,1-9 / 100 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
276161,Multiple endocrine neoplasia,Clinical group,Annual incidence,0.05,<1 / 1 000 000,Value and class,Ireland,Validated,2575263[PMID]
276161,Multiple endocrine neoplasia,Clinical group,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET_[EXPERT]
3412,VACTERL with hydrocephalus,Malformation syndrome,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
3412,VACTERL with hydrocephalus,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
276152,Multiple endocrine neoplasia type 4,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3403,Uhl anomaly,Morphological anomaly,Cases/families,84.0,,Case(s),Worldwide,Validated,ORPHANET
3403,Uhl anomaly,Morphological anomaly,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,ORPHANET
3403,Uhl anomaly,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3404,Ulbright-Hodes syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,6711618[PMID]_2240030[PMID]
3404,Ulbright-Hodes syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6711618[PMID]_2240030[PMID]
276066,Bile acid CoA ligase deficiency and defective amidation,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
275872,Frontotemporal dementia with motor neuron disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3383,Humerus trochlea aplasia,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,Mead 1963[AUTHOR]
3383,Humerus trochlea aplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1656,Dermatitis herpetiformis,Disease,Point prevalence,27.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
1656,Dermatitis herpetiformis,Disease,Annual incidence,0.9,1-9 / 1 000 000,Value and class,Italy,Validated,[EXPERT]
1656,Dermatitis herpetiformis,Disease,Annual incidence,1.5,1-9 / 100 000,Value and class,Ireland,Validated,5023901[PMID]_6641006[PMID]_[EXPERT]_ORPHANET
1656,Dermatitis herpetiformis,Disease,Point prevalence,17.6,1-5 / 10 000,Value and class,Ireland,Validated,5023901[PMID]_6641006[PMID]_[EXPERT]_ORPHANET
1656,Dermatitis herpetiformis,Disease,Annual incidence,1.1,1-9 / 100 000,Value and class,Sweden,Validated,6208718[PMID]
1656,Dermatitis herpetiformis,Disease,Point prevalence,21.0,1-5 / 10 000,Value and class,Sweden,Not yet validated,6208718[PMID]
1656,Dermatitis herpetiformis,Disease,Annual incidence,0.98,1-9 / 1 000 000,Value and class,United States,Validated,1456754[PMID]
1656,Dermatitis herpetiformis,Disease,Point prevalence,11.2,1-5 / 10 000,Value and class,United States,Validated,1456754[PMID]
1656,Dermatitis herpetiformis,Disease,Annual incidence,3.5,1-9 / 100 000,Value and class,Finland,Validated,21517799[PMID]
1656,Dermatitis herpetiformis,Disease,Point prevalence,75.3,6-9 / 10 000,Value and class,Finland,Validated,21517799[PMID]
1656,Dermatitis herpetiformis,Disease,Point prevalence,11.5,1-5 / 10 000,Value and class,United Kingdom,Validated,6693042[PMID]
275864,Behavioral variant of frontotemporal dementia,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Netherlands,Validated,22950490[PMID]
2929,Juvenile polyposis syndrome,Disease,Annual incidence,3.85,1-9 / 100 000,Value and class,Europe,Validated,20301642[PMID]_[EXPERT]
2929,Juvenile polyposis syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3387,Isolated anterior cervical hypertrichosis,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
3387,Isolated anterior cervical hypertrichosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
131,Budd-Chiari syndrome,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
131,Budd-Chiari syndrome,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,Sweden,Validated,18694401[PMID]
131,Budd-Chiari syndrome,Disease,Point prevalence,0.14,1-9 / 1 000 000,Value and class,Sweden,Validated,18694401[PMID]
131,Budd-Chiari syndrome,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Denmark,Validated,2010159[PMID]
131,Budd-Chiari syndrome,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Japan,Validated,7751574[PMID]
131,Budd-Chiari syndrome,Disease,Point prevalence,0.24,1-9 / 1 000 000,Value and class,Japan,Validated,7751574[PMID]
131,Budd-Chiari syndrome,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,France,Validated,19433611[PMID]
131,Budd-Chiari syndrome,Disease,Annual incidence,0.21,1-9 / 1 000 000,Value and class,Italy,Validated,28180235[PMID]
131,Budd-Chiari syndrome,Disease,Annual incidence,0.087,<1 / 1 000 000,Value and class,"Korea, Republic of",Validated,26558363[PMID]
131,Budd-Chiari syndrome,Disease,Point prevalence,0.529,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,26558363[PMID]
131,Budd-Chiari syndrome,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Worldwide,Validated,30528513[PMID]
131,Budd-Chiari syndrome,Disease,Point prevalence,1.1,1-9 / 100 000,Value and class,Worldwide,Validated,30528513[PMID]
646,Niemann-Pick disease type C,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,20525256[PMID]_European Medicines Agency 2011[INST]
646,Niemann-Pick disease type C,Disease,Prevalence at birth,0.77,1-9 / 1 000 000,Value and class,France,Validated,20525256[PMID]_12974729[PMID]_[EXPERT]
646,Niemann-Pick disease type C,Disease,Prevalence at birth,0.75,1-9 / 1 000 000,Value and class,United Kingdom,Not yet validated,12974729[PMID]
646,Niemann-Pick disease type C,Disease,Prevalence at birth,0.75,1-9 / 1 000 000,Value and class,Germany,Not yet validated,12974729[PMID]
646,Niemann-Pick disease type C,Disease,Prevalence at birth,0.35,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
646,Niemann-Pick disease type C,Disease,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Portugal,Validated,14685153[PMID]
646,Niemann-Pick disease type C,Disease,Prevalence at birth,0.47,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
646,Niemann-Pick disease type C,Disease,Prevalence at birth,0.91,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
646,Niemann-Pick disease type C,Disease,Prevalence at birth,0.48,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
654,Nephroblastoma,Disease,Annual incidence,0.14,1-9 / 1 000 000,Value and class,Europe,Validated,22357215[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Lifetime Prevalence,3.65,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.144,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
654,Nephroblastoma,Disease,Annual incidence,0.072,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.089,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.065,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.066,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.121,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.195,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.155,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.139,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.158,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.17,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.111,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.157,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.131,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.111,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.162,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.144,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.113,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.135,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
654,Nephroblastoma,Disease,Annual incidence,0.176,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3353,Trichodermodysplasia-dental alterations syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3720011[PMID]
3353,Trichodermodysplasia-dental alterations syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3720011[PMID]
275523,Dianzani autoimmune lymphoproliferative disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
275523,Dianzani autoimmune lymphoproliferative disease,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,[EXPERT]
3351,Trichodental syndrome,Malformation syndrome,Cases/families,5.0,,Family(ies),Worldwide,Validated,8574424[PMID]
3351,Trichodental syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8574424[PMID]
275517,Autoimmune lymphoproliferative syndrome-recurrent viral infections due to CASP8 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12353035[PMID]
275517,Autoimmune lymphoproliferative syndrome-recurrent viral infections due to CASP8 deficiency,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,12353035[PMID]_Dr Koneti RAO[EXPERT]
3352,Tricho-dento-osseous syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
3352,Tricho-dento-osseous syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3350,Tremor-nystagmus-duodenal ulcer syndrome,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,1248168[PMID]
3350,Tremor-nystagmus-duodenal ulcer syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1248168[PMID]
3344,Weismann-Netter syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,19839038[PMID]
3344,Weismann-Netter syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_19839038[PMID]
3347,Mounier-Kühn syndrome,Clinical syndrome,Cases/families,300.0,,Case(s),Worldwide,Validated,[EXPERT]_25130790[PMID]
3347,Mounier-Kühn syndrome,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25130790[PMID]
3341,Torticollis-keloids-cryptorchidism-renal dysplasia syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,12725596[PMID]_4387470[PMID]
3341,Torticollis-keloids-cryptorchidism-renal dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12725596[PMID]_4387470[PMID]
3342,Arterial tortuosity syndrome,Malformation syndrome,Cases/families,102.0,,Case(s),Worldwide,Validated,29323665[PMID]
3342,Arterial tortuosity syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29323665[PMID]
3339,Oculoectodermal syndrome,Malformation syndrome,Cases/families,19.0,,Case(s),Worldwide,Validated,25251940[PMID]
3339,Oculoectodermal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25251940[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.2222,1-9 / 1 000 000,Value and class,Worldwide,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1474,1-9 / 1 000 000,Value and class,Argentina,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.147,1-9 / 1 000 000,Value and class,Australia,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1511,1-9 / 1 000 000,Value and class,Austria,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1484,1-9 / 1 000 000,Value and class,Bangladesh,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1504,1-9 / 1 000 000,Value and class,Belgium,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.5694,1-9 / 1 000 000,Value and class,Bulgaria,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1476,1-9 / 1 000 000,Value and class,Canada,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1481,1-9 / 1 000 000,Value and class,China,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,4.25,1-9 / 100 000,Value and class,Cyprus,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1509,1-9 / 1 000 000,Value and class,Czech Republic,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1403,1-9 / 1 000 000,Value and class,Denmark,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.149,1-9 / 1 000 000,Value and class,Ecuador,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1454,1-9 / 1 000 000,Value and class,Finland,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.7514,1-9 / 1 000 000,Value and class,France,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1486,1-9 / 1 000 000,Value and class,Germany,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1481,1-9 / 1 000 000,Value and class,Greece,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.153,1-9 / 1 000 000,Value and class,Hungary,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1481,1-9 / 1 000 000,Value and class,India,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1578,1-9 / 1 000 000,Value and class,Ireland,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1428,1-9 / 1 000 000,Value and class,Israel,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.9046,1-9 / 1 000 000,Value and class,Italy,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1473,1-9 / 1 000 000,Value and class,Poland,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,19.9126,1-5 / 10 000,Value and class,Portugal,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1464,1-9 / 1 000 000,Value and class,Romania,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1485,1-9 / 1 000 000,Value and class,Russian Federation,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1428,1-9 / 1 000 000,Value and class,Slovenia,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1487,1-9 / 1 000 000,Value and class,Spain,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1476,1-9 / 1 000 000,Value and class,Sri Lanka,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,2.5816,1-9 / 100 000,Value and class,Sweden,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Lifetime Prevalence,0.1445,1-9 / 1 000 000,Value and class,Switzerland,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1489,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.0317,<1 / 1 000 000,Value and class,Turkey,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.149,1-9 / 1 000 000,Value and class,United Kingdom,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.0968,<1 / 1 000 000,Value and class,Japan,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1482,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1666,1-9 / 1 000 000,Value and class,Luxembourg,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1485,1-9 / 1 000 000,Value and class,Malaysia,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.148,1-9 / 1 000 000,Value and class,Mexico,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.2662,1-9 / 1 000 000,Value and class,Netherlands,Validated,29211930[PMID]
271861,Hereditary ATTR amyloidosis,Disease,Point prevalence,0.1521,1-9 / 100 000,Value and class,New Zealand,Validated,29211930[PMID]
3338,Toriello-Carey syndrome,Malformation syndrome,Cases/families,59.0,,Case(s),Worldwide,Validated,27510950[PMID]
3338,Toriello-Carey syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27510950[PMID]
3469,XK aprosencephaly syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
3469,XK aprosencephaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3472,Yunis-Varon syndrome,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,23623387[PMID]
3472,Yunis-Varon syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3471,Young syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3319,Congenital amegakaryocytic thrombocytopenia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3319,Congenital amegakaryocytic thrombocytopenia,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,21337678[PMID]_22102270[PMID]
3319,Congenital amegakaryocytic thrombocytopenia,Disease,Prevalence at birth,0.15,1-9 / 1 000 000,Value and class,United Kingdom,Validated,[EXPERT]
3473,Zimmermann-Laband syndrome,Malformation syndrome,Cases/families,52.0,,Case(s),Worldwide,Validated,23994350[PMID]
3473,Zimmermann-Laband syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,23994350[PMID]_ORPHANET
3459,Wilson-Turner syndrome,Malformation syndrome,Cases/families,28.0,,Case(s),Worldwide,Validated,1746601[PMID]_22889856[PMID]
3459,Wilson-Turner syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1746601[PMID]_22889856[PMID]
3464,Woodhouse-Sakati syndrome,Disease,Cases/families,25.0,,Family(ies),Worldwide,Validated,18175354[PMID]
3464,Woodhouse-Sakati syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18175354[PMID]
3466,WT limb-blood syndrome,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,890097[PMID]
3466,WT limb-blood syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_890097[PMID]
3465,Worster-Drought syndrome,Malformation syndrome,Point prevalence,3.7,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET
2749,Oromandibular-limb hypogenesis syndrome,Clinical group,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2995,Baraitser-Winter cerebrofrontofacial syndrome,Malformation syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,27625340[PMID]
2995,Baraitser-Winter cerebrofrontofacial syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27625340[PMID]
3200,Arthrogryposis-ectodermal dysplasia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1590979[PMID]
3200,Arthrogryposis-ectodermal dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1590979[PMID]
1570,Symbrachydactyly of hands and feet,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,9555583[PMID]
1570,Symbrachydactyly of hands and feet,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9555583[PMID]
3243,Sweet syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_17655751[PMID]
1827,Acromelic frontonasal dysplasia,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,15264282[PMID]_25105228[PMID]_26706854[PMID]
1827,Acromelic frontonasal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15264282[PMID]_25105228[PMID]_26706854[PMID]
2076,X-linked intellectual disability-epilepsy syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268980,Isolated focal cortical dysplasia type Ib,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268987,Isolated focal cortical dysplasia type Ic,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3424,Velo-facial-skeletal syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7573161[PMID]
3424,Velo-facial-skeletal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7573161[PMID]
268973,Isolated focal cortical dysplasia type Ia,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
269008,Isolated focal cortical dysplasia type IIb,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3433,Microcephaly-brachydactyly-kyphoscoliosis syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,1884519[PMID]
3433,Microcephaly-brachydactyly-kyphoscoliosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1884519[PMID]
268994,Isolated focal cortical dysplasia type II,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3429,Verloove Vanhorick-Brubakk syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7324930[PMID]
3429,Verloove Vanhorick-Brubakk syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7324930[PMID]
269001,Isolated focal cortical dysplasia type IIa,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2460,Van den Ende-Gupta syndrome,Malformation syndrome,Cases/families,29.0,,Case(s),Worldwide,Validated,24478002[PMID]
2460,Van den Ende-Gupta syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24478002[PMID]
268940,Bilateral polymicrogyria,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268943,Unilateral polymicrogyria,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3416,Hyperostosis corticalis generalisata,Malformation syndrome,Cases/families,35.0,,Case(s),Worldwide,Validated,26968112[PMID]
3416,Hyperostosis corticalis generalisata,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26968112[PMID]
268926,Midline cerebral malformation,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268936,Isolated arhinencephaly,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268961,Isolated focal cortical dysplasia type I,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268947,Unilateral focal polymicrogyria,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3417,Van den Bosch syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,DOI:10.1159/000303582[OTHER]
3417,Van den Bosch syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_DOI:10.1159/000303582[OTHER]
268950,Cerebral cortical dysplasia,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
269229,Pontine tegmental cap dysplasia,Morphological anomaly,Cases/families,22.0,,Case(s),Worldwide,Validated,21651769[PMID]_21705787[PMID]
269229,Pontine tegmental cap dysplasia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3453,Autoimmune polyendocrinopathy type 1,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Finland,Validated,[EXPERT]
3453,Autoimmune polyendocrinopathy type 1,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,France,Validated,[EXPERT]
3453,Autoimmune polyendocrinopathy type 1,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
269224,Global cerebellar malformation,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3448,Weaver-Williams syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,890101[PMID]
3448,Weaver-Williams syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_890101[PMID]
269221,Isolated bilateral hemispheric cerebellar hypoplasia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3449,Weill-Marchesani syndrome,Malformation syndrome,Point prevalence,1.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,20301293[PMID]
269218,Isolated unilateral hemispheric cerebellar hypoplasia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3456,Wildervanck syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20534924[PMID]
269510,Congenital non-communicating hydrocephalus,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3454,Wieacker-Wolff syndrome,Malformation syndrome,Cases/families,5.0,,Family(ies),Worldwide,Validated,ORPHANET_23623388[PMID]
3454,Wieacker-Wolff syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3455,Wiedemann-Rautenstrauch syndrome,Malformation syndrome,Cases/families,37.0,,Case(s),Worldwide,Validated,EXPERT
3455,Wiedemann-Rautenstrauch syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28447407[PMID]
269505,Congenital communicating hydrocephalus,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
269203,Isolated cerebellar vermis agenesis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_10488899[PMID]_7724272[PMID]
269197,Glioependymal/ependymal cyst,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3434,MMEP syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
269215,Isolated Dandy-Walker malformation without hydrocephalus,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
269212,Isolated Dandy-Walker malformation with hydrocephalus,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
269209,Isolated partial cerebellar vermis agenesis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
269206,Isolated total cerebellar vermis agenesis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1856,Spondyloperipheral dysplasia-short ulna syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23545312[PMID]
1856,Spondyloperipheral dysplasia-short ulna syndrome,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,23545312[PMID]
280302,Autoimmune pancreatitis type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
280333,Alpha-dystroglycan-related limb-girdle muscular dystrophy R16,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,14678799[PMID]_21388311[PMID]
280333,Alpha-dystroglycan-related limb-girdle muscular dystrophy R16,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21388311[PMID]
280325,Distal deletion 12p syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,21144913[PMID]
280325,Distal deletion 12p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280293,Pelizaeus-Merzbacher-like disease due to AIMP1 mutation,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
280288,Pelizaeus-Merzbacher-like disease due to HSPD1 mutation,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3194,Corneodermatoosseous syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,6234802[PMID]
3194,Corneodermatoosseous syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6234802[PMID]
280365,Autosomal semi-dominant severe lipodystrophic laminopathy,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,21346069[PMID]
280365,Autosomal semi-dominant severe lipodystrophic laminopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280379,Erythropoietic uroporphyria associated with myeloid malignancy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
3197,Hereditary hyperekplexia,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,ORPHANET
3197,Hereditary hyperekplexia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3199,Stimmler syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,5477682[PMID]
3199,Stimmler syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5477682[PMID]
3184,Steatocystoma multiplex-natal teeth syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
3186,Holoprosencephaly-radial heart renal anomalies syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,20583155[PMID]
3186,Holoprosencephaly-radial heart renal anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20583155[PMID]
3191,Subaortic stenosis-short stature syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,573203[PMID]
3191,Subaortic stenosis-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_573203[PMID]
3193,Supravalvular aortic stenosis,Morphological anomaly,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
3193,Supravalvular aortic stenosis,Morphological anomaly,Point prevalence,13.3,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
280356,PLIN1-related familial partial lipodystrophy,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,21345103[PMID]
280356,PLIN1-related familial partial lipodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3214,"Deaf blind hypopigmentation syndrome, Yemenite type",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2280978[PMID]
3214,"Deaf blind hypopigmentation syndrome, Yemenite type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280403,Familial omphalocele syndrome with facial dysmorphism,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,21333766[PMID]
280403,Familial omphalocele syndrome with facial dysmorphism,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280406,Familial steroid-resistant nephrotic syndrome with sensorineural deafness,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,21540551[PMID]
280406,Familial steroid-resistant nephrotic syndrome with sensorineural deafness,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3201,Ventricular extrasystoles with syncopal episodes-perodactyly-Robin sequence syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
280384,Recessive intellectual disability-motor dysfunction-multiple joint contractures syndrome,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,21330303[PMID]
280384,Recessive intellectual disability-motor dysfunction-multiple joint contractures syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280397,Familial Alzheimer-like prion disease,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,21416485[PMID]
280397,Familial Alzheimer-like prion disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21416485[PMID]
280576,Nestor-Guillermo progeria syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,21932319[PMID]_21549337[PMID]
280576,Nestor-Guillermo progeria syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3220,Deafness-enamel hypoplasia-nail defects syndrome,Malformation syndrome,Cases/families,15.0,,Family(ies),Worldwide,Validated,26387595[PMID]_27633571[PMID]_27302843[PMID]
3220,Deafness-enamel hypoplasia-nail defects syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26387595[PMID]_27633571[PMID]_27302843[PMID]
3219,Fountain syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,8897038[PMID]
3219,Fountain syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8897038[PMID]
3222,Phosphoribosylpyrophosphate synthetase superactivity,Disease,Cases/families,30.0,,Family(ies),Worldwide,Validated,23190330[PMID]
3222,Phosphoribosylpyrophosphate synthetase superactivity,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280586,"Chondrodysplasia with joint dislocations, gPAPP type",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,21549340[PMID]
280586,"Chondrodysplasia with joint dislocations, gPAPP type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3217,Deafness-small bowel diverticulosis-neuropathy syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,4028504[PMID]
3217,Deafness-small bowel diverticulosis-neuropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4028504[PMID]
280553,Fatal infantile hypertonic myofibrillar myopathy,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,21337604[PMID]_22734908[PMID]
280553,Fatal infantile hypertonic myofibrillar myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21337604[PMID]_22734908[PMID]
280558,Warsaw breakage syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,20137776[PMID]_21490908[PMID]_23033317[PMID]
280558,Warsaw breakage syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3216,Conductive deafness-malformed external ear syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,5771216[PMID]_624552[PMID]
3216,Conductive deafness-malformed external ear syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5771216[PMID]_624552[PMID]
3218,Deafness-epiphyseal dysplasia-short stature syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8867655[PMID]
3218,Deafness-epiphyseal dysplasia-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8867655[PMID]
647,Nijmegen breakage syndrome,Malformation syndrome,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,20301355[PMID]
647,Nijmegen breakage syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
647,Nijmegen breakage syndrome,Malformation syndrome,Point prevalence,0.7,<1 / 1 000 000,Value and class,Russian Federation,Validated,33488600[PMID]
647,Nijmegen breakage syndrome,Malformation syndrome,Point prevalence,3.1,1-9 / 1 000 000,Value and class,Poland,Validated,33488600[PMID]
647,Nijmegen breakage syndrome,Malformation syndrome,Point prevalence,3.1,1-9 / 1 000 000,Value and class,Czech Republic,Validated,33488600[PMID]
647,Nijmegen breakage syndrome,Malformation syndrome,Point prevalence,2.6,1-9 / 1 000 000,Value and class,Slovakia,Validated,33488600[PMID]
647,Nijmegen breakage syndrome,Malformation syndrome,Point prevalence,2.3,1-9 / 1 000 000,Value and class,Belarus,Validated,33488600[PMID]
647,Nijmegen breakage syndrome,Malformation syndrome,Point prevalence,1.3,1-9 / 1 000 000,Value and class,Ukraine,Validated,33488600[PMID]
280062,Calciphylaxis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
279947,Postorgasmic illness syndrome,Clinical syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
279947,Postorgasmic illness syndrome,Clinical syndrome,Cases/families,45.0,,Case(s),Worldwide,Validated,21241453[PMID]
1267,Botulism,Disease,Annual incidence,0.022,<1 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,[EXPERT]
1267,Botulism,Disease,Annual incidence,0.255,1-9 / 1 000 000,Value and class,France,Validated,Institut de Veille Sanitaire 2016[INST]
1267,Botulism,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,United States,Validated,Center for Diseases Control and Prevention 2006[INST]_ORPHANET
1267,Botulism,Disease,Annual incidence,0.026,<1 / 1 000 000,Value and class,Austria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Belgium,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.028,<1 / 1 000 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2013-2015[INST]
1267,Botulism,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Czech Republic,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.024,<1 / 1 000 000,Value and class,Denmark,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.052,<1 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Ireland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.052,<1 / 1 000 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.086,<1 / 1 000 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Netherlands,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.038,<1 / 1 000 000,Value and class,Poland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.104,1-9 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Spain,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
1267,Botulism,Disease,Annual incidence,0.098,<1 / 1 000 000,Value and class,Norway,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
2897,Pityriasis rubra pilaris,Disease,Cases/families,48.0,,Case(s),Worldwide,Validated,ORPHANET
2897,Pityriasis rubra pilaris,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3163,SHORT syndrome,Malformation syndrome,Cases/families,32.0,,Case(s),Worldwide,Validated,26497935[PMID]
3163,SHORT syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26497935[PMID]
1479,Atrial septal defect-atrioventricular conduction defects syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,9561886[PMID]
1479,Atrial septal defect-atrioventricular conduction defects syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280071,ALG11-CDG,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,28122681[PMID]
280071,ALG11-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28122681[PMID]
3157,Septo-optic dysplasia spectrum,Malformation syndrome,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
3157,Septo-optic dysplasia spectrum,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
2070,Eosinophilic gastroenteritis,Disease,Cases/families,280.0,,Case(s),Worldwide,Validated,11345185[PMID]_23904840[PMID]
2070,Eosinophilic gastroenteritis,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
2070,Eosinophilic gastroenteritis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_11345185[PMID]_23904840[PMID]
183707,Infantile LAD-like disease due to RAC2 deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,10758162[PMID]
183707,Infantile LAD-like disease due to RAC2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10758162[PMID]
2314,Autosomal dominant hyper-IgE syndrome due to STAT3 deficiency,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
2314,Autosomal dominant hyper-IgE syndrome due to STAT3 deficiency,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]_ORPHANET
3177,Spinocerebellar degeneration-corneal dystrophy syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3872072[PMID]
3177,Spinocerebellar degeneration-corneal dystrophy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3872072[PMID]
280205,Laryngotracheoesophageal cleft type 0,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3175,X-linked spasticity-intellectual disability-epilepsy syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,12177367[PMID]
3175,X-linked spasticity-intellectual disability-epilepsy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12177367[PMID]
280195,Septopreoptic holoprosencephaly,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3172,Eyebrow duplication-syndactyly syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3359678[PMID]_2736796[PMID]
3172,Eyebrow duplication-syndactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3359678[PMID]_2736796[PMID]
280183,Methylmalonic aciduria due to transcobalamin receptor defect,Biological anomaly,Cases/families,5.0,,Case(s),Worldwide,Validated,20524213[PMID]
280183,Methylmalonic aciduria due to transcobalamin receptor defect,Biological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280282,Pelizaeus-Merzbacher-like disease due to GJC2 mutation,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
280270,Pelizaeus-Merzbacher-like disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
183675,Recurrent infections associated with rare immunoglobulin isotypes deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2177,Hydranencephaly,Malformation syndrome,Prevalence at birth,0.0,1-9 / 100 000,Class only,Worldwide,Validated,10207424[PMID]
2177,Hydranencephaly,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2177,Hydranencephaly,Malformation syndrome,Prevalence at birth,2.1,1-9 / 100 000,Value and class,Japan,Validated,26545857[PMID]
2177,Hydranencephaly,Malformation syndrome,Prevalence at birth,2.8,1-9 / 100 000,Value and class,United States,Validated,18383510[PMID]
3258,Cenani-Lenz syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,[EXPERT]
3258,Cenani-Lenz syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
276575,Autosomal dominant hyperinsulinism due to SUR1 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3262,Dobrow syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,6580396[PMID]_15365455[PMID]
3262,Dobrow syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6580396[PMID]_15365455[PMID]
276598,Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
276608,Non-insulinoma pancreatogenous hypoglycemia syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3265,Isolated humero-radial synostosis,Morphological anomaly,Cases/families,150.0,,Case(s),Worldwide,Validated,ORPHANET
3265,Isolated humero-radial synostosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
276603,Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3266,Isolated humero-radio-ulnar synostosis,Morphological anomaly,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
3266,Isolated humero-radio-ulnar synostosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
276621,Sporadic pheochromocytoma/secreting paraganglioma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
183713,OBSOLETE:Bacterial susceptibility due to TLR signaling pathway deficiency,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,[EXPERT]
183713,OBSOLETE:Bacterial susceptibility due to TLR signaling pathway deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2380,Legg-Calvé-Perthes disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
276630,Symptomatic form of Coffin-Lowry syndrome in female carriers,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3270,Radioulnar synostosis-developmental delay-hypotonia syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,1384331[PMID]_18618994[PMID]
3270,Radioulnar synostosis-developmental delay-hypotonia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1384331[PMID]_18618994[PMID]
3275,Spondylocarpotarsal synostosis,Malformation syndrome,Cases/families,35.0,,Case(s),Worldwide,Validated,29566257[PMID]
3275,Spondylocarpotarsal synostosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29566257[PMID]
425,Apolipoprotein A-I deficiency,Disease,Cases/families,30.0,,Family(ies),Worldwide,Validated,17991756[PMID]
425,Apolipoprotein A-I deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
425,Apolipoprotein A-I deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2014[INST]
3291,Teebi-Shaltout syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,23918592[PMID]
3291,Teebi-Shaltout syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23918592[PMID]
3293,Telecanthus-hypertelorism-strabismus-pes cavus syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3970067[PMID]
3293,Telecanthus-hypertelorism-strabismus-pes cavus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3970067[PMID]
3292,Tel Hashomer camptodactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
279882,Spasmus nutans,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3294,Extensor tendons of finger anomalies,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7363507[PMID]
3294,Extensor tendons of finger anomalies,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7363507[PMID]
279888,Acute endophthalmitis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
279891,Chronic endophthalmitis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
897,Waardenburg-Shah syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,Dr Véronique PINGAULT[EXPERT]
897,Waardenburg-Shah syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3301,Tetraamelia-multiple malformations syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301453[PMID]
3301,Tetraamelia-multiple malformations syndrome,Malformation syndrome,Cases/families,5.0,,Family(ies),Worldwide,Validated,20301453[PMID]
279897,Primary oculocerebral lymphoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
279904,Primary intraocular lymphoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3027,Caudal regression syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3027,Caudal regression syndrome,Malformation syndrome,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3027,Caudal regression syndrome,Malformation syndrome,Prevalence at birth,1.75,1-9 / 100 000,Value and class,Australia,Validated,20734338[PMID]
3312,Thalidomide embryopathy,Malformation syndrome,Point prevalence,0.77,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,ORPHANET
279914,Intermediate uveitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
643,Giant axonal neuropathy,Disease,Cases/families,50.0,,Family(ies),Worldwide,Validated,20301315[PMID]
643,Giant axonal neuropathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301315[PMID]
276193,Spinocerebellar ataxia type 35,Disease,Cases/families,28.0,,Case(s),Worldwide,Validated,30229425[PMID]
276193,Spinocerebellar ataxia type 35,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
276183,Spinocerebellar ataxia type 32,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,Jiang_Zhu_Gomez 2010[AUTHOR]
276183,Spinocerebellar ataxia type 32,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2828,Young-onset Parkinson disease,Disease,Point prevalence,15.0,1-5 / 10 000,Value and class,Europe,Validated,ORPHANET_23083512[PMID]
2828,Young-onset Parkinson disease,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Worldwide,Not yet validated,15172778[PMID]
276238,Machado-Joseph disease type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
276234,Non-syndromic male infertility due to sperm motility disorder,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
638,Neurofibromatosis-Noonan syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3231,Deafness-onychodystrophy syndrome,Clinical group,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
3231,Deafness-onychodystrophy syndrome,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
526,Liddle syndrome,Disease,Cases/families,72.0,,Family(ies),Worldwide,Validated,29534496[PMID]_[EXPERT]
526,Liddle syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
276241,Machado-Joseph disease type 2,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
427,Familial hypoaldosteronism,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
215,Congenital stationary night blindness,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3232,Deafness-ear malformation-facial palsy syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,6851230[PMID]
3232,Deafness-ear malformation-facial palsy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6851230[PMID]
3233,Cochleosaccular degeneration-cataract syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,7121157[PMID]_1623624[PMID]
3233,Cochleosaccular degeneration-cataract syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7121157[PMID]_1623624[PMID]
180,Choroideremia,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2014[INST]
276280,Hemihyperplasia-multiple lipomatosis syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,9781913[PMID]_20058713[PMID]_19438675[PMID]_20105568[PMID]
276280,Hemihyperplasia-multiple lipomatosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
276399,Familial multinodular goiter,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3239,Deafness-vitiligo-achalasia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,5100941[PMID]
3239,Deafness-vitiligo-achalasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5100941[PMID]
183518,Hereditary ataxia,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,22689585[PMID]
3237,Multiple synostoses syndrome,Malformation syndrome,Cases/families,30.0,,Family(ies),Worldwide,Validated,ORPHANET
3237,Multiple synostoses syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
403,Familial hyperaldosteronism type I,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,23610123[PMID]_ORPHANET
276413,10q22.3q23.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
653,Multiple endocrine neoplasia type 2,Disease,Point prevalence,2.9,1-9 / 100 000,Value and class,Europe,Validated,ISBN:9283224167[OTHER]_[EXPERT]
653,Multiple endocrine neoplasia type 2,Disease,Point prevalence,1.25,1-9 / 100 000,Value and class,Germany,Validated,23211574[PMID]
276405,Hyperbiliverdinemia,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,19580635[PMID]_21278388[PMID]
276405,Hyperbiliverdinemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
157,Carnitine palmitoyltransferase II deficiency,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,ORPHANET
157,Carnitine palmitoyltransferase II deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
157,Carnitine palmitoyltransferase II deficiency,Disease,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,United States,Validated,22766612[PMID]
157,Carnitine palmitoyltransferase II deficiency,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
847,X-linked alpha-thalassemia-intellectual disability syndrome,Malformation syndrome,Cases/families,200.0,,Case(s),Worldwide,Validated,20301622[PMID]_16722615[PMID]
847,X-linked alpha-thalassemia-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,20301622[PMID]_16722615[PMID]_ORPHANET
3255,Filippi syndrome,Malformation syndrome,Cases/families,29.0,,Case(s),Worldwide,Validated,26813917[PMID]
3255,Filippi syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26813917[PMID]
183435,Inherited ichthyosis,Category,Point prevalence,1.33,1-9 / 100 000,Value and class,France,Not yet validated,24393603[PMID]
2268,ICF syndrome,Malformation syndrome,Cases/families,66.0,,Case(s),Worldwide,Validated,23486536[PMID]
2268,ICF syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3253,Cleft lip/palate-ectodermal dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3253,Cleft lip/palate-ectodermal dysplasia syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
392,Holt-Oram syndrome,Malformation syndrome,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Europe,Validated,25344219[PMID]_EUROCAT European surveillance of congenital anomalies 1990-2011[REG]
392,Holt-Oram syndrome,Malformation syndrome,Prevalence at birth,0.95,1-9 / 1 000 000,Value and class,Hungary,Validated,1996196[PMID]_[EXPERT]
392,Holt-Oram syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3325,Heparin-induced thrombocytopenia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
243,"46,XX gonadal dysgenesis",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,8178824[PMID]_16877870[PMID]_ORPHANET
243,"46,XX gonadal dysgenesis",Malformation syndrome,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,8178824[PMID]_16877870[PMID]_ORPHANET
183422,Polymalformative genetic syndrome with increased risk of developing cancer,Category,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Europe,Validated,12146805[PMID]_15834040[PMID]_22422895[PMID]_[EXPERT]_ORPHANET
136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,United Kingdom,Validated,22422895[PMID]_15834040[PMID]_ [EXPERT]
136,Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Finland,Validated,12146805[PMID]_[EXPERT]_ ORPHANET
182114,Rare urogenital tumor,Category,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Europe,Not yet validated,22425262[PMID]
182114,Rare urogenital tumor,Category,Annual incidence,0.21,1-9 / 1 000 000,Value and class,United States,Validated,22425262[PMID]
48,Congenital bilateral absence of vas deferens,Morphological anomaly,Point prevalence,50.0,1-5 / 10 000,Value and class,Europe,Not yet validated,ORPHANET
424,Familial hyperthyroidism due to mutations in TSH receptor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
424,Familial hyperthyroidism due to mutations in TSH receptor,Disease,Cases/families,28.0,,Family(ies),Worldwide,Validated,[EXPERT]
325,Congenital factor II deficiency,Disease,Point prevalence,0.05,<1 / 1 000 000,Value and class,Europe,Validated,10595621[PMID]
343,Hyperimmunoglobulinemia D with periodic fever,Clinical subtype,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
343,Hyperimmunoglobulinemia D with periodic fever,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
572,Immunodeficiency by defective expression of MHC class II,Disease,Cases/families,179.0,,Case(s),Worldwide,Validated,27510876[PMID]
572,Immunodeficiency by defective expression of MHC class II,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27510876[PMID]
1930,Herpes simplex virus encephalitis,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Worldwide,Validated,16675036[PMID]
1930,Herpes simplex virus encephalitis,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,United Kingdom,Validated,20657024[PMID]
1930,Herpes simplex virus encephalitis,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,United States,Validated,16675036[PMID]
1930,Herpes simplex virus encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
158,Systemic primary carnitine deficiency,Disease,Prevalence at birth,3.2,1-9 / 100 000,Value and class,Europe,Validated,22989098[PMID]
158,Systemic primary carnitine deficiency,Disease,Prevalence at birth,3.2,1-9 / 100 000,Value and class,United States,Validated,22989098[PMID]
158,Systemic primary carnitine deficiency,Disease,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Japan,Validated,10545605[PMID]
158,Systemic primary carnitine deficiency,Disease,Prevalence at birth,0.83,1-9 / 1 000 000,Value and class,Australia,Validated,12788994[PMID]
158,Systemic primary carnitine deficiency,Disease,Point prevalence,77.0,6-9 / 10 000,Value and class,Faroe Islands,Validated,17417720[PMID]
158,Systemic primary carnitine deficiency,Disease,Annual incidence,138.9,>1 / 1000,Value and class,Faroe Islands,Validated,17417720[PMID]
158,Systemic primary carnitine deficiency,Disease,Point prevalence,0.0069,<1 / 1 000 000,Value and class,China,Validated,34103049[PMID]
2056,Essential fructosuria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
206436,Infantile Krabbe disease,Clinical subtype,Annual incidence,0.254,1-9 / 1 000 000,Value and class,United States,Validated,26795590[PMID]
206436,Infantile Krabbe disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29391017[PMID]
1344,Atrial standstill,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
206428,Hypoxanthine-guanine phosphoribosyltransferase deficiency,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3103,Roberts syndrome,Malformation syndrome,Cases/families,150.0,,Case(s),Worldwide,Validated,20301332[PMID]
3103,Roberts syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301332[PMID]
832,Succinyl-CoA:3-oxoacid CoA transferase deficiency,Disease,Cases/families,32.0,,Case(s),Worldwide,Validated,[EXPERT]
832,Succinyl-CoA:3-oxoacid CoA transferase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Prevalence at birth,2.65,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Prevalence at birth,1.9,1-9 / 100 000,Value and class,United States,Validated,12872837[PMID]
6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Prevalence at birth,3.3,1-9 / 100 000,Value and class,Germany,Validated,11170888[PMID]
6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Prevalence at birth,1.36,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,20567911[PMID]
6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
6,3-methylcrotonyl-CoA carboxylase deficiency,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
888,Van der Woude syndrome,Malformation syndrome,Point prevalence,1.7,1-9 / 100 000,Value and class,Finland,Validated,7459520[PMID]
888,Van der Woude syndrome,Malformation syndrome,Prevalence at birth,1.3,1-9 / 100 000,Value and class,France,Validated,22925539[PMID]
888,Van der Woude syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,France,Validated,22925539[PMID]
888,Van der Woude syndrome,Malformation syndrome,Point prevalence,1.4,1-9 / 100 000,Value and class,Australia,Validated,20415912[PMID]
888,Van der Woude syndrome,Malformation syndrome,Prevalence at birth,0.85,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,18177185[PMID]_ORPHANET
888,Van der Woude syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,"Taiwan, Province of China",Validated,18177185[PMID]_ORPHANET
888,Van der Woude syndrome,Malformation syndrome,Prevalence at birth,0.9,1-9 / 1 000 000,Value and class,United States,Validated,9450872[PMID]
888,Van der Woude syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,United States,Validated,9450872[PMID]
888,Van der Woude syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET
888,Van der Woude syndrome,Malformation syndrome,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Australia,Validated,34626670[PMID]
2831,"Rhizomelic dysplasia, Patterson-Lowry type",Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,15103724[PMID]
2831,"Rhizomelic dysplasia, Patterson-Lowry type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15103724[PMID]
1129,Arachnodactyly-abnormal ossification-intellectual disability syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,8533819[PMID]
1129,Arachnodactyly-abnormal ossification-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8533819[PMID]
548,Leprosy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
548,Leprosy,Disease,Annual incidence,3.7,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
1383,Cataract-deafness-hypogonadism syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,8574417[PMID]
1383,Cataract-deafness-hypogonadism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8574417[PMID]
206538,Malignant non-dysgerminomatous germ cell tumor of ovary,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
206554,Fukutin-related limb-girdle muscular dystrophy R13,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,17878207[PMID]_19342235[PMID]_19179078[PMID]
206554,Fukutin-related limb-girdle muscular dystrophy R13,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17878207[PMID]_19342235[PMID]_19179078[PMID]
1524,Craniomicromelic syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
206549,Anoctamin-5-related limb-girdle muscular dystrophy R12,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_23670307[PMID]
569,Familial or sporadic hemiplegic migraine,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
569,Familial or sporadic hemiplegic migraine,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Denmark,Validated,12023326[PMID]
206569,Immune-mediated necrotizing myopathy,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,[EXPERT]
206569,Immune-mediated necrotizing myopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
206580,Autosomal recessive lower motor neuron disease with childhood onset,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,16728649[PMID]
206580,Autosomal recessive lower motor neuron disease with childhood onset,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16728649[PMID]
3439,Von Voss-Cherstvoy syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,DOI:10.2147/IMCRJ.S108746[OTHER]
3439,Von Voss-Cherstvoy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_DOI:10.2147/IMCRJ.S108746[OTHER]
1217,Spinal atrophy-ophthalmoplegia-pyramidal syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,8068160[PMID]
1217,Spinal atrophy-ophthalmoplegia-pyramidal syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8068160[PMID]
2680,Hypomyelination neuropathy-arthrogryposis syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,24319099[PMID]
2680,Hypomyelination neuropathy-arthrogryposis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24319099[PMID]
1681,Diprosopus,Morphological anomaly,Cases/families,33.0,,Case(s),Worldwide,Validated,27704687[PMID]
1681,Diprosopus,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27704687[PMID]
1681,Diprosopus,Morphological anomaly,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Argentina,Validated,27704687[PMID]
1655,Müllerian derivatives-lymphangiectasia-polydactyly syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,8256813[PMID]_11746031[PMID]_11746030[PMID]
1655,Müllerian derivatives-lymphangiectasia-polydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8256813[PMID]_11746031[PMID]_11746030[PMID]
633,Laron syndrome,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2003[INST]
633,Laron syndrome,Disease,Point prevalence,4.86,1-9 / 100 000,Value and class,China,Validated,34103049[PMID]
478,Kallmann syndrome,Clinical subtype,Point prevalence,3.75,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
478,Kallmann syndrome,Clinical subtype,Annual incidence,5.0,1-9 / 100 000,Value and class,France,Validated,4147392[PMID]
478,Kallmann syndrome,Clinical subtype,Annual incidence,2.1,1-9 / 100 000,Value and class,Finland,Validated,21682876[PMID]
478,Kallmann syndrome,Clinical subtype,Annual incidence,0.6,1-9 / 1 000 000,Value and class,Specific population,Validated,3791676[PMID]
240,Léri-Weill dyschondrosteosis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
2311,Autosomal recessive spondylocostal dysostosis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
358,Gitelman syndrome,Disease,Point prevalence,2.5,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
242,"46,XY complete gonadal dysgenesis",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,18410658[PMID]_27603905[PMID]_ORPHANET
242,"46,XY complete gonadal dysgenesis",Malformation syndrome,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,18410658[PMID]_27603905[PMID]_ORPHANET
2052,Fraser syndrome,Malformation syndrome,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,23532946[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
2052,Fraser syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2052,Fraser syndrome,Malformation syndrome,Prevalence at birth,0.43,1-9 / 1 000 000,Value and class,Spain,Validated,9662850[PMID]
1354,Heart defects-limb shortening syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2074559[PMID]
1354,Heart defects-limb shortening syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2074559[PMID]
28,Vitamin B12-responsive methylmalonic acidemia,Disease,Cases/families,192.0,,Case(s),Worldwide,Validated,[EXPERT]
28,Vitamin B12-responsive methylmalonic acidemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,20.0,1-5 / 10 000,Value and class,Worldwide,Validated,17651510[PMID]_[EXPERT]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,24.0,1-5 / 10 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2009[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,78.0,6-9 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2006[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,26.2,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,11.4,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,21.3,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,23.6,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,53.5,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,43.2,1-5 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,28.9,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,11.3,1-5 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,29.2,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,29.5,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,11.6,1-5 / 10 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,4.7,1-9 / 100 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,13.8,1-5 / 10 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,49.0,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,21.6,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,28.6,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
557,Non-syndromic anorectal malformation,Clinical group,Prevalence at birth,60.8,6-9 / 10 000,Value and class,Saudi Arabia,Validated,23232683[PMID]
557,Non-syndromic anorectal malformation,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
111,Barth syndrome,Disease,Point prevalence,0.22,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
111,Barth syndrome,Disease,Prevalence at birth,0.29,1-9 / 1 000 000,Value and class,United States,Validated,[EXPERT]
111,Barth syndrome,Disease,Prevalence at birth,0.15,1-9 / 1 000 000,Value and class,France,Validated,23656970[PMID]
111,Barth syndrome,Disease,Prevalence at birth,0.71,1-9 / 1 000 000,Value and class,United Kingdom,Validated,23398819[PMID]_[EXPERT]
10,"48,XXYY syndrome",Malformation syndrome,Prevalence at birth,1.9,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_568179[PMID]_14477077[PMID]_2090319[PMID]
10,"48,XXYY syndrome",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1308,C syndrome,Malformation syndrome,Point prevalence,0.11,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_17162528[PMID]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,China,Validated,8061578[PMID]
150,Nasopharyngeal carcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
150,Nasopharyngeal carcinoma,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.36,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.337,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.317,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.766,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.423,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.437,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.177,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.383,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.207,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.618,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.254,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.228,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.264,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.426,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.62,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.491,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.394,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.779,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.462,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.288,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,0.211,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
150,Nasopharyngeal carcinoma,Disease,Annual incidence,1.256,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
3207,White matter hypoplasia-corpus callosum agenesis-intellectual disability syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,8327066[PMID]
3207,White matter hypoplasia-corpus callosum agenesis-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8327066[PMID]
2058,Fryns-Smeets-Thiry syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8172258[PMID]
2058,Fryns-Smeets-Thiry syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8172258[PMID]
2538,Microgastria-limb reduction defect syndrome,Malformation syndrome,Cases/families,16.0,,Case(s),Worldwide,Validated,12072798[PMID]
2538,Microgastria-limb reduction defect syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1192,Atherosclerosis-deafness-diabetes-epilepsy-nephropathy syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8172238[PMID]
1192,Atherosclerosis-deafness-diabetes-epilepsy-nephropathy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8172238[PMID]
1437,Ring chromosome 1 syndrome,Malformation syndrome,Cases/families,35.0,,Case(s),Worldwide,Validated,17710876[PMID]
1437,Ring chromosome 1 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17710876[PMID]
2015,Cleft palate-short stature-vertebral anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8110419[PMID]
2015,Cleft palate-short stature-vertebral anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8110419[PMID]
1447,Ring chromosome 4 syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,27610251[PMID]
1447,Ring chromosome 4 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27610251[PMID]
2898,X-linked intellectual disability-plagiocephaly syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1433236[PMID]
2898,X-linked intellectual disability-plagiocephaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1433236[PMID]
1439,Ring chromosome 12 syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,17880954[PMID]_20933620[PMID]
1439,Ring chromosome 12 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17880954[PMID]_20933620[PMID]
1423,Lethal recessive chondrodysplasia,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,3396596[PMID]
1423,Lethal recessive chondrodysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3306,Inverted duplicated chromosome 15 syndrome,Malformation syndrome,Prevalence at birth,3.33,1-9 / 100 000,Value and class,Worldwide,Validated,11579431[PMID]
3306,Inverted duplicated chromosome 15 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3375,Trisomy X syndrome,Malformation syndrome,Point prevalence,42.5,1-5 / 10 000,Value and class,Europe,Not yet validated,ORPHANET
3310,Tetrasomy 9p syndrome,Malformation syndrome,Cases/families,70.0,,Case(s),Worldwide,Validated,ORPHANET_25847481[PMID]_25944096[PMID]_25951732[PMID]_26216333[PMID]
3310,Tetrasomy 9p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25847481[PMID]
3000,Familial peripheral male-limited precocious puberty,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
1101,Anophthalmia-megalocornea-cardiopathy-skeletal anomalies syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,1415344[PMID]
1101,Anophthalmia-megalocornea-cardiopathy-skeletal anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1415344[PMID]
1708,Mosaic trisomy 16 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_16557642[PMID]
1708,Mosaic trisomy 16 syndrome,Malformation syndrome,Cases/families,226.0,,Case(s),Worldwide,Validated,16557642[PMID]
208650,NLRP3-associated autoinflammatory disease,Clinical group,Point prevalence,0.28,1-9 / 1 000 000,Value and class,France,Validated,21109514[PMID]
3376,Triploidy syndrome,Malformation syndrome,Prevalence at birth,12.6,1-5 / 10 000,Value and class,Europe,Validated,22234154[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
3376,Triploidy syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
208513,Spinocerebellar ataxia type 29,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET_[EXPERT]
208513,Spinocerebellar ataxia type 29,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1698,Mosaic trisomy 12 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28345774[PMID]
3051,Nicolaides-Baraitser syndrome,Malformation syndrome,Cases/families,61.0,,Case(s),Worldwide,Validated,25169878[PMID]
3051,Nicolaides-Baraitser syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25169878[PMID]
916,Aase-Smith syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
916,Aase-Smith syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1768,Familial caudal dysgenesis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2225526[PMID]
1768,Familial caudal dysgenesis,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,2225526[PMID]
1445,Ring chromosome 21 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
7,3C syndrome,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,18957854[PMID]
7,3C syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18957854[PMID]
931,Isolated acheiropodia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
931,Isolated acheiropodia,Morphological anomaly,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Brazil,Validated,1155460[PMID]
931,Isolated acheiropodia,Morphological anomaly,Point prevalence,0.03,<1 / 1 000 000,Value and class,Brazil,Validated,1155460[PMID]
1541,"Craniosynostosis, Boston type",Malformation syndrome,Cases/families,3.0,,Family(ies),Worldwide,Validated,23949913[PMID]_23918290[PMID]_8357019[PMID]
1541,"Craniosynostosis, Boston type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23949913[PMID]_23918290[PMID]_8357019[PMID]
2297,Insulin-resistance syndrome type A,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
209335,Autosomal dominant adult-onset proximal spinal muscular atrophy,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
921,Abruzzo-Erickson syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,839509[PMID]_[EXPERT]
921,Abruzzo-Erickson syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3167,Siegler-Brewer-Carey syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1442888[PMID]
3167,Siegler-Brewer-Carey syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1442888[PMID]
1277,Brachydactyly-mesomelia-intellectual disability-heart defects syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8484398[PMID]_8074158[PMID]
1277,Brachydactyly-mesomelia-intellectual disability-heart defects syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8484398[PMID]_8074158[PMID]
2547,Microphthalmia-microtia-fetal akinesia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8484406[PMID]
2547,Microphthalmia-microtia-fetal akinesia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8484406[PMID]
1778,Facial dysmorphism-shawl scrotum-joint laxity syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1776627[PMID]
1778,Facial dysmorphism-shawl scrotum-joint laxity syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1776627[PMID]
3074,Intellectual disability-short stature-hypertelorism syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,1877628[PMID]
3074,Intellectual disability-short stature-hypertelorism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1877628[PMID]
210110,Intermediate osteopetrosis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3405,Umbilical cord ulceration-intestinal atresia syndrome,Malformation syndrome,Cases/families,66.0,,Case(s),Worldwide,Validated,[EXPERT]_20881370[PMID]_29516584[PMID]
3405,Umbilical cord ulceration-intestinal atresia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
210115,Sterile multifocal osteomyelitis with periostitis and pustulosis,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,24131530[PMID]
210115,Sterile multifocal osteomyelitis with periostitis and pustulosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24131530[PMID]
1884,Ectopia lentis-chorioretinal dystrophy-myopia syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,8334934[PMID]_10420198[PMID]_12049599[PMID]
1884,Ectopia lentis-chorioretinal dystrophy-myopia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8334934[PMID]_10420198[PMID]_12049599[PMID]
939,3-hydroxyisobutyric aciduria,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,16466957[PMID]_19650361[PMID]
939,3-hydroxyisobutyric aciduria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16466957[PMID]_19650361[PMID]
209989,Non-papillary transitional cell carcinoma of the bladder,Disease,Point prevalence,37.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2009[INST]
935,Short-limb skeletal dysplasia with severe combined immunodeficiency,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,1999827[PMID]
935,Short-limb skeletal dysplasia with severe combined immunodeficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1999827[PMID]
210133,Leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,19401242[PMID]
210133,Leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19401242[PMID]
37,Acrodermatitis enteropathica,Disease,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Denmark,Validated,17190629[PMID]_8562288[PMID]
37,Acrodermatitis enteropathica,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Denmark,Not yet validated,17190629[PMID]
37,Acrodermatitis enteropathica,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,[EXPERT]
210122,Congenital alveolar capillary dysplasia,Disease,Prevalence at birth,1.2,1-9 / 100 000,Value and class,Canada,Validated,10735455[PMID]_9369882[PMID]
210122,Congenital alveolar capillary dysplasia,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,10735455[PMID]
210122,Congenital alveolar capillary dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
949,Acrocraniofacial dysostosis,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3344780[PMID]
949,Acrocraniofacial dysostosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3344780[PMID]
2254,Pontocerebellar hypoplasia type 1,Malformation syndrome,Cases/families,40.0,,Family(ies),Worldwide,Validated,[EXPERT]
2254,Pontocerebellar hypoplasia type 1,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
957,Acropectorovertebral dysplasia,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
957,Acropectorovertebral dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
209964,Solitary rectal ulcer syndrome,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Europe,Not yet validated,18188027[PMID]
209964,Solitary rectal ulcer syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
955,Hajdu-Cheney syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,25491639[PMID]
955,Hajdu-Cheney syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25491639[PMID]
209956,Idiopathic uveal effusion syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1713,17p11.2 microduplication syndrome,Malformation syndrome,Cases/families,170.0,,Case(s),Worldwide,Validated,ORPHANET
1713,17p11.2 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
209967,Episodic ataxia type 6,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,ORPHANET_19139306[PMID]_16116111[PMID]_23107647[PMID]
209967,Episodic ataxia type 6,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1742,Trisomy 5p syndrome,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,ORPHANET
1742,Trisomy 5p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2795,Fowler urethral sphincter dysfunction syndrome,Disease,Cases/families,33.0,,Case(s),Worldwide,Validated,3147005[PMID]
2795,Fowler urethral sphincter dysfunction syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3147005[PMID]
1752,Trisomy 8q syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,15581839[PMID]
1752,Trisomy 8q syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
209905,Brain-lung-thyroid syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,28286255[PMID]
209905,Brain-lung-thyroid syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28286255[PMID]
1878,TRIM32-related limb-girdle muscular dystrophy R8,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2666,Adult familial nephronophthisis-spastic quadriparesia syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,2354560[PMID]
2666,Adult familial nephronophthisis-spastic quadriparesia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2354560[PMID]
1948,Epilepsy-microcephaly-skeletal dysplasia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8867658[PMID]
1948,Epilepsy-microcephaly-skeletal dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8867658[PMID]
209932,Cone dystrophy with supernormal rod response,Disease,Cases/families,45.0,,Case(s),Worldwide,Validated,ORPHANET
209932,Cone dystrophy with supernormal rod response,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
209919,Idiopathic copper-associated cirrhosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
381,Griscelli syndrome,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,30207398[PMID]
381,Griscelli syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30207398[PMID]
2519,Microcephaly-seizures-intellectual disability-heart disease syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2585466[PMID]
2519,Microcephaly-seizures-intellectual disability-heart disease syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2585466[PMID]
156,Carnitine palmitoyl transferase 1A deficiency,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,20301700[PMID]
156,Carnitine palmitoyl transferase 1A deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301700[PMID]
156,Carnitine palmitoyl transferase 1A deficiency,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Israel,Validated,33239050[PMID]
156,Carnitine palmitoyl transferase 1A deficiency,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Specific population,Validated,33239050[PMID]
209867,Autosomal dominant rhegmatogenous retinal detachment,Disease,Cases/families,38.0,,Case(s),Worldwide,Validated,ORPHANET
209867,Autosomal dominant rhegmatogenous retinal detachment,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2598,Mitochondrial myopathy and sideroblastic anemia,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,15971356[PMID]
2598,Mitochondrial myopathy and sideroblastic anemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3286,Catecholaminergic polymorphic ventricular tachycardia,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Validated,23916535[PMID]
210272,Mal de débarquement,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1053,Vein of Galen aneurysmal malformation,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET_1997895[PMID]
210159,Adult hepatocellular carcinoma,Disease,Annual incidence,3.22,1-9 / 100 000,Value and class,Europe,Validated,PMID: 22033323
1040,Metaphyseal anadysplasia,Disease,Cases/families,27.0,,Case(s),Worldwide,Validated,ORPHANET
1040,Metaphyseal anadysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1041,Hydrops fetalis,Malformation syndrome,Prevalence at birth,134.0,>1 / 1000,Value and class,Ireland,Validated,16964808[PMID]
1041,Hydrops fetalis,Malformation syndrome,Prevalence at birth,380.0,>1 / 1000,Value and class,Turkey,Validated,24094760[PMID]
1041,Hydrops fetalis,Malformation syndrome,Prevalence at birth,180.0,>1 / 1000,Value and class,Thailand,Validated,19459517[PMID]
1041,Hydrops fetalis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3240,Early-onset progressive leukoencephalopathy-central nervous system calcification-deafness-visual impairment syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,9112970[PMID]
3240,Early-onset progressive leukoencephalopathy-central nervous system calcification-deafness-visual impairment syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9112970[PMID]
210141,Inherited congenital spastic tetraplegia,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,16301218[PMID]_23836506[PMID]_9084927[PMID]
210141,Inherited congenital spastic tetraplegia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16301218[PMID]_23836506[PMID]_9084927[PMID]
1126,Aprosencephaly cerebellar dysgenesis,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8826432[PMID]
1126,Aprosencephaly cerebellar dysgenesis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8826432[PMID]
1546,Cryptococcosis,Disease,Annual incidence,11.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
1546,Cryptococcosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1121,Radial deficiency-tibial hypoplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8723109[PMID]
210584,Spindle cell hemangioma,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,[WHO Classification of Tumours]
210584,Spindle cell hemangioma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[WHO Classification of Tumours]
1122,Ulnar hypoplasia-split foot syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_565745[PMID]
1122,Ulnar hypoplasia-split foot syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,565745[PMID]
1116,Aplasia cutis congenita-intestinal lymphangiectasia syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,3984978[PMID]
1116,Aplasia cutis congenita-intestinal lymphangiectasia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3984978[PMID]
1118,Fibular aplasia-ectrodactyly syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
1118,Fibular aplasia-ectrodactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
599,Distal myopathy,Category,Point prevalence,0.33,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]_[EXPERT]
3392,Tularemia,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3392,Tularemia,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,United Kingdom,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Netherlands,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,4.0,1-9 / 100 000,Value and class,Sweden,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,1.27,1-9 / 100 000,Value and class,Czech Republic,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,9.1,1-9 / 100 000,Value and class,Finland,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Austria,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Belgium,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Denmark,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Croatia,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.6,1-9 / 1 000 000,Value and class,Bulgaria,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.075,<1 / 1 000 000,Value and class,Estonia,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,France,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Germany,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.035,<1 / 1 000 000,Value and class,Italy,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.145,1-9 / 1 000 000,Value and class,Latvia,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,Lithuania,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Poland,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Romania,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Slovenia,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.25,1-9 / 1 000 000,Value and class,Switzerland,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,0.75,1-9 / 1 000 000,Value and class,Spain,Validated,26738841[PMID]
3392,Tularemia,Disease,Annual incidence,1.83,1-9 / 100 000,Value and class,Norway,Validated,26738841[PMID]
3392,Tularemia,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
3392,Tularemia,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
3392,Tularemia,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1094,Anonychia-microcephaly syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,8985482[PMID]
1094,Anonychia-microcephaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8985482[PMID]
2737,Onchocerciasis,Disease,Point prevalence,0.0,>1 / 1000,Class only,Specific population,Not yet validated,ORPHANET
2737,Onchocerciasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
990,Agnathia-holoprosencephaly-situs inversus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,20849990[PMID]_ORPHANET
3343,Toxocariasis,Disease,Annual incidence,3.3,1-9 / 100 000,Value and class,United States,Not yet validated,emedicine[OTHER]
3343,Toxocariasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
994,Fetal akinesia deformation sequence,Malformation syndrome,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
994,Fetal akinesia deformation sequence,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET_EUROCAT European surveillance of congenital anomalies 2010[REG]
2034,Filariasis,Category,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
2034,Filariasis,Category,Point prevalence,0.0,>1 / 1000,Class only,Specific population,Validated,World Health Organization 2016[INST]
981,Internal carotid absence,Morphological anomaly,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]_22851490[PMID]
981,Internal carotid absence,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
211017,Spinocerebellar ataxia type 30,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,18996908[PMID]
211017,Spinocerebellar ataxia type 30,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18996908[PMID]
977,Adrenomyodystrophy,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,7153060[PMID]
977,Adrenomyodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7153060[PMID]
656,Hereditary steroid-resistant nephrotic syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
970,Hereditary sensory and autonomic neuropathy type 2,Disease,Cases/families,35.0,,Case(s),Worldwide,Validated,ORPHANET
970,Hereditary sensory and autonomic neuropathy type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2415,Rare lymphatic malformation,Category,Point prevalence,12.5,1-5 / 10 000,Value and class,Europe,Validated,ORPHANET
40,"Acromesomelic dysplasia, Maroteaux type",Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
40,"Acromesomelic dysplasia, Maroteaux type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2591,Infantile myofibromatosis,Disease,Prevalence at birth,0.67,1-9 / 1 000 000,Value and class,Europe,Validated,ISBN:443043469[OTHER]_23686518[PMID]
2591,Infantile myofibromatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
35,Propionic acidemia,Disease,Prevalence at birth,100.0,>1 / 1000,Value and class,Canada,Validated,10820128[PMID]_23509210[PMID]
35,Propionic acidemia,Disease,Annual incidence,1.5,1-9 / 100 000,Value and class,Worldwide,Validated,22593918[PMID]_14586648[PMID]
35,Propionic acidemia,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,23509210[PMID]
35,Propionic acidemia,Disease,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,Italy,Validated,11953730[PMID]
35,Propionic acidemia,Disease,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Germany,Validated,23509210[PMID]
35,Propionic acidemia,Disease,Prevalence at birth,33.0,1-5 / 10 000,Value and class,Saudi Arabia,Validated,23509210[PMID]
35,Propionic acidemia,Disease,Prevalence at birth,5.7,1-9 / 100 000,Value and class,Japan,Validated,12189489[PMID]_23509210[PMID]
35,Propionic acidemia,Disease,Prevalence at birth,1.23,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,24101962[PMID]
35,Propionic acidemia,Disease,Point prevalence,0.0278,<1 / 1 000 000,Value and class,China,Validated,34103049[PMID]
968,"Acromesomelic dysplasia, Hunter-Thompson type",Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
968,"Acromesomelic dysplasia, Hunter-Thompson type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
139411,Carney triad,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
139411,Carney triad,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,23652673[PMID]
2968,Leukocyte adhesion deficiency,Disease,Cases/families,350.0,,Case(s),Worldwide,Validated,ORPHANET
2968,Leukocyte adhesion deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Latin America,Not yet validated,22965369[PMID]
2968,Leukocyte adhesion deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1028,Amelo-onycho-hypohidrotic syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,122795[PMID]
1028,Amelo-onycho-hypohidrotic syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_122795[PMID]
139417,Acute transverse myelitis,Disease,Annual incidence,8.6,1-9 / 100 000,Value and class,United States,Validated,PMID: 31235660
139417,Acute transverse myelitis,Disease,Point prevalence,7.9,1-9 / 100 000,Value and class,United States,Validated,PMID: 31235660
139417,Acute transverse myelitis,Disease,Annual incidence,4.72,1-9 / 100 000,Value and class,Worldwide,Validated,PMID: 19812117 ; 19896453 ; 31235660
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Australia,Validated,20373143[PMID]
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,United States,Validated,20373143[PMID]
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Germany,Validated,15896654[PMID]
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Sweden,Validated,7564259[PMID]
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.84,1-9 / 1 000 000,Value and class,Poland,Validated,20814823[PMID]
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,1.09,1-9 / 100 000,Value and class,Estonia,Validated,23430857[PMID]
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Point prevalence,8.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Israel,Validated,33239050[PMID]
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Specific population,Validated,33239050[PMID]
5,Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,1.24,1-9 / 100 000,Value and class,Czech Republic,Validated,31241292[PMID]
139426,Perioral myoclonia with absences,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
139426,Perioral myoclonia with absences,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
139431,Epilepsy with eyelid myoclonia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
25,Glutaryl-CoA dehydrogenase deficiency,Disease,Point prevalence,333.0,>1 / 1000,Value and class,Specific population,Validated,[EXPERT]
25,Glutaryl-CoA dehydrogenase deficiency,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Specific population,Validated,[EXPERT]
25,Glutaryl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,15505392[PMID]
25,Glutaryl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,2.85,1-9 / 100 000,Value and class,Spain,Validated,22000754[PMID]
25,Glutaryl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.48,1-9 / 1 000 000,Value and class,Japan,Validated,12127323[PMID]
25,Glutaryl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.76,1-9 / 1 000 000,Value and class,United States,Validated,6601872[PMID]
25,Glutaryl-CoA dehydrogenase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
25,Glutaryl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]
25,Glutaryl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,4.3,1-9 / 100 000,Value and class,Specific population,Validated,33239050[PMID]
25,Glutaryl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.56,1-9 / 1 000 000,Value and class,Czech Republic,Validated,31241292[PMID]
64,Alström syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,[EXPERT]_22043170[PMID]
64,Alström syndrome,Disease,Cases/families,950.0,,Case(s),Worldwide,Validated,[EXPERT]
1246,Brachydactyly-nystagmus-cerebellar ataxia syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,PDF:1934114230001a[OTHER]
1246,Brachydactyly-nystagmus-cerebellar ataxia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_PDF:1934114230001a[OTHER]
139396,X-linked cerebral adrenoleukodystrophy,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
139402,Drug reaction with eosinophilia and systemic symptoms,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
139406,Encephalopathy due to prosaposin deficiency,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
139406,Encephalopathy due to prosaposin deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1008,Alopecia-epilepsy-pyorrhea-intellectual disability syndrome,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,830443[PMID]
1008,Alopecia-epilepsy-pyorrhea-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_830443[PMID]
818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Prevalence at birth,3.7,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_10807690[PMID]
818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Prevalence at birth,1.7,1-9 / 100 000,Value and class,United Kingdom,Validated,9678700[PMID]
818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Prevalence at birth,5.85,1-9 / 100 000,Value and class,Slovakia,Validated,10678669[PMID]
818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Prevalence at birth,2.6,1-9 / 100 000,Value and class,Canada,Not yet validated,7395908[PMID]_11471166[PMID]_15480380[PMID]
818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Prevalence at birth,2.65,1-9 / 100 000,Value and class,United States,Not yet validated,9024554[PMID]
818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Prevalence at birth,0.0,1-5 / 10 000,Class only,Czech Republic,Validated,10439210[PMID]_23059950[PMID]
818,Smith-Lemli-Opitz syndrome,Malformation syndrome,Annual incidence,1.4314,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,33836803[PMID]
1014,Alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,8721564[PMID]
1014,Alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8721564[PMID]
1001,2q37 microdeletion syndrome,Malformation syndrome,Cases/families,115.0,,Case(s),Worldwide,Validated,36833393[PMID]
1001,2q37 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,36833393[PMID]_ORPHANET
59,Allan-Herndon-Dudley syndrome,Disease,Cases/families,320.0,,Case(s),Worldwide,Validated,25905294[PMID]
59,Allan-Herndon-Dudley syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25905294[PMID]
59,Allan-Herndon-Dudley syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medecines Agency 2017[INST]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,5.97,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,5.635,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,6.773,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,6.162,1-9 / 100 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,6.103,1-9 / 100 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,7.229,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,6.881,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,5.973,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,6.593,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,4.09,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,5.079,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,5.518,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,8.353,1-9 / 100 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,7.79,1-9 / 100 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,5.653,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,7.116,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,5.698,1-9 / 100 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,2.834,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,5.519,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,6.575,1-9 / 100 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,4.263,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,6.379,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,5.306,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213504,Adenocarcinoma of ovary,Disease,Annual incidence,6.09,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
127,Borjeson-Forssman-Lehmann syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,22190899[PMID]_15994862[PMID]_14756673[PMID]_[EXPERT]
127,Borjeson-Forssman-Lehmann syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1264,Tricho-retino-dento-digital syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,8279493[PMID]
1264,Tricho-retino-dento-digital syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8279493[PMID]
1262,Böök syndrome,Malformation syndrome,Cases/families,26.0,,Case(s),Worldwide,Validated,[EXPERT]
1262,Böök syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1263,Boomerang dysplasia,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,15994868[PMID]_22354125[PMID]
1263,Boomerang dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15994868[PMID]_22354125[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,12.0,1-5 / 10 000,Value and class,Europe,Validated,Haute Autorité de Santé 2011[INST]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,16.1,1-5 / 10 000,Value and class,Germany,Not yet validated,11388605[PMID]_15832312[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,7.25,1-9 / 100 000,Value and class,United Kingdom,Not yet validated,22166308[PMID]_9797590[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,8.5,1-9 / 100 000,Value and class,Portugal,Validated,23842438[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,4.8,1-9 / 100 000,Value and class,Spain,Not yet validated,23842438[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,11.49,1-5 / 10 000,Value and class,Netherlands,Validated,22630369[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,4.3,1-9 / 100 000,Value and class,Canada,Validated,23543005[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,5.26,1-9 / 100 000,Value and class,Australia,Validated,19620191[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,1.96,1-9 / 100 000,Value and class,Japan,Validated,12127323[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,23700290[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,11.1,1-5 / 10 000,Value and class,Denmark,Validated,22542437[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,6.3,1-9 / 100 000,Value and class,Greece,Validated,22683754[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,5.85,1-9 / 100 000,Value and class,United States,Not yet validated,12142359[PMID]_16617240[PMID]_ ORPHANET
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Point prevalence,6.85,1-9 / 100 000,Value and class,Worldwide,Validated,ORPHANET_16763904[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,4.02,1-9 / 100 000,Value and class,Austria,Validated,20938748[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,4.35,1-9 / 100 000,Value and class,Italy,Validated,24294134[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Specific population,Validated,33239050[PMID]
42,Medium chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,4.5,1-9 / 100 000,Value and class,Czech Republic,Validated,31241292[PMID]
1231,Barber-Say syndrome,Malformation syndrome,Cases/families,16.0,,Case(s),Worldwide,Validated,27196381[PMID]
1231,Barber-Say syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27196381[PMID]
1229,Congenital intrauterine infection-like syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
1229,Congenital intrauterine infection-like syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
109,Bannayan-Riley-Ruvalcaba syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1228,Banki syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,DOI: 10.1055/s-0029-1227792[OTHER]
1228,Banki syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_DOI: 10.1055/s-0029-1227792[OTHER]
1241,Bencze syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,519901[PMID]
1241,Bencze syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_519901[PMID]
1237,Beemer-Ertbruggen syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,6507485[PMID]
1237,Beemer-Ertbruggen syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6507485[PMID]
2066,Gamma-aminobutyric acid transaminase deficiency,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,25738457[PMID]
2066,Gamma-aminobutyric acid transaminase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25738457[PMID]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.081,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.059,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.074,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.065,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.096,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.084,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.031,<1 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.045,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.082,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.074,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.226,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.136,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.108,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.104,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.163,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.128,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.135,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213531,Metaplastic carcinoma of the breast,Disease,Annual incidence,0.238,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,3.55,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,0.898,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.325,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.221,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.397,1-9 / 100 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.175,1-9 / 100 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.717,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,3.371,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.615,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,3.812,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.428,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.305,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,4.103,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,1.191,1-9 / 100 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.199,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,3.017,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,1.812,1-9 / 100 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,1.697,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.171,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.315,1-9 / 100 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,2.142,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,3.187,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,3.264,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213528,Rare adenocarcinoma of the breast,Disease,Annual incidence,3.638,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1293,Brachyolmia,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1293,Brachyolmia,Clinical group,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
860,Congenitally uncorrected transposition of the great arteries,Morphological anomaly,Prevalence at birth,24.25,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
860,Congenitally uncorrected transposition of the great arteries,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
137639,Hypomyelinating leukodystrophy-ataxia-hypodontia-hypomyelination syndrome,Clinical subtype,Cases/families,8.0,,Case(s),Worldwide,Validated,15851747[PMID]_17712733[PMID]
137639,Hypomyelinating leukodystrophy-ataxia-hypodontia-hypomyelination syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15851747[PMID]_17712733[PMID]
137577,Neonatal hypoxic and ischemic brain injury,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,European Medicines Agency 2015[INST]
137583,Vulvar intraepithelial neoplasia,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2008[INST]
1276,Brachydactyly-arterial hypertension syndrome,Malformation syndrome,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
1276,Brachydactyly-arterial hypertension syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1275,Brachydactyly-elbow wrist dysplasia syndrome,Malformation syndrome,Cases/families,4.0,,Family(ies),Worldwide,Validated,23587911[PMID]
1275,Brachydactyly-elbow wrist dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23587911[PMID]
1270,Bowen-Conradi syndrome,Malformation syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,[EXPERT]
1270,Bowen-Conradi syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1270,Bowen-Conradi syndrome,Malformation syndrome,Prevalence at birth,281.0,>1 / 1000,Value and class,Specific population,Validated,12838567[PMID]
137605,Legius syndrome,Malformation syndrome,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
137605,Legius syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
137596,Neurotrophic keratopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24672223[PMID]
137596,Neurotrophic keratopathy,Disease,Point prevalence,4.2,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
3400,Aorto-ventricular tunnel,Morphological anomaly,Cases/families,130.0,,Case(s),Worldwide,Validated,ORPHANET
3400,Aorto-ventricular tunnel,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
137599,Herpes simplex virus stromal keratitis,Disease,Point prevalence,4.2091,1-9 / 100 000,Value and class,Worldwide,Validated,32732703[PMID]_34622738[PMID]_33607690[PMID]_3391390{PMID]
137599,Herpes simplex virus stromal keratitis,Disease,Annual incidence,5.4,1-9 / 100 000,Value and class,France,Validated,22944008[PMID]
1166,Congenital unilateral hypoplasia of depressor anguli oris,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1168,Ataxia-oculomotor apraxia type 1,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1160,Chylous ascites,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_22319743[PMID]
137817,Arachnoiditis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1174,Cerebellar ataxia-ectodermal dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
137839,Lemierre syndrome,Disease,Annual incidence,10.0,1-5 / 10 000,Value and class,Europe,Not yet validated,20181152[PMID]
137839,Lemierre syndrome,Disease,Annual incidence,36.0,1-5 / 10 000,Value and class,Denmark,Validated,22633566[PMID]
137839,Lemierre syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
137834,Frank-Ter Haar syndrome,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,22037860[PMID]_23140272[PMID]
137834,Frank-Ter Haar syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22037860[PMID]_23140272[PMID]
137831,X-linked intellectual disability-cerebellar hypoplasia syndrome,Disease,Cases/families,14.0,,Family(ies),Worldwide,Validated,20528889[PMID]
137831,X-linked intellectual disability-cerebellar hypoplasia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20528889[PMID]
1170,Autosomal recessive cerebelloparenchymal disorder type 3,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
213746,Transitional cell carcinoma of the corpus uteri,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1175,X-linked progressive cerebellar ataxia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1180,Ataxia-hypogonadism-choroidal dystrophy syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1179,Benign paroxysmal tonic upgaze of childhood with ataxia,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,8495825[PMID]
1179,Benign paroxysmal tonic upgaze of childhood with ataxia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8495825[PMID]
1173,Cerebellar ataxia-hypogonadism syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
137867,Madras motor neuron disease,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
137867,Madras motor neuron disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
137681,Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,21119709[PMID]
137681,Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21119709[PMID]
2849,Perlman syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
2849,Perlman syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,1.01,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.762,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.966,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.968,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.85,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.899,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.987,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.789,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.734,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.774,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.471,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.766,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.868,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.738,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.765,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,0.918,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,1.108,1-9 / 100 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,1.108,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,1.065,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,1.118,1-9 / 100 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,1.177,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,1.007,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,1.048,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213772,Adenocarcinoma of the cervix uteri,Disease,Annual incidence,1.12,1-9 / 100 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1144,Arthrogryposis-like hand anomaly-sensorineural deafness syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,5539065[PMID]
1144,Arthrogryposis-like hand anomaly-sensorineural deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5539065[PMID]
137686,Asherman syndrome,Disease,Point prevalence,44.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2017[INST]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,4.28,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,11.822,1-5 / 10 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,10.336,1-5 / 10 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,11.192,1-5 / 10 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,4.104,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,4.67,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,5.539,1-9 / 100 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,8.277,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,1.885,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,4.871,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,3.707,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,4.204,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,3.307,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,7.362,1-9 / 100 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,1.759,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,4.756,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,7.941,1-9 / 100 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,5.478,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,8.555,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,7.507,1-9 / 100 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,2.867,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,2.657,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,3.063,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213767,Squamous cell carcinoma of the cervix uteri,Disease,Annual incidence,3.312,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
213792,Adenosarcoma of the cervix uteri,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19685064[PMID]
213787,Carcinosarcoma of the cervix uteri,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26023676[PMID]
1215,Autosomal dominant optic atrophy plus syndrome,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,22197506[PMID]_22776096[PMID]_ORPHANET
747,Autoimmune pulmonary alveolar proteinosis,Disease,Annual incidence,0.165,1-9 / 1 000 000,Value and class,Japan,Validated,30895185[PMID]
747,Autoimmune pulmonary alveolar proteinosis,Disease,Point prevalence,2.66,1-9 / 1 000 000,Value and class,Japan,Validated,30895185[PMID]
747,Autoimmune pulmonary alveolar proteinosis,Disease,Point prevalence,2.66,1-9 / 1 000 000,Value and class,Worldwide,Validated,30895185[PMID]_30064481[PMID]
747,Autoimmune pulmonary alveolar proteinosis,Disease,Point prevalence,0.687,1-9 / 1 000 000,Value and class,United States,Validated,30064481[PMID]
1225,Baller-Gerold syndrome,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,29080750[PMID]
1225,Baller-Gerold syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29080750[PMID]
2953,Musculocontractural Ehlers-Danlos syndrome,Disease,Cases/families,34.0,,Case(s),Worldwide,Validated,26373698[PMID]
2953,Musculocontractural Ehlers-Danlos syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26373698[PMID]
1227,Bangstad syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2662702[PMID]
1227,Bangstad syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2662702[PMID]
782,Axenfeld-Rieger syndrome,Malformation syndrome,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
1182,Spastic ataxia with congenital miosis,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,6821680[PMID]_17584505[PMID]
1182,Spastic ataxia with congenital miosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17584505[PMID]
3259,Syndactyly-polydactyly-ear lobe syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,182299[PMID]
3259,Syndactyly-polydactyly-ear lobe syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_182299[PMID]
1186,Infantile-onset spinocerebellar ataxia,Disease,Cases/families,29.0,,Case(s),Worldwide,Validated,27551684[PMID]
1186,Infantile-onset spinocerebellar ataxia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301746[PMID]_27551684[PMID]
1185,Spinocerebellar ataxia-dysmorphism syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,3980016[PMID]
1185,Spinocerebellar ataxia-dysmorphism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3980016[PMID]
216675,Transposition of the great arteries,Category,Prevalence at birth,31.7,1-5 / 10 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,50.0,1-5 / 10 000,Value and class,United States,Validated,17051527[PMID]_Center for Diseases Control and Prevention[INST]
216675,Transposition of the great arteries,Category,Prevalence at birth,23.3,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,59.5,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,33.4,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,47.5,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,28.8,1-5 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,18.1,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,22.6,1-5 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,40.9,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,31.1,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,14.0,1-5 / 10 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,4.7,1-9 / 100 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,15.7,1-5 / 10 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,37.7,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,33.9,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
216675,Transposition of the great arteries,Category,Prevalence at birth,22.3,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
216675,Transposition of the great arteries,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
137908,Hypotonia with lactic acidemia and hyperammonemia,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,17873122[PMID]_21189481[PMID]
137908,Hypotonia with lactic acidemia and hyperammonemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17873122[PMID]_21189481[PMID]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,8.6,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2012[REG]
137914,Choanal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,9.8,1-9 / 100 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,14.6,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,21.3,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,15.7,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,5.9,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,7.2,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,5.7,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,11.7,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,4.9,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,6.3,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,12.6,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,8.9,1-9 / 100 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
137914,Choanal atresia,Morphological anomaly,Prevalence at birth,3.2,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1193,Atkin-Flaitz syndrome,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,4025397[PMID]
1193,Atkin-Flaitz syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4025397[PMID]
137917,"Choanal atresia, unilateral",Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies[REG]
137917,"Choanal atresia, unilateral",Clinical subtype,Prevalence at birth,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_EUROCAT European surveillance of congenital anomalies[REG]
1200,Burn-McKeown syndrome,Malformation syndrome,Cases/families,20.0,,Family(ies),Worldwide,Validated,25434003[PMID]
1200,Burn-McKeown syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25434003[PMID]
137920,"Choanal atresia, bilateral",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
1198,Colonic atresia,Morphological anomaly,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Worldwide,Validated,31891361[PMID]
1198,Colonic atresia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1198,Colonic atresia,Morphological anomaly,Prevalence at birth,1.5,1-9 / 100 000,Value and class,United Kingdom,Validated,2342005[PMID]
1198,Colonic atresia,Morphological anomaly,Prevalence at birth,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_2342005[PMID]_16080929[PMID]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,9.0,1-9 / 100 000,Value and class,Europe,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,9.0,1-9 / 100 000,Value and class,Europe,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,9.0,1-9 / 100 000,Value and class,Belgium,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Belgium,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,4.0,1-9 / 100 000,Value and class,Spain,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Spain,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,6.0,1-9 / 100 000,Value and class,Ireland,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Ireland,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,7.0,1-9 / 100 000,Value and class,Italy,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Italy,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,11.0,1-5 / 10 000,Value and class,United Kingdom,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,United Kingdom,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Malta,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Malta,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,9.0,1-9 / 100 000,Value and class,Denmark,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Denmark,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,11.0,1-5 / 10 000,Value and class,France,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,France,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,7.0,1-9 / 100 000,Value and class,Reunion,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Reunion,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Portugal,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Portugal,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,9.0,1-9 / 100 000,Value and class,Germany,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Germany,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Austria,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Austria,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Switzerland,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1203,Duodenal atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Switzerland,Validated,22933095[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
1208,Pulmonary atresia-intact ventricular septum syndrome,Morphological anomaly,Prevalence at birth,4.5,1-9 / 100 000,Value and class,United Kingdom,Validated,9714114[PMID]
1208,Pulmonary atresia-intact ventricular septum syndrome,Morphological anomaly,Prevalence at birth,4.2,1-9 / 100 000,Value and class,Sweden,Validated,11515692[PMID]
1208,Pulmonary atresia-intact ventricular septum syndrome,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,United Kingdom,Validated,9714114[PMID]_ORPHANET
1208,Pulmonary atresia-intact ventricular septum syndrome,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Sweden,Validated,11515692[PMID]_ORPHANET
1449,Ring chromosome 7 syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,23509645[PMID]
1449,Ring chromosome 7 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23509645[PMID]
1453,Cleidorhizomelic syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3239579[PMID]
1453,Cleidorhizomelic syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3239579[PMID]
1440,Ring chromosome 14 syndrome,Malformation syndrome,Cases/families,80.0,,Case(s),Worldwide,Validated,28399932[PMID]
1440,Ring chromosome 14 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28399932[PMID]
1443,Ring chromosome 19 syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,15270770[PMID]
1443,Ring chromosome 19 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15270770[PMID]
141258,Tessier number 4 facial cleft,Morphological anomaly,Cases/families,2.0,,Case(s),Worldwide,Validated,3398011[PMID]_21703590[PMID]
141258,Tessier number 4 facial cleft,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3398011[PMID]_21703590[PMID]
1458,CODAS syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,25574826[PMID]_20503327[PMID]
1458,CODAS syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
141253,Oblique facial cleft,Clinical group,Prevalence at birth,0.31,1-9 / 1 000 000,Value and class,United States,Not yet validated,21703590[PMID]_ORPHANET
141253,Oblique facial cleft,Clinical group,Point prevalence,0.0,1-9 / 1 000 000,Class only,United States,Not yet validated,21703590[PMID]_ORPHANET
141253,Oblique facial cleft,Clinical group,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
1454,Joubert syndrome with hepatic defect,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,ORPHANET
1454,Joubert syndrome with hepatic defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
190,Coats disease,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,United Kingdom,Validated,20865031[PMID]_[EXPERT]
190,Coats disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1426,Greenberg dysplasia,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,14684697[PMID]
1426,Greenberg dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
141184,Rapidly involuting congenital hemangioma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1427,Autosomal recessive otospondylomegaepiphyseal dysplasia,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
1427,Autosomal recessive otospondylomegaepiphyseal dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1435,Xq21 microdeletion syndrome,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,7258279[PMID]_2624260[PMID]_17935254[PMID]
1435,Xq21 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7258279[PMID]_2624260[PMID]_17935254[PMID]
1436,X-linked skeletal dysplasia-intellectual disability syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,837562[PMID]
1436,X-linked skeletal dysplasia-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_837562[PMID]
1433,Choroidal atrophy-alopecia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,10994447[PMID]
1433,Choroidal atrophy-alopecia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10994447[PMID]
1484,Contractures-ectodermal dysplasia-cleft lip/palate syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7504881[PMID]
1484,Contractures-ectodermal dysplasia-cleft lip/palate syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7504881[PMID]
141333,Biemond syndrome type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9098485[PMID]
1490,Corneal dystrophy-perceptive deafness syndrome,Malformation syndrome,Cases/families,24.0,,Case(s),Worldwide,Validated,18922146[PMID]
1490,Corneal dystrophy-perceptive deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18922146[PMID]
1487,Cooks syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,22329539[PMID]
1487,Cooks syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22329539[PMID]
1486,Lethal congenital contracture syndrome type 1,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Finland,Validated,32670090[PMID]_ORPHANET
1486,Lethal congenital contracture syndrome type 1,Malformation syndrome,Prevalence at birth,3.96,1-9 / 100 000,Value and class,Finland,Validated,16892327[PMID]
1466,COFS syndrome,Clinical subtype,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
1466,COFS syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1471,Coloboma of macula-brachydactyly type B syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,3385739[PMID]_12919145[PMID]
1471,Coloboma of macula-brachydactyly type B syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3385739[PMID]_12919145[PMID]
141291,Cleft lip and alveolus,Morphological anomaly,Point prevalence,0.0,6-9 / 10 000,Class only,Europe,Not yet validated,ORPHANET
141091,Polyrrhinia,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
141083,Nasolacrimal duct cyst,Morphological anomaly,Prevalence at birth,25.7,1-5 / 10 000,Value and class,United States,Validated,21035068[PMID]
141083,Nasolacrimal duct cyst,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
1410,Uncombable hair syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
141099,Proboscis lateralis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
141096,Supernumerary nostril,Malformation syndrome,Cases/families,32.0,,Case(s),Worldwide,Validated,23348320[PMID]
141096,Supernumerary nostril,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,23348320[PMID]
1412,Tarsal-carpal coalition syndrome,Malformation syndrome,Cases/families,10.0,,Family(ies),Worldwide,Validated,[EXPERT]
1412,Tarsal-carpal coalition syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1416,Familial calcium pyrophosphate deposition,Disease,Cases/families,100.0,,Family(ies),Worldwide,Validated,[EXPERT]
1416,Familial calcium pyrophosphate deposition,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1394,Cerebrofaciothoracic dysplasia,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,24194475[PMID]
1394,Cerebrofaciothoracic dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24194475[PMID]
1397,Hydrocephaly-cerebellar agenesis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_657584[PMID]
1397,Hydrocephaly-cerebellar agenesis syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,657584[PMID]
1398,Isolated cerebellar agenesis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1399,Richards-Rundle syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
141077,Epignathus,Clinical subtype,Point prevalence,0.0017,<1 / 1 000 000,Value and class,Worldwide,Validated,21701667[PMID]_ORPHANET
141077,Epignathus,Clinical subtype,Prevalence at birth,1.68,1-9 / 100 000,Value and class,Worldwide,Validated,ORPHANET_21701667[PMID]
1401,CHAND syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28940926[PMID]
141152,Isolated congenital hypoglossia/aglossia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
174,"Metaphyseal chondrodysplasia, Schmid type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
141163,Glossopalatine ankylosis,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
141163,Glossopalatine ankylosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1425,Desbuquois syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,16642505[PMID]_[EXPERT]
1425,Desbuquois syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
141179,Non-involuting congenital hemangioma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
141127,Congenital tracheal stenosis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Canada,Validated,16410137[PMID]_30159250[PMID]_32851317[PMID]_ORPHANET
141127,Congenital tracheal stenosis,Morphological anomaly,Prevalence at birth,1.6,1-9 / 100 000,Value and class,Canada,Validated,17712567[PMID]
141132,Oculo-auriculo-vertebral spectrum,Malformation syndrome,Prevalence at birth,0.0,1-9 / 100 000,Class only,Worldwide,Validated,ORPHANET
141132,Oculo-auriculo-vertebral spectrum,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Validated,ORPHANET
141132,Oculo-auriculo-vertebral spectrum,Malformation syndrome,Point prevalence,4.0,1-9 / 100 000,Value and class,Japan,Validated,2092586[PMID}
141132,Oculo-auriculo-vertebral spectrum,Malformation syndrome,Prevalence at birth,0.65,1-9 / 1 000 000,Value and class,France,Validated,22925539[PMID]
141132,Oculo-auriculo-vertebral spectrum,Malformation syndrome,Prevalence at birth,11.7,1-5 / 10 000,Value and class,Australia,Validated,34626670[PMID]
141145,Hemifacial hyperplasia,Malformation syndrome,Point prevalence,1.16,1-9 / 100 000,Value and class,United States,Validated,ISBN-10:0867153903[OTHER]_28163490[PMID]_ORPHANET
141145,Hemifacial hyperplasia,Malformation syndrome,Prevalence at birth,1.16,1-9 / 100 000,Value and class,United States,Validated,ISBN-10:0867153903[OTHER]_28163490[PMID]
141148,Hemifacial myohyperplasia,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,20583183[PMID]
141148,Hemifacial myohyperplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20583183[PMID]
156728,"Spondyloepimetaphyseal dysplasia, matrilin-3 type",Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,15121775[PMID]
156728,"Spondyloepimetaphyseal dysplasia, matrilin-3 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15121775[PMID]
1375,Cataract-hypertrichosis-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
163,Hereditary hyperferritinemia-cataract syndrome,Disease,Cases/families,120.0,,Case(s),Worldwide,Validated,34789084[PMID]_36287435[PMID]
163,Hereditary hyperferritinemia-cataract syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,34789084[PMID]_36287435[PMID]_ORPHANET
1373,Cataract-aberrant oral frenula-growth delay syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,1951441[PMID]
1373,Cataract-aberrant oral frenula-growth delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1951441[PMID]
1368,Cataract-ataxia-deafness syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,1661780[PMID]
1368,Cataract-ataxia-deafness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1661780[PMID]
1366,Autosomal recessive palmoplantar keratoderma and congenital alopecia,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,ORPHANET
1366,Autosomal recessive palmoplantar keratoderma and congenital alopecia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1361,Carnosinase deficiency,Biological anomaly,Cases/families,24.0,,Case(s),Worldwide,Validated,ISBN:0-7817-3063-5[OTHER]
1361,Carnosinase deficiency,Biological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1361,Carnosinase deficiency,Biological anomaly,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Worldwide,Validated,16722645[PMID]
1393,Cerebrocostomandibular syndrome,Malformation syndrome,Cases/families,75.0,,Case(s),Worldwide,Validated,20507350[PMID]
1393,Cerebrocostomandibular syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
157826,Congenital epulis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
1390,Night blindness-skeletal anomalies-dysmorphism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,314984 [PMID]
1390,Night blindness-skeletal anomalies-dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_314984 [PMID]
157820,Cold-induced sweating syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,ORPHANET
157820,Cold-induced sweating syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1389,Cortical blindness-intellectual disability-polydactyly syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,4064363[PMID]
1389,Cortical blindness-intellectual disability-polydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4064363[PMID]
157798,Serrated polyposis syndrome,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,22851664[PMID]_21636642[PMID]
157798,Serrated polyposis syndrome,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
1388,Catel-Manzke syndrome,Malformation syndrome,Cases/families,33.0,,Case(s),Worldwide,Validated,ORPHANET
1388,Catel-Manzke syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
157801,Mesoaxial synostotic syndactyly with phalangeal reduction,Morphological anomaly,Cases/families,6.0,,Family(ies),Worldwide,Validated,25466284[PMID]
157801,Mesoaxial synostotic syndactyly with phalangeal reduction,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1387,Cataract-intellectual disability-hypogonadism syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,23420520[PMID]
1387,Cataract-intellectual disability-hypogonadism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
157791,Epithelioid hemangioendothelioma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET_25992243[PMID]
1381,Cataract-intellectual disability-anal atresia-urinary defects syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,541035[PMID]
1381,Cataract-intellectual disability-anal atresia-urinary defects syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_541035[PMID]
1380,Cataract-nephropathy-encephalopathy syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,14065995[PMID]
1380,Cataract-nephropathy-encephalopathy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14065995[PMID]
1377,Cataract-microcornea syndrome,Malformation syndrome,Cases/families,8.0,,Family(ies),Worldwide,Validated,ORPHANET
1377,Cataract-microcornea syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25406294[PMID]
157215,Hereditary hypophosphatemic rickets with hypercalciuria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
1325,Camptodactyly-taurinuria syndrome,Malformation syndrome,Cases/families,17.0,,Case(s),Worldwide,Validated,16178082[PMID]
1325,Camptodactyly-taurinuria syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16178082[PMID]
1326,"Camptodactyly syndrome, Guadalajara type 2",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,4040823[PMID]
1326,"Camptodactyly syndrome, Guadalajara type 2",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4040823[PMID]
1327,"Camptodactyly syndrome, Guadalajara type 1",Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,7192193[PMID]_7681735[PMID]_8116673[PMID]_12002144[PMID]
1327,"Camptodactyly syndrome, Guadalajara type 1",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7192193[PMID]_7681735[PMID]_8116673[PMID]_12002144[PMID]
1328,Camurati-Engelmann disease,Malformation syndrome,Cases/families,300.0,,Case(s),Worldwide,Validated,20301335[PMID]
1328,Camurati-Engelmann disease,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1323,Camptodactyly-joint contractures-facial skeletal defects syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,16688750[PMID]
1323,Camptodactyly-joint contractures-facial skeletal defects syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16688750[PMID]
156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Clinical group,Point prevalence,14.9,1-5 / 10 000,Value and class,Germany,Not yet validated,24425780[PMID]
156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Clinical group,Annual incidence,3.3,1-9 / 100 000,Value and class,United States,Validated,28881446[PMID]
156152,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Clinical group,Point prevalence,42.1,1-5 / 10 000,Value and class,United States,Validated,28881446[PMID]
1314,Symmetrical thalamic calcifications,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,28063749[PMID]
1314,Symmetrical thalamic calcifications,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28063749[PMID]
1318,"Campomelia, Cumming type",Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,15754354[PMID]
1318,"Campomelia, Cumming type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15754354[PMID]
1319,Camptobrachydactyly,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,5031984[PMID]
1319,Camptobrachydactyly,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5031984[PMID]
1305,Feingold syndrome,Malformation syndrome,Cases/families,123.0,,Case(s),Worldwide,Validated,ORPHANET
1305,Feingold syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1307,Distal limb deficiencies-micrognathia syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,19584065[PMID]
1307,Distal limb deficiencies-micrognathia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19584065[PMID]
1313,Infantile choroidocerebral calcification syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,315525[PMID]_8232964[PMID]
1313,Infantile choroidocerebral calcification syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_315525[PMID]_8232964[PMID]
1350,Heart-hand syndrome type 2,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,1976459[PMID]
1350,Heart-hand syndrome type 2,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1355,Congenital heart defect-round face-developmental delay syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3225826[PMID]
1355,Congenital heart defect-round face-developmental delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3225826[PMID]
1352,Atrioventricular defect-blepharophimosis-radial and anal defect syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8031543[PMID]
1352,Atrioventricular defect-blepharophimosis-radial and anal defect syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8031543[PMID]
1345,Cardiomyopathy-cataract-hip spine disease syndrome,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,3965265[PMID]
1345,Cardiomyopathy-cataract-hip spine disease syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3965265[PMID]
1338,Heart defect-tongue hamartoma-polysyndactyly syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,25427950[PMID]_1516223[PMID]_8733055[PMID]
1338,Heart defect-tongue hamartoma-polysyndactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25427950[PMID]_1516223[PMID]_8733055[PMID]
1340,Cardiofaciocutaneous syndrome,Malformation syndrome,Point prevalence,0.12,1-9 / 1 000 000,Value and class,Japan,Validated,22495831[PMID]
1340,Cardiofaciocutaneous syndrome,Malformation syndrome,Cases/families,300.0,,Case(s),Worldwide,Validated,22495831[PMID]_[EXPERT]
1340,Cardiofaciocutaneous syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2856,Persistent Müllerian duct syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1336,Hyperkeratosis-hyperpigmentation syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,151611[PMID]_8448904[PMID]
1336,Hyperkeratosis-hyperpigmentation syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_151611[PMID]_8448904[PMID]
1335,Pentalogy of Cantrell,Malformation syndrome,Prevalence at birth,0.55,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET
1335,Pentalogy of Cantrell,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
1335,Pentalogy of Cantrell,Malformation syndrome,Prevalence at birth,0.67,1-9 / 1 000 000,Value and class,Worldwide,Validated,25092102[PMID]_[EXPERT]
1682,Arterial dissection-lentiginosis syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,7838191[PMID]
1682,Arterial dissection-lentiginosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7838191[PMID]
1757,Fibular dimelia-diplopodia syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,ORPHANET
1757,Fibular dimelia-diplopodia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1756,Caudal duplication,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1766,Dysequilibrium syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22973972[PMID]_21885617[PMID]_19461874[PMID]_22892528[PMID]
1766,Dysequilibrium syndrome,Disease,Cases/families,51.0,,Case(s),Worldwide,Validated,Dr Kym Boycott[EXPERT]_22973972[PMID]_21885617[PMID]_19461874[PMID]_22892528[PMID]
1777,Temtamy syndrome,Malformation syndrome,Cases/families,56.0,,Case(s),Worldwide,Validated,24798461[PMID]
1777,Temtamy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24798461[PMID]
1780,Thakker-Donnai syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1956065[PMID]
1780,Thakker-Donnai syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1956065[PMID]
1772,"45,X/46,XY mixed gonadal dysgenesis",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1784,Acrofrontofacionasal dysostosis,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,22052670[PMID]_18553510[PMID]_2830788[PMID]_2986457[PMID]
1784,Acrofrontofacionasal dysostosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22052670[PMID]_18553510[PMID]_2830788[PMID]_2986457[PMID]
1782,Dysosteosclerosis,Malformation syndrome,Cases/families,23.0,,Case(s),Worldwide,Validated,20499338[PMID]
1782,Dysosteosclerosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,20499338[PMID]_ORPHANET
1790,Hypomandibular faciocranial dysostosis,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,8135280[PMID]
1790,Hypomandibular faciocranial dysostosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8135280[PMID]
1786,"Acrofacial dysostosis, Catania type",Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,8826434[PMID]
1786,"Acrofacial dysostosis, Catania type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8826434[PMID]
1788,"Acrofacial dysostosis, Rodríguez type",Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,18000904[PMID]
1788,"Acrofacial dysostosis, Rodríguez type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18000904[PMID]
859,Transcobalamin deficiency,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,21312325[PMID]
859,Transcobalamin deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
139441,Hypomyelination with atrophy of basal ganglia and cerebellum,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,ORPHANET
139441,Hypomyelination with atrophy of basal ganglia and cerebellum,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3196,Steroid dehydrogenase deficiency-dental anomalies syndrome,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,8832133[PMID]
3196,Steroid dehydrogenase deficiency-dental anomalies syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8832133[PMID]
139444,Leukoencephalopathy with bilateral anterior temporal lobe cysts,Disease,Cases/families,29.0,,Case(s),Worldwide,Validated,ORPHANET
139444,Leukoencephalopathy with bilateral anterior temporal lobe cysts,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
139447,Progressive cavitating leukoencephalopathy,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,ORPHANET
139447,Progressive cavitating leukoencephalopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1573,Hypotrichosis with juvenile macular degeneration,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
1573,Hypotrichosis with juvenile macular degeneration,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
726,Alpers-Huttenlocher syndrome,Disease,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Europe,Validated,19766516_Pr Robert NAVIAUX[EXPERT]
726,Alpers-Huttenlocher syndrome,Disease,Point prevalence,0.07,<1 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
139450,Microtia-eye coloboma-imperforation of the nasolacrimal duct syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,18179897[PMID]
139450,Microtia-eye coloboma-imperforation of the nasolacrimal duct syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18179897[PMID]
139455,Autosomal recessive bestrophinopathy,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,21825197[PMID]_24337562[PMID]
139455,Autosomal recessive bestrophinopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1574,Retinal degeneration-nanophthalmos-glaucoma syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,3827713[PMID]
1574,Retinal degeneration-nanophthalmos-glaucoma syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3827713[PMID]
139466,SERKAL syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,18179883[PMID]
139466,SERKAL syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18179883[PMID]
1596,Distal deletion 15q syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,22065603[PMID]
1596,Distal deletion 15q syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22065603[PMID]
139471,Microphthalmia with brain and digit anomalies,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,18252212[PMID]
139471,Microphthalmia with brain and digit anomalies,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18252212[PMID]
139474,17q11.2 microduplication syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,18183042[PMID]
139474,17q11.2 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18183042[PMID]
1617,Developmental delay-language impairment-dopa responsive dystonia-parkinsonism syndrome due to 2q24 microdeletion,Etiological subtype,Cases/families,23.0,,Case(s),Worldwide,Validated,[EXPERT]
1617,Developmental delay-language impairment-dopa responsive dystonia-parkinsonism syndrome due to 2q24 microdeletion,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1606,1p36 deletion syndrome,Malformation syndrome,Prevalence at birth,15.0,1-5 / 10 000,Value and class,United States,Validated,9326330[PMID]
1606,1p36 deletion syndrome,Malformation syndrome,Point prevalence,15.0,1-5 / 10 000,Value and class,United States,Validated,9326330[PMID]_ORPHANET
139480,Autosomal recessive spastic paraplegia type 39,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,24355708[PMID]
139480,Autosomal recessive spastic paraplegia type 39,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24355708[PMID]
1647,Oculocerebrocutaneous syndrome,Malformation syndrome,Cases/families,38.0,,Case(s),Worldwide,Validated,ORPHANET
1647,Oculocerebrocutaneous syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
139485,Autosomal recessive ataxia due to ubiquinone deficiency,Disease,Cases/families,31.0,,Case(s),Worldwide,Validated,24164873[PMID]
139485,Autosomal recessive ataxia due to ubiquinone deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1653,Dentin dysplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
139515,Charcot-Marie-Tooth disease type 4J,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,21705420[PMID]_23489662[PMID]_24878229[PMID]
139515,Charcot-Marie-Tooth disease type 4J,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21705420[PMID]_23489662[PMID]_24878229[PMID]
139512,Neuropathy with hearing impairment,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,11309368[PMID]
139512,Neuropathy with hearing impairment,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11309368[PMID]
1657,"Dermatoosteolysis, Kirghizian type",Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,6224420[PMID]
1657,"Dermatoosteolysis, Kirghizian type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6224420[PMID]
139525,Distal hereditary motor neuropathy type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3789668[PMID]_7125978[PMID]_3789668[PMID]_1517763[PMID]
139525,Distal hereditary motor neuropathy type 2,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,3789668[PMID]_7125978[PMID]_3789668[PMID]_1517763[PMID]
1658,Absence of fingerprints-congenital milia syndrome,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,26932190[PMID]
1658,Absence of fingerprints-congenital milia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26932190[PMID]
1659,Dermatoleukodystrophy,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,655904[PMID]
1659,Dermatoleukodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_655904[PMID]
139547,Distal spinal muscular atrophy type 3,Disease,Cases/families,28.0,,Case(s),Worldwide,Validated,512678[PMID]_12112104[PMID]_15054395[PMID]
139547,Distal spinal muscular atrophy type 3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_512678[PMID]_12112104[PMID]_15054395[PMID]
1660,Dermoodontodysplasia,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,6616948[PMID]
1660,Dermoodontodysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6616948[PMID]
139557,X-linked distal spinal muscular atrophy type 3,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,14985388[PMID]_19153371[PMID]_20170900[PMID]
139557,X-linked distal spinal muscular atrophy type 3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14985388[PMID]_19153371[PMID]_20170900[PMID]
1661,X-linked corneal dermoid,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,11594343[PMID]
1661,X-linked corneal dermoid,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11594343[PMID]
1662,Restrictive dermopathy,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
1662,Restrictive dermopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
139552,"Distal hereditary motor neuropathy, Jerash type",Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,11117544[PMID]_26078401[PMID]
139552,"Distal hereditary motor neuropathy, Jerash type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11117544[PMID]_26078401[PMID]
139573,Hereditary sensory and autonomic neuropathy with deafness and global delay,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,12160974[PMID]
139573,Hereditary sensory and autonomic neuropathy with deafness and global delay,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12160974[PMID]
139564,Hereditary sensory and autonomic neuropathy type 1B,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,12870133[PMID]
139564,Hereditary sensory and autonomic neuropathy type 1B,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12870133[PMID]
139583,X-linked hereditary sensory and autonomic neuropathy with deafness,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,25986071[PMID]
139583,X-linked hereditary sensory and autonomic neuropathy with deafness,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25986071
1667,Wolcott-Rallison syndrome,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,21050479[PMID]
1667,Wolcott-Rallison syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
139578,Mutilating hereditary sensory neuropathy with spastic paraplegia,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,218673[PMID]_7922454[PMID]_16333315[PMID]
139578,Mutilating hereditary sensory neuropathy with spastic paraplegia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16333315[PMID]
1671,Split cord malformation type I,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_22371545[PMID]
140917,Stapes ankylosis with broad thumbs and toes,Malformation syndrome,Cases/families,6.0,,Family(ies),Worldwide,Validated,ORPHANET
140917,Stapes ankylosis with broad thumbs and toes,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1548,Cryptorchidism-arachnodactyly-intellectual disability syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,4394203[PMID]
1548,Cryptorchidism-arachnodactyly-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4394203[PMID]
1547,Cryptomicrotia-brachydactyly-excess fingertip arch syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3400730[PMID]
1547,Cryptomicrotia-brachydactyly-excess fingertip arch syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3400730[PMID]
140922,Titin-related limb-girdle muscular dystrophy R10,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,1745277[PMID]_1487757[PMID]
140922,Titin-related limb-girdle muscular dystrophy R10,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1745277[PMID]_1487757[PMID]
1545,Crisponi syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
1545,Crisponi syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1540,Jackson-Weiss syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1540,Jackson-Weiss syndrome,Malformation syndrome,Cases/families,200.0,,Case(s),Worldwide,Not yet validated,ORPHANET
140874,Joubert syndrome and related disorders,Category,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Worldwide,Validated,18054307[PMID]_17377524[PMID]_20301500[PMID]_20615230[PMID]_[EXPERT]
140874,Joubert syndrome and related disorders,Category,Prevalence at birth,1.0,1-9 / 100 000,Value and class,United States,Validated,20615230[PMID]
140874,Joubert syndrome and related disorders,Category,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Netherlands,Validated,18054307[PMID]
140874,Joubert syndrome and related disorders,Category,Point prevalence,666.67,>1 / 1000,Value and class,North America,Validated,22152675[PMID]
140874,Joubert syndrome and related disorders,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
140896,Severe acute respiratory syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
140896,Severe acute respiratory syndrome,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
1532,Gómez-López-Hernández syndrome,Malformation syndrome,Cases/families,36.0,,Case(s),Worldwide,Validated,28357184[PMID]
1532,Gómez-López-Hernández syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28357184[PMID]
140952,Syndactyly-telecanthus-anogenital and renal malformations syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,PMID: 18297069 ; EXPERT
140952,Syndactyly-telecanthus-anogenital and renal malformations syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18297069[PMID]
140957,Autosomal dominant macrothrombocytopenia,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,18065693[PMID]_18849486[PMID]_24069336[PMID]
140957,Autosomal dominant macrothrombocytopenia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
140944,CLOVES syndrome,Malformation syndrome,Cases/families,150.0,,Case(s),Worldwide,Validated,31334068[PMID]
140944,CLOVES syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_31334068[PMID]
140949,Low-flow priapism,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,European Medicines Agency 2010[INST]
1555,Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,19610084[PMID]
1555,Cutis gyrata-acanthosis nigricans-craniosynostosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19610084[PMID]
140936,Lelis syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,1628512[PMID]_12457412[PMID]_18627052[PMID]
140936,Lelis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1628512[PMID]_12457412[PMID]_18627052[PMID]
140941,Short stature due to primary acid-labile subunit deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
1553,Curry-Jones syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,18798318[PMID]
1553,Curry-Jones syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
140927,Self-limited neonatal-infantile epilepsy,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,15048894[PMID]
140927,Self-limited neonatal-infantile epilepsy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15048894[PMID]
140933,Linear atrophoderma of Moulin,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
140933,Linear atrophoderma of Moulin,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
140989,Primary angiitis of the central nervous system,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,United States,Validated,21601163[PMID]_21180634[PMID]_22575778[PMID]
140989,Primary angiitis of the central nervous system,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1566,Dandy-Walker malformation-postaxial polydactyly syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,23324646[PMID]
1566,Dandy-Walker malformation-postaxial polydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23324646[PMID]
140976,RHYNS syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,9375913[PMID]
140976,RHYNS syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9375913[PMID]
1563,Dahlberg-Borer-Newcomer syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,6638075[PMID]
1563,Dahlberg-Borer-Newcomer syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6638075[PMID
140969,Saldino-Mainzer syndrome,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,22503633[PMID]_23418020[PMID]_28724397[PMID]
140969,Saldino-Mainzer syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22503633[PMID]_23418020[PMID]_28724397[PMID]
140966,"Palmoplantar keratoderma, Nagashima type",Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,27666198[PMID]
140966,"Palmoplantar keratoderma, Nagashima type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27666198[PMID]
140963,Bilateral microtia-deafness-cleft palate syndrome,Malformation syndrome,Cases/families,3.0,,Family(ies),Worldwide,Validated,23775976[PMID]_27503514[PMID]
140963,Bilateral microtia-deafness-cleft palate syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23775976[PMID]_27503514[PMID]
382,Guanidinoacetate methyltransferase deficiency,Disease,Cases/families,80.0,,Case(s),Worldwide,Validated,20301745[PMID]
382,Guanidinoacetate methyltransferase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
742,Prolidase deficiency,Disease,Cases/families,90.0,,Case(s),Worldwide,Validated,26110198[PMID]
742,Prolidase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,Dr Heng Wang[EXPERT]_ORPHANET
742,Prolidase deficiency,Disease,Prevalence at birth,0.08,<1 / 1 000 000,Value and class,Canada,Validated,ISBN:978-2-550-55181-2[OTHER]
1979,Lipodystrophy due to peptidic growth factors deficiency,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,2477323[PMID]
1979,Lipodystrophy due to peptidic growth factors deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2477323[PMID]
1571,Knobloch syndrome,Malformation syndrome,Cases/families,119.0,,Case(s),Worldwide,Validated,35693012[PMID]_36684549[PMID]_ORPHANET
1571,Knobloch syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,35693012[PMID]_36684549[PMID]_ORPHANET
141007,Orofaciodigital syndrome type 9,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
141007,Orofaciodigital syndrome type 9,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1551,Familial benign copper deficiency,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,2978614[PMID]
1551,Familial benign copper deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2978614[PMID]
1568,X-linked intellectual disability-Dandy-Walker malformation-basal ganglia disease-seizures syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,23756445[PMID]_23756445[PMID]
1568,X-linked intellectual disability-Dandy-Walker malformation-basal ganglia disease-seizures syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
141000,Orofaciodigital syndrome type 11,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
1497,X-linked complicated corpus callosum dysgenesis,Clinical subtype,Cases/families,11.0,,Case(s),Worldwide,Validated,ORPHANET
1497,X-linked complicated corpus callosum dysgenesis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1493,Vici syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,26917586[PMID]
1493,Vici syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26917586[PMID]
140286,Secondary hypoparathyroidism due to impaired parathormon secretion,Disease,Point prevalence,24.75,1-5 / 10 000,Value and class,Europe,Validated,29087618[PMID]_23661265[PMID]_29516129[PMID]_30375660[PMID]
140286,Secondary hypoparathyroidism due to impaired parathormon secretion,Disease,Annual incidence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
140286,Secondary hypoparathyroidism due to impaired parathormon secretion,Disease,Annual incidence,0.8,1-9 / 1 000 000,Value and class,Denmark,Validated,23661265[PMID]
140286,Secondary hypoparathyroidism due to impaired parathormon secretion,Disease,Annual incidence,1.7,1-9 / 100 000,Value and class,Spain,Validated,32155210[PMID]
1495,Intellectual disability-hypoplastic corpus callosum-preauricular tag syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3400727[PMID]
1495,Intellectual disability-hypoplastic corpus callosum-preauricular tag syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3400727[PMID]
1509,Coxopodopatellar syndrome,Disease,Cases/families,47.0,,Case(s),Worldwide,Validated,11303519[PMID]
1509,Coxopodopatellar syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11303519[PMID]
1512,Crane-Heise syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,21094705[PMID]
1512,Crane-Heise syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21094705[PMID]
1506,Thin ribs-tubular bones-dysmorphism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2400886[PMID]
1506,Thin ribs-tubular bones-dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2400886[PMID]
1508,Coxoauricular syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,7282772[PMID]
1508,Coxoauricular syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7282772[PMID]
1507,Autosomal recessive Robinow syndrome,Clinical subtype,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
1507,Autosomal recessive Robinow syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1517,Cantú syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,28690487[PMID]
1517,Cantú syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28690487[PMID]
1519,SPECC1L-related hypertelorism syndrome,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,26111080[PMID]
1519,SPECC1L-related hypertelorism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26111080[PMID]
1520,Craniofrontonasal dysplasia,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1513,Craniodiaphyseal dysplasia,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,21221996[PMID]
1513,Craniodiaphyseal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1514,Craniodigital-intellectual disability syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,17715284[PMID]
1514,Craniodigital-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17715284[PMID]
140481,Autosomal dominant slowed nerve conduction velocity,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,9678704[PMID]
140481,Autosomal dominant slowed nerve conduction velocity,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9678704[PMID]
1515,Cranioectodermal dysplasia,Malformation syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,24027799[PMID]
1515,Cranioectodermal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24027799[PMID]
1516,Non-syndromic bilambdoid and sagittal craniosynostosis,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,15723305[PMID]
1516,Non-syndromic bilambdoid and sagittal craniosynostosis,Malformation syndrome,Prevalence at birth,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
1516,Non-syndromic bilambdoid and sagittal craniosynostosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1516,Non-syndromic bilambdoid and sagittal craniosynostosis,Malformation syndrome,Prevalence at birth,0.05,<1 / 1 000 000,Value and class,Spain,Validated,15551327[PMID]_[EXPERT]
1527,"Craniosynostosis, Philadelphia type",Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,8882401[PMID]
1527,"Craniosynostosis, Philadelphia type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8882401[PMID]
1528,Craniotelencephalic dysplasia,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,6859106[PMID]
1528,Craniotelencephalic dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6859106[PMID]
1529,Craniofacial-deafness-hand syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,14556253[PMID]
1529,Craniofacial-deafness-hand syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14556253[PMID]
1521,Craniofrontonasal dysplasia-Poland anomaly syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2225532[PMID]
1521,Craniofrontonasal dysplasia-Poland anomaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2225532[PMID]
1522,Craniometaphyseal dysplasia,Malformation syndrome,Cases/families,160.0,,Case(s),Worldwide,Validated,ISBN:781730635[OTHER]
1522,Craniometaphyseal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ISBN:0781730635[OTHER]
1525,Cranio-osteoarthropathy,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
1525,Cranio-osteoarthropathy,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1969,Facial dysmorphism-anorexia-cachexia-eye and skin anomalies syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,6438152[PMID]
1969,Facial dysmorphism-anorexia-cachexia-eye and skin anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6438152[PMID]
1968,Flat face-microstomia-ear anomaly syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2929657[PMID]
1968,Flat face-microstomia-ear anomaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2929657[PMID]
1970,Facial dysmorphism-macrocephaly-myopia-Dandy-Walker malformation syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,2591071[PMID]
1970,Facial dysmorphism-macrocephaly-myopia-Dandy-Walker malformation syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2591071[PMID]
1973,Faciocardiorenal syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,880742[PMID]_1887846[PMID]
1973,Faciocardiorenal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_880742[PMID]_1887846[PMID]
1972,Lethal faciocardiomelic dysplasia,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,1218241[PMID]
1972,Lethal faciocardiomelic dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1218241[PMID]
1974,Autosomal recessive faciodigitogenital syndrome,Malformation syndrome,Cases/families,26.0,,Case(s),Worldwide,Validated,3398008[PMID]_1770541[PMID]_20607856[PMID]
1974,Autosomal recessive faciodigitogenital syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3398008[PMID]_1770541[PMID]_20607856[PMID]
1962,Exostoses-anetodermia-brachydactyly type E syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,6334993[PMID]
1962,Exostoses-anetodermia-brachydactyly type E syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6334993[PMID]
1964,Extrasystoles-short stature-hyperpigmentation-microcephaly syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1218236[PMID]
1964,Extrasystoles-short stature-hyperpigmentation-microcephaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1218236[PMID]
1822,Dysplasia epiphysealis hemimelica,Malformation syndrome,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,13295331[PMID]_29252895[PMID]
1822,Dysplasia epiphysealis hemimelica,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1824,Lowry-Wood syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,12605445[PMID]_19288552[PMID]
1824,Lowry-Wood syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12605445[PMID]_19288552[PMID]
1952,Epiphyseal stippling-osteoclastic hyperplasia syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,12709756[PMID]
1952,Epiphyseal stippling-osteoclastic hyperplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12709756[PMID]
1954,Congenital lethal erythroderma,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,1535034[PMID]
1954,Congenital lethal erythroderma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1535034[PMID]
1955,Spinocerebellar ataxia type 34,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_31105016[PMID]_31750392[PMID]_[EXPERT]
1955,Spinocerebellar ataxia type 34,Disease,Cases/families,45.0,,Case(s),Worldwide,Validated,31105016[PMID]_31750392[PMID]_[EXPERT]
1926,Diabetic embryopathy,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2209,Maternal phenylketonuria,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
2209,Maternal phenylketonuria,Malformation syndrome,Annual incidence,10.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
1927,Emery-Nelson syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,5501704[PMID]
1927,Emery-Nelson syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5501704[PMID]
1937,Eng-Strom syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3812565[PMID]
1937,Eng-Strom syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3812565[PMID]
1920,Toluene embryopathy,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1919,Phenobarbital embryopathy,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1917,Fetal methylmercury syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,34881051[PMID]_https://www3.kumagaku.ac.jp/srs/pdf/no14_no01_200901_005.pdf_ORPHANET
1923,Methimazole embryofetopathy,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,ORPHANET
1923,Methimazole embryofetopathy,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1912,Fetal hydantoin syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1918,Fetal minoxidil syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1911,Cocaine embryofetopathy,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1910,Fetal iodine syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1916,Diethylstilbestrol syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
294,Fetal cytomegalovirus syndrome,Disease,Point prevalence,40.0,1-5 / 10 000,Value and class,Europe,Not yet validated,ORPHANET
1914,Vitamin K antagonist embryofetopathy,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1913,Fetal trimethadione syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1896,EEC syndrome,Malformation syndrome,Prevalence at birth,1.11,1-9 / 100 000,Value and class,Europe,Validated,ISBN:978-0-387-21753-6[OTHER]
1896,EEC syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_ISBN:978-0-387-21753-6[OTHER]
1897,EEM syndrome,Malformation syndrome,Cases/families,7.0,,Family(ies),Worldwide,Validated,15805154[PMID]
1897,EEM syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1908,Aminopterin/methotrexate embryofetopathy,Malformation syndrome,Cases/families,17.0,,Case(s),Worldwide,Validated,ORPHANET
1908,Aminopterin/methotrexate embryofetopathy,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1909,Indomethacin embryofetopathy,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1906,Fetal valproate spectrum disorder,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_Dr Asher Ornoy[PMID]
1906,Fetal valproate spectrum disorder,Malformation syndrome,Prevalence at birth,1.02,1-9 / 100 000,Value and class,Europe,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1906,Fetal valproate spectrum disorder,Malformation syndrome,Prevalence at birth,11.7,1-5 / 10 000,Value and class,Reunion,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1906,Fetal valproate spectrum disorder,Malformation syndrome,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Belgium,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1906,Fetal valproate spectrum disorder,Malformation syndrome,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Netherlands,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1906,Fetal valproate spectrum disorder,Malformation syndrome,Prevalence at birth,1.3,1-9 / 100 000,Value and class,Switzerland,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1906,Fetal valproate spectrum disorder,Malformation syndrome,Prevalence at birth,1.2,1-9 / 100 000,Value and class,Germany,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1906,Fetal valproate spectrum disorder,Malformation syndrome,Prevalence at birth,1.3,1-9 / 100 000,Value and class,Ireland,Validated,29753923[PMID]_EUROCAT European surveillance of congenital anomalies 2005-2014[REG]
1895,Edinburgh malformation syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,2057251[PMID]
1895,Edinburgh malformation syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2057251[PMID]
1891,Intellectual disability-spasticity-ectrodactyly syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,8368260[PMID]
1891,Intellectual disability-spasticity-ectrodactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8368260[PMID]
1892,Ectrodactyly-polydactyly syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,7151304[PMID]
1892,Ectrodactyly-polydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7151304[PMID]
1816,Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,13867923[PMID]
1816,Leukomelanoderma-infantilism-intellectual disability-hypodontia-hypotrichosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_13867923[PMID]
1807,Focal facial dermal dysplasia type III,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1807,Focal facial dermal dysplasia type III,Clinical subtype,Cases/families,20.0,,Case(s),Worldwide,Validated,21931173[PMID]
1818,"Ectodermal dysplasia, trichoodontoonychial type",Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,3740884[PMID]
1818,"Ectodermal dysplasia, trichoodontoonychial type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3740884[PMID]
1883,Ectodermal dysplasia-sensorineural deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5422345[PMID]
1883,Ectodermal dysplasia-sensorineural deafness syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,5422345[PMID]
1882,Hypohidrotic ectodermal dysplasia-hypothyroidism-ciliary dyskinesia syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,7463217[PMID]_3944674[PMID]
1882,Hypohidrotic ectodermal dysplasia-hypothyroidism-ciliary dyskinesia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7463217[PMID]_3944674[PMID]
1875,Congenital muscular dystrophy-infantile cataract-hypogonadism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_13385309[PMID]
1875,Congenital muscular dystrophy-infantile cataract-hypogonadism syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,13385309[PMID]
1873,Jalili syndrome,Malformation syndrome,Point prevalence,8.3,1-9 / 100 000,Value and class,"Palestinian Territory, occupied",Validated,20706282[PMID]
1873,Jalili syndrome,Malformation syndrome,Cases/families,49.0,,Case(s),Worldwide,Validated,23362848[PMID]_20706282[PMID]_21728811[PMID]_[EXPERT]
1873,Jalili syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1879,Melorheostosis with osteopoikilosis,Malformation syndrome,Cases/families,5.0,,Family(ies),Worldwide,Validated,[EXPERT]
1879,Melorheostosis with osteopoikilosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1867,"Hereditary bullous dystrophy, macular type",Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,7943046[PMID]
1867,"Hereditary bullous dystrophy, macular type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7943046[PMID]
1872,Cone rod dystrophy,Disease,Point prevalence,2.5,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
1871,Progressive cone dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1860,Thanatophoric dysplasia type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1861,Thoracic dysplasia-hydrocephalus syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3295244[PMID]
1861,Thoracic dysplasia-hydrocephalus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3295244[PMID]
1865,"Dyssegmental dysplasia, Silverman-Handmaker type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20542149[PMID]
1858,Skeletal dysplasia-epilepsy-short stature syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,9916849[PMID]_1488978[PMID]_8882779[PMID]
1858,Skeletal dysplasia-epilepsy-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9916849[PMID]_1488978[PMID]_8882779[PMID]
254,Spondylometaphyseal dysplasia,Clinical group,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET
254,Spondylometaphyseal dysplasia,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1852,X-linked retinal dysplasia,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,7333018[PMID]
1852,X-linked retinal dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,7333018[PMID]_ORPHANET
1842,"Bone dysplasia, lethal Holmgren type",Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,3396596[PMID]
1842,"Bone dysplasia, lethal Holmgren type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3396596[PMID]
1839,Hereditary mucoepithelial dysplasia,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1837,"Metaphyseal chondrodysplasia, Rosenberg type",Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,3732330[PMID]
1837,"Metaphyseal chondrodysplasia, Rosenberg type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3732330[PMID]
1836,"Mesomelic dysplasia, Kantaputra type",Malformation syndrome,Cases/families,5.0,,Family(ies),Worldwide,Validated,15211647[PMID]_15264287[PMID]_1481840[PMID]_20577005[PMID]_21654727[PMID]
1836,"Mesomelic dysplasia, Kantaputra type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15211647[PMID]_15264287[PMID]_1481840[PMID]_20577005[PMID]_21654727[PMID]
1834,Axial mesodermal dysplasia spectrum,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_7243441[PMID]_26949683[PMID]
1830,Schimke immuno-osseous dysplasia,Disease,Cases/families,133.0,,Case(s),Worldwide,Validated,37051678[PMID]_ORPHANET
1830,Schimke immuno-osseous dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,37051678[PMID]_ORPHANET
1825,Epiphyseal dysplasia-hearing loss-dysmorphism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1642273[PMID]
1825,Epiphyseal dysplasia-hearing loss-dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1642273[PMID]
251,Multiple epiphyseal dysplasia,Clinical group,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
1811,Odontomicronychial dysplasia,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,8728698[PMID]
1811,Odontomicronychial dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8728698[PMID]
1812,Ectodermal dysplasia-intellectual disability-central nervous system malformation syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1808,"Hidrotic ectodermal dysplasia, Christianson-Fourie type",Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,8826433[PMID]
1808,"Hidrotic ectodermal dysplasia, Christianson-Fourie type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8826433[PMID]
1809,"Hidrotic ectodermal dysplasia, Halal type",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,2063897[PMID]
1809,"Hidrotic ectodermal dysplasia, Halal type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1806,Ectodermal dysplasia-blindness syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1583659[PMID]
1806,Ectodermal dysplasia-blindness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1583659[PMID]
1802,Ghosal hematodiaphyseal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
1803,Thoracomelic dysplasia,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,3184141[PMID]
1803,Thoracomelic dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3184141[PMID]
1798,Craniofacial dysostosis-diaphyseal hyperplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
1799,Familial developmental dysphasia,Clinical syndrome,Cases/families,6.0,,Family(ies),Worldwide,Validated,8031532[PMID]
1799,Familial developmental dysphasia,Clinical syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8031532[PMID]
1794,Oculomaxillofacial dysostosis,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,7856656[PMID]
1794,Oculomaxillofacial dysostosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7856656[PMID]
2130,Non-syndromic hemimelia,Clinical group,Point prevalence,4.15,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
2136,Hennekam syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,29560340[PMID]
2136,Hennekam syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,29560340[PMID]_ORPHANET
2138,"46,XX ovotesticular difference of sex development",Malformation syndrome,Cases/families,500.0,,Case(s),Worldwide,Validated,[EXPERT]_23926413[PMID]
2138,"46,XX ovotesticular difference of sex development",Malformation syndrome,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
2138,"46,XX ovotesticular difference of sex development",Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_[EXPERT]
2139,Hernández-Aguirre Negrete syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2141,Diaphragmatic defect-limb deficiency-skull defect syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,8779324[PMID]_19318925[PMID]_23448910[PMID]
2141,Diaphragmatic defect-limb deficiency-skull defect syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8779324[PMID]_19318925[PMID]_23448910[PMID]
2143,Donnai-Barrow syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
2143,Donnai-Barrow syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2145,"Craniosynostosis, Herrmann-Opitz type",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3300335[PMID]_5783388[PMID]
2145,"Craniosynostosis, Herrmann-Opitz type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3300335[PMID]_5783388[PMID]
2149,Nodular neuronal heterotopia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2148,Lissencephaly type 1 due to doublecortin gene mutation,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
158048,Hemophagocytic syndrome associated with an infection,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
158057,Acquired hemophagocytic lymphohistiocytosis associated with malignant disease,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2108,Hallermann-Streiff syndrome,Malformation syndrome,Cases/families,150.0,,Case(s),Worldwide,Validated,10388418[PMID]
2108,Hallermann-Streiff syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_10388418[PMID]
2108,Hallermann-Streiff syndrome,Malformation syndrome,Prevalence at birth,3.6,1-9 / 100 000,Value and class,Japan,Validated,2092586[PMID]
158061,Macrophage activation syndrome,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2107,Hall-Riggs syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,11185076[PMID]
2107,Hall-Riggs syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11185076[PMID]
2110,Hallux varus-preaxial polysyndactyly syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,6255798[PMID]
2110,Hallux varus-preaxial polysyndactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6255798[PMID]
2109,Hallermann-Streiff-like syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8585575[PMID]
2109,Hallermann-Streiff-like syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8585575[PMID]
2111,Cystic hamartoma of lung and kidney,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,3605206[PMID]
2111,Cystic hamartoma of lung and kidney,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3605206[PMID]
158266,Huntington disease-like syndrome,Clinical group,Point prevalence,1.85,1-9 / 100 000,Value and class,Brazil,Validated,35209917[PMID]
2115,Harrod syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,8669446[PMID]
2115,Harrod syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8669446[PMID]
2114,"Hip dysplasia, Beukes type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2994,Short stature-craniofacial anomalies-genital hypoplasia syndrome,Malformation syndrome,Cases/families,3.0,,Family(ies),Worldwide,Validated,10733241[PMID]
2994,Short stature-craniofacial anomalies-genital hypoplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10733241[PMID]
2117,Hartsfield syndrome,Malformation syndrome,Cases/families,35.0,,Case(s),Worldwide,Validated,23812909[PMID]_EXPERT
2117,Hartsfield syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,23812909[PMID]_ORPHANET
2119,HEC syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7747788[PMID]
2119,HEC syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7747788[PMID]
2123,Multifocal infantile hemangioma with extracutenous involvement,Malformation syndrome,Cases/families,70.0,,Case(s),Worldwide,Validated,ORPHANET
2123,Multifocal infantile hemangioma with extracutenous involvement,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
157997,Benign cephalic histiocytosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2090,GMS syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,1308345[PMID]
2090,GMS syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1308345[PMID]
157991,Generalized eruptive histiocytosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2091,Multinodular goiter-cystic kidney-polydactyly syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,4020555[PMID]
2091,Multinodular goiter-cystic kidney-polydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4020555[PMID]
376,Gordon syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2092,Focal dermal hypoplasia,Malformation syndrome,Cases/families,300.0,,Case(s),Worldwide,Validated,ORPHANET
2092,Focal dermal hypoplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
158000,Juvenile xanthogranuloma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Germany,Validated,22969141[PMID]
158000,Juvenile xanthogranuloma,Disease,Point prevalence,0.0225,<1 / 1 000 000,Value and class,Germany,Validated,22969141[PMID]_ORPHANET
2098,"Acromesomelic dysplasia, Grebe type",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
158025,Hereditary progressive mucinous histiocytosis,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,28556021[PMID]
158025,Hereditary progressive mucinous histiocytosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28556021[PMID]
380,Greig cephalopolysyndactyly syndrome,Malformation syndrome,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET_ 25297527[PMID]_[EXPERT]
380,Greig cephalopolysyndactyly syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
2095,Gorlin-Chaudhry-Moss syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,23686885[PMID]
2095,Gorlin-Chaudhry-Moss syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
158014,Rosaï-Dorfman disease,Disease,Cases/families,1000.0,,Case(s),Worldwide,Validated,21816647[PMID]
158014,Rosaï-Dorfman disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2097,Grant syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,3742858[PMID]
2097,Grant syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3742858[PMID]
2101,Grubben-de Cock-Borghgraef syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,1378778[PMID]
2101,Grubben-de Cock-Borghgraef syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1378778[PMID]
2104,Dysmorphism-pectus carinatum-joint laxity syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7438507[PMID]
2104,Dysmorphism-pectus carinatum-joint laxity syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7438507[PMID]
158032,Hemophagocytic syndrome,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
158032,Hemophagocytic syndrome,Category,Annual incidence,0.198,1-9 / 100 000,Value and class,United Kingdom,Validated,34875131[PMID]
158029,Sea-blue histiocytosis,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,ORPHANET
158029,Sea-blue histiocytosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2069,Gastrocutaneous syndrome,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,7065007[PMID]
2069,Gastrocutaneous syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7065007[PMID]
157846,Neuroferritinopathy,Disease,Cases/families,90.0,,Case(s),Worldwide,Validated,27022507[PMID]
157846,Neuroferritinopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27022507[PMID]
157832,Craniorhiny,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,1896543[PMID]_1897582[PMID]
157832,Craniorhiny,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1896543[PMID]_1897582[PMID]
2067,GAPO syndrome,Malformation syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,30575274[PMID]_29304326[PMID]_30255493[PMID]_31448094[PMID]
2067,GAPO syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
157835,Paroxysmal hemicrania,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,[EXPERT]_29720814[PMID]
2065,Galloway-Mowat syndrome,Malformation syndrome,Cases/families,159.0,,Case(s),Worldwide,Validated,33791874[PMID]_ORPHANET
2065,Galloway-Mowat syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,33791874[PMID]_ORPHANET
2075,Genitopalatocardiac syndrome,Malformation syndrome,Cases/families,15.0,,Case(s),Worldwide,Validated,19283856[PMID]
2075,Genitopalatocardiac syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19283856[PMID]
2074,Gemignani syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3958822[PMID]
2074,Gemignani syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3958822[PMID]
157850,Pantothenate kinase-associated neurodegeneration,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Europe,Validated,22027213[PMID]_[EXPERT]_ ORPHANET
2072,Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
2072,Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
157954,ANE syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,18439547[PMID]
157954,ANE syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18439547[PMID]
157962,"Oculoauricular syndrome, Schorderet type",Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,18423520[PMID]_25574057[PMID]
157962,"Oculoauricular syndrome, Schorderet type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18423520[PMID]_25574057[PMID]
157946,Huntington disease-like 3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2078,Geroderma osteodysplastica,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,18304158[PMID]
2078,Geroderma osteodysplastica,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2077,German syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,3812590[PMID]
2077,German syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3812590[PMID]
157973,Congenital muscular dystrophy due to LMNA mutation,Disease,Cases/families,23.0,,Case(s),Worldwide,Validated,28125586[PMID]
157973,Congenital muscular dystrophy due to LMNA mutation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28125586[PMID]
2085,Glaucoma-sleep apnea syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,7164003[PMID]
2085,Glaucoma-sleep apnea syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7164003[PMID]
2084,Glaucoma-ectopia lentis-microspherophakia-stiff joints-short stature syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,1519650[PMID]
2084,Glaucoma-ectopia lentis-microspherophakia-stiff joints-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1519650[PMID]
157965,SLC39A13-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Cases/families,8.0,,Case(s),Worldwide,Validated,18513683[PMID]_18985159[PMID]
157965,SLC39A13-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18513683[PMID]_18985159[PMID]
2083,Prominent glabella-microcephaly-hypogenitalism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2705483[PMID]
2083,Prominent glabella-microcephaly-hypogenitalism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2705483[PMID]
1791,Frontofacionasal dysplasia,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,26495166[PMID]
1791,Frontofacionasal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26495166[PMID]
1826,Frontometaphyseal dysplasia,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
1826,Frontometaphyseal dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2047,Flynn-Aird syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,5878601[PMID]
2047,Flynn-Aird syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5878601[PMID]
2048,Foix-Chavany-Marie syndrome,Malformation syndrome,Cases/families,150.0,,Case(s),Worldwide,Validated,ORPHANET
2048,Foix-Chavany-Marie syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2050,Cole-Carpenter syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,25683117[PMID]
2050,Cole-Carpenter syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25683117[PMID]
2063,Splenogonadal fusion-limb defects-micrognathia syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,10494091[PMID]_12884431[PMID]
2063,Splenogonadal fusion-limb defects-micrognathia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10494091[PMID]_12884431[PMID]
2064,Posterior fusion of lumbosacral vertebrae-blepharoptosis syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,5443339[PMID]
2064,Posterior fusion of lumbosacral vertebrae-blepharoptosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5443339[PMID]
250,Frontonasal dysplasia,Clinical group,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
250,Frontonasal dysplasia,Clinical group,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
2057,Blepharophimosis-ptosis-esotropia-syndactyly-short stature syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,1311991[PMID]
2057,Blepharophimosis-ptosis-esotropia-syndactyly-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1311991[PMID]
2059,Fryns syndrome,Malformation syndrome,Prevalence at birth,7.0,1-9 / 100 000,Value and class,France,Validated,2650934[PMID]
2059,Fryns syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2059,Fryns syndrome,Malformation syndrome,Prevalence at birth,7.0,1-9 / 100 000,Value and class,Europe,Validated,2650934[PMID]
2026,Gingival fibromatosis-hypertrichosis syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2025,Gingival fibromatosis-facial dysmorphism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1493643[PMID]
2025,Gingival fibromatosis-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1493643[PMID]
2028,Juvenile hyaline fibromatosis,Clinical subtype,Cases/families,70.0,,Case(s),Worldwide,Validated,DOI: 10.1016/j.jdds.2014.06.003[OTHER]
2028,Juvenile hyaline fibromatosis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_DOI: 10.1016/j.jdds.2014.06.003[OTHER]
2027,Gingival fibromatosis-progressive deafness syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,4061496[PMID]
2027,Gingival fibromatosis-progressive deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4061496[PMID]
2021,Fibrochondrogenesis,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,24127948[PMID]
2021,Fibrochondrogenesis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24127948[PMID]
2019,Femur-fibula-ulna complex,Malformation syndrome,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
2019,Femur-fibula-ulna complex,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
2024,Hereditary gingival fibromatosis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,26818898[PMID]
2022,Endocardial fibroelastosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2824,Paraplegia-intellectual disability-hyperkeratosis syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,23613454[PMID]
2824,Paraplegia-intellectual disability-hyperkeratosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2045,FLOTCH syndrome,Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,24816854[PMID]
2045,FLOTCH syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24816854[PMID]
2044,Floating-Harbor syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_30425916[PMID]
2031,Hepatic fibrosis-renal cysts-intellectual disability syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,3085498[PMID]_4430157[PMID]
2031,Hepatic fibrosis-renal cysts-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3085498[PMID]_4430157[PMID]
2036,Scalp-ear-nipple syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
2036,Scalp-ear-nipple syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2006,Median cleft lip/mandible,Morphological anomaly,Cases/families,70.0,,Case(s),Worldwide,Validated,ORPHANET
2006,Median cleft lip/mandible,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2007,Alar cartilages hypoplasia-coloboma-telecanthus syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1273139[PMID]
2007,Alar cartilages hypoplasia-coloboma-telecanthus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1273139[PMID]
2003,Cleft lip/palate-deafness-sacral lipoma syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2002486[PMID]
2003,Cleft lip/palate-deafness-sacral lipoma syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2002486[PMID]
158687,Lethal acantholytic erosive disorder,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,20613772[PMID]_20302578[PMID]
158687,Lethal acantholytic erosive disorder,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20613772[PMID]_20302578[PMID]
158684,Epidermolysis bullosa simplex with pyloric atresia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2004,Laryngotracheoesophageal cleft,Morphological anomaly,Prevalence at birth,7.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
2004,Laryngotracheoesophageal cleft,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2001,Cleft lip/palate-intestinal malrotation-cardiopathy syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,8779326[PMID]_9415467[PMID]
2001,Cleft lip/palate-intestinal malrotation-cardiopathy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8779326[PMID]_9415467[PMID]
158681,Epidermolysis bullosa simplex with circinate migratory erythema,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
158676,"Localized dystrophic epidermolysis bullosa, nails only",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
158676,"Localized dystrophic epidermolysis bullosa, nails only",Clinical subtype,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
158673,"Localized dystrophic epidermolysis bullosa, acral form",Clinical subtype,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
158673,"Localized dystrophic epidermolysis bullosa, acral form",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
158668,Ectodermal dysplasia-skin fragility syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2016,Cleft palate-lateral synechia syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,19368978[PMID]_24163560[PMID]
2016,Cleft palate-lateral synechia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2017,Sternal cleft,Morphological anomaly,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
2017,Sternal cleft,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
2013,Cleft palate-large ears-small head syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,10449654[PMID]
2013,Cleft palate-large ears-small head syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10449654[PMID]
2010,Cleft palate-stapes fixation-oligodontia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,5173249[PMID]
2010,Cleft palate-stapes fixation-oligodontia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5173249[PMID]
158775,Smoldering systemic mastocytosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
2008,Acrocardiofacial syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,20920258[PMID]_1746602[PMID]_15937946[PMID]
2008,Acrocardiofacial syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20920258[PMID]
1986,Gollop-Wolfgang complex,Malformation syndrome,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET_[EXPERT]
1986,Gollop-Wolfgang complex,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
1980,Bilateral striopallidodentate calcinosis,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,9065541[PMID]
1980,Bilateral striopallidodentate calcinosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1997,Blepharo-cheilo-odontic syndrome,Malformation syndrome,Cases/families,55.0,,Case(s),Worldwide,Validated,EXPERT_24719364[PMID]_28181393[PMID]
1997,Blepharo-cheilo-odontic syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,EXPERT_ORPHANET
1995,Cleft lip-retinopathy syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8905195[PMID]
1995,Cleft lip-retinopathy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1993,Pai syndrome,Malformation syndrome,Cases/families,67.0,,Case(s),Worldwide,Validated,30195458[PMID]
1993,Pai syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30195458[PMID]
1988,Femoral-facial syndrome,Malformation syndrome,Cases/families,62.0,,Case(s),Worldwide,Validated,25210574[PMID]
1988,Femoral-facial syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25210574[PMID]
2348,"Familial partial lipodystrophy, Dunnigan type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
247775,Mayer-Rokitansky-Küster-Hauser syndrome type 1,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,ORPHANET
2351,Kousseff syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,22380655[PMID]
2351,Kousseff syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22380655[PMID]
247768,Müllerian aplasia and hyperandrogenism,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2353,Schilbach-Rott syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,19921646[PMID]
2353,Schilbach-Rott syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19921646[PMID]
247790,FTH1-related iron overload,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,11389486[PMID]
247790,FTH1-related iron overload,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11389486[PMID]
247794,Juvenile cataract-microcornea-renal glucosuria syndrome,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,18304496[PMID]
247794,Juvenile cataract-microcornea-renal glucosuria syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18304496[PMID]
247815,Autosomal recessive ataxia due to PEX10 deficiency,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,27230853[PMID]
247815,Autosomal recessive ataxia due to PEX10 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27230853[PMID]
2363,Lacrimoauriculodentodigital syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,23010692[PMID]_Pr MANOUVRIER-HANU Sylvie[EXPERT]
2363,Lacrimoauriculodentodigital syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23010692[PMID]
247691,Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2340,Keratosis follicularis spinulosa decalvans,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
247685,Odontohypophosphatasia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2342,Haim-Munk syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
2342,Haim-Munk syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
247709,Multiple endocrine neoplasia type 2B,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
485,Kniest dysplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
247762,Lipoblastoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2347,Lethal Kniest-like dysplasia,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,6358440[PMID]
2347,Lethal Kniest-like dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6358440[PMID]
247585,Citrullinemia type II,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2333,Kenny-Caffey syndrome,Malformation syndrome,Cases/families,65.0,,Case(s),Worldwide,Validated,22522175[PMID]
2333,Kenny-Caffey syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
247598,Neonatal intrahepatic cholestasis due to citrin deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2332,KBG syndrome,Malformation syndrome,Cases/families,164.0,,Case(s),Worldwide,Validated,21782149[PMID]_29565525[PMID]
2332,KBG syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
247604,Juvenile primary lateral sclerosis,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,ORPHANET
247604,Juvenile primary lateral sclerosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
247623,Perinatal lethal hypophosphatasia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
247638,Prenatal benign hypophosphatasia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2337,"Diffuse palmoplantar keratoderma, Bothnian type",Disease,Point prevalence,2.5,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
247651,Infantile hypophosphatasia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
247667,Childhood-onset hypophosphatasia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2339,Keratosis follicularis-dwarfism-cerebral atrophy syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,4834251[PMID]
2339,Keratosis follicularis-dwarfism-cerebral atrophy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4834251[PMID]
247676,Adult hypophosphatasia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
494,Keratoderma hereditarium mutilans,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,19282408[PMID]
494,Keratoderma hereditarium mutilans,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19282408[PMID]
2322,Kabuki syndrome,Malformation syndrome,Prevalence at birth,1.16,1-9 / 100 000,Value and class,New Zealand,Validated,15108197[PMID]
2322,Kabuki syndrome,Malformation syndrome,Prevalence at birth,1.16,1-9 / 100 000,Value and class,Australia,Validated,15108197[PMID]
2322,Kabuki syndrome,Malformation syndrome,Point prevalence,3.1,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_21882399[PMID]
2322,Kabuki syndrome,Malformation syndrome,Prevalence at birth,3.1,1-9 / 100 000,Value and class,Japan,Validated,3067577[PMID]
247378,Autosomal recessive secondary polycythemia not associated with VHL gene,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2321,Jung syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7537583[PMID]
2321,Jung syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7537583[PMID]
2324,Osteopenia-intellectual disability-sparse hair syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1415349[PMID]
2324,Osteopenia-intellectual disability-sparse hair syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1415349[PMID]
247511,Autosomal dominant secondary polycythemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2323,Sanjad-Sakati syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
247522,Primary ciliary dyskinesia-retinitis pigmentosa syndrome,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
247522,Primary ciliary dyskinesia-retinitis pigmentosa syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
247525,Citrullinemia type I,Disease,Point prevalence,2.4,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
247525,Citrullinemia type I,Disease,Prevalence at birth,1.28,1-9 / 100 000,Value and class,Austria,Validated,20938748[PMID]
247525,Citrullinemia type I,Disease,Prevalence at birth,4.5,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,15906713[PMID]
247525,Citrullinemia type I,Disease,Prevalence at birth,0.84,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,20567911[PMID]
247525,Citrullinemia type I,Disease,Prevalence at birth,1.13,1-9 / 100 000,Value and class,United States,Not yet validated,ISBN:79130356[OTHER]_15906712[PMID]_ ORPHANET
2325,Epidermolysis bullosa simplex with anodontia/hypodontia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2325,Epidermolysis bullosa simplex with anodontia/hypodontia,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,2420118[PMID]_7911628[PMID]_25251718[PMID]
2329,Karsch-Neugebauer syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,9450888[PMID]_23066244[PMID]
2329,Karsch-Neugebauer syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9450888[PMID]_23066244[PMID]
247582,Citrin deficiency,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2328,Kapur-Toriello syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,1776630[PMID]_10319207[PMID]_18831061[PMID]_20358618[PMID]_26049588[PMID]
2328,Kapur-Toriello syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1776630[PMID]_10319207[PMID]_18831061[PMID]_20358618[PMID]_26049588[PMID]
2408,Lowe-Kohn-Cohen syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,6627722[PMID]
2408,Lowe-Kohn-Cohen syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6627722[PMID]
2409,Lowry-MacLean syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,9415481[PMID]
2409,Lowry-MacLean syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9415481[PMID]
2405,Thickened earlobes-conductive deafness syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,5657116[PMID]_5428055[PMID]
2405,Thickened earlobes-conductive deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5657116[PMID]_5428055[PMID]
2407,Laryngo-onycho-cutaneous syndrome,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
2407,Laryngo-onycho-cutaneous syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2412,Dislocation of the hip-dysmorphism syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,8574416[PMID]
2412,Dislocation of the hip-dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8574416[PMID]
2575,Cystic fibrosis-gastritis-megaloblastic anemia syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,2029916[PMID]
2575,Cystic fibrosis-gastritis-megaloblastic anemia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2029916[PMID]
2410,Hypergonadotropic hypogonadism-cataract syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,6418006[PMID]
2410,Hypergonadotropic hypogonadism-cataract syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6418006[PMID]
2399,Nasopalpebral lipoma-coloboma syndrome,Malformation syndrome,Cases/families,19.0,,Case(s),Worldwide,Validated,27139419[PMID]_ORPHANET
2399,Nasopalpebral lipoma-coloboma syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2400,Peripheral motor neuropathy-dysautonomia syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,7282784[PMID]
2400,Peripheral motor neuropathy-dysautonomia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7282784[PMID]
2396,Encephalocraniocutaneous lipomatosis,Disease,Cases/families,77.0,,Case(s),Worldwide,Validated,24881613[PMID]
2396,Encephalocraniocutaneous lipomatosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2388,Choreoacanthocytosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
248111,Juvenile Huntington disease,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
248111,Juvenile Huntington disease,Disease,Point prevalence,0.6,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
2386,Leukoencephalopathy-palmoplantar keratoderma syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,7854535[PMID]
2386,Leukoencephalopathy-palmoplantar keratoderma syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7854535[PMID]
248095,Primary hypertrophic osteoarthropathy,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2379,Early-onset parkinsonism-intellectual disability syndrome,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,4025396[PMID]_25434005[PMID]
2379,Early-onset parkinsonism-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4025396[PMID]_25434005[PMID]
2391,Congenitally short costocoracoid ligament,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,2596500[PMID]
2391,Congenitally short costocoracoid ligament,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2596500[PMID]
2390,Lichtenstein syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,Lichtenstein 1972[AUTHOR]
2390,Lichtenstein syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
247834,Occult macular dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2371,Lethal Larsen-like syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,19014058[PMID]
2371,Lethal Larsen-like syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19014058[PMID]
2369,Limb body wall complex,Malformation syndrome,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Australia,Validated,12420845[PMID]
2369,Limb body wall complex,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
2369,Limb body wall complex,Malformation syndrome,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Japan,Validated,8092190[PMID]
247820,Ectodermal dysplasia-pili torti-cutaneous syndactyly syndrome,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,25529316[PMID]
247820,Ectodermal dysplasia-pili torti-cutaneous syndactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25529316[PMID]
247827,Ectodermal dysplasia-hyperhidrosis-cutaneous syndactyly syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,19221800[PMID]
247827,Ectodermal dysplasia-hyperhidrosis-cutaneous syndactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19221800[PMID]
2378,Laurin-Sandrow syndrome,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,18792985[PMID]
2378,Laurin-Sandrow syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18792985[PMID]
247868,NLRP12-associated hereditary periodic fever syndrome,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,24131530[PMID]
247868,NLRP12-associated hereditary periodic fever syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24131530[PMID]
2375,Laryngeal abductor paralysis-intellectual disability syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
2375,Laryngeal abductor paralysis-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2457,Mandibuloacral dysplasia,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,24123119[PMID]
2457,Mandibuloacral dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24123119[PMID]
2451,Mucocutaneous venous malformations,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2439,Patterson-Stevenson-Fontaine syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,9098499[PMID]
2439,Patterson-Stevenson-Fontaine syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9098499[PMID]
244305,Dominant hypophosphatemia with nephrolithiasis or osteoporosis,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,12324554[PMID]_18784102[PMID]_26787776[PMID]_29924459[PMID]
244305,Dominant hypophosphatemia with nephrolithiasis or osteoporosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29924459[PMID]
244283,Biliary atresia with splenic malformation syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2440,Isolated split hand-split foot malformation,Malformation syndrome,Prevalence at birth,5.4,1-9 / 100 000,Value and class,Europe,Validated,8766141[PMID]_EUROCAT European surveillance of congenital anomalies[REG]
2440,Isolated split hand-split foot malformation,Malformation syndrome,Prevalence at birth,16.4,1-5 / 10 000,Value and class,China,Validated,20506663[PMID]
2440,Isolated split hand-split foot malformation,Malformation syndrome,Prevalence at birth,5.1,1-9 / 100 000,Value and class,Canada,Validated,20506663[PMID]
2440,Isolated split hand-split foot malformation,Malformation syndrome,Prevalence at birth,6.0,1-9 / 100 000,Value and class,Hungary,Validated,ISBN:9630566311[OTHER]
2440,Isolated split hand-split foot malformation,Malformation syndrome,Prevalence at birth,6.0,1-9 / 100 000,Value and class,United States,Validated,11581472[PMID]
2440,Isolated split hand-split foot malformation,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
244310,RFT1-CDG,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,23111317[PMID]
244310,RFT1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23111317[PMID]
244242,HELLP syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
296,Ollier disease,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,16995932[PMID]
2437,Czeizel-Losonci syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3308683[PMID]
2437,Czeizel-Losonci syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3308683[PMID]
244275,De novo thrombotic microangiopathy after kidney transplantation,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
243343,Dimethylglycine dehydrogenase deficiency,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,10102904[PMID]
243343,Dimethylglycine dehydrogenase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10102904[PMID]
2435,Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,666331[PMID]
2435,Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_666331[PMID]
2429,Macrocephaly-spastic paraplegia-dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2432,Macrosomia-microphthalmia-cleft palate syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,2791331[PMID]
2432,Macrosomia-microphthalmia-cleft palate syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2791331[PMID]
2489,Upper limb defect-eye and ear abnormalities syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1518028[PMID]
2489,Upper limb defect-eye and ear abnormalities syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1518028[PMID]
247353,Generalized pustular psoriasis,Disease,Point prevalence,0.18,1-9 / 1 000 000,Value and class,France,Validated,17229609[PMID]
247353,Generalized pustular psoriasis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
247262,Hyperphosphatasia-intellectual disability syndrome,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,ORPHANET
247262,Hyperphosphatasia-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2487,Lower limb malformation-hypospadias syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,592351[PMID]
2487,Lower limb malformation-hypospadias syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_592351[PMID]
247257,Inhalational anthrax,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2018[INST]
247245,Superficial siderosis,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,20083040[PMID]
247245,Superficial siderosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2485,Melorheostosis,Malformation syndrome,Point prevalence,0.09,<1 / 1 000 000,Value and class,Europe,Validated,9040882[PMID]
247234,Sporadic adult-onset ataxia of unknown etiology,Disease,Point prevalence,7.6,1-9 / 100 000,Value and class,Europe,Not yet validated,20083040[PMID]
247234,Sporadic adult-onset ataxia of unknown etiology,Disease,Point prevalence,6.9,1-9 / 100 000,Value and class,Italy,Validated,7793232[PMID]
247234,Sporadic adult-onset ataxia of unknown etiology,Disease,Point prevalence,8.4,1-9 / 100 000,Value and class,United Kingdom,Validated,15258214[PMID]
2483,Melkersson-Rosenthal syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
247203,Collecting duct carcinoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2484,Melnick-Needles syndrome,Malformation syndrome,Cases/families,70.0,,Case(s),Worldwide,Validated,ORPHANET
2484,Melnick-Needles syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
247198,Progressive cerebello-cerebral atrophy,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,12920088[PMID]_25044680[PMID]
247198,Progressive cerebello-cerebral atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12920088[PMID]_25044680[PMID]
2481,Neurocutaneous melanocytosis,Disease,Point prevalence,1.25,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
2482,Melhem-Fahl syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3969298[PMID]
2482,Melhem-Fahl syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3969298[PMID]
247165,Infantile mercury poisoning,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2475,White forelock with malformations,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7398117[PMID]
2475,White forelock with malformations,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7398117[PMID]
2476,Dysraphism-cleft lip/palate-limb reduction defects syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,7981865[PMID]
2476,Dysraphism-cleft lip/palate-limb reduction defects syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7981865[PMID]
2473,McKusick-Kaufman syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301675[PMID]
2473,McKusick-Kaufman syndrome,Malformation syndrome,Cases/families,90.0,,Case(s),Worldwide,Validated,20301675[PMID]
2473,McKusick-Kaufman syndrome,Malformation syndrome,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Specific population,Validated,20301675[PMID]
2471,McDonough syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,6147215[PMID]_1189520[PMID]
2471,McDonough syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6147215[PMID]_1189520[PMID]
2470,Matthew-Wood syndrome,Malformation syndrome,Cases/families,43.0,,Case(s),Worldwide,Validated,26373900[PMID]
2470,Matthew-Wood syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26373900[PMID]
561,Marshall-Smith syndrome,Malformation syndrome,Cases/families,74.0,,Case(s),Worldwide,Validated,34925682[PMID]_ORPHANET
561,Marshall-Smith syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2464,"Marfanoid syndrome, De Silva type",Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,13880014[PMID]_8976669[PMID]
2464,"Marfanoid syndrome, De Silva type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_13880014[PMID]_8976669[PMID]
559,Marinesco-Sjögren syndrome,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
559,Marinesco-Sjögren syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2463,Marfanoid habitus-autosomal recessive intellectual disability syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,6705253[PMID]
2463,Marfanoid habitus-autosomal recessive intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6705253[PMID]
2462,Shprintzen-Goldberg syndrome,Malformation syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,20301454[PMID]
2462,Shprintzen-Goldberg syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301454[PMID]
2461,Marden-Walker syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
2461,Marden-Walker syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2461,Marden-Walker syndrome,Malformation syndrome,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Belgium,Validated,[EXPERT]
251630,Anaplastic oligodendroglioma,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
251630,Anaplastic oligodendroglioma,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2172,Microcephaly-glomerulonephritis-marfanoid habitus syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1345513[PMID]
2172,Microcephaly-glomerulonephritis-marfanoid habitus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1345513[PMID]
251636,Ependymoma,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
251636,Ependymoma,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
251639,Subependymoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2176,Infantile systemic hyalinosis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25754064[PMID]
251643,Myxopapillary ependymoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
251643,Myxopapillary ependymoma,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
251646,Anaplastic ependymoma,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,United States,Validated,23660944[PMID]
251651,Oligoastrocytic tumor,Clinical group,Annual incidence,0.11,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
251651,Oligoastrocytic tumor,Clinical group,Annual incidence,0.19,1-9 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2181,Hydrocephaly-tall stature-joint laxity syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2918526[PMID]
2181,Hydrocephaly-tall stature-joint laxity syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2918526[PMID]
2180,Hydrocephalus-costovertebral dysplasia-Sprengel anomaly syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,8585573[PMID]_6893487[PMID]
2180,Hydrocephalus-costovertebral dysplasia-Sprengel anomaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8585573[PMID]_6893487[PMID]
2186,Hydrocephalus-blue sclerae-nephropathy syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,728573[PMID]
2186,Hydrocephalus-blue sclerae-nephropathy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_728573[PMID]
251671,Angiocentric glioma,Disease,Cases/families,52.0,,Case(s),Worldwide,Validated,24348765[PMID]
251671,Angiocentric glioma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,24348765[PMID]
2189,Hydrolethalus,Malformation syndrome,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Finland,Validated,11152149[PMID]
2189,Hydrolethalus,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Finland,Not yet validated,11152149[PMID]
2189,Hydrolethalus,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
251679,Astroblastoma,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
312,Autosomal dominant epidermolytic ichthyosis,Disease,Point prevalence,0.4317,1-9 / 1 000 000,Value and class,Japan,Validated,23182068[PMID]
312,Autosomal dominant epidermolytic ichthyosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
312,Autosomal dominant epidermolytic ichthyosis,Disease,Point prevalence,0.29,1-9 / 1 000 000,Value and class,Denmark,Validated,22930352[PMID]
312,Autosomal dominant epidermolytic ichthyosis,Disease,Point prevalence,0.65,1-9 / 1 000 000,Value and class,United States,Not yet validated,8053700[PMID]_7692917[PMID]_ ORPHANET
312,Autosomal dominant epidermolytic ichthyosis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2196,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement,Clinical subtype,Cases/families,72.0,,Case(s),Worldwide,Validated,[EXPERT]
2196,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis with severe ocular involvement,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
251852,Embryonal tumor of neuroepithelial tissue,Category,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
251576,Gliosarcoma,Histopathological subtype,Annual incidence,0.03,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2150,Hirschsprung disease-type D brachydactyly syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,6823428[PMID]
2150,Hirschsprung disease-type D brachydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6823428[PMID]
251582,Gliomatosis cerebri,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
251579,Giant cell glioblastoma,Histopathological subtype,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2152,Mowat-Wilson syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,35646055[PMID]_ORPHANET
2152,Mowat-Wilson syndrome,Malformation syndrome,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Europe,Validated,21343952[PMID]_20301585[PMID]_ ISBN:470191414[OTHER]
2153,Hirschsprung disease-nail hypoplasia-dysmorphism syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3236354[PMID]
2153,Hirschsprung disease-nail hypoplasia-dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
251589,Anaplastic astrocytoma,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
251598,Protoplasmic astrocytoma,Histopathological subtype,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2155,Hirschsprung disease-deafness-polydactyly syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3351909[PMID]
2155,Hirschsprung disease-deafness-polydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3351909[PMID]
251595,Diffuse astrocytoma,Disease,Annual incidence,0.48,1-9 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2158,Histidinuria-renal tubular defect syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,1481808[PMID]
2158,Histidinuria-renal tubular defect syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1481808[PMID]
251612,Pilocytic astrocytoma,Disease,Annual incidence,0.36,1-9 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2163,Holoprosencephaly-craniosynostosis syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,20104614[PMID]
2163,Holoprosencephaly-craniosynostosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20104614[PMID]
251607,Pleomorphic xanthoastrocytoma,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2165,Holoprosencephaly-caudal dysgenesis syndrome,Malformation syndrome,Prevalence at birth,0.9,1-9 / 1 000 000,Value and class,Spain,Validated,7802035[PMID]
2165,Holoprosencephaly-caudal dysgenesis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Spain,Validated,ORPHANET
2166,Holoprosencephaly-postaxial polydactyly syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
251627,Oligodendroglioma,Disease,Annual incidence,0.25,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2167,Holzgreve syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,6741992[PMID]_3309184[PMID]_3232694[PMID]
2167,Holzgreve syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6741992[PMID]_3309184[PMID]_3232694[PMID]
2169,Methylcobalamin deficiency type cblE,Clinical subtype,Cases/families,27.0,,Case(s),Worldwide,Validated,ORPHANET
2169,Methylcobalamin deficiency type cblE,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2222,Hypertrichosis lanuginosa congenita,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
2222,Hypertrichosis lanuginosa congenita,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2220,Hypertrichosis cubiti,Malformation syndrome,Cases/families,28.0,,Case(s),Worldwide,Validated,16355816[PMID]
2220,Hypertrichosis cubiti,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1051,Ramos-Arroyo syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,21910235[PMID]
1051,Ramos-Arroyo syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2228,Hypodontia-dysplasia of nails syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2224,Hypertryptophanemia,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,[EXPERT]
2224,Hypertryptophanemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2232,Primary hypergonadotropic hypogonadism-partial alopecia syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,19213036[PMID]
2232,Primary hypergonadotropic hypogonadism-partial alopecia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19213036[PMID]
2230,Hypogonadotropic hypogonadism-frontoparietal alopecia syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,466617[PMID]
2230,Hypogonadotropic hypogonadism-frontoparietal alopecia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_466617[PMID]
2229,Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome,Malformation syndrome,Cases/families,20.0,,Family(ies),Worldwide,Validated,ORPHANET
2229,Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2238,Familial isolated hypoparathyroidism,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
2238,Familial isolated hypoparathyroidism,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2237,Hypoparathyroidism-sensorineural deafness-renal disease syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29663634[PMID]
2237,Hypoparathyroidism-sensorineural deafness-renal disease syndrome,Malformation syndrome,Cases/families,180.0,,Case(s),Worldwide,Validated,29663634[PMID]
2235,Hypogonadotropic hypogonadism-retinitis pigmentosa syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,6795223[PMID]
2235,Hypogonadotropic hypogonadism-retinitis pigmentosa syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6795223[PMID]
2234,Male hypergonadotropic hypogonadism-intellectual disability-skeletal anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,13030490[PMID]
2234,Male hypergonadotropic hypogonadism-intellectual disability-skeletal anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_13030490[PMID]
251863,Desmoplastic/nodular medulloblastoma,Histopathological subtype,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2198,Palmoplantar keratoderma-esophageal carcinoma syndrome,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
2198,Palmoplantar keratoderma-esophageal carcinoma syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2206,Ankylosing vertebral hyperostosis with tylosis,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,5346342[PMID]
2206,Ankylosing vertebral hyperostosis with tylosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5346342[PMID]
2201,Palmoplantar keratoderma-spastic paralysis syndrome,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,6227331[PMID]
2201,Palmoplantar keratoderma-spastic paralysis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6227331[PMID]
2202,Palmoplantar keratoderma-deafness syndrome,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
2202,Palmoplantar keratoderma-deafness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
251870,Central nervous system embryonal tumor,Clinical group,Annual incidence,0.07,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
251899,Choroid plexus carcinoma,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,2033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
251899,Choroid plexus carcinoma,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,2033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
251899,Choroid plexus carcinoma,Disease,Lifetime Prevalence,0.35,1-9 / 1 000 000,Value and class,Europe,Validated,2033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
2213,Hypertelorism-microtia-facial clefting syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,11152141[PMID]
2213,Hypertelorism-microtia-facial clefting syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11152141[PMID]
251896,Choroid plexus tumor,Clinical group,Annual incidence,0.05,<1 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2211,Hypertelorism-hypospadias-polysyndactyly syndrome,Malformation syndrome,Cases/families,3.0,,Family(ies),Worldwide,Validated,18553510[PMID]
2211,Hypertelorism-hypospadias-polysyndactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18553510[PMID]
2218,Cervical hypertrichosis-peripheral neuropathy syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,1666396[PMID]_8281287[PMID]
2218,Cervical hypertrichosis-peripheral neuropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1666396[PMID]_8281287[PMID]
251909,Pineoblastoma,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
2215,Multiple pterygium-malignant hyperthermia syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,3346884[PMID]
2215,Multiple pterygium-malignant hyperthermia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3346884[PMID]
251019,2q32q33 microdeletion syndrome,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,[EXPERT]
251019,2q32q33 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2266,"Hypotrichosis-intellectual disability, Lopes type",Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,8652088[PMID]
2266,"Hypotrichosis-intellectual disability, Lopes type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8652088[PMID]
251028,SATB2-associated syndrome due to a chromosomal rearrangement,Etiological subtype,Cases/families,20.0,,Case(s),Worldwide,Validated,21343628[PMID]
251028,SATB2-associated syndrome due to a chromosomal rearrangement,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2269,Ichthyosis-alopecia-eclabion-ectropion-intellectual disability syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,3829441[PMID]
2269,Ichthyosis-alopecia-eclabion-ectropion-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3829441[PMID]
251038,3q29 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
250999,1q41q42 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2261,"Hypospadias-intellectual disability, Goldblatt type syndrome",Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3673966[PMID]
2261,"Hypospadias-intellectual disability, Goldblatt type syndrome",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3673966[PMID]
251004,Paternal uniparental disomy of chromosome 1 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
251009,Maternal uniparental disomy of chromosome 1 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
672,Pallister-Hall syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,20301638[PMID]
672,Pallister-Hall syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301638[PMID]
251014,2q31.1 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
455,Superficial epidermolytic ichthyosis,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
455,Superficial epidermolytic ichthyosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
251061,7q31 microdeletion syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,27075776[PMID]
251061,7q31 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27075776[PMID]
251066,8p11.2 deletion syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,15948194[PMID]
251066,8p11.2 deletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15948194[PMID]
2272,Ichthyosis-oral and digital anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2732996[PMID]
2272,Ichthyosis-oral and digital anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2732996[PMID]
251071,8p23.1 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2274,Ichthyosis-hepatosplenomegaly-cerebellar degeneration syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,444432[PMID]
2274,Ichthyosis-hepatosplenomegaly-cerebellar degeneration syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_444432[PMID]
251076,8p23.1 duplication syndrome,Malformation syndrome,Point prevalence,1.72,1-9 / 100 000,Value and class,Worldwide,Validated,23345203[PMID]
2273,Ichthyosis follicularis-alopecia-photophobia syndrome,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,21600032[PMID]
2273,Ichthyosis follicularis-alopecia-photophobia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
251043,Ring chromosome 5 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
165,Neutral lipid storage disease,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
165,Neutral lipid storage disease,Clinical group,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
139,CHILD syndrome,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,20929975[PMID]
139,CHILD syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
251046,6p22 microdeletion syndrome,Malformation syndrome,Cases/families,19.0,,Case(s),Worldwide,Validated,23294540[PMID]
251046,6p22 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
457,Harlequin ichthyosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24920541[PMID]
457,Harlequin ichthyosis,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,24920541[PMID]
2271,Congenital ichthyosis-microcephalus-tetraplegia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7619196[PMID]
2271,Congenital ichthyosis-microcephalus-tetraplegia syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,7619196[PMID]
251056,6q25.2q25.3 microdeletion syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,19034313[PMID]
251056,6q25.2q25.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19034313[PMID]
2246,Cerebellar hypoplasia-tapetoretinal degeneration syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,1622524[PMID]
2246,Cerebellar hypoplasia-tapetoretinal degeneration syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1622524[PMID]
2249,Ulna hypoplasia-intellectual disability syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7625433[PMID]
2249,Ulna hypoplasia-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7625433[PMID]
2239,Familial isolated hypoparathyroidism due to agenesis of parathyroid gland,Clinical subtype,Cases/families,2.0,,Family(ies),Worldwide,Validated,14431322[PMID]_8981958[PMID]
2239,Familial isolated hypoparathyroidism due to agenesis of parathyroid gland,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14431322[PMID]_8981958[PMID]
2241,Megacystis-microcolon-intestinal hypoperistalsis syndrome,Malformation syndrome,Cases/families,230.0,,Case(s),Worldwide,Validated,[EXPERT]
2241,Megacystis-microcolon-intestinal hypoperistalsis syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
250984,Autosomal recessive Stickler syndrome,Clinical subtype,Cases/families,15.0,,Case(s),Worldwide,Validated,16909383[PMID]_ 21421862[PMID]_21671392[PMID]
250984,Autosomal recessive Stickler syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16909383[PMID]_ 21421862[PMID]_21671392[PMID]
2256,Fibulo-ulnar hypoplasia-renal anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2773984[PMID]
2256,Fibulo-ulnar hypoplasia-renal anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2773984[PMID]
250977,AICA-ribosiduria,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,15114530[PMID]_32557644[PMID]
250977,AICA-ribosiduria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15114530[PMID]_32557644[PMID]
250994,1q21.1 microduplication syndrome,Malformation syndrome,Cases/families,46.0,,Case(s),Worldwide,Validated,ORPHANET
250994,1q21.1 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
250989,1q21.1 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2250,Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,6802865[PMID]
2250,Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6802865[PMID]
250923,Isolated aniridia,Morphological anomaly,Annual incidence,1.31,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
250923,Isolated aniridia,Morphological anomaly,Point prevalence,1.38,1-9 / 100 000,Value and class,Norway,Validated,18494745[PMID]
250923,Isolated aniridia,Morphological anomaly,Point prevalence,1.38,1-9 / 100 000,Value and class,Sweden,Validated,18494745[PMID]
250923,Isolated aniridia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
2251,Thumb deformity-alopecia-pigmentation anomaly syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,3344769[PMID]
2251,Thumb deformity-alopecia-pigmentation anomaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3344769[PMID]
2252,Radial hypoplasia-triphalangeal thumbs-hypospadias-maxillary diastema syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,7137222[PMID]
2252,Radial hypoplasia-triphalangeal thumbs-hypospadias-maxillary diastema syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7137222[PMID]
250972,Polymicrogyria with optic nerve hypoplasia,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,19896110[PMID]
250972,Polymicrogyria with optic nerve hypoplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19896110[PMID]
2255,Pancreatic hypoplasia-diabetes-congenital heart disease syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
2255,Pancreatic hypoplasia-diabetes-congenital heart disease syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
251380,Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome,Disease,Prevalence at birth,10.6,1-5 / 10 000,Value and class,United States,Validated,22766612[PMID]
251380,Hereditary persistence of fetal hemoglobin-sickle cell disease syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
2306,Isotretinoin-like syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,15602090[PMID]
2306,Isotretinoin-like syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15602090[PMID]
251383,CK syndrome,Malformation syndrome,Cases/families,24.0,,Case(s),Worldwide,Validated,21290788[PMID]
251383,CK syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21290788[PMID]
2305,Isotretinoin syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
251370,Sickle cell-hemoglobin D disease syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
251375,Sickle cell-hemoglobin E disease syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
251359,Sickle cell-beta-thalassemia disease syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
251365,Sickle cell-hemoglobin C disease syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2295,Familial articular hypermobility syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2319,Juberg-Hayward syndrome,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,22811276[PMID]
2319,Juberg-Hayward syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22811276[PMID]
251523,Hyperzincemia and hypercalprotectinemia,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,12480428[PMID]_DOI: 10.1007/978-3-319-96929-9_4[OTHER]
251523,Hyperzincemia and hypercalprotectinemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_DOI: 10.1007/978-3-319-96929-9_4[OTHER]
2316,Johnson neuroectodermal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2315,Johanson-Blizzard syndrome,Malformation syndrome,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,16311597[PMID]
2315,Johanson-Blizzard syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
251510,"46,XY partial gonadal dysgenesis",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
251515,Distal arthrogryposis type 10,Malformation syndrome,Cases/families,53.0,,Case(s),Worldwide,Validated,17103435[PMID]
251515,Distal arthrogryposis type 10,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2310,Absence deformity of leg-cataract syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,5694533[PMID]
2310,Absence deformity of leg-cataract syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5694533[PMID]
2309,Pachyonychia congenita,Disease,Cases/families,1000.0,,Case(s),Worldwide,Validated,[EXPERT]
2309,Pachyonychia congenita,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
251393,Localized junctional epidermolysis bullosa,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
251393,Localized junctional epidermolysis bullosa,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2307,IVIC syndrome,Malformation syndrome,Cases/families,4.0,,Family(ies),Worldwide,Validated,17256792[PMID]
2307,IVIC syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
251295,Pigmented paravenous retinochoroidal atrophy,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,24926324[PMID]
251295,Pigmented paravenous retinochoroidal atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24926324[PMID]
251290,Parietal foramina with clavicular hypoplasia,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,14571277[PMID]
251290,Parietal foramina with clavicular hypoplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14571277[PMID]
2282,Dysmorphism-short stature-deafness-difference of sex development syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3757305[PMID]
2282,Dysmorphism-short stature-deafness-difference of sex development syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3757305[PMID]
251287,Benign concentric annular macular dystrophy,Disease,Cases/families,27.0,,Case(s),Worldwide,Validated,ORPHANET
251287,Benign concentric annular macular dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
251282,Autosomal dominant spastic ataxia type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22958904[PMID]
251282,Autosomal dominant spastic ataxia type 1,Disease,Cases/families,53.0,,Case(s),Worldwide,Validated,22958904[PMID]
251279,Microphthalmia-retinitis pigmentosa-foveoschisis-optic disc drusen syndrome,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,19753314[PMID]
251279,Microphthalmia-retinitis pigmentosa-foveoschisis-optic disc drusen syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19753314[PMID]
251274,Familial hyperaldosteronism type III,Disease,Cases/families,7.0,,Family(ies),Worldwide,Validated,24037882[PMID]
251274,Familial hyperaldosteronism type III,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2278,Ichthyosis-intellectual disability-dwarfism-renal impairment syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,1149323[PMID]
2278,Ichthyosis-intellectual disability-dwarfism-renal impairment syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ 1149323[PMID]
251262,Familial osteochondritis dissecans,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
251347,Ataxia-telangiectasia-like disorder,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2289,Neuronal intranuclear inclusion disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2290,Microvillus inclusion disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,16800870[PMID]
2290,Microvillus inclusion disease,Disease,Cases/families,137.0,,Case(s),Worldwide,Validated,24014347[PMID]
2290,Microvillus inclusion disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24014347[PMID]
2285,Primary basilar invagination,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
251307,Idiopathic recurrent pericarditis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
251304,Infantile onset panniculitis with uveitis and systemic granulomatosis,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,18035159[PMID]
251304,Infantile onset panniculitis with uveitis and systemic granulomatosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18035159[PMID]
2674,Cyprus facial-neuromusculoskeletal syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,1481843[PMID]
2674,Cyprus facial-neuromusculoskeletal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1481843[PMID]
2673,Neurofaciodigitorenal syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,7081297[PMID]_9354842[PMID]
2673,Neurofaciodigitorenal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7081297[PMID]
2672,Neuhauser-Eichner-Opitz syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,6859111[PMID]
2672,Neuhauser-Eichner-Opitz syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6859111[PMID]
2678,Familial isolated café-au-lait macules,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2668,Nephropathy-deafness-hyperparathyroidism syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,2732989[PMID]
2668,Nephropathy-deafness-hyperparathyroidism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2732989[PMID]
2663,Nathalie syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,1204231[PMID]
2663,Nathalie syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1204231[PMID]
2662,Keipert syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,21567928[PMID]
2662,Keipert syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21567928[PMID]
2671,Neu-Laxova syndrome,Malformation syndrome,Cases/families,91.0,,Case(s),Worldwide,Validated,25152457[PMID]_24371398[PMID]
2671,Neu-Laxova syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25152457[PMID]_24371398[PMID]
1475,Renal coloboma syndrome,Malformation syndrome,Cases/families,180.0,,Case(s),Worldwide,Validated,22213154[PMID]
1475,Renal coloboma syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2670,Pierson syndrome,Malformation syndrome,Cases/families,98.0,,Case(s),Worldwide,Validated,29051055[PMID]
2670,Pierson syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,29051055[PMID]_ORPHANET
2669,Nephrosis-deafness-urinary tract-digital malformations syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,13872585[PMID]
2669,Nephrosis-deafness-urinary tract-digital malformations syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_13872585[PMID]
254930,Combined oxidative phosphorylation defect type 7,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,24284555[PMID]
254930,Combined oxidative phosphorylation defect type 7,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24284555[PMID]
254925,Combined oxidative phosphorylation defect type 4,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,17160893[PMID]
254925,Combined oxidative phosphorylation defect type 4,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17160893[PMID]
2697,Arthrogryposis-renal dysfunction-cholestasis syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
2697,Arthrogryposis-renal dysfunction-cholestasis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
254920,Combined oxidative phosphorylation defect type 2,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,15505824[PMID]
254920,Combined oxidative phosphorylation defect type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15505824[PMID]
2695,Bifid nose,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
255182,Pyruvate dehydrogenase E3-binding protein deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2701,Noonan syndrome-like disorder with loose anagen hair,Malformation syndrome,Cases/families,70.0,,Case(s),Worldwide,Validated,ORPHANET
2701,Noonan syndrome-like disorder with loose anagen hair,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
255138,Pyruvate dehydrogenase E1-beta deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
255132,Adult-onset autosomal recessive sideroblastic anemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17485548[PMID]_25342667[PMID]
255132,Adult-onset autosomal recessive sideroblastic anemia,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,17485548[PMID]_25342667[PMID]
2698,Knuckle pads-leukonychia-sensorineural deafness-palmoplantar hyperkeratosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22421650[PMID]
2699,Median nodule of the upper lip,Malformation syndrome,Cases/families,4.0,,Family(ies),Worldwide,Validated,8030663[PMID]_1068420[PMID]
2699,Median nodule of the upper lip,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,8030663[PMID]_1068420[PMID]_ORPHANET
254875,"Mitochondrial DNA depletion syndrome, myopathic form",Disease,Cases/families,45.0,,Case(s),Worldwide,Validated,23230576[PMID]
254875,"Mitochondrial DNA depletion syndrome, myopathic form",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23230576[PMID]
2690,Neutropenia-monocytopenia-deafness syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,6604450[PMID]
2690,Neutropenia-monocytopenia-deafness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6604450[PMID]
254898,Deafness-encephaloneuropathy-obesity-valvulopathy syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,17332895[PMID]
254898,Deafness-encephaloneuropathy-obesity-valvulopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17332895[PMID]
2712,Oculofaciocardiodental syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2714,Oculo-palato-cerebral syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,3995792[PMID]_11241490[PMID]_15368502[PMID]
2714,Oculo-palato-cerebral syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3995792[PMID]_11241490[PMID]_15368502[PMID]
2713,Oculoosteocutaneous syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,4974459[PMID]
2713,Oculoosteocutaneous syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4974459[PMID]
2715,Severe oculo-renal-cerebellar syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,7091183[PMID]
2715,Severe oculo-renal-cerebellar syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7091183[PMID]
2718,Oculotrichodysplasia,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3398012[PMID]
2718,Oculotrichodysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3398012[PMID]
2717,Oculotrichoanal syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,20301721[PMID]
2717,Oculotrichoanal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301721[PMID]
2704,Urofacial syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
2704,Urofacial syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2703,Port-wine nevi-mega cisterna magna-hydrocephalus syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,501430[PMID]
2703,Port-wine nevi-mega cisterna magna-hydrocephalus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_501430[PMID]
255210,Mitochondrial DNA-associated Leigh syndrome,Disease,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
255210,Mitochondrial DNA-associated Leigh syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
255229,Navajo neurohepatopathy,Disease,Cases/families,49.0,,Case(s),Worldwide,Validated,23714749[PMID]
255229,Navajo neurohepatopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,23714749[PMID]
2707,"Oculocerebrofacial syndrome, Kaufman type",Malformation syndrome,Cases/families,19.0,,Case(s),Worldwide,Validated,27763745[PMID]
2707,"Oculocerebrofacial syndrome, Kaufman type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27763745[PMID]
255235,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy",Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,17486094[PMID]_19138848[PMID]
255235,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17486094[PMID]_19138848[PMID]
2710,Oculodentodigital dysplasia,Malformation syndrome,Cases/families,243.0,,Case(s),Worldwide,Validated,12021949[PMID]
2710,Oculodentodigital dysplasia,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2709,"Oculodental syndrome, Rutherfurd type",Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,25714557[PMID]
2709,"Oculodental syndrome, Rutherfurd type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25714557[PMID]
2728,"Blepharophimosis-intellectual disability syndrome, Ohdo type",Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
2728,"Blepharophimosis-intellectual disability syndrome, Ohdo type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2730,Postaxial tetramelic oligodactyly,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,8100684[PMID]
2730,Postaxial tetramelic oligodactyly,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8100684[PMID]
2732,Olivopontocerebellar atrophy-deafness syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2733,Omodysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2733,Omodysplasia,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
2719,"Oculocerebral hypopigmentation syndrome, Cross type",Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,9112000[PMID]
2719,"Oculocerebral hypopigmentation syndrome, Cross type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9112000[PMID]
2720,"Oculocerebral hypopigmentation syndrome, Preus type",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,6663291[PMID]
2720,"Oculocerebral hypopigmentation syndrome, Preus type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6663291[PMID]
2721,Odonto-onycho-dermal dysplasia,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,26964878[PMID]
2721,Odonto-onycho-dermal dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26964878[PMID]
2722,Odonto-onycho dysplasia-alopecia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2982262[PMID]
2722,Odonto-onycho dysplasia-alopecia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2982262[PMID]
2723,Odontotrichomelic syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,5432287[PMID]
2723,Odontotrichomelic syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5432287[PMID]
2724,Odontomatosis-aortae esophagus stenosis syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,4424740[PMID]_5229432[PMID]
2724,Odontomatosis-aortae esophagus stenosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4424740[PMID]_5229432[PMID]
2755,Orofaciodigital syndrome type 8,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
2755,Orofaciodigital syndrome type 8,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,[EXPERT]_ORPHANET
2754,Orofaciodigital syndrome type 6,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,20512146[PMID]
2754,Orofaciodigital syndrome type 6,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20512146[PMID]
252164,Benign schwannoma,Disease,Point prevalence,6.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
2753,Orofaciodigital syndrome type 4,Malformation syndrome,Cases/families,29.0,,Case(s),Worldwide,Validated,ORPHANET
2753,Orofaciodigital syndrome type 4,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2751,Orofaciodigital syndrome type 2,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,Pr Marie-Paule VAZQUEZ [EXPERT]
2751,Orofaciodigital syndrome type 2,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2750,Orofaciodigital syndrome type 1,Malformation syndrome,Prevalence at birth,0.65,1-9 / 1 000 000,Value and class,France,Validated,22925539[PMID]
2750,Orofaciodigital syndrome type 1,Malformation syndrome,Prevalence at birth,1.2,1-9 / 100 000,Value and class,Europe,Validated,20301367[PMID]
2750,Orofaciodigital syndrome type 1,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
252057,Tumor of cranial and spinal nerves,Category,Annual incidence,1.89,1-9 / 100 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
2743,Ophthalmoplegia-intellectual disability-lingua scrotalis syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,1167409[PMID]
2743,Ophthalmoplegia-intellectual disability-lingua scrotalis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1167409[PMID]
2741,Ophthalmomandibulomelic dysplasia,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,14161103[PMID]
2741,Ophthalmomandibulomelic dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14161103[PMID]
252028,Primary melanocytic tumor of central nervous system,Category,Annual incidence,0.01,<1 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
661,Congenital central hypoventilation syndrome,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,France,Validated,15653965[PMID]
661,Congenital central hypoventilation syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2736,Lethal omphalocele-cleft palate syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,6873946[PMID]_26867152[PMID]
2736,Lethal omphalocele-cleft palate syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6873946[PMID]_26867152[PMID]
254367,Rare lichen planus,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2776,Autosomal recessive distal osteolysis syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2777,Osteomesopyknosis,Malformation syndrome,Cases/families,35.0,,Case(s),Worldwide,Validated,26185059[PMID]
2777,Osteomesopyknosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26185059[PMID]
254361,Plectin-related limb-girdle muscular dystrophy R17,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,21109228[PMID]
254361,Plectin-related limb-girdle muscular dystrophy R17,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21109228[PMID]
2774,Multicentric carpo-tarsal osteolysis with or without nephropathy,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
254351,Distal 7q11.23 microdeletion syndrome,Malformation syndrome,Cases/families,41.0,,Case(s),Worldwide,Validated,23637006[PMID]
254351,Distal 7q11.23 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2769,"Familial osteodysplasia, Anderson type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5067603[PMID]
2769,"Familial osteodysplasia, Anderson type",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,5067603[PMID]
254346,19p13.12 microdeletion syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,22419660[PMID]
254346,19p13.12 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22419660[PMID]
2770,Nasu-Hakola disease,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2770,Nasu-Hakola disease,Malformation syndrome,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Finland,Validated,9463329[PMID]
254343,Autosomal recessive spastic ataxia-optic atrophy-dysarthria syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,20970105[PMID]
254343,Autosomal recessive spastic ataxia-optic atrophy-dysarthria syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20970105[PMID]
2767,Carpotarsal osteochondromatosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
254334,Autosomal recessive intermediate Charcot-Marie-Tooth disease type B,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,20920668[PMID]
254334,Autosomal recessive intermediate Charcot-Marie-Tooth disease type B,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20920668[PMID]
2768,Blount disease,Malformation syndrome,Point prevalence,0.0,Not yet documented,Class only,Worldwide,Not yet validated,ORPHANET
252212,Malignant triton tumor,Histopathological subtype,Cases/families,170.0,,Case(s),Worldwide,Validated,24474920[PMID]
252212,Malignant triton tumor,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24474920[PMID]
2763,Osteocraniostenosis,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,12210352[PMID]
2763,Osteocraniostenosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2759,Imperforate oropharynx-costovertebral anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2929659[PMID]
2759,Imperforate oropharynx-costovertebral anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2929659[PMID]
2760,OSLAM syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,201363[PMID]
2760,OSLAM syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_201363[PMID]
252175,Vestibular schwannoma,Clinical subtype,Annual incidence,2.0,1-9 / 100 000,Value and class,Denmark,Validated,20871439[PMID]_24655069[PMID]
252175,Vestibular schwannoma,Clinical subtype,Annual incidence,1.2,1-9 / 100 000,Value and class,United States,Validated,National Cancer Institute[INST]_23432451[PMID]
252175,Vestibular schwannoma,Clinical subtype,Annual incidence,0.8,1-9 / 1 000 000,Value and class,Specific population,Validated,21897393[PMID]
252175,Vestibular schwannoma,Clinical subtype,Annual incidence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,
254516,Temple syndrome,Malformation syndrome,Cases/families,53.0,,Case(s),Worldwide,Validated,26377239[PMID]
254516,Temple syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26377239[PMID]
2793,Otoonychoperoneal syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,15216555[PMID]
2793,Otoonychoperoneal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15216555[PMID]
254519,Kagami-Ogata syndrome,Malformation syndrome,Cases/families,84.0,,Case(s),Worldwide,Validated,28640239[PMID]
254519,Kagami-Ogata syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28640239[PMID]
254525,Temple syndrome due to paternal 14q32.2 microdeletion,Etiological subtype,Cases/families,9.0,,Case(s),Worldwide,Validated,26377239[PMID]
254525,Temple syndrome due to paternal 14q32.2 microdeletion,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26377239[PMID]
2798,Pachygyria-intellectual disability-epilepsy syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,17343267[PMID]_8129645[PMID]
2798,Pachygyria-intellectual disability-epilepsy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17343267[PMID]_8129645[PMID]
2796,Pachydermoperiostosis,Malformation syndrome,Cases/families,204.0,,Case(s),Worldwide,Validated,16283874[PMID]
2796,Pachydermoperiostosis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
254528,Kagami-Ogata syndrome due to maternal 14q32.2 microdeletion,Etiological subtype,Cases/families,8.0,,Case(s),Worldwide,Validated,28640239[PMID]_24891339[PMID]
254528,Kagami-Ogata syndrome due to maternal 14q32.2 microdeletion,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28640239[PMID]_24891339[PMID]
254478,Lichen planus pemphigoides,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,23237497[PMID]
254478,Lichen planus pemphigoides,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2789,Lateral meningocele syndrome,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,23696373[PMID]_24311540[PMID]
2789,Lateral meningocele syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2788,Osteoporosis-pseudoglioma syndrome,Disease,Point prevalence,0.05,<1 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
254492,Frontal fibrosing alopecia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2791,Otodental syndrome,Malformation syndrome,Cases/families,10.0,,Family(ies),Worldwide,Validated,16722606[PMID]
2791,Otodental syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
254504,Inhalational botulism,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
254504,Inhalational botulism,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2790,"Endosteal hyperostosis, Worth type",Malformation syndrome,Cases/families,6.0,,Family(ies),Worldwide,Validated,8030669[PMID]_18031587 [PMID]
2790,"Endosteal hyperostosis, Worth type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8030669[PMID]_18031587 [PMID]
254509,Iatrogenic botulism,Clinical subtype,Cases/families,180.0,,Case(s),Worldwide,Validated,[EXPERT]
254509,Iatrogenic botulism,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
254411,Annular atrophic lichen planus,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
254411,Annular atrophic lichen planus,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
254424,Annular lichen planus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2783,Autosomal dominant osteopetrosis type 1,Malformation syndrome,Cases/families,33.0,,Case(s),Worldwide,Validated,ORPHANET
2783,Autosomal dominant osteopetrosis type 1,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
254449,Atrophic lichen planus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2786,Osteoporosis-oculocutaneous hypopigmentation syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8721572[PMID]
2786,Osteoporosis-oculocutaneous hypopigmentation syndrome,Malformation syndrome,Cases/families,1.0,,Case(s),Worldwide,Validated,8721572[PMID]
254463,Lichen planus pigmentosus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2780,Osteopathia striata-cranial sclerosis syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,15266607[PMID]
2780,Osteopathia striata-cranial sclerosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2779,Osteopathia striata-pigmentary dermopathy-white forelock syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,7405956[PMID]
2779,Osteopathia striata-pigmentary dermopathy-white forelock syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7405956[PMID]
254379,Linear lichen planus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
254395,Actinic lichen planus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
667,Autosomal recessive malignant osteopetrosis,Malformation syndrome,Prevalence at birth,0.75,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
667,Autosomal recessive malignant osteopetrosis,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2815,Spastic paraparesis-deafness syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,3741213[PMID]
2815,Spastic paraparesis-deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3741213[PMID]
2818,Spastic paraplegia-glaucoma-intellectual disability syndrome,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,7298353[PMID_3802560[PMID]
2818,Spastic paraplegia-glaucoma-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7298353[PMID_3802560[PMID]
2808,Laryngeal abductor paralysis,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,2277390[PMID]_7149532[PMID]_4058983[PMID]
2808,Laryngeal abductor paralysis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2277390[PMID]_7149532[PMID]_4058983[PMID]
2812,Parana hard skin syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,4129896[PMID]
2812,Parana hard skin syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4129896[PMID]
2805,Partial pancreatic agenesis,Morphological anomaly,Cases/families,50.0,,Case(s),Worldwide,Validated,8988180[PMID]
2805,Partial pancreatic agenesis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
254698,Epithelioid trophoblastic tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
254698,Epithelioid trophoblastic tumor,Disease,Annual incidence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
254698,Epithelioid trophoblastic tumor,Disease,Lifetime Prevalence,0.0,,Class only,Worldwide,Validated,ORPHANET
254693,Partial hydatidiform mole,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
675,Annular pancreas,Morphological anomaly,Prevalence at birth,1.8,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,29.4,1-5 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,2.9,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,21.3,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,7.9,1-9 / 100 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,5.9,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,3.6,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,5.7,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,24.9,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,17.1,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,3.1,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,0.8,1-9 / 1 000 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
675,Annular pancreas,Morphological anomaly,Prevalence at birth,3.2,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
675,Annular pancreas,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
678,Papillon-Lefèvre syndrome,Disease,Point prevalence,0.25,1-9 / 1 000 000,Value and class,Worldwide,Validated,14244097[PMID]
254704,Genetic hyperferritinemia without iron overload,Biological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
254534,Kagami-Ogata syndrome due to maternal 14q32.2 hypermethylation,Etiological subtype,Cases/families,7.0,,Case(s),Worldwide,Validated,26377239[PMID]
254534,Kagami-Ogata syndrome due to maternal 14q32.2 hypermethylation,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26377239[PMID]
2802,X-linked sideroblastic anemia and spinocerebellar ataxia,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,22398176[PMID]
2802,X-linked sideroblastic anemia and spinocerebellar ataxia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,22398176[PMID]_ORPHANET
254531,Temple syndrome due to paternal 14q32.2 hypomethylation,Etiological subtype,Cases/families,12.0,,Case(s),Worldwide,Validated,28640239[PMID]_24891339[PMID]
254531,Temple syndrome due to paternal 14q32.2 hypomethylation,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28640239[PMID]_24891339[PMID]
254688,Complete hydatidiform mole,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2804,W syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,10594887[PMID]
2804,W syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2491,Müllerian duct anomalies-limb anomalies syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,3706400[PMID]
2491,Müllerian duct anomalies-limb anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3706400[PMID]
2492,FATCO syndrome,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,DOI:10.15520.v3i12.33[OTHER]
2492,FATCO syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_DOI:10.15520.v3i12.33[OTHER]
2499,Metachondromatosis,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,ORPHANET
2499,Metachondromatosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2496,Mesomelia-synostoses syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,PMID: 30450550 & ORPHANET
2496,Mesomelia-synostoses syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19725128[PMID]
2497,"Upper limb mesomelic dysplasia, type Fryns",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,3342548[PMID]_16283892[PMID]
2497,"Upper limb mesomelic dysplasia, type Fryns",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3342548[PMID]_16283892[PMID]
2502,Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,5173335[PMID]
2502,Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5173335[PMID]
2501,"Metaphyseal chondrodysplasia, Spahr type",Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,24648384[PMID]_2225533[PMID]_19615667[PMID]_24781753[PMID]_18553549[PMID]
2501,"Metaphyseal chondrodysplasia, Spahr type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24648384[PMID]
2504,Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,23290074[PMID]
2504,Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2511,Microbrachycephaly-ptosis-cleft lip syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1605250[PMID]
2511,Microbrachycephaly-ptosis-cleft lip syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1605250[PMID]
2510,Micro syndrome,Malformation syndrome,Cases/families,203.0,,Case(s),Worldwide,Validated,23420520[PMID]_24239381[PMID]
2510,Micro syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2508,Corpus callosum agenesis-abnormal genitalia syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2516,Microcephaly-cardiac defect-lung malsegmentation syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,8723562[PMID]
2516,Microcephaly-cardiac defect-lung malsegmentation syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8723562[PMID]
2515,Microcephaly-cardiomyopathy syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,1956062[PMID]_10544231[PMID]
2515,Microcephaly-cardiomyopathy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1956062[PMID]_10544231[PMID]
2513,Microcephaly-albinism-digital anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,6660641[PMID]
2513,Microcephaly-albinism-digital anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6660641[PMID]
2521,Microcephaly-cleft palate-abnormal retinal pigmentation syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,6859112[PMID]
2521,Microcephaly-cleft palate-abnormal retinal pigmentation syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6859112[PMID]
2524,Pontocerebellar hypoplasia type 2,Malformation syndrome,Cases/families,81.0,,Family(ies),Worldwide,Validated,[EXPERT]
2524,Pontocerebellar hypoplasia type 2,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2523,Microcephaly-brain defect-spasticity-hypernatremia syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3784440[PMID]
2523,Microcephaly-brain defect-spasticity-hypernatremia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3784440[PMID]
2522,Microcephaly-cervical spine fusion anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,5033742[PMID]
2522,Microcephaly-cervical spine fusion anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5033742[PMID]
2526,Microcephaly-lymphedema-chorioretinopathy syndrome,Malformation syndrome,Cases/families,50.0,,Family(ies),Worldwide,Validated,[EXPERT]
2526,Microcephaly-lymphedema-chorioretinopathy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19076985[PMID]
2528,"Microcephaly-microcornea syndrome, Seemanova type",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8958326[PMID]
2528,"Microcephaly-microcornea syndrome, Seemanova type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8958326[PMID]
2533,Microcephaly-deafness-intellectual disability syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3608216[PMID]
2533,Microcephaly-deafness-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3608216[PMID]
2536,Microcornea-glaucoma-absent frontal sinuses syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,5781804[PMID]_7636671[PMID]
2536,Microcornea-glaucoma-absent frontal sinuses syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5781804[PMID]_7636671[PMID
2551,Microspherophakia-metaphyseal dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2554,Ear-patella-short stature syndrome,Malformation syndrome,Cases/families,67.0,,Case(s),Worldwide,Validated,26381604[PMID]
2554,Ear-patella-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26381604[PMID]
2556,Microphthalmia with linear skin defects syndrome,Malformation syndrome,Cases/families,55.0,,Case(s),Worldwide,Validated,23122588[PMID]
2556,Microphthalmia with linear skin defects syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2558,Mikati-Najjar-Sahli syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,2998187[PMID]
2558,Mikati-Najjar-Sahli syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2998187[PMID]
2557,Mietens syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,16760739[PMID]
2557,Mietens syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16760739[PMID]
2561,Pyramidal molars-abnormal upper lip syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,4349385[PMID]
2561,Pyramidal molars-abnormal upper lip syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4349385[PMID]
2560,Moebius syndrome-axonal neuropathy-hypogonadotropic hypogonadism syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,17401577[PMID]
2560,Moebius syndrome-axonal neuropathy-hypogonadotropic hypogonadism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17401577[PMID]
2564,Tetramelic monodactyly,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1308366[PMID]
2563,MOMO syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,23034868[PMID]_22821547[PMID]
2563,MOMO syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2565,Mononen-Karnes-Senac syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,1632443[PMID]
2565,Mononen-Karnes-Senac syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1632443[PMID]
2574,Moynahan syndrome,Malformation syndrome,Cases/families,26.0,,Case(s),Worldwide,Validated,2319580[PMID]
2574,Moynahan syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2319580[PMID]
575,Muckle-Wells syndrome,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
575,Muckle-Wells syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
2572,Spastic ataxia-corneal dystrophy syndrome,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,3465874[PMID]
2572,Spastic ataxia-corneal dystrophy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3465874[PMID]
2573,Moyamoya disease,Disease,Annual incidence,0.74,1-9 / 1 000 000,Value and class,Japan,Not yet validated,9409395[PMID]_18048855[PMID]
2573,Moyamoya disease,Disease,Point prevalence,6.2,1-9 / 100 000,Value and class,Japan,Not yet validated,9409395[PMID]_18048855[PMID]_23041378[PMID]
2573,Moyamoya disease,Disease,Annual incidence,0.43,1-9 / 1 000 000,Value and class,China,Validated,20004511[PMID]
2573,Moyamoya disease,Disease,Point prevalence,3.92,1-9 / 100 000,Value and class,China,Validated,20004511[PMID]
2573,Moyamoya disease,Disease,Annual incidence,0.048,<1 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,9409399[PMID]
2573,Moyamoya disease,Disease,Point prevalence,0.44,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,9409399[PMID]
2573,Moyamoya disease,Disease,Annual incidence,0.086,<1 / 1 000 000,Value and class,United States,Validated,16186547[PMID]
2573,Moyamoya disease,Disease,Point prevalence,0.33,1-9 / 1 000 000,Value and class,France,Validated,[EXPERT]
2573,Moyamoya disease,Disease,Annual incidence,0.035,<1 / 1 000 000,Value and class,Europe,Not yet validated,ISBN:9783211243381[OTHER]
2573,Moyamoya disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2570,Lethal intrauterine growth restriction-cortical malformation-congenital contractures syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,3321025[PMID]_3211858[PMID]
2570,Lethal intrauterine growth restriction-cortical malformation-congenital contractures syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3321025[PMID]_3211858[PMID]
2571,X-linked immunoneurologic disorder,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,7783167[PMID]
2571,X-linked immunoneurologic disorder,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7783167[PMID]
261183,15q11.2 microdeletion syndrome,Malformation syndrome,Cases/families,200.0,,Case(s),Worldwide,Validated,25689425[PMID]
261183,15q11.2 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25689425[PMID]
261144,FOXG1 syndrome due to 14q12 microdeletion,Clinical subtype,Cases/families,3.0,,Case(s),Worldwide,Validated,19303466[PMID]_18627055[PMID]
261144,FOXG1 syndrome due to 14q12 microdeletion,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
261120,14q11.2 microdeletion syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,17545556[PMID]
261120,14q11.2 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2578,Mayer-Rokitansky-Küster-Hauser syndrome type 2,Clinical subtype,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Not yet validated,19821675[PMID]
2578,Mayer-Rokitansky-Küster-Hauser syndrome type 2,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
2579,Muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,5748751[PMID]_6302225[PMID]
2579,Muscular atrophy-ataxia-retinitis pigmentosa-diabetes mellitus syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5748751[PMID]_6302225[PMID]
261102,Distal 7q11.23 microduplication syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,DOI:10.1159/000448698[OTHER]
261102,Distal 7q11.23 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_DOI:10.1159/000448698[OTHER]
2576,Mulibrey nanism,Malformation syndrome,Cases/families,150.0,,Case(s),Worldwide,Validated,29731032[PMID]
2576,Mulibrey nanism,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29731032[PMID]
2576,Mulibrey nanism,Malformation syndrome,Annual incidence,2.7,1-9 / 100 000,Value and class,Finland,Validated,12627297[PMID]
261236,16p13.11 microdeletion syndrome,Malformation syndrome,Prevalence at birth,7.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,24105370[PMID]
261236,16p13.11 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET_23637818[PMID]
261243,16p13.11 microduplication syndrome,Malformation syndrome,Cases/families,162.0,,Case(s),Worldwide,Validated,27378146[PMID]
261243,16p13.11 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27378146[PMID]
2608,N syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,4216437[PMID]
2608,N syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4216437[PMID]
261222,Distal 16p11.2 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1359,Carney complex,Disease,Cases/families,750.0,,Case(s),Worldwide,Validated,34167977[PMID]_35165607[PMID]
1359,Carney complex,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,34167977[PMID]_35165607[PMID]_ORPHANET
261229,14q11.2 microduplication syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,20736978[PMID]
261229,14q11.2 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2590,Spinal muscular atrophy-progressive myoclonic epilepsy syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
2590,Spinal muscular atrophy-progressive myoclonic epilepsy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
261204,16p11.2p12.2 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24259393[PMID]
261204,16p11.2p12.2 microduplication syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,24259393[PMID]
261211,16p11.2p12.2 microdeletion syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,24259393[PMID]
261211,16p11.2p12.2 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24259393[PMID]
2589,Myoclonus-cerebellar ataxia-deafness syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,5698045[PMID]_6537856[PMID]
2589,Myoclonus-cerebellar ataxia-deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5698045[PMID]_6537856[PMID]
261190,Cleft palate-congenital heart defect-intellectual disability syndrome due to 15q14 microdeletion,Clinical subtype,Cases/families,9.0,,Case(s),Worldwide,Validated,24678003[PMID]
261190,Cleft palate-congenital heart defect-intellectual disability syndrome due to 15q14 microdeletion,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24678003[PMID]
2588,Myhre syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28406602[PMID]
261197,Proximal 16p11.2 microdeletion syndrome,Malformation syndrome,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,19306953[PMID]_[EXPERT]
261197,Proximal 16p11.2 microdeletion syndrome,Malformation syndrome,Point prevalence,20.0,1-5 / 10 000,Value and class,United States,Validated,21731881[PMID]
261295,20p12.3 microdeletion syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,18812404[PMID]
261295,20p12.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18812404[PMID]
261304,Paternal 20q13.2q13.3 microdeletion syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,15915160[PMID]
261304,Paternal 20q13.2q13.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15915160[PMID]
261279,17q23.1q23.2 microdeletion syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,20206336[PMID]
261279,17q23.1q23.2 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20206336[PMID]
261290,Trisomy 17p syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2617,"Microcephalic primordial dwarfism, Montreal type",Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,5458566[PMID]
2617,"Microcephalic primordial dwarfism, Montreal type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5458566[PMID]
261265,17q12 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27409573[PMID]
261265,17q12 microdeletion syndrome,Malformation syndrome,Point prevalence,0.16,1-9 / 1 000 000,Value and class,Denmark,Validated,27409573[PMID]
261265,17q12 microdeletion syndrome,Malformation syndrome,Cases/families,103.0,,Case(s),Worldwide,Validated,27409573[PMID]
261272,17q12 microduplication syndrome,Malformation syndrome,Cases/families,118.0,,Case(s),Worldwide,Validated,27409573[PMID]
261272,17q12 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27409573[PMID]
261272,17q12 microduplication syndrome,Malformation syndrome,Point prevalence,0.46,1-9 / 1 000 000,Value and class,Denmark,Validated,27409573[PMID]
2616,3M syndrome,Malformation syndrome,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET_22624670[PMID]
2616,3M syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
261250,16q24.3 microdeletion syndrome,Malformation syndrome,Cases/families,27.0,,Case(s),Worldwide,Validated,28422132[PMID]
261250,16q24.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28422132[PMID]
2613,Nail-patella-like renal disease,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,6507504[PMID]
2613,Nail-patella-like renal disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6507504[PMID]
261257,Distal 17p13.3 microdeletion syndrome,Malformation syndrome,Cases/families,16.0,,Case(s),Worldwide,Validated,20599530[PMID]
261257,Distal 17p13.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20599530[PMID]
261344,Trisomy 1q syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,28437579[PMID]
261344,Trisomy 1q syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28437579[PMID]
261337,Distal 22q11.2 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
261476,Xp21 deletion syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25917374[PMID]
261476,Xp21 deletion syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,25917374[PMID]
261349,2p15p16.1 microdeletion syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,24810580[PMID]
261349,2p15p16.1 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24810580[PMID]
261318,Trisomy 20p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
261311,20q13.33 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2623,Geleophysic dysplasia,Malformation syndrome,Cases/families,27.0,,Case(s),Worldwide,Validated,15088061[PMID]
2623,Geleophysic dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
261330,Distal 22q11.2 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
261323,21q22.11q22.12 microdeletion syndrome,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,20578134[PMID]_7515754[PMID]
261323,21q22.11q22.12 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20578134[PMID]_7515754[PMID]
261524,Paternal uniparental disomy of chromosome X syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
261519,Maternal uniparental disomy of chromosome X syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
261534,"49,XXXYY syndrome",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3697588[PMID]_14015109[PMID]
261534,"49,XXXYY syndrome",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
261529,Ring chromosome Y syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2631,Mesomelic dwarfism-cleft palate-camptodactyly syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8267013[PMID]
2631,Mesomelic dwarfism-cleft palate-camptodactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8267013[PMID]
261494,Kleefstra syndrome,Malformation syndrome,Cases/families,114.0,,Case(s),Worldwide,Validated,22670141[PMID]_[EXPERT]
261494,Kleefstra syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
261483,Xq27.3q28 duplication syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,19844254[PMID]
261483,Xq27.3q28 duplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2632,Langer mesomelic dysplasia,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,23863349[PMID]_[EXPERT]
2632,Langer mesomelic dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
261501,Atypical Norrie disease due to Xp11.3 microdeletion,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2634,"Mesomelic dwarfism, Reinhardt-Pfeiffer type",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2645,Osteoglosphonic dysplasia,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,3409933[PMID]
2645,Osteoglosphonic dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3409933[PMID]
261600,Alagille syndrome due to 20p12 microdeletion,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2643,"Microcephalic primordial dwarfism, Toriello type",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,3799711[PMID]
2643,"Microcephalic primordial dwarfism, Toriello type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3799711[PMID]
2636,Microcephalic osteodysplastic primordial dwarfism types I and III,Malformation syndrome,Cases/families,53.0,,Case(s),Worldwide,Validated,ORPHANET
2636,Microcephalic osteodysplastic primordial dwarfism types I and III,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2658,Lenz-Majewski hyperostotic dwarfism,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,10756342[PMID]_24241535[PMID]
2658,Lenz-Majewski hyperostotic dwarfism,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
261638,Okihiro syndrome due to 20q13 microdeletion,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
261652,Kleefstra syndrome due to a point mutation,Etiological subtype,Cases/families,23.0,,Case(s),Worldwide,Validated,22670141[PMID]_[EXPERT]
261652,Kleefstra syndrome due to a point mutation,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
264200,14q22q23 microdeletion syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,24311462[PMID]
264200,14q22q23 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24311462[PMID]
3057,Monoamine oxidase A deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3055,X-linked intellectual disability-hypogonadism-ichthyosis-obesity-short stature syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,7175926[PMID]
3055,X-linked intellectual disability-hypogonadism-ichthyosis-obesity-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7175926[PMID]
3052,X-linked intellectual disability-seizures-psoriasis syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,3177453[PMID]
3052,X-linked intellectual disability-seizures-psoriasis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3177453[PMID]
3047,"Blepharophimosis-intellectual disability syndrome, SBBYS type",Malformation syndrome,Cases/families,122.0,,Case(s),Worldwide,Validated,[EXPERT]
3047,"Blepharophimosis-intellectual disability syndrome, SBBYS type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3044,Intellectual disability-dysmorphism-hypogonadism-diabetes mellitus syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,2107046[PMID]
3044,Intellectual disability-dysmorphism-hypogonadism-diabetes mellitus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2107046[PMID]
3042,Intellectual disability-cataracts-calcified pinnae-myopathy syndrome,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,27061120[PMID]_28462983[PMID]
3042,Intellectual disability-cataracts-calcified pinnae-myopathy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28462983[PMID]
3041,Intellectual disability-balding-patella luxation-acromicria syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,2002488[PMID]_8487281[PMID]
3041,Intellectual disability-balding-patella luxation-acromicria syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2002488[PMID]_8487281[PMID]
3038,Delayed speech-facial asymmetry-strabismus-ear lobe creases syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,16055361[PMID]
3038,Delayed speech-facial asymmetry-strabismus-ear lobe creases syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16055361[PMID]
263665,NK-cell enteropathy,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,20966166[PMID]
263665,NK-cell enteropathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3035,Growth delay-hydrocephaly-lung hypoplasia syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,2764038[PMID]
3035,Growth delay-hydrocephaly-lung hypoplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2764038[PMID]
263662,Familial multiple meningioma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3034,Delayed membranous cranial ossification,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,10861662[PMID]_1481847[PMID]
3034,Delayed membranous cranial ossification,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10861662[PMID]_1481847[PMID]
263548,Peeling skin syndrome type A,Clinical subtype,Cases/families,40.0,,Family(ies),Worldwide,Validated,ORPHANET
263548,Peeling skin syndrome type A,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3033,Renal tubular dysgenesis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3033,Renal tubular dysgenesis,Malformation syndrome,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16790508[PMID]_19344005[PMID]_ 33163725[PMID]
263553,Peeling skin syndrome type B,Clinical subtype,Cases/families,30.0,,Family(ies),Worldwide,Validated,ORPHANET
263553,Peeling skin syndrome type B,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3032,NPHP3-related Meckel-like syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
3032,NPHP3-related Meckel-like syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
263534,Acral peeling skin syndrome,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,22622422[PMID]
263534,Acral peeling skin syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
263543,Generalized peeling skin syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
263516,Progressive myoclonic epilepsy type 3,Disease,Cases/families,9.0,,Family(ies),Worldwide,Validated,22693283[PMID]_22748208[PMID]
263516,Progressive myoclonic epilepsy type 3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22693283[PMID]_22748208[PMID]
263524,Acute necrotizing encephalopathy of childhood,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
263501,COG4-CDG,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,22516080[PMID]
263501,COG4-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3026,Radial ray hypoplasia-choanal atresia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3425633[PMID]
3026,Radial ray hypoplasia-choanal atresia syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3425633[PMID]
263508,COG1-CDG,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,16537452[PMID]_19008299[PMID]
263508,COG1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16537452[PMID]_19008299[PMID]
263482,"Spondyloepimetaphyseal dysplasia, Maroteaux type",Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
263482,"Spondyloepimetaphyseal dysplasia, Maroteaux type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3021,RAPADILINO syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,18716613[PMID]
3021,RAPADILINO syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18716613[PMID]
263479,Fuchs heterochromic iridocyclitis,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,Finland,Validated,9088407[PMID]
263479,Fuchs heterochromic iridocyclitis,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Finland,Validated,9088407[PMID]
263479,Fuchs heterochromic iridocyclitis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
263494,DPM3-CDG,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,19576565[PMID]
263494,DPM3-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19576565[PMID]
3023,External auditory canal atresia-vertical talus-hypertelorism syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,22152683[PMID]_495079[PMID]_12116258[PMID]
3023,External auditory canal atresia-vertical talus-hypertelorism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22152683[PMID]_495079[PMID]_12116258[PMID]
263487,COG5-CDG,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,22516080[PMID]_23228021[PMID]
263487,COG5-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
263458,Hyperinsulinism due to INSR deficiency,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,15161766[PMID]
263458,Hyperinsulinism due to INSR deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15161766[PMID]
263455,Congenital hyperinsulinism due to HNF4A deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1832,Osteosclerotic bone dysplasia,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,25974638[PMID]
1832,Osteosclerotic bone dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25974638[PMID]
3018,Retinal ischemic syndrome-digestive tract small vessel hyalinosis-diffuse cerebral calcifications syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3485063[PMID]
3018,Retinal ischemic syndrome-digestive tract small vessel hyalinosis-diffuse cerebral calcifications syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3485063[PMID]
3019,Ramon syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,11746043[PMID]
3019,Ramon syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11746043[PMID]_6829604[PMID]
263463,CHST3-related skeletal dysplasia,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,24458487[PMID]
263463,CHST3-related skeletal dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24458487[PMID]
263432,Nevus of Ito,Disease,Point prevalence,1.17,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
263432,Nevus of Ito,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
263425,Nevus of Ota,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3015,Radio-renal syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,7363497[PMID]_6829604[PMID]
3015,Radio-renal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7363497[PMID]_
263440,Neuroacanthocytosis,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,22027213[PMID]
263435,Congenital smooth muscle hamartoma,Disease,Prevalence at birth,38.5,1-5 / 10 000,Value and class,Israel,Validated,2356798[PMID]
263435,Congenital smooth muscle hamartoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3016,Absent radius-anogenital anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8456854[PMID]
3016,Absent radius-anogenital anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8456854[PMID]
263410,Infantile spasms-psychomotor retardation-progressive brain atrophy-basal ganglia disease syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,21176162[PMID]
263410,Infantile spasms-psychomotor retardation-progressive brain atrophy-basal ganglia disease syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3010,Qazi-Markouizos syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,8064821[PMID]
3010,Qazi-Markouizos syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8064821[PMID]
3011,Spastic tetraplegia-retinitis pigmentosa-intellectual disability syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,1271602[PMID]
3011,Spastic tetraplegia-retinitis pigmentosa-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1271602[PMID]
769,Rabson-Mendenhall syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
263413,Angiosarcoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
263413,Angiosarcoma,Disease,Lifetime Prevalence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
263413,Angiosarcoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
3003,Pyknoachondrogenesis,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,7460382[PMID]_3791681[PMID]
3003,Pyknoachondrogenesis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7460382[PMID]_3791681[PMID]
263335,Moderately-differentiated thymic neuroendocrine carcinoma,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
263339,Poorly differentiated thymic neuroendocrine carcinoma,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3005,Pyle disease,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
3005,Pyle disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
263347,MRCS syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,16458719[PMID]_12543751[PMID]
263347,MRCS syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16458719[PMID]_12543751[PMID]
263352,Postcardiotomy right ventricular failure,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,European Medicines Agency 2010[INST]
3004,Mirror polydactyly-vertebral segmentation-limbs defects syndrome,Malformation syndrome,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Spain,Validated,9409874[PMID]
3004,Mirror polydactyly-vertebral segmentation-limbs defects syndrome,Malformation syndrome,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
263310,Thymoma type A,Histopathological subtype,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
263310,Thymoma type A,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2997,Ptosis-vocal cord paralysis syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,6633110[PMID]
2997,Ptosis-vocal cord paralysis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6633110[PMID]
263317,Thymoma type B,Histopathological subtype,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
263317,Thymoma type B,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
263324,Thymoma type AB,Histopathological subtype,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
263324,Thymoma type AB,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2999,Ptosis-strabismus-ectopic pupils syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,949861[PMID]
2999,Ptosis-strabismus-ectopic pupils syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_949861[PMID]
263331,Well-differentiated thymic neuroendocrine carcinoma,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2990,Autosomal recessive multiple pterygium syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30868735[PMID]
2990,Autosomal recessive multiple pterygium syndrome,Malformation syndrome,Cases/families,64.0,,Case(s),Worldwide,Validated,30868735[PMID]
263297,Glycogen storage disease with severe cardiomyopathy due to glycogenin deficiency,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,20357282[PMID]
263297,Glycogen storage disease with severe cardiomyopathy due to glycogenin deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20357282[PMID]
2987,Antecubital pterygium syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,3409540[PMID]
2987,Antecubital pterygium syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3409540[PMID]
2985,Pseudoprogeria syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,4418946[PMID]
2985,Pseudoprogeria syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4418946[PMID]
2988,Pterygium colli-intellectual disability-digital anomalies syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,7977463[PMID]
2988,Pterygium colli-intellectual disability-digital anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7977463[PMID]
3138,Ulnar-mammary syndrome,Malformation syndrome,Cases/families,128.0,,Case(s),Worldwide,Validated,24679913[PMID]_30654152[PMID]_ 30550377[PMID]_ 28145909[PMID]
3138,Ulnar-mammary syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3145,Arginine vasopressin resistance-intracranial calcification-short stature-facial dysmorphism syndrome,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,24053747[PMID]
3145,Arginine vasopressin resistance-intracranial calcification-short stature-facial dysmorphism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,24053747[PMID]
3143,Autoimmune polyendocrinopathy type 2,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3144,Schneckenbecken dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25997753[PMID]
3132,Say-Barber-Miller syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,3746838[PMID]_8728697[PMID]_19108857[PMID]
3132,Say-Barber-Miller syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3746838[PMID]_8728697[PMID]
3130,Satoyoshi syndrome,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,19839037[PMID]
3130,Satoyoshi syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19839037[PMID]
798,Schinzel-Giedion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18398855[PMID]
798,Schinzel-Giedion syndrome,Malformation syndrome,Prevalence at birth,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
798,Schinzel-Giedion syndrome,Malformation syndrome,Cases/families,46.0,,Case(s),Worldwide,Validated,18398855[PMID]_[EXPERT]
262941,Partial duplication of the long arm of chromosome 14 syndrome,Category,Cases/families,50.0,,Case(s),Worldwide,Validated,27286879[PMID]
262941,Partial duplication of the long arm of chromosome 14 syndrome,Category,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27286879[PMID]
3134,SCARF syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2596519[PMID]
3134,SCARF syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2596519[PMID]
3121,Ruvalcaba syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2909,Rothmund-Thomson syndrome,Disease,Cases/families,400.0,,Case(s),Worldwide,Validated,29642415[PMID]
2909,Rothmund-Thomson syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29642415[PMID]
3110,Rombo syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
3101,Richieri Costa-da Silva syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,6716408[PMID]
3101,Richieri Costa-da Silva syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6716408[PMID]
3102,Richieri Costa-Pereira syndrome,Malformation syndrome,Cases/families,33.0,,Case(s),Worldwide,Validated,23794199[PMID]
3102,Richieri Costa-Pereira syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3104,Robin sequence-oligodactyly syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3777025[PMID]_3425604[PMID]
3104,Robin sequence-oligodactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3777025[PMID]_3425604[PMID]
3107,Autosomal dominant Robinow syndrome,Clinical subtype,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
3107,Autosomal dominant Robinow syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3109,Mayer-Rokitansky-Küster-Hauser syndrome,Malformation syndrome,Prevalence at birth,11.0,1-5 / 10 000,Value and class,Worldwide,Validated,[EXPERT]_22740494[PMID]_17359527[PMID]
3109,Mayer-Rokitansky-Küster-Hauser syndrome,Malformation syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Worldwide,Validated,[EXPERT]
3086,Autosomal dominant vitreoretinochoroidopathy,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,15452077[PMID]
3086,Autosomal dominant vitreoretinochoroidopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
3088,Revesz syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,1404302[PMID]_18252230[PMID]_21477109[PMID]
3088,Revesz syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET_1404302[PMID]_18252230[PMID]_21477109[PMID]
3097,Meacham syndrome,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,17853480[PMID]
3097,Meacham syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17853480[PMID]
3098,"Rhizomelic syndrome, Urbach type",Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,3948431[PMID]
3098,"Rhizomelic syndrome, Urbach type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3591839[PMID]
3078,"Severe X-linked intellectual disability, Gustavson type",Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,8456840[PMID]
3078,"Severe X-linked intellectual disability, Gustavson type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8456840[PMID]
3077,X-linked intellectual disability-psychosis-macroorchidism syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,8651288[PMID]
3077,X-linked intellectual disability-psychosis-macroorchidism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8651288[PMID]
3080,"Intellectual disability, Wolff type",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8151642[PMID]
3080,"Intellectual disability, Wolff type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8151642[PMID]
3079,"Intellectual disability, Buenos-Aires type",Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,5025484[PMID]_10190479[PMID]
3079,"Intellectual disability, Buenos-Aires type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5025484[PMID]_10190479[PMID]
3063,"X-linked intellectual disability, Snyder type",Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,23897707[PMID]_23696453[PMID]
3063,"X-linked intellectual disability, Snyder type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23897707[PMID]_23696453[PMID]
3068,Intellectual disability-myopathy-short stature-endocrine defect syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,3970066[PMID]
3068,Intellectual disability-myopathy-short stature-endocrine defect syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3970066[PMID]
268843,"Malformation of the neurenteric canal, spinal cord and column",Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2886,TARP syndrome,Malformation syndrome,Cases/families,6.0,,Family(ies),Worldwide,Validated,24259342[PMID]
2886,TARP syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,"ORPHANET_24259342,[PMID]"
268861,Primary tethered cord syndrome,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2885,Piebald trait-neurologic defects syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,5097904[PMID]
2885,Piebald trait-neurologic defects syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5097904[PMID]
2884,Piebaldism,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2881,Cutaneous photosensitivity-lethal colitis syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,2002480[PMID]
2881,Cutaneous photosensitivity-lethal colitis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2002480[PMID]
2879,"Phocomelia, Schinzel type",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268826,Parietal encephalocele,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268829,Basal encephalocele,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268920,Isolated megalencephaly,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268882,Arnold-Chiari malformation type I,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2892,Pilodental dysplasia-refractive errors syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,4018802[PMID]
2892,Pilodental dysplasia-refractive errors syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4018802[PMID]
2891,Pili torti-developmental delay-neurological abnormalities syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1379303[PMID]
2891,Pili torti-developmental delay-neurological abnormalities syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1379303[PMID]
2889,Pili torti,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2890,Pili torti-onychodysplasia syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,1879585[PMID]
2890,Pili torti-onychodysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1879585[PMID]
268865,Neurenteric cyst,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2888,Pierre Robin syndrome-faciodigital anomaly syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,1897570[PMID]
2888,Pierre Robin syndrome-faciodigital anomaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1897570[PMID]
268868,Isolated amyelia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2865,Short stature-webbed neck-heart disease syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,8905197[PMID]
2865,Short stature-webbed neck-heart disease syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8905197[PMID]
2866,Short stature-deafness-neutrophil dysfunction-dysmorphism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,654917[PMID]
2866,Short stature-deafness-neutrophil dysfunction-dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_654917[PMID]
2863,Short stature-wormian bones-dextrocardia syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,15211658[PMID]
2863,Short stature-wormian bones-dextrocardia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15211658[PMID]
268744,Spinal dysraphism with a posterior meningocele,Clinical group,Prevalence at birth,33.0,1-5 / 10 000,Value and class,Saudi Arabia,Validated,17587020[PMID]
268744,Spinal dysraphism with a posterior meningocele,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268823,Occipital encephalocele,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2876,PHAVER syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8279476[PMID]
2876,PHAVER syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8279476[PMID]
268820,Cranial meningocele,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268817,Cephalocele,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2874,Phakomatosis pigmentokeratotica,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2874,Phakomatosis pigmentokeratotica,Malformation syndrome,Cases/families,34.0,,Case(s),Worldwide,Validated,24877171[PMID]
268813,Myelocystocele,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268810,Isolated posterior meningocele,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2871,Pfeiffer-Palm-Teller syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,144791[PMID]
2871,Pfeiffer-Palm-Teller syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_144791[PMID]
2872,"Cardiocranial syndrome, Pfeiffer type",Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,16531733[PMID]_9415478[PMID]
2872,"Cardiocranial syndrome, Pfeiffer type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16531733[PMID]_9415478[PMID]
2867,"Short stature, Brussels type",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8867654[PMID]
2867,"Short stature, Brussels type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8867654[PMID]
2868,Short stature-valvular heart disease-characteristic facies syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,2302822[PMID]
2868,Short stature-valvular heart disease-characteristic facies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2302822[PMID]
2846,Congenital pericardium anomaly,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2842,Penoscrotal transposition,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2848,Camptodactyly-arthropathy-coxa-vara-pericarditis syndrome,Disease,Cases/families,30.0,,Family(ies),Worldwide,Validated,15702367[PMID]
2848,Camptodactyly-arthropathy-coxa-vara-pericarditis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2847,Pericardial and diaphragmatic defect,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
2847,Pericardial and diaphragmatic defect,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
268357,Neural tube closure defect,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2838,Renal caliceal diverticuli-deafness syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,6785452[PMID]
2838,Renal caliceal diverticuli-deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6785452[PMID]
268322,Hereditary thrombocytopenia with normal platelets,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2840,Pelvic dysplasia-arthrogryposis of lower limbs syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,9489787[PMID]
2840,Pelvic dysplasia-arthrogryposis of lower limbs syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9489787[PMID]
2839,Pelvis-shoulder dysplasia,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
2839,Pelvis-shoulder dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2855,Perrault syndrome,Disease,Cases/families,124.0,,Case(s),Worldwide,Validated,Haute Autorité de Santé[OTHER]
2855,Perrault syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2854,Fuhrmann syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,16826533[PMID]_12868468[PMID]
2854,Fuhrmann syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12868468[PMID]_16826533[PMID]
708,Peters anomaly,Morphological anomaly,Cases/families,60.0,,Case(s),Worldwide,Validated,21448066[PMID]
708,Peters anomaly,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
268363,Open iniencephaly,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268366,Closed iniencephaly,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2850,Alopecia-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28054173[PMID]
2850,Alopecia-intellectual disability syndrome,Disease,Cases/families,15.0,,Family(ies),Worldwide,Validated,18616779[PMID]_28054173[PMID]
268369,Open spinal dysraphism,Clinical group,Prevalence at birth,51.5,1-5 / 10 000,Value and class,Germany,Validated,2785614[PMID]
268369,Open spinal dysraphism,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268369,Open spinal dysraphism,Clinical group,Prevalence at birth,50.0,1-5 / 10 000,Value and class,France,Not yet validated,ORPHANET
268369,Open spinal dysraphism,Clinical group,Prevalence at birth,400.0,>1 / 1000,Value and class,Ireland,Not yet validated,ORPHANET
268369,Open spinal dysraphism,Clinical group,Prevalence at birth,62.0,6-9 / 10 000,Value and class,Latin America,Validated,3907353[PMID]
268369,Open spinal dysraphism,Clinical group,Point prevalence,400.0,>1 / 1000,Value and class,United Kingdom,Not yet validated,ORPHANET
268114,RAS-associated autoimmune leukoproliferative disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
268114,RAS-associated autoimmune leukoproliferative disease,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
2825,PARC syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,2242783[PMID]
2825,PARC syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2242783[PMID]
2826,Spastic paraplegia-precocious puberty syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,6639408[PMID]
2826,Spastic paraplegia-precocious puberty syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6639408[PMID]
268139,Intraocular medulloepithelioma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268129,Spheroid body myopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2819,Spastic paraplegia-facial-cutaneous lesions syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,7117711[PMID]
2819,Spastic paraplegia-facial-cutaneous lesions syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7117711[PMID]
2820,Spastic paraplegia-nephritis-deafness syndrome,Clinical syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,3351903[PMID]
2820,Spastic paraplegia-nephritis-deafness syndrome,Clinical syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3351903[PMID]
2821,Spastic paraplegia-neuropathy-poikiloderma syndrome,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,1623621[PMID]
2821,Spastic paraplegia-neuropathy-poikiloderma syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1623621[PMID]
2822,Autosomal recessive spastic paraplegia type 11,Disease,Point prevalence,0.26,1-9 / 1 000 000,Value and class,Portugal,Validated,23609960[PMID]
2835,Pectus excavatum-macrocephaly-dysplastic nails syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,Zori 1992[AUTHOR]
2835,Pectus excavatum-macrocephaly-dysplastic nails syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
268261,DYRK1A-related intellectual disability syndrome due to 21q22.13q22.2 microdeletion,Etiological subtype,Cases/families,19.0,,Case(s),Worldwide,Validated,26922654[PMID]
268261,DYRK1A-related intellectual disability syndrome due to 21q22.13q22.2 microdeletion,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26922654[PMID]
2836,PEHO syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
268249,Mycophenolate mofetil embryopathy,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,[EXPERT]
268249,Mycophenolate mofetil embryopathy,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
216694,Congenitally corrected transposition of the great arteries,Morphological anomaly,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
216694,Congenitally corrected transposition of the great arteries,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
216718,Isolated congenitally uncorrected transposition of the great arteries,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
216729,Congenitally uncorrected transposition of the great arteries with cardiac malformation,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3411,Double uterus-hemivagina-renal agenesis syndrome,Malformation syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,ORPHANET
3411,Double uterus-hemivagina-renal agenesis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
882,Tyrosinemia type 1,Disease,Prevalence at birth,0.9,1-9 / 1 000 000,Value and class,Worldwide,Validated,20301688[PMID]
882,Tyrosinemia type 1,Disease,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Norway,Not yet validated,20301688[PMID]_22554029[PMID]
882,Tyrosinemia type 1,Disease,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Finland,Validated,33046095[PMID]
882,Tyrosinemia type 1,Disease,Prevalence at birth,6.7,1-9 / 100 000,Value and class,Tunisia,Validated,22481200[PMID]
882,Tyrosinemia type 1,Disease,Prevalence at birth,6.25,1-9 / 100 000,Value and class,Specific population,Validated,20301688[PMID]
882,Tyrosinemia type 1,Disease,Prevalence at birth,54.0,1-5 / 10 000,Value and class,Specific population,Validated,2378355[PMID]
882,Tyrosinemia type 1,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
216796,Osteogenesis imperfecta type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
216796,Osteogenesis imperfecta type 1,Clinical subtype,Prevalence at birth,5.16,1-9 / 100 000,Value and class,Sweden,Validated,25944380[PMID]
903,Von Willebrand disease,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Worldwide,Validated,10959685[PMID]_19874468[PMID]
216804,Osteogenesis imperfecta type 2,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
216812,Osteogenesis imperfecta type 3,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
216812,Osteogenesis imperfecta type 3,Clinical subtype,Prevalence at birth,0.89,1-9 / 1 000 000,Value and class,Sweden,Validated,25944380[PMID]
216820,Osteogenesis imperfecta type 4,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
216820,Osteogenesis imperfecta type 4,Clinical subtype,Prevalence at birth,1.35,1-9 / 100 000,Value and class,Sweden,Validated,25944380[PMID]
216828,Osteogenesis imperfecta type 5,Clinical subtype,Cases/families,47.0,,Case(s),Worldwide,Validated,ORPHANET
216828,Osteogenesis imperfecta type 5,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3474,CHIME syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,22444671[PMID]
3474,CHIME syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22444671[PMID]
1441,Ring chromosome 17 syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,24393457[PMID]_25635406[PMID]
1441,Ring chromosome 17 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24393457[PMID]_25635406[PMID]
216978,"Niemann-Pick disease type C, late infantile neurologic onset",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
361,Familial glucocorticoid deficiency,Disease,Point prevalence,0.4953,1-9 / 1 000 000,Value and class,Ireland,Validated,18430777[PMID]
361,Familial glucocorticoid deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
216975,"Niemann-Pick disease type C, severe early infantile neurologic onset",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1787,"Acrofacial dysostosis, Palagonia type",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,9098488[PMID]
1787,"Acrofacial dysostosis, Palagonia type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9098488[PMID]
216981,"Niemann-Pick disease type C, juvenile neurologic onset",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217008,Bockenheimer syndrome,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,ISBN-13: 978-0323073677[OTHER]
217008,Bockenheimer syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ISBN-13: 978-0323073677[OTHER]
217017,Zechi-Ceide syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,17907157[PMID]
217017,Zechi-Ceide syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17907157[PMID]
217012,Spinocerebellar ataxia type 31,Disease,Cases/families,30.0,,Family(ies),Worldwide,Validated,22353852[PMID]_24344778[PMID]
217012,Spinocerebellar ataxia type 31,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2088,Fanconi-Bickel syndrome,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,11949937[PMID]
2088,Fanconi-Bickel syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2088,Fanconi-Bickel syndrome,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Israel,Validated,33239050[PMID]
2088,Fanconi-Bickel syndrome,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Specific population,Validated,33239050[PMID]
217026,"Microcephaly-facio-cardio-skeletal syndrome, Hadziselimovic type",Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,11152145[PMID]_19373080[PMID]
217026,"Microcephaly-facio-cardio-skeletal syndrome, Hadziselimovic type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11152145[PMID]_19373080[PMID]
217266,BNAR syndrome,Malformation syndrome,Cases/families,9.0,,Family(ies),Worldwide,Validated,24115501[PMID]
217266,BNAR syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
179,Birdshot chorioretinopathy,Disease,Point prevalence,0.35,1-9 / 1 000 000,Value and class,Worldwide,Validated,27175923[PMID]
179,Birdshot chorioretinopathy,Disease,Point prevalence,0.14,1-9 / 1 000 000,Value and class,United States,Validated,16263368[PMID]
217260,Progressive multifocal leukoencephalopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217260,Progressive multifocal leukoencephalopathy,Disease,Annual incidence,0.068,<1 / 1 000 000,Value and class,Sweden,Validated,29321229[PMID]
217260,Progressive multifocal leukoencephalopathy,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,France,Validated,35779271[PMID]
292,Congenital enterovirus infection,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217253,NMDA receptor encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
767,Polyarteritis nodosa,Disease,Point prevalence,3.16,1-9 / 100 000,Value and class,Europe,Validated,9805179[PMID]_14872461[PMID]_17553910[PMID]_ORPHANET
767,Polyarteritis nodosa,Disease,Point prevalence,3.1,1-9 / 100 000,Value and class,Sweden,Validated,17553910[PMID]
767,Polyarteritis nodosa,Disease,Annual incidence,0.9,1-9 / 1 000 000,Value and class,United Kingdom,Not yet validated,10693883[PMID]_11156552[PMID]
767,Polyarteritis nodosa,Disease,Point prevalence,3.07,1-9 / 100 000,Value and class,France,Validated,14872461[PMID]
767,Polyarteritis nodosa,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,Australia,Validated,18771432[PMID]
767,Polyarteritis nodosa,Disease,Annual incidence,0.62,1-9 / 1 000 000,Value and class,Spain,Validated,11156552[PMID]
767,Polyarteritis nodosa,Disease,Point prevalence,3.3,1-9 / 100 000,Value and class,Norway,Validated,9805179[PMID]
767,Polyarteritis nodosa,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Norway,Not yet validated,ORPHANET
767,Polyarteritis nodosa,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Germany,Validated,15696553[PMID]
2584,Classic mycosis fungoides,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
2584,Classic mycosis fungoides,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
217093,"Mucopolysaccharidosis type 2, attenuated form",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3162,Sézary syndrome,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,United States,Validated,17638728[PMID]_National Cancer Institute[INST]_ORPHANET
3162,Sézary syndrome,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Norway,Validated,18808419[PMID]_ ORPHANET_[EXPERT]
3162,Sézary syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217085,"Mucopolysaccharidosis type 2, severe form",Clinical subtype,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
217085,"Mucopolysaccharidosis type 2, severe form",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217080,Pulmonary fungal infections in patients deemed at risk,Particular clinical situation in a disease or syndrome,Point prevalence,22.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
217074,Rare carcinoma of pancreas,Category,Annual incidence,11.79,1-5 / 10 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
217074,Rare carcinoma of pancreas,Category,Lifetime Prevalence,8.3,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
217074,Rare carcinoma of pancreas,Category,Point prevalence,15.5,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2013[INST]_ORPHANET
217074,Rare carcinoma of pancreas,Category,Annual incidence,3.9,1-9 / 100 000,Value and class,Worldwide,Validated,World Health Organization 2008[INST]
217074,Rare carcinoma of pancreas,Category,Point prevalence,3.5,1-9 / 100 000,Value and class,Worldwide,Validated,World Health Organization 2008[INST]
2330,Kasabach-Merritt phenomenon,Particular clinical situation in a disease or syndrome,Cases/families,300.0,,Case(s),Worldwide,Validated,ISBN-10: 0071354557[OTHER]
2330,Kasabach-Merritt phenomenon,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_ISBN-10: 0071354557[OTHER]
217071,Renal cell carcinoma,Clinical group,Point prevalence,42.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2010[INST]
217071,Renal cell carcinoma,Clinical group,Annual incidence,8.35,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
217067,Pouchitis,Particular clinical situation in a disease or syndrome,Point prevalence,22.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
2700,Noma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217064,5-fluorouracil poisoning,Particular clinical situation in a disease or syndrome,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
1451,CINCA syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]_21109514[PMID]
217059,Isolated nail clubbing,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET_24036948[PMID]
217055,Autosomal recessive intermediate Charcot-Marie-Tooth disease type A,Disease,Cases/families,8.0,,Family(ies),Worldwide,Validated,ORPHANET
217055,Autosomal recessive intermediate Charcot-Marie-Tooth disease type A,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
556,Malakoplakia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217335,RIN2 syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,27277385[PMID]
217335,RIN2 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27277385[PMID]
2745,Opitz GBBB syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,EXPERT
217340,17q21.31 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
3260,Idiopathic hypereosinophilic syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET_22740191[PMID]
217330,REN-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Cases/families,35.0,,Family(ies),Worldwide,Validated,ORPHANET
217330,REN-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2086,Optic pathway glioma,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,22796286[PMID]
2086,Optic pathway glioma,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
2566,Chronic Epstein-Barr virus infection syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_21348109[PMID]
3385,African trypanosomiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,23260189[PMID]
1560,Cysticercosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
566,Congenital microcoria,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
341,Viral hemorrhagic fever,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.74,1-9 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Point prevalence,37.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2004[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.92,1-9 / 1 000 000,Value and class,Austria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.78,1-9 / 1 000 000,Value and class,Belgium,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,2.2,1-9 / 100 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2012-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,Czech Republic,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,1.36,1-9 / 100 000,Value and class,Estonia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,29.16,1-5 / 10 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.18,1-9 / 1 000 000,Value and class,France,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,1.16,1-9 / 100 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Latvia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,1.44,1-9 / 100 000,Value and class,Luxembourg,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Poland,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,2.32,1-9 / 100 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,2.52,1-9 / 100 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
340,Hemorrhagic fever-renal syndrome,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Norway,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
2552,Microsporidiosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1171,Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,24468074[PMID]
1171,Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24468074[PMID]
217560,Neuroendocrine cell hyperplasia of infancy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217557,Pulmonary interstitial glycogenosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1686,Cardiac diverticulum,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217563,Neonatal acute respiratory distress syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
217563,Neonatal acute respiratory distress syndrome,Disease,Prevalence at birth,0.067,<1 / 1 000 000,Value and class,Worldwide,Validated,14977415[PMID]
217407,Hereditary hypotrichosis with recurrent skin vesicles,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,19765682[PMID]
217407,Hereditary hypotrichosis with recurrent skin vesicles,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19765682[PMID]
1456,Middle aortic syndrome,Morphological anomaly,Prevalence at birth,0.17,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
1456,Middle aortic syndrome,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,35.6,1-5 / 10 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,78.5,6-9 / 10 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,43.7,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,22.7,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,21.3,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,27.5,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,59.4,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,31.0,1-5 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,32.5,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,39.6,1-5 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,24.9,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,11.7,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,21.3,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,8.0,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,9.5,1-9 / 100 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,16.9,1-5 / 10 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,25.1,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,40.1,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1457,Aorta coarctation,Morphological anomaly,Prevalence at birth,38.1,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
1457,Aorta coarctation,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217390,Combined immunodeficiency due to DOCK8 deficiency,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,19776401[PMID]
217390,Combined immunodeficiency due to DOCK8 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19776401[PMID]
1132,Aortic arch defects,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217385,17p13.3 microduplication syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,23813913[PMID]
217385,17p13.3 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
217399,Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,19836135[PMID]
217399,Congenital insensitivity to pain-hyperhidrosis-absence of cutaneous sensory innervation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19836135[PMID]
217396,Progressive polyneuropathy with bilateral striatal necrosis,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,19798730[PMID]
217396,Progressive polyneuropathy with bilateral striatal necrosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19798730[PMID]
982,Pulmonary valve agenesis,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217371,Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins,Disease,Cases/families,32.0,,Case(s),Worldwide,Validated,33365252[PMID]_ 33485800[PMID]
217371,Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
217346,19q13.11 microdeletion syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,24243649[PMID]
217346,19q13.11 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
980,Absence of the pulmonary artery,Morphological anomaly,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
980,Absence of the pulmonary artery,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217382,Neurodegenerative syndrome due to cerebral folate transport deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,19732866[PMID]
217382,Neurodegenerative syndrome due to cerebral folate transport deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19732866[PMID]
1054,Aneurysm of sinus of Valsalva,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
217377,Microduplication Xp11.22p11.23 syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,19716111[PMID]
217377,Microduplication Xp11.22p11.23 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19716111[PMID]
217622,Sensorineural deafness with dilated cardiomyopathy,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,10769282[PMID]
217622,Sensorineural deafness with dilated cardiomyopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10769282[PMID]
3092,Fixed subaortic stenosis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2299,Aortic arch interruption,Morphological anomaly,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Europe,Not yet validated,24457106[PMID]
2299,Aortic arch interruption,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
3427,Double outlet left ventricle,Morphological anomaly,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Worldwide,Validated,21106011[PMID]_22644696[PMID]
3427,Double outlet left ventricle,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
3426,Double outlet right ventricle,Morphological anomaly,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Germany,Validated,22644696[PMID]
3426,Double outlet right ventricle,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
439,Isolated right ventricular hypoplasia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,United States,Validated,20558556[PMID]
422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Point prevalence,0.65,1-9 / 1 000 000,Value and class,France,Validated,16456139[PMID]
422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,France,Validated,16456139[PMID]
422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Point prevalence,1.4,1-9 / 100 000,Value and class,Czech Republic,Validated,24629043[PMID]
422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Annual incidence,0.62,1-9 / 1 000 000,Value and class,Czech Republic,Validated,24629043[PMID]
422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,16456139[PMID]_24629043[PMID]
422,Idiopathic/heritable pulmonary arterial hypertension,Disease,Point prevalence,6.25,1-9 / 100 000,Value and class,China,Validated,34103049[PMID]
2038,Pulmonary arteriovenous malformation,Morphological anomaly,Annual incidence,2.5,1-9 / 100 000,Value and class,Worldwide,Not yet validated,24008954[PMID]
2038,Pulmonary arteriovenous malformation,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
2041,Coronary arterial fistula,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET_24940026[PMID]
282,Frontotemporal dementia,Clinical group,Point prevalence,3.0,1-9 / 100 000,Value and class,Europe,Not yet validated,20971753[PMID]
282,Frontotemporal dementia,Clinical group,Annual incidence,3.05,1-9 / 100 000,Value and class,Italy,Validated,30979859[PMID]
331,Congenital factor XIII deficiency,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
331,Congenital factor XIII deficiency,Disease,Point prevalence,0.05,<1 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency[INST]
159,Carnitine-acylcarnitine translocase deficiency,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,24088670[PMID]
159,Carnitine-acylcarnitine translocase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
542,Primary cutaneous lymphoma,Category,Annual incidence,0.75,1-9 / 1 000 000,Value and class,Europe,Not yet validated,15692063[PMID]_16192622[PMID]_ ORPHANET
542,Primary cutaneous lymphoma,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
707,Plague,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
707,Plague,Disease,Annual incidence,2.2,1-9 / 100 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
335,Congenital fibrinogen deficiency,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Europe,Not yet validated,National haemophilia foundation[OTHER]
79,Congenital alpha2-antiplasmin deficiency,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,23396430[PMID]
79,Congenital alpha2-antiplasmin deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23396430[PMID]
217656,Inherited isolated arrhythmogenic cardiomyopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1070,Anisakiasis,Disease,Annual incidence,1.6,1-9 / 100 000,Value and class,Japan,Validated,ORPHANET_17428725[PMID]
1070,Anisakiasis,Disease,Annual incidence,0.32,1-9 / 1 000 000,Value and class,Worldwide,Validated,23092000[PMID]
1070,Anisakiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,24630706[PMID]
1467,Cogan syndrome,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,18037121[PMID]
1467,Cogan syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_18037121[PMID]
2157,Histidinemia,Disease,Prevalence at birth,2.7,1-9 / 100 000,Value and class,Sweden,Validated,8463510[PMID]
2157,Histidinemia,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET
2157,Histidinemia,Disease,Prevalence at birth,8.3,1-9 / 100 000,Value and class,United States,Validated,[EXPERT]
2157,Histidinemia,Disease,Prevalence at birth,11.9,1-5 / 10 000,Value and class,Japan,Validated,6468444[PMID]
3124,Saccharopinuria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
220407,Limited systemic sclerosis,Clinical subtype,Cases/families,200.0,,Case(s),Worldwide,Validated,23661427[PMID]
220407,Limited systemic sclerosis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
220386,Semilobar holoprosencephaly,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
2203,Hyperlysinemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
220393,Diffuse cutaneous systemic sclerosis,Clinical subtype,Point prevalence,3.8,1-9 / 100 000,Value and class,"Taiwan, Province of China",Not yet validated,22899470[PMID]
220393,Diffuse cutaneous systemic sclerosis,Clinical subtype,Annual incidence,1.5,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,22899470[PMID]
332,Congenital intrinsic factor deficiency,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
332,Congenital intrinsic factor deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
220448,Macrothrombocytopenia with mitral valve insufficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,9482416[PMID]
220448,Macrothrombocytopenia with mitral valve insufficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9482416[PMID]
220436,Quebec platelet disorder,Disease,Point prevalence,0.45,1-9 / 1 000 000,Value and class,Specific population,Validated,21495923[PMID]_22102275[PMID]
220436,Quebec platelet disorder,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Canada,Validated,18988861[PMID]_21495923[PMID]_22102275[PMID]
2195,Dicarboxylic aminoaciduria,Disease,Point prevalence,0.0,Unknown,Class only,Specific population,Validated,17570073[PMID]_21123949[PMID]_ORPHANET
2195,Dicarboxylic aminoaciduria,Disease,Prevalence at birth,2.76,1-9 / 100 000,Value and class,Specific population,Validated,17570073[PMID]_21123949[PMID]
2170,Methylcobalamin deficiency type cblG,Clinical subtype,Cases/families,33.0,,Case(s),Worldwide,Validated,ORPHANET
2170,Methylcobalamin deficiency type cblG,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
220295,Xeroderma pigmentosum-Cockayne syndrome complex,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,[EXPERT]
220295,Xeroderma pigmentosum-Cockayne syndrome complex,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
414,Gyrate atrophy of choroid and retina,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Finland,Not yet validated,ORPHANET
414,Gyrate atrophy of choroid and retina,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
414,Gyrate atrophy of choroid and retina,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
622,Homocystinuria without methylmalonic aciduria,Disease,Cases/families,73.0,,Case(s),Worldwide,Validated,[EXPERT]
622,Homocystinuria without methylmalonic aciduria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
927,Hyperammonemia due to N-acetylglutamate synthase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
927,Hyperammonemia due to N-acetylglutamate synthase deficiency,Disease,Cases/families,99.0,,Case(s),Worldwide,Validated,33036647[PMID]_33231058[PMID]
2880,Phosphoenolpyruvate carboxykinase deficiency,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
2880,Phosphoenolpyruvate carboxykinase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
941,D-glyceric aciduria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
220465,Laron syndrome with immunodeficiency,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
220465,Laron syndrome with immunodeficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
220489,Rare hereditary hemochromatosis,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
19,2-hydroxyglutaric aciduria,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2843,Pentosuria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
220497,Joubert syndrome with renal defect,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
212,Cystathioninuria,Disease,Prevalence at birth,7.1,1-9 / 100 000,Value and class,Canada,Validated,519848[PMID]
212,Cystathioninuria,Disease,Point prevalence,7.1,1-9 / 100 000,Value and class,Canada,Validated,519848[PMID]
212,Cystathioninuria,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
220493,Joubert syndrome with ocular defect,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
470,Lysinuric protein intolerance,Disease,Prevalence at birth,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
470,Lysinuric protein intolerance,Disease,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Italy,Validated,[EXPERT]
470,Lysinuric protein intolerance,Disease,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Finland,Validated,15050971[PMID]
470,Lysinuric protein intolerance,Disease,Prevalence at birth,1.75,1-9 / 100 000,Value and class,Japan,Validated,10980538[PMID]
470,Lysinuric protein intolerance,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
221074,Marchiafava-Bignami disease,Disease,Cases/families,250.0,,Case(s),Worldwide,Validated,11328337[PMID]
221074,Marchiafava-Bignami disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_11328337[PMID]
145,Hereditary breast and/or ovarian cancer syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,28632866[PMID]
2965,Prolactinoma,Disease,Point prevalence,44.4,1-5 / 10 000,Value and class,United Kingdom,Validated,19650784[PMID]
2965,Prolactinoma,Disease,Point prevalence,62.0,6-9 / 10 000,Value and class,Belgium,Validated,16968795[PMID]
2965,Prolactinoma,Disease,Point prevalence,45.7,1-5 / 10 000,Value and class,Switzerland,Validated,19968031[PMID]
2965,Prolactinoma,Disease,Annual incidence,2.05,1-9 / 100 000,Value and class,Malta,Validated,23239049[PMID]
2965,Prolactinoma,Disease,Point prevalence,50.7,1-5 / 10 000,Value and class,Europe,Validated,16968795[PMID]_ 19650784[PMID]_ 19968031[PMID]_ORPHANET
221091,Trigeminal neuralgia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
221091,Trigeminal neuralgia,Disease,Annual incidence,4.3,1-9 / 100 000,Value and class,United States,Validated,15062534[PMID]
221091,Trigeminal neuralgia,Disease,Annual incidence,8.0,1-9 / 100 000,Value and class,United Kingdom,Validated,10733998[PMID]
538,Lymphangioleiomyomatosis,Disease,Annual incidence,0.0135,<1 / 1 000 000,Value and class,Worldwide,Validated,21764810[PMID]
538,Lymphangioleiomyomatosis,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Worldwide,Validated,21764810[PMID]_ ORPHANET_[EXPERT]
538,Lymphangioleiomyomatosis,Disease,Annual incidence,0.015,<1 / 1 000 000,Value and class,United States,Validated,21764810[PMID]
538,Lymphangioleiomyomatosis,Disease,Point prevalence,0.17,1-9 / 1 000 000,Value and class,United States,Validated,21764810[PMID]
538,Lymphangioleiomyomatosis,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,France,Validated,10499073[PMID]
538,Lymphangioleiomyomatosis,Disease,Point prevalence,0.19,1-9 / 1 000 000,Value and class,Germany,Validated,21764810[PMID]
538,Lymphangioleiomyomatosis,Disease,Point prevalence,0.21,1-9 / 1 000 000,Value and class,Canada,Validated,21764810[PMID]
538,Lymphangioleiomyomatosis,Disease,Point prevalence,0.25,1-9 / 1 000 000,Value and class,United Kingdom,Validated,21764810[PMID]
538,Lymphangioleiomyomatosis,Disease,Point prevalence,0.32,1-9 / 1 000 000,Value and class,Switzerland,Validated,21764810[PMID]
538,Lymphangioleiomyomatosis,Disease,Point prevalence,0.39,1-9 / 1 000 000,Value and class,New Zealand,Validated,21764810[PMID]
538,Lymphangioleiomyomatosis,Disease,Point prevalence,0.26,1-9 / 1 000 000,Value and class,Australia,Validated,21764810[PMID]
538,Lymphangioleiomyomatosis,Disease,Point prevalence,0.25,1-9 / 1 000 000,Value and class,Europe,Validated,21764810[PMID]
538,Lymphangioleiomyomatosis,Disease,Point prevalence,0.25,1-9 / 1 000 000,Value and class,Netherlands,Validated,DOI:10.1517/21678707.2015.1022529[OTHER]
221098,Glossopharyngeal neuralgia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
221098,Glossopharyngeal neuralgia,Disease,Annual incidence,0.7,1-9 / 1 000 000,Value and class,United States,Validated,1798430[PMID]
2942,Postpoliomyelitis syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1578,Pterin-4 alpha-carbinolamine dehydratase deficiency,Clinical subtype,Cases/families,21.0,,Case(s),Worldwide,Validated,ORPHANET
1578,Pterin-4 alpha-carbinolamine dehydratase deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
3208,Isolated succinate-CoQ reductase deficiency,Disease,Cases/families,37.0,,Case(s),Worldwide,Validated,23322652[PMID]
3208,Isolated succinate-CoQ reductase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,23322652[PMID]
221008,Rothmund-Thomson syndrome type 1,Clinical subtype,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
221008,Rothmund-Thomson syndrome type 1,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
24,Fumaric aciduria,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,22069215[PMID]
24,Fumaric aciduria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22069215[PMID]
221016,Rothmund-Thomson syndrome type 2,Clinical subtype,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
221016,Rothmund-Thomson syndrome type 2,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
221039,"Hereditary sclerosing poikiloderma, Weary type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10233244[PMID]
221039,"Hereditary sclerosing poikiloderma, Weary type",Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,10233244[PMID]
851,Paris-Trousseau thrombocytopenia,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
851,Paris-Trousseau thrombocytopenia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
221043,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,26471370[PMID]
221043,Hereditary fibrosing poikiloderma-tendon contractures-myopathy-pulmonary fibrosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26471370[PMID]
221046,Poikiloderma with neutropenia,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,18925663[PMID]_20004881[PMID]
221046,Poikiloderma with neutropenia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
745,Severe hereditary thrombophilia due to congenital protein C deficiency,Disease,Prevalence at birth,0.16,1-9 / 1 000 000,Value and class,Worldwide,Validated,16689776[PMID]
745,Severe hereditary thrombophilia due to congenital protein C deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
221054,Acrocephalopolydactyly,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,22413886[PMID]
221054,Acrocephalopolydactyly,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22413886[PMID]
221061,Familial cerebral cavernous malformation,Malformation syndrome,Point prevalence,15.0,1-5 / 10 000,Value and class,Worldwide,Validated,[EXPERT]
849,Glanzmann thrombasthenia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
225154,Familial infantile bilateral striatal necrosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
225123,TFR2-related hemochromatosis,Disease,Cases/families,33.0,,Case(s),Worldwide,Validated,ORPHANET
225123,TFR2-related hemochromatosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
225147,Sporadic infantile bilateral striatal necrosis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
223727,Bone sarcoma,Clinical group,Annual incidence,0.8,1-9 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
223727,Bone sarcoma,Clinical group,Point prevalence,9.29,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
221120,Pseudoaminopterin syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,22811276[PMID]
221120,Pseudoaminopterin syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22811276[PMID]
221126,Fowler vasculopathy,Malformation syndrome,Cases/families,44.0,,Case(s),Worldwide,Validated,25677735[PMID]
221126,Fowler vasculopathy,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25677735[PMID]
221139,Combined immunodeficiency with facio-oculo-skeletal anomalies,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,19863561[PMID]
221139,Combined immunodeficiency with facio-oculo-skeletal anomalies,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19863561[PMID]
221142,Confetti-like macular atrophy,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,19878392[PMID]
221142,Confetti-like macular atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19878392[PMID]
221145,"Cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies",Malformation syndrome,Cases/families,21.0,,Case(s),Worldwide,Validated,26866239[PMID]
221145,"Cutis laxa with severe pulmonary, gastrointestinal and urinary anomalies",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26866239[PMID]
228003,Severe combined immunodeficiency due to CORO1A deficiency,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,29942301[PMID]
228003,Severe combined immunodeficiency due to CORO1A deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29942301[PMID]
3398,Thymic epithelial neoplasm,Category,Annual incidence,0.17,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_RARECARE surveillance of rare cancers in Europe 2011[REG]
3398,Thymic epithelial neoplasm,Category,Annual incidence,1.3,1-9 / 100 000,Value and class,United States,Validated,22406029[PMID]
3398,Thymic epithelial neoplasm,Category,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
228000,Idiopathic CD4 lymphocytopenia,Biological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
547,Non-Hodgkin lymphoma,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,22835603[PMID]
547,Non-Hodgkin lymphoma,Category,Annual incidence,11.6,1-5 / 10 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
842,Testicular seminomatous germ cell tumor,Disease,Annual incidence,1.71,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
842,Testicular seminomatous germ cell tumor,Disease,Lifetime Prevalence,46.01,1-5 / 10 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
842,Testicular seminomatous germ cell tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
227976,"Autosomal recessive optic atrophy, OPA7 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22815638[PMID]_20405026[PMID]_19327736[PMID]
227976,"Autosomal recessive optic atrophy, OPA7 type",Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,22815638[PMID]_20405026[PMID]_19327736[PMID]
876,Yolk sac tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
876,Yolk sac tumor,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
227972,Toxic oil syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_12192735[PMID]
227972,Toxic oil syndrome,Disease,Cases/families,20000.0,,Case(s),Worldwide,Validated,12192735[PMID]
227796,Fundus albipunctatus,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
228123,Coccidioidomycosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
228119,Fusariosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
228116,Hughes-Stovin syndrome,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,21489283[PMID]_15696563[PMID]_ [EXPERT]
228116,Hughes-Stovin syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
228113,Anal fistula,Particular clinical situation in a disease or syndrome,Point prevalence,18.3,1-5 / 10 000,Value and class,Europe,Validated,DOI:10.12998/wjcc.v7.i14.1795[OTHER]
228113,Anal fistula,Particular clinical situation in a disease or syndrome,Point prevalence,18.0,1-5 / 10 000,Value and class,United Kingdom,Validated,DOI:10.12998/wjcc.v7.i14.1795[OTHER]
3399,Germ cell tumor,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
389,Langerhans cell histiocytosis,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
228012,Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,18212818[PMID]
228012,Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18212818[PMID]
616,Medulloblastoma,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
616,Medulloblastoma,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2010[INST]
616,Medulloblastoma,Disease,Annual incidence,0.74,1-9 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2004-2007[REG]
301,Ependymal tumor,Clinical group,Annual incidence,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,22227039[PMID]_22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
301,Ependymal tumor,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
301,Ependymal tumor,Clinical group,Lifetime Prevalence,3.85,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
301,Ependymal tumor,Clinical group,Annual incidence,0.2,1-9 / 1 000 000,Value and class,United Kingdom,Validated,22227039[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
301,Ependymal tumor,Clinical group,Annual incidence,0.43,1-9 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
541,Primary cutaneous CD30+ T-cell lymphoproliferative disease,Clinical group,Annual incidence,0.18,1-9 / 1 000 000,Value and class,Europe,Validated,Institut de Veille Sanitaire 1990[INST]
541,Primary cutaneous CD30+ T-cell lymphoproliferative disease,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
543,Burkitt lymphoma,Disease,Annual incidence,0.17,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2003[REG]
543,Burkitt lymphoma,Disease,Point prevalence,12.5,1-5 / 10 000,Value and class,Africa,Validated,National Institutes of Health[INST]
543,Burkitt lymphoma,Disease,Point prevalence,0.4,1-9 / 1 000 000,Value and class,United States,Validated,National Cancer Institute 2001-2009[INST]
543,Burkitt lymphoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
319,Skeletal Ewing sarcoma,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
319,Skeletal Ewing sarcoma,Disease,Lifetime Prevalence,2.33,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
319,Skeletal Ewing sarcoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
668,Osteosarcoma,Disease,Annual incidence,0.23,1-9 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
668,Osteosarcoma,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
668,Osteosarcoma,Disease,Lifetime Prevalence,3.17,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
668,Osteosarcoma,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,United States,Validated,19197972[PMID]
227510,"Multiple system atrophy, cerebellar type",Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
94,Astrocytoma,Clinical group,Annual incidence,4.8,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Point prevalence,2.5,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]_ ORPHANET
94,Astrocytoma,Clinical group,Annual incidence,4.909,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,5.777,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,3.768,1-9 / 100 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,4.184,1-9 / 100 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,4.251,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,4.443,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,5.263,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,5.829,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,5.538,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,5.147,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,4.786,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,3.632,1-9 / 100 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,4.801,1-9 / 100 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,3.392,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,5.78,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,3.543,1-9 / 100 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,3.931,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,3.707,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,4.523,1-9 / 100 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,5.087,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,5.574,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,4.544,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
94,Astrocytoma,Clinical group,Annual incidence,5.591,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
360,Glioblastoma,Disease,Annual incidence,3.0,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
360,Glioblastoma,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
360,Glioblastoma,Disease,Annual incidence,2.52,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2003[REG]
360,Glioblastoma,Disease,Annual incidence,3.2,1-9 / 100 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
360,Glioblastoma,Disease,Annual incidence,4.2,1-9 / 100 000,Value and class,Croatia,Validated,15103760[PMID]
360,Glioblastoma,Disease,Annual incidence,3.7,1-9 / 100 000,Value and class,Greece,Validated,19494549[PMID]
360,Glioblastoma,Disease,Annual incidence,3.0,1-9 / 100 000,Value and class,Specific population,Validated,14648713[PMID]
226292,Permanent congenital hypothyroidism,Category,Prevalence at birth,33.3,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
226292,Permanent congenital hypothyroidism,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
513,Acute lymphoblastic leukemia,Clinical group,Annual incidence,2.75,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
513,Acute lymphoblastic leukemia,Clinical group,Annual incidence,1.3,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
513,Acute lymphoblastic leukemia,Clinical group,Annual incidence,1.6,1-9 / 100 000,Value and class,United States,Validated,National Cancer institute[INST]_23523389[PMID]
513,Acute lymphoblastic leukemia,Clinical group,Lifetime Prevalence,22.0,1-5 / 10 000,Value and class,United States,Validated,National Cancer institute 2009[INST]
513,Acute lymphoblastic leukemia,Clinical group,Point prevalence,11.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2005[INST]
1957,Esthesioneuroblastoma,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1957,Esthesioneuroblastoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
226298,Central congenital hypothyroidism,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2030,Fibrosarcoma,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2030,Fibrosarcoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2126,Solitary fibrous tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,24625420[PMID]
226295,Primary congenital hypothyroidism,Clinical group,Point prevalence,37.5,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
226295,Primary congenital hypothyroidism,Clinical group,Prevalence at birth,58.62,1-5 / 10 000,Value and class,United States,Validated,22766612[PMID]
226295,Primary congenital hypothyroidism,Clinical group,Prevalence at birth,33.0,1-5 / 10 000,Value and class,Finland,Validated,35661828[PMID]
758,Pseudoxanthoma elasticum,Disease,Point prevalence,2.5,1-9 / 100 000,Value and class,Europe,Validated,22209248[PMID]
419,Hyperprolinemia type 1,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1501,Adrenocortical carcinoma,Disease,Point prevalence,0.75,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency[INST]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,Europe,Not yet validated,22796286[PMID]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.082,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.173,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.18,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.249,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.547,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.271,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.314,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.225,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.173,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.17,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.133,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.288,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.514,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.464,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.188,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.226,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.433,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.234,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.244,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.215,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.141,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.167,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1501,Adrenocortical carcinoma,Disease,Annual incidence,0.183,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
226307,Hypothyroidism due to deficient transcription factors involved in pituitary development or function,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3148,Malignant peripheral nerve sheath tumor,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,24470531[PMID]
3148,Malignant peripheral nerve sheath tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24470531[PMID]
3273,Synovial sarcoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.463,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe [REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.95,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
391,Classic Hodgkin lymphoma,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2010[REG]
391,Classic Hodgkin lymphoma,Disease,Lifetime Prevalence,22.9,1-5 / 10 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2010[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.8,1-9 / 100 000,Value and class,United States,Validated,National Cancer Institute 2008[INST]_emedicine[OTHER]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,0.25,1-9 / 1 000 000,Value and class,China,Not yet validated,emedicine[OTHER]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,0.25,1-9 / 1 000 000,Value and class,Japan,Not yet validated,emedicine[OTHER]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.012,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.443,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.083,1-9 / 100 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.923,1-9 / 100 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.418,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.392,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.232,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.333,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.599,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.355,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,3.361,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,1.868,1-9 / 100 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.372,1-9 / 100 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.701,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.267,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.2,1-9 / 100 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.435,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.261,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.265,1-9 / 100 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.617,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,3.091,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.27,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
391,Classic Hodgkin lymphoma,Disease,Annual incidence,2.504,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
2260,Oligomeganephronia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
503,Larsen syndrome,Malformation syndrome,Prevalence at birth,0.65,1-9 / 1 000 000,Value and class,France,Validated,22925539[PMID]
503,Larsen syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,France,Validated,22925539[PMID]
503,Larsen syndrome,Malformation syndrome,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
503,Larsen syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,[EXPERT]_EUROCAT European surveillance of congenital anomalies 2010[REG]
1652,Dent disease,Disease,Cases/families,250.0,,Family(ies),Worldwide,Validated,20946626[PMID]
1652,Dent disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2542,Isolated microphthalmia-anophthalmia-coloboma,Clinical group,Prevalence at birth,2.18,1-9 / 100 000,Value and class,France,Validated,8921488[PMID]
2542,Isolated microphthalmia-anophthalmia-coloboma,Clinical group,Prevalence at birth,3.33,1-9 / 100 000,Value and class,Sweden,Validated,8921488[PMID]
2542,Isolated microphthalmia-anophthalmia-coloboma,Clinical group,Prevalence at birth,3.7,1-9 / 100 000,Value and class,United States,Validated,8921488[PMID]
2542,Isolated microphthalmia-anophthalmia-coloboma,Clinical group,Prevalence at birth,0.0,1-9 / 100 000,Class only,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]_[EXPERT]
2542,Isolated microphthalmia-anophthalmia-coloboma,Clinical group,Point prevalence,0.0,Unknown,Class only,Europe,Validated,[EXPERT]
3280,Syringomyelia,Clinical group,Point prevalence,8.4,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
3280,Syringomyelia,Clinical group,Point prevalence,8.4,1-9 / 100 000,Value and class,United Kingdom,Validated,4224973[PMID]
3280,Syringomyelia,Clinical group,Point prevalence,9.0,1-9 / 100 000,Value and class,Spain,Validated,2054207[PMID]
3280,Syringomyelia,Clinical group,Point prevalence,1.94,1-9 / 100 000,Value and class,Japan,Validated,21943925[PMID]
3280,Syringomyelia,Clinical group,Point prevalence,8.2,1-9 / 100 000,Value and class,New Zealand,Validated,16549414[PMID]
2478,Megalencephalic leukoencephalopathy with subcortical cysts,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,21977097[PMID]_12189496[PMID]
2478,Megalencephalic leukoencephalopathy with subcortical cysts,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3337,Primary Fanconi renotubular syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
223,Arginine vasopressin resistance,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
223,Arginine vasopressin resistance,Disease,Prevalence at birth,0.44,1-9 / 1 000 000,Value and class,Specific population,Validated,10820168[PMID]
757,Pseudohypoaldosteronism type 2,Disease,Cases/families,180.0,,Case(s),Worldwide,Validated,22073419[PMID]
757,Pseudohypoaldosteronism type 2,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_22073419[PMID]
228423,GATA2 deficiency spectrum,Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,20040766[PMID]_21242295[PMID]
228423,GATA2 deficiency spectrum,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
521,Chronic myeloid leukemia,Disease,Annual incidence,1.25,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
521,Chronic myeloid leukemia,Disease,Annual incidence,1.25,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
521,Chronic myeloid leukemia,Disease,Point prevalence,6.0,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
521,Chronic myeloid leukemia,Disease,Lifetime Prevalence,5.63,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
521,Chronic myeloid leukemia,Disease,Annual incidence,1.7,1-9 / 100 000,Value and class,United States,Validated,SEER Surveillance Epidemiology and End Results Program 2008-2012[REG]
228415,5q35 microduplication syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,24819041[PMID]
228415,5q35 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24819041[PMID]
132,Hereditary butyrylcholinesterase deficiency,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET
1172,Autosomal recessive cerebellar ataxia,Category,Point prevalence,3.3,1-9 / 100 000,Value and class,Portugal,Validated,23609960[PMID]
1172,Autosomal recessive cerebellar ataxia,Category,Point prevalence,3.3,1-9 / 100 000,Value and class,Worldwide,Validated,24603320[PMID]
1172,Autosomal recessive cerebellar ataxia,Category,Point prevalence,5.3,1-9 / 100 000,Value and class,France,Validated,19440741[PMID]
1172,Autosomal recessive cerebellar ataxia,Category,Point prevalence,2.3,1-9 / 100 000,Value and class,Norway,Validated,19339254[PMID]
1172,Autosomal recessive cerebellar ataxia,Category,Point prevalence,3.6,1-9 / 100 000,Value and class,Europe,Validated,19440741[PMID]_19339254[PMID]_23609960[PMID]
229717,Isolated agammaglobulinemia,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET
228426,Syndromic multisystem autoimmune disease due to Itch deficiency,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,20170897[PMID]
228426,Syndromic multisystem autoimmune disease due to Itch deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20170897[PMID]
2345,Isolated Klippel-Feil syndrome,Malformation syndrome,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
2345,Isolated Klippel-Feil syndrome,Malformation syndrome,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
1333,Familial pancreatic carcinoma,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
228396,Ptosis-upper ocular movement limitation-absence of lacrimal punctum syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,19941420[PMID]
228396,Ptosis-upper ocular movement limitation-absence of lacrimal punctum syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19941420[PMID]
228387,Spondylo-megaepiphyseal-metaphyseal dysplasia,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,22791571[PMID]
228387,Spondylo-megaepiphyseal-metaphyseal dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22791571[PMID]
228390,Frontonasal dysplasia-alopecia-genital anomalies syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,24668755[PMID]
228390,Frontonasal dysplasia-alopecia-genital anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
228410,Cardiac anomalies-short stature-joint hypermobility-facial dysmorphism syndrome,Malformation syndrome,Cases/families,19.0,,Case(s),Worldwide,Validated,19932204[PMID]
228410,Cardiac anomalies-short stature-joint hypermobility-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19932204[PMID]
228399,8q12 microduplication syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,22902603[PMID]
228399,8q12 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2781,Osteopetrosis and related disorders,Clinical group,Annual incidence,1.0,1-9 / 100 000,Value and class,Europe,Not yet validated,16307387[PMID]
2781,Osteopetrosis and related disorders,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
228402,2q23.1 microdeletion syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,22407754[PMID]
228402,2q23.1 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
228384,5q14.3 microdeletion syndrome,Etiological subtype,Cases/families,40.0,,Case(s),Worldwide,Validated,23824879[PMID]
228384,5q14.3 microdeletion syndrome,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23824879[PMID]
228379,Virus-associated trichodysplasia spinulosa,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,ORPHANET
228379,Virus-associated trichodysplasia spinulosa,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
228374,Charcot-Marie-Tooth disease type 2B5,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,20039262[PMID]
228374,Charcot-Marie-Tooth disease type 2B5,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20039262[PMID]
228371,Foodborne botulism,Clinical subtype,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,21495856[PMID]_[EXPERT]
228371,Foodborne botulism,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
228371,Foodborne botulism,Clinical subtype,Annual incidence,0.01,<1 / 1 000 000,Value and class,United States,Validated,21495856[PMID]
228371,Foodborne botulism,Clinical subtype,Annual incidence,0.18,1-9 / 1 000 000,Value and class,Romania,Validated,21495856[PMID]
228290,White fibrous papulosis of the neck,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
228293,Pseudoxanthoma elasticum-like papillary dermal elastolysis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
228299,Mid-dermal elastolysis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
228302,"Carnitine palmitoyl transferase II deficiency, myopathic form",Clinical subtype,Cases/families,300.0,,Case(s),Worldwide,Validated,20301431[PMID]
228302,"Carnitine palmitoyl transferase II deficiency, myopathic form",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301431[PMID]
228305,"Carnitine palmitoyl transferase II deficiency, severe infantile form",Clinical subtype,Cases/families,30.0,,Family(ies),Worldwide,Validated,20301431[PMID]
228305,"Carnitine palmitoyl transferase II deficiency, severe infantile form",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301431[PMID]
228308,"Carnitine palmitoyl transferase II deficiency, neonatal form",Clinical subtype,Cases/families,20.0,,Family(ies),Worldwide,Validated,20301431[PMID]
228308,"Carnitine palmitoyl transferase II deficiency, neonatal form",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301431[PMID]
228312,"Autoimmune hemolytic anemia, cold type",Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
228240,Elastoderma,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,25072684[PMID]
228240,Elastoderma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25072684[PMID]
135,CACH syndrome,Disease,Cases/families,148.0,,Case(s),Worldwide,Validated,ORPHANET
135,CACH syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
228247,Acquired pseudoxanthoma elasticum,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
228247,Acquired pseudoxanthoma elasticum,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
228254,Elastoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
228264,Papular elastorrhexis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
228272,Primary anetoderma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
228277,Familial anetoderma,Disease,Cases/families,12.0,,Family(ies),Worldwide,Validated,21719400[PMID]
228277,Familial anetoderma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21719400[PMID]
228285,Acquired cutis laxa,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
228190,Patent ductus arteriosus-bicuspid aortic valve-hand anomalies syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,10533032[PMID]
228190,Patent ductus arteriosus-bicuspid aortic valve-hand anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3203,Overhydrated hereditary stomatocytosis,Disease,Cases/families,20.0,,Family(ies),Worldwide,Validated,ORPHANET
3203,Overhydrated hereditary stomatocytosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3202,Dehydrated hereditary stomatocytosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9718354[PMID]_11001917[PMID]_23479567[PMID]
3202,Dehydrated hereditary stomatocytosis,Disease,Cases/families,20.0,,Family(ies),Worldwide,Validated,9718354[PMID]_11001917[PMID]_23479567[PMID]_Pr Loïc GARÇON_Dr Véronique PICARD[EXPERT]
228236,Linear focal elastosis,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
228236,Linear focal elastosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
228227,Late-onset focal dermal elastosis,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,15670180[PMID]
228227,Late-onset focal dermal elastosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15670180[PMID]
228140,"Idiopathic ventricular fibrillation, non Brugada type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1018,X-linked Alport syndrome-diffuse leiomyomatosis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
228165,Baló concentric sclerosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
306,Self-limited infantile epilepsy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
228157,Marburg acute multiple sclerosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
328,Congenital factor X deficiency,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2008[INST]
228174,Autosomal dominant Charcot-Marie-Tooth disease type 2N,Disease,Cases/families,28.0,,Case(s),Worldwide,Validated,ORPHANET
228174,Autosomal dominant Charcot-Marie-Tooth disease type 2N,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
228169,Autosomal dominant striatal neurodegeneration,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,15210883[PMID]_26769607[PMID]_26475694[PMID]
228169,Autosomal dominant striatal neurodegeneration,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15210883[PMID]_26769607[PMID]_26475694[PMID]
2132,Hemoglobin C disease,Disease,Point prevalence,166.66,>1 / 1000,Value and class,United States,Validated,23591685[PMID]
2132,Hemoglobin C disease,Disease,Prevalence at birth,3.65,1-9 / 100 000,Value and class,Belgium,Validated,19103861[PMID]
2133,Hemoglobin E disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
228179,Autosomal dominant Charcot-Marie-Tooth disease type 2M,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
228179,Autosomal dominant Charcot-Marie-Tooth disease type 2M,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
288,Hereditary elliptocytosis,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Worldwide,Validated,[EXPERT]
231531,Hermansky-Pudlak syndrome due to BLOC-1 deficiency,Clinical subtype,Cases/families,9.0,,Case(s),Worldwide,Validated,PMID: 12923531; 23364359 ; 22461475 ; 16385460
231531,Hermansky-Pudlak syndrome due to BLOC-1 deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
231512,Hermansky-Pudlak syndrome due to BLOC-2 deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1320,Idiopathic camptocormia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
256,Early-onset generalized limb-onset dystonia,Disease,Annual incidence,20.0,1-5 / 10 000,Value and class,Specific population,Validated,7719342[PMID]
256,Early-onset generalized limb-onset dystonia,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,United States,Validated,3264051[PMID]
256,Early-onset generalized limb-onset dystonia,Disease,Point prevalence,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,17129379[PMID]_23596437[PMID]
256,Early-onset generalized limb-onset dystonia,Disease,Point prevalence,3.4,1-9 / 100 000,Value and class,United States,Validated,3264051[PMID]
256,Early-onset generalized limb-onset dystonia,Disease,Prevalence at birth,8.3,1-9 / 100 000,Value and class,France,Validated,17290457[PMID]
231500,Hermansky-Pudlak syndrome due to BLOC-3 deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
441,Pure autonomic failure,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2007[INST]
1576,Infantile bilateral striatal necrosis,Clinical group,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
231445,Paraparetic variant of Guillain-Barré syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
231445,Paraparetic variant of Guillain-Barré syndrome,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2073,Narcolepsy type 1,Disease,Point prevalence,30.0,1-5 / 10 000,Value and class,Europe,Validated,24849861[PMID]_[EXPERT]
2073,Narcolepsy type 1,Disease,Annual incidence,0.74,1-9 / 1 000 000,Value and class,United States,Validated,11902429[PMID]
2073,Narcolepsy type 1,Disease,Point prevalence,22.0,1-5 / 10 000,Value and class,Norway,Validated,19456307[PMID]_24849861[PMID]
2073,Narcolepsy type 1,Disease,Point prevalence,26.0,1-5 / 10 000,Value and class,Finland,Validated,8210228[PMID]_24849861[PMID]
2073,Narcolepsy type 1,Disease,Point prevalence,34.0,1-5 / 10 000,Value and class,China,Validated,11164060[PMID]_24849861[PMID]
2073,Narcolepsy type 1,Disease,Point prevalence,28.9,1-5 / 10 000,Value and class,United States,Not yet validated,11902429[PMID]_19013100[PMID]_24849861[PMID]_ORPHANET
2073,Narcolepsy type 1,Disease,Point prevalence,40.0,1-5 / 10 000,Value and class,United Kingdom,Validated,8894197[PMID]_24849861[PMID]
231401,Alpha-thalassemia-myelodysplastic syndrome,Disease,Cases/families,80.0,,Case(s),Worldwide,Validated,[EXPERT]
231401,Alpha-thalassemia-myelodysplastic syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1866,"Focal, segmental or multifocal dystonia",Category,Annual incidence,2.0,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
1866,"Focal, segmental or multifocal dystonia",Category,Point prevalence,11.7,1-5 / 10 000,Value and class,Europe,Not yet validated,11127535[PMID]
1866,"Focal, segmental or multifocal dystonia",Category,Point prevalence,11.2,1-5 / 10 000,Value and class,Serbia,Validated,14639690[PMID]
1866,"Focal, segmental or multifocal dystonia",Category,Point prevalence,31.2,1-5 / 10 000,Value and class,Iceland,Validated,16211610[PMID]
1866,"Focal, segmental or multifocal dystonia",Category,Point prevalence,29.5,1-5 / 10 000,Value and class,United States,Validated,3264051[PMID]
1866,"Focal, segmental or multifocal dystonia",Category,Point prevalence,13.7,1-5 / 10 000,Value and class,Japan,Validated,16755586[PMID]
1866,"Focal, segmental or multifocal dystonia",Category,Point prevalence,10.0,1-5 / 10 000,Value and class,Egypt,Validated,7969703[PMID]
1866,"Focal, segmental or multifocal dystonia",Category,Point prevalence,14.3,1-5 / 10 000,Value and class,Thailand,Validated,21999890[PMID]
231393,Beta-thalassemia-X-linked thrombocytopenia syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
809,Mixed connective tissue disease,Disease,Annual incidence,0.17,1-9 / 1 000 000,Value and class,Norway,Validated,21398332[PMID]
809,Mixed connective tissue disease,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Norway,Validated,21398332[PMID]
809,Mixed connective tissue disease,Disease,Point prevalence,2.7,1-9 / 100 000,Value and class,Japan,Validated,[EXPERT]
809,Mixed connective tissue disease,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
809,Mixed connective tissue disease,Disease,Annual incidence,1.9,1-9 / 100 000,Value and class,United States,Validated,26946215[PMID]
809,Mixed connective tissue disease,Disease,Annual incidence,0.8,1-9 / 1 000 000,Value and class,Finland,Validated,8810933[PMID]_26946215[PMID]
1309,Medullary sponge kidney,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
231249,Hemoglobin E-beta-thalassemia syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
231242,Hemoglobin C-beta-thalassemia syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2197,Idiopathic hypercalciuria,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2197,Idiopathic hypercalciuria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
231237,Delta-beta-thalassemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
231226,Dominant beta-thalassemia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
18,Distal renal tubular acidosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_22872862[PMID]
231222,Beta-thalassemia intermedia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
160,Castleman disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
160,Castleman disease,Disease,Annual incidence,0.0,1-9 / 100 000,Class only,United States,Validated,ORPHANET_25120049[PMID]
231214,Beta-thalassemia major,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
231214,Beta-thalassemia major,Clinical subtype,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,United States,Validated,22766612[PMID]
231214,Beta-thalassemia major,Clinical subtype,Point prevalence,160.0,>1 / 1000,Value and class,Bahrain,Validated,24044606[PMID]
231214,Beta-thalassemia major,Clinical subtype,Point prevalence,40.0,1-5 / 10 000,Value and class,Oman,Validated,11360093[PMID]_12934793[PMID]
2841,Hailey-Hailey disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
231183,Usher syndrome type 3,Clinical subtype,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Denmark,Validated,9212179[PMID]
231183,Usher syndrome type 3,Clinical subtype,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
231183,Usher syndrome type 3,Clinical subtype,Point prevalence,1.2,1-9 / 100 000,Value and class,Specific population,Validated,14569126[PMID]
347,Frasier syndrome,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,[EXPERT]_25623218[PMID]
347,Frasier syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]_25623218[PMID]
231178,Usher syndrome type 2,Clinical subtype,Point prevalence,2.2,1-9 / 100 000,Value and class,Denmark,Validated,9212179[PMID]
231178,Usher syndrome type 2,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
1670,Chronic diarrhea with villous atrophy,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,8283377[PMID]
1670,Chronic diarrhea with villous atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8283377[PMID]
231154,Combined immunodeficiency due to partial RAG1 deficiency,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,16276422[PMID]
231154,Combined immunodeficiency due to partial RAG1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16276422[PMID]
231160,Familial cerebral saccular aneurysm,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
231160,Familial cerebral saccular aneurysm,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
231169,Usher syndrome type 1,Clinical subtype,Point prevalence,1.5,1-9 / 100 000,Value and class,Denmark,Validated,9212179[PMID]
231169,Usher syndrome type 1,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
231147,Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
231080,High-grade dysplasia in patients with Barrett esophagus,Particular clinical situation in a disease or syndrome,Point prevalence,36.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2002[INST]
231108,Rhabdoid tumor predisposition syndrome,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,ORPHANET
231108,Rhabdoid tumor predisposition syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
405,Familial hypocalciuric hypercalcemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
231111,Drug-induced lupus erythematosus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1223,Balantidiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
231040,Familial generalized lentiginosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3318,Essential thrombocythemia,Disease,Point prevalence,24.0,1-5 / 10 000,Value and class,United States,Validated,18181200[PMID]
3318,Essential thrombocythemia,Disease,Annual incidence,1.55,1-9 / 100 000,Value and class,Sweden,Validated,16673273[PMID]
3318,Essential thrombocythemia,Disease,Point prevalence,30.0,1-5 / 10 000,Value and class,Sweden,Validated,16673273[PMID]
3318,Essential thrombocythemia,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
3318,Essential thrombocythemia,Disease,Annual incidence,0.48,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
230857,Ehlers-Danlos/osteogenesis imperfecta syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET_23692737[PMID]
230851,Cardiac-valvular Ehlers-Danlos syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,16816023[PMID]_1507720[PMID]_2952379[PMID]
230851,Cardiac-valvular Ehlers-Danlos syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
231031,Erythema palmare hereditarium,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
913,Zollinger-Ellison syndrome,Disease,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
913,Zollinger-Ellison syndrome,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
913,Zollinger-Ellison syndrome,Disease,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Denmark,Validated,ISBN:0849359937[OTHER]
913,Zollinger-Ellison syndrome,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Switzerland,Not yet validated,ISBN:0849359937[OTHER]
913,Zollinger-Ellison syndrome,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Ireland,Validated,2575263[PMID]
913,Zollinger-Ellison syndrome,Disease,Annual incidence,0.125,1-9 / 1 000 000,Value and class,Worldwide,Validated,22261919[PMID]
231013,Congenital trigeminal anesthesia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
230800,Toxin-mediated infectious botulism,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
82,Hereditary thrombophilia due to congenital antithrombin deficiency,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Worldwide,Validated,ORPHANET
230839,Classical-like Ehlers-Danlos syndrome type 1,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,27582382[PMID]
230839,Classical-like Ehlers-Danlos syndrome type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27582382[PMID]
519,Acute myeloid leukemia,Clinical group,Annual incidence,2.5,1-9 / 100 000,Value and class,Worldwide,Validated,17019734[PMID]
519,Acute myeloid leukemia,Clinical group,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
519,Acute myeloid leukemia,Clinical group,Annual incidence,3.39,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
519,Acute myeloid leukemia,Clinical group,Lifetime Prevalence,10.98,1-5 / 10 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
519,Acute myeloid leukemia,Clinical group,Annual incidence,4.4,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
519,Acute myeloid leukemia,Clinical group,Annual incidence,2.8,1-9 / 100 000,Value and class,Denmark,Validated,24039451[PMID]
519,Acute myeloid leukemia,Clinical group,Annual incidence,3.7,1-9 / 100 000,Value and class,United States,Validated,National Cancer institute 2010[INST]
235936,Familial hyperaldosteronism,Clinical group,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
238446,15q11q13 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
238446,15q11q13 microduplication syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
238329,Severe X-linked mitochondrial encephalomyopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20362274[PMID]
238329,Severe X-linked mitochondrial encephalomyopathy,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,20362274[PMID]
231573,Congenital erosive and vesicular dermatosis,Disease,Cases/families,31.0,,Case(s),Worldwide,Validated,28247410[PMID]
231573,Congenital erosive and vesicular dermatosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28247410[PMID]
231580,Primary unilateral adrenal hyperplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
231556,Late-onset localized junctional epidermolysis bullosa-intellectual disability syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,1642260[PMID]
231556,Late-onset localized junctional epidermolysis bullosa-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1642260[PMID]
231568,Autosomal dominant generalized dystrophic epidermolysis bullosa,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
231637,Rare surgically correctable form of primary aldosteronism,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
231625,Adrenocortical carcinoma with pure aldosterone hypersecretion,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1900,Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency,Clinical subtype,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,21699693[PMID]_15666309[PMID]
1900,Kyphoscoliotic Ehlers-Danlos syndrome due to lysyl hydroxylase 1 deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
286,Vascular Ehlers-Danlos syndrome,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,35779834[PMID]
285,Hypermobile Ehlers-Danlos syndrome,Disease,Point prevalence,12.5,1-5 / 10 000,Value and class,Europe,Not yet validated,ORPHANET
231736,Microcornea-posterior megalolenticonus-persistent fetal vasculature-coloboma syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,20417569[PMID]
231736,Microcornea-posterior megalolenticonus-persistent fetal vasculature-coloboma syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20417569[PMID]
231742,Epibulbar lipodermoid-preauricular appendage-polythelia syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,20450310[PMID]
231742,Epibulbar lipodermoid-preauricular appendage-polythelia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20450310[PMID]
257,Epidermolysis bullosa simplex with muscular dystrophy,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,[EXPERT]
257,Epidermolysis bullosa simplex with muscular dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1901,Dermatosparaxis Ehlers-Danlos syndrome,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,26765342[PMID]
1901,Dermatosparaxis Ehlers-Danlos syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26765342[PMID]
231720,Non-acquired combined pituitary hormone deficiency-sensorineural hearing loss-spine abnormalities syndrome,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,ORPHANET_19762173[PMID]
231720,Non-acquired combined pituitary hormone deficiency-sensorineural hearing loss-spine abnormalities syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
1899,Arthrochalasia Ehlers-Danlos syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
839,"Congenital nephrotic syndrome, Finnish type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
839,"Congenital nephrotic syndrome, Finnish type",Disease,Prevalence at birth,12.2,1-5 / 10 000,Value and class,Finland,Validated,4127143[PMID]
531,Miller-Dieker syndrome,Malformation syndrome,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
531,Miller-Dieker syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3394,Soft tissue sarcoma,Clinical group,Annual incidence,3.6,1-9 / 100 000,Value and class,France,Validated,21826194[PMID]
3394,Soft tissue sarcoma,Clinical group,Point prevalence,30.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
3394,Soft tissue sarcoma,Clinical group,Annual incidence,4.74,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
1084,Isolated lissencephaly type 1 without known genetic defects,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1083,Microlissencephaly,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
452,X-linked lissencephaly with abnormal genitalia,Malformation syndrome,Cases/families,30.0,,Family(ies),Worldwide,Validated,17480217[PMID]
452,X-linked lissencephaly with abnormal genitalia,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_17480217[PMID]
238750,4q21 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
238750,4q21 microdeletion syndrome,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,20522426[PMID]_22903878[PMID]_21834054[PMID]
238763,Glaucoma secondary to spherophakia/ectopia lentis and megalocornea,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,22025892[PMID]
238763,Glaucoma secondary to spherophakia/ectopia lentis and megalocornea,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22025892[PMID]
238722,Familial congenital mirror movements,Disease,Cases/families,75.0,,Case(s),Worldwide,Validated,19127048[PMID]_19720981[PMID]_21242494[PMID]_27830107[PMID]_25098561[PMID]
238722,Familial congenital mirror movements,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19127048[PMID]_19720981[PMID]_21242494[PMID]_27830107[PMID]_25098561[PMID]
238744,Mammary-digital-nail syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,20145678[PMID]
238744,Mammary-digital-nail syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20145678[PMID]
238769,1q44 microdeletion syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,21800092[PMID]
238769,1q44 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
238517,Hypotonia-cystinuria type 1 syndrome,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
238505,Combined immunodeficiency due to CD27 deficiency,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,29942301[PMID]
238505,Combined immunodeficiency due to CD27 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29942301[PMID]
238468,Hypohidrotic ectodermal dysplasia,Disease,Point prevalence,6.7,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
238475,Familial hypercholanemia,Disease,Cases/families,23.0,,Case(s),Worldwide,Validated,ORPHANET
238475,Familial hypercholanemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
238455,Infantile dystonia-parkinsonism,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,24613933[PMID]_19478460[PMID]_22279524[PMID]
238455,Infantile dystonia-parkinsonism,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24613933[PMID]_19478460[PMID]_22279524[PMID]
238459,SLC35A1-CDG,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,11157507[PMID]_23873973[PMID]_28856833[PMID]
238459,SLC35A1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11157507[PMID]_23873973[PMID]_28856833[PMID]
238578,Familial clubfoot due to 17q23.1q23.2 microduplication,Etiological subtype,Cases/families,4.0,,Family(ies),Worldwide,Validated,20598276[PMID]_22678995[PMID]
238578,Familial clubfoot due to 17q23.1q23.2 microduplication,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20598276[PMID]_22678995[PMID]
238583,Hyperphenylalaninemia due to tetrahydrobiopterin deficiency,Disease,Prevalence at birth,0.22,1-9 / 1 000 000,Value and class,Japan,Validated,6468444[PMID]
238583,Hyperphenylalaninemia due to tetrahydrobiopterin deficiency,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Worldwide,Validated,[EXPERT]
238583,Hyperphenylalaninemia due to tetrahydrobiopterin deficiency,Disease,Point prevalence,0.21,1-9 / 1 000 000,Value and class,Brazil,Validated,35209917[PMID]
238557,Chuvash erythrocytosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
238569,Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections syndrome,Disease,Cases/families,80.0,,Case(s),Worldwide,Validated,24089328[PMID]
238569,Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
238547,Acquired secondary polycythemia,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
238523,Atypical hypotonia-cystinuria syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,18234729[PMID]
238523,Atypical hypotonia-cystinuria syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18234729[PMID]
238536,Congenital secondary polycythemia,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
238624,Idiopathic intracranial hypertension,Disease,Point prevalence,14.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2016[INST]
238621,Ileal pouch anal anastomosis related faecal incontinence,Particular clinical situation in a disease or syndrome,Point prevalence,3.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2009[INST]
238606,Primary orthostatic tremor,Disease,Cases/families,390.0,,Case(s),Worldwide,Validated,[EXPERT]
238606,Primary orthostatic tremor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
238593,IgG4-related mesenteritis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
238670,Isolated thyrotropin-releasing hormone deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
238666,Isolated congenital hypogonadotropic hypogonadism,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
238666,Isolated congenital hypogonadotropic hypogonadism,Disease,Prevalence at birth,0.0,1-9 / 100 000,Class only,Worldwide,Validated,21682876[PMID]_ORPHANET
238654,"Congenital primary megaureter, nonrefluxing and unobstructed form",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
238650,"Congenital primary megaureter, refluxing form",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
238646,"Congenital primary megaureter, obstructed form",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
238642,"Primary megaureter, adult-onset form",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
240071,Classic progressive supranuclear palsy syndrome,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
240112,Progressive supranuclear palsy-progressive non-fluent aphasia syndrome,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
240112,Progressive supranuclear palsy-progressive non-fluent aphasia syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
240103,Progressive supranuclear palsy-corticobasal syndrome,Clinical subtype,Point prevalence,0.6,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
240094,Progressive supranuclear palsy-pure akinesia with gait freezing syndrome,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
240085,Progressive supranuclear palsy-predominant parkinsonism syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
240760,Nijmegen breakage syndrome-like disorder,Malformation syndrome,Cases/families,1.0,,Case(s),Worldwide,Validated,1887849[PMID]_19409520[PMID]
240760,Nijmegen breakage syndrome-like disorder,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1887849[PMID]_19409520[PMID]
331226,Susceptibility to infection due to TYK2 deficiency,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,26304966[PMID]
331226,Susceptibility to infection due to TYK2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26304966[PMID]
331235,Selective IgM deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_23760686[PMID]
331176,Severe congenital neutropenia due to G6PC3 deficiency,Disease,Cases/families,57.0,,Case(s),Worldwide,Validated,23758768[PMID]
331176,Severe congenital neutropenia due to G6PC3 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
331187,Immunodeficiency due to MASP-2 deficiency,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,12904520[PMID]
331187,Immunodeficiency due to MASP-2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12904520[PMID]
331190,Immunodeficiency due to ficolin3 deficiency,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,19535802[PMID]
331190,Immunodeficiency due to ficolin3 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19535802[PMID]
331206,Severe combined immunodeficiency due to complete RAG1/2 deficiency,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2014[INST]
330064,Chronic actinic dermatitis,Disease,Point prevalence,16.7,1-5 / 10 000,Value and class,United Kingdom,Validated,15813653[PMID]
330064,Chronic actinic dermatitis,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
330001,Wild type ATTR amyloidosis,Disease,Point prevalence,1.72,1-5 / 10 000,Value and class,Worldwide,Validated,32633805[PMID]
329977,Classic neuroendocrine tumor of appendix,Clinical subtype,Annual incidence,0.25,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,20524865[PMID]
329977,Classic neuroendocrine tumor of appendix,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
329984,Goblet cell carcinoma,Clinical subtype,Annual incidence,0.025,<1 / 1 000 000,Value and class,Worldwide,Not yet validated,20524865[PMID]
329984,Goblet cell carcinoma,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
330012,High altitude pulmonary edema,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2013[INST]
330015,Lead poisoning,Disease,Point prevalence,2.3,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2013[INST]
330015,Lead poisoning,Disease,Point prevalence,0.68,1-9 / 1 000 000,Value and class,France,Validated,Institut de Veille Sanitaire 2010[INST]_ORPHANET
330032,Hemoglobin Lepore-beta-thalassemia syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
330041,Hemoglobin M disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
330021,Mercury poisoning,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,European Medicines Agency 2012[INST]
330029,Hypotrichosis-deafness syndrome,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,16280295[PMID]
330029,Hypotrichosis-deafness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
330058,Hydroa vacciniforme,Disease,Point prevalence,0.34,1-9 / 1 000 000,Value and class,United Kingdom,Validated,10642674[PMID]
330058,Hydroa vacciniforme,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
330061,Actinic prurigo,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,Etiological subtype,Cases/families,11.0,,Case(s),Worldwide,Validated,17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]
330050,DNM1L-related encephalopathy due to mitochondrial and peroxisomal fission defect,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]
330054,Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,19409522[PMID]
330054,Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329813,Mosaic genome-wide paternal uniparental disomy syndrome,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,23804593[PMID]
329813,Mosaic genome-wide paternal uniparental disomy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23804593[PMID]
329802,5p13 microduplication syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,20052029[PMID]_21211577[PMID]_23085304[PMID]
329802,5p13 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329883,Non-hypoproteinemic hypertrophic gastropathy,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,22711003[PMID]
329883,Non-hypoproteinemic hypertrophic gastropathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329874,Idiopathic giant cell myocarditis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
329475,Spastic paraplegia-Paget disease of bone syndrome,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,22991237[PMID]
329475,Spastic paraplegia-Paget disease of bone syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329481,Lipoprotein glomerulopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24149835[PMID]
329481,Lipoprotein glomerulopathy,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,24149835[PMID]
329478,Adult-onset distal myopathy due to VCP mutation,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,21684747[PMID]
329478,Adult-onset distal myopathy due to VCP mutation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329942,Transient neonatal multiple acyl-CoA dehydrogenase deficiency,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,17689999[PMID]_21089064[PMID]_21089064[PMID]
329942,Transient neonatal multiple acyl-CoA dehydrogenase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329971,Generalized juvenile polyposis/juvenile polyposis coli,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
329967,Intermittent hydrarthrosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
329918,C3 glomerulopathy,Clinical subtype,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Europe,Validated,27056062[PMID]
329903,Immunoglobulin-mediated membranoproliferative glomerulonephritis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,,ORPHANET
329308,Fatty acid hydroxylase-associated neurodegeneration,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21735565[PMID]
329314,Adult-onset multiple mitochondrial DNA deletion syndrome due to DGUOK deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
329319,Thrombocythemia with distal limb defects,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,19553636[PMID]
329319,Thrombocythemia with distal limb defects,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329324,Inverse Klippel-Trénaunay syndrome,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,17341861[PMID]_23000147[PMID]
329324,Inverse Klippel-Trénaunay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329284,Beta-propeller protein-associated neurodegeneration,Disease,Cases/families,68.0,,Case(s),Worldwide,Validated,29445477[PMID]
329284,Beta-propeller protein-associated neurodegeneration,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29445477[PMID]
329457,Distal arthrogryposis type 5D,Disease,Cases/families,33.0,,Case(s),Worldwide,Validated,25099528[PMID]_24782201[PMID]
329457,Distal arthrogryposis type 5D,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25099528[PMID]_24782201[PMID]
329466,"Autosomal dominant focal dystonia, DYT25 type",Disease,Cases/families,28.0,,Case(s),Worldwide,Validated,23222958[PMID]
329466,"Autosomal dominant focal dystonia, DYT25 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23222958[PMID]
329469,Acute megakaryoblastic leukemia in children without Down syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
329329,Autosomal recessive frontotemporal pachygyria,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,23022981[PMID]
329329,Autosomal recessive frontotemporal pachygyria,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329332,Microcephaly-cerebellar hypoplasia-cardiac conduction defect syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,22002884[PMID]
329332,Microcephaly-cerebellar hypoplasia-cardiac conduction defect syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329336,Adult-onset chronic progressive external ophthalmoplegia with mitochondrial myopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
329228,Microcephalic primordial dwarfism due to ZNF335 deficiency,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,23178126[PMID]_27540107[PMID]_29652087[PMID]
329228,Microcephalic primordial dwarfism due to ZNF335 deficiency,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29652087[PMID]
329224,Schuurs-Hoeijmakers syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,23159249[PMID]
329224,Schuurs-Hoeijmakers syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329217,Cerebral sinovenous thrombosis,Disease,Annual incidence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,15858188[PMID]_ORPHANET
329217,Cerebral sinovenous thrombosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
329211,Autosomal dominant neovascular inflammatory vitreoretinopathy,Disease,Cases/families,99.0,,Case(s),Worldwide,Validated,23055945[PMID]
329211,Autosomal dominant neovascular inflammatory vitreoretinopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329195,Developmental delay with autism spectrum disorder and gait instability,Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,23065719[PMID]_23243086[PMID]
329195,Developmental delay with autism spectrum disorder and gait instability,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329191,Tall stature-long halluces-multiple extra-epiphyses syndrome,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,22870295[PMID]_23243086[PMID]_24259409[PMID]
329191,Tall stature-long halluces-multiple extra-epiphyses syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329178,Congenital muscular dystrophy with intellectual disability and severe epilepsy,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,23109149[PMID]
329178,Congenital muscular dystrophy with intellectual disability and severe epilepsy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329258,Autosomal dominant Charcot-Marie-Tooth disease type 2Q,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,23141294[PMID]
329258,Autosomal dominant Charcot-Marie-Tooth disease type 2Q,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329249,Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency,Etiological subtype,Cases/families,13.0,,Case(s),Worldwide,Validated,23160192[PMID]
329249,Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23160192[PMID]
329242,Congenital chronic diarrhea with protein-losing enteropathy,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23114594[PMID]
329242,Congenital chronic diarrhea with protein-losing enteropathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329235,X-linked central congenital hypothyroidism with late-onset testicular enlargement,Disease,Cases/families,27.0,,Case(s),Worldwide,Validated,23143598[PMID]
329235,X-linked central congenital hypothyroidism with late-onset testicular enlargement,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
329173,Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,30936877[PMID]_23104095[PMID]_26008899[PMID]
329173,Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30936877[PMID]
329,Congenital factor XI deficiency,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
1243,Best vitelliform macular dystrophy,Disease,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Denmark,Validated,22633354[PMID]
1243,Best vitelliform macular dystrophy,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Sweden,Validated,4448697[PMID]
1243,Best vitelliform macular dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1243,Best vitelliform macular dystrophy,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Denmark,Validated,22633354[PMID]
1243,Best vitelliform macular dystrophy,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_22633354[PMID]_4448697[PMID]
324964,Chronic nonbacterial osteomyelitis/Chronic recurrent multifocal osteomyelitis,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Worldwide,Validated,12183714[PMID]
324964,Chronic nonbacterial osteomyelitis/Chronic recurrent multifocal osteomyelitis,Disease,Annual incidence,2.5,1-9 / 100 000,Value and class,Worldwide,Validated,12183714[PMID]
324972,MAGIC syndrome,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,27293269[PMID]
324972,MAGIC syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27293269[PMID]
324977,Proteasome-associated autoinflammatory syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24131530[PMID]
324977,Proteasome-associated autoinflammatory syndrome,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,24131530[PMID]
324718,ABetaA21G amyloidosis,Clinical subtype,Cases/families,2.0,,Family(ies),Worldwide,Validated,[EXPERT]
324718,ABetaA21G amyloidosis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324713,"ABeta amyloidosis, Italian type",Clinical subtype,Cases/families,7.0,,Family(ies),Worldwide,Validated,20697050[PMID]_10821838[PMID]
324713,"ABeta amyloidosis, Italian type",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20697050[PMID]_10821838[PMID]
324737,SRD5A3-CDG,Disease,Cases/families,7.0,,Family(ies),Worldwide,Validated,18271001[PMID]_20637498[PMID]
324737,SRD5A3-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18271001[PMID]_20637498[PMID]
324723,"ABeta amyloidosis, Arctic type",Clinical subtype,Cases/families,1.0,,Family(ies),Worldwide,Validated,11528419[PMID]
324723,"ABeta amyloidosis, Arctic type",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11528419[PMID]
324648,Invasive non-typhoidal salmonellosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
324636,Autoerythrocyte sensitization syndrome,Disease,Cases/families,170.0,,Case(s),Worldwide,Validated,19192020[PMID]
324636,Autoerythrocyte sensitization syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
324708,"ABeta amyloidosis, Iowa type",Clinical subtype,Cases/families,2.0,,Family(ies),Worldwide,Validated,11409420[PMID]_12654973[PMID]
324708,"ABeta amyloidosis, Iowa type",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11409420[PMID]_12654973[PMID]
324703,ABetaL34V amyloidosis,Clinical subtype,Cases/families,1.0,,Family(ies),Worldwide,Validated,16178030[PMID]_19225789[PMID]
324703,ABetaL34V amyloidosis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16178030[PMID]_19225789[PMID]
324611,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to KIF5A mutation,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
324632,Hendra virus infection,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,22752412[PMID]
324632,Hendra virus infection,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324625,Chikungunya,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,France,Validated,Institut de Veille Sanitaire 2009[INST]
324625,Chikungunya,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
324625,Chikungunya,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.32,1-9 / 1 000 000,Value and class,Belgium,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Latvia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,Spain,Validated,European Centre for Disease prevention and Control 2014-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
324625,Chikungunya,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Portugal,Validated,European Centre for Disease prevention and Control 2015-2017[INST]
324588,Familial dyskinesia and facial myokymia,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,11310626[PMID]_22782511[PMID]
324588,Familial dyskinesia and facial myokymia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324601,X-linked cleft palate and ankyloglossia,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
324581,Benign Samaritan congenital myopathy,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,22752422[PMID]
324581,Benign Samaritan congenital myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324585,Autosomal dominant intermediate Charcot-Marie-Tooth disease with neuropathic pain,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,22704856[PMID]
324585,Autosomal dominant intermediate Charcot-Marie-Tooth disease with neuropathic pain,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324569,Pontocerebellar hypoplasia type 8,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,23023333[PMID]
324569,Pontocerebellar hypoplasia type 8,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324575,Hyperinsulinism due to HNF1A deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,22802087[PMID]
324575,Hyperinsulinism due to HNF1A deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324540,Aphonia-deafness-retinal dystrophy-bifid halluces-intellectual disability syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,22991300[PMID]
324540,Aphonia-deafness-retinal dystrophy-bifid halluces-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324561,Hypopigmentation-punctate palmoplantar keratoderma syndrome,Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,24075184[PMID]
324561,Hypopigmentation-punctate palmoplantar keratoderma syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324530,Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23000145[PMID]
324530,Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23000145[PMID]
324535,Combined oxidative phosphorylation defect type 11,Disease,Cases/families,32.0,,Case(s),Worldwide,Validated,27412952[PMID]
324535,Combined oxidative phosphorylation defect type 11,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27412952[PMID]
324525,Hypertrophic cardiomyopathy with kidney anomalies due to mitochondrial DNA mutation,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,22781753[PMID]
324525,Hypertrophic cardiomyopathy with kidney anomalies due to mitochondrial DNA mutation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324442,Autosomal recessive axonal neuropathy with neuromyotonia,Disease,Cases/families,33.0,,Family(ies),Worldwide,Validated,22961002[PMID]
324442,Autosomal recessive axonal neuropathy with neuromyotonia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324416,Muscular hypertrophy-hepatomegaly-polyhydramnios syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,22683912[PMID]
324416,Muscular hypertrophy-hepatomegaly-polyhydramnios syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324422,ALG13-CDG,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,22492991[PMID]
324422,ALG13-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22492991[PMID]
324410,X-linked intellectual disability-cardiomegaly-congestive heart failure syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,22814392[PMID]
324410,X-linked intellectual disability-cardiomegaly-congestive heart failure syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324381,Hereditary inclusion body myopathy type 4,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,22723986[PMID]
324381,Hereditary inclusion body myopathy type 4,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324364,Mixed sclerosing bone dystrophy with extra-skeletal manifestations,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,22821701[PMID]
324364,Mixed sclerosing bone dystrophy with extra-skeletal manifestations,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22821701[PMID]
324353,Congenital achiasma,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
324321,Sinoatrial node dysfunction and deafness,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,21131953[PMID]
324321,Sinoatrial node dysfunction and deafness,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324313,9p13 microdeletion syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,22887577[PMID]
324313,9p13 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324307,Severe lateral tibial bowing-short stature-mild winged scapula-mild facial dysmorphism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,22927185[PMID]
324307,Severe lateral tibial bowing-short stature-mild winged scapula-mild facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324299,Multiple paragangliomas associated with polycythemia,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,22931260[PMID]
324299,Multiple paragangliomas associated with polycythemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324294,T-cell immunodeficiency with epidermodysplasia verruciformis,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,22850876[PMID]
324294,T-cell immunodeficiency with epidermodysplasia verruciformis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
324290,Early-onset Lafora body disease,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,22961547[PMID]
324290,Early-onset Lafora body disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22961547[PMID]
324262,Autosomal recessive congenital cerebellar ataxia due to MGLUR1 deficiency,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,22901947[PMID]
324262,Autosomal recessive congenital cerebellar ataxia due to MGLUR1 deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
320360,MT-ATP6-related mitochondrial spastic paraplegia,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,20656066[PMID]
320360,MT-ATP6-related mitochondrial spastic paraplegia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20656066[PMID]
320355,Autosomal dominant spastic paraplegia type 41,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,18364116[PMID]
320355,Autosomal dominant spastic paraplegia type 41,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18364116[PMID]
320370,Autosomal recessive spastic paraplegia type 43,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,20039086[PMID]
320370,Autosomal recessive spastic paraplegia type 43,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20039086[PMID]
320365,Autosomal dominant spastic paraplegia type 36,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,19357379[PMID]
320365,Autosomal dominant spastic paraplegia type 36,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19357379[PMID]
320380,Autosomal recessive spastic paraplegia type 54,Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,23486545[PMID]_24482476[PMID]
320380,Autosomal recessive spastic paraplegia type 54,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23486545[PMID]_24482476[PMID]
320375,Autosomal recessive spastic paraplegia type 55,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24080142[PMID]_24424123[PMID]
320375,Autosomal recessive spastic paraplegia type 55,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,24080142[PMID]_24424123[PMID]
320391,Autosomal recessive spastic paraplegia type 46,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,20593214[PMID]
320391,Autosomal recessive spastic paraplegia type 46,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20593214[PMID]
320385,Hereditary sensory and autonomic neuropathy due to TECPR2 mutation,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,23176824[PMID]
320385,Hereditary sensory and autonomic neuropathy due to TECPR2 mutation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23176824[PMID]
320401,Autosomal recessive spastic paraplegia type 44,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,19056803[PMID]
320401,Autosomal recessive spastic paraplegia type 44,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19056803[PMID]
320396,Autosomal recessive spastic paraplegia type 45,Disease,Cases/families,7.0,,Family(ies),Worldwide,Validated,28884889[PMID]
320396,Autosomal recessive spastic paraplegia type 45,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28884889[PMID]
320411,Autosomal recessive spastic paraplegia type 56,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,23176821[PMID]
320411,Autosomal recessive spastic paraplegia type 56,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23176821[PMID]
320406,Spastic paraplegia-optic atrophy-neuropathy syndrome,Disease,Cases/families,75.0,,Case(s),Worldwide,Validated,26385635[PMID]
320406,Spastic paraplegia-optic atrophy-neuropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26385635[PMID]
319543,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to a partial deficiency,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
319547,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR2 deficiency,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,25453225[PMID]
319547,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25453225[PMID]
319535,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a complete deficiency,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
319539,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to a partial deficiency,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
319519,Combined oxidative phosphorylation defect type 14,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,22833457[PMID]_22499341[PMID]
319519,Combined oxidative phosphorylation defect type 14,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22833457[PMID]_22499341[PMID]
319524,Combined oxidative phosphorylation defect type 15,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,24461907[PMID]
319524,Combined oxidative phosphorylation defect type 15,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24461907[PMID]
319509,Combined oxidative phosphorylation defect type 9,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,21786366[PMID]
319509,Combined oxidative phosphorylation defect type 9,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21786366[PMID]
319514,Combined oxidative phosphorylation defect type 13,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23084291[PMID]
319514,Combined oxidative phosphorylation defect type 13,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23084291[PMID]
319589,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,[EXPERT]_23963039[PMID]
319589,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
319595,Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,25453225[PMID]
319595,Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25453225[PMID]
319574,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,25453225[PMID]
319574,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25453225[PMID]
319581,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,Disease,Cases/families,68.0,,Case(s),Worldwide,Validated,25453225[PMID]
319581,Autosomal dominant mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25453225[PMID]
319563,Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,25453225[PMID]
319563,Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25453225[PMID]
319569,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,25453225[PMID]
319569,Autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25453225[PMID]
319552,Mendelian susceptibility to mycobacterial diseases due to complete IL12RB1 deficiency,Disease,Cases/families,180.0,,Case(s),Worldwide,Validated,25453225[PMID]
319552,Mendelian susceptibility to mycobacterial diseases due to complete IL12RB1 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25453225[PMID]
319558,Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency,Disease,Cases/families,49.0,,Case(s),Worldwide,Validated,[EXPERT]
319558,Mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
319651,Constitutional megaloblastic anemia with severe neurologic disease,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,21310276[PMID]_21310277[PMID]
319651,Constitutional megaloblastic anemia with severe neurologic disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21310276[PMID]_21310277[PMID]
319646,PGM1-CDG,Disease,Cases/families,46.0,,Case(s),Worldwide,Validated,27206562[PMID]_24499211[PMID]
319646,PGM1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27206562[PMID]_24499211[PMID]
319640,Retinal macular dystrophy type 2,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,20393116[PMID]
319640,Retinal macular dystrophy type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20393116[PMID]
319635,Amyloidosis cutis dyschromia,Disease,Cases/families,27.0,,Case(s),Worldwide,Validated,24746296[PMID]
319635,Amyloidosis cutis dyschromia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24746296[PMID]
319623,X-linked mendelian susceptibility to mycobacterial diseases due to CYBB deficiency,Etiological subtype,Cases/families,7.0,,Case(s),Worldwide,Validated,21278736[PMID]
319623,X-linked mendelian susceptibility to mycobacterial diseases due to CYBB deficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21278736[PMID]
319612,X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency,Etiological subtype,Cases/families,6.0,,Case(s),Worldwide,Validated,25453225[PMID]
319612,X-linked mendelian susceptibility to mycobacterial diseases due to IKBKG deficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25453225[PMID]
319605,X-linked mendelian susceptibility to mycobacterial diseases,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,21278736[PMID]_16818673[PMID]
319605,X-linked mendelian susceptibility to mycobacterial diseases,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21278736[PMID]_16818673[PMID]
319600,Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25453225[PMID]
319600,Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25453225[PMID]
319678,Encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,11562630[PMID]
319678,Encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11562630[PMID]
319675,"Microcephalic primordial dwarfism, Dauber type",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,22933543[PMID]
319675,"Microcephalic primordial dwarfism, Dauber type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22933543[PMID]
319671,Alazami syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,22865833[PMID]
319671,Alazami syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22865833[PMID]
319276,Clear cell renal carcinoma,Disease,Annual incidence,1.99,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
319251,Rift valley fever,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
319319,Renal medullary carcinoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
319298,Papillary renal cell carcinoma,Disease,Annual incidence,0.14,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
319303,Chromophobe renal cell carcinoma,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
319332,Autosomal recessive myogenic arthrogryposis multiplex congenita,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,19542096[PMID]
319332,Autosomal recessive myogenic arthrogryposis multiplex congenita,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19542096[PMID]
319340,Carney complex-trismus-pseudocamptodactyly syndrome,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,15282353[PMID]
319340,Carney complex-trismus-pseudocamptodactyly syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15282353[PMID]
319504,Combined oxidative phosphorylation defect type 8,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,21549344[PMID]_25058219[PMID]
319504,Combined oxidative phosphorylation defect type 8,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21549344[PMID]_25058219[PMID]
319195,Chondroectodermal dysplasia with night blindness,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,22579605[PMID]
319195,Chondroectodermal dysplasia with night blindness,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22579605[PMID]
319199,Autosomal recessive spastic paraplegia type 53,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,22717650[PMID]
319199,Autosomal recessive spastic paraplegia type 53,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22717650[PMID]
319218,Ebola hemorrhagic fever,Disease,Cases/families,28220.0,,Case(s),Worldwide,Validated,World health Organisation 2015[INST]_26607790[PMID]
319218,Ebola hemorrhagic fever,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Centre for Disease prevention and Control 2011[INST]
319218,Ebola hemorrhagic fever,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2018[INST]
319160,Congenital myopathy with internal nuclei and atypical cores,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,22818856[PMID]
319160,Congenital myopathy with internal nuclei and atypical cores,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22818856[PMID]
319171,Distal 17p13.1 microdeletion syndrome,Malformation syndrome,Cases/families,16.0,,Case(s),Worldwide,Validated,24501763[PMID]
319171,Distal 17p13.1 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24501763[PMID]
319189,Familial cortical myoclonus,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,2292685[PMID]
319189,Familial cortical myoclonus,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2292685[PMID]
319182,Wiedemann-Steiner syndrome,Malformation syndrome,Cases/families,84.0,,Case(s),Worldwide,Validated,ftp://ftp.sanger.ac.uk/pub/resources/theses/wj1/
319182,Wiedemann-Steiner syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27777327[PMID]
317428,Combined immunodeficiency due to ORAI1 deficiency,Clinical subtype,Cases/families,6.0,,Case(s),Worldwide,Validated,20004786[PMID]
317428,Combined immunodeficiency due to ORAI1 deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20004786[PMID]
317425,Severe combined immunodeficiency due to DNA-PKcs deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,19075392[PMID]_23722905[PMID]
317425,Severe combined immunodeficiency due to DNA-PKcs deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19075392[PMID]_23722905[PMID]
317430,Combined immunodeficiency due to STIM1 deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
317473,Pancytopenia due to IKZF1 mutations,Disease,Cases/families,39.0,,Case(s),Worldwide,Validated,21548011[PMID]_26981933[PMID]_27939403[PMID]
317473,Pancytopenia due to IKZF1 mutations,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21548011[PMID]_26981933[PMID]_27939403[PMID]
317476,XMEN,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,24550228[PMID]
317476,XMEN,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24550228[PMID]
315311,"Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing form",Clinical subtype,Point prevalence,2.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
315306,"Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form",Clinical subtype,Prevalence at birth,7.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
315306,"Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form",Clinical subtype,Point prevalence,7.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
314993,Cataract-congenital heart disease-neural tube defect syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,11836368[PMID]
314993,Cataract-congenital heart disease-neural tube defect syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11836368[PMID]
314978,X-linked non progressive cerebellar ataxia,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,18241076[PMID]_22912398[PMID]
314978,X-linked non progressive cerebellar ataxia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314970,Lymphocytic hypereosinophilic syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314962,Secondary hypereosinophilic syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314950,Primary hypereosinophilic syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314918,Mild Canavan disease,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
314911,Severe Canavan disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314701,Primary systemic amyloidosis,Clinical subtype,Point prevalence,30.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2003[INST]
314679,Cerebrofacioarticular syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,22473091[PMID]_24056717[PMID]
314679,Cerebrofacioarticular syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314667,TMEM165-CDG,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,22683087[PMID]_26238249[PMID]
314667,TMEM165-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22683087[PMID]_26238249[PMID]
314689,Combined immunodeficiency due to STK4 deficiency,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,22294732[PMID]_22174160[PMID]
314689,Combined immunodeficiency due to STK4 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314684,Primary bone lymphoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314652,Variant ABeta2M amyloidosis,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,22693999[PMID]
314652,Variant ABeta2M amyloidosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22693999[PMID]
314647,Non-progressive cerebellar ataxia with intellectual disability,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,22693284[PMID]
314647,Non-progressive cerebellar ataxia with intellectual disability,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314662,Segmental progressive overgrowth syndrome with fibroadipose hyperplasia,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,22729222[PMID]
314662,Segmental progressive overgrowth syndrome with fibroadipose hyperplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314655,Severe neonatal hypotonia-seizures-encephalopathy syndrome due to 5q31.3 microdeletion,Etiological subtype,Cases/families,7.0,,Case(s),Worldwide,Validated,23950017[PMID]
314655,Severe neonatal hypotonia-seizures-encephalopathy syndrome due to 5q31.3 microdeletion,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23950017[PMID]
314621,Duplication of the pituitary gland,Morphological anomaly,Cases/families,38.0,,Case(s),Worldwide,Validated,22439114[PMID]
314621,Duplication of the pituitary gland,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314637,Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,23929671[PMID]
314637,Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314632,CLN12 disease,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,22388936[PMID]
314632,CLN12 disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314802,Short stature due to partial GHR deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314811,Short stature due to GHSR deficiency,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,16511605[PMID]
314811,Short stature due to GHSR deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16511605[PMID]
314889,Autosomal dominant proximal renal tubular acidosis,Clinical subtype,Cases/families,1.0,,Family(ies),Worldwide,Validated,10972690[PMID]
314889,Autosomal dominant proximal renal tubular acidosis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10972690[PMID]
314777,Familial isolated pituitary adenoma,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,22720333[PMID]
314777,Familial isolated pituitary adenoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
314795,SHOX-related short stature,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314718,Lethal arteriopathy syndrome due to fibulin-4 deficiency,Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,22943132[PMID]
314718,Lethal arteriopathy syndrome due to fibulin-4 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314721,Atypical dentin dysplasia due to SMOC2 deficiency,Clinical subtype,Cases/families,4.0,,Case(s),Worldwide,Validated,15243476[PMID]_22152679[PMID]
314721,Atypical dentin dysplasia due to SMOC2 deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370127,Medich giant platelet syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,22931192[PMID]_15370096[PMID]
370127,Medich giant platelet syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370103,"Primary dystonia, DYT17 type",Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,18688663[PMID]
370103,"Primary dystonia, DYT17 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18688663[PMID]
370097,Oculocutaneous albinism type 6,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,23364476[PMID]
370097,Oculocutaneous albinism type 6,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370091,Oculocutaneous albinism type 5,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,23050561[PMID]
370091,Oculocutaneous albinism type 5,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370348,Peripheral primitive neuroectodermal tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.077,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.056,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.023,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.052,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.083,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.071,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.055,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.068,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.076,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.092,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.081,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.087,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.056,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.089,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.058,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.112,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.126,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370334,Extraskeletal Ewing sarcoma,Disease,Annual incidence,0.106,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
370131,White platelet syndrome,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,15203719[PMID]
370131,White platelet syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370046,Didymosis aplasticosebacea,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,11385232[PMID]
370046,Didymosis aplasticosebacea,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370034,Familial syringomyelia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,7482254[PMID]_18050067[PMID]
370039,Angora hair nevus,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23858341[PMID]
370039,Angora hair nevus,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370022,Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,24013853[PMID]
370022,Ataxia-intellectual disability-oculomotor apraxia-cerebellar cysts syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370026,Acute myeloid leukemia with t(8;16)(p11;p13) translocation,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,23974201[PMID]
370015,"Spondyloepimetaphyseal dysplasia, Isidor-Toutain type",Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23956136[PMID]
370015,"Spondyloepimetaphyseal dysplasia, Isidor-Toutain type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370088,Acute infantile liver failure-multisystemic involvement syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,22607940[PMID]
370088,Acute infantile liver failure-multisystemic involvement syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370076,Fetal carbamazepine syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
370052,SCALP syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,22122611[PMID]
370052,SCALP syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22122611[PMID]
371007,Congenital muscular dystrophy with hyperlaxity,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,16760198[PMID]
371007,Congenital muscular dystrophy with hyperlaxity,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16760198[PMID]
370997,Muscle-eye-brain disease with bilateral multicystic leucodystrophy,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24052401[PMID]
370997,Muscle-eye-brain disease with bilateral multicystic leucodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24052401[PMID]
370921,STT3A-CDG,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23842455[PMID]
370921,STT3A-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23842455[PMID
370924,STT3B-CDG,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,23842455[PMID]
370924,STT3B-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23842455[PMID]
370927,SSR4-CDG,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,26264460[PMID]
370927,SSR4-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26264460[PMID]
370930,XYLT1-CDG,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23982343[PMID]
370930,XYLT1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370968,Congenital muscular dystrophy with intellectual disability,Disease,Point prevalence,0.0,Not yet documented,Class only,Worldwide,Validated,ORPHANET
370968,Congenital muscular dystrophy with intellectual disability,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
370980,Congenital muscular dystrophy without intellectual disability,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
370980,Congenital muscular dystrophy without intellectual disability,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
370943,Autism spectrum disorder-epilepsy-arthrogryposis syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,24031089[PMID]
370943,Autism spectrum disorder-epilepsy-arthrogryposis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24031089[PMID]
369929,Primary hyperaldosteronism-seizures-neurological abnormalities syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23913001[PMID]
369929,Primary hyperaldosteronism-seizures-neurological abnormalities syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369920,Pontocerebellar hypoplasia type 9,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,28815207[PMID]
369920,Pontocerebellar hypoplasia type 9,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28815207[PMID]
369942,CADDS,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,11992258[PMID]_22994209[PMID]
369942,CADDS,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369939,Severe motor and intellectual disabilities-sensorineural deafness-dystonia syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,24011989[PMID]
369939,Severe motor and intellectual disabilities-sensorineural deafness-dystonia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369955,"Methylmalonic acidemia with homocystinuria, type cblJ",Clinical subtype,Cases/families,2.0,,Case(s),Worldwide,Validated,24011988[PMID]_22922874[PMID]
369955,"Methylmalonic acidemia with homocystinuria, type cblJ",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369950,Intellectual disability-seizures-macrocephaly-obesity syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,23980137[PMID]
369950,Intellectual disability-seizures-macrocephaly-obesity syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369970,Microcornea-myopic chorioretinal atrophy-telecanthus syndrome,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,23818446[PMID]
369970,Microcornea-myopic chorioretinal atrophy-telecanthus syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369962,"Methylmalonic acidemia with homocystinuria, type cblX",Clinical subtype,Cases/families,18.0,,Case(s),Worldwide,Validated,24011988[PMID]_22922874[PMID]
369962,"Methylmalonic acidemia with homocystinuria, type cblX",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369979,Finger hyperphalangy-toe anomalies-severe pectus excavatum syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,23824731[PMID]
369979,Finger hyperphalangy-toe anomalies-severe pectus excavatum syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369992,Severe dermatitis-multiple allergies-metabolic wasting syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,23974871[PMID]
369992,Severe dermatitis-multiple allergies-metabolic wasting syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
370002,Focal palmoplantar keratoderma with joint keratoses,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,16484817[PMID]
369999,Diffuse palmoplantar keratoderma with painful fissures,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,15897387[PMID]
370010,Intellectual disability-facial dysmorphism-hand anomalies syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,23949889[PMID]
370010,Intellectual disability-facial dysmorphism-hand anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369837,Intellectual disability-seizures-hypophosphatasia-ophthalmic-skeletal anomalies syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,23636107[PMID]
369837,Intellectual disability-seizures-hypophosphatasia-ophthalmic-skeletal anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369840,TRAPPC11-related limb-girdle muscular dystrophy R18,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,23830518[PMID]
369840,TRAPPC11-related limb-girdle muscular dystrophy R18,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369847,Intellectual disability-hyperkinetic movement-truncal ataxia syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,23830518[PMID]
369847,Intellectual disability-hyperkinetic movement-truncal ataxia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369852,Congenital neutropenia-myelofibrosis-nephromegaly syndrome,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,26358756[PMID]_28453180[PMID]
369852,Congenital neutropenia-myelofibrosis-nephromegaly syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26358756[PMID]_28453180[PMID]]
369861,Congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,25193871[PMID]
369861,Congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25193871[PMID]
369867,Autosomal recessive intermediate Charcot-Marie-Tooth disease type C,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,23844677[PMID]
369867,Autosomal recessive intermediate Charcot-Marie-Tooth disease type C,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
369873,Obesity due to SIM1 deficiency,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,23778136[PMID]_23778139[PMID]
369881,2p21 microdeletion syndrome without cystinuria,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,23794250[PMID]
369881,2p21 microdeletion syndrome without cystinuria,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369886,Homozygous 2p21 microdeletion syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,23794250[PMID]
369891,Developmental delay-facial dysmorphism syndrome due to MED13L deficiency,Malformation syndrome,Cases/families,70.0,,Case(s),Worldwide,Validated,28645799[PMID]
369891,Developmental delay-facial dysmorphism syndrome due to MED13L deficiency,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28645799[PMID]
369897,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with variable craniofacial anomalies",Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,23993193[PMID]_23993194[PMID]
369897,"Mitochondrial DNA depletion syndrome, encephalomyopathic form with variable craniofacial anomalies",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
369913,Combined oxidative phosphorylation defect type 17,Disease,Cases/families,20.0,,Family(ies),Worldwide,Validated,23849775[PMID]_27769300[PMID]_28441660[PMID]
369913,Combined oxidative phosphorylation defect type 17,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27769300[PMID]_28441660[PMID]
364055,Severe early-childhood-onset retinal dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,Pr Birgit LORENZ_Dr Markus PREISING[EXPERT]
364028,X-linked intellectual disability due to GRIA3 mutations,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,24721225[PMID]
364028,X-linked intellectual disability due to GRIA3 mutations,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24721225[PMID]
364033,Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
772,Infantile Refsum disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1194,TMEM70-related mitochondrial encephalo-cardio-myopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
363999,Non-immune hydrops fetalis,Clinical subtype,Prevalence at birth,42.0,1-5 / 10 000,Value and class,Worldwide,Not yet validated,ORPHANET
363999,Non-immune hydrops fetalis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
363999,Non-immune hydrops fetalis,Clinical subtype,Point prevalence,300.0,>1 / 1000,Value and class,Thailand,Validated,9280003[PMID]
1048,Isolated anencephaly/exencephaly,Morphological anomaly,Prevalence at birth,35.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
1048,Isolated anencephaly/exencephaly,Morphological anomaly,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,[EXPERT]
1048,Isolated anencephaly/exencephaly,Morphological anomaly,Prevalence at birth,20.6,1-5 / 10 000,Value and class,United States,Validated,20878909[PMID]_Center for Diseases Control and Prevention 2004-2006[INST]
1048,Isolated anencephaly/exencephaly,Morphological anomaly,Prevalence at birth,210.0,>1 / 1000,Value and class,India,Validated,23873811[PMID]
1048,Isolated anencephaly/exencephaly,Morphological anomaly,Prevalence at birth,120.0,>1 / 1000,Value and class,"Iran, Islamic Republic of",Validated,20039767[PMID]
1048,Isolated anencephaly/exencephaly,Morphological anomaly,Prevalence at birth,26.0,1-5 / 10 000,Value and class,Thailand,Validated,16858850[PMID]
1048,Isolated anencephaly/exencephaly,Morphological anomaly,Prevalence at birth,58.0,1-5 / 10 000,Value and class,Singapore,Validated,17245510[PMID]
364013,Immune hydrops fetalis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
364013,Immune hydrops fetalis,Clinical subtype,Prevalence at birth,33.3,1-5 / 10 000,Value and class,United Kingdom,Validated,19334091[PMID]_[EXPERT]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,18.6,1-5 / 10 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2007-2011[REG]
823,Spina bifida and other spinal dysraphisms,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2007-2011[REG]
823,Spina bifida and other spinal dysraphisms,Category,Point prevalence,50.0,1-5 / 10 000,Value and class,France,Validated,[EXPERT]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,24.8,1-5 / 10 000,Value and class,United States,Validated,22140002[PMID]_Center for Diseases Control and Prevention 19129744[INST]_ ORPHANET
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,9.8,1-9 / 100 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,17.5,1-5 / 10 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,11.4,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,21.3,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,19.6,1-5 / 10 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,17.8,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,14.4,1-5 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,50.6,1-5 / 10 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,12.7,1-5 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,24.9,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,17.5,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,14.7,1-5 / 10 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,24.4,1-5 / 10 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,18.9,1-5 / 10 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,12.6,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,13.1,1-5 / 10 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
823,Spina bifida and other spinal dysraphisms,Category,Prevalence at birth,41.3,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
363992,Ichthyosis-short stature-brachydactyly-microspherophakia syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,23754960[PMID]_24940034[PMID]
363992,Ichthyosis-short stature-brachydactyly-microspherophakia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24940034[PMID]
363976,Giant cell tumor of bone,Disease,Annual incidence,0.1404,1-9 / 1 000 000,Value and class,Worldwide,Validated,[WHO Classification of Tumours]
363976,Giant cell tumor of bone,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[WHO Classification of Tumours]
363981,Charcot-Marie-Tooth disease type 4B3,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,23749797[PMID]
363981,Charcot-Marie-Tooth disease type 4B3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363969,Autosomal recessive cerebral atrophy,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,23957953[PMID]
363969,Autosomal recessive cerebral atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363965,Koolen-De Vries syndrome due to a point mutation,Etiological subtype,Cases/families,4.0,,Case(s),Worldwide,Validated,22544363[PMID]_22544367[PMID]
363965,Koolen-De Vries syndrome due to a point mutation,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363958,17q21.31 microdeletion syndrome,Etiological subtype,Point prevalence,1.82,1-9 / 100 000,Value and class,Europe,Validated,26306646[PMID]_[EXPERT]
363746,Balint syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,22999103[PMID]
363741,Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,9098485[PMID]
363727,X-linked dyserythropoietic anemia with abnormal platelets and neutropenia,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,16783379[PMID]
363727,X-linked dyserythropoietic anemia with abnormal platelets and neutropenia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
363722,Alexander disease type II,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,23700170[PMID]
363717,Alexander disease type I,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,23700170[PMID]
363710,Spinocerebellar ataxia type 37,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,23700170[PMID]
363710,Spinocerebellar ataxia type 37,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363705,Craniofaciofrontodigital syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,7151302[PMID]
363705,Craniofaciofrontodigital syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7151302[PMID]
363694,Hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,21255763[PMID]
363694,Hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363686,Severe intellectual disability-poor language-strabismus-grimacing face-long fingers syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,23644463[PMID]
363686,Severe intellectual disability-poor language-strabismus-grimacing face-long fingers syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363680,2p13.2 microdeletion syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,23837398[PMID]
363680,2p13.2 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363677,Childhood-onset autosomal recessive myopathy with external ophthalmoplegia,Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,15548556[PMID]_23388406[PMID]
363677,Childhood-onset autosomal recessive myopathy with external ophthalmoplegia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
364577,Intellectual disability-brachydactyly-Pierre Robin syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,15057987[PMID]
364577,Intellectual disability-brachydactyly-Pierre Robin syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15057987[PMID]
364198,Bipartite talus,Morphological anomaly,Cases/families,23.0,,Case(s),Worldwide,Validated,24095243[PMID]
364198,Bipartite talus,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24095243[PMID]
363417,Temtamy preaxial brachydactyly syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,21129727[PMID]_2129728[PMID]_19952732[PMID]_15365460[PMID]_9823490[PMID]
363417,Temtamy preaxial brachydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363409,Fetal akinesia-cerebral and retinal hemorrhage syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,23092955[PMID]
363409,Fetal akinesia-cerebral and retinal hemorrhage syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363412,Hypomyelination with brain stem and spinal cord involvement and leg spasticity,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,25527264[PMID]
363412,Hypomyelination with brain stem and spinal cord involvement and leg spasticity,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25527264[PMID]
363429,Autosomal recessive cerebellar ataxia-pyramidal signs-nystagmus-oculomotor apraxia syndrome,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,22901947[PMID]_24078737[PMID]_23611888[PMID]
363429,Autosomal recessive cerebellar ataxia-pyramidal signs-nystagmus-oculomotor apraxia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22901947[PMID]_24078737[PMID]_23611888[PMID]
363432,Autosomal recessive congenital cerebellar ataxia due to GRID2 deficiency,Clinical subtype,Cases/families,7.0,,Case(s),Worldwide,Validated,23611888[PMID]_24078737[PMID]
363432,Autosomal recessive congenital cerebellar ataxia due to GRID2 deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363424,Multiple mitochondrial dysfunctions syndrome type 3,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23462291[PMID]
363424,Multiple mitochondrial dysfunctions syndrome type 3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363396,High myopia-sensorineural deafness syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,23543054[PMID]
363396,High myopia-sensorineural deafness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363400,Severe neurodegenerative syndrome with lipodystrophy,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,27632409[PMID]
363400,Severe neurodegenerative syndrome with lipodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27632409[PMID]
363203,Ring chromosome syndrome,Category,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Worldwide,Validated,1175321[PMID]
363618,LMNA-related cardiocutaneous progeria syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,23666920[PMID]
363618,LMNA-related cardiocutaneous progeria syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23666920[PMID]
363623,GMPPB-related limb-girdle muscular dystrophy R19,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23768512[PMID]
363623,GMPPB-related limb-girdle muscular dystrophy R19,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363649,Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,28521875[PMID]
363649,Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28521875[PMID]
363654,X-linked parkinsonism-spasticity syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,20629132[PMID]_23595882[PMID]
363654,X-linked parkinsonism-spasticity syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363659,20q11.2 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,23704076[PMID]
363665,Acroosteolysis-keloid-like lesions-premature aging syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,26279204[PMID]
363665,Acroosteolysis-keloid-like lesions-premature aging syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26279204[PMID]
363540,Leukoencephalopathy with mild cerebellar ataxia and white matter edema,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,23707145[PMID]
363540,Leukoencephalopathy with mild cerebellar ataxia and white matter edema,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363549,Acute encephalopathy with biphasic seizures and late reduced diffusion,Disease,Cases/families,283.0,,Case(s),Worldwide,Validated,21924570[PMID]_23772250[PMID]
363549,Acute encephalopathy with biphasic seizures and late reduced diffusion,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
363558,New-onset refractory status epilepticus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_28396650[PMID]
363567,Acute encephalopathy with inflammation-mediated status epilepticus,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
363579,Extragonadal germ cell tumor,Category,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363611,CTCF-related neurodevelopmental disorder,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,28619046[PMID]
363611,CTCF-related neurodevelopmental disorder,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28619046[PMID]
363494,Non-seminomatous germ cell tumor of testis,Disease,Annual incidence,1.21,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
363494,Non-seminomatous germ cell tumor of testis,Disease,Lifetime Prevalence,33.53,1-5 / 10 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
363523,Hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,23606727[PMID]
363523,Hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363534,"Mitochondrial DNA depletion syndrome, hepatocerebrorenal form",Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,23375728[PMID]
363534,"Mitochondrial DNA depletion syndrome, hepatocerebrorenal form",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363528,Intellectual disability-strabismus syndrome,Disease,Cases/families,34.0,,Case(s),Worldwide,Validated,23620220[PMID]
363528,Intellectual disability-strabismus syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363444,THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,23621916[PMID]
363444,THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
363454,BICD2-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Etiological subtype,Cases/families,60.0,,Case(s),Worldwide,Validated,26594138[PMID]_26998597[PMID]_27784775[PMID]
363454,BICD2-related autosomal dominant childhood-onset proximal spinal muscular atrophy,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26594138[PMID]_27784775[PMID]
363447,Autosomal dominant childhood-onset proximal spinal muscular atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20697106[PMID]_22459677[PMID]_22847149[PMID]_26594138[PMID]_26998597[PMID]_27784775[PMID]
363447,Autosomal dominant childhood-onset proximal spinal muscular atrophy,Disease,Cases/families,97.0,,Case(s),Worldwide,Validated,20697106[PMID]_22459677[PMID]_22847149[PMID]_26594138[PMID]_26998597[PMID]_27784775[PMID]
363478,Paratesticular adenocarcinoma,Disease,Lifetime Prevalence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363478,Paratesticular adenocarcinoma,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363472,Tumor of testis and paratestis,Category,Annual incidence,3.15,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
363472,Tumor of testis and paratestis,Category,Lifetime Prevalence,87.77,6-9 / 10 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
363472,Tumor of testis and paratestis,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Lifetime Prevalence,0.44,1-9 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.049,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.048,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.034,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.022,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.021,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.023,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363489,Sex cord-stromal tumor of testis,Disease,Annual incidence,0.023,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
363483,Testicular teratoma,Disease,Lifetime Prevalence,0.04,<1 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
363483,Testicular teratoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
357175,Short ulna-dysmorphism-hypotonia-intellectual disability syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,20950399[PMID]
357175,Short ulna-dysmorphism-hypotonia-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
357329,Combined immunodeficiency due to IL21R deficiency,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,23440042[PMID]_25769540[PMID]_25398835[PMID]
357329,Combined immunodeficiency due to IL21R deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23440042[PMID]_25769540[PMID]_25398835[PMID]
357332,Syndactyly-camptodactyly and clinodactyly of fifth fingers-bifid toes syndrome,Malformation syndrome,Cases/families,26.0,,Case(s),Worldwide,Validated,20683984[PMID]
357332,Syndactyly-camptodactyly and clinodactyly of fifth fingers-bifid toes syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
357237,Combined immunodeficiency due to CARD11 deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,25087226[PMID]
357237,Combined immunodeficiency due to CARD11 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25087226[PMID]
357502,Idiopathic nephrotic syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
356978,"D,L-2-hydroxyglutaric aciduria",Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,23561848[PMID]
356978,"D,L-2-hydroxyglutaric aciduria",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
356947,3q26q27 microdeletion syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,23357683[PMID]_24055528[PMID]
356947,3q26q27 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
356961,SLC35A2-CDG,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,25778940[PMID]
356961,SLC35A2-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
357008,Hemolytic uremic syndrome with DGKE deficiency,Disease,Cases/families,47.0,,Case(s),Worldwide,Validated,23542698[PMID]_28526779 [PMID]_ 28242109[PMID]
357008,Hemolytic uremic syndrome with DGKE deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28526779 [PMID]
357001,19p13.13 microdeletion syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,23495138[PMID]
357001,19p13.13 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
356996,ANK3-related intellectual disability-sleep disturbance syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,23390136[PMID]_28687526[PMID]
356996,ANK3-related intellectual disability-sleep disturbance syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23390136[PMID]_28687526[PMID]
357043,Amyotrophic lateral sclerosis type 4,Disease,Cases/families,70.0,,Case(s),Worldwide,Validated,9497266[PMID]_12023320[PMID]
357043,Amyotrophic lateral sclerosis type 4,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9497266[PMID]_12023320[PMID]
357034,Non-hereditary retinoblastoma,Clinical subtype,Annual incidence,0.038,<1 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
357034,Non-hereditary retinoblastoma,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
357027,Hereditary retinoblastoma,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
357158,Mandibulofacial dysostosis-macroblepharon-macrostomia syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,9018413[PMID]_23448909[PMID]
357158,Mandibulofacial dysostosis-macroblepharon-macrostomia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9018413[PMID]_23448909[PMID
357154,Oral submucous fibrosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
352654,Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,23359680[PMID]_28007905[PMID]
352654,Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28007905[PMID]
352662,Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,23349227[PMID]_27662089[PMID]
352662,Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET__27662089[PMID]
352657,Hereditary benign intraepithelial dyskeratosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
352641,Autosomal recessive cerebellar ataxia with late-onset spasticity,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,23332917[PMID]
352641,Autosomal recessive cerebellar ataxia with late-onset spasticity,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352636,Phalangeal microgeodic syndrome,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
352636,Phalangeal microgeodic syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352649,Brain dopamine-serotonin vesicular transport disease,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,23363473[PMID]
352649,Brain dopamine-serotonin vesicular transport disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352596,Progressive myoclonic epilepsy with dystonia,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,21087195[PMID]
352596,Progressive myoclonic epilepsy with dystonia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352629,16q24.1 microdeletion syndrome,Disease,Cases/families,42.0,,Case(s),Worldwide,Validated,27071622[PMID]
352629,16q24.1 microdeletion syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27071622[PMID]
352577,Bainbridge-Ropers syndrome,Disease,Cases/families,77.0,,Case(s),Worldwide,Validated,PMID: 28955728 & EXPERT
352577,Bainbridge-Ropers syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET & PMID: 28955728
352587,Focal epilepsy-intellectual disability-cerebro-cerebellar malformation,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,23517570[PMID]
352587,Focal epilepsy-intellectual disability-cerebro-cerebellar malformation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352582,Familial infantile myoclonic epilepsy,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,20727515[PMID]
352582,Familial infantile myoclonic epilepsy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352731,Oculocutaneous albinism type 1,Disease,Point prevalence,2.5,1-9 / 100 000,Value and class,Worldwide,Not yet validated,ORPHANET
352734,Minimal pigment oculocutaneous albinism type 1,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
352734,Minimal pigment oculocutaneous albinism type 1,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352737,Temperature-sensitive oculocutaneous albinism type 1,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
352737,Temperature-sensitive oculocutaneous albinism type 1,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352712,Facial dysmorphism-immunodeficiency-livedo-short stature syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,23230001[PMID]
352712,Facial dysmorphism-immunodeficiency-livedo-short stature syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352718,Progressive retinal dystrophy due to retinol transport defect,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,9888420[PMID]_23189188[PMID]_27892788[PMID]
352718,Progressive retinal dystrophy due to retinol transport defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23189188[PMID]_27892788[PMID]
352723,Attenuated Chédiak-Higashi syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
352723,Attenuated Chédiak-Higashi syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
352665,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to 9q21.3 microdeletion,Etiological subtype,Cases/families,2.0,,Case(s),Worldwide,Validated,24501764[PMID]_25348648[PMID]
352665,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to 9q21.3 microdeletion,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24501764[PMID]_25348648[PMID]
352670,Autosomal dominant intermediate Charcot-Marie-Tooth disease type F,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,23434117[PMID]
352670,Autosomal dominant intermediate Charcot-Marie-Tooth disease type F,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352675,X-linked Charcot-Marie-Tooth disease type 6,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,23297365[PMID]
352675,X-linked Charcot-Marie-Tooth disease type 6,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23297365[PMID]
352682,Cobblestone lissencephaly without muscular or ocular involvement,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,23472759[PMID]_25925986[PMID]
352682,Cobblestone lissencephaly without muscular or ocular involvement,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23472759[PMID]_25925986[PMID]
353253,Burning mouth syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_10478959[PMID]
353253,Burning mouth syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET_10478959[PMID]
353220,Familial primary localized cutaneous amyloidosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
352763,Scleredema,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
352745,Oculocutaneous albinism type 7,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,23395477[PMID]
352745,Oculocutaneous albinism type 7,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
353334,Congenital retinal arteriovenous communication,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
353320,"Pyruvate carboxylase deficiency, benign type",Clinical subtype,Cases/families,5.0,,Case(s),Worldwide,Validated,20301764[PMID]
353320,"Pyruvate carboxylase deficiency, benign type",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301764[PMID]
353327,Congenital myasthenic syndromes with glycosylation defect,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
353308,"Pyruvate carboxylase deficiency, infantile type",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
353314,"Pyruvate carboxylase deficiency, severe neonatal type",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
353298,Roifman syndrome,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,PMID: 16901296; 21977988 & EXPERT
353298,Roifman syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
353284,Rubinstein-Taybi syndrome due to EP300 haploinsufficiency,Etiological subtype,Cases/families,34.0,,Case(s),Worldwide,Validated,27465822[PMID]
353284,Rubinstein-Taybi syndrome due to EP300 haploinsufficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27465822[PMID]
352403,Spectrin-associated autosomal recessive cerebellar ataxia,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,23236289[PMID]_23838597[PMID]
352403,Spectrin-associated autosomal recessive cerebellar ataxia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352333,Congenital ichthyosis-intellectual disability-spastic quadriplegia syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,22100072[PMID]
352333,Congenital ichthyosis-intellectual disability-spastic quadriplegia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352328,MEGDEL syndrome,Disease,Cases/families,67.0,,Case(s),Worldwide,Validated,29205472[PMID]
352328,MEGDEL syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29205472[PMID]
352447,Progressive external ophthalmoplegia-myopathy-emaciation syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,23313956[PMID]
352447,Progressive external ophthalmoplegia-myopathy-emaciation syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352530,Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,22549410[PMID]
352530,Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352563,Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23315540[PMID]
352563,Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352540,Oncogenic osteomalacia,Disease,Cases/families,400.0,,Case(s),Worldwide,Validated,23220596[PMID]
352540,Oncogenic osteomalacia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
352479,ISPD-related limb-girdle muscular dystrophy R20,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,23288328[PMID]
352479,ISPD-related limb-girdle muscular dystrophy R20,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352470,DNA2-related mitochondrial DNA deletion syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,23352259[PMID]
352470,DNA2-related mitochondrial DNA deletion syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
352490,Autism spectrum disorder due to AUTS2 deficiency,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,23332918[PMID]_27075013[PMID]
352490,Autism spectrum disorder due to AUTS2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23332918[PMID]_27075013[PMID]
294422,Chronic intestinal failure,Clinical syndrome,Prevalence at birth,86.0,6-9 / 10 000,Value and class,Italy,Validated,18589446[PMID]
294422,Chronic intestinal failure,Clinical syndrome,Point prevalence,42.4691,1-5 / 10 000,Value and class,Italy,Validated,36215864[PMID]_ORPHANET
293987,Rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome,Disease,Cases/families,96.0,,Case(s),Worldwide,Validated,[EXPERT]_30584530[PMID]
293987,Rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
294016,Microcephaly-capillary malformation syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,23542699[PMID]
294016,Microcephaly-capillary malformation syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
294023,Neonatal inflammatory skin and bowel disease,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,22010916[PMID]_24691054[PMID]
294023,Neonatal inflammatory skin and bowel disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22010916[PMID]_24691054[PMID]
294026,Syndactyly-nystagmus syndrome due to 2q31.1 microduplication,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,21654727[PMID]
294026,Syndactyly-nystagmus syndrome due to 2q31.1 microduplication,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21654727[PMID]
293964,Hypoinsulinemic hypoglycemia and body hemihypertrophy,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,14764948[PMID]_21979934[PMID]
293964,Hypoinsulinemic hypoglycemia and body hemihypertrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293967,Hypogonadotropic hypogonadism-severe microcephaly-sensorineural hearing loss-dysmorphism syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,22002932[PMID]
293967,Hypogonadotropic hypogonadism-severe microcephaly-sensorineural hearing loss-dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293978,Deficiency in anterior pituitary function-variable immunodeficiency syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,22013103[PMID]
293978,Deficiency in anterior pituitary function-variable immunodeficiency syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293958,Hypertelorism-preauricular sinus-punctual pits-deafness syndrome,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,21480481[PMID]
293958,Hypertelorism-preauricular sinus-punctual pits-deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293955,Childhood encephalopathy due to thiamine pyrophosphokinase deficiency,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,22152682[PMID]
293955,Childhood encephalopathy due to thiamine pyrophosphokinase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293948,1p21.3 microdeletion syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,22003227[PMID]_21114665[PMID]
293948,1p21.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293939,Distal Xq28 microduplication syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,21984752[PMID]
293939,Distal Xq28 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293936,EDICT syndrome,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,22131394[PMID]_24138095[PMID]
293936,EDICT syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22131394[PMID]_24138095[PMID]
293925,Lethal occipital encephalocele-skeletal dysplasia syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,27410456[PMID]
293925,Lethal occipital encephalocele-skeletal dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27410456
293864,Hypoplastic pancreas-intestinal atresia-hypoplastic gallbladder syndrome,Malformation syndrome,Cases/families,16.0,,Case(s),Worldwide,Validated,21965172[PMID]
293864,Hypoplastic pancreas-intestinal atresia-hypoplastic gallbladder syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293843,3MC syndrome,Malformation syndrome,Cases/families,32.0,,Case(s),Worldwide,Validated,21258343[PMID]
293843,3MC syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21258343[PMID]
293822,MITF-related melanoma and renal cell carcinoma predisposition syndrome,Disease,Cases/families,30.0,,Family(ies),Worldwide,Validated,ORPHANET
293822,MITF-related melanoma and renal cell carcinoma predisposition syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293825,Congenital dyserythropoietic anemia type IV,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,23522491[PMID]
293825,Congenital dyserythropoietic anemia type IV,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23522491[PMID]
293812,Fixed drug eruption,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26548517[PMID]
293807,Ketamine-induced biliary dilatation,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,22124288[PMID]
293807,Ketamine-induced biliary dilatation,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_22124288[PMID]
293725,"Blepharophimosis-intellectual disability syndrome, Verloes type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
293642,Blepharophimosis-intellectual disability syndrome,Clinical group,Cases/families,58.0,,Case(s),Worldwide,Validated,22077973[PMID]_21567902[PMID]_18798845[PMID]_16700052[PMID]_15176598[PMID]_15127758[PMID]_12868473[PMID]_10955481[PMID]_10631927[PMID]_9605288[PMID]_9546834[PMID]
293642,Blepharophimosis-intellectual disability syndrome,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293707,"Blepharophimosis-intellectual disability syndrome, MKB type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
294975,Isolated absence of upper arm and forearm with hand present,Morphological anomaly,Prevalence at birth,0.62,1-9 / 1 000 000,Value and class,Worldwide,Validated,22002800[PMID]
294975,Isolated absence of upper arm and forearm with hand present,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_22002800[PMID]
294963,Popliteal pterygium syndrome,Clinical group,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,2352260[PMID]
294971,Isolated tetra-amelia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
289863,Atypical glycine encephalopathy,Clinical subtype,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
289863,Atypical glycine encephalopathy,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
289877,Transient hyperammonemia of the newborn,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289916,Vitamin B12-unresponsive methylmalonic acidemia type mut0,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289661,Epstein-Barr virus-positive diffuse large B-cell lymphoma,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,[WHO Classification of Tumours]
289661,Epstein-Barr virus-positive diffuse large B-cell lymphoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[WHO Classification of Tumours]
289857,Neonatal glycine encephalopathy,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289860,Infantile glycine encephalopathy,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289560,Mitochondrial membrane protein-associated neurodegeneration,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Worldwide,Validated,[EXPERT]_24575447[PMID]
289553,Dysmorphism-conductive hearing loss-heart defect syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289548,Inherited isolated adrenal insufficiency due to partial CYP11A1 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289539,BAP1-related tumor predisposition syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289601,Hereditary arterial and articular multiple calcification syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21288095[PMID]
289601,Hereditary arterial and articular multiple calcification syndrome,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,21288095[PMID]
289596,Juvenile nasopharyngeal angiofibroma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
289596,Juvenile nasopharyngeal angiofibroma,Disease,Annual incidence,0.6666,1-9 / 1 000 000,Value and class,Worldwide,Validated,28199045[PMID]
289586,Exfoliative ichthyosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
293355,Methylmalonic acidemia without homocystinuria,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
293355,Methylmalonic acidemia without homocystinuria,Clinical group,Point prevalence,0.0555,<1 / 1 000 000,Value and class,China,Validated,34103049[PMID]
293375,Grayson-Wilbrandt corneal dystrophy,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,8230838[PMID]_[EXPERT]
293375,Grayson-Wilbrandt corneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8230838[PMID]
293381,Epithelial recurrent erosion dystrophy,Disease,Cases/families,186.0,,Case(s),Worldwide,Validated,18700883[PMID]_6887751[PMID]_12035594[PMID]_18700883[PMID]_187789[PMID]_19710953[PMID]_20597871[PMID]
293381,Epithelial recurrent erosion dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
293462,Pre-Descemet corneal dystrophy,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,ORPHANET
293462,Pre-Descemet corneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293603,Congenital hereditary endothelial dystrophy type II,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
293621,X-linked endothelial corneal dystrophy,Disease,Cases/families,35.0,,Case(s),Worldwide,Validated,16490493[PMID]
293621,X-linked endothelial corneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
811,Shwachman-Diamond syndrome,Disease,Prevalence at birth,0.59,1-9 / 1 000 000,Value and class,Italy,Validated,22887728[PMID]
811,Shwachman-Diamond syndrome,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,United Kingdom,Validated,ISBN:407002049[OTHER]
811,Shwachman-Diamond syndrome,Disease,Prevalence at birth,0.67,1-9 / 1 000 000,Value and class,Puerto rico,Validated,8637967[PMID]
811,Shwachman-Diamond syndrome,Disease,Prevalence at birth,1.3,1-9 / 100 000,Value and class,Canada,Validated,11254457[PMID]
811,Shwachman-Diamond syndrome,Disease,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
811,Shwachman-Diamond syndrome,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Worldwide,Validated,[EXPERT]
811,Shwachman-Diamond syndrome,Disease,Point prevalence,0.28,1-9 / 1 000 000,Value and class,Worldwide,Validated,22491737[PMID]
293168,Infantile-onset ascending hereditary spastic paralysis,Disease,Cases/families,17.0,,Family(ies),Worldwide,Validated,12145748[PMID]_12919135[PMID]_12601111[PMID]_12509863[PMID]_18394004[PMID]_16718699[PMID]_18810511[PMID]_18523452[PMID]
293168,Infantile-onset ascending hereditary spastic paralysis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
293165,Skin fragility-woolly hair-palmoplantar keratoderma syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,20738328[PMID]
293165,Skin fragility-woolly hair-palmoplantar keratoderma syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
428,Autosomal dominant hypocalcemia,Clinical subtype,Point prevalence,0.161,1-9 / 1 000 000,Value and class,Denmark,Validated,25753591[PMID]
428,Autosomal dominant hypocalcemia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
428,Autosomal dominant hypocalcemia,Clinical subtype,Point prevalence,3.9,1-9 / 100 000,Value and class,United States,Validated,32386559[PMID]
293181,Epilepsy of infancy with migrating focal seizures,Disease,Cases/families,114.0,,Case(s),Worldwide,Validated,19469847[PMID]_23086397[PMID]_23599387[PMID]
293181,Epilepsy of infancy with migrating focal seizures,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_235999387[PMID]
293181,Epilepsy of infancy with migrating focal seizures,Disease,Point prevalence,0.11,1-9 / 1 000 000,Value and class,United Kingdom,Validated,23599387[PMID]
293181,Epilepsy of infancy with migrating focal seizures,Disease,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,United Kingdom,Validated,235999387[PMID]
2298,Insulin-resistance syndrome type B,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
2207,Familial primary hyperparathyroidism,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
293173,Acute generalized exanthematous pustulosis,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,11168761[PMID]_ORPHANET
293173,Acute generalized exanthematous pustulosis,Disease,Annual incidence,0.035,<1 / 1 000 000,Value and class,Israel,Validated,18669133[PMID]
293173,Acute generalized exanthematous pustulosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
293199,Pleomorphic rhabdomyosarcoma,Clinical subtype,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
293199,Pleomorphic rhabdomyosarcoma,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
393,"46,XX testicular difference of sex development",Malformation syndrome,Point prevalence,2.5,1-9 / 100 000,Value and class,Worldwide,Validated,16200839[PMID]_6945286[PMID]_[EXPERT]
293202,Epithelioid sarcoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
293202,Epithelioid sarcoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
293202,Epithelioid sarcoma,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,United States,Validated,1922430[PMID]
293284,Tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
293208,Celiac artery compression syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2459,Mansonelliasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2459,Mansonelliasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2404,Loiasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,22784545[PMID]
2404,Loiasis,Disease,Point prevalence,0.0,>1 / 1000,Class only,Specific population,Not yet validated,ORPHANET
2394,Pyruvate dehydrogenase E3 deficiency,Clinical subtype,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
2394,Pyruvate dehydrogenase E3 deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
2356,Arachnoid cyst,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
829,Adult-onset Still disease,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,France,Validated,7668903[PMID]
829,Adult-onset Still disease,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Japan,Validated,9465547[PMID]
829,Adult-onset Still disease,Disease,Point prevalence,3.9,1-9 / 100 000,Value and class,Japan,Validated,25382730[PMID]
829,Adult-onset Still disease,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Norway,Validated,16467042[PMID]
829,Adult-onset Still disease,Disease,Point prevalence,6.9,1-9 / 100 000,Value and class,Norway,Validated,16467042[PMID]
829,Adult-onset Still disease,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_16467042[PMID]
829,Adult-onset Still disease,Disease,Annual incidence,0.62,1-9 / 1 000 000,Value and class,Turkey,Validated,26320744[PMID]
829,Adult-onset Still disease,Disease,Point prevalence,6.77,1-9 / 100 000,Value and class,Turkey,Validated,26320744[PMID]
1929,Rasmussen subacute encephalitis,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
1929,Rasmussen subacute encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1183,Opsoclonus-myoclonus syndrome,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_19423368[PMID]
1183,Opsoclonus-myoclonus syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
1183,Opsoclonus-myoclonus syndrome,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,United Kingdom,Validated,19423368[PMID]
2688,Adult idiopathic neutropenia,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2688,Adult idiopathic neutropenia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
2686,Cyclic neutropenia,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
890,Hepatic veno-occlusive disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
176,Non-rhizomelic chondrodysplasia punctata,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
231,Dracunculiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
231,Dracunculiasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
2035,Lymphatic filariasis,Disease,Point prevalence,0.0,>1 / 1000,Class only,Specific population,Validated,World Health Organization[INST]
2035,Lymphatic filariasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
284448,CLIPPERS,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,24028073[PMID]
284448,CLIPPERS,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
284454,Acute zonal occult outer retinopathy,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,21056448[PMID]
284454,Acute zonal occult outer retinopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
284460,Acute annular outer retinopathy,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,16181293[PMID]
284460,Acute annular outer retinopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
284417,"Phosphoserine aminotransferase deficiency, infantile/juvenile form",Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
284426,Glycogen storage disease due to lactate dehydrogenase M-subunit deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
284435,Glycogen storage disease due to lactate dehydrogenase H-subunit deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
284984,Aneurysm-osteoarthritis syndrome,Disease,Cases/families,45.0,,Case(s),Worldwide,Validated,22167769[PMID]
284984,Aneurysm-osteoarthritis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
284979,Neonatal Marfan syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289365,Familial vesicoureteral reflux,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289347,Infective dermatitis associated with HTLV-1,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289356,Primary non-gestational choriocarcinoma of ovary,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
289377,Early-onset myopathy with fatal cardiomyopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289380,Myosclerosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289290,Hypermethioninemia encephalopathy due to adenosine kinase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289266,Early-onset epileptic encephalopathy and intellectual disability due to GRIN2A mutation,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289326,Tropical spastic paraparesis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289307,Developmental delay due to methylmalonate semialdehyde dehydrogenase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
289504,Combined malonic and methylmalonic acidemia,Disease,Annual incidence,3.3,1-9 / 100 000,Value and class,United States,Validated,21841779[PMID]
289504,Combined malonic and methylmalonic acidemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289499,Congenital cataract microcornea with corneal opacity,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289494,4H leukodystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
289494,4H leukodystrophy,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,[EXPERT]_22855961[PMID]_25339210[PMID]
289522,Microtriplication 11q24.1 syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,21617255[PMID]
289522,Microtriplication 11q24.1 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21617255[PMID]
289513,12q15q21.1 microdeletion syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,28159701[PMID]
289513,12q15q21.1 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28159701[PMID]
289465,Isolated congenital adermatoglyphia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289390,Primary Sjögren syndrome,Disease,Point prevalence,11.343,1-5 / 10 000,Value and class,France,Validated,23983119[PMID]_25387476[PMID]
289390,Primary Sjögren syndrome,Disease,Point prevalence,48.99,1-5 / 10 000,Value and class,Europe,Validated,25387476[PMID]
289390,Primary Sjögren syndrome,Disease,Point prevalence,86.398,6-9 / 10 000,Value and class,Greece,Validated,16332955[PMID]_25387476[PMID]
289390,Primary Sjögren syndrome,Disease,Point prevalence,49.745,1-5 / 10 000,Value and class,Norway,Validated,21231797[PMID]_25387476[PMID]
289390,Primary Sjögren syndrome,Disease,Point prevalence,45.47,1-5 / 10 000,Value and class,Denmark,Validated,17582741[PMID]_25387476[PMID]
289390,Primary Sjögren syndrome,Disease,Annual incidence,3.95,1-9 / 100 000,Value and class,United States,Validated,11393497[PMID]
289390,Primary Sjögren syndrome,Disease,Point prevalence,37.15,1-5 / 10 000,Value and class,"Taiwan, Province of China",Validated,22899470[PMID]_23916348[PMID]_24938285[PMID]
289390,Primary Sjögren syndrome,Disease,Point prevalence,207.83,>1 / 1000,Value and class,Turkey,Validated,18422594[PMID]_24938285[PMID]
289390,Primary Sjögren syndrome,Disease,Point prevalence,30.91,1-5 / 10 000,Value and class,Italy,Validated,22396771[PMID]_24938285[PMID]
289390,Primary Sjögren syndrome,Disease,Point prevalence,165.98,>1 / 1000,Value and class,Brazil,Validated,23588513[PMID]_24938285[PMID]
289390,Primary Sjögren syndrome,Disease,Annual incidence,9.5,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,21239759[PMID]_23916348[PMID]_22899470[PMID]_24938285[PMID]
289390,Primary Sjögren syndrome,Disease,Annual incidence,5.3,1-9 / 100 000,Value and class,Greece,Validated,16332955[PMID]_24938285[PMID]
289390,Primary Sjögren syndrome,Disease,Annual incidence,3.9,1-9 / 100 000,Value and class,Slovenia,Validated,15194588[PMID]_24938285[PMID]
289390,Primary Sjögren syndrome,Disease,Annual incidence,6.92,1-9 / 100 000,Value and class,Worldwide,Validated,24938285[PMID]
289385,Malignancy diagnosed during pregnancy,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289483,Intellectual disability-alacrima-achalasia syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289478,PASH syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28696038[PMID]
289478,PASH syndrome,Disease,Cases/families,36.0,,Case(s),Worldwide,Validated,28696038[PMID]
289176,Autosomal recessive hypophosphatemic rickets,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
289157,Hypocalcemic vitamin D-dependent rickets,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
280921,Idiopathic panuveitis,Disease,Point prevalence,2.0194,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET
280921,Idiopathic panuveitis,Disease,Annual incidence,0.5051,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET
280921,Idiopathic panuveitis,Disease,Point prevalence,16.0,1-5 / 10 000,Value and class,United States,Validated,27608193[PMID]
280921,Idiopathic panuveitis,Disease,Annual incidence,3.6,1-9 / 100 000,Value and class,United States,Validated,34802369[PMID]
280898,Panuveitis,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
280892,Posterior uveitis,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
280886,Anterior uveitis,Category,Point prevalence,185.0,>1 / 1000,Value and class,Denmark,Validated,20066507[PMID]
280886,Anterior uveitis,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
281103,Keratinopathic ichthyosis,Clinical group,Point prevalence,0.11,1-9 / 1 000 000,Value and class,France,Validated,24393603[PMID]
281097,Autosomal recessive congenital ichthyosis,Clinical group,Annual incidence,0.5,1-9 / 1 000 000,Value and class,United States,Not yet validated,20301593[PMID]_ORPHANET
281097,Autosomal recessive congenital ichthyosis,Clinical group,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,8006437[PMID]_European Medicines Agency 2012[INST]
281097,Autosomal recessive congenital ichthyosis,Clinical group,Point prevalence,0.77,1-9 / 1 000 000,Value and class,Spain,Not yet validated,22000705[PMID]_21668430[PMID]
281097,Autosomal recessive congenital ichthyosis,Clinical group,Annual incidence,1.1,1-9 / 100 000,Value and class,Norway,Validated,9887377[PMID]
281090,Syndromic recessive X-linked ichthyosis,Disease,Point prevalence,1.3,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
281085,Inherited ichthyosis syndromic form,Category,Point prevalence,0.19,1-9 / 1 000 000,Value and class,France,Not yet validated,24393603[PMID]
281082,Inherited non-syndromic ichthyosis,Category,Point prevalence,1.13,1-9 / 100 000,Value and class,France,Not yet validated,24393603[PMID]
281190,Congenital reticular ichthyosiform erythroderma,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,26381864[PMID]
281190,Congenital reticular ichthyosiform erythroderma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26381864[PMID]
281201,Keratosis linearis-ichthyosis congenita-sclerosing keratoderma syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
281139,Annular epidermolytic ichthyosis,Disease,Cases/families,7.0,,Family(ies),Worldwide,Validated,17596149[PMID]_14594577[PMID]
281139,Annular epidermolytic ichthyosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
281122,Self-improving collodion baby,Disease,Cases/families,25.0,,Case(s),Worldwide,Validated,[EXPERT]
281122,Self-improving collodion baby,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
281127,Acral self-healing collodion baby,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,19500103[PMID]_[EXPERT]
281127,Acral self-healing collodion baby,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280628,Familial progressive hyper- and hypopigmentation,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,21368769[PMID]
280628,Familial progressive hyper- and hypopigmentation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280633,Multiple congenital anomalies-hypotonia-seizures syndrome,Malformation syndrome,Cases/families,15.0,,Case(s),Worldwide,Validated,26394714[PMID]_26364997[PMID]
280633,Multiple congenital anomalies-hypotonia-seizures syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26394714[PMID]_26364997[PMID]
280615,Hemoglobinopathy Toms River,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,21561349[PMID]
280615,Hemoglobinopathy Toms River,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280598,Hereditary sensorimotor neuropathy with hyperelastic skin,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,21576112[PMID]
280598,Hereditary sensorimotor neuropathy with hyperelastic skin,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280620,Progressive myoclonic epilepsy type 6,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,21549339[PMID]_23449775[PMID]
280620,Progressive myoclonic epilepsy type 6,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21549339[PMID]_23449775[PMID]
280671,Megaconial congenital muscular dystrophy,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,23945283[PMID]
280671,Megaconial congenital muscular dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280640,Occipital pachygyria and polymicrogyria,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,21572413[PMID]
280640,Occipital pachygyria and polymicrogyria,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280654,Autosomal recessive nail dysplasia,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,21665003[PMID]
280654,Autosomal recessive nail dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280779,Cutaneous collagenous vasculopathy,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,21916964[PMID]_21571177[PMID]_20525488[PMID]_20451292[PMID]_20000878[PMID]_18537865[PMID]_10660131[PMID]_[EXPERT]
280779,Cutaneous collagenous vasculopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280785,Bullous diffuse cutaneous mastocytosis,Clinical subtype,Cases/families,40.0,,Case(s),Worldwide,Validated,ORPHANET
280785,Bullous diffuse cutaneous mastocytosis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280794,Pseudoxanthomatous diffuse cutaneous mastocytosis,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
280794,Pseudoxanthomatous diffuse cutaneous mastocytosis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280679,Moyamoya angiopathy-short stature-facial dysmorphism-hypergonadotropic hypogonadism syndrome,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,21596366[PMID]
280679,Moyamoya angiopathy-short stature-facial dysmorphism-hypergonadotropic hypogonadism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280763,Severe intellectual disability and progressive spastic paraplegia,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,21620353[PMID]
280763,Severe intellectual disability and progressive spastic paraplegia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
280774,Generalized essential telangiectasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
284149,Craniosynostosis-dental anomalies,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
284139,"Larsen-like syndrome, B3GAT3 type",Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,25893793[PMID]
284139,"Larsen-like syndrome, B3GAT3 type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25893793[PMID]
284180,Xp22.13p22.2 duplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
284169,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to 10p11.21p12.31 microdeletion,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29663678[PMID]
284169,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to 10p11.21p12.31 microdeletion,Clinical subtype,Cases/families,19.0,,Case(s),Worldwide,Validated,29663678[PMID]
284160,8q21.11 microdeletion syndrome,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,21802062[PMID]_[EXPERT]
284160,8q21.11 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
284247,Familial retinal arterial macroaneurysm,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
284232,Autosomal dominant Charcot-Marie-Tooth disease type 2O,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
284227,TEMPI syndrome,Clinical syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
284227,TEMPI syndrome,Clinical syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
284271,Autosomal recessive cerebellar ataxia-psychomotor delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
284264,IgG4-related disease,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
284324,Childhood-onset autosomal recessive slowly progressive spinocerebellar ataxia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
284282,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to WWOX deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
284289,Adult-onset autosomal recessive cerebellar ataxia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25182700[PMID]
284289,Adult-onset autosomal recessive cerebellar ataxia,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,25182700[PMID]
284343,DICER1 tumor-predisposition syndrome,Disease,Annual incidence,0.007,<1 / 1 000 000,Value and class,Worldwide,Not yet validated,22796286[PMID]
284332,Infantile-onset autosomal recessive nonprogressive cerebellar ataxia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
284339,Pontocerebellar hypoplasia type 7,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,21594990[PMID]_[EXPERT]
284339,Pontocerebellar hypoplasia type 7,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
284388,Reversible cerebral vasoconstriction syndrome,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
284395,Well-differentiated fetal adenocarcinoma of the lung,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
284400,Small cell carcinoma of the bladder,Disease,Annual incidence,0.14,1-9 / 1 000 000,Value and class,United States,Validated,21567387[PMID]
284400,Small cell carcinoma of the bladder,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
284400,Small cell carcinoma of the bladder,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,[EXPERT]
282166,Inherited Creutzfeldt-Jakob disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
309854,Cirrhosis-dystonia-polycythemia-hypermanganesemia syndrome,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,22934317[PMID]
309854,Cirrhosis-dystonia-polycythemia-hypermanganesemia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22934317[PMID]
314029,High bone mass osteogenesis imperfecta,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,21344539[PMID]
314029,High bone mass osteogenesis imperfecta,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314022,Gastric adenocarcinoma and proximal polyposis of the stomach,Disease,Cases/families,28.0,,Case(s),Worldwide,Validated,21813476[PMID]
314022,Gastric adenocarcinoma and proximal polyposis of the stomach,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314017,Idiopathic linear interstitial keratitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314002,Contractures-webbed neck-micrognathia-hypoplastic nipples syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,22383252[PMID]
314002,Contractures-webbed neck-micrognathia-hypoplastic nipples syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
313947,2q23.1 microduplication syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,22085900[PMID]
313947,2q23.1 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
313936,PENS syndrome,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,22414678[PMID]_21315481[PMID]
313936,PENS syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
313920,Epstein-Barr virus-associated gastric carcinoma,Disease,Annual incidence,1.2,1-9 / 100 000,Value and class,Worldwide,Not yet validated,22392024[PMID]_ORPHANET
313920,Epstein-Barr virus-associated gastric carcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
313906,Congenital pancreatic cyst,Morphological anomaly,Cases/families,10.0,,Case(s),Worldwide,Validated,19231513[PMID]_2202976[PMID]
313906,Congenital pancreatic cyst,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
313892,Developmental and speech delay due to SOX5 deficiency,Clinical subtype,Cases/families,14.0,,Case(s),Worldwide,Validated,26111154[PMID]_29477873[PMID]
313892,Developmental and speech delay due to SOX5 deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29477873[PMID]
313884,12p12.1 microdeletion syndrome,Clinical subtype,Cases/families,11.0,,Case(s),Worldwide,Validated,22290657[PMID]_29477873[PMID]
313884,12p12.1 microdeletion syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29477873[PMID]
313855,FGFR2-related bent bone dysplasia,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,27240702[PMID]
313855,FGFR2-related bent bone dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27240702[PMID]
313850,Infantile cerebellar-retinal degeneration,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,22405087[PMID]_25351951[PMID]
313850,Infantile cerebellar-retinal degeneration,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22405087[PMID]_25351951[PMID]
313846,Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,22341969[PMID]
313846,Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
313838,Coats plus syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
313800,Retinal dystrophy-optic nerve edema-splenomegaly-anhidrosis-migraine headache syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,22307799[PMID]
313800,Retinal dystrophy-optic nerve edema-splenomegaly-anhidrosis-migraine headache syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
313808,Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia,Disease,Cases/families,27.0,,Case(s),Worldwide,Validated,22197934[PMID]_10668715[PMID]
313808,Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
313781,20p13 microdeletion syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,22274139[PMID]_23165892[PMID]
313781,20p13 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
313795,Jawad syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,21998596[PMID]_8434622[PMID]
313795,Jawad syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21998596[PMID]_8434622[PMID]
313772,Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,22022284[PMID]
313772,Early-onset spastic ataxia-myoclonic epilepsy-neuropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22022284[PMID]
314603,Autosomal recessive spastic ataxia with leukoencephalopathy,Disease,Cases/families,54.0,,Case(s),Worldwide,Validated,22448145[PMID]
314603,Autosomal recessive spastic ataxia with leukoencephalopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22448145[PMID]
314597,Chudley-McCullough syndrome,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,ORPHANET
314597,Chudley-McCullough syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314613,Growing teratoma syndrome,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314575,Intellectual disability-hypotonia-brachycephaly-pyloric stenosis-cryptorchidism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,22611637[PMID]
314575,Intellectual disability-hypotonia-brachycephaly-pyloric stenosis-cryptorchidism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314572,Autosomal recessive leukoencephalopathy-ischemic stroke-retinitis pigmentosa syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,22436252[PMID]
314572,Autosomal recessive leukoencephalopathy-ischemic stroke-retinitis pigmentosa syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314588,Distal triplication 15q syndrome,Etiological subtype,Cases/families,23.0,,Case(s),Worldwide,Validated,24793337[PMID]
314588,Distal triplication 15q syndrome,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24793337[PMID]
314585,15q overgrowth syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,19133692[PMID]
314585,15q overgrowth syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314485,Young adult-onset distal hereditary motor neuropathy,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,22522442[PMID]
314485,Young adult-onset distal hereditary motor neuropathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314566,Primary progressive apraxia of speech,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,22382356[PMID]_23078273[PMID]
314566,Primary progressive apraxia of speech,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314555,Facial dysmorphism-ocular anomalies-osteopenia-intellectual disability-dental anomalies syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,22581230[PMID]
314555,Facial dysmorphism-ocular anomalies-osteopenia-intellectual disability-dental anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314466,Atypical Meigs syndrome,Clinical syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,7112481[PMID]_9336761[PMID]_12632574[PMID]_12087934[PMID]_15739106[PMID]
314466,Atypical Meigs syndrome,Clinical syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314459,Pseudo-Meigs syndrome,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314478,Ovarian fibrothecoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314473,Ovarian fibroma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314422,Ameloblastic carcinoma,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,22493395[PMID]_19674470[PMID]_23251064[PMID]_23099227[PMID]
314422,Ameloblastic carcinoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314432,Spigelian hernia-cryptorchidism syndrome,Malformation syndrome,Cases/families,15.0,,Case(s),Worldwide,Validated,20680633[PMID]
314432,Spigelian hernia-cryptorchidism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314451,Meigs syndrome,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314394,Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,22440536[PMID]_22840364[PMID]_22840363[PMID]
314394,Short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314399,Autosomal dominant aplasia and myelodysplasia,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,22541560[PMID]
314399,Autosomal dominant aplasia and myelodysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22541560[PMID]
314404,Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome,Disease,Cases/families,80.0,,Case(s),Worldwide,Validated,EXPERT
314404,Autosomal dominant cerebellar ataxia-deafness-narcolepsy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22328086[PMID]_23904686[PMID]
314419,Ameloblastoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
314373,Chronic infantile diarrhea due to guanylate cyclase 2C overactivity,Disease,Cases/families,32.0,,Case(s),Worldwide,Validated,22436048[PMID]
314373,Chronic infantile diarrhea due to guanylate cyclase 2C overactivity,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314376,Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,22521417[PMID]_25370039[PMID]
314376,Intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22521417[PMID]_25370039[PMID]
314381,Hereditary sensory and autonomic neuropathy type 6,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,22522446[PMID]
314381,Hereditary sensory and autonomic neuropathy type 6,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314389,Xq12-q13.3 duplication syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,22213401[PMID]
314389,Xq12-q13.3 duplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314034,7p22.1 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26297194[PMID]
314034,7p22.1 microduplication syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,26297194[PMID]
314041,Marfanoid habitus-inguinal hernia-advanced bone age syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,22489068[PMID]
314041,Marfanoid habitus-inguinal hernia-advanced bone age syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
314051,Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,22492562[PMID]_23008233[PMID]_25854774[PMID]
314051,Leukoencephalopathy-thalamus and brainstem anomalies-high lactate syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22492562[PMID]_23008233[PMID]_25854774[PMID]
306674,Kufor-Rakeb syndrome,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,20853184[PMID]_21094623[PMID]_DOI: 10.1002/mdc3.12175[OTHER]
306674,Kufor-Rakeb syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20853184[PMID]_21094623[PMID]
306669,Hemiparkinsonism-hemiatrophy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23986429[PMID]
306669,Hemiparkinsonism-hemiatrophy syndrome,Disease,Cases/families,68.0,,Case(s),Worldwide,Validated,23986429[PMID]
306741,Hemidystonia-hemiatrophy syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]_ORPHANET
306741,Hemidystonia-hemiatrophy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,[EXPERT]_ORPHANET
306734,"Primary dystonia, DYT21 type",Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,21301909[PMID]
306734,"Primary dystonia, DYT21 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21301909[PMID]
306731,Sydenham chorea,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
308166,Erythrokeratoderma variabilis progressiva,Clinical group,Point prevalence,0.046,<1 / 1 000 000,Value and class,France,Validated,24393603[PMID]_[EXPERT]
308386,Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET_European Medicines Agency 2010[INST]
308410,Autism-epilepsy syndrome due to branched chain ketoacid dehydrogenase kinase deficiency,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,24449431[PMID]
308410,Autism-epilepsy syndrome due to branched chain ketoacid dehydrogenase kinase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,24449431[PMID]
308425,Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,27699154[PMID]
308425,Methylmalonic acidemia due to methylmalonyl-CoA epimerase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27699154[PMID]
307766,Curly hair-acral keratoderma-caries syndrome,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,11453928[PMID]
307766,Curly hair-acral keratoderma-caries syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11453928[PMID]
307936,Hypotrichosis-osteolysis-periodontitis-palmoplantar keratoderma syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12207605[PMID]
307936,Hypotrichosis-osteolysis-periodontitis-palmoplantar keratoderma syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,12207605[PMID]
309111,Combined pancreatic lipase-colipase deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,2265786[PMID]
309111,Combined pancreatic lipase-colipase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2265786[PMID]
309031,Pancreatic triacylglycerol lipase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
309031,Pancreatic triacylglycerol lipase deficiency,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
309108,Pancreatic colipase deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,7068048[PMID]
309108,Pancreatic colipase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7068048[PMID]
309025,Mevalonate kinase deficiency,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,27142780[PMID]
309025,Mevalonate kinase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27142780[PMID]
309015,Familial lipoprotein lipase deficiency,Etiological subtype,Point prevalence,0.1,1-9 / 1 000 000,Value and class,United States,Validated,20301485[PMID]
309015,Familial lipoprotein lipase deficiency,Etiological subtype,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
309020,Familial apolipoprotein C-II deficiency,Etiological subtype,Cases/families,10.0,,Family(ies),Worldwide,Validated,25732519[PMID]
309020,Familial apolipoprotein C-II deficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25732519[PMID]
178,Chordoma,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,United States,Validated,22300861[PMID]_ ORPHANET_[EXPERT]
2637,Microcephalic osteodysplastic primordial dwarfism type II,Malformation syndrome,Cases/families,150.0,,Case(s),Worldwide,Validated,23498563[PMID]
2637,Microcephalic osteodysplastic primordial dwarfism type II,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
592,Macrophagic myofasciitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
308552,"Glycogen storage disease due to acid maltase deficiency, infantile onset",Clinical subtype,Prevalence at birth,3.0,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,18519449[PMID]_24243590[PMID]
308552,"Glycogen storage disease due to acid maltase deficiency, infantile onset",Clinical subtype,Prevalence at birth,0.72,1-9 / 1 000 000,Value and class,Netherlands,Validated,10482961[PMID]
308552,"Glycogen storage disease due to acid maltase deficiency, infantile onset",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
309271,"Metachromatic leukodystrophy, adult form",Clinical subtype,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
309271,"Metachromatic leukodystrophy, adult form",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
309246,"GM2 gangliosidosis, AB variant",Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,26082327[PMID]
309246,"GM2 gangliosidosis, AB variant",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26082327[PMID]
309256,"Metachromatic leukodystrophy, late infantile form",Clinical subtype,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET_24001781[PMID]
309256,"Metachromatic leukodystrophy, late infantile form",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
309263,"Metachromatic leukodystrophy, juvenile form",Clinical subtype,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
309263,"Metachromatic leukodystrophy, juvenile form",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
309324,"Free sialic acid storage disease, infantile form",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
309324,"Free sialic acid storage disease, infantile form",Clinical subtype,Prevalence at birth,0.14,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
309334,Salla disease,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,16584062[PMID]_ORPHANET
309334,Salla disease,Clinical subtype,Prevalence at birth,1.59,1-9 / 100 000,Value and class,Sweden,Validated,25274184[PMID]
309294,Sialidosis,Clinical group,Prevalence at birth,0.05,<1 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
309294,Sialidosis,Clinical group,Prevalence at birth,0.02,<1 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
309294,Sialidosis,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
309294,Sialidosis,Clinical group,Prevalence at birth,0.05,<1 / 1 000 000,Value and class,Europe,Validated,10480370[PMID]
309294,Sialidosis,Clinical group,Prevalence at birth,0.07,<1 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
309294,Sialidosis,Clinical group,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Point prevalence,15.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2009[INST]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Canada,Validated,25404155[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Germany,Validated,16435194[PMID]_25404155[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Point prevalence,0.12,1-9 / 1 000 000,Value and class,Germany,Validated,25404155[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Prevalence at birth,1.4,1-9 / 100 000,Value and class,United Arab Emirates,Validated,23430803[PMID]_25404155[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Point prevalence,0.46,1-9 / 1 000 000,Value and class,United Arab Emirates,Validated,25404155[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Prevalence at birth,0.497,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]_25404155[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Point prevalence,0.153,1-9 / 1 000 000,Value and class,Australia,Validated,25404155[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Prevalence at birth,0.48,1-9 / 1 000 000,Value and class,Canada,Validated,10617747[PMID]_25404155[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Prevalence at birth,0.29,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Point prevalence,0.029,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Prevalence at birth,0.11,1-9 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
309297,Mucopolysaccharidosis type 4A,Clinical subtype,Point prevalence,0.0848,<1 / 1 000 000,Value and class,Brazil,Validated,35209917[PMID]
309310,Mucopolysaccharidosis type 4B,Clinical subtype,Point prevalence,0.001,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
309310,Mucopolysaccharidosis type 4B,Clinical subtype,Prevalence at birth,0.004,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
309147,Hyper-beta-alaninemia,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,17926374[PMID]_7936305[PMID]_ORPHANET
309147,Hyper-beta-alaninemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17926374[PMID]_7936305[PMID]
309152,GM2 gangliosidosis,Clinical group,Prevalence at birth,0.87,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
309152,GM2 gangliosidosis,Clinical group,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,European Medecines Agency 2017[INST]
300547,Autosomal recessive infantile hypercalcemia,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,ORPHANET
300547,Autosomal recessive infantile hypercalcemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300552,Follicular cholangitis and pancreatitis,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,22211284[PMID]
300552,Follicular cholangitis and pancreatitis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300557,Carcinoma of the ampulla of Vater,Disease,Annual incidence,0.59,1-9 / 1 000 000,Value and class,France,Validated,10656214[PMID]
300557,Carcinoma of the ampulla of Vater,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
300557,Carcinoma of the ampulla of Vater,Disease,Annual incidence,0.57,1-9 / 1 000 000,Value and class,United Kingdom,Validated,3664230[PMID]
300564,Combined pulmonary fibrosis-emphysema syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
300570,Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,20829227[PMID]
300570,Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300573,Polymicrogyria due to TUBB2B mutation,Malformation syndrome,Cases/families,36.0,,Case(s),Worldwide,Validated,19465910[PMID]_17036343[PMID]
300573,Polymicrogyria due to TUBB2B mutation,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300576,Oligodontia-cancer predisposition syndrome,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,15042511[PMID]_21416598[PMID]
300576,Oligodontia-cancer predisposition syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300496,Multiple congenital anomalies-hypotonia-seizures syndrome type 2,Malformation syndrome,Cases/families,24.0,,Case(s),Worldwide,Validated,16783569[PMID]_22305531[PMID]_24357517[PMID]_24259288[PMID]_24259184[PMID]_24706016[PMID]_26545172[PMID]
300496,Multiple congenital anomalies-hypotonia-seizures syndrome type 2,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26545172[PMID]
300501,Painful orbital and systemic neurofibromas-marfanoid habitus syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,22258529[PMID]
300501,Painful orbital and systemic neurofibromas-marfanoid habitus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300504,Onychocytic matricoma,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,22197859[PMID]
300504,Onychocytic matricoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300512,Onychomatricoma,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,21965578[PMID]
300512,Onychomatricoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300525,Pseudohypoaldosteronism type 2D,Etiological subtype,Cases/families,24.0,,Case(s),Worldwide,Validated,22266938[PMID]
300525,Pseudohypoaldosteronism type 2D,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300530,Pseudohypoaldosteronism type 2E,Etiological subtype,Cases/families,17.0,,Case(s),Worldwide,Validated,22266938[PMID]
300530,Pseudohypoaldosteronism type 2E,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300536,DDOST-CDG,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,22305527[PMID]
300536,DDOST-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22305527[PMID]
300865,Primary cutaneous anaplastic large cell lymphoma,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
300857,T-cell/histiocyte rich large B cell lymphoma,Disease,Annual incidence,0.023,<1 / 1 000 000,Value and class,United States,Validated,29845599[PMID]
300878,Hairy cell leukemia variant,Disease,Annual incidence,0.22,1-9 / 1 000 000,Value and class,United States,Validated,[EXPERT]_ORPHANET
300878,Hairy cell leukemia variant,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
300895,ALK-positive anaplastic large cell lymphoma,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
300605,Juvenile amyotrophic lateral sclerosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
300755,Laminopathy with striated muscle involvement,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
300751,Familial dilated cardiomyopathy with conduction defect due to LMNA mutation,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
300763,Laminopathy with lipodystrophy,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
300758,Laminopathy with peripheral neuropathy,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
300842,Indolent B-cell non-Hodgkin lymphoma,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
300766,Laminopathy with premature aging,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
300903,ALK-negative anaplastic large cell lymphoma,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
300912,Marginal zone lymphoma,Clinical group,Annual incidence,2.8,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
300912,Marginal zone lymphoma,Clinical group,Point prevalence,7.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
300912,Marginal zone lymphoma,Clinical group,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
306431,Adult-onset immunodeficiency with anti-interferon-gamma autoantibodies,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
306550,FADD-related immunodeficiency,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,21109225[PMID]
306550,FADD-related immunodeficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21109225[PMID]
306553,Myospherulosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
306542,Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,20451171[PMID]
306542,Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
306547,Porencephaly-microcephaly-bilateral congenital cataract syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,21109224[PMID]
306547,Porencephaly-microcephaly-bilateral congenital cataract syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
306530,Congenital hereditary facial paralysis-variable hearing loss syndrome,Morphological anomaly,Cases/families,13.0,,Case(s),Worldwide,Validated,3775291[PMID]_22770981[PMID]
306530,Congenital hereditary facial paralysis-variable hearing loss syndrome,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3775291[PMID]_22770981[PMID]
306527,Isolated hereditary congenital facial paralysis,Morphological anomaly,Cases/families,8.0,,Family(ies),Worldwide,Validated,ORPHANET
306527,Isolated hereditary congenital facial paralysis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
306516,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,23334384[PMID]
306516,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
306511,Autosomal recessive spastic paraplegia type 48,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,20613862[PMID]
306511,Autosomal recessive spastic paraplegia type 48,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
306498,PTEN hamartoma tumor syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
306504,Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,22512483[PMID]
306504,Interstitial lung disease-nephrotic syndrome-epidermolysis bullosa syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22512483[PMID]
306644,Complication after organ transplantation,Particular clinical situation in a disease or syndrome,Point prevalence,9.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2013[INST]
306577,Hereditary sodium channelopathy-related small fibers neuropathy,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,21698661[PMID]
306577,Hereditary sodium channelopathy-related small fibers neuropathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
306558,Primary microcephaly-epilepsy-permanent neonatal diabetes syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,28711742[PMID]
306558,Primary microcephaly-epilepsy-permanent neonatal diabetes syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28711742[PMID]
298644,Disorder of thiamine metabolism and transport,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
300179,Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency,Clinical subtype,Cases/families,9.0,,Case(s),Worldwide,Validated,27149304[PMID]
300179,Kyphoscoliotic Ehlers-Danlos syndrome due to FKBP22 deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27149304[PMID]
300319,Charcot-Marie-Tooth disease type 2P,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,22781092[PMID]
300319,Charcot-Marie-Tooth disease type 2P,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300324,Persistent polyclonal B-cell lymphocytosis,Disease,Cases/families,154.0,,Case(s),Worldwide,Validated,18668130[PMID]_21396665[PMID]_2785931[PMID]_7934138[PMID]_11552996[PMID]
300324,Persistent polyclonal B-cell lymphocytosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
300313,Congenital cataract-hearing loss-severe developmental delay syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,15902551[PMID]_22243965[PMID]
300313,Congenital cataract-hearing loss-severe developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15902551[PMID]_22243965[PMID]
300298,Severe congenital hypochromic anemia with ringed sideroblasts,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,22031863[PMID]
300298,Severe congenital hypochromic anemia with ringed sideroblasts,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300305,11p15.4 microduplication syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,22052655[PMID]
300305,11p15.4 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300284,Connective tissue disorder due to lysyl hydroxylase-3 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18834968[PMID]
300284,Connective tissue disorder due to lysyl hydroxylase-3 deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,18834968[PMID]
300293,Transient infantile hypertriglyceridemia and hepatosteatosis,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,22226083[PMID]_24549054[PMID]
300293,Transient infantile hypertriglyceridemia and hepatosteatosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22226083[PMID]_24549054[PMID]
300385,Pituitary carcinoma,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Europe,Validated,22361014[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Lifetime Prevalence,0.87,1-9 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
300385,Pituitary carcinoma,Disease,Annual incidence,0.026,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.041,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.019,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.033,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.099,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.052,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.025,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.063,<1 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.025,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.021,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.021,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.015,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.036,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.135,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.213,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300385,Pituitary carcinoma,Disease,Annual incidence,0.171,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
300493,Sagliker syndrome,Particular clinical situation in a disease or syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,22200434[PMID]
300493,Sagliker syndrome,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300373,X-linked acrogigantism,Disease,Cases/families,33.0,,Case(s),Worldwide,Validated,29389097[PMID]
300373,X-linked acrogigantism,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
300382,Progeroid and marfanoid aspect-lipodystrophy syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,24613577[PMID]_24665001[PMID]
300382,Progeroid and marfanoid aspect-lipodystrophy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300345,Autosomal systemic lupus erythematosus,Disease,Cases/families,7.0,,Family(ies),Worldwide,Validated,22019780[PMID]
300345,Autosomal systemic lupus erythematosus,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300359,PLCG2-associated antibody deficiency and immune dysregulation,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,22236196[PMID]
300359,PLCG2-associated antibody deficiency and immune dysregulation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
300333,Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,15265795[PMID]
300333,Nephrotic syndrome-epidermolysis bullosa-sensorineural deafness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15265795[PMID]
464724,Fever-associated acute infantile liver failure syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,26073778[PMID]
464724,Fever-associated acute infantile liver failure syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26073778[PMID]
464738,Basel-Vanagaite-Smirin-Yosef syndrome,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,PMID: 25792360
464738,Basel-Vanagaite-Smirin-Yosef syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25792360[PMID]
464760,Familial cavitary optic disc anomaly,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25581579[PMID]
464760,Familial cavitary optic disc anomaly,Morphological anomaly,Cases/families,17.0,,Case(s),Worldwide,Validated,25581579[PMID]
464756,Familial gastric type 1 neuroendocrine tumor,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,25678551[PMID]
464756,Familial gastric type 1 neuroendocrine tumor,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25678551[PMID]
465508,Symptomatic form of HFE-related hemochromatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
464282,Spastic paraplegia-severe developmental delay-epilepsy syndrome,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,26424145[PMID]_26437029[PMID]
464282,Spastic paraplegia-severe developmental delay-epilepsy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26424145[PMID]_26437029[PMID]
464288,Short stature-brachydactyly-obesity-global developmental delay syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,26437029[PMID]
464288,Short stature-brachydactyly-obesity-global developmental delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26437029[PMID]
464306,DYRK1A-related intellectual disability syndrome,Malformation syndrome,Cases/families,54.0,,Case(s),Worldwide,Validated,26922654[PMID]
464306,DYRK1A-related intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26922654[PMID]
464329,Kaposiform lymphangiomatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27053281[PMID]
464321,Multifocal lymphangioendotheliomatosis-thrombocytopenia syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26148948[PMID]
464318,Verrucous hemangioma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25263605[PMID]
464311,Intellectual disability syndrome due to a DYRK1A point mutation,Etiological subtype,Cases/families,35.0,,Case(s),Worldwide,Validated,26922654[PMID]
464311,Intellectual disability syndrome due to a DYRK1A point mutation,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26922654[PMID]
464366,NEK9-related lethal skeletal dysplasia,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,26908619[PMID]
464366,NEK9-related lethal skeletal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26908619[PMID]
464359,Benign metanephric tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26870216[PMID]_27227914[PMID]
464343,Catastrophic antiphospholipid syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27375916[PMID]
464336,BENTA disease,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,25930198[PMID]
464336,BENTA disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25930198[PMID]
464453,Acquired methemoglobinemia,Disease,Cases/families,242.0,,Case(s),Worldwide,Validated,15342970[PMID]_19224791[PMID]
464453,Acquired methemoglobinemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_15342970[PMID]_19224791[PMID]
464443,COG6-CGD,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,26260076[PMID]_23430903[PMID]
464443,COG6-CGD,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26260076[PMID]_23430903[PMID]
464440,"Primary dystonia, DYT27 type",Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,26260724[PMID]_26004199[PMID]
464440,"Primary dystonia, DYT27 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26260724[PMID]_26004199[PMID]
464370,Neonatal alloimmune neutropenia,Disease,Prevalence at birth,16.6,1-5 / 10 000,Value and class,Poland,Validated,11696231[PMID]
464370,Neonatal alloimmune neutropenia,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
464458,Paracetamol poisoning,Particular clinical situation in a disease or syndrome,Annual incidence,16.0,1-5 / 10 000,Value and class,Iceland,Validated,22827594[PMID]_15543083[PMID]
464458,Paracetamol poisoning,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
639,Polyneuropathy associated with IgM monoclonal gammopathy with anti-MAG,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
662,Lymphedema with yellow nails,Disease,Cases/families,400.0,,Case(s),Worldwide,Validated,28241848[PMID]
662,Lymphedema with yellow nails,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_28241848[PMID]
537,Toxic epidermal necrolysis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
793,SAPHO syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
456298,1p35.2 microdeletion syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,25900906[PMID]
456298,1p35.2 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25900906[PMID]
456328,X-linked myotubular myopathy-abnormal genitalia syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,10449925[PMID]
456328,X-linked myotubular myopathy-abnormal genitalia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10449925[PMID]
456312,Infantile multisystem neurologic-endocrine-pancreatic disease,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25574476[PMID]
456312,Infantile multisystem neurologic-endocrine-pancreatic disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25574476[PMID]
456318,Hereditary sensory neuropathy-deafness-dementia syndrome,Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,23365052[PMID]
456318,Hereditary sensory neuropathy-deafness-dementia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23365052[PMID]
454831,Acute radiation syndrome,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2018[INST]
454836,Avian influenza,Disease,Cases/families,826.0,,Case(s),Worldwide,Validated,World Health Organization 2015[INST]
454836,Avian influenza,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
454836,Avian influenza,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET_World Health Organization 2015[INST]
454887,Corticobasal syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
454723,Endometrioid carcinoma of ovary,Disease,Annual incidence,0.51,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,26463436[PMID]
454723,Endometrioid carcinoma of ovary,Disease,Annual incidence,0.81,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
454718,Holmes-Adie syndrome,Disease,Annual incidence,4.7,1-9 / 100 000,Value and class,United States,Validated,613531[PMID]
454718,Holmes-Adie syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
454714,Plasma cell leukemia,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Europe,Validated,20664057[PMID]
454821,OBSOLETE: Pleomorphic salivary gland adenoma,Histopathological subtype,Annual incidence,2.725,1-9 / 100 000,Value and class,Worldwide,Validated,World Health Organization 2005[INST]
454750,Isolated tracheoesophageal fistula,Morphological anomaly,Prevalence at birth,4.2,1-9 / 100 000,Value and class,Australia,Validated,25976171[PMID]
454750,Isolated tracheoesophageal fistula,Morphological anomaly,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Worldwide,Validated,22945024[PMID]
454750,Isolated tracheoesophageal fistula,Morphological anomaly,Point prevalence,2.2,1-9 / 100 000,Value and class,Worldwide,Validated,22945024[PMID]_ORPHANET
454750,Isolated tracheoesophageal fistula,Morphological anomaly,Point prevalence,4.2,1-9 / 100 000,Value and class,Australia,Validated,25976171[PMID]_ORPHANET
454745,Kuru,Disease,Cases/families,2700.0,,Case(s),Worldwide,Validated,PMID: 16798390
454745,Kuru,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET & PMID: 16798390
453533,Polyendocrine-polyneuropathy syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,25248098[PMID]
453533,Polyendocrine-polyneuropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25248098[PMID]
453521,Autosomal recessive cerebellar ataxia due to CWF19L1 deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,15981765[PMID]
453521,Autosomal recessive cerebellar ataxia due to CWF19L1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15981765[PMID]
454710,Anti-p200 pemphigoid,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,24767733[PMID]
454710,Anti-p200 pemphigoid,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24767733[PMID]
454700,Acquired Creutzfeldt-Jakob disease,Clinical group,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
451602,Primary cutaneous plasmacytosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
451607,Cutaneous pseudolymphoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27057027[PMID]
451607,Cutaneous pseudolymphoma,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,27057027[PMID]
451612,Familial congenital nasolacrimal duct obstruction,Morphological anomaly,Cases/families,4.0,,Case(s),Worldwide,Validated,24372406[PMID]
451612,Familial congenital nasolacrimal duct obstruction,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24372406[PMID]
453499,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,29904177[PMID]_30998304[PMID]
453499,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30998304[PMID]
453504,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to a point mutation,Etiological subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,29904177[PMID]
453504,Neurodevelopmental disorder-craniofacial dysmorphism-cardiac defect-skeletal anomalies syndrome due to a point mutation,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29904177[PMID]
453510,Congenital insensitivity to pain with severe intellectual disability,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,26068709[PMID]
453510,Congenital insensitivity to pain with severe intellectual disability,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26068709[PMID]
450322,Polyclonal hyperviscosity syndrome,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
449566,Eosinophilic angiocentric fibrosis,Disease,Cases/families,52.0,,Case(s),Worldwide,Validated,26674883[PMID]
449566,Eosinophilic angiocentric fibrosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26674883[PMID]
449563,IgG4-related ophthalmic disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24513111[PMID]
449291,Symptomatic form of fragile X syndrome in female carriers,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_19642710[PMID]
449400,IgG4-related aortitis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_21124083[PMID]
449395,IgG4-related kidney disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26666884[PMID]
449432,IgG4-related submandibular gland disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24844187[PMID]
449427,IgG4-related pachymeningitis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24733677[PMID]
449280,Scedosporiosis,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Australia,Validated,19549223[PMID]
449280,Scedosporiosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2014[INST]
449285,Snakebite envenomation,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,European Medicines Agency 2015[INST]
449266,Pleural empyema,Particular clinical situation in a disease or syndrome,Point prevalence,13.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2014[INST]
448264,Isolated focal non-epidermolytic palmoplantar keratoderma,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25285920[PMID]
448264,Isolated focal non-epidermolytic palmoplantar keratoderma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25285920[PMID]
448251,Progressive autosomal recessive ataxia-deafness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3739762[PMID]_25205112[PMID]_3465984[PMID]_2603781[PMID]
448251,Progressive autosomal recessive ataxia-deafness syndrome,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,3739762[PMID]_25205112[PMID]_3465984[PMID]_2603781[PMID]
448270,Ectopia cordis,Morphological anomaly,Prevalence at birth,0.67,1-9 / 1 000 000,Value and class,Worldwide,Validated,20965559[PMID]
448270,Ectopia cordis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
448267,Regressive spondylometaphyseal dysplasia,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,25348816[PMID]_23824842[PMID]
448267,Regressive spondylometaphyseal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25348816[PMID]_23824842[PMID]
448010,CAD-CDG,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,25678555[PMID]
448010,CAD-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25678555[PMID]
447997,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,25930971[PMID]_26041762[PMID]_26138499[PMID]
447997,Spastic tetraplegia-thin corpus callosum-progressive postnatal microcephaly syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25930971[PMID]_26041762[PMID]_26138499[PMID]
448242,Autosomal recessive brachyolmia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
448242,Autosomal recessive brachyolmia,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,Dr Gen NISHIMURA[EXPERT]
448237,Zika virus disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
448237,Zika virus disease,Disease,Annual incidence,58.8,1-5 / 10 000,Value and class,Brazil,Validated,World Health Organization 2016[INST]
447977,Progressive scapulohumeroperoneal distal myopathy,Disease,Cases/families,33.0,,Case(s),Worldwide,Validated,25938801[PMID]
447977,Progressive scapulohumeroperoneal distal myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25938801[PMID]
447974,Klippel-Feil anomaly-myopathy-facial dysmorphism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,25748484[PMID]
447974,Klippel-Feil anomaly-myopathy-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25748484[PMID]
447980,19p13.3 microduplication syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,25858326[PMID]
447980,19p13.3 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25858326[PMID]
447954,Combined oxidative phosphorylation defect type 25,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25754315[PMID]
447954,Combined oxidative phosphorylation defect type 25,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25754315[PMID]
447964,Autosomal dominant Charcot-Marie-Tooth disease type 2V,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,25818867[PMID]
447964,Autosomal dominant Charcot-Marie-Tooth disease type 2V,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25818867[PMID]
447961,Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25315659[PMID]
447961,Pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25315659[PMID]
459033,Ataxia-oculomotor apraxia type 4,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,25728773[PMID]_27066586[PMID]
459033,Ataxia-oculomotor apraxia type 4,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25728773[PMID]_27066586[PMID]
459051,"Spondyloepiphyseal dysplasia, Stanescu type",Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,6430256[PMID]_26183434[PMID]_9592900[PMID]
459051,"Spondyloepiphyseal dysplasia, Stanescu type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6430256[PMID]_26183434[PMID]_9592900[PMID]
459061,Craniofacial dysplasia-short stature-ectodermal anomalies-intellectual disability syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,26220823[PMID]
459061,Craniofacial dysplasia-short stature-ectodermal anomalies-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26220823[PMID]
459056,Autosomal recessive spastic paraplegia type 75,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,24482476[PMID]_26179919[PMID]
459056,Autosomal recessive spastic paraplegia type 75,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]_26179919[PMID]
459074,Corpus callosum agenesis-macrocephaly-hypertelorism syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,25944787[PMID]
459074,Corpus callosum agenesis-macrocephaly-hypertelorism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25944787[PMID]
459070,X-linked intellectual disability-cerebellar hypoplasia-spondylo-epiphyseal dysplasia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,26290468[PMID]
459070,X-linked intellectual disability-cerebellar hypoplasia-spondylo-epiphyseal dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26290468[PMID]
458718,Idiopathic spontaneous coronary artery dissection,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
458758,Composite hemangioendothelioma,Disease,Cases/families,39.0,,Case(s),Worldwide,Validated,25666464[PMID]
458758,Composite hemangioendothelioma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25666464[PMID]
458763,Retiform hemangioendothelioma,Disease,Cases/families,32.0,,Case(s),Worldwide,Validated,25812740[PMID]
458763,Retiform hemangioendothelioma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25812740[PMID]
458768,Papillary intralymphatic angioendothelioma,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,21238627[PMID]
458768,Papillary intralymphatic angioendothelioma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21238627[PMID]
458798,Spinocerebellar ataxia type 41,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,25477146[PMID]
458798,Spinocerebellar ataxia type 41,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25477146[PMID]
458803,Spinocerebellar ataxia type 42,Disease,Cases/families,25.0,,Case(s),Worldwide,Validated,26456284[PMID]_26715324[PMID]
458803,Spinocerebellar ataxia type 42,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26456284[PMID]_26715324[PMID]
457485,Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,27753196[PMID]_DOI:10.4137/JGE.S12583[OTHER]_25851998[PMID]_26542245[PMID]
457485,Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27753196[PMID]_DOI:10.4137/JGE.S12583[OTHER]_25851998[PMID]_26542245[PMID]
457265,Progressive myoclonic epilepsy type 9,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25954030[PMID]
457265,Progressive myoclonic epilepsy type 9,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25954030[PMID]
457279,Intellectual disability-macrocephaly-hypotonia-behavioral abnormalities syndrome,Malformation syndrome,Cases/families,16.0,,Case(s),Worldwide,Validated,26168268[PMID]
457279,Intellectual disability-macrocephaly-hypotonia-behavioral abnormalities syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26168268[PMID]
457260,X-linked intellectual disability-hypotonia-movement disorder syndrome,Disease,Cases/families,38.0,,Case(s),Worldwide,Validated,26235985[PMID]
457260,X-linked intellectual disability-hypotonia-movement disorder syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26235985[PMID]
457240,X-linked intellectual disability-short stature-overweight syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,26166480[PMID]
457240,X-linked intellectual disability-short stature-overweight syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26166480[PMID]
457395,Progressive spondyloepimetaphyseal dysplasia-short stature-short fourth metatarsals-intellectual disability syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,26365341[PMID]
457395,Progressive spondyloepimetaphyseal dysplasia-short stature-short fourth metatarsals-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26365341[PMID]
457406,Multiple mitochondrial dysfunctions syndrome type 4,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,25539947[PMID]
457406,Multiple mitochondrial dysfunctions syndrome type 4,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25539947[PMID]
457375,ITPA-related lethal infantile neurological disorder with cataract and cardiac involvement,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,26224535[PMID]
457375,ITPA-related lethal infantile neurological disorder with cataract and cardiac involvement,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26224535[PMID]
457378,Complex lethal osteochondrodysplasia,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,26365339[PMID]
457378,Complex lethal osteochondrodysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26365339[PMID]
457359,Megalencephaly-severe kyphoscoliosis-overgrowth syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,26138117[PMID]
457359,Megalencephaly-severe kyphoscoliosis-overgrowth syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26138117[PMID]
457365,Intellectual disability-muscle weakness-short stature-facial dysmorphism syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,26192890[PMID]
457365,Intellectual disability-muscle weakness-short stature-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26192890[PMID]
457284,Microcephaly-corpus callosum hypoplasia-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,25533962[PMID]_26168268[PMID]
457284,Microcephaly-corpus callosum hypoplasia-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25533962[PMID]_26168268[PMID]
457351,Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,26299366[PMID]
457351,Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26299366[PMID]
457185,Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,26185144[PMID]
457185,Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26185144[PMID]
457083,Isolated splenogonadal fusion,Morphological anomaly,Cases/families,145.0,,Case(s),Worldwide,Validated,15349548[PMID]
457083,Isolated splenogonadal fusion,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_15349548[PMID]
457077,TAFRO syndrome,Disease,Cases/families,28.0,,Case(s),Worldwide,Validated,27084250[PMID]
457077,TAFRO syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27084250[PMID]
457095,Actinomycosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_18078685[PMID]
457223,Syndromic sensorineural deafness due to combined oxidative phosphorylation defect,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25556185[PMID]
457223,Syndromic sensorineural deafness due to combined oxidative phosphorylation defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25556185[PMID]
457212,Progressive essential tremor-speech impairment-facial dysmorphism-intellectual disability-abnormal behavior syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,25704603[PMID]
457212,Progressive essential tremor-speech impairment-facial dysmorphism-intellectual disability-abnormal behavior syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25704603[PMID]
457193,KAT6-related intellectual disability-craniofacial anomalies-cardiac defects syndrome,Malformation syndrome,Cases/families,76.0,,Case(s),Worldwide,Validated,EXPERT
457193,KAT6-related intellectual disability-craniofacial anomalies-cardiac defects syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25728775[PMID]_25728777[PMID]_27133397[PMID]
457205,Infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25504045[PMID]
457205,Infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25504045[PMID]
456369,Polyglucosan body myopathy type 2,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,25272951[PMID]_26203156[PMID]_26255073[PMID]_26652229[PMID]
456369,Polyglucosan body myopathy type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25272951[PMID]_26203156[PMID]_26255073[PMID]_26652229[PMID]
457050,Autosomal dominant mitochondrial myopathy with exercise intolerance,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,9324076[PMID]
457050,Autosomal dominant mitochondrial myopathy with exercise intolerance,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9324076[PMID]
317,Erythrokeratodermia variabilis,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
317,Erythrokeratodermia variabilis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
629,Short stature due to growth hormone qualitative anomaly,Clinical subtype,Cases/families,3.0,,Case(s),Worldwide,Validated,263308[PMID]_3965948[PMID]
629,Short stature due to growth hormone qualitative anomaly,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_263308[PMID]_3965948[PMID]
248,Autosomal recessive hypohidrotic ectodermal dysplasia,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1810,Autosomal dominant hypohidrotic ectodermal dysplasia,Etiological subtype,Cases/families,40.0,,Case(s),Worldwide,Validated,9375732[PMID]
1810,Autosomal dominant hypohidrotic ectodermal dysplasia,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
3437,Vogt-Koyanagi-Harada disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3437,Vogt-Koyanagi-Harada disease,Disease,Annual incidence,3.75,1-9 / 100 000,Value and class,United States,Validated,27008848[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Point prevalence,16.125,1-5 / 10 000,Value and class,Worldwide,Validated,34233665[PMID]_ORPHANET
2032,Idiopathic pulmonary fibrosis,Disease,Annual incidence,5.55,1-9 / 100 000,Value and class,Worldwide,Validated,34233665[PMID]_ORPHANET
2032,Idiopathic pulmonary fibrosis,Disease,Point prevalence,29.8,1-5 / 10 000,Value and class,Canada,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Annual incidence,15.35,1-5 / 10 000,Value and class,Canada,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Point prevalence,8.6,1-9 / 100 000,Value and class,Finland,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Annual incidence,1.3,1-9 / 100 000,Value and class,Finland,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Point prevalence,8.2,1-9 / 100 000,Value and class,France,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Annual incidence,2.8,1-9 / 100 000,Value and class,France,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Point prevalence,21.2,1-5 / 10 000,Value and class,Italy,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Annual incidence,2.6,1-9 / 100 000,Value and class,Italy,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Point prevalence,5.9,1-9 / 100 000,Value and class,Japan,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Point prevalence,37.0,1-5 / 10 000,Value and class,"Korea, Republic of",Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Annual incidence,13.0,1-5 / 10 000,Value and class,"Korea, Republic of",Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Point prevalence,11.6,1-5 / 10 000,Value and class,United Kingdom,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Annual incidence,1.2,1-9 / 100 000,Value and class,United Kingdom,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Point prevalence,6.7,1-9 / 100 000,Value and class,United States,Validated,34233665[PMID]
2032,Idiopathic pulmonary fibrosis,Disease,Annual incidence,2.6,1-9 / 100 000,Value and class,United States,Validated,34233665[PMID]
1303,Bronchiolitis obliterans,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
3348,Tracheobronchopathia osteochondroplastica,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
3348,Tracheobronchopathia osteochondroplastica,Disease,Cases/families,400.0,,Case(s),Worldwide,Validated,24865333[PMID]
2902,Idiopathic chronic eosinophilic pneumonia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2902,Idiopathic chronic eosinophilic pneumonia,Disease,Annual incidence,0.23,1-9 / 1 000 000,Value and class,Iceland,Validated,17277407[PMID]
1302,Cryptogenic organizing pneumonia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
1302,Cryptogenic organizing pneumonia,Disease,Point prevalence,0.81,1-9 / 1 000 000,Value and class,Spain,Validated,15127977[PMID]
1302,Cryptogenic organizing pneumonia,Disease,Point prevalence,0.92,1-9 / 1 000 000,Value and class,Greece,Validated,19345567[PMID]
1302,Cryptogenic organizing pneumonia,Disease,Annual incidence,1.1,1-9 / 100 000,Value and class,Iceland,Validated,18204109[PMID]
198,Occipital horn syndrome,Disease,Cases/families,35.0,,Case(s),Worldwide,Validated,[EXPERT]
198,Occipital horn syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
891,Familial exudative vitreoretinopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
466677,Scorpion envenomation,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27912864[PMID]
466688,Severe intellectual disability-corpus callosum agenesis-facial dysmorphism-cerebellar ataxia syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,25388005[PMID]
466688,Severe intellectual disability-corpus callosum agenesis-facial dysmorphism-cerebellar ataxia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25388005[PMID]
466695,Supratip dysplasia,Morphological anomaly,Cases/families,5.0,,Case(s),Worldwide,Validated,26947355[PMID]
466695,Supratip dysplasia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26947355[PMID]
466670,Cyanide poisoning,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_7662055[PMID]
466650,Exercise-induced malignant hyperthermia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_22538307[PMID]_23476141[PMID]
466962,SMARCA4-deficient sarcoma of thorax,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,26343384[PMID]
466962,SMARCA4-deficient sarcoma of thorax,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26343384[PMID]
466950,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to WAC point mutation,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,27119754[PMID]
466950,Facial dysmorphism-developmental delay-behavioral abnormalities syndrome due to WAC point mutation,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27119754[PMID]
466943,WAC-related facial dysmorphism-developmental delay-behavioral abnormalities syndrome,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,27119754[PMID]
466943,WAC-related facial dysmorphism-developmental delay-behavioral abnormalities syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27119754[PMID]
466926,Seizures-scoliosis-macrocephaly syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,30997052[PMID]
466926,Seizures-scoliosis-macrocephaly syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30997052[PMID]
466934,VPS11-related autosomal recessive hypomyelinating leukodystrophy,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,26307567[PMID]_27119754[PMID]
466934,VPS11-related autosomal recessive hypomyelinating leukodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26307567[PMID]_27119754[PMID]
466921,Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,26581302[PMID]
466921,Childhood-onset progressive contractures-limb-girdle weakness-muscle dystrophy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26581302[PMID]
466806,Autosomal dominant thrombocytopenia with platelet secretion defect,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,26280575[PMID]_26769223[PMID]
466806,Autosomal dominant thrombocytopenia with platelet secretion defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26280575[PMID]_26769223[PMID]
466794,Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,26581903[PMID]
466794,Acute infantile liver failure-cerebellar ataxia-peripheral sensory motor neuropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26581903[PMID]
466791,Macrocephaly-intellectual disability-left ventricular non compaction syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,26571461[PMID]_27329731[PMID]_27550220[PMID]
466791,Macrocephaly-intellectual disability-left ventricular non compaction syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26571461[PMID]_27329731[PMID]_27550220[PMID]
466784,Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,26522469[PMID]
466784,Neonatal severe cardiopulmonary failure due to mitochondrial methylation defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26522469[PMID]
466775,Autosomal recessive Charcot-Marie-Tooth disease type 2X,Disease,Cases/families,29.0,,Case(s),Worldwide,Validated,26556829[PMID]
466775,Autosomal recessive Charcot-Marie-Tooth disease type 2X,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26556829[PMID]
466768,Autosomal dominant Charcot-Marie-Tooth disease type 2Z,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,26497905[PMID]_26659848[PMID]_26912637[PMID]_27105897[PMID]_27329773[PMID]
466768,Autosomal dominant Charcot-Marie-Tooth disease type 2Z,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26497905[PMID]_26659848[PMID]_26912637[PMID]_27105897[PMID]_27329773[PMID]
466722,Autosomal recessive spastic paraplegia type 77,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,26553276[PMID]_29126765[PMID]_25851414[PMID]
466722,Autosomal recessive spastic paraplegia type 77,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29126765[PMID]
466718,Martinique crinkled retinal pigment epitheliopathy,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,23370609[PMID]_26744326[PMID]
466718,Martinique crinkled retinal pigment epitheliopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23370609[PMID]_26744326[PMID]
466703,TMEM199-CDG,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,19067230[PMID]_26833330[PMID]_29321044[PMID]
466703,TMEM199-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19067230[PMID]_26833330[PMID]_29321044[PMID]
465824,Fetal encasement syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,20961246[PMID]
465824,Fetal encasement syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20961246[PMID]
466026,Class I glucose-6-phosphate dehydrogenase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20200584[PMID]
468620,Intellectual disability-epilepsy-extrapyramidal syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,26048982[PMID]
468620,Intellectual disability-epilepsy-extrapyramidal syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26048982[PMID]
468631,Microcephalic cortical malformations-short stature due to RTTN deficiency,Malformation syndrome,Cases/families,28.0,,Case(s),Worldwide,Validated,PMID: 30879067
468631,Microcephalic cortical malformations-short stature due to RTTN deficiency,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,PMID: 30879067
467166,Tubulinopathy-associated dysgyria,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,26130693[PMID]
467166,Tubulinopathy-associated dysgyria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26130693[PMID]
467176,Severe hypotonia-psychomotor developmental delay-strabismus-cardiac septal defect syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,26358778[PMID]
467176,Severe hypotonia-psychomotor developmental delay-strabismus-cardiac septal defect syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26358778[PMID]
468635,Cryptogenic multifocal ulcerous stenosing enteritis,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,24369459[PMID]_25708899[PMID]
468635,Cryptogenic multifocal ulcerous stenosing enteritis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24369459[PMID]_25708899[PMID]
468641,Chronic enteropathy associated with SLCO2A1 gene,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,26539716[PMID]_17709045[PMID]
468641,Chronic enteropathy associated with SLCO2A1 gene,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24035666[PMID]_23268370[PMID]_25708899[PMID]_26539716[PMID]_17709045[PMID]
468661,Autosomal recessive spastic paraplegia type 74,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,25609768[PMID]
468661,Autosomal recessive spastic paraplegia type 74,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25609768[PMID]
468666,Isolated generalized anhidrosis with normal sweat glands,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,25329695[PMID]_2401610[PMID]
468666,Isolated generalized anhidrosis with normal sweat glands,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25329695[PMID]_2401610[PMID]
468678,White-Sutton syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26739615[PMID]_27148570[PMID]
468684,CCDC115-CDG,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,26833332[PMID]_26833330[PMID]
468684,CCDC115-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26833332[PMID]_26833330[PMID]
468672,Colobomatous macrophthalmia-microcornea syndrome,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,12900897[PMID]
468672,Colobomatous macrophthalmia-microcornea syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12900897[PMID]
468726,Severe primary trimethylaminuria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25335494[PMID]
468699,SLC39A8-CDG,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,26637978[PMID]_26637979[PMID]
468699,SLC39A8-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26637978[PMID]_26637979[PMID]
468717,Rhizomelic chondrodysplasia punctata type 5,Etiological subtype,Cases/families,4.0,,Case(s),Worldwide,Validated,26220973[PMID]
468717,Rhizomelic chondrodysplasia punctata type 5,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26220973[PMID]
401785,Autosomal recessive spastic paraplegia type 62,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,24482476[PMID]
401785,Autosomal recessive spastic paraplegia type 62,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
401780,Autosomal recessive spastic paraplegia type 61,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24482476[PMID]
401780,Autosomal recessive spastic paraplegia type 61,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
401800,Autosomal recessive spastic paraplegia type 60,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,24482476[PMID]
401800,Autosomal recessive spastic paraplegia type 60,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
401795,Autosomal recessive spastic paraplegia type 59,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24482476[PMID]
401795,Autosomal recessive spastic paraplegia type 59,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
401768,Proximal myopathy with extrapyramidal signs,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,24336167[PMID]
401768,Proximal myopathy with extrapyramidal signs,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24336167[PMID]
401764,Pancytopenia-developmental delay syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24507776[PMID]_27185855[PMID]
401764,Pancytopenia-developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24507776[PMID]_27185855[PMID]
401777,Optic atrophy-intellectual disability syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,24462372[PMID]
401777,Optic atrophy-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24462372[PMID]
401830,Autosomal recessive spastic paraplegia type 69,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24482476[PMID]
401830,Autosomal recessive spastic paraplegia type 69,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
401835,Autosomal recessive spastic paraplegia type 70,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24482476[PMID]
401835,Autosomal recessive spastic paraplegia type 70,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
401840,Autosomal recessive spastic paraplegia type 71,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,24482476[PMID]
401840,Autosomal recessive spastic paraplegia type 71,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
401805,Autosomal recessive spastic paraplegia type 63,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24482476[PMID]
401805,Autosomal recessive spastic paraplegia type 63,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
401810,Autosomal recessive spastic paraplegia type 64,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24482476[PMID]
401810,Autosomal recessive spastic paraplegia type 64,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
401815,Autosomal recessive spastic paraplegia type 66,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24482476[PMID]
401815,Autosomal recessive spastic paraplegia type 66,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
401820,Autosomal recessive spastic paraplegia type 67,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24482476[PMID]
401820,Autosomal recessive spastic paraplegia type 67,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
401866,Childhood-onset spasticity with hyperglycinemia,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24777537[PMID]_17485548[PMID]_24334290[PMID]
401866,Childhood-onset spasticity with hyperglycinemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17485548[PMID]_24334290[PMID]
401869,Multiple mitochondrial dysfunctions syndrome type 1,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,24777537[PMID]_22077971[PMID]
401869,Multiple mitochondrial dysfunctions syndrome type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24777537[PMID]_22077971[PMID]
401874,Multiple mitochondrial dysfunctions syndrome type 2,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,24777537[PMID]_21944046[PMID]_24334290[PMID]_22562699[PMID]
401874,Multiple mitochondrial dysfunctions syndrome type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24777537[PMID]_21944046[PMID]_24334290[PMID]_22562699[PMID]
401849,Autosomal spastic paraplegia type 72,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,24388663[PMID]
401849,Autosomal spastic paraplegia type 72,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24388663[PMID]
401859,Lipoic acid synthetase deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24777537[PMID]_22152680[PMID]_24334290[PMID]
401859,Lipoic acid synthetase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24777537[PMID]_22152680[PMID]_24334290[PMID]
401862,Lipoyl transferase 1 deficiency,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,27247813[PMID]
401862,Lipoyl transferase 1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27247813[PMID]
402823,Hepatitis delta,Disease,Point prevalence,40.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2014[INST]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,United States,Validated,SEER Surveillance Epidemiology and end results [REG]_14999699[PMID]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.019,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.029,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.029,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.031,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.019,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.022,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.022,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.022,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401920,Fibrolamellar hepatocellular carcinoma,Disease,Annual incidence,0.025,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
401911,AXIN2-related attenuated familial adenomatous polyposis,Clinical subtype,Cases/families,4.0,,Family(ies),Worldwide,Validated,23838596[PMID]
401911,AXIN2-related attenuated familial adenomatous polyposis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23838596[PMID]
401901,Huntington disease-like syndrome due to C9ORF72 expansions,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,24363131[PMID]
401901,Huntington disease-like syndrome due to C9ORF72 expansions,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24363131[PMID]
401942,Familial median cleft of the upper and lower lips,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,23860042[PMID]
401942,Familial median cleft of the upper and lower lips,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23860042[PMID]
401935,14q24.1q24.3 microdeletion syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,24357125[PMID]
401935,14q24.1q24.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24357125[PMID]
401923,9q31.1q31.3 microdeletion syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,24376033[PMID]
401923,9q31.1q31.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24376033[PMID]
401959,Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,24045845[PMID]
401959,Partial corpus callosum agenesis-cerebellar vermis hypoplasia with posterior fossa cysts syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24045845[PMID]
401953,Episodic ataxia with slurred speech,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,23982692[PMID]
401953,Episodic ataxia with slurred speech,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23982692[PMID]
401948,Hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,25834911[PMID]
401948,Hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25834911[PMID]
401945,Moyamoya disease with early-onset achalasia,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,24581742[PMID]
401945,Moyamoya disease with early-onset achalasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24581742[PMID]
401986,1p31p32 microdeletion syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,24462883[PMID]
401986,1p31p32 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24462883[PMID]
401979,"Autosomal recessive spondylometaphyseal dysplasia, Mégarbané type",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,18925669[PMID]_2445848[PMID]
401979,"Autosomal recessive spondylometaphyseal dysplasia, Mégarbané type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18925669[PMID]_2445848[PMID]
401973,MEND syndrome,Malformation syndrome,Cases/families,24.0,,Case(s),Worldwide,Validated,22229330[PMID]_24459067[PMID]_24700572[PMID]_27276700[PMID]
401973,MEND syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22229330[PMID]_24459067[PMID]_24700572[PMID]_27276700[PMID]
401964,Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,24500646[PMID]_15111691[PMID]_14557576[PMID]
401964,Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24500646[PMID]_15111691[PMID]_14557576[PMID]
402003,Autosomal dominant focal non-epidermolytic palmoplantar keratoderma with plantar blistering,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,21801157[PMID]_19609311[PMID]
402003,Autosomal dominant focal non-epidermolytic palmoplantar keratoderma with plantar blistering,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21801157[PMID]_19609311[PMID]
401996,Karyomegalic interstitial nephritis,Disease,Cases/families,12.0,,Family(ies),Worldwide,Validated,22772369[PMID]
401996,Karyomegalic interstitial nephritis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22772369[PMID]
402035,Eosinophilic colitis,Disease,Cases/families,196.0,,Case(s),Worldwide,Validated,22012125[PMID]
402035,Eosinophilic colitis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22012125[PMID]
402082,Progressive myoclonic epilepsy type 5,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,21276947[PMID]
402082,Progressive myoclonic epilepsy type 5,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21276947[PMID]
402364,Infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,20950787[PMID]
402364,Infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20950787[PMID]
402041,Autosomal recessive distal renal tubular acidosis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
806,Scott syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,8608230[PMID]_15790791[PMID]_19814742[PMID]
806,Scott syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
404473,Severe intellectual disability-progressive spastic diplegia syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,24668549[PMID]_23033978[PMID]_24614104[PMID]
404473,Severe intellectual disability-progressive spastic diplegia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24668549[PMID]_23033978[PMID]_24614104[PMID]
404463,Multisystemic smooth muscle dysfunction syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,20734336[PMID]
404463,Multisystemic smooth muscle dysfunction syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20734336[PMID]
404466,Female infertility due to zona pellucida defect,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24670168[PMID]
404466,Female infertility due to zona pellucida defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24670168[PMID]
404451,FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,24084572[PMID]
404451,FBLN1-related developmental delay-central nervous system anomaly-syndactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24084572[PMID]
404454,Alacrimia-choreoathetosis-liver dysfunction syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,24651605[PMID]_22581936[PMID]
404454,Alacrimia-choreoathetosis-liver dysfunction syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24651605[PMID]_22581936[PMID]
404443,Tatton-Brown-Rahman syndrome,Malformation syndrome,Cases/families,17.0,,Case(s),Worldwide,Validated,24614070[PMID]_27991732[PMID]_28941052[PMID]
404443,Tatton-Brown-Rahman syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24614070[PMID]_27991732[PMID]_28941052[PMID]
404448,ADNP syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Validated,24531329[PMID]_[EXPERT]
404437,Diffuse cerebral and cerebellar atrophy-intractable seizures-progressive microcephaly syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,24656866[PMID]
404437,Diffuse cerebral and cerebellar atrophy-intractable seizures-progressive microcephaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24656866[PMID]
404440,Intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,24680889[PMID]
404440,Intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24680889[PMID]
404560,Familial atypical multiple mole melanoma syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
404553,Adenosine deaminase 2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28516235[PMID]
404553,Adenosine deaminase 2 deficiency,Disease,Cases/families,48.0,,Case(s),Worldwide,Validated,28516235[PMID]
404546,DITRA,Disease,Cases/families,70.0,,Case(s),Worldwide,Validated,25848350[PMID]
404546,DITRA,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25848350[PMID]
404521,Spinal muscular atrophy with respiratory distress type 2,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,24647030[PMID]
404521,Spinal muscular atrophy with respiratory distress type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24647030[PMID]
404507,Chondromyxoid fibroma,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,24658000[PMID]
404507,Chondromyxoid fibroma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24658000[PMID]
404499,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23728897[PMID]
404499,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to RUBCN deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23728897[PMID]
404493,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to TUD deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24658003[PMID]
404493,Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to TUD deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24658003[PMID]
404476,Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,24676357[PMID]
404476,Global developmental delay-lung cysts-overgrowth-Wilms tumor syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24676357[PMID]
411527,Central retinal vein occlusion,Particular clinical situation in a disease or syndrome,Point prevalence,28.0,1-5 / 10 000,Value and class,Europe,Validated,European Medecines Agency 2014[INST]
411536,Mild phosphoribosylpyrophosphate synthetase superactivity,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
411543,Severe phosphoribosylpyrophosphate synthetase superactivity,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,20301734[PMID]_ORPHANET
411543,Severe phosphoribosylpyrophosphate synthetase superactivity,Clinical subtype,Cases/families,33.0,,Case(s),Worldwide,Validated,20301734[PMID]
411593,Insulin autoimmune syndrome,Disease,Cases/families,404.0,,Case(s),Worldwide,Validated,24111525[PMID]
411593,Insulin autoimmune syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24111525[PMID]
411602,Hereditary late-onset Parkinson disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
411629,Infantile nephropathic cystinosis,Clinical subtype,Prevalence at birth,0.0,1-9 / 1 000 000,Class only,Europe,Validated,[EXPERT]_12110740[PMID]
411629,Infantile nephropathic cystinosis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
411493,Pontocerebellar hypoplasia type 10,Malformation syndrome,Cases/families,23.0,,Case(s),Worldwide,Validated,24766809[PMID]_24766810[PMID]
411493,Pontocerebellar hypoplasia type 10,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24766809[PMID]_24766810[PMID]
411777,Generalized eruptive keratoacanthoma,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,25070745[PMID]
411777,Generalized eruptive keratoacanthoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25070745[PMID]
411712,Maternal riboflavin deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,21089064[PMID]_29122468[PMID]
411712,Maternal riboflavin deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21089064[PMID]_29122468[PMID]
411788,Familial isolated trichomegaly,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,24989505[PMID]
411788,Familial isolated trichomegaly,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ 24989505[PMID]
411986,Early-onset epileptic encephalopathy-cortical blindness-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,24814191[PMID]
411986,Early-onset epileptic encephalopathy-cortical blindness-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24814191[PMID]
412035,13q12.3 microdeletion syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,24664804[PMID]
412035,13q12.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24664804[PMID]
412022,Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome,Malformation syndrome,Cases/families,4.0,,Family(ies),Worldwide,Validated,24768550[PMID]
412022,Facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24768550[PMID]
411641,Ocular cystinosis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
411634,Juvenile nephropathic cystinosis,Clinical subtype,Prevalence at birth,0.0,<1 / 1 000 000,Class only,Europe,Validated,[EXPERT]
411634,Juvenile nephropathic cystinosis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
411696,Proton-pump inhibitor-responsive esophageal eosinophilia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,23567357[PMID]_25132757[PMID]
411709,Renal agenesis,Morphological anomaly,Prevalence at birth,0.0,1-5 / 10 000,Class only,Worldwide,Validated,24370773[PMID]
411709,Renal agenesis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24370773[PMID]
411703,Pulmonary non-tuberculous mycobacterial infection,Disease,Point prevalence,6.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2014[INST]
371428,Multicentric osteolysis-nodulosis-arthropathy spectrum,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
371428,Multicentric osteolysis-nodulosis-arthropathy spectrum,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
371364,Hypotonia-speech impairment-severe cognitive delay syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,23749988[PMID]_24075186[PMID]
391673,Necrotizing enterocolitis,Disease,Point prevalence,45.0,1-5 / 10 000,Value and class,Worldwide,Validated,European Medicines Agency 2015[INST]
391677,Short stature-optic atrophy-Pelger-Huët anomaly syndrome,Malformation syndrome,Cases/families,39.0,,Case(s),Worldwide,Validated,20577004[PMID]_26286438[PMID]_29955634[PMID]_27789416[PMID]
391677,Short stature-optic atrophy-Pelger-Huët anomaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20577004[PMID]_29955634[PMID]_27789416[PMID]
391474,Frontorhiny,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
391504,Transient neonatal myasthenia gravis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
391497,Juvenile myasthenia gravis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
391490,Adult-onset myasthenia gravis,Clinical subtype,Point prevalence,31.8,1-5 / 10 000,Value and class,Serbia,Validated,23363926[PMID]
391490,Adult-onset myasthenia gravis,Clinical subtype,Annual incidence,1.33,1-9 / 100 000,Value and class,Serbia,Validated,23363926[PMID]
391490,Adult-onset myasthenia gravis,Clinical subtype,Point prevalence,17.0,1-5 / 10 000,Value and class,United States,Validated,[EXPERT]_ORPHANET
391490,Adult-onset myasthenia gravis,Clinical subtype,Point prevalence,28.0,1-5 / 10 000,Value and class,United Kingdom,Validated,[EXPERT]_ORPHANET
391490,Adult-onset myasthenia gravis,Clinical subtype,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,ORPHANET
391487,STAT1-related autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,23534974[PMID]
391487,STAT1-related autoimmune enteropathy and endocrinopathy-susceptibility to chronic infections syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET_23534974[PMID]
391646,Feingold syndrome type 2,Clinical subtype,Cases/families,7.0,,Case(s),Worldwide,Validated,28159702[PMID]
391646,Feingold syndrome type 2,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28159702[PMID]
391641,Feingold syndrome type 1,Clinical subtype,Cases/families,120.0,,Case(s),Worldwide,Validated,[EXPERT]
391641,Feingold syndrome type 1,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391665,Homozygous familial hypercholesterolemia,Disease,Annual incidence,0.5842,1-9 / 1 000 000,Value and class,Japan,Validated,21146822[PMID]
391665,Homozygous familial hypercholesterolemia,Disease,Point prevalence,0.3194,1-9 / 1 000 000,Value and class,Worldwide,Validated,31947532[PMID]_32439005[PMID]_ORPHANET
391665,Homozygous familial hypercholesterolemia,Disease,Point prevalence,0.22,1-9 / 1 000 000,Value and class,Spain,Validated,27784735[PMID]
391665,Homozygous familial hypercholesterolemia,Disease,Point prevalence,0.625,1-9 / 1 000 000,Value and class,Denmark,Validated,23956253[PMID]
391665,Homozygous familial hypercholesterolemia,Disease,Point prevalence,0.33,1-9 / 1 000 000,Value and class,Netherlands,Validated,24585268[PMID]
391665,Homozygous familial hypercholesterolemia,Disease,Point prevalence,0.125,1-9 / 1 000 000,Value and class,Germany,Validated,23662069[PMID]
391655,Off-periods in Parkinson disease not responding to oral treatment,Particular clinical situation in a disease or syndrome,Point prevalence,4.15,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2004[INST]
391343,Fatal post-viral neurodegenerative disorder,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23443029[PMID]
391343,Fatal post-viral neurodegenerative disorder,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391348,Growth and developmental delay-hypotonia-vision impairment-lactic acidosis syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24119684[PMID]
391348,Growth and developmental delay-hypotonia-vision impairment-lactic acidosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391351,SURF1-related Charcot-Marie-Tooth disease type 4,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24027061[PMID]
391351,SURF1-related Charcot-Marie-Tooth disease type 4,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391366,Growth retardation-mild developmental delay-chronic hepatitis syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23908464[PMID]
391366,Growth retardation-mild developmental delay-chronic hepatitis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391372,FOXP1 Syndrome,Malformation syndrome,Cases/families,48.0,,Case(s),Worldwide,Validated,28735298[PMID]
391372,FOXP1 Syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28735298[PMID]
391376,Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,28776279[PMID]
391376,Congenital microcephaly-severe encephalopathy-progressive cerebral atrophy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28776279[PMID]
391384,Familial episodic pain syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
391389,Familial episodic pain syndrome with predominantly upper body involvement,Clinical subtype,Cases/families,21.0,,Case(s),Worldwide,Validated,24207120[PMID]_23115331[PMID]_20547126[PMID]
391389,Familial episodic pain syndrome with predominantly upper body involvement,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391392,Familial episodic pain syndrome with predominantly lower limb involvement,Clinical subtype,Cases/families,28.0,,Case(s),Worldwide,Validated,21698661[PMID]
391392,Familial episodic pain syndrome with predominantly lower limb involvement,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391397,Hereditary sensory and autonomic neuropathy type 7,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24036948[PMID]_24813307[PMID]
391397,Hereditary sensory and autonomic neuropathy type 7,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391408,Primary microcephaly-mild intellectual disability-young-onset diabetes syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,25053765[PMID]_26159176[PMID]
391408,Primary microcephaly-mild intellectual disability-young-onset diabetes syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25053765[PMID]_26159176[PMID]
391411,Atypical juvenile parkinsonism,Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,25085748[PMID]
391411,Atypical juvenile parkinsonism,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391417,HSD10 disease,Disease,Cases/families,37.0,,Case(s),Worldwide,Validated,27306202[PMID]_27295195[PMID]
391417,HSD10 disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27306202[PMID]_27295195[PMID]
391457,"HSD10 disease, neonatal type",Clinical subtype,Cases/families,3.0,,Case(s),Worldwide,Validated,22127393[PMID]
391457,"HSD10 disease, neonatal type",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391307,Severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,23956177[PMID]
391307,Severe intellectual disability-short stature-behavioral abnormalities-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391316,Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,23686771[PMID]
391316,Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391327,X-linked calvarial hyperostosis,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,24145306[PMID]
391327,X-linked calvarial hyperostosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
391320,East Texas bleeding disorder,Etiological subtype,Cases/families,19.0,,Case(s),Worldwide,Validated,23979162[PMID]_25634741[PMID]
391320,East Texas bleeding disorder,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25634741[PMID]
391330,X-linked osteoporosis with fractures,Disease,Cases/families,8.0,,Family(ies),Worldwide,Validated,24088043[PMID]_24616189[PMID]_25209159[PMID]
391330,X-linked osteoporosis with fractures,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24088043[PMID]_24616189[PMID]_25209159[PMID]
398063,Refractory celiac disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,23609613[PMID]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.57,1-9 / 1 000 000,Value and class,Europe,Validated,22119351[PMID]_RARECARE Surveillance of Rare Cancers in Europe 2003[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.612,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.491,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.605,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.516,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.423,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.684,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.6,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.426,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.638,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.682,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.475,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.606,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.552,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.517,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.628,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.744,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.396,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.745,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.499,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.45,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.791,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.597,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398058,Squamous cell carcinoma of the penis,Disease,Annual incidence,0.691,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,22119351[PMID]_RARECARE Surveillance of Rare Cancers in Europe 2003[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.025,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398053,Adenocarcinoma of the penis,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398043,Malignant tumor of penis,Category,Annual incidence,4.85,1-9 / 100 000,Value and class,Brazil,Validated,26076979[PMID]_18986562[PMID]
398043,Malignant tumor of penis,Category,Annual incidence,3.5,1-9 / 100 000,Value and class,Uganda,Validated,26076979[PMID]_10789729[PMID]
398043,Malignant tumor of penis,Category,Annual incidence,1.075,1-9 / 100 000,Value and class,Europe,Validated,26076979[PMID]_IARC International Agency for research on cancer 2002[INST]
398043,Malignant tumor of penis,Category,Annual incidence,1.21,1-9 / 100 000,Value and class,United Kingdom,Validated,26076979[PMID]_24101363[PMID]
398043,Malignant tumor of penis,Category,Annual incidence,0.58,1-9 / 1 000 000,Value and class,United States,Validated,26076979[PMID]_17826651[PMID]
397973,Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,11746007[PMID]
397973,Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11746007[PMID]
397968,Charcot-Marie-Tooth disease type 2R,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,23562820[PMID]
397968,Charcot-Marie-Tooth disease type 2R,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23562820[PMID]
397964,Combined immunodeficiency due to MALT1 deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,23727036[PMID]_24332264[PMID]
397964,Combined immunodeficiency due to MALT1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23727036[PMID]_24332264[PMID]
397959,TCR-alpha-beta-positive T-cell deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,21206088[PMID]
397959,TCR-alpha-beta-positive T-cell deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21206088[PMID]
397951,Microcephaly-thin corpus callosum-intellectual disability syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24084144[PMID]
397951,Microcephaly-thin corpus callosum-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24084144[PMID]
397946,Autosomal spastic paraplegia type 58,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,24482476[PMID]_24319291[PMID]_24482476[PMID]_24808017[PMID]
397946,Autosomal spastic paraplegia type 58,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24482476[PMID]
397941,MAN1B1-CDG,Disease,Cases/families,25.0,,Case(s),Worldwide,Validated,21763484[PMID]_24348268[PMID]_26307094[PMID]
397941,MAN1B1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21763484[PMID]_24348268[PMID]_26307094[PMID]
397937,Polyglucosan body myopathy type 1,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,23798481[PMID]
397937,Polyglucosan body myopathy type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23798481[PMID]
397933,Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,23674175[PMID]
397933,Severe intellectual disability-progressive postnatal microcephaly-midline stereotypic hand movements syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23674175[PMID]
397927,Sacral agenesis-abnormal ossification of the vertebral bodies-persistent notochordal canal syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,24369075[PMID]
397927,Sacral agenesis-abnormal ossification of the vertebral bodies-persistent notochordal canal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24369075[PMID]
397922,Ferro-cerebro-cutaneous syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24259288[PMID]
397922,Ferro-cerebro-cutaneous syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24259288[PMID]
397787,Combined immunodeficiency due to IKK2 deficiency,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,25139357[PMID]
397787,Combined immunodeficiency due to IKK2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25139357[PMID]
397755,Periodic paralysis with transient compartment-like syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24240197[PMID]
397755,Periodic paralysis with transient compartment-like syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24240197[PMID]
397758,Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,24026677[PMID]
397758,Retinal dystrophy with inner retinal dysfunction and ganglion cell anomalies,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24026677[PMID]
397744,Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,21480433[PMID]
397744,Peripheral neuropathy-myopathy-hoarseness-hearing loss syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21480433[PMID]
397750,Periodic paralysis with later-onset distal motor neuropathy,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,24153443[PMID]
397750,Periodic paralysis with later-onset distal motor neuropathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24153443[PMID]
397725,COASY protein-associated neurodegeneration,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24360804[PMID]
397725,COASY protein-associated neurodegeneration,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24360804[PMID]
397735,Autosomal dominant Charcot-Marie-Tooth disease type 2U,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23729695[PMID]
397735,Autosomal dominant Charcot-Marie-Tooth disease type 2U,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23729695[PMID]
397709,Intellectual disability-coarse face-macrocephaly-cerebellar hypotrophy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27913285[PMID]
397709,Intellectual disability-coarse face-macrocephaly-cerebellar hypotrophy syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,27913285[PMID]
397715,Joubert syndrome with Jeune asphyxiating thoracic dystrophy,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,24360808[PMID]_20503315[PMID]
397715,Joubert syndrome with Jeune asphyxiating thoracic dystrophy,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24360808[PMID]_20503315[PMID]
397692,Hereditary isolated aplastic anemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
397695,3q27.3 microdeletion syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,24133203[PMID]
397695,3q27.3 microdeletion syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24133203[PMID]
397623,Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,24290375[PMID]
397623,Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24290375[PMID]
397685,Familial hyperprolactinemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
397615,Obesity due to CEP19 deficiency,Etiological subtype,Cases/families,15.0,,Case(s),Worldwide,Validated,24268657[PMID]
397615,Obesity due to CEP19 deficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24268657[PMID]
397618,Foveal hypoplasia-optic nerve decussation defect-anterior segment dysgenesis syndrome,Disease,Cases/families,7.0,,Family(ies),Worldwide,Validated,24290379[PMID]
397618,Foveal hypoplasia-optic nerve decussation defect-anterior segment dysgenesis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24290379[PMID]
397596,Activated PI3K-delta syndrome,Disease,Cases/families,250.0,,Case(s),Worldwide,Validated,34052541[PMID]
397596,Activated PI3K-delta syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,34052541[PMID]_31111319[PMID]_ORPHANET
397593,Severe neonatal lactic acidosis due to NFS1-ISD11 complex deficiency,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,23814038[PMID]_24498631[PMID]
397593,Severe neonatal lactic acidosis due to NFS1-ISD11 complex deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23814038[PMID]_24498631[PMID]
397612,Macrocephaly-developmental delay syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,24239382[PMID]
397612,Macrocephaly-developmental delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24239382[PMID]
397606,PrP systemic amyloidosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25623792[PMID]
397606,PrP systemic amyloidosis,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,25623792[PMID]
397590,Silver-Russell syndrome due to a point mutation,Etiological subtype,Cases/families,8.0,,Case(s),Worldwide,Validated,24065356[PMID]
397590,Silver-Russell syndrome due to a point mutation,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24065356[PMID]
397587,Deep dermatophytosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
399329,Epiphysiolysis of the hip,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
399180,Secondary non-traumatic avascular necrosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
399058,Alpha-B crystallin-related late-onset myopathy,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,21920752[PMID]_9731540[PMID]_14681890[PMID]_20171888[PMID]
399058,Alpha-B crystallin-related late-onset myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21920752[PMID]_9731540[PMID]_14681890[PMID]_20171888[PMID]
398987,Malignant teratoma of ovary,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.051,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.052,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.056,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.034,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.074,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.053,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.042,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.052,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.039,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.031,<1 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.084,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.048,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.045,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.045,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.075,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.063,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.084,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.082,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398987,Malignant teratoma of ovary,Disease,Annual incidence,0.056,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
399086,Finnish upper limb-onset distal myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12847162[PMID]
399086,Finnish upper limb-onset distal myopathy,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,12847162[PMID]
399081,KLHL9-related early-onset distal myopathy,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,20554658[PMID]
399081,KLHL9-related early-onset distal myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20554658[PMID]
399103,Distal nebulin myopathy,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,29070751[PMID]_25205138[PMID]
399103,Distal nebulin myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29070751[PMID]_25205138[PMID]
399096,Distal anoctaminopathy,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,9673985[PMID]_17132147[PMID]_22402862[PMID]_25864073[PMID]_23663589[PMID]_23606453[PMID]
399096,Distal anoctaminopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9673985[PMID]_25864073[PMID]
398934,Malignant epithelial tumor of ovary,Category,Annual incidence,9.39,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.85,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.497,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.883,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.815,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.995,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.666,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.469,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.706,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.666,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.503,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.567,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.717,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.665,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.49,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.945,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.601,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.695,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.563,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.76,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,0.815,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,1.154,1-9 / 100 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,1.108,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,1.062,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398961,Mucinous adenocarcinoma of ovary,Disease,Annual incidence,1.162,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398940,Malignant non-epithelial tumor of ovary,Category,Annual incidence,0.43,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.32,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.112,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.361,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.201,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.147,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.165,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.359,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.182,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.383,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.395,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.227,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.162,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.166,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.534,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.425,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.118,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.119,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.273,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.388,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.343,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.282,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.342,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398971,Clear cell adenocarcinoma of the ovary,Disease,Annual incidence,0.451,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
398124,Neonatal lupus erythematosus,Disease,Prevalence at birth,5.0,1-9 / 100 000,Value and class,United States,Validated,9061661[PMID]
398124,Neonatal lupus erythematosus,Disease,Point prevalence,5.0,1-9 / 1 000 000,Value and class,United States,Validated,30252317[PMID]_ORPHANET
398127,Neonatal scleroderma,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,16887444[PMID]
398127,Neonatal scleroderma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16887444[PMID]
398147,Persistent idiopathic facial pain,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
398147,Persistent idiopathic facial pain,Disease,Annual incidence,4.4,1-9 / 100 000,Value and class,Netherlands,Validated,19783099[PMID]
398147,Persistent idiopathic facial pain,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Germany,Validated,12911872[PMID]
398147,Persistent idiopathic facial pain,Disease,Lifetime Prevalence,30.0,1-5 / 10 000,Value and class,Germany,Validated,21960648[PMID]
398156,Oculoauriculofrontonasal syndrome,Malformation syndrome,Cases/families,41.0,,Case(s),Worldwide,Validated,23637006[PMID]
398156,Oculoauriculofrontonasal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23637006[PMID]
398166,Focal facial dermal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21931173[PMID]
398166,Focal facial dermal dysplasia,Malformation syndrome,Cases/families,147.0,,Case(s),Worldwide,Validated,21931173[PMID]
398173,Focal facial dermal dysplasia type II,Clinical subtype,Cases/families,22.0,,Case(s),Worldwide,Validated,21931173[PMID]
398173,Focal facial dermal dysplasia type II,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21931173[PMID]
398189,Focal facial dermal dysplasia type IV,Clinical subtype,Cases/families,21.0,,Case(s),Worldwide,Validated,23161670[PMID]
398189,Focal facial dermal dysplasia type IV,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23161670[PMID]
398069,Schaaf-Yang syndrome,Disease,Cases/families,28.0,,Case(s),Worldwide,Validated,27195816[PMID]
398069,Schaaf-Yang syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27195816[PMID]
398073,Prader-Willi-like syndrome,Clinical group,Cases/families,117.0,,Case(s),Worldwide,Validated,24737477[PMID]
398073,Prader-Willi-like syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24737477[PMID]
398079,SIM1-related Prader-Willi-like syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,23778136[PMID]
398079,SIM1-related Prader-Willi-like syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23778136[PMID]
398088,Hereditary cryohydrocytosis with normal stomatin,Disease,Cases/families,53.0,,Case(s),Worldwide,Validated,16227998[PMID]
398088,Hereditary cryohydrocytosis with normal stomatin,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16227998[PMID]
398097,Neonatal antiphospholipid syndrome,Disease,Cases/families,34.0,,Case(s),Worldwide,Validated,24830792[PMID]
398097,Neonatal antiphospholipid syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24830792[PMID]
398109,Neonatal autoimmune hemolytic anemia,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,12819171[PMID]
398109,Neonatal autoimmune hemolytic anemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12819171[PMID]
398117,Neonatal dermatomyositis,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,3508696[PMID]_8888050[PMID]_3508696[PMID]
398117,Neonatal dermatomyositis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3508696[PMID]_8888050[PMID]_3508696[PMID]
435628,Keppen-Lubinsky syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,25620207[PMID]
435628,Keppen-Lubinsky syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25620207[PMID]
435660,LIPE-related familial partial lipodystrophy,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24848981[PMID]_27862896[PMID]
435660,LIPE-related familial partial lipodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24848981[PMID]_27862896[PMID]
435651,CIDEC-related familial partial lipodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20049731[PMID]
435651,CIDEC-related familial partial lipodystrophy,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,20049731[PMID]
435638,3p25.3 microdeletion syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,25256099[PMID]
435638,3p25.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25256099[PMID]
435804,Short stature-advanced bone age-early-onset osteoarthritis syndrome,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,24762113[PMID]
435804,Short stature-advanced bone age-early-onset osteoarthritis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24762113[PMID]
435845,Lethal neonatal spasticity-epileptic encephalopathy syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,25500575[PMID]
435845,Lethal neonatal spasticity-epileptic encephalopathy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25500575[PMID]
435930,Colobomatous optic disc-macular atrophy-chorioretinopathy syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24702266[PMID]
435930,Colobomatous optic disc-macular atrophy-chorioretinopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24702266[PMID]
435819,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to TFG mutation,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25098539[PMID]
435819,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to TFG mutation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25098539[PMID]
435953,Progeroid features-hepatocellular carcinoma predisposition syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,25261934[PMID]
435953,Progeroid features-hepatocellular carcinoma predisposition syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25261934[PMID]
435988,Chronic atrial and intestinal dysrhythmia syndrome,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,25282101[PMID]
435988,Chronic atrial and intestinal dysrhythmia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25282101[PMID]
435934,COG2-CDG,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,24784932[PMID]
435934,COG2-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24784932[PMID]
435938,X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,25316788[PMID]
435938,X-linked microcephaly-growth retardation-prognathism-cryptorchidism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25316788[PMID]
436141,HIDEA syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,25078763[PMID]
436141,HIDEA syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25078763[PMID]
436144,Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,25057881[PMID]
436144,Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25057881[PMID]
435998,Autosomal recessive intermediate Charcot-Marie-Tooth disease type D,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,25152455[PMID]_26302975[PMID]
435998,Autosomal recessive intermediate Charcot-Marie-Tooth disease type D,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25152455[PMID]_26302975[PMID]
436003,Contractures-developmental delay-Pierre Robin syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,25195018[PMID]
436003,Contractures-developmental delay-Pierre Robin syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25195018[PMID]
436159,Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,25213377[PMID]_25329329[PMID]
436159,Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25213377[PMID]_25329329[PMID]
436169,Thrombomodulin-related bleeding disorder,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,25049278[PMID]_25564403[PMID]
436169,Thrombomodulin-related bleeding disorder,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25049278[PMID]_25564403[PMID]
436166,Periodic fever-infantile enterocolitis-autoinflammatory syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,25217959[PMID]_25217960[PMID]
436166,Periodic fever-infantile enterocolitis-autoinflammatory syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25217959[PMID]_25217960[PMID]
436182,Microcephalic primordial dwarfism-insulin resistance syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,25105364 [PMID]
436182,Microcephalic primordial dwarfism-insulin resistance syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25105364[PMID]
436174,Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,25130867[PMID]
436174,Cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25130867[PMID]
436245,Retinitis pigmentosa-juvenile cataract-short stature-intellectual disability syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24916380[PMID]
436245,Retinitis pigmentosa-juvenile cataract-short stature-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24916380[PMID]
436242,Familial atrial tachyarrhythmia-infra-Hisian cardiac conduction disease,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,24925317[PMID]
436242,Familial atrial tachyarrhythmia-infra-Hisian cardiac conduction disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24925317[PMID]
436274,Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,24739904[PMID]
436274,Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24739904[PMID]
437552,Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,23006327[PMID]
437552,Autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23006327[PMID]
438178,Fatty acyl-CoA reductase 1 deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,25439727[PMID]
438178,Fatty acyl-CoA reductase 1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25439727[PMID]
438159,STAT3-related early-onset multisystem autoimmune disease,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,26574998[PMID]
438159,STAT3-related early-onset multisystem autoimmune disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26574998[PMID]
438134,PCNA-related progressive neurodegenerative photosensitivity syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24911150[PMID]
438134,PCNA-related progressive neurodegenerative photosensitivity syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24911150[PMID]
438117,Steel syndrome,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,8423186[PMID]_20357596[PMID]_24986830[PMID]
438117,Steel syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8423186[PMID]_20357596[PMID]_24986830[PMID]
438114,RARS-related autosomal recessive hypomyelinating leukodystrophy,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24777941[PMID]
438114,RARS-related autosomal recessive hypomyelinating leukodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24777941[PMID]
438075,Ketoacidosis due to monocarboxylate transporter-1 deficiency,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,25390740[PMID]
438075,Ketoacidosis due to monocarboxylate transporter-1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25390740[PMID]
438279,Human infection by orthopoxvirus,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2010[INST]
438274,GCGR-related hyperglucagonemia,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,25914784[PMID]
438274,GCGR-related hyperglucagonemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25914784[PMID]
438266,Progressive encephalomyelitis with rigidity and myoclonus,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
438216,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation,Etiological subtype,Cases/families,24.0,,Case(s),Worldwide,Validated,25533962[PMID]_DOI: 10.1101/mcs.a000356[OTHER]
438216,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25533962[PMID]_DOI: 10.1101/mcs.a000356[OTHER]
438213,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,27148565[PMID]_25533962[PMID]
438213,PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27148565[PMID]_25533962[PMID]
438207,Severe autosomal recessive macrothrombocytopenia,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25061177[PMID]
438207,Severe autosomal recessive macrothrombocytopenia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25061177[PMID]
439232,AApoAIV amyloidosis,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,11467836[PMID]_21900878[PMID]
439232,AApoAIV amyloidosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11467836[PMID]_21900878[PMID]
439212,Early-onset myopathy-areflexia-respiratory distress-dysphagia syndrome,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,29128256[PMID]
439212,Early-onset myopathy-areflexia-respiratory distress-dysphagia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29128256[PMID]
439218,KCNQ2-related epileptic encephalopathy,Disease,Cases/families,11.0,,Family(ies),Worldwide,Validated,20437616[PMID]
439218,KCNQ2-related epileptic encephalopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20437616[PMID]
439196,Zinc-responsive necrolytic acral erythema,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
439167,Placental insufficiency,Clinical syndrome,Point prevalence,33.0,1-5 / 10 000,Value and class,Worldwide,Validated,European Medicines Agency 2015[INST]
439822,PDE4D haploinsufficiency syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,24203977[PMID]_21594994[PMID]
439822,PDE4D haploinsufficiency syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24203977[PMID]_21594994[PMID]
439254,ITM2B amyloidosis,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,24473189[PMID]
439254,ITM2B amyloidosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24473189[PMID]
439854,Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,10368461[PMID]_15877279[PMID]
439854,Fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10368461[PMID]_15877279[PMID]
439897,Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,24128419[PMID]
439897,Lethal fetal cerebrorenogenitourinary agenesis/hypoplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24128419[PMID]
439881,Plastic bronchitis,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
440354,Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25091507[PMID]
440354,Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,25091507[PMID]
440713,Isolated sedoheptulokinase deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25647543[PMID]
440713,Isolated sedoheptulokinase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25647543[PMID]
440727,Combined hamartoma of the retina and retinal pigment epithelium,Disease,Cases/families,120.0,,Case(s),Worldwide,Validated,23960997[PMID]
440727,Combined hamartoma of the retina and retinal pigment epithelium,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23960997[PMID]
440731,L-ferritin deficiency,Biological anomaly,Cases/families,2.0,,Case(s),Worldwide,Validated,23940258[PMID]_15173247[PMID]
440731,L-ferritin deficiency,Biological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23940258[PMID]_15173247[PMID]
440706,Ribose-5-P isomerase deficiency,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,14988808[PMID]
440706,Ribose-5-P isomerase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14988808[PMID]
443084,Baroreflex failure,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
443073,Charcot-Marie-Tooth disease type 2S,Disease,Cases/families,35.0,,Case(s),Worldwide,Validated,28065684[PMID]_28202949[PMID]
443073,Charcot-Marie-Tooth disease type 2S,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28065684[PMID]_28202949[PMID]
442835,Non-specific early-onset epileptic encephalopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
442582,AH amyloidosis,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,20876678[PMID]_23302715[PMID]_23446254[PMID]
442582,AH amyloidosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20876678[PMID]_23302715[PMID]_23446254[PMID]
443197,X-linked erythropoietic protoporphyria,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,24131146[PMID]
443197,X-linked erythropoietic protoporphyria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24131146[PMID]
3008,Pyruvate carboxylase deficiency,Disease,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,ISBN:79130356[OTHER]
3008,Pyruvate carboxylase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
443192,Classic stiff person syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
595,Centronuclear myopathy,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
298,Mitochondrial neurogastrointestinal encephalomyopathy,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency[INST]
298,Mitochondrial neurogastrointestinal encephalomyopathy,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Israel,Validated,33239050[PMID]
298,Mitochondrial neurogastrointestinal encephalomyopathy,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Specific population,Validated,33239050[PMID]
396,Chronic hiccup,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
443236,Postural orthostatic tachycardia syndrome due to NET deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,10684912[PMID]
443236,Postural orthostatic tachycardia syndrome due to NET deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10684912[PMID]
552,MODY,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,ORPHANET
552,MODY,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,United Kingdom,Validated,20499044[PMID]
854,Non-malignant and non-cirrhotic portal vein thrombosis,Clinical syndrome,Point prevalence,3.7,1-9 / 100 000,Value and class,Sweden,Validated,21039677[PMID]
854,Non-malignant and non-cirrhotic portal vein thrombosis,Clinical syndrome,Annual incidence,0.7,1-9 / 1 000 000,Value and class,Sweden,Validated,21039677[PMID]
854,Non-malignant and non-cirrhotic portal vein thrombosis,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
854,Non-malignant and non-cirrhotic portal vein thrombosis,Clinical syndrome,Annual incidence,2.75,,Value and class,Italy,Validated,28180235[PMID]
854,Non-malignant and non-cirrhotic portal vein thrombosis,Clinical syndrome,Annual incidence,1.72,1-9 / 100 000,Value and class,Europe,Validated,21039677[PMID]_28180235[PMID]
443098,Hyperostosis cranialis interna,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,20140965[PMID]
443098,Hyperostosis cranialis interna,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20140965[PMID]
443087,"46,XY difference of sex development due to testicular 17,20-desmolase deficiency",Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,21802064[PMID]
443087,"46,XY difference of sex development due to testicular 17,20-desmolase deficiency",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21802064[PMID]
130,Brugada syndrome,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Not yet validated,ORPHANET
130,Brugada syndrome,Disease,Point prevalence,75.0,6-9 / 10 000,Value and class,South East Asia,Not yet validated,15898165[PMID]_23916535[PMID]
277,Severe combined immunodeficiency due to adenosine deaminase deficiency,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,20301656[PMID]_ ORPHANET_[EXPERT]
277,Severe combined immunodeficiency due to adenosine deaminase deficiency,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency[INST]
443162,NDE1-related microhydranencephaly,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,22526350[PMID]
443162,NDE1-related microhydranencephaly,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22526350[PMID]
443804,Focal stiff limb syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
443804,Focal stiff limb syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
443811,PGM3-CDG,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,24698316[PMID]_24589341[PMID]_24931394[PMID]
443811,PGM3-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24698316[PMID]_24589341[PMID]_24931394[PMID]
443950,DNAJB2-related Charcot-Marie-Tooth disease type 2,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25274842[PMID]
443950,DNAJB2-related Charcot-Marie-Tooth disease type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25274842[PMID]
443988,Ventriculomegaly-cystic kidney disease,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,25557780[PMID]_2478019[PMID]
443988,Ventriculomegaly-cystic kidney disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25557780[PMID]_2478019[PMID]
444092,Autoimmune interstitial lung disease-arthritis syndrome,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,25894502[PMID]
444092,Autoimmune interstitial lung disease-arthritis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25894502[PMID]
444099,Autosomal dominant spastic paraplegia type 73,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,25751282[PMID]
444099,Autosomal dominant spastic paraplegia type 73,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25751282[PMID]
444138,Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,25683118[PMID]
444138,Peeling skin-leukonychia-acral punctate keratoses-cheilitis-knuckle pads syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25683118[PMID]
444002,11q22.2q22.3 microdeletion syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,25735893[PMID]
444002,11q22.2q22.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25735893[PMID]
443995,Mandibulofacial dysostosis with alopecia,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,25772936[PMID]
443995,Mandibulofacial dysostosis with alopecia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25772936[PMID]
444048,"46,XX ovarian dysgenesis-short stature syndrome",Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,25480036[PMID]
444048,"46,XX ovarian dysgenesis-short stature syndrome",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25480036[PMID]
444013,Combined oxidative phosphorylation defect type 23,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,25434004[PMID]
444013,Combined oxidative phosphorylation defect type 23,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25434004[PMID]
444069,Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,25564561[PMID]
444069,Lethal fetal brain malformation-duodenal atresia-bilateral renal hypoplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25564561[PMID]
444051,20q11.2 microdeletion syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,25572454[PMID]
444051,20q11.2 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25572454[PMID]
444077,Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,31058441[PMID]
444077,Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_31058441[PMID]
444072,Cerebellar-facial-dental syndrome,Malformation syndrome,Cases/families,3.0,,Family(ies),Worldwide,Validated,25561519[PMID]
444072,Cerebellar-facial-dental syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25561519[PMID]
444463,Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome due to TPP2 deficiency,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,25414442[PMID]_25525876[PMID]
444463,Autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome due to TPP2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25414442[PMID]_25525876[PMID]
444490,Familial chylomicronemia syndrome,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,United States,Validated,15758547[PMID]
444490,Familial chylomicronemia syndrome,Disease,Point prevalence,0.97,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2014[INST]
444458,Combined oxidative phosphorylation defect type 24,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,25629079[PMID]_25385316[PMID]
444458,Combined oxidative phosphorylation defect type 24,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25629079[PMID]_25385316[PMID]
445110,Limb-girdle muscular dystrophy due to POMK deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24925318[PMID]
445110,Limb-girdle muscular dystrophy due to POMK deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24925318[PMID]
445062,Juvenile-onset diabetes mellitus-central and peripheral neurodegeneration syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,25466870[PMID]
445062,Juvenile-onset diabetes mellitus-central and peripheral neurodegeneration syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25466870[PMID]
445038,3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome,Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,25650066[PMID]_25597511[PMID]_25597510[PMID]
445038,3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25650066[PMID]_25597511[PMID]_25597510[PMID]
445018,Combined immunodeficiency due to LRBA deficiency,Disease,Cases/families,23.0,,Case(s),Worldwide,Validated,22721650[PMID]_22981790[PMID]_25468195[PMID]_26206937[PMID]_22608502[PMID]
445018,Combined immunodeficiency due to LRBA deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22721650[PMID]_22981790[PMID]_25468195[PMID]_26206937[PMID]_22608502[PMID]
447731,NIK deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25406581[PMID]
447731,NIK deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25406581[PMID]
447737,Combined immunodeficiency due to DOCK2 deficiency,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,26083206[PMID]
447737,Combined immunodeficiency due to DOCK2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26083206[PMID]
447881,Idiopathic dropped head syndrome,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
447896,Tremor-ataxia-central hypomyelination syndrome,Clinical subtype,Cases/families,7.0,,Case(s),Worldwide,Validated,20640464[PMID]_22384513[PMID]
447896,Tremor-ataxia-central hypomyelination syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20640464[PMID]
447893,Hypomyelination-cerebellar atrophy-hypoplasia of the corpus callosum syndrome,Clinical subtype,Cases/families,4.0,,Case(s),Worldwide,Validated,18851904[PMID]_22036171[PMID]
447893,Hypomyelination-cerebellar atrophy-hypoplasia of the corpus callosum syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18851904[PMID]_22036171[PMID]
447788,Cerebral visual impairment,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
447795,Lipoyl transferase 2 deficiency,Biological anomaly,Point prevalence,0.0,Not yet documented,Class only,Worldwide,Validated,ORPHANET
447784,Mitochondrial pyruvate carrier deficiency,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,22628558[PMID]_12649063[PMID]
447784,Mitochondrial pyruvate carrier deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22628558[PMID]_12649063[PMID]
447757,Autosomal dominant spastic paraplegia type 9B,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,26026163[PMID]
447757,Autosomal dominant spastic paraplegia type 9B,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26026163[PMID]
447753,Autosomal dominant spastic paraplegia type 9A,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,8779323[PMID]_9973297[PMID]
447753,Autosomal dominant spastic paraplegia type 9A,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8779323[PMID]_9973297[PMID]
447760,Autosomal recessive spastic paraplegia type 9B,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,26026163[PMID]
447760,Autosomal recessive spastic paraplegia type 9B,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26026163[PMID]
412066,PRKAR1B-related neurodegenerative dementia with intermediate filaments,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,24722252[PMID]_25108559[PMID]
412066,PRKAR1B-related neurodegenerative dementia with intermediate filaments,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24722252[PMID]_25108559[PMID]
412057,Autosomal recessive cerebellar ataxia due to STUB1 deficiency,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,24312598[PMID]_24742043[PMID]_25258038[PMID]_25592071[PMID]_24719489[PMID]
412057,Autosomal recessive cerebellar ataxia due to STUB1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24312598[PMID]_24742043[PMID]_25258038[PMID]_25592071[PMID]_24719489[PMID]
412181,Epidermolysis bullosa simplex due to BP230 deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,20164846[PMID]_22113475[PMID]_24690439[PMID]
412181,Epidermolysis bullosa simplex due to BP230 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20164846[PMID]_22113475[PMID]_24690439[PMID]
412069,AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,24791903[PMID]
412069,AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24791903[PMID]
412189,Epidermolysis bullosa simplex due to exophilin 5 deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24690439[PMID]_23176819[PMID]
412189,Epidermolysis bullosa simplex due to exophilin 5 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24690439[PMID]_23176819[PMID]
412217,Dystonia-aphonia syndrome,Disease,Cases/families,32.0,,Case(s),Worldwide,Validated,24359844[PMID]_26924602[PMID]
412217,Dystonia-aphonia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26924602[PMID]
418959,Squamous cell carcinoma of the stomach,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.115,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.063,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.025,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.034,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.092,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.176,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.065,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.079,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.207,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.401,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.137,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.031,<1 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.046,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.115,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.111,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.128,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.051,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.053,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418959,Squamous cell carcinoma of the stomach,Disease,Annual incidence,0.18,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.007,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418945,"Carcinoma of esophagus, salivary gland type",Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.044,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.029,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.077,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.115,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.118,1-9 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.042,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.085,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.041,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.087,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.021,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.038,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.101,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.021,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.082,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.051,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.023,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.025,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
418951,Undifferentiated carcinoma of esophagus,Disease,Annual incidence,0.039,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
420179,Malan overgrowth syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,25118028[PMID]
420179,Malan overgrowth syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25118028[PMID]
415286,Bilirubin encephalopathy,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,15254556[PMID]
420789,Autoimmune encephalopathy with parasomnia and obstructive sleep apnea,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,2623676[PMID]
420789,Autoimmune encephalopathy with parasomnia and obstructive sleep apnea,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2623676[PMID]
420794,Cono-spondylar dysplasia,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,24975242[PMID]
420794,Cono-spondylar dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24975242[PMID]
420702,Autosomal recessive severe congenital neutropenia due to CSF3R deficiency,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24753537[PMID]
420702,Autosomal recessive severe congenital neutropenia due to CSF3R deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24753537[PMID]
420728,Combined oxidative phosphorylation defect type 20,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24958846[PMID]_25058219[PMID]
420728,Combined oxidative phosphorylation defect type 20,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24958846[PMID]_25058219[PMID]
420733,Combined oxidative phosphorylation defect type 21,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24827421[PMID]
420733,Combined oxidative phosphorylation defect type 21,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24827421[PMID]
420741,RIDDLE syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,17940005[PMID]_21394101[PMID]
420741,RIDDLE syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17940005[PMID]_21394101[PMID]
420492,"Adult-onset cervical dystonia, DYT23 type",Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,8232359[PMID]_21370267[PMID]
420492,"Adult-onset cervical dystonia, DYT23 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8232359[PMID]_21370267[PMID]
420402,Semicircular canal dehiscence syndrome,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
420429,"Glycogen storage disease due to acid maltase deficiency, late-onset",Clinical subtype,Prevalence at birth,1.75,1-9 / 100 000,Value and class,Worldwide,Validated,6789760[PMID]
420584,Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome,Malformation syndrome,Cases/families,112.0,,Case(s),Worldwide,Validated,24744436[PMID]
420584,Postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24744436[PMID]
420699,Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24777453[PMID]
420699,Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24777453[PMID]
420686,Woolly hair-palmoplantar keratoderma syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,24671081[PMID]
420686,Woolly hair-palmoplantar keratoderma syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET_24671081[PMID]
420561,Temple-Baraitser syndrome,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,27282200[PMID]
420561,Temple-Baraitser syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27282200[PMID]
420573,Severe combined immunodeficiency due to CTPS1 deficiency,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,29942301[PMID]
420573,Severe combined immunodeficiency due to CTPS1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29942301[PMID]
420566,Bleeding disorder due to CalDAG-GEFI deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24958846[PMID]
420566,Bleeding disorder due to CalDAG-GEFI deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24958846[PMID]
423461,Mucolipidosis type III alpha/beta,Clinical subtype,Point prevalence,13.0,1-5 / 10 000,Value and class,Worldwide,Validated,20301730[PMID]
423470,Mucolipidosis type III gamma,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301784[PMID]
423454,Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,25152456[PMID]
423454,Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25152456[PMID]
423384,Severe congenital neutropenia due to JAGN1 deficiency,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,25129144[PMID]
423384,Severe congenital neutropenia due to JAGN1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25129144[PMID]
423296,Spinocerebellar ataxia type 38,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,25065913[PMID]
423296,Spinocerebellar ataxia type 38,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25065913[PMID]
423306,Microcephaly-short stature-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,24709618[PMID]
423306,Microcephaly-short stature-intellectual disability-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24709618[PMID]
423479,X-linked intellectual disability-limb spasticity-retinal dystrophy-arginine vasopressin deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24961627[PMID]
423479,X-linked intellectual disability-limb spasticity-retinal dystrophy-arginine vasopressin deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24961627[PMID]
422526,Hereditary clear cell renal cell carcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
423275,Spinocerebellar ataxia type 40,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,25062847[PMID]
423275,Spinocerebellar ataxia type 40,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25062847[PMID]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424065,Solid pseudopapillary carcinoma of pancreas,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.028,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.031,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.048,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.041,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.028,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424058,Intraductal papillary mucinous carcinoma of pancreas,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424080,Undifferentiated carcinoma with osteoclast-like giant cells of pancreas,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424073,Serous cystadenocarcinoma of pancreas,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424073,Serous cystadenocarcinoma of pancreas,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424073,Serous cystadenocarcinoma of pancreas,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424073,Serous cystadenocarcinoma of pancreas,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424107,Congenital myopathy with myasthenic-like onset,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24951453[PMID]
424107,Congenital myopathy with myasthenic-like onset,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24951453[PMID]
424099,Colobomatous microphthalmia-rhizomelic dysplasia syndrome,Malformation syndrome,Cases/families,5.0,,Family(ies),Worldwide,Validated,24906020[PMID]
424099,Colobomatous microphthalmia-rhizomelic dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24906020[PMID]
424261,TOR1AIP1-related limb-girdle muscular dystrophy,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24856141[PMID]
424261,TOR1AIP1-related limb-girdle muscular dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24856141[PMID]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.253,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.238,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.226,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.485,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.076,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.269,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.105,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.256,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.299,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.499,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.287,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.215,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.144,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.217,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.406,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.382,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.343,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.135,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424016,Adenocarcinoma of the anal canal,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424027,Progressive myoclonic epilepsy type 8,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24782409[PMID]
424027,Progressive myoclonic epilepsy type 8,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24782409[PMID]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.81,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.923,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.707,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.268,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.251,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.568,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.6,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.464,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,1.096,1-9 / 100 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,1.307,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.809,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.416,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.872,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.238,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.153,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,1.071,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.411,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.603,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.194,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.331,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,1.712,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,0.621,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424019,Squamous cell carcinoma of the anal canal,Disease,Annual incidence,1.038,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.023,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.044,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.028,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.045,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.028,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.015,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.032,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.034,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.019,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.058,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424039,Squamous cell carcinoma of pancreas,Disease,Annual incidence,0.023,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,RARECARE
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.019,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.024,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.019,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424053,Mucinous cystadenocarcinoma of the pancreas,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.029,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.049,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.039,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.034,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.044,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.083,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.024,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.058,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.028,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.039,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.024,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.039,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424046,Acinar cell carcinoma of pancreas,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.007,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.022,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423968,Squamous cell carcinoma of the small intestine,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.026,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.072,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.035,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.022,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.026,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.028,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.025,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.041,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.035,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.024,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423994,Squamous cell carcinoma of the colon,Disease,Annual incidence,0.021,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.113,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.126,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.052,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.088,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.157,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.045,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.074,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.083,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.128,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.096,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.149,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.346,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.116,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.071,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.111,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.119,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.042,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.084,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.028,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424002,Squamous cell carcinoma of the rectum,Disease,Annual incidence,0.143,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.211,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.086,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.077,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.764,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.068,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.328,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,2.743,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.221,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.085,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.399,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,2.571,1-9 / 100 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.877,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.251,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.087,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.386,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.072,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.456,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.098,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.045,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423786,Undifferentiated carcinoma of stomach,Disease,Annual incidence,0.032,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
423894,Microcephaly-complex motor and sensory axonal neuropathy syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24126608[PMID]
423894,Microcephaly-complex motor and sensory axonal neuropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24126608[PMID]
431140,X-linked colobomatous microphthalmia-microcephaly-intellectual disability-short stature syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,4998085[PMID]_24993872[PMID]
431140,X-linked colobomatous microphthalmia-microcephaly-intellectual disability-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4998085[PMID]_24993872[PMID]
425120,STING-associated vasculopathy with onset in infancy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25401470[PMID]_25029335[PMID]
425120,STING-associated vasculopathy with onset in infancy,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,25401470[PMID]_25029335[PMID]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.412,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.715,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.201,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.219,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.659,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.471,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.309,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.262,1-9 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.582,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.256,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.642,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.426,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.267,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.481,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.365,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.154,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.471,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.377,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.753,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.157,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.206,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.467,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424943,Adenocarcinoma of the liver and intrahepatic biliary tract,Disease,Annual incidence,0.118,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.015,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.056,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.046,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.019,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.049,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.033,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.098,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.015,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.028,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424970,Undifferentiated carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424991,Adenocarcinoma of the gallbladder and extrahepatic biliary tract,Disease,Annual incidence,2.62,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.032,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.026,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.025,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.124,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.026,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.055,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.033,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.015,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.077,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.042,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.051,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424996,Squamous cell carcinoma of gallbladder and extrahepatic biliary tract,Disease,Annual incidence,0.021,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.007,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.019,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424975,Squamous cell carcinoma of liver and intrahepatic biliary tract,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
424982,Biliary cystadenocarcinoma,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
431361,Progressive encephalopathy with leukodystrophy due to DECR deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,24847004[PMID]_2332510[PMID]
431361,Progressive encephalopathy with leukodystrophy due to DECR deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24847004[PMID]_2332510[PMID]
431353,Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis,Category,Annual incidence,0.015,<1 / 1 000 000,Value and class,France,Validated,20456932[PMID]
431341,Patent urachus,Morphological anomaly,Prevalence at birth,1.75,1-9 / 100 000,Value and class,United States,Validated,3404578[PMID]
431341,Patent urachus,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
431344,Urachal sinus,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
431272,X-linked scapuloperoneal muscular dystrophy,Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,18179901[PMID]_20633900[PMID]
431272,X-linked scapuloperoneal muscular dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18179901[PMID]_20633900[PMID]
431329,Autosomal recessive spastic paraplegia type 57,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,23479643[PMID]
431329,Autosomal recessive spastic paraplegia type 57,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23479643[PMID]
431255,Scapuloperoneal spinal muscular atrophy,Disease,Cases/families,31.0,,Case(s),Worldwide,Validated,26948711[PMID]
431255,Scapuloperoneal spinal muscular atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26948711[PMID]
431149,Combined immunodeficiency due to OX40 deficiency,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,23897980[PMID]
431149,Combined immunodeficiency due to OX40 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23897980[PMID]
431166,Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,26424569[PMID]
431166,Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26424569[PMID]
435438,Progressive myoclonic epilepsy type 7,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,25401298[PMID]
435438,Progressive myoclonic epilepsy type 7,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25401298[PMID]
435387,Autosomal dominant Charcot-Marie-Tooth disease type 2Y,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,25125609[PMID]_25125609[PMID]
435387,Autosomal dominant Charcot-Marie-Tooth disease type 2Y,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25125609[PMID]_25125609[PMID]
435329,Familial ossifying fibroma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
434179,Orofaciodigital syndrome type 14,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,24997988[PMID]
434179,Orofaciodigital syndrome type 14,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24997988[PMID]
504476,Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25564090[PMID]_30926972[PMID]
504476,Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,25564090[PMID]_30926972[PMID]
504523,Severe combined immunodeficiency due to LAT deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,27522155[PMID]
504523,Severe combined immunodeficiency due to LAT deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27522155[PMID]
504530,Combined immunodeficiency due to Moesin deficiency,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,27405666[PMID]
504530,Combined immunodeficiency due to Moesin deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27405666[PMID]
26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,3.2,1-9 / 100 000,Value and class,Australia,Validated,16488171[PMID]
26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,1.8,1-9 / 100 000,Value and class,United States,Validated,22766612[PMID]
26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Germany,Validated,20547398[PMID]
26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,2.3,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]
26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,4.3,1-9 / 100 000,Value and class,Specific population,Validated,33239050[PMID]
26793,Very long chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.45,1-9 / 1 000 000,Value and class,Czech Republic,Validated,31241292[PMID]
29072,Hereditary pheochromocytoma-paraganglioma,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,20301715[PMID]_23162105[PMID]
29072,Hereditary pheochromocytoma-paraganglioma,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
28378,Tyrosinemia type 2,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,8912606[PMID]
28378,Tyrosinemia type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
29207,Reactive arthritis,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Validated,ORPHANET
29073,Multiple myeloma,Disease,Prevalence at birth,3.8,1-9 / 100 000,Value and class,United States,Validated,National Cancer Institute 2005[INST]
29073,Multiple myeloma,Disease,Annual incidence,6.0,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
29073,Multiple myeloma,Disease,Point prevalence,11.9,1-5 / 10 000,Value and class,Europe,Validated,World Health Organization 2008[INST]
29073,Multiple myeloma,Disease,Annual incidence,7.7,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
29073,Multiple myeloma,Disease,Annual incidence,2.4,1-9 / 100 000,Value and class,Europe,Validated,World Health Organization 2008[INST]
29073,Multiple myeloma,Disease,Annual incidence,5.6,1-9 / 100 000,Value and class,United States,Validated,National Cancer Institute 2005[INST]
29073,Multiple myeloma,Disease,Annual incidence,2.0,1-9 / 100 000,Value and class,"Iran, Islamic Republic of",Validated,23725136[PMID]
29073,Multiple myeloma,Disease,Annual incidence,5.1,1-9 / 100 000,Value and class,Australia,Validated,Cancer Institute New South Wales 2008[INST]
29073,Multiple myeloma,Disease,Annual incidence,6.2,1-9 / 100 000,Value and class,Denmark,Validated,36413106[PMID]
29822,Spontaneous periodic hypothermia,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,21166673[PMID]_15990200[PMID]
29822,Spontaneous periodic hypothermia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
30391,Isolated biliary atresia,Morphological anomaly,Point prevalence,10.6,1-5 / 10 000,Value and class,Specific population,Validated,4824812[PMID]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,2.9,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
30391,Isolated biliary atresia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,2.9,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,5.9,1-9 / 100 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,11.9,1-5 / 10 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,4.2,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,16.6,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,1.6,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,1.9,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,12.6,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,2.3,1-9 / 100 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,12.7,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,18.5,1-5 / 10 000,Value and class,Worldwide,Validated,[EXPERT]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,7.4,1-9 / 100 000,Value and class,Japan,Validated,Japanese biliary atresia registry[REG]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,7.0,1-9 / 100 000,Value and class,United States,Not yet validated,9041292[PMID]_7069535[PMID]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,32.0,1-5 / 10 000,Value and class,French Polynesia,Validated,7987462[PMID]
30391,Isolated biliary atresia,Morphological anomaly,Prevalence at birth,7.0,1-9 / 100 000,Value and class,Australia,Validated,559475[PMID]
320,Apparent mineralocorticoid excess,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
724,Idiopathic acute eosinophilic pneumonia,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,12403693[PMID]
724,Idiopathic acute eosinophilic pneumonia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
230,Dopamine beta-hydroxylase deficiency,Disease,Cases/families,25.0,,Case(s),Worldwide,Validated,33034372[PMID]
230,Dopamine beta-hydroxylase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,33034372[PMID]
725,Developmental and epileptic encephalopathy with spike-wave activation in sleep,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
590,Congenital myasthenic syndrome,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
590,Congenital myasthenic syndrome,Disease,Point prevalence,0.92,1-9 / 1 000 000,Value and class,United Kingdom,Validated,24500997[PMID]
404,Familial hyperaldosteronism type II,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
756,Pseudohypoaldosteronism type 1,Disease,Prevalence at birth,2.12,1-9 / 100 000,Value and class,United Kingdom,Validated,24616761[PMID]
756,Pseudohypoaldosteronism type 1,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
162,Congenital cataract-anterior segment dysgenesis syndrome,Malformation syndrome,Cases/families,3.0,,Family(ies),Worldwide,Validated,15665340[PMID]
162,Congenital cataract-anterior segment dysgenesis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15665340[PMID]
544,Diffuse large B-cell lymphoma,Clinical group,Point prevalence,43.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,6.5,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,2.79,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,0.765,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,0.298,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,2.227,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,5.51,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,1.229,1-9 / 100 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,3.304,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,3.815,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,1.244,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,4.586,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,4.559,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,3.458,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,6.47,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,2.984,1-9 / 100 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,2.827,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,5.115,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,1.673,1-9 / 100 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,2.635,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,3.259,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,4.773,1-9 / 100 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,4.78,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,6.328,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,6.478,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
544,Diffuse large B-cell lymphoma,Clinical group,Annual incidence,4.931,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Point prevalence,37.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
545,Follicular lymphoma,Disease,Annual incidence,3.95,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
545,Follicular lymphoma,Disease,Annual incidence,2.192,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,0.348,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,0.72,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,0.579,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,0.363,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,0.277,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,0.368,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,1.52,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,3.04,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,1.665,1-9 / 100 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,1.687,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,2.456,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,2.769,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,2.08,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,2.541,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,1.759,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,3.298,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,1.364,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,1.046,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,1.389,1-9 / 100 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,2.375,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,2.916,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,2.977,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
545,Follicular lymphoma,Disease,Annual incidence,2.766,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88,Idiopathic aplastic anemia,Disease,Point prevalence,0.4,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
88,Idiopathic aplastic anemia,Disease,Annual incidence,0.27,1-9 / 1 000 000,Value and class,Brazil,Validated,35209917[PMID]
102,Multiple system atrophy,Disease,Point prevalence,3.7,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
102,Multiple system atrophy,Disease,Point prevalence,3.5,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
102,Multiple system atrophy,Disease,Annual incidence,1.8,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
102,Multiple system atrophy,Disease,Annual incidence,0.7,1-9 / 1 000 000,Value and class,Iceland,Validated,23192520[PMID]
102,Multiple system atrophy,Disease,Point prevalence,3.4,1-9 / 100 000,Value and class,Iceland,Validated,23192520[PMID]
102,Multiple system atrophy,Disease,Annual incidence,2.1,1-9 / 100 000,Value and class,Sweden,Validated,20108376[PMID]
102,Multiple system atrophy,Disease,Point prevalence,4.4,1-9 / 100 000,Value and class,United Kingdom,Validated,10577638[PMID]
102,Multiple system atrophy,Disease,Annual incidence,0.6,1-9 / 1 000 000,Value and class,United States,Validated,9371909[PMID]
102,Multiple system atrophy,Disease,Point prevalence,1.9,1-9 / 100 000,Value and class,France,Validated,10841152[PMID]_15272223[PMID]
102,Multiple system atrophy,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,Russian Federation,Validated,20108378[PMID]
102,Multiple system atrophy,Disease,Point prevalence,4.9,1-9 / 100 000,Value and class,Italy,Validated,9613728[PMID]
102,Multiple system atrophy,Disease,Point prevalence,10.3,1-5 / 10 000,Value and class,Japan,Validated,20880268[PMID]_19169038[PMID]
102,Multiple system atrophy,Disease,Point prevalence,2.3,1-9 / 100 000,Value and class,Faroe Islands,Validated,9270572[PMID]
824,Primary myelofibrosis,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
824,Primary myelofibrosis,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
748,Mendelian susceptibility to mycobacterial diseases,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
729,Polycythemia vera,Disease,Annual incidence,1.9,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
729,Polycythemia vera,Disease,Point prevalence,30.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]_European Medicines Agency 2014[INST]
729,Polycythemia vera,Disease,Point prevalence,30.0,1-5 / 10 000,Value and class,Italy,Validated,13679323[PMID]
25980,X-linked myopathy with excessive autophagy,Disease,Cases/families,18.0,,Family(ies),Worldwide,Validated,25809233[PMID]
25980,X-linked myopathy with excessive autophagy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25809233[PMID]
26137,Juvenile temporal arteritis,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
26137,Juvenile temporal arteritis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
26106,Hereditary diffuse gastric cancer,Disease,Annual incidence,1.5,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
26106,Hereditary diffuse gastric cancer,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
505395,Ventilator-induced diaphragmatic dysfunction,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_28887062[PMID]
25968,Self-limited childhood occipital epilepsy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
26790,Pseudomyxoma peritonei,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Worldwide,Validated,19838447[PMID]_17524597[PMID]_16678994[PMID]_[EXPERT]
26790,Pseudomyxoma peritonei,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,Netherlands,Validated,17524597[PMID]
26790,Pseudomyxoma peritonei,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
26790,Pseudomyxoma peritonei,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
26792,Short chain acyl-CoA dehydrogenase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
26792,Short chain acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Netherlands,Validated,21500142[PMID]_22608595[PMID]_22241096[PMID]
26791,Multiple acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.47,1-9 / 1 000 000,Value and class,United States,Not yet validated,ORPHANET_24190796[PMID]
26791,Multiple acyl-CoA dehydrogenase deficiency,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
26791,Multiple acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Israel,Validated,33239050[PMID]
26791,Multiple acyl-CoA dehydrogenase deficiency,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Specific population,Validated,33239050[PMID]
49,Penile agenesis,Morphological anomaly,Cases/families,80.0,,Case(s),Worldwide,Validated,25786436[PMID]
49,Penile agenesis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25786436[PMID]
227,Diphallia,Morphological anomaly,Prevalence at birth,0.02,<1 / 1 000 000,Value and class,Worldwide,Not yet validated,23056729[PMID]
227,Diphallia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,23056729[PMID]
674,Accessory pancreas,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
266,Autosomal dominant limb-girdle muscular dystrophy type 1A,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,21336781[PMID]
266,Autosomal dominant limb-girdle muscular dystrophy type 1A,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21336781[PMID]
353,Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2011[INST]
353,Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
353,Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5,Disease,Annual incidence,0.18,1-9 / 1 000 000,Value and class,Japan,Validated,20350330[PMID]
219,Delta-sarcoglycan-related limb-girdle muscular dystrophy R6,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2011[INST]
641,Multifocal motor neuropathy,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Worldwide,Validated,17075524[PMID]_11282149[PMID]_23623583[PMID]
641,Multifocal motor neuropathy,Disease,Point prevalence,0.16,1-9 / 1 000 000,Value and class,Japan,Validated,23196468[PMID]
119,Beta-sarcoglycan-related limb-girdle muscular dystrophy R4,Disease,Point prevalence,0.07,<1 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
119,Beta-sarcoglycan-related limb-girdle muscular dystrophy R4,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2011[INST]
603,"Distal myopathy, Welander type",Disease,Point prevalence,100.0,>1 / 1000,Value and class,Sweden,Validated,DOI:https://doi.org/10.1016/S0960-8966(02)00116-5[OTHER]_ [EXPERT]
603,"Distal myopathy, Welander type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
505227,Combined immunodeficiency due to GINS1 deficiency,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,28414293[PMID]
505227,Combined immunodeficiency due to GINS1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28414293[PMID]
505237,Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,28343629[PMID]
505237,Early-onset seizures-distal limb anomalies-facial dysmorphism-global developmental delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28343629[PMID]
588,Muscle-eye-brain disease,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
899,Walker-Warburg syndrome,Disease,Point prevalence,0.03,<1 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
899,Walker-Warburg syndrome,Disease,Prevalence at birth,1.65,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
899,Walker-Warburg syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,[EXPERT]
899,Walker-Warburg syndrome,Disease,Prevalence at birth,1.2,1-9 / 100 000,Value and class,Italy,Validated,8786062[PMID]
505216,3-methylglutaconic aciduria type 9,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,27573165[PMID]
505216,3-methylglutaconic aciduria type 9,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27573165[PMID]
272,"Congenital muscular dystrophy, Fukuyama type",Malformation syndrome,Prevalence at birth,2.8,1-9 / 100 000,Value and class,Japan,Validated,20301385[PMID]
272,"Congenital muscular dystrophy, Fukuyama type",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,20301385[PMID]_ORPHANET
505208,3-methylglutaconic aciduria type 8,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,27208207[PMID]_27696117[PMID]
505208,3-methylglutaconic aciduria type 8,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27208207[PMID]_27696117[PMID]
268,Dysferlin-related limb-girdle muscular dystrophy R2,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
268,Dysferlin-related limb-girdle muscular dystrophy R2,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
263,Limb-girdle muscular dystrophy,Clinical group,Point prevalence,0.81,1-9 / 1 000 000,Value and class,Netherlands,Validated,8931572[PMID]
263,Limb-girdle muscular dystrophy,Clinical group,Point prevalence,2.27,1-9 / 100 000,Value and class,United Kingdom,Validated,19767415[PMID]
263,Limb-girdle muscular dystrophy,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
263,Limb-girdle muscular dystrophy,Clinical group,Point prevalence,1.55,1-9 / 100 000,Value and class,Japan,Validated,1745328[PMID]
263,Limb-girdle muscular dystrophy,Clinical group,Point prevalence,2.32,1-9 / 100 000,Value and class,Worldwide,Validated,25532075[PMID]
263,Limb-girdle muscular dystrophy,Clinical group,Lifetime Prevalence,5.7,1-9 / 100 000,Value and class,Egypt,Validated,16210862[PMID]
263,Limb-girdle muscular dystrophy,Clinical group,Point prevalence,6.9,1-9 / 100 000,Value and class,Spain,Validated,9762961[PMID]
263,Limb-girdle muscular dystrophy,Clinical group,Point prevalence,1.1,1-9 / 100 000,Value and class,Ireland,Validated,8845721[PMID]
600,Vocal cord and pharyngeal distal myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25952333[PMID]_29628183[PMID]
505248,Mucopolysaccharidosis-like syndrome with congenital heart defects and hematopoietic disorders,Malformation syndrome,Cases/families,19.0,,Case(s),Worldwide,Validated,28013294[PMID]
505248,Mucopolysaccharidosis-like syndrome with congenital heart defects and hematopoietic disorders,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28013294[PMID]
609,Tibial muscular dystrophy,Disease,Point prevalence,6.0,1-9 / 100 000,Value and class,Europe,Validated,24395473[PMID]
609,Tibial muscular dystrophy,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Finland,Validated,24395473[PMID]
602,GNE myopathy,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,25002140[PMID]
602,GNE myopathy,Disease,Point prevalence,66.7,6-9 / 10 000,Value and class,Specific population,Validated,12743242[PMID]
505242,Psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,28334855[PMID]
505242,Psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28334855[PMID]
508093,MEPAN syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,27817865[PMID]
508093,MEPAN syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27817865[PMID]
508533,Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,28132690[PMID]_28148688[PMID]
508533,Skeletal dysplasia-T-cell immunodeficiency-developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28132690[PMID]_28148688[PMID]
508542,Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,28115216[PMID]
508542,Congenital progressive bone marrow failure-B-cell immunodeficiency-skeletal dysplasia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28115216[PMID]
508512,Intrauterine growth restriction-congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,27977684[PMID]
508512,Intrauterine growth restriction-congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27977684[PMID]
508529,Intermediate epidermolysis bullosa simplex with cardiomyopathy,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,27889062[PMID]
508529,Intermediate epidermolysis bullosa simplex with cardiomyopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27889062[PMID]
508523,Hyperphenylalaninemia due to DNAJC12 deficiency,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,28132689[PMID]
508523,Hyperphenylalaninemia due to DNAJC12 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28132689[PMID]
508488,8q24.3 microdeletion syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,27804958[PMID]
508488,8q24.3 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27804958[PMID]
508476,Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,28081210[PMID]
508476,Cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28081210[PMID]
508501,Oral-facial-digital syndrome with short stature and brachymesophalangy,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,27060890[PMID]
508501,Oral-facial-digital syndrome with short stature and brachymesophalangy,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27060890[PMID]
508498,Intellectual disability-cardiac anomalies-short stature-joint laxity syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,28327570[PMID]
508498,Intellectual disability-cardiac anomalies-short stature-joint laxity syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28327570[PMID]
505652,CDKL5-deficiency disorder,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_22872100[PMID]_24564546[PMID]
505652,CDKL5-deficiency disorder,Disease,Prevalence at birth,0.21,1-9 / 1 000 000,Value and class,Australia,Validated,29264392[PMID]
505652,CDKL5-deficiency disorder,Disease,Prevalence at birth,2.36,1-9 / 100 000,Value and class,United Kingdom,Validated,31302675[PMID]
505652,CDKL5-deficiency disorder,Disease,Prevalence at birth,0.0,1-9 / 100 000,Class only,Europe,Validated,EpiCARE[EXPERT]_31302675[PMID]
506307,Stromme syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,18203155[PMID]_26820108[PMID]_28407396[PMID]
506307,Stromme syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28407396[PMID]
506358,Gabriele-de Vries syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,28575647[PMID]
506358,Gabriele-de Vries syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28575647[PMID]
506353,Autosomal recessive complex spastic paraplegia due to Kennedy pathway dysfunction,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,28052917[PMID]
506353,Autosomal recessive complex spastic paraplegia due to Kennedy pathway dysfunction,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28052917[PMID]
495274,Charcot-Marie-Tooth disease type 2T,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,26991897[PMID]
495274,Charcot-Marie-Tooth disease type 2T,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26991897[PMID]
495844,C11ORF73-related autosomal recessive hypomyelinating leukodystrophy,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,26545878[PMID]
495844,C11ORF73-related autosomal recessive hypomyelinating leukodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26545878[PMID]
495818,9q33.3q34.11 microdeletion syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,26395556[PMID]
495818,9q33.3q34.11 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26395556[PMID]
495879,Congenital agenesis of the scrotum,Morphological anomaly,Cases/families,6.0,,Case(s),Worldwide,Validated,23374822[PMID]
495879,Congenital agenesis of the scrotum,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23374822[PMID]
495875,Congenital labioscrotal agenesis-cerebellar malformation-corneal dystrophy-facial dysmorphism syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,27075597[PMID]_27103078[PMID]
495875,Congenital labioscrotal agenesis-cerebellar malformation-corneal dystrophy-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27075597[PMID]_27103078[PMID]
495930,Familial monosomy 7 syndrome,Disease,Cases/families,14.0,,Family(ies),Worldwide,Validated,20614583[PMID]
495930,Familial monosomy 7 syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20614583[PMID]
496641,Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome,Malformation syndrome,Cases/families,39.0,,Case(s),Worldwide,Validated,27807845[PMID]_27666374[PMID]_27666370[PMID]_27928163[PMID]
496641,Early-onset progressive diffuse brain atrophy-microcephaly-muscle weakness-optic atrophy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27807845[PMID]_27666374[PMID]_27666370[PMID]_27928163[PMID]
496686,Kyphosis-lateral tongue atrophy-myofibrillar myopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27484770[PMID]_27485408[PMID]
496686,Kyphosis-lateral tongue atrophy-myofibrillar myopathy syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,27484770[PMID]_27485408[PMID]
496689,Kyphoscoliosis-lateral tongue atrophy-hereditary spastic paraplegia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28488683[PMID]
496689,Kyphoscoliosis-lateral tongue atrophy-hereditary spastic paraplegia syndrome,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,28488683[PMID]
496693,Omphalocele-diaphragmatic hernia-cardiovascular anomalies-radial ray defect syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,26639892[PMID]
496693,Omphalocele-diaphragmatic hernia-cardiovascular anomalies-radial ray defect syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26639892[PMID]
496751,EVEN-plus syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,26598328[PMID]
496751,EVEN-plus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26598328[PMID]
496756,Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,27666369[PMID]
496756,Early-onset progressive encephalopathy-spastic ataxia-distal spinal muscular atrophy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27666369[PMID]
496790,Ocular anomalies-axonal neuropathy-developmental delay syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,27640307[PMID]
496790,Ocular anomalies-axonal neuropathy-developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27640307[PMID]
494433,MIRAGE syndrome,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,27182967[PMID]_28346228[PMID]
494433,MIRAGE syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27182967[PMID]_28346228[PMID]
494439,Retinitis pigmentosa-hearing loss-premature aging-short stature-facial dysmorphism syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,26843489[PMID]
494439,Retinitis pigmentosa-hearing loss-premature aging-short stature-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26843489[PMID]
494424,Extracranial carotid artery aneurysm,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26116488[PMID]
494428,Idiopathic pleuroparenchymal fibroelastosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27141432[PMID]_28344924[PMID]
494428,Idiopathic pleuroparenchymal fibroelastosis,Disease,Cases/families,37.0,,Case(s),Worldwide,Validated,27141432[PMID]
494444,DIAPH1-related sensorineural hearing loss-thrombocytopenia syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,27808407[PMID]
494444,DIAPH1-related sensorineural hearing loss-thrombocytopenia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27808407[PMID]
494344,RERE-related neurodevelopmental syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,27087320[PMID]
494344,RERE-related neurodevelopmental syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27087320[PMID]
494547,Squamous cell carcinoma of the hypopharynx,Disease,Annual incidence,1.27,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
494541,Childhood-onset benign chorea with striatal involvement,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,27058447[PMID]
494541,Childhood-onset benign chorea with striatal involvement,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27058447[PMID]
494526,Infantile-onset generalized dyskinesia with orofacial involvement,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,27058446[PMID]
494526,Infantile-onset generalized dyskinesia with orofacial involvement,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27058446[PMID]
494550,Squamous cell carcinoma of the larynx,Disease,Annual incidence,4.61,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
500180,Childhood-onset motor and cognitive regression syndrome with extrapyramidal movement disorder,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,28777933[PMID]
500180,Childhood-onset motor and cognitive regression syndrome with extrapyramidal movement disorder,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28777933[PMID]
500188,X-linked external auditory canal atresia-dilated internal auditory canal-facial dysmorphism syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,28096187[PMID]
500188,X-linked external auditory canal atresia-dilated internal auditory canal-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28096187[PMID]
68,Amoebiasis due to free-living amoebae,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
781,Q fever,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,United States,Validated,23535757[PMID]_Center for Diseases Control and Prevention[INST]
781,Q fever,Disease,Annual incidence,3.0,1-9 / 100 000,Value and class,Australia,Validated,16503466[PMID]
781,Q fever,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
781,Q fever,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,Belgium,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.32,1-9 / 1 000 000,Value and class,Cyprus,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,France,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Greece,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.64,1-9 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Ireland,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,Latvia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Luxembourg,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Malta,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.18,1-9 / 1 000 000,Value and class,Netherlands,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Sweden,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
781,Q fever,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Norway,Validated,European Centre for Disease prevention and Control 2012-2016[INST]
500150,Brain malformations-musculoskeletal abnormalities-facial dysmorphism-intellectual disability syndrome,Malformation syndrome,Cases/families,33.0,,Case(s),Worldwide,Validated,PMID: 32926520: 27545680: 27545676: 27256762
500150,Brain malformations-musculoskeletal abnormalities-facial dysmorphism-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27545680[PMID]_27545676[PMID]_27256762[PMID]
500159,Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,28886345[PMID]
500159,Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28886345[PMID]
500163,Witteveen-Kolk syndrome,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,PMID: 27399968 & EXPERT
500163,Witteveen-Kolk syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27399968[PMID]
302,Inherited epidermodysplasia verruciformis,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
302,Inherited epidermodysplasia verruciformis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
297,Tick-borne encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
182,Chromomycosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
128,Diphyllobothriasis,Disease,Annual incidence,0.88,1-9 / 1 000 000,Value and class,France,Not yet validated,ORPHANET
128,Diphyllobothriasis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
210,Cyclosporiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
76,Strongyloidiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
76,Strongyloidiasis,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Spain,Validated,29284005[PMID]
74,Angiostrongyliasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
108,Babesiosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,emedicine[OTHER]
78,Ankylostomiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
500135,Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,28264986[PMID]
500135,Multinucleated neurons-anhydramnios-renal dysplasia-cerebellar hypoplasia-hydranencephaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28264986[PMID]
500144,Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,28777934[PMID]_32347653[PMID]_32369837[PMID]
500144,Early-onset progressive encephalopathy-hearing loss-pons hypoplasia-brain atrophy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28777934[PMID]
500055,Hao-Fountain syndrome due to 16p13.2 microdeletion,Etiological subtype,Cases/families,6.0,,Case(s),Worldwide,Validated,26365382[PMID]
500055,Hao-Fountain syndrome due to 16p13.2 microdeletion,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26365382[PMID]
500095,Tall stature-intellectual disability-renal anomalies syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,26660953[PMID]_27183861[PMID]
500095,Tall stature-intellectual disability-renal anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26660953[PMID]_27183861[PMID]
500062,Infantile-onset periodic fever-panniculitis-dermatosis syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,27523608[PMID]_27559085[PMID]
500062,Infantile-onset periodic fever-panniculitis-dermatosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27523608[PMID]_27559085[PMID]
129,Pseudopelade of Brocq,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
123,Björnstad syndrome,Disease,Cases/families,33.0,,Case(s),Worldwide,Validated,11807445[PMID]
123,Björnstad syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
898,Wagner disease,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
898,Wagner disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
500478,Squamous cell carcinoma of the oropharynx,Disease,Annual incidence,3.12,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
518,Acute megakaryoblastic leukemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
518,Acute megakaryoblastic leukemia,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
318,Acute erythroid leukemia,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,[WHO Classification of Tumours]
318,Acute erythroid leukemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[WHO Classification of Tumours]
514,Acute monoblastic/monocytic leukemia,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
514,Acute monoblastic/monocytic leukemia,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
517,Acute myelomonocytic leukemia,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
517,Acute myelomonocytic leukemia,Disease,Annual incidence,0.17,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
505,Graham Little-Piccardi-Lassueur syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
346,Quinquaud folliculitis decalvans,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
222,Erosive pustular dermatosis of the scalp,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
202,Crandall syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
170,Woolly hair,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
500548,Osteosclerotic metaphyseal dysplasia,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,27829680[PMID]
500548,Osteosclerotic metaphyseal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27829680[PMID]
169,Ringed hair disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
500533,Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,27170158[PMID]
500533,Polyhydramnios-megalencephaly-symptomatic epilepsy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27170158[PMID]
168,Loose anagen syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
500545,Severe neurodevelopmental disorder with feeding difficulties-stereotypic hand movement-bilateral cataract,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,28132692[PMID]
500545,Severe neurodevelopmental disorder with feeding difficulties-stereotypic hand movement-bilateral cataract,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28132692[PMID]
345,Dissecting cellulitis of the scalp,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
591,Furuncular myiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
723,Pneumocystosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
472,Isosporiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
401,Hymenolepiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
400,Cystic echinococcosis,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
400,Cystic echinococcosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
500464,Squamous cell carcinoma of the nasal cavity and paranasal sinuses,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,Worldwide,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
520,Acute promyelocytic leukemia,Disease,Annual incidence,0.28,1-9 / 1 000 000,Value and class,United States,Validated,22707337[PMID]_21653939[PMID]_ ORPHANET
520,Acute promyelocytic leukemia,Disease,Annual incidence,0.11,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
520,Acute promyelocytic leukemia,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
520,Acute promyelocytic leukemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
450,Heterotaxia,Category,Prevalence at birth,10.0,1-5 / 10 000,Value and class,United States,Validated,11256661[PMID]
450,Heterotaxia,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
529,Roch-Leri mesosomatous lipomatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
224,Neonatal diabetes mellitus,Category,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Europe,Not yet validated,21953423[PMID]_19499210[PMID]_20546293[PMID]
224,Neonatal diabetes mellitus,Category,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Italy,Validated,21953423[PMID]
224,Neonatal diabetes mellitus,Category,Prevalence at birth,1.12,1-9 / 100 000,Value and class,Germany,Validated,20546293[PMID]
224,Neonatal diabetes mellitus,Category,Annual incidence,0.62,1-9 / 1 000 000,Value and class,Austria,Validated,19496964[PMID]
224,Neonatal diabetes mellitus,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
826,Sporotrichosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25526781[PMID]
826,Sporotrichosis,Disease,Point prevalence,2500.0,>1 / 1000,Value and class,Mexico,Validated,25526781[PMID]
826,Sporotrichosis,Disease,Annual incidence,54.0,1-5 / 10 000,Value and class,Peru,Validated,10619735[PMID]
879,Tungiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,22941398[PMID]
502363,Squamous cell carcinoma of the oral cavity,Disease,Annual incidence,3.51,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
502366,Squamous cell carcinoma of the lip,Disease,Annual incidence,1.02,1-9 / 100 000,Value and class,Worldwide,Validated,RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
502423,Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,28544275[PMID]_28554942[PMID]_29339779[PMID]
502423,Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28544275[PMID]_28554942[PMID]_29339779[PMID]
502430,Weiss-Kruszka Syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,28513610[PMID]
502430,Weiss-Kruszka Syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28513610[PMID]
502434,STAG1-related intellectual disability-facial dysmorphism-gastroesophageal reflux syndrome,Malformation syndrome,Cases/families,17.0,,Case(s),Worldwide,Validated,28119487[PMID]
502434,STAG1-related intellectual disability-facial dysmorphism-gastroesophageal reflux syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28119487[PMID]
502437,4q25 proximal deletion syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,27587989[PMID]
502437,4q25 proximal deletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27587989[PMID]
502444,Alkaline ceramidase 3 deficiency,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,26792856[PMID]
502444,Alkaline ceramidase 3 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26792856[PMID]
91,Aromatase deficiency,Disease,Cases/families,38.0,,Case(s),Worldwide,Validated,27256151[PMID]_27693882[PMID]_29324451[PMID]_29553041[PMID]
91,Aromatase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27256151[PMID]_27693882[PMID]_29324451[PMID]_29553041[PMID]
785,Estrogen resistance syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,8090165[PMID]_23841731[PMID]
785,Estrogen resistance syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8090165[PMID]_23841731[PMID]
873,Desmoid tumor,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
873,Desmoid tumor,Disease,Annual incidence,0.33,1-9 / 1 000 000,Value and class,Finland,Not yet validated,3946757[PMID]
873,Desmoid tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
679,Malignant atrophic papulosis,Clinical subtype,Cases/families,200.0,,Case(s),Worldwide,Validated,[EXPERT]
679,Malignant atrophic papulosis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
901,Wells syndrome,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,23730155[PMID]
901,Wells syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23730155[PMID]
703,Bullous pemphigoid,Disease,Annual incidence,2.17,1-9 / 100 000,Value and class,France,Validated,22418872[PMID]_23237497[PMID]
703,Bullous pemphigoid,Disease,Annual incidence,1.34,1-9 / 100 000,Value and class,Germany,Validated,19170813[PMID]
703,Bullous pemphigoid,Disease,Annual incidence,4.3,1-9 / 100 000,Value and class,United Kingdom,Validated,18614511[PMID]
703,Bullous pemphigoid,Disease,Annual incidence,1.21,1-9 / 100 000,Value and class,Switzerland,Validated,19566661[PMID]
703,Bullous pemphigoid,Disease,Point prevalence,25.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
703,Bullous pemphigoid,Disease,Point prevalence,25.93,1-5 / 10 000,Value and class,Germany,Validated,27456755[PMID]
841,Sebocystomatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
817,Peeling skin syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
867,Familial multiple trichoepithelioma,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
735,Porokeratosis of Mibelli,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_Pr KANITAKIS Jean[EXPERT]
497906,Childhood-onset basal ganglia degeneration syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,27292112[PMID]
497906,Childhood-onset basal ganglia degeneration syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27292112[PMID
659,Mutilating palmoplantar keratoderma with periorificial keratotic plaques,Disease,Cases/families,73.0,,Case(s),Worldwide,Validated,25886873[PMID]
659,Mutilating palmoplantar keratoderma with periorificial keratotic plaques,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
737,Porokeratosis plantaris palmaris et disseminata,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_Pr KANITAKIS Jean[EXPERT]
497623,C12ORF65-related combined oxidative phosphorylation defect,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27858754[PMID]
497623,C12ORF65-related combined oxidative phosphorylation defect,Clinical group,Cases/families,30.0,,Case(s),Worldwide,Validated,27858754[PMID]_28091420[PMID]_28804760[PMID]
523,Hereditary leiomyomatosis and renal cell cancer,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
523,Hereditary leiomyomatosis and renal cell cancer,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
497757,MME-related autosomal dominant Charcot Marie Tooth disease type 2,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,27588448[PMID]
497757,MME-related autosomal dominant Charcot Marie Tooth disease type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27588448[PMID]
497764,Spinocerebellar ataxia type 43,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,27583304[PMID]
497764,Spinocerebellar ataxia type 43,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27583304[PMID]
530,Lipoid proteinosis,Malformation syndrome,Cases/families,500.0,,Case(s),Worldwide,Validated,26803878[PMID]
530,Lipoid proteinosis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26803878[PMID]
497188,Diffuse intrinsic pontine glioma,Disease,Annual incidence,0.056,<1 / 1 000 000,Value and class,Netherlands,Validated,25435089[PMID]
454,Acquired ichthyosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
617,Congenital primary megaureter,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
488,Urachal cyst,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
105,Atresia of urethra,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
105,Atresia of urethra,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
237,Duplication of urethra,Morphological anomaly,Cases/families,300.0,,Case(s),Worldwide,Validated,19231292[PMID]
237,Duplication of urethra,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_19231292[PMID]
721,Gray platelet syndrome,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,[EXPERT]
721,Gray platelet syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
722,Hypoplasminogenemia,Disease,Point prevalence,0.16,1-9 / 1 000 000,Value and class,Europe,Validated,32001536[PMID]
853,Fetal and neonatal alloimmune thrombocytopenia,Disease,Point prevalence,39.6307,1-5 / 10 000,Value and class,Worldwide,Validated,23384054[PMID]_ORPHANET
853,Fetal and neonatal alloimmune thrombocytopenia,Disease,Prevalence at birth,66.6667,6-9 / 10 000,Value and class,Worldwide,Validated,23384054[PMID]_ORPHANET
498359,Aquagenic palmoplantar keratoderma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24283504[PMID]
465,Congenital plasminogen activator inhibitor type 1 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
310,Reflex epilepsy,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
498251,Menstrual cycle-dependent periodic fever,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,7684743[PMID]_16006734[PMID]_21990073[PMID]_21501330[PMID]
498251,Menstrual cycle-dependent periodic fever,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7684743[PMID]_16006734[PMID]_21990073[PMID]_21501330[PMID]
1332,Medullary thyroid carcinoma,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
1332,Medullary thyroid carcinoma,Disease,Annual incidence,0.17,1-9 / 1 000 000,Value and class,United States,Validated,21186939[PMID]_National Cancer Institute 1992-2006[INST]
1332,Medullary thyroid carcinoma,Disease,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
877,Neuroendocrine neoplasm,Category,Annual incidence,3.2,1-9 / 100 000,Value and class,Norway,Validated,18853416[PMID]
877,Neuroendocrine neoplasm,Category,Annual incidence,5.25,1-9 / 100 000,Value and class,United States,Validated,18565894[PMID]_National Cancer Institute[INST]
877,Neuroendocrine neoplasm,Category,Annual incidence,2.53,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
877,Neuroendocrine neoplasm,Category,Point prevalence,35.0,1-5 / 10 000,Value and class,United States,Validated,18565894[PMID]
877,Neuroendocrine neoplasm,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
73,Gorham-Stout disease,Malformation syndrome,Cases/families,300.0,,Case(s),Worldwide,Validated,[EXPERT]_20972870[PMID]_23897792[PMID]_25227772[PMID]
73,Gorham-Stout disease,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20972870[PMID]_23897792[PMID]_25227772[PMID]
498228,Phyllodes tumor of the prostate,Disease,Cases/families,90.0,,Case(s),Worldwide,Validated,25210561[PMID]
728,Relapsing polychondritis,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,United States,Validated,21962557[PMID]_14673390[PMID]
728,Relapsing polychondritis,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,Worldwide,Validated,21962557[PMID]_14673390[PMID]
728,Relapsing polychondritis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
728,Relapsing polychondritis,Disease,Annual incidence,0.071,<1 / 1 000 000,Value and class,United Kingdom,Validated,26187053[PMID]
728,Relapsing polychondritis,Disease,Point prevalence,0.52,1-9 / 1 000 000,Value and class,United Kingdom,Validated,26187053[PMID]
467,Non-acquired combined pituitary hormone deficiency,Category,Prevalence at birth,29.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
467,Non-acquired combined pituitary hormone deficiency,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,[EXPERT]
142,Anaplastic thyroid carcinoma,Disease,Annual incidence,0.17,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
142,Anaplastic thyroid carcinoma,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2004[INST]
143,Parathyroid carcinoma,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe 2011[REG]
143,Parathyroid carcinoma,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Lifetime Prevalence,0.28,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,United States,Validated,26708847[PMID]_17372919[PMID]_SEER Surveillance Epidemiology and End Results Program 2003[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.015,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.015,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.045,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.017,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.031,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.052,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.031,<1 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.045,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.015,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
143,Parathyroid carcinoma,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
786,Generalized glucocorticoid resistance syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,23392096[PMID]
1461,Criss-cross heart,Morphological anomaly,Prevalence at birth,0.8,1-9 / 1 000 000,Value and class,Europe,Validated,ISBN:9781416023906[OTHER]_22555779[PMID]
1461,Criss-cross heart,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
875,Primary pediatric heart tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
615,Familial atrial myxoma,Disease,Cases/families,17.0,,Family(ies),Worldwide,Validated,1540058[PMID]
615,Familial atrial myxoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1540058[PMID]
874,Primary adult heart tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
499009,Congenital syphilis,Disease,Point prevalence,1.3,1-9 / 100 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]_ORPHANET
499009,Congenital syphilis,Disease,Point prevalence,15.7,1-5 / 10 000,Value and class,United States,Validated,CDC Centers for disease Control and prevention 2016[INST]_ORPHANET
499009,Congenital syphilis,Disease,Prevalence at birth,15.7,1-5 / 10 000,Value and class,United States,Validated,CDC Centers for disease Control and prevention 2016[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,1.3,1-9 / 100 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,26.6,1-5 / 10 000,Value and class,Bulgaria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,1.3,1-9 / 100 000,Value and class,Czech Republic,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,1.04,1-9 / 100 000,Value and class,Denmark,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Greece,Validated,European Centre for Disease prevention and Control 2013-2015[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2013-2015[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,4.6,1-9 / 100 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,1.9,1-9 / 100 000,Value and class,Poland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,5.4,1-9 / 100 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
499009,Congenital syphilis,Disease,Prevalence at birth,0.8,1-9 / 1 000 000,Value and class,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
1330,Partial atrioventricular septal defect,Morphological anomaly,Prevalence at birth,20.0,1-5 / 10 000,Value and class,Europe,Not yet validated,23040494[PMID]
1330,Partial atrioventricular septal defect,Morphological anomaly,Point prevalence,30.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]_17341403[PMID]_12084585[PMID]
1677,Familial idiopathic dilatation of the right atrium,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
498497,Short rib-polydactyly syndrome type 5,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,17935248[PMID]
498497,Short rib-polydactyly syndrome type 5,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17935248[PMID]
720,Pili bifurcati,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
671,Primary cutis verticis gyrata,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
864,Trichofolliculoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
498602,Sugarman brachydactyly,Morphological anomaly,Cases/families,1.0,,Family(ies),Worldwide,Validated,4469972[PMID]_7083610[PMID]
498602,Sugarman brachydactyly,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4469972[PMID]_7083610[PMID]
247,Inherited arrhythmogenic cardiomyopathy,Clinical group,Point prevalence,43.5,1-5 / 10 000,Value and class,Italy,Validated,16585401[PMID]_Pr Cristina BASSO_Dr Kalliopi PILICHOU_Pr Domenico CORRADO_Pr Gaetano THIENE[EXPERT]
247,Inherited arrhythmogenic cardiomyopathy,Clinical group,Point prevalence,20.0,1-5 / 10 000,Value and class,Worldwide,Validated,23736219[PMID]
498693,MYBPC1-related autosomal recessive non-lethal arthrogryposis multiplex congenita syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,26661508[PMID]
498693,MYBPC1-related autosomal recessive non-lethal arthrogryposis multiplex congenita syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26661508[PMID]
444,Marie Unna hereditary hypotrichosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2221,Acquired hypertrichosis lanuginosa,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,ORPHANET
2221,Acquired hypertrichosis lanuginosa,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
498474,Hyaline fibromatosis syndrome,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,25186005[PMID]
498474,Hyaline fibromatosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25186005[PMID]
499,Kerion celsi,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
498485,Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,15214018[PMID]_17618504[PMID]
498485,Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15214018[PMID]_17618504[PMID]
573,Monilethrix,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
498488,Overgrowth syndrome with 2q37 translocation,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,25728306[PMID]
498488,Overgrowth syndrome with 2q37 translocation,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25728306[PMID]
525,Lichen planopilaris,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,ORPHANET
525,Lichen planopilaris,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
700,Alopecia totalis,Disease,Point prevalence,10.5,1-5 / 10 000,Value and class,Europe,Not yet validated,ORPHANET
840,Syringocystadenoma papilliferum,Disease,Cases/families,730.0,,Case(s),Worldwide,Validated,16418676[PMID]_EXPERT
840,Syringocystadenoma papilliferum,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16418676[PMID]_EXPERT_ORPHANET
315,Erythrokeratoderma ''en cocardes'',Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
409,Hyperkeratosis lenticularis perstans,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
41,Dyschromatosis symmetrica hereditaria,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,ORPHANET
41,Dyschromatosis symmetrica hereditaria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
41,Dyschromatosis symmetrica hereditaria,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Japan,Validated,12916015[PMID]
122,Birt-Hogg-Dubé syndrome,Malformation syndrome,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
38,Acrokeratoelastoidosis of Costa,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
39,Acromelanosis,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
39,Acromelanosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
316,Progressive symmetric erythrokeratodermia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
658,Non-histaminic angioedema,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
3282,Multifocal atrial tachycardia,Disease,Prevalence at birth,0.67,1-9 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET
3282,Multifocal atrial tachycardia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
188,Systemic capillary leak syndrome,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,[EXPERT]
188,Systemic capillary leak syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
303,Dystrophic epidermolysis bullosa,Clinical group,Point prevalence,0.572,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET
303,Dystrophic epidermolysis bullosa,Clinical group,Point prevalence,0.6,1-9 / 1 000 000,Value and class,Spain,Validated,23809583[PMID]
303,Dystrophic epidermolysis bullosa,Clinical group,Point prevalence,0.39,1-9 / 1 000 000,Value and class,Australia,Validated,20566927[PMID]
303,Dystrophic epidermolysis bullosa,Clinical group,Point prevalence,0.14,1-9 / 1 000 000,Value and class,United States,Validated,27463098[PMID]
303,Dystrophic epidermolysis bullosa,Clinical group,Point prevalence,0.28,1-9 / 1 000 000,Value and class,Romania,Validated,25201089[PMID]
303,Dystrophic epidermolysis bullosa,Clinical group,Point prevalence,0.83,1-9 / 1 000 000,Value and class,Netherlands,Validated,33095945[PMID]
303,Dystrophic epidermolysis bullosa,Clinical group,Annual incidence,1.41,1-9 / 100 000,Value and class,Netherlands,Validated,33095945[PMID]
305,Junctional epidermolysis bullosa,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
305,Junctional epidermolysis bullosa,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
305,Junctional epidermolysis bullosa,Clinical group,Point prevalence,0.08,<1 / 1 000 000,Value and class,Sweden,Validated,ISBN:443048517[OTHER]
305,Junctional epidermolysis bullosa,Clinical group,Point prevalence,0.07,<1 / 1 000 000,Value and class,Ireland,Validated,1419751[PMID]
305,Junctional epidermolysis bullosa,Clinical group,Point prevalence,0.02,<1 / 1 000 000,Value and class,Finland,Validated,6203284[PMID]
305,Junctional epidermolysis bullosa,Clinical group,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Italy,Validated,[EXPERT]
305,Junctional epidermolysis bullosa,Clinical group,Point prevalence,0.07,<1 / 1 000 000,Value and class,Australia,Validated,20566927[PMID]
305,Junctional epidermolysis bullosa,Clinical group,Point prevalence,0.02,<1 / 1 000 000,Value and class,Japan,Validated,2601109[PMID]
305,Junctional epidermolysis bullosa,Clinical group,Prevalence at birth,0.22,1-9 / 1 000 000,Value and class,United States,Validated,ISBN:801860245[OTHER]
305,Junctional epidermolysis bullosa,Clinical group,Point prevalence,0.04,<1 / 1 000 000,Value and class,United States,Validated,ISBN:801860245[OTHER]
305,Junctional epidermolysis bullosa,Clinical group,Point prevalence,0.07,<1 / 1 000 000,Value and class,South Africa,Validated,ISBN:951563203[OTHER]
305,Junctional epidermolysis bullosa,Clinical group,Annual incidence,0.93,1-9 / 1 000 000,Value and class,Netherlands,Validated,33095945[PMID]
305,Junctional epidermolysis bullosa,Clinical group,Point prevalence,0.21,1-9 / 1 000 000,Value and class,Netherlands,Validated,33095945[PMID]
3406,Ulerythema ophryogenesis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
2908,Kindler epidermolysis bullosa,Disease,Cases/families,250.0,,Case(s),Worldwide,Validated,26937547[PMID]
2908,Kindler epidermolysis bullosa,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26937547[PMID]
81,Antisynthetase syndrome,Disease,Point prevalence,3.5,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
563,Peripartum cardiomyopathy,Disease,Prevalence at birth,30.0,1-5 / 10 000,Value and class,Worldwide,Not yet validated,10703781[PMID]
563,Peripartum cardiomyopathy,Disease,Prevalence at birth,36.0,1-5 / 10 000,Value and class,United States,Not yet validated,23090517[PMID]_10703781[PMID]_16765131[PMID]
563,Peripartum cardiomyopathy,Disease,Prevalence at birth,89.0,6-9 / 10 000,Value and class,Singapore,Validated,23338912[PMID]
563,Peripartum cardiomyopathy,Disease,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Japan,Validated,21617320[PMID]
563,Peripartum cardiomyopathy,Disease,Prevalence at birth,334.0,>1 / 1000,Value and class,Haiti,Validated,16342653[PMID]
563,Peripartum cardiomyopathy,Disease,Prevalence at birth,100.0,>1 / 1000,Value and class,South Africa,Validated,16920474[PMID]
563,Peripartum cardiomyopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
764,Pyomyositis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
779,Reynolds syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
838,Susac syndrome,Disease,Cases/families,304.0,,Case(s),Worldwide,Validated,23628737[PMID]
838,Susac syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
889,Cutaneous small vessel vasculitis,Disease,Point prevalence,2.7,1-9 / 100 000,Value and class,Norway,Validated,9805179[PMID]
889,Cutaneous small vessel vasculitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
482,Kimura disease,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,18808562[PMID]
482,Kimura disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
486811,Prenatal-onset spinal muscular atrophy with congenital bone fractures,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26924529[PMID]_28218388[PMID]
486811,Prenatal-onset spinal muscular atrophy with congenital bone fractures,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,26924529[PMID]_28218388[PMID]
486815,Congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,27008887[PMID]
486815,Congenital muscular dystrophy-respiratory failure-skin abnormalities-joint hyperlaxity syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27008887[PMID]
485418,EMILIN-1-related connective tissue disease,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,26462740[PMID]
485418,EMILIN-1-related connective tissue disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26462740[PMID]
485421,MFF-related encephalopathy due to mitochondrial and peroxisomal fission defect,Etiological subtype,Cases/families,4.0,,Case(s),Worldwide,Validated,26783368[PMID]
485421,MFF-related encephalopathy due to mitochondrial and peroxisomal fission defect,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26783368[PMID]
485405,16p12.1p12.3 triplication syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,26647099[PMID]
485405,16p12.1p12.3 triplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26647099[PMID]
485350,CLCN4-related X-linked intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27550844[PMID]
485350,CLCN4-related X-linked intellectual disability syndrome,Disease,Cases/families,38.0,,Case(s),Worldwide,Validated,27550844[PMID]
485358,Propylthiouracil embryofetopathy,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET_25974033[PMID]
482606,X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome,Malformation syndrome,Cases/families,15.0,,Case(s),Worldwide,Validated,26804200[PMID]_26686323[PMID]
482606,X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26804200[PMID]_26686323[PMID]
482601,Adenylosuccinate synthetase-like 1-related distal myopathy,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,26506222[PMID]_27868399[PMID]_28268051[PMID]
482601,Adenylosuccinate synthetase-like 1-related distal myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26506222[PMID]_27868399[PMID]_28268051[PMID]
31828,Digitalis poisoning,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
480864,Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,26805781[PMID]_26805782[PMID]
480864,Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26805781[PMID]_26805782[PMID]
31837,Pulmonary venoocclusive disease,Disease,Annual incidence,0.015,<1 / 1 000 000,Value and class,France,Validated,21510732[PMID]_16456139[PMID]
31837,Pulmonary venoocclusive disease,Disease,Annual incidence,0.015,<1 / 1 000 000,Value and class,Europe,Validated,16456139[PMID]_21510732[PMID]_ [EXPERT]
31837,Pulmonary venoocclusive disease,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
480907,X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,26637982[PMID]
480907,X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26637982[PMID]
480898,Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,26942288[PMID]
480898,Global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26942288[PMID]
480880,X-linked female restricted facial dysmorphism-short stature-choanal atresia-intellectual disability,Malformation syndrome,Cases/families,17.0,,Case(s),Worldwide,Validated,26833328[PMID]
480880,X-linked female restricted facial dysmorphism-short stature-choanal atresia-intellectual disability,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26833328[PMID]
31740,Hypersensitivity pneumonitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
480556,Isolated neonatal sclerosing cholangitis,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,27319779[PMID]_27469900[PMID]
480556,Isolated neonatal sclerosing cholangitis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27319779[PMID]_27469900[PMID]
31709,Infantile convulsions and choreoathetosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
31826,Ethylene glycol poisoning,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
480851,Hereditary thrombocytopenia with early-onset myelofibrosis,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,26936507[PMID]
480851,Hereditary thrombocytopenia with early-onset myelofibrosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26936507[PMID]
31827,Paraquat poisoning,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
31824,Colchicine poisoning,Particular clinical situation in a disease or syndrome,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2011[INST]
480682,POGLUT1-related limb-girdle muscular dystrophy R21,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,27807076[PMID]
480682,POGLUT1-related limb-girdle muscular dystrophy R21,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27807076[PMID]
31825,Methanol poisoning,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
481665,USP18 deficiency,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,27821552[PMID]_2732588[PMID]
481665,USP18 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27821552[PMID]_2732588[PMID]
482077,HTRA1-related autosomal dominant cerebral small vessel disease,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,26063658[PMID]
482077,HTRA1-related autosomal dominant cerebral small vessel disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26063658[PMID]
481152,PYCR2-related microcephaly-progressive leukoencephalopathy,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,25865492[PMID]_27130255[PMID]
481152,PYCR2-related microcephaly-progressive leukoencephalopathy,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25865492[PMID]_27130255[PMID]
481662,Familial Chilblain lupus,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,27566796[PMID]
481662,Familial Chilblain lupus,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27566796[PMID]
480476,Progressive familial intrahepatic cholestasis type 5,Clinical subtype,Cases/families,4.0,,Case(s),Worldwide,Validated,26888176[PMID]
480476,Progressive familial intrahepatic cholestasis type 5,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26888176[PMID]
480491,MYO5B-related progressive familial intrahepatic cholestasis,Clinical subtype,Cases/families,5.0,,Case(s),Worldwide,Validated,27532546[PMID]
480491,MYO5B-related progressive familial intrahepatic cholestasis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27532546[PMID]
480483,Progressive familial intrahepatic cholestasis type 4,Clinical subtype,Cases/families,14.0,,Case(s),Worldwide,Validated,26983395[PMID]_24614073[PMID]
480483,Progressive familial intrahepatic cholestasis type 4,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26983395[PMID]_24614073[PMID]
480528,Lethal hydranencephaly-diaphragmatic hernia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27417437[PMID]
480528,Lethal hydranencephaly-diaphragmatic hernia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,27417437[PMID]
480536,MSH3-related attenuated familial adenomatous polyposis,Clinical subtype,Cases/families,4.0,,Case(s),Worldwide,Validated,27476653[PMID]
480536,MSH3-related attenuated familial adenomatous polyposis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27476653[PMID]
480520,Caroli syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_17461493[PMID]
477814,Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,24781755[PMID]_26463574[PMID]
477814,Progressive microcephaly-seizures-cortical blindness-developmental delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24781755[PMID]_26463574[PMID]
477781,Primary condylar hyperplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26629479[PMID]
477787,Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,25102815[PMID]_18451993[PMID]
477787,Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25102815[PMID]_18451993[PMID]
478029,Combined oxidative phosphorylation defect type 29,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,26626369[PMID]
478029,Combined oxidative phosphorylation defect type 29,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26626369[PMID]
478042,Combined oxidative phosphorylation defect type 30,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,27132592[PMID]
478042,Combined oxidative phosphorylation defect type 30,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27132592[PMID]
477993,Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,24838796[PMID]_26656649[PMID]
477993,Palatal anomalies-widely spaced teeth-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24838796[PMID]_26656649[PMID]
477857,Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,26160376[PMID]
477857,Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26160376[PMID]
477817,PMP22-RAI1 contiguous gene duplication syndrome,Malformation syndrome,Cases/families,23.0,,Case(s),Worldwide,Validated,26544804[PMID]
477817,PMP22-RAI1 contiguous gene duplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26544804[PMID]
477831,Kosaki overgrowth syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,25454926[PMID]_26455322[PMID]
477831,Kosaki overgrowth syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25454926[PMID]_26455322
478049,Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,27799064[PMID]_25778941[PMID]
478049,Lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27799064[PMID]_25778941[PMID]
478664,Hereditary sensory and autonomic neuropathy type 8,Disease,Cases/families,11.0,,Family(ies),Worldwide,Validated,26005867[PMID]_26975306[PMID]_28050684[PMID]
478664,Hereditary sensory and autonomic neuropathy type 8,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26005867[PMID]_26975306[PMID]_28050684[PMID]
477650,Fibroblastic rheumatism,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,25545215[PMID]
477650,Fibroblastic rheumatism,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25545215[PMID]
477661,IL21-related infantile inflammatory bowel disease,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,19890111[PMID]_24746753[PMID]
477661,IL21-related infantile inflammatory bowel disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19890111[PMID]_24746753[PMID]
477684,Combined oxidative phosphorylation defect type 26,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,26189817[PMID]_2544623[PMID]
477684,Combined oxidative phosphorylation defect type 26,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26189817[PMID]_2544623[PMID]
477673,Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,25758935[PMID]_27601654[PMID]
477673,Postnatal microcephaly-infantile hypotonia-spastic diplegia-dysarthria-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25758935[PMID]_27601654[PMID]
477749,Pontine autosomal dominant microangiopathy with leukoencephalopathy,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,19187480[PMID]_27666438[PMID]
477749,Pontine autosomal dominant microangiopathy with leukoencephalopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19187480[PMID]_27666438[PMID]
477742,Nodular fasciitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
477774,Combined oxidative phosphorylation defect type 27,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,25361775[PMID]_25787132[PMID]
477774,Combined oxidative phosphorylation defect type 27,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25361775[PMID]_25787132[PMID]
476119,Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,25782671[PMID]
476119,Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25782671[PMID]
476113,Combined immunodeficiency due to TFRC deficiency,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,26642240[PMID]
476113,Combined immunodeficiency due to TFRC deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26642240[PMID]
476126,Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,26721934[PMID]
476126,Micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26721934[PMID]
476406,Congenital generalized hypercontractile muscle stiffness syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,26418456[PMID]
476406,Congenital generalized hypercontractile muscle stiffness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26418456[PMID]
476394,PMP2-related Charcot-Marie-Tooth disease type 1,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,26828946[PMID]
476394,PMP2-related Charcot-Marie-Tooth disease type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26828946[PMID]
493342,Vibratory urticaria,Disease,Cases/families,37.0,,Case(s),Worldwide,Validated,26841242[PMID]
493342,Vibratory urticaria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26841242[PMID]
488642,TELO2-related intellectual disability-neurodevelopmental disorder,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,27132593[PMID]
488642,TELO2-related intellectual disability-neurodevelopmental disorder,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27132593[PMID]
488647,DDX41-related hematologic malignancy predisposition syndrome,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,26712909[PMID]
488647,DDX41-related hematologic malignancy predisposition syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26712909[PMID]
488650,"Distal myopathy, Tateyama type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11805270[PMID]_15580566[PMID]_18930476[PMID]
488650,"Distal myopathy, Tateyama type",Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,11805270[PMID]_15580566[PMID]_18930476[PMID]
488618,Transketolase deficiency,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,27259054[PMID]
488618,Transketolase deficiency,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27259054[PMID]
488627,Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,27055666[PMID]
488627,Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27055666[PMID]
488632,TBCK-related intellectual disability syndrome,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,27748029[PMID]
488632,TBCK-related intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27748029[PMID]
488635,Early-onset epilepsy-intellectual disability-brain anomalies syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,26996948[PMID]
488635,Early-onset epilepsy-intellectual disability-brain anomalies syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26996948[PMID]
488239,Acute macular neuroretinopathy,Disease,Cases/families,101.0,,Case(s),Worldwide,Validated,26973287[PMID]
488239,Acute macular neuroretinopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26973287[PMID]
488232,Split-foot malformation-mesoaxial polydactyly syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,26755636[PMID]
488232,Split-foot malformation-mesoaxial polydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26755636[PMID]
488333,Autosomal dominant Charcot-Marie-Tooth disease type 2W,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,26072516[PMID]
488333,Autosomal dominant Charcot-Marie-Tooth disease type 2W,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26072516[PMID]
488280,14q32 duplication syndrome,Disease,Cases/families,33.0,,Case(s),Worldwide,Validated,26280900[PMID]
488280,14q32 duplication syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26280900[PMID]
488437,SIX2-related frontonasal dysplasia,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,26581443[PMID]
488437,SIX2-related frontonasal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26581443[PMID]
488434,"Camptodactyly syndrome, Guadalajara type 3",Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,12401988[PMID]
488434,"Camptodactyly syndrome, Guadalajara type 3",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12401988[PMID]
488613,Global developmental delay-neuro-ophthalmological abnormalities-seizures-intellectual disability syndrome,Malformation syndrome,Cases/families,26.0,,Case(s),Worldwide,Validated,28087732[PMID]
488613,Global developmental delay-neuro-ophthalmological abnormalities-seizures-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28087732[PMID]
488594,Autosomal recessive spastic paraplegia type 76,Disease,Cases/families,7.0,,Family(ies),Worldwide,Validated,27153400[PMID]_27320912[PMID]
488594,Autosomal recessive spastic paraplegia type 76,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27153400[PMID]_27320912[PMID]
488197,Familial progressive retinal dystrophy-iris coloboma-congenital cataract syndrome,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,26056285[PMID]
488197,Familial progressive retinal dystrophy-iris coloboma-congenital cataract syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26056285[PMID]
488168,Microcephaly-congenital cataract-psoriasiform dermatitis syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,28673550[PMID]
488168,Microcephaly-congenital cataract-psoriasiform dermatitis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28673550[PMID]
488191,Female infertility due to oocyte meiotic arrest,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,27273344[PMID]
488191,Female infertility due to oocyte meiotic arrest,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27273344[PMID]
487796,Takenouchi-Kosaki syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,26708094[PMID]
487796,Takenouchi-Kosaki syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26708094[PMID]
487814,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to DGAT2 mutation,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,26786738[PMID]
487814,Autosomal dominant Charcot-Marie-Tooth disease type 2 due to DGAT2 mutation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26786738[PMID]
487809,Pediatric collagenous gastritis,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,23538318[PMID]_25789098[PMID]
487809,Pediatric collagenous gastritis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25789098[PMID]
487825,Pierpont syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,28562391[PMID]
487825,Pierpont syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28562391[PMID]
31205,Rat-bite fever,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
31204,Nocardiosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
31202,Melioidosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
31202,Melioidosis,Disease,Annual incidence,50.0,1-5 / 10 000,Value and class,Australia,Validated,22970946[PMID]
31202,Melioidosis,Disease,Annual incidence,50.0,1-5 / 10 000,Value and class,Thailand,Validated,22970946[PMID]
31150,Tangier disease,Disease,Cases/families,185.0,,Case(s),Worldwide,Validated,27565770[PMID]
31150,Tangier disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22913675[PMID]
31043,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis without severe ocular involvement,Clinical subtype,Cases/families,110.0,,Case(s),Worldwide,Validated,ORPHANET
31043,Primary hypomagnesemia with hypercalciuria and nephrocalcinosis without severe ocular involvement,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
31112,Dermatofibrosarcoma protuberans,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]_European Medicines Agency[INST]
30924,Primary hypomagnesemia with secondary hypocalcemia,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
30924,Primary hypomagnesemia with secondary hypocalcemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
30925,Hereditary arginine vasopressin deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
476084,BVES-related limb-girdle muscular dystrophy,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,26642364[PMID]
476084,BVES-related limb-girdle muscular dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26642364[PMID]
476096,Erythrokeratodermia-cardiomyopathy syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,26604139[PMID]_27408699[PMID]
476096,Erythrokeratodermia-cardiomyopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26604139[PMID]_27408699[PMID]
476093,Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,26718575[PMID]
476093,Autosomal dominant distal axonal motor neuropathy-myofibrillar myopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26718575[PMID]
71278,Congenital brain dysgenesis due to glutamine synthetase deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,21353613[PMID]
71278,Congenital brain dysgenesis due to glutamine synthetase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21353613[PMID]
71279,CANOMAD syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
71279,CANOMAD syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
71271,Split hand-split foot-deafness syndrome,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,ORPHANET
71271,Split hand-split foot-deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
71272,Sandifer syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
71273,Renal nutcracker syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
71274,Disseminated peritoneal leiomyomatosis,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,[EXPERT]
71274,Disseminated peritoneal leiomyomatosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
71275,Rh deficiency syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
71276,Silent sinus syndrome,Disease,Cases/families,558.0,,Case(s),Worldwide,Validated,37219052[PMID]
71276,Silent sinus syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,37219052[PMID]_ORPHANET
71277,Classic glucose transporter type 1 deficiency syndrome,Disease,Point prevalence,0.26,1-9 / 1 000 000,Value and class,Norway,Validated,32913944[PMID]
71277,Classic glucose transporter type 1 deficiency syndrome,Disease,Point prevalence,1.11,1-9 / 100 000,Value and class,Australia,Validated,16712556[PMID]
71277,Classic glucose transporter type 1 deficiency syndrome,Disease,Point prevalence,0.538,1-9 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET_32913944[PMID]
71277,Classic glucose transporter type 1 deficiency syndrome,Disease,Point prevalence,1.2,1-9 / 100 000,Value and class,Denmark,Validated,26537434[PMID]
71212,Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
71212,Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.73,1-9 / 1 000 000,Value and class,Martinique,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.054,<1 / 1 000 000,Value and class,Austria,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.1877,1-9 / 1 000 000,Value and class,Worldwide,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,2.071,1-9 / 100 000,Value and class,Worldwide,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,0.7,1-9 / 1 000 000,Value and class,Austria,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.08,<1 / 1 000 000,Value and class,United Kingdom,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,1.43,1-9 / 100 000,Value and class,United Kingdom,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,Netherlands,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.063,<1 / 1 000 000,Value and class,Spain,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,0.89,1-9 / 1 000 000,Value and class,Spain,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,Denmark,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,1.09,1-9 / 100 000,Value and class,Denmark,Validated,33310876[PMID]
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.079,<1 / 1 000 000,Value and class,Sweden,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,1.04,1-9 / 100 000,Value and class,Sweden,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.132,1-9 / 1 000 000,Value and class,Hungary,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,1.91,1-9 / 100 000,Value and class,Hungary,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,Australia,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,0.7,1-9 / 1 000 000,Value and class,Australia,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,United States,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,3.9,1-9 / 100 000,Value and class,United States,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.495,1-9 / 1 000 000,Value and class,India,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.495,1-9 / 1 000 000,Value and class,Canada,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,2.6,1-9 / 100 000,Value and class,India,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,3.42,1-9 / 100 000,Value and class,Japan,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.39,1-9 / 1 000 000,Value and class,Malaysia,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,1.94,1-9 / 100 000,Value and class,Malaysia,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,1.51,1-9 / 100 000,Value and class,"Iran, Islamic Republic of",Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.053,<1 / 1 000 000,Value and class,Cuba,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,0.52,1-9 / 1 000 000,Value and class,Cuba,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Martinique,Validated,PMID: 33310876
71211,Neuromyelitis optica spectrum disorder,Disease,Annual incidence,0.285,1-9 / 1 000 000,Value and class,Costa rica,Validated,PMID: 33310876
71267,Dentinogenesis imperfecta-short stature-hearing loss-intellectual disability syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,16011615[PMID]
71267,Dentinogenesis imperfecta-short stature-hearing loss-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16011615[PMID]
71213,Retinal capillary malformation,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
71198,Rare pulmonary hypertension,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25385937[PMID]
558411,Idiopathic gastroparesis,Disease,Point prevalence,11.4,1-5 / 10 000,Value and class,Specific population,Validated,ORPHANET_30396519[PMID]
70591,Chronic thromboembolic pulmonary hypertension,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,EXPERT
70591,Chronic thromboembolic pulmonary hypertension,Disease,Annual incidence,4.2,1-9 / 100 000,Value and class,Europe,Validated,28356407[PMID]
70591,Chronic thromboembolic pulmonary hypertension,Disease,Annual incidence,5.1,1-9 / 100 000,Value and class,United States,Validated,28356407[PMID]
70591,Chronic thromboembolic pulmonary hypertension,Disease,Annual incidence,1.9,1-9 / 100 000,Value and class,Japan,Validated,28356407[PMID]
70592,Transient predisposition to invasive pyogenic bacterial infection,Disease,Cases/families,49.0,,Case(s),Worldwide,Validated,21734245[PMID]
70592,Transient predisposition to invasive pyogenic bacterial infection,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21734245[PMID]
70589,Bronchopulmonary dysplasia,Malformation syndrome,Point prevalence,13.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
70595,Sensory ataxic neuropathy-dysarthria-ophthalmoparesis syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
70596,Congenital Epstein-Barr virus infection,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
70593,Immunodeficiency due to selective anti-polysaccharide antibody deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_28588580[PMID]
70594,Dopa-responsive dystonia due to sepiapterin reductase deficiency,Disease,Cases/families,43.0,,Case(s),Worldwide,Validated,22522443[PMID]
70594,Dopa-responsive dystonia due to sepiapterin reductase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
70578,Adult acute respiratory distress syndrome,Disease,Annual incidence,64.0,6-9 / 10 000,Value and class,United States,Validated,16236739[PMID]
70578,Adult acute respiratory distress syndrome,Disease,Point prevalence,51.0,1-5 / 10 000,Value and class,United States,Not yet validated,ORPHANET
70578,Adult acute respiratory distress syndrome,Disease,Annual incidence,11.5,1-5 / 10 000,Value and class,Iceland,Not yet validated,23216361[PMID]_10351930[PMID]_ ORPHANET
70578,Adult acute respiratory distress syndrome,Disease,Annual incidence,7.2,1-9 / 100 000,Value and class,Spain,Validated,21997128[PMID]
70578,Adult acute respiratory distress syndrome,Disease,Annual incidence,4.9,1-9 / 100 000,Value and class,Finland,Validated,10579250[PMID]
70578,Adult acute respiratory distress syndrome,Disease,Annual incidence,13.5,1-5 / 10 000,Value and class,Sweden,Validated,10351930[PMID]
70578,Adult acute respiratory distress syndrome,Disease,Annual incidence,13.5,1-5 / 10 000,Value and class,Denmark,Validated,10351930[PMID]
70578,Adult acute respiratory distress syndrome,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,European Medicines Agency 2008[INST]
70573,Small cell lung cancer,Disease,Point prevalence,12.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
70568,Post-transplant lymphoproliferative disease,Disease,Point prevalence,26.2,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
70588,Meconium aspiration syndrome,Disease,Point prevalence,2.44,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
70472,"Congenital lactic acidosis, Saguenay-Lac-Saint-Jean type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
70567,Cholangiocarcinoma,Disease,Annual incidence,4.2,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]_emedicine 2011[OTHER]
70567,Cholangiocarcinoma,Disease,Point prevalence,2.1,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
70567,Cholangiocarcinoma,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,United States,Validated,15765398[PMID]_19245868[PMID]_24140396[PMID]
70567,Cholangiocarcinoma,Disease,Annual incidence,113.0,>1 / 1000,Value and class,Thailand,Validated,18408464[PMID]
70567,Cholangiocarcinoma,Disease,Annual incidence,5.5,1-9 / 100 000,Value and class,Japan,Not yet validated,emedicine 2011[OTHER]
70567,Cholangiocarcinoma,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Australia,Validated,15192785[PMID]
70567,Cholangiocarcinoma,Disease,Annual incidence,4.0,1-9 / 100 000,Value and class,Europe,Not yet validated,emedicine 2011[OTHER]_22895392[PMID]
70567,Cholangiocarcinoma,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,European Medicines Agency 2004[INST]_22173164[PMID]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,7.0,1-9 / 100 000,Value and class,Worldwide,Validated,World Health Organization 2008[INST]
70482,Carcinoma of esophagus,Clinical group,Point prevalence,7.1,1-9 / 100 000,Value and class,Europe,Validated,World Health Organization 2008[INST]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,6.67,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Lifetime Prevalence,12.2,1-5 / 10 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]_[EXPERT]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,5.5,1-9 / 100 000,Value and class,United States,Validated,National Cancer Institute 2012[INST]
70482,Carcinoma of esophagus,Clinical group,Point prevalence,9.8,1-9 / 100 000,Value and class,Worldwide,Validated,World Health Organization 2008[INST]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,6.873,1-9 / 100 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,10.82,1-5 / 10 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.9,1-9 / 100 000,Value and class,India,Validated,World Health Organization 2008[INST]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,20.0,1-5 / 10 000,Value and class,China,Validated,World Health Organization 2008[INST]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,2.3,1-9 / 100 000,Value and class,Africa,Validated,World Health Organization 2008[INST]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,9.0,1-9 / 100 000,Value and class,Japan,Validated,ISBN:443075956[OTHER]_14530066[PMID]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.9,1-9 / 100 000,Value and class,Canada,Not yet validated,23061066[PMID]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,8.0,1-9 / 100 000,Value and class,Russian Federation,Validated,ISBN:443075956[OTHER]_14530066[PMID]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,13.0,1-5 / 10 000,Value and class,Latin America,Validated,ISBN:443075956[OTHER]_14530066[PMID]
70482,Carcinoma of esophagus,Clinical group,Point prevalence,0.34,1-9 / 1 000 000,Value and class,"Iran, Islamic Republic of",Validated,23120941[PMID]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.293,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,7.892,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,1.194,1-9 / 100 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.281,1-9 / 100 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.718,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.473,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.83,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,5.854,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,4.772,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,7.2,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.612,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.372,1-9 / 100 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.468,1-9 / 100 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,2.575,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.592,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,2.414,1-9 / 100 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,4.592,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,4.54,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,3.904,1-9 / 100 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,4.777,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,6.413,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70482,Carcinoma of esophagus,Clinical group,Annual incidence,8.362,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
70476,Vernal keratoconjunctivitis,Disease,Point prevalence,151.0,>1 / 1000,Value and class,Italy,Validated,18356259[PMID]
70476,Vernal keratoconjunctivitis,Disease,Point prevalence,45.5,1-5 / 10 000,Value and class,Finland,Validated,18356259[PMID]
70476,Vernal keratoconjunctivitis,Disease,Point prevalence,49.5,1-5 / 10 000,Value and class,Sweden,Validated,18356259[PMID]
70476,Vernal keratoconjunctivitis,Disease,Point prevalence,26.0,1-5 / 10 000,Value and class,Netherlands,Validated,18356259[PMID]
70476,Vernal keratoconjunctivitis,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,France,Validated,18356259[PMID]
70476,Vernal keratoconjunctivitis,Disease,Point prevalence,11.0,1-5 / 10 000,Value and class,Norway,Validated,18356259[PMID]
70476,Vernal keratoconjunctivitis,Disease,Point prevalence,32.0,1-5 / 10 000,Value and class,Europe,Not yet validated,18356259[PMID]
70475,Radiation proctitis,Disease,Point prevalence,35.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
69744,Circumscribed palmoplantar hypokeratosis,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,16700830[PMID]
69744,Circumscribed palmoplantar hypokeratosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
69745,Warty dyskeratoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
69735,Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,ORPHANET_12740761[PMID]
69735,Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
69736,Bilateral acute depigmentation of the iris,Disease,Cases/families,62.0,,Case(s),Worldwide,Validated,23812527[PMID]
69736,Bilateral acute depigmentation of the iris,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23812527[PMID]
69737,Bosley-Salih-Alorainy syndrome,Malformation syndrome,Cases/families,16.0,,Case(s),Worldwide,Validated,16155570[PMID]_17875913[PMID]_18412118[PMID]
69737,Bosley-Salih-Alorainy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16155570[PMID]_17875913[PMID]_18412118[PMID]
69739,Athabaskan brainstem dysgenesis syndrome,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,12833395[PMID]_18412118[PMID]
69739,Athabaskan brainstem dysgenesis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12833395[PMID]_18412118[PMID]
69663,Low phospholipid-associated cholelithiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
69665,Intrahepatic cholestasis of pregnancy,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET_22892336[PMID]
69723,Tyrosinemia type 3,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
69723,Tyrosinemia type 3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
69126,PAPA syndrome,Disease,Cases/families,53.0,,Case(s),Worldwide,Validated,DOI:10.1007/978-3-319-96929-9_4[OTHER]
69126,PAPA syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_DOI:10.1007/978-3-319-96929-9_4[OTHER]
69087,Naegeli-Franceschetti-Jadassohn syndrome,Disease,Point prevalence,0.035,<1 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
69125,Anonychia with flexural pigmentation,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,1156563[PMID]
69125,Anonychia with flexural pigmentation,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1156563[PMID]
69088,Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,11242109[PMID]
69088,Anhidrotic ectodermal dysplasia-immunodeficiency-osteopetrosis-lymphedema syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11242109[PMID]
69083,"Ectodermal dysplasia with natal teeth, Turnpenny type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8574423[PMID]
69083,"Ectodermal dysplasia with natal teeth, Turnpenny type",Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,8574423[PMID]
69082,Odonto-tricho-ungual-digito-palmar syndrome,Malformation syndrome,Cases/families,21.0,,Case(s),Worldwide,Validated,9217212[PMID]
69082,Odonto-tricho-ungual-digito-palmar syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9217212[PMID]
69085,Limb-mammary syndrome,Malformation syndrome,Cases/families,38.0,,Case(s),Worldwide,Validated,Pr MANOUVRIER-HANU Sylvie[EXPERT]_26075610[PMID]_9973291[PMID]_20410354[PMID]
69085,Limb-mammary syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26075610[PMID]_9973291[PMID]_20410354[PMID]
69084,Pure hair and nail ectodermal dysplasia,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
69084,Pure hair and nail ectodermal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
69077,Rhabdoid tumor,Disease,Cases/families,500.0,,Case(s),Worldwide,Validated,ORPHANET
69077,Rhabdoid tumor,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
69077,Rhabdoid tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
69076,Familial renal glucosuria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
69078,Liposarcoma,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Europe,Validated,22517534[PMID]_[EXPERT]
69078,Liposarcoma,Disease,Annual incidence,0.59,1-9 / 1 000 000,Value and class,United States,Validated,17013893[PMID]
69078,Liposarcoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
69061,Idiopathic steroid-sensitive nephrotic syndrome,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
69063,Congenital membranous nephropathy due to fetomaternal anti-neutral endopeptidase alloimmunization,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,19154696[PMID]_15464186[PMID]
69063,Congenital membranous nephropathy due to fetomaternal anti-neutral endopeptidase alloimmunization,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
67048,3-methylglutaconic aciduria type 4,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
69028,Dysostosis with brachydactyly,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
67046,3-methylglutaconic aciduria type 1,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
67046,3-methylglutaconic aciduria type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
67047,3-methylglutaconic aciduria type 3,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
67044,Thrombocytopenia with congenital dyserythropoietic anemia,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,20301538[PMID]
67044,Thrombocytopenia with congenital dyserythropoietic anemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
67045,X-linked intellectual disability with isolated growth hormone deficiency,Clinical subtype,Cases/families,2.0,,Family(ies),Worldwide,Validated,9508246[PMID]_8826446[PMID]
67045,X-linked intellectual disability with isolated growth hormone deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9508246[PMID]_8826446[PMID]
67042,Late-onset retinal degeneration,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
67043,Amoebic keratitis,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
67039,Segmental odontomaxillary dysplasia,Disease,Cases/families,32.0,,Case(s),Worldwide,Validated,ORPHANET
67039,Segmental odontomaxillary dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
67041,Hyaluronidase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
67038,B-cell chronic lymphocytic leukemia,Disease,Point prevalence,48.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
67038,B-cell chronic lymphocytic leukemia,Disease,Annual incidence,7.05,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
67036,Autosomal dominant optic atrophy and cataract,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,22797356[PMID]
67036,Autosomal dominant optic atrophy and cataract,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22797356[PMID]
66646,Cutaneous mastocytosis,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
66637,Diaphanospondylodysostosis,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,26467725[PMID]_21990102[PMID]_22581610[PMID]
66637,Diaphanospondylodysostosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26467725[PMID]_21990102[PMID]_22581610[PMID]
66634,Dilated cardiomyopathy with ataxia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
66633,Sensorineural hearing loss-early graying-essential tremor syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,16025060[PMID]
66633,Sensorineural hearing loss-early graying-essential tremor syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16025060[PMID]
66631,CEDNIK syndrome,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,25958742[PMID]
66631,CEDNIK syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
66630,Congenital pseudoarthrosis of the clavicle,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
66630,Congenital pseudoarthrosis of the clavicle,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
66629,Goldberg-Shprintzen megacolon syndrome,Malformation syndrome,Cases/families,24.0,,Case(s),Worldwide,Validated,[EXPERT]_28277559[PMID]_23427148[PMID]
66629,Goldberg-Shprintzen megacolon syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
66628,Obesity due to congenital leptin deficiency,Etiological subtype,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
66628,Obesity due to congenital leptin deficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
66627,Tenosynovial giant cell tumor,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
66625,Cerebrooculonasal syndrome,Malformation syndrome,Cases/families,21.0,,Case(s),Worldwide,Validated,19206156[PMID]
66625,Cerebrooculonasal syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19206156[PMID]
66624,PANDAS,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
66529,Tako-Tsubo cardiomyopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
66529,Tako-Tsubo cardiomyopathy,Disease,Annual incidence,2.98,1-9 / 100 000,Value and class,France,Validated,23623669[PMID]
66518,Short fifth metacarpals-insulin resistance syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,16132981[PMID]_12786688[PMID]
66518,Short fifth metacarpals-insulin resistance syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
65283,Timothy syndrome,Malformation syndrome,Cases/families,56.0,,Case(s),Worldwide,Validated,33987151[PMID]_34079780[PMID]_34844894[PMID]_36336572[PMID]_36347939[PMID]
65283,Timothy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
65282,Carvajal syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,22795705[PMID]_20940358[PMID]_16628197[PMID]
65282,Carvajal syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22795705[PMID]_20940358[PMID]_16628197[PMID]
562639,Primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
65285,Lhermitte-Duclos disease,Disease,Cases/families,220.0,,Case(s),Worldwide,Validated,16459996[PMID]
65285,Lhermitte-Duclos disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
65287,Beta-ureidopropionase deficiency,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,17964839[PMID]
65287,Beta-ureidopropionase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17964839[PMID]
65286,3q29 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
65681,Vaginal atresia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
65288,Permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,24212882[PMID]
65288,Permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
65683,Isolated focal cortical dysplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24649472[PMID]
65682,Benign recurrent intrahepatic cholestasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
65720,Arthrogryposis-severe scoliosis syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,3565478[PMID]_7039311[PMID]
65720,Arthrogryposis-severe scoliosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3565478[PMID]_7039311[PMID]
65684,Monomelic amyotrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
65748,Multiple self-healing squamous epithelioma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24747516[PMID]
65748,Multiple self-healing squamous epithelioma,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,24747516[PMID]
65743,Autosomal dominant multiple pterygium syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,2831369[PMID]
65743,Autosomal dominant multiple pterygium syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
65759,Carpenter syndrome,Malformation syndrome,Cases/families,70.0,,Case(s),Worldwide,Validated,23063620[PMID]
65759,Carpenter syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
65753,Charcot-Marie-Tooth disease type 1,Clinical group,Point prevalence,17.5,1-5 / 10 000,Value and class,Worldwide,Validated,20301384[PMID]
64744,IgG4-related thyroid disease,Clinical subtype,Annual incidence,1.06,1-9 / 100 000,Value and class,United States,Validated,3906289[PMID]_21832114[PMID]
64744,IgG4-related thyroid disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
64745,Pruritic urticarial papules and plaques of pregnancy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27960565[PMID]
64746,Autosomal dominant Charcot-Marie-Tooth disease type 2,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
64747,X-linked Charcot-Marie-Tooth disease,Clinical group,Point prevalence,1.6,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
64748,Dejerine-Sottas syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12090401[PMID]
64749,Charcot-Marie-Tooth disease type 4,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,ORPHANET
562509,Heme oxygenase-1 deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,9884342[PMID]_21088618[PMID]_22023467[PMID]
562509,Heme oxygenase-1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22023467[PMID]
64752,Hereditary sensory and autonomic neuropathy type 5,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
64752,Hereditary sensory and autonomic neuropathy type 5,Disease,Point prevalence,0.035,<1 / 1 000 000,Value and class,Japan,Not yet validated,23495212[PMID]
64753,Spinocerebellar ataxia with axonal neuropathy type 2,Disease,Point prevalence,0.11,1-9 / 1 000 000,Value and class,France,Validated,19440741[PMID]
64754,Nevus comedonicus syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_23888253[PMID]
562528,Congenital limbs-face contractures-hypotonia-developmental delay syndrome,Malformation syndrome,Cases/families,14.0,,Case(s),Worldwide,Validated,25683120[PMID]
562528,Congenital limbs-face contractures-hypotonia-developmental delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25683120[PMID]_28133733[PMID]
64755,Becker nevus syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26265883[PMID]
562559,Anterior maxillary protrusion-strabismus-intellectual disability syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,17618476[PMID]_21035105[PMID]
562559,Anterior maxillary protrusion-strabismus-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17618476[PMID]_21035105[PMID]
562569,TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,30526868[PMID]
562569,TMEM94-associated congenital heart defect-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30526868[PMID]
64542,"Acrofacial dysostosis, Kennedy-Teebi type",Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,15266620[PMID]
64542,"Acrofacial dysostosis, Kennedy-Teebi type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15266620[PMID]
64280,Childhood absence epilepsy,Disease,Annual incidence,5.0,1-9 / 100 000,Value and class,United States,Validated,24668022[PMID]
64280,Childhood absence epilepsy,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
64720,Leiomyosarcoma,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,[WHO Classification of Tumours]
64720,Leiomyosarcoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[WHO Classification of Tumours]
64739,Ovarian hyperstimulation syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
64734,Iridocorneal endothelial syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
64743,Hepatoportal sclerosis,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
64742,Pleuropulmonary blastoma,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
64742,Pleuropulmonary blastoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
64741,Pulmonary blastoma,Disease,Cases/families,350.0,,Case(s),Worldwide,Validated,[EXPERT]
64741,Pulmonary blastoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
64741,Pulmonary blastoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
64741,Pulmonary blastoma,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
64741,Pulmonary blastoma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
64741,Pulmonary blastoma,Disease,Annual incidence,0.001,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
64741,Pulmonary blastoma,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
64741,Pulmonary blastoma,Disease,Annual incidence,0.002,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
63259,Iniencephaly,Morphological anomaly,Prevalence at birth,50.0,1-5 / 10 000,Value and class,Europe,Validated,ORPHANET
63259,Iniencephaly,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
63442,Angel-shaped phalango-epiphyseal dysplasia,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,15173244[PMID]
63442,Angel-shaped phalango-epiphyseal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
63273,Distal myopathy with posterior leg and anterior hand involvement,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,15824355[PMID]_21620354[PMID]
63273,Distal myopathy with posterior leg and anterior hand involvement,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15824355[PMID]_21620354[PMID]
63275,Pemphigoid gestationis,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,Germany,Validated,19170813[PMID]
63275,Pemphigoid gestationis,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,France,Validated,7826096[PMID]_23237497[PMID]
63275,Pemphigoid gestationis,Disease,Annual incidence,0.18,1-9 / 1 000 000,Value and class,Kuwait,Validated,15569006[PMID]
63275,Pemphigoid gestationis,Disease,Point prevalence,0.693,1-9 / 1 000 000,Value and class,Germany,Validated,27456755[PMID]
63454,Pattern dystrophy,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
63455,Paraneoplastic pemphigus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,31536300[PMID]
63443,Rare epithelial tumor of stomach,Category,Annual incidence,18.6,1-5 / 10 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
63443,Rare epithelial tumor of stomach,Category,Lifetime Prevalence,49.17,1-5 / 10 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
63443,Rare epithelial tumor of stomach,Category,Annual incidence,7.5,1-9 / 100 000,Value and class,United States,Validated,National Cancer Institute 2010[INST]
63443,Rare epithelial tumor of stomach,Category,Point prevalence,24.0,1-5 / 10 000,Value and class,United States,Validated,National Cancer Institute 2010[INST]
63443,Rare epithelial tumor of stomach,Category,Annual incidence,11.2,1-5 / 10 000,Value and class,United Kingdom,Validated,National Cancer Intelligence Network 2006[OTHER]
63443,Rare epithelial tumor of stomach,Category,Point prevalence,3.9,1-9 / 100 000,Value and class,United Kingdom,Validated,National Cancer Intelligence Network 2006[OTHER]
63443,Rare epithelial tumor of stomach,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET
63446,Acrocapitofemoral dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
63862,Schisis association,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
60040,Megalencephaly-capillary malformation-polymicrogyria syndrome,Malformation syndrome,Cases/families,170.0,,Case(s),Worldwide,Validated,15712320[PMID]
60040,Megalencephaly-capillary malformation-polymicrogyria syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
60039,Pudendal nerve entrapment syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,20071246[PMID]
60039,Pudendal nerve entrapment syndrome,Disease,Point prevalence,16.67,1-5 / 10 000,Value and class,France,Validated,[EXPERT]
60041,Congenital heart block,Disease,Prevalence at birth,4.54,1-9 / 100 000,Value and class,Worldwide,Validated,4273004[PMID]
60041,Congenital heart block,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
60032,Recurrent respiratory papillomatosis,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Netherlands,Validated,EXPERT_ORPHANET
60032,Recurrent respiratory papillomatosis,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,Netherlands,Validated,EXPERT_ORPHANET
60032,Recurrent respiratory papillomatosis,Disease,Annual incidence,2.34,1-9 / 100 000,Value and class,United States,Validated,7488368[PMID]_20553527[PMID]
60032,Recurrent respiratory papillomatosis,Disease,Annual incidence,0.76,1-9 / 1 000 000,Value and class,Denmark,Validated,2350888[PMID]_20553527[PMID]
60032,Recurrent respiratory papillomatosis,Disease,Point prevalence,1.42,1-9 / 100 000,Value and class,United Kingdom,Validated,27208548[PMID]
60032,Recurrent respiratory papillomatosis,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_27208548[PMID]
60033,Idiopathic bronchiectasis,Disease,Annual incidence,1.8,1-9 / 100 000,Value and class,Finland,Validated,9787927[PMID]
60033,Idiopathic bronchiectasis,Disease,Prevalence at birth,29.0,1-5 / 10 000,Value and class,Finland,Validated,9787927[PMID]
59303,Neonatal ichthyosis-sclerosing cholangitis syndrome,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,22030598[PMID]
59303,Neonatal ichthyosis-sclerosing cholangitis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22030598[PMID]
59305,Gestational trophoblastic neoplasm,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
59305,Gestational trophoblastic neoplasm,Clinical group,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
59306,McLeod neuroacanthocytosis syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,22027213[PMID]
59306,McLeod neuroacanthocytosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
59298,Schilder disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
60015,Enlarged parietal foramina,Malformation syndrome,Point prevalence,4.3,1-9 / 100 000,Value and class,Europe,Validated,23543411[PMID]
60015,Enlarged parietal foramina,Malformation syndrome,Point prevalence,3.7,1-9 / 100 000,Value and class,Worldwide,Validated,23543411[PMID]
564003,Osteochondrosis of the metatarsal bone,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
60025,Pulmonary alveolar microlithiasis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
563991,Osteochondrosis of the tarsal bone,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
60026,Pulmonary nodular lymphoid hyperplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
564178,Primary hypomagnesemia-refractory seizures-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30388404[PMID]
564178,Primary hypomagnesemia-refractory seizures-intellectual disability syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,30388404[PMID]
60030,Loeys-Dietz syndrome,Malformation syndrome,Cases/families,52.0,,Family(ies),Worldwide,Validated,16928994[PMID]
60030,Loeys-Dietz syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_16928994[PMID
59315,Rhombencephalosynapsis,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,25816977[PMID]
59315,Rhombencephalosynapsis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25816977[PMID]
60014,Argyria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
57196,Medial condensing osteitis of the clavicle,Disease,Cases/families,58.0,,Case(s),Worldwide,Validated,27622150[PMID]
57196,Medial condensing osteitis of the clavicle,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27622150[PMID]
563690,Furuncular myiasis due to Cordylobia rodhaini,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29090455[PMID]
57145,SUNCT syndrome,Disease,Point prevalence,6.7,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
57145,SUNCT syndrome,Disease,Point prevalence,6.7,1-9 / 100 000,Value and class,Australia,Validated,18325769[PMID]
563684,Furuncular myiasis due to Dermatobia hominis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29090455[PMID]
563687,Furuncular myiasis due to Cordylobia anthropophaga,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29090455[PMID]
56970,Human prion disease,Category,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
56970,Human prion disease,Category,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
56425,Cold agglutinin disease,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
59181,Sorsby pseudoinflammatory fundus dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
59135,Laing distal myopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
58017,Classic hairy cell leukemia,Disease,Annual incidence,0.29,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
58017,Classic hairy cell leukemia,Disease,Lifetime Prevalence,3.12,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
58017,Classic hairy cell leukemia,Disease,Annual incidence,0.33,1-9 / 1 000 000,Value and class,United States,Validated,16150940[PMID]_National Cancer Institute[INST]
58017,Classic hairy cell leukemia,Disease,Annual incidence,0.29,1-9 / 1 000 000,Value and class,United Kingdom,Validated,7918034[PMID]
58017,Classic hairy cell leukemia,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,Israel,Not yet validated,17044834[PMID]
58017,Classic hairy cell leukemia,Disease,Annual incidence,0.47,1-9 / 1 000 000,Value and class,Iceland,Validated,12111650[PMID]
58017,Classic hairy cell leukemia,Disease,Annual incidence,0.035,<1 / 1 000 000,Value and class,Hong Kong,Validated,11135356[PMID]
58017,Classic hairy cell leukemia,Disease,Annual incidence,0.37,1-9 / 1 000 000,Value and class,Denmark,Validated,21122460[PMID]
58017,Classic hairy cell leukemia,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
57782,Mazabraud syndrome,Malformation syndrome,Cases/families,54.0,,Case(s),Worldwide,Validated,ORPHANET
57782,Mazabraud syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
55595,TNP03-related limb-girdle muscular dystrophy D2,Disease,Cases/families,64.0,,Case(s),Worldwide,Validated,23667635[PMID]
55595,TNP03-related limb-girdle muscular dystrophy D2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23667635[PMID]
55596,HNRNPDL-related limb-girdle muscular dystrophy D3,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,24647604[PMID]
55596,HNRNPDL-related limb-girdle muscular dystrophy D3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24647604[PMID]
54595,Craniopharyngioma,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,17825241[PMID]_22969141[PMID]
54595,Craniopharyngioma,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,17425791[PMID]_European Medicines Agency 2015[INST]
54595,Craniopharyngioma,Disease,Annual incidence,0.19,1-9 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
54595,Craniopharyngioma,Disease,Annual incidence,0.17,1-9 / 1 000 000,Value and class,Sweden,Validated,25375987[PMID]_Swedish national Health registries 1987-2011[REG]
54368,Sarcocystosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
54370,Primary membranoproliferative glomerulonephritis,Disease,Point prevalence,16.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
54272,Hepatocellular adenoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_21175790[PMID]
56304,Atelosteogenesis type II,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,ORPHANET
56304,Atelosteogenesis type II,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
56305,Atelosteogenesis type III,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,ORPHANET
56305,Atelosteogenesis type III,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Annual incidence,12.0,1-5 / 10 000,Value and class,Worldwide,Validated,ORPHANET
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Annual incidence,5.3,1-9 / 100 000,Value and class,Japan,Not yet validated,ORPHANET
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Annual incidence,1.5,1-9 / 100 000,Value and class,United States,Not yet validated,13835134[PMID]_17857545[PMID]_13425293[PMID]_22570746[PMID]
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Annual incidence,14.0,1-5 / 10 000,Value and class,Poland,Validated,16397865[PMID]
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Annual incidence,1.27,1-9 / 100 000,Value and class,France,Not yet validated,10951337[PMID]
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
56044,Carcinoma of gallbladder and extrahepatic biliary tract,Clinical group,Annual incidence,4.37,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
55880,Chondrosarcoma,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
55880,Chondrosarcoma,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
55880,Chondrosarcoma,Disease,Lifetime Prevalence,3.55,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
55881,Adamantinoma,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
55881,Adamantinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
55881,Adamantinoma,Disease,Lifetime Prevalence,0.11,1-9 / 1 000 000,Value and class,Worldwide,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
55654,Hypotrichosis simplex,Disease,Cases/families,38.0,,Case(s),Worldwide,Validated,ORPHANET
55654,Hypotrichosis simplex,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
565858,Craniosynostosis-microretrognathia-severe intellectual disability syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,29432562[PMID]_30254215[PMID]
565858,Craniosynostosis-microretrognathia-severe intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29432562[PMID]_30254215[PMID]
565788,Infantile inflammatory bowel disease with neurological involvement,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,29483653[PMID]
565788,Infantile inflammatory bowel disease with neurological involvement,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29483653[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,4.5,1-9 / 100 000,Value and class,Netherlands,Validated,10480370[PMID]_26586959[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,3.9,1-9 / 100 000,Value and class,Australia,Validated,ORPHANET_9918480[PMID]_14608657[PMID]_26586959[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,4.8,1-9 / 100 000,Value and class,Portugal,Validated,14685153[PMID]_26586959[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,3.53,1-9 / 100 000,Value and class,Germany,Validated,16435194[PMID]_26586959[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,2.22,1-9 / 100 000,Value and class,Sweden,Validated,18681890[PMID]_25274184[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,3.08,1-9 / 100 000,Value and class,Norway,Validated,18681890[PMID]_26586959[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,1.77,1-9 / 100 000,Value and class,Denmark,Validated,18681890[PMID]_26586959[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,1.81,1-9 / 100 000,Value and class,Poland,Validated,25472774[PMID]_26586959[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,3.72,1-9 / 100 000,Value and class,Czech Republic,Validated,14685153[PMID]_26586959[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,2.29,1-9 / 100 000,Value and class,Tunisia,Validated,20209839[PMID]_26586959[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,2.04,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,19396827[PMID]_26586959[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,4.05,1-9 / 100 000,Value and class,Estonia,Validated,22480138[PMID]_26586959[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,0.0,1-9 / 100 000,Class only,Worldwide,Validated,ORPHANET_28595941[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_28595941[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,1.53,1-9 / 100 000,Value and class,Japan,Validated,28595941[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,1.56,1-9 / 100 000,Value and class,Switzerland,Validated,28595941[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,1.25,1-9 / 100 000,Value and class,Brazil,Validated,PMID: 31926052
79213,Mucopolysaccharidosis,Category,Prevalence at birth,16.9,1-5 / 10 000,Value and class,Saudi Arabia,Validated,20626343[PMID]_28595941[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,1.35,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,25364648[PMID]_28595941[PMID]
79213,Mucopolysaccharidosis,Category,Prevalence at birth,0.98,1-9 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
79213,Mucopolysaccharidosis,Category,Point prevalence,0.267,1-9 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
79213,Mucopolysaccharidosis,Category,Point prevalence,1.04,1-9 / 100 000,Value and class,Brazil,Validated,35209917[PMID]
565899,POMGNT2-related limb-girdle muscular dystrophy R24,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,27066570[PMID]
565899,POMGNT2-related limb-girdle muscular dystrophy R24,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27066570[PMID]
565909,Calpain-3-related limb-girdle muscular dystrophy D4,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27259757[PMID]_28881388[PMID]_30055862[PMID]
565909,Calpain-3-related limb-girdle muscular dystrophy D4,Disease,Cases/families,47.0,,Case(s),Worldwide,Validated,27259757[PMID]_28881388[PMID]
79233,Hypoxanthine guanine phosphoribosyltransferase partial deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79230,HJV or HAMP-related hemochromatosis,Disease,Cases/families,74.0,,Case(s),Worldwide,Validated,ORPHANET
79230,HJV or HAMP-related hemochromatosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79237,Galactokinase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
566067,CEBPE-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,31201888[PMID]
566067,CEBPE-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_31201888[PMID]
79234,Crigler-Najjar syndrome type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79235,Crigler-Najjar syndrome type 2,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79189,Peroxisome biogenesis disorder,Clinical group,Prevalence at birth,2.0,1-9 / 100 000,Value and class,United States,Validated,20301621[PMID]
79189,Peroxisome biogenesis disorder,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,United States,Not yet validated,20301621[PMID]
79189,Peroxisome biogenesis disorder,Clinical group,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Japan,Validated,12794690[PMID]
79189,Peroxisome biogenesis disorder,Clinical group,Point prevalence,0.0,1-9 / 1 000 000,Class only,Japan,Not yet validated,12794690[PMID]
79189,Peroxisome biogenesis disorder,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
565624,Combined oxidative phosphorylation defect type 39,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,22700954[PMID]_26016410[PMID]_29075935[PMID]
565624,Combined oxidative phosphorylation defect type 39,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22700954[PMID]_26016410[PMID]_29075935[PMID]
565612,Primary triglyceride deposit cardiomyovasculopathy,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,[EXPERT]
565612,Primary triglyceride deposit cardiomyovasculopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]_31186072[PMID]
79201,Glycogen storage disease,Category,Point prevalence,1.51,1-9 / 100 000,Value and class,China,Validated,34103049[PMID]
565782,Methotrexate toxicity,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
79157,2-methylbutyryl-CoA dehydrogenase deficiency,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
79157,2-methylbutyryl-CoA dehydrogenase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79156,Seizures-intellectual disability due to hydroxylysinuria syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,DOI:10.1007/978-3-642-55878-8_18[OTHER]
79156,Seizures-intellectual disability due to hydroxylysinuria syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_DOI:10.1007/978-3-642-55878-8_18[OTHER]
79155,Hydroxykynureninuria,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
79155,Hydroxykynureninuria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79154,2-aminoadipic 2-oxoadipic aciduria,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,23141293[PMID]
79154,2-aminoadipic 2-oxoadipic aciduria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79153,Idiopathic trachyonychia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79152,Disseminated superficial actinic porokeratosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_Pr KANITAKIS Jean[EXPERT]
79151,Acrokeratosis verruciformis of Hopf,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
79149,Dermochondrocorneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26440764[PMID]
79149,Dermochondrocorneal dystrophy,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,26440764[PMID]
79148,Elastosis perforans serpiginosa,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27881947[PMID]
79147,Familial reactive perforating collagenosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17567305[PMID]_20101333[PMID]
79147,Familial reactive perforating collagenosis,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,17567305[PMID]_20101333[PMID]
79145,Dowling-Degos disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79144,Isolated congenital onychodysplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26509026[PMID]
79143,Isolated congenital anonychia,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
79143,Isolated congenital anonychia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79172,Creatine deficiency syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
79168,Disorder of bile acid synthesis,Category,Point prevalence,0.6,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency[INST]
79158,Cerebral organic aciduria,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79159,Isobutyryl-CoA dehydrogenase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79107,Developmental malformations-deafness-dystonia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,12325076[PMID]
79107,Developmental malformations-deafness-dystonia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12325076[PMID]
566231,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha,Disease,Cases/families,35.0,,Case(s),Worldwide,Validated,30842990[PMID]
566231,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30842990[PMID]
79106,Eiken syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,15525660[PMID]
79106,Eiken syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15525660[PMID]
566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Disease,Point prevalence,0.0,Unknown,Class only,United States,Validated,ORPHANET
566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Disease,Point prevalence,0.0,Unknown,Class only,Japan,Validated,ORPHANET
566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Disease,Prevalence at birth,2.47,1-9 / 100 000,Value and class,United States,Validated,14517508[PMID]_31149222[PMID]
566243,Resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta,Disease,Prevalence at birth,2.4,1-9 / 100 000,Value and class,Japan,Validated,ORPHANET_19542904[PMID]_31149222[PMID]
79118,Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,12966531[PMID]_16715098[PMID]
79118,Neonatal diabetes-congenital hypothyroidism-congenital glaucoma-hepatic fibrosis-polycystic kidneys syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12966531[PMID]_16715098[PMID]
79113,Mandibulofacial dysostosis-microcephaly syndrome,Malformation syndrome,Cases/families,107.0,,Case(s),Worldwide,Validated,PMID: 26507355
79113,Mandibulofacial dysostosis-microcephaly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26507355[PMID]
79102,Thyrotoxic periodic paralysis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
79105,Myxofibrosarcoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79099,Interstitial granulomatous dermatitis with arthritis,Disease,Cases/families,53.0,,Case(s),Worldwide,Validated,22059717[PMID]
79099,Interstitial granulomatous dermatitis with arthritis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79098,Sympathetic ophthalmia,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,United Kingdom,Validated,10684834[PMID]
79098,Sympathetic ophthalmia,Disease,Point prevalence,0.6,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
79101,Hyperprolinemia type 2,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
566192,Congenital autosomal recessive small-platelet thrombocytopenia,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,25876182[PMID]
566192,Congenital autosomal recessive small-platelet thrombocytopenia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25876182[PMID]
79100,Atrophoderma vermiculata,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79095,Congenital bile acid synthesis defect type 4,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,10655068[PMID]_12512044[PMID]_ [EXPERT]
79095,Congenital bile acid synthesis defect type 4,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79094,Grange syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,22987684[PMID]
79094,Grange syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
566175,Complement hyperactivation-angiopathic thrombosis-protein-losing enteropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30565236[PMID]_28657829[PMID]_28657861[PMID]
79097,Folinic acid-responsive seizures,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79096,Pyridoxal phosphate-responsive seizures,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79096,Pyridoxal phosphate-responsive seizures,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2018[INST]
79138,Bickerstaff brainstem encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79139,Japanese encephalitis,Disease,Annual incidence,0.65,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
79139,Japanese encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79140,Cutaneous neuroendocrine carcinoma,Disease,Annual incidence,0.27,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,ORPHANET
79140,Cutaneous neuroendocrine carcinoma,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
79140,Cutaneous neuroendocrine carcinoma,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
79140,Cutaneous neuroendocrine carcinoma,Disease,Lifetime Prevalence,0.86,1-9 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
79140,Cutaneous neuroendocrine carcinoma,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Finland,Not yet validated,21729823[PMID]
79140,Cutaneous neuroendocrine carcinoma,Disease,Annual incidence,2.7,1-9 / 100 000,Value and class,United States,Validated,33932460[PMID]
79140,Cutaneous neuroendocrine carcinoma,Disease,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Denmark,Validated,20424236[PMID]
79140,Cutaneous neuroendocrine carcinoma,Disease,Annual incidence,0.378,1-9 / 1 000 000,Value and class,France,Validated,12951176[PMID]
79140,Cutaneous neuroendocrine carcinoma,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,United Kingdom,Validated,16764197[PMID]
79140,Cutaneous neuroendocrine carcinoma,Disease,Annual incidence,1.8,1-9 / 100 000,Value and class,Australia,Validated,33932460[PMID]
79140,Cutaneous neuroendocrine carcinoma,Disease,Annual incidence,2.0,1-9 / 100 000,Value and class,New Zealand,Validated,33932460[PMID]
79140,Cutaneous neuroendocrine carcinoma,Disease,Annual incidence,4.0,1-9 / 100 000,Value and class,Norway,Validated,33932460[PMID]
79141,Hereditary painful callosities,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,646376[PMID]_3812560[PMID]
79141,Hereditary painful callosities,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_646376[PMID]_3812560[PMID]
79134,DEND syndrome,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,16670688[PMID]
79134,DEND syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79135,Episodic ataxia type 3,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,11673600[PMID]
79135,Episodic ataxia type 3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11673600[PMID]
79136,Episodic ataxia type 4,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,8929156[PMID]
79136,Episodic ataxia type 4,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8929156[PMID]
79137,Generalized epilepsy-paroxysmal dyskinesia syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79129,Trichodysplasia-amelogenesis imperfecta syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,8419879[PMID]
79129,Trichodysplasia-amelogenesis imperfecta syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8419879[PMID]
79133,Focal facial dermal dysplasia type I,Clinical subtype,Cases/families,81.0,,Case(s),Worldwide,Validated,21931173[PMID]
79133,Focal facial dermal dysplasia type I,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79124,Hepatic veno-occlusive disease-immunodeficiency syndrome,Disease,Cases/families,28.0,,Case(s),Worldwide,Validated,20301448[PMID]_22621957[PMID]_16648851[PMID]
79124,Hepatic veno-occlusive disease-immunodeficiency syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301448[PMID]
79126,Acute interstitial pneumonia,Disease,Point prevalence,3.8,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET
79127,Respiratory bronchiolitis-interstitial lung disease syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79128,Lymphoid interstitial pneumonia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
77293,Chronic visceral acid sphingomyelinase deficiency,Disease,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Europe,Not yet validated,23412609[PMID]
77293,Chronic visceral acid sphingomyelinase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
77295,Odontoleukodystrophy,Clinical subtype,Cases/families,4.0,,Case(s),Worldwide,Validated,12605447[PMID]
77295,Odontoleukodystrophy,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12605447[PMID]
77261,Gaucher disease type 3,Clinical subtype,Point prevalence,0.05,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
77292,Infantile neurovisceral acid sphingomyelinase deficiency,Disease,Prevalence at birth,0.25,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
77292,Infantile neurovisceral acid sphingomyelinase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
77298,Anophthalmia/microphthalmia-esophageal atresia syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,15578584[PMID]_16543359[PMID]
77298,Anophthalmia/microphthalmia-esophageal atresia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
77299,Microphthalmia-brain atrophy syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,16566018[PMID]
77299,Microphthalmia-brain atrophy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16566018[PMID]
77296,Morgagni-Stewart-Morel syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
77297,Majeed syndrome,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,20301735[PMID]
77297,Majeed syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301735[PMID]
567502,B-cell immunodeficiency-limb anomaly-urogenital malformation syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,31409799[PMID]
567502,B-cell immunodeficiency-limb anomaly-urogenital malformation syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_31409799[PMID]
77300,Auricular abnormalities-cleft lip with or without cleft palate-ocular abnormalities syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,16317305[PMID]
77300,Auricular abnormalities-cleft lip with or without cleft palate-ocular abnormalities syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16317305[PMID]
77301,Monosomy 9q22.3 syndrome,Malformation syndrome,Cases/families,42.0,,Case(s),Worldwide,Validated,21850767[PMID]
77301,Monosomy 9q22.3 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21850767[PMID]
567550,Idiopathic multidrug-resistant nephrotic syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
567548,Idiopathic steroid-resistant nephrotic syndrome,Clinical syndrome,Annual incidence,0.2582,1-9 / 1 000 000,Value and class,Worldwide,Validated,30552564[PMID]_ORPHANET
567548,Idiopathic steroid-resistant nephrotic syndrome,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
567546,Idiopathic steroid-sensitive nephrotic syndrome with secondary steroid resistance,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
567544,Idiopathic non-lupus full-house nephropathy,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
79083,PPARG-related familial partial lipodystrophy,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,16409151[PMID]
79083,PPARG-related familial partial lipodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79078,IgG4-related dacryoadenitis and sialadenitis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79076,Juvenile polyposis of infancy,Clinical subtype,Cases/families,11.0,,Case(s),Worldwide,Validated,ORPHANET
79076,Juvenile polyposis of infancy,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79087,Acquired partial lipodystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
79087,Acquired partial lipodystrophy,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2015[INST]
79086,Acquired generalized lipodystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
79086,Acquired generalized lipodystrophy,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
79085,AKT2-related familial partial lipodystrophy,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,16409151[PMID]
79085,AKT2-related familial partial lipodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79084,"Familial partial lipodystrophy, Köbberling type",Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,16409151[PMID]
79084,"Familial partial lipodystrophy, Köbberling type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
567983,Parenteral nutrition-associated cholestasis,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
79093,Foix-Alajouanine syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79091,Hereditary inclusion body myopathy-joint contractures-ophthalmoplegia syndrome,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,9708547[PMID]_23489661[PMID]_25529940[PMID]
79091,Hereditary inclusion body myopathy-joint contractures-ophthalmoplegia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9708547[PMID]_23489661[PMID]_25529940[PMID]
79088,Localized lipodystrophy,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
75327,North Carolina macular dystrophy,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,21310494[PMID]_5100467[PMID]
75327,North Carolina macular dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21310494[PMID]_5100467[PMID]
75373,Progressive bifocal chorioretinal atrophy,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,5686965[PMID]_8541856[PMID]
75373,Progressive bifocal chorioretinal atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5686965[PMID]_8541856[PMID]
75374,Bradyopsia,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,14702087[PMID]
75374,Bradyopsia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14702087[PMID]
75376,Familial drusen,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
75377,Central areolar choroidal dystrophy,Disease,Point prevalence,3.33,1-9 / 100 000,Value and class,France,Not yet validated,ORPHANET
75377,Central areolar choroidal dystrophy,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
75378,Oligocone trichromacy,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,14736794[PMID]_17090894[PMID]_ [EXPERT]
75378,Oligocone trichromacy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
75381,Cystoid macular dystrophy,Disease,Cases/families,97.0,,Case(s),Worldwide,Validated,25267528[PMID]
75381,Cystoid macular dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25267528[PMID]
75382,Oguchi disease,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
75382,Oguchi disease,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
75389,Brain malformation-congenital heart disease-postaxial polydactyly syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,16531731[PMID]
75389,Brain malformation-congenital heart disease-postaxial polydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
566841,Liver adenomatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26011213[PMID]
75391,Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,22354167[PMID]
75391,Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22354167[PMID]
75392,Periodontal Ehlers-Danlos syndrome,Disease,Cases/families,62.0,,Case(s),Worldwide,Validated,22739343[PMID]
75392,Periodontal Ehlers-Danlos syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
75496,B4GALT7-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26940150[PMID]
75496,B4GALT7-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Cases/families,34.0,,Case(s),Worldwide,Validated,26940150[PMID]
75497,X-linked Ehlers-Danlos syndrome,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,4006272[PMID]
75497,X-linked Ehlers-Danlos syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4006272[PMID]
75508,Angioosteohypotrophic syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
75563,X-linked sideroblastic anemia,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
75563,X-linked sideroblastic anemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
566943,Mueller-Weiss syndrome,Disease,Cases/families,277.0,,Case(s),Worldwide,Validated,27145453[PMID]
566943,Mueller-Weiss syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27145453[PMID]
75565,Tropical endomyocardial fibrosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
75564,Acquired idiopathic sideroblastic anemia,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
75564,Acquired idiopathic sideroblastic anemia,Disease,Annual incidence,0.09,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
75567,Primary progressive freezing gait,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
75566,Loeffler endocarditis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
75857,6q terminal deletion syndrome,Malformation syndrome,Cases/families,19.0,,Case(s),Worldwide,Validated,16329114[PMID]
75857,6q terminal deletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
75840,Ullrich congenital muscular dystrophy,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
75840,Ullrich congenital muscular dystrophy,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
77240,Primary lymphedema,Category,Point prevalence,16.7,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]_24212289[PMID]
75858,MORM syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
77258,Trichorhinophalangeal syndrome type 1,Malformation syndrome,Cases/families,250.0,,Case(s),Worldwide,Validated,[EXPERT]
77258,Trichorhinophalangeal syndrome type 1,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]_ORPHANET
77260,Gaucher disease type 2,Clinical subtype,Point prevalence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
77259,Gaucher disease type 1,Clinical subtype,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
77259,Gaucher disease type 1,Clinical subtype,Prevalence at birth,2.48,1-9 / 100 000,Value and class,Italy,Validated,11953730[PMID]
73271,Bleeding diathesis due to a collagen receptor defect,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,7687896[PMID]
73271,Bleeding diathesis due to a collagen receptor defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
73263,Zygomycosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
73267,Non-24-hour sleep-wake syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
73256,Central neurocytoma,Disease,Cases/families,500.0,,Case(s),Worldwide,Validated,23810386[PMID]
73256,Central neurocytoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
73260,Paracoccidioidomycosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
73246,Visceral neuropathy-brain anomalies-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,16378921[PMID]
73246,Visceral neuropathy-brain anomalies-facial dysmorphism-developmental delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16378921[PMID]
569821,Congenital primary lymphedema of Gordon,Disease,Cases/families,23.0,,Case(s),Worldwide,Validated,30071673[PMID]
569821,Congenital primary lymphedema of Gordon,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30071673[PMID]
73423,Acute ackee fruit intoxication,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
569816,CELSR1-related late-onset primary lymphedema,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_31215153[PMID]_31403174[PMID]
569816,CELSR1-related late-onset primary lymphedema,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,31215153[PMID]_31403174[PMID]
73272,Growth delay due to insulin-like growth factor type 1 deficiency,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,24389050[PMID]
73272,Growth delay due to insulin-like growth factor type 1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24389050[PMID]
73273,Growth delay due to insulin-like growth factor I resistance,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
75326,Familial isolated retinal arteriolar tortuosity,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,12745002[PMID]
75326,Familial isolated retinal arteriolar tortuosity,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
75325,Osteosclerosis-ichthyosis-premature ovarian failure syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,15995452[PMID]
75325,Osteosclerosis-ichthyosis-premature ovarian failure syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
75249,Familial isolated restrictive cardiomyopathy,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,[EXPERT]
75234,Cholesteryl ester storage disease,Clinical subtype,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Germany,Validated,17634524[PMID]
75234,Cholesteryl ester storage disease,Clinical subtype,Point prevalence,0.8,1-9 / 1 000 000,Value and class,Specific population,Validated,23424026[PMID]
75234,Cholesteryl ester storage disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
75233,Wolman disease,Clinical subtype,Prevalence at birth,0.19,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
75233,Wolman disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
568065,EPHB4-related lymphatic-related hydrops fetalis,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,27400125[PMID]
568065,EPHB4-related lymphatic-related hydrops fetalis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27400125[PMID]
568062,PIEZO1-related generalized lymphatic dysplasia with non-immune hydrops fetalis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26333996[PMID]
568062,PIEZO1-related generalized lymphatic dysplasia with non-immune hydrops fetalis,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,26333996[PMID]
71493,Familial thrombocytosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,23736217[PMID]
71505,Cancer-associated retinopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
568056,Warts-immunodeficiency-lymphedema-anogenital dysplasia syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,18347293[PMID]
568056,Warts-immunodeficiency-lymphedema-anogenital dysplasia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18347293[PMID]
568051,GJC2-related late-onset primary lymphedema,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29906362[PMID]
71289,Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
71289,Radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
71526,Obesity due to pro-opiomelanocortin deficiency,Etiological subtype,Cases/families,7.0,,Case(s),Worldwide,Validated,16150380[PMID]
71526,Obesity due to pro-opiomelanocortin deficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
71528,Obesity due to prohormone convertase I deficiency,Etiological subtype,Cases/families,16.0,,Case(s),Worldwide,Validated,23562752[PMID]
71528,Obesity due to prohormone convertase I deficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
71529,Obesity due to melanocortin 4 receptor deficiency,Etiological subtype,Point prevalence,50.0,1-5 / 10 000,Value and class,France,Validated,[EXPERT]
71529,Obesity due to melanocortin 4 receptor deficiency,Etiological subtype,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
569164,Angiomatoid fibrous histiocytoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
71517,Rapid-onset dystonia-parkinsonism,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,17282997[PMID]_15260953[PMID]
71517,Rapid-onset dystonia-parkinsonism,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
71518,Benign paroxysmal torticollis of infancy,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,[EXPERT]_19182151[PMID]_29956301[PMID]_29656928[PMID]
71518,Benign paroxysmal torticollis of infancy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
71519,Psychogenic movement disorders,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
569274,Multiple mitochondrial dysfunctions syndrome type 5,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,29767723[PMID]_30105122[PMID]
569274,Multiple mitochondrial dysfunctions syndrome type 5,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29767723[PMID]_30105122[PMID]
569290,Multiple mitochondrial dysfunctions syndrome type 6,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,29576218[PMID]
569290,Multiple mitochondrial dysfunctions syndrome type 6,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29576218[PMID]
569248,Microcystic stromal tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
73229,HANAC syndrome,Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,20818663[PMID]
73229,HANAC syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20818663[PMID]
73224,Kidney tubulopathy-dilated cardiomyopathy syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,15769815[PMID]
73224,Kidney tubulopathy-dilated cardiomyopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15769815[PMID]
73245,Spinal muscular atrophy-Dandy-Walker malformation-cataracts syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,16024908[PMID]
73245,Spinal muscular atrophy-Dandy-Walker malformation-cataracts syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16024908[PMID]
73230,Ossification anomalies-psychomotor developmental delay syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,16086393[PMID]
73230,Ossification anomalies-psychomotor developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16086393[PMID]
73217,Müllerian aplasia,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Finland,Not yet validated,ORPHANET_11570363[PMID]
73217,Müllerian aplasia,Clinical group,Prevalence at birth,10.0,1-5 / 10 000,Value and class,Finland,Validated,11570363[PMID]
73217,Müllerian aplasia,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
73223,Global developmental delay-osteopenia-ectodermal defect syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,16368207[PMID]
73223,Global developmental delay-osteopenia-ectodermal defect syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16368207[PMID]
40366,Acitretin/etretinate embryopathy,Malformation syndrome,Cases/families,26.0,,Case(s),Worldwide,Validated,18410980[PMID]
40366,Acitretin/etretinate embryopathy,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
40923,Eales disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
39812,Graft versus host disease,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
530849,Familial apolipoprotein A5 deficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25732519[PMID]
530849,Familial apolipoprotein A5 deficiency,Etiological subtype,Cases/families,3.0,,Family(ies),Worldwide,Validated,25732519[PMID]
39041,Omenn syndrome,Disease,Cases/families,25.0,,Case(s),Worldwide,Validated,ORPHANET
39041,Omenn syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
530838,KRT1-related diffuse nonepidermolytic keratoderma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_30452289[PMID]
39044,Uveal melanoma,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,17498805[PMID]_22119735[PMID]_EUROCARE Survival of cancer patients in Europe[REG]
39044,Uveal melanoma,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
39044,Uveal melanoma,Disease,Lifetime Prevalence,6.0,1-9 / 100 000,Value and class,Europe,Validated,22119735[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
39044,Uveal melanoma,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,Africa,Not yet validated,19704035[PMID]
530792,RELA fusion-positive ependymoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
38874,Dihydropyrimidinuria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26771602[PMID]
37748,Schnitzler syndrome,Malformation syndrome,Cases/families,150.0,,Case(s),Worldwide,Validated,ORPHANET
37748,Schnitzler syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
37612,Episodic ataxia type 1,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
37553,Andersen-Tawil syndrome,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
37553,Andersen-Tawil syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
37553,Andersen-Tawil syndrome,Disease,Point prevalence,0.08,<1 / 1 000 000,Value and class,United Kingdom,Validated,23516313[PMID]
37553,Andersen-Tawil syndrome,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Netherlands,Validated,29606556[PMID]
37202,Interstitial cystitis,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET_1137336[PMID]
37202,Interstitial cystitis,Disease,Point prevalence,10.6,1-5 / 10 000,Value and class,Finland,Validated,1137336[PMID]
37202,Interstitial cystitis,Disease,Point prevalence,30.0,1-5 / 10 000,Value and class,United States,Validated,ISBN:978-4471-3295-0[OTHER]
37202,Interstitial cystitis,Disease,Annual incidence,0.66,1-9 / 1 000 000,Value and class,Finland,Validated,1137336[PMID]
37042,Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome,Disease,Cases/families,195.0,,Case(s),Worldwide,Validated,32234571[PMID]
37042,Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,32234571[PMID]_ORPHANET
36913,Autoimmune hypoparathyroidism,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
36913,Autoimmune hypoparathyroidism,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
36913,Autoimmune hypoparathyroidism,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,"Korea, Republic of",Not yet validated,32384131[PMID]
36913,Autoimmune hypoparathyroidism,Disease,Point prevalence,0.023,<1 / 1 000 000,Value and class,Denmark,Not yet validated,25753591 [PMID]
36899,Myoclonus-dystonia syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
531151,9q21.13 microdeletion syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,23279911[PMID]_24355400[PMID]
531151,9q21.13 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23279911[PMID]_24355400[PMID]
530983,Lamb-Shaffer syndrome,Disease,Cases/families,70.0,,Case(s),Worldwide,Validated,29477873[PMID]
530983,Lamb-Shaffer syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29477873[PMID]
530995,Mixed phenotype acute leukemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
41751,Bietti crystalline dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
42062,Iminoglycinuria,Disease,Prevalence at birth,6.67,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
42062,Iminoglycinuria,Disease,Point prevalence,6.68,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
35705,Neurometabolic disorder due to serine deficiency,Category,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
35705,Neurometabolic disorder due to serine deficiency,Category,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
35706,Glutaric acidemia type 3,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
35704,L-Arginine:glycine amidinotransferase deficiency,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,20301745[PMID]_20625172[PMID]
35704,L-Arginine:glycine amidinotransferase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
35710,Glucose-galactose malabsorption,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_22843301[PMID]
35710,Glucose-galactose malabsorption,Disease,Prevalence at birth,0.22,1-9 / 1 000 000,Value and class,France,Validated,23107089[PMID]
35737,Morning glory disc anomaly,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
35708,Aromatic L-amino acid decarboxylase deficiency,Disease,Cases/families,140.0,,Case(s),Worldwide,Validated,30689738[PMID]
35708,Aromatic L-amino acid decarboxylase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30689738[PMID]
35689,Primary lateral sclerosis,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET
35701,3-hydroxy-3-methylglutaryl-CoA synthase deficiency,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,23751782[PMID]
35701,3-hydroxy-3-methylglutaryl-CoA synthase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
35698,Mitochondrial DNA depletion syndrome,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
35698,Mitochondrial DNA depletion syndrome,Category,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Israel,Validated,33239050[PMID]
35698,Mitochondrial DNA depletion syndrome,Category,Prevalence at birth,1.1,1-9 / 100 000,Value and class,Specific population,Validated,33239050[PMID]
35612,Nanophthalmos,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
35173,X-linked dominant chondrodysplasia punctata,Disease,Prevalence at birth,0.25,1-9 / 1 000 000,Value and class,Europe,Validated,21634086[PMID]
35173,X-linked dominant chondrodysplasia punctata,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
35687,Erdheim-Chester disease,Disease,Cases/families,500.0,,Case(s),Worldwide,Validated,20724540[PMID]
35687,Erdheim-Chester disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
35664,ALDH18A1-related De Barsy syndrome,Etiological subtype,Cases/families,32.0,,Case(s),Worldwide,Validated,ORPHANET
35664,ALDH18A1-related De Barsy syndrome,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
35656,Coenzyme Q10 deficiency,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
35107,Desmosterolosis,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,29175559[PMID]
35107,Desmosterolosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29175559[PMID]
35125,Epidermal nevus syndrome,Disease,Cases/families,400.0,,Case(s),Worldwide,Validated,ORPHANET
35125,Epidermal nevus syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
35122,Congenital sucrase-isomaltase deficiency,Disease,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Not yet validated,ORPHANET
35121,Lysosomal acid phosphatase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
36387,Genetic epilepsy with febrile seizure plus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
36388,Paraneoplastic neurologic syndrome,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
36397,Adiposis dolorosa,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
36412,Hypocomplementemic urticarial vasculitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
36426,Stevens-Johnson syndrome,Clinical subtype,Annual incidence,0.36,1-9 / 1 000 000,Value and class,Europe,Not yet validated,23866878[PMID]
36426,Stevens-Johnson syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
36355,Bleeding disorder due to P2Y12 defect,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,15852220[PMID]_19229056[PMID]
36355,Bleeding disorder due to P2Y12 defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
36386,Hereditary sensory and autonomic neuropathy type 1,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,18348718[PMID]
36234,Bacterial toxic-shock syndrome,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,15264985[PMID]
36236,Staphylococcal scalded skin syndrome,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Germany,Not yet validated,15816826[PMID]
36236,Staphylococcal scalded skin syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
36238,Staphylococcal necrotizing pneumonia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
36237,Bullous impetigo,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
36273,Gastric linitis plastica,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
36258,Buerger disease,Disease,Point prevalence,16.0,1-5 / 10 000,Value and class,Worldwide,Validated,[EXPERT]
36258,Buerger disease,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
35808,Malignant sex cord stromal tumor of ovary,Category,Point prevalence,1.85,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.13,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.1,1-9 / 1 000 000,Value and class,United States,Validated,15863154[PMID]
35808,Malignant sex cord stromal tumor of ovary,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.05,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.043,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.074,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.069,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.094,<1 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.045,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.063,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.039,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.073,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.093,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.089,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.133,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.102,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.367,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.152,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.314,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.296,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.135,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.401,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.236,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.232,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35808,Malignant sex cord stromal tumor of ovary,Category,Annual incidence,0.212,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.08,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Lifetime Prevalence,2.3,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.2,1-9 / 1 000 000,Value and class,United States,Validated,15863154[PMID]
35807,Malignant germ cell tumor of ovary,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.072,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.07,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.089,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.093,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.087,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.062,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.065,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.085,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.065,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.065,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.081,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.095,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.09,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.098,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.064,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.075,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.072,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.051,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.061,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.064,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.157,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.126,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35807,Malignant germ cell tumor of ovary,Category,Annual incidence,0.141,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
35878,Hyperinsulinism-hyperammonemia syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
35858,Imerslund-Gräsbeck syndrome,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Finland,Validated,Pr Ralph GRÄSBECK[EXPERT]
35858,Imerslund-Gräsbeck syndrome,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Norway,Validated,Pr Ralph GRÄSBECK[EXPERT]
35858,Imerslund-Gräsbeck syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
35858,Imerslund-Gräsbeck syndrome,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,Pr Ralph GRÄSBECK[EXPERT]_ORPHANET
35909,Combined deficiency of factor V and factor VIII,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
35909,Combined deficiency of factor V and factor VIII,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,"Iran, Islamic Republic of",Validated,9531348[PMID]
35889,Acute opioid intoxication,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
36204,Intestinal lymphangiectasia,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
35981,Polymicrogyria,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
33572,5-oxoprolinase deficiency,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,ORPHANET
33572,5-oxoprolinase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
33543,Kleine-Levin syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
33543,Kleine-Levin syndrome,Disease,Point prevalence,0.18,1-9 / 1 000 000,Value and class,France,Validated,25559212[PMID]
33475,Meningococcal meningitis,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,European Medicines Agency 2006[INST]
33475,Meningococcal meningitis,Disease,Annual incidence,2.3,1-9 / 100 000,Value and class,France,Validated,Institut de Veille Sanitaire 2010[INST]
33475,Meningococcal meningitis,Disease,Annual incidence,2.7,1-9 / 100 000,Value and class,New Zealand,Validated,Institute of Environmental Science and Research 2011[INST]
33475,Meningococcal meningitis,Disease,Annual incidence,0.8,1-9 / 1 000 000,Value and class,United States,Validated,Center for Diseases Control and Prevention[INST]
33445,Neuroectodermal melanolysosomal disease,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,474620[PMID]_10052404[PMID]_11170073[PMID]_17710870[PMID]
33445,Neuroectodermal melanolysosomal disease,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
33408,Bullous lichen planus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
535458,Familial GPIHBP1 deficiency,Etiological subtype,Cases/families,10.0,,Family(ies),Worldwide,Validated,25732519[PMID]
535458,Familial GPIHBP1 deficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25732519[PMID]
33402,Pediatric hepatocellular carcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,24439603[PMID]
33402,Pediatric hepatocellular carcinoma,Disease,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
33402,Pediatric hepatocellular carcinoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,United States,Validated,24439603[PMID]
34217,Naxos disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,15210133[PMID]_34926342[PMID]_ORPHANET
33577,Nodular non-suppurative panniculitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
33574,Glutamate-cysteine ligase deficiency,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,18024385[PMID]
33574,Glutamate-cysteine ligase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18024385[PMID]
33573,Gamma-glutamyl transpeptidase deficiency,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,15702405[PMID]
33573,Gamma-glutamyl transpeptidase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15702405[PMID]
33110,Autosomal agammaglobulinemia,Clinical subtype,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
33110,Autosomal agammaglobulinemia,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
33111,Granulomatous slack skin,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,14726855[PMID]
33111,Granulomatous slack skin,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
33108,Lethal multiple pterygium syndrome,Malformation syndrome,Cases/families,28.0,,Family(ies),Worldwide,Validated,ORPHANET
33108,Lethal multiple pterygium syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
33067,"Metaphyseal chondrodysplasia, Jansen type",Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,ORPHANET
33067,"Metaphyseal chondrodysplasia, Jansen type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
33069,Dravet syndrome,Disease,Prevalence at birth,3.3,1-9 / 100 000,Value and class,Europe,Validated,22719002[PMID]_25772213[PMID]_ 31302675[PMID]
33069,Dravet syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
33001,Lymphedema-distichiasis syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET_24215208[PMID]
33355,Reticular dysgenesis,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
33355,Reticular dysgenesis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
535453,Familial lipase maturation factor 1 deficiency,Etiological subtype,Cases/families,2.0,,Family(ies),Worldwide,Validated,25732519[PMID]
535453,Familial lipase maturation factor 1 deficiency,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25732519[PMID]
33364,Trichothiodystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
33364,Trichothiodystrophy,Disease,Cases/families,201.0,,Case(s),Worldwide,Validated,18603627[PMID]_18329345[PMID]_19681155[PMID]
33364,Trichothiodystrophy,Disease,Prevalence at birth,0.12,1-9 / 1 000 000,Value and class,Europe,Validated,18329345[PMID]
33276,Kaposi sarcoma,Disease,Annual incidence,0.34,1-9 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Lifetime Prevalence,2.11,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.051,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.075,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.099,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.092,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.065,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.076,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.027,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.043,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.056,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.133,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.111,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.108,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.112,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.597,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.915,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.546,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.163,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.278,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,0.192,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,1.363,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33276,Kaposi sarcoma,Disease,Annual incidence,1.142,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33314,Jessner lymphocytic infiltration of the skin,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
33208,Idiopathic hypersomnia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
33208,Idiopathic hypersomnia,Disease,Point prevalence,30.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
33226,Waldenström macroglobulinemia,Disease,Annual incidence,0.81,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
33226,Waldenström macroglobulinemia,Disease,Annual incidence,2.05,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
33226,Waldenström macroglobulinemia,Disease,Annual incidence,0.38,1-9 / 1 000 000,Value and class,United States,Validated,22139816[PMID]
33226,Waldenström macroglobulinemia,Disease,Annual incidence,0.55,1-9 / 1 000 000,Value and class,United Kingdom,Validated,17416416[PMID]
33226,Waldenström macroglobulinemia,Disease,Annual incidence,0.31,1-9 / 1 000 000,Value and class,Spain,Validated,11736938[PMID]
33226,Waldenström macroglobulinemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
33226,Waldenström macroglobulinemia,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,European Medicines Agency 2014[INST]
35069,Infantile neuroaxonal dystrophy,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,ORPHANET
35069,Infantile neuroaxonal dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
35093,Non-syndromic sagittal craniosynostosis,Morphological anomaly,Point prevalence,20.7,1-5 / 10 000,Value and class,Australia,Validated,34626670[PMID]_ORPHANET
35093,Non-syndromic sagittal craniosynostosis,Morphological anomaly,Prevalence at birth,20.7,1-5 / 10 000,Value and class,Australia,Validated,34626670[PMID]
35078,T-B+ severe combined immunodeficiency due to JAK3 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
35062,Severe disseminated cytomegalovirus infection in immunocompetent patients,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
34520,Congenital muscular dystrophy with integrin alpha-7 deficiency,Disease,Point prevalence,0.03,<1 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
34514,Telethonin-related limb-girdle muscular dystrophy R7,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,12921790[PMID]_18948002[PMID]_25298746[PMID]
34514,Telethonin-related limb-girdle muscular dystrophy R7,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12921790[PMID]_18948002[PMID]_25298746[PMID]
34515,FKRP-related limb-girdle muscular dystrophy R9,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,19767415[PMID]_20961759[PMID]_ORPHANET
34515,FKRP-related limb-girdle muscular dystrophy R9,Disease,Point prevalence,0.43,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
34515,FKRP-related limb-girdle muscular dystrophy R9,Disease,Point prevalence,1.85,1-9 / 100 000,Value and class,Norway,Validated,20961759[PMID]
34516,DNAJB6-related limb-girdle muscular dystrophy D1,Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,26847086[PMID]
34516,DNAJB6-related limb-girdle muscular dystrophy D1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26847086[PMID]
34587,Danon disease,Disease,Cases/families,84.0,,Case(s),Worldwide,Validated,ORPHANET
34587,Danon disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
34587,Danon disease,Disease,Prevalence at birth,0.05,<1 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
34592,Immunodeficiency by defective expression of MHC class I,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,25001848[PMID]
34592,Immunodeficiency by defective expression of MHC class I,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25001848[PMID]
34528,Autosomal dominant primary hypomagnesemia with hypocalciuria,Disease,Cases/families,28.0,,Case(s),Worldwide,Validated,25765846[PMID]
34528,Autosomal dominant primary hypomagnesemia with hypocalciuria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25765846[PMID]
34533,Corneal dystrophy,Category,Point prevalence,110.0,>1 / 1000,Value and class,United States,Not yet validated,21791583[PMID]
34533,Corneal dystrophy,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
536516,Myopathic Ehlers-Danlos syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,28306225[PMID]
536516,Myopathic Ehlers-Danlos syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28306225[PMID]
536471,Spondylodysplastic Ehlers-Danlos syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29931299[PMID]_26940150[PMID]_18513683[PMID]_18985159[PMID]
536471,Spondylodysplastic Ehlers-Danlos syndrome,Disease,Cases/families,24.0,,Family(ies),Worldwide,Validated,29931299[PMID]_26940150[PMID]_18513683[PMID]_18985159[PMID]
536467,B3GALT6-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Cases/families,41.0,,Family(ies),Worldwide,Validated,23664117[PMID]_29931299[PMID]_23664118[PMID]
536467,B3GALT6-related spondylodysplastic Ehlers-Danlos syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29931299[PMID]
536545,Kyphoscoliotic Ehlers-Danlos syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_28306225[PMID]
536532,Classical-like Ehlers-Danlos syndrome type 2,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,30759870[PMID]
536532,Classical-like Ehlers-Danlos syndrome type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30759870[PMID]
537072,PLG-related hereditary angioedema with normal C1Inh,Clinical subtype,Cases/families,105.0,,Case(s),Worldwide,Validated,30809376[PMID]
537072,PLG-related hereditary angioedema with normal C1Inh,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30809376[PMID]
32960,Tumor necrosis factor receptor 1 associated periodic syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
32960,Tumor necrosis factor receptor 1 associated periodic syndrome,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
52530,Pseudo-von Willebrand disease,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,23327637[PMID]_21301777[PMID]_23934752[PMID]
52530,Pseudo-von Willebrand disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
52688,Myelodysplastic syndrome,Clinical group,Annual incidence,1.5,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
52688,Myelodysplastic syndrome,Clinical group,Lifetime Prevalence,5.02,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
52688,Myelodysplastic syndrome,Clinical group,Annual incidence,4.15,1-9 / 100 000,Value and class,Germany,Validated,21708407[PMID]
52688,Myelodysplastic syndrome,Clinical group,Point prevalence,7.0,1-9 / 100 000,Value and class,Germany,Validated,21708407[PMID]
52688,Myelodysplastic syndrome,Clinical group,Annual incidence,6.4,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
52688,Myelodysplastic syndrome,Clinical group,Point prevalence,1.35,1-9 / 100 000,Value and class,Japan,Not yet validated,7718765[PMID]
52688,Myelodysplastic syndrome,Clinical group,Annual incidence,3.35,1-9 / 100 000,Value and class,United States,Validated,18443215[PMID]_17345612[PMID]_National Cancer Institute[INST]_ORPHANET
52688,Myelodysplastic syndrome,Clinical group,Annual incidence,5.4,1-9 / 100 000,Value and class,Greece,Not yet validated,23572136[PMID]
52688,Myelodysplastic syndrome,Clinical group,Annual incidence,8.5,1-9 / 100 000,Value and class,United Kingdom,Not yet validated,7986716[PMID]_7819118[PMID]_ ORPHANET
52688,Myelodysplastic syndrome,Clinical group,Annual incidence,3.5,1-9 / 100 000,Value and class,Sweden,Not yet validated,7720834[PMID]
52688,Myelodysplastic syndrome,Clinical group,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Romania,Validated,19411107[PMID]
52688,Myelodysplastic syndrome,Clinical group,Annual incidence,8.1,1-9 / 100 000,Value and class,Spain,Validated,14555322[PMID]
52688,Myelodysplastic syndrome,Clinical group,Point prevalence,15.0,1-5 / 10 000,Value and class,United States,Not yet validated,emedicine 2009[OTHER]
52688,Myelodysplastic syndrome,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
52688,Myelodysplastic syndrome,Clinical group,Annual incidence,1.95,1-9 / 100 000,Value and class,Poland,Validated,27699872[PMID]
52688,Myelodysplastic syndrome,Clinical group,Point prevalence,6.2,1-9 / 100 000,Value and class,Poland,Validated,27699872[PMID]
52688,Myelodysplastic syndrome,Clinical group,Annual incidence,3.8,1-9 / 100 000,Value and class,Switzerland,Validated,28056392[PMID]
538096,Autosomal recessive lethal neonatal axonal sensorimotor polyneuropathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
538096,Autosomal recessive lethal neonatal axonal sensorimotor polyneuropathy,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,22971091[PMID]_9771672[PMID]
52503,X-linked creatine transporter deficiency,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,23644449[PMID]
52503,X-linked creatine transporter deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_23644449[PMID]
538101,Congenital axonal neuropathy with encephalopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18358405[PMID]
538101,Congenital axonal neuropathy with encephalopathy,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,18358405[PMID]
52430,Inclusion body myopathy with Paget disease of bone and frontotemporal dementia,Disease,Cases/families,26.0,,Family(ies),Worldwide,Validated,20301649[PMID]
52430,Inclusion body myopathy with Paget disease of bone and frontotemporal dementia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301649[PMID]
52416,Mantle cell lymphoma,Disease,Annual incidence,0.8,1-9 / 1 000 000,Value and class,United States,Validated,28444739[PMID]_SEER Surveillance Epidemiology and End Results 2007-2013[INST]
52416,Mantle cell lymphoma,Disease,Point prevalence,3.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_European Medicines Agency 2015[INST]
52416,Mantle cell lymphoma,Disease,Annual incidence,1.05,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
52427,Retinitis punctata albescens,Disease,Point prevalence,0.125,1-9 / 1 000 000,Value and class,Worldwide,Validated,23929416[PMID]
52427,Retinitis punctata albescens,Disease,Point prevalence,0.175,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET_European Medecines Agency 2016[INST]
52417,MALT lymphoma,Disease,Annual incidence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
52417,MALT lymphoma,Disease,Annual incidence,1.59,1-9 / 100 000,Value and class,United States,Validated,22893605[PMID]_National Cancer Institute[INST]
52417,MALT lymphoma,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2013[INST]
52056,Ulnar/fibula ray defect-brachydactyly syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,14564152[PMID]
52056,Ulnar/fibula ray defect-brachydactyly syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14564152[PMID]
52055,Corpus callosum agenesis-intellectual disability-coloboma-micrognathia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,14556245[PMID]
52055,Corpus callosum agenesis-intellectual disability-coloboma-micrognathia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14556245[PMID]
52368,Mohr-Tranebjaerg syndrome,Disease,Cases/families,91.0,,Case(s),Worldwide,Validated,20301395[PMID]
52368,Mohr-Tranebjaerg syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301395[PMID]
53271,Muenke syndrome,Malformation syndrome,Prevalence at birth,3.33,1-9 / 100 000,Value and class,Worldwide,Validated,15241680[PMID]
53271,Muenke syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
53271,Muenke syndrome,Malformation syndrome,Prevalence at birth,2.3,1-9 / 100 000,Value and class,Australia,Validated,34626670[PMID]
53296,Familial cutaneous collagenoma,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,5657391[PMID]_486326[PMID]_22028557[PMID]
53296,Familial cutaneous collagenoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5657391[PMID]_486326[PMID]_22028557[PMID]
53347,Brody myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_32040565[PMID]_22704959[PMID]
52994,Orbital leiomyoma,Disease,Cases/families,26.0,,Case(s),Worldwide,Validated,23562416[PMID]
52994,Orbital leiomyoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23562416[PMID]
53035,Caroli disease,Malformation syndrome,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Worldwide,Validated,14696493[PMID]
53035,Caroli disease,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_15559623[PMID]
52759,Vasculitis,Category,Point prevalence,6.3,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
52901,Isolated follicle stimulating hormone deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
538863,Classic pyoderma gangrenosum,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25213386[PMID]
538863,Classic pyoderma gangrenosum,Clinical subtype,Annual incidence,0.0,1-9 / 1 000 000,Class only,Italy,Validated,ORPHANET_29877043[PMID]
538756,Familial multiple discoid fibromas,Disease,Cases/families,44.0,,Case(s),Worldwide,Validated,29067220[PMID]
538756,Familial multiple discoid fibromas,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29067220[PMID]
538574,Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome,Disease,Cases/families,23.0,,Case(s),Worldwide,Validated,6446889[PMID]_2976839[PMID]_27639257[PMID]
538574,Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6446889[PMID]_2976839[PMID]_27639257[PMID]
53583,Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,21832227[PMID]
53583,Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21832227[PMID]
53540,Goldmann-Favre syndrome,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
53540,Goldmann-Favre syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
53372,Hereditary geniospasm,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
53351,X-linked dystonia-parkinsonism,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,15390042[PMID]
53351,X-linked dystonia-parkinsonism,Disease,Point prevalence,0.31,1-9 / 1 000 000,Value and class,Philippines,Validated,21047175[PMID]_20301662[PMID]_ [EXPERT]
54247,Posterior cortical atrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
538934,X-linked lymphoproliferative disease due to XIAP deficiency,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,29942301[PMID]
538934,X-linked lymphoproliferative disease due to XIAP deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29942301[PMID]
54251,Aseptic abscess syndrome,Disease,Cases/families,49.0,,Case(s),Worldwide,Validated,ORPHANET
54251,Aseptic abscess syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
538931,X-linked lymphoproliferative disease due to SAP deficiency,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,29942301[PMID]
538931,X-linked lymphoproliferative disease due to SAP deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29942301[PMID]
54057,Thrombotic thrombocytopenic purpura,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
54057,Thrombotic thrombocytopenic purpura,Disease,Annual incidence,0.35,1-9 / 1 000 000,Value and class,Worldwide,Validated,18637802[PMID]_23729372[PMID]_31730475[PMID]
54028,Plummer-Vinson syndrome,Disease,Cases/families,25.0,,Case(s),Worldwide,Validated,ORPHANET
54028,Plummer-Vinson syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
53719,Wyburn-Mason syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ISBN:3211695001[OTHER]
53719,Wyburn-Mason syndrome,Malformation syndrome,Cases/families,90.0,,Case(s),Worldwide,Validated,ISBN:3211695001[OTHER]
53721,Spinal arteriovenous metameric syndrome,Malformation syndrome,Cases/families,45.0,,Case(s),Worldwide,Validated,26130930[PMID]
53721,Spinal arteriovenous metameric syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26130930[PMID]
53715,Familial tumoral calcinosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
53696,Arthrogryposis-anterior horn cell disease syndrome,Malformation syndrome,Cases/families,15.0,,Case(s),Worldwide,Validated,7821908[PMID]
53696,Arthrogryposis-anterior horn cell disease syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,7821908[PMID]_ORPHANET
538872,Vegetative pyoderma gangrenosum,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25213386[PMID]
538872,Vegetative pyoderma gangrenosum,Clinical subtype,Annual incidence,0.0,<1 / 1 000 000,Class only,Italy,Validated,ORPHANET_29877043[PMID]
53697,Gnathodiaphyseal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27068316[PMID]
538869,Bullous pyoderma gangrenosum,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25213386[PMID]
538869,Bullous pyoderma gangrenosum,Clinical subtype,Annual incidence,0.0,<1 / 1 000 000,Class only,Italy,Validated,ORPHANET_29877043[PMID]
538866,Pustular pyoderma gangrenosum,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25213386[PMID]
538866,Pustular pyoderma gangrenosum,Clinical subtype,Annual incidence,0.0,<1 / 1 000 000,Class only,Italy,Validated,ORPHANET_29877043[PMID]
53693,GRACILE syndrome,Disease,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Finland,Validated,22970607[PMID]
53693,GRACILE syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Finland,Not yet validated,22970607[PMID]
53693,GRACILE syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
48818,Aceruloplasminemia,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Japan,Validated,10449129[PMID]
48818,Aceruloplasminemia,Disease,Point prevalence,0.09,<1 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET
49041,IgG4-related retroperitoneal fibrosis,Clinical subtype,Annual incidence,0.35,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
49041,IgG4-related retroperitoneal fibrosis,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Finland,Not yet validated,16427494[PMID]
49041,IgG4-related retroperitoneal fibrosis,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
48918,Focal myositis,Disease,Cases/families,115.0,,Case(s),Worldwide,Validated,15546587[PMID]
48918,Focal myositis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
49382,Achromatopsia,Disease,Point prevalence,2.7,1-9 / 100 000,Value and class,Worldwide,Validated,ISBN:521590531[OTHER]
49042,Dentinogenesis imperfecta,Disease,Point prevalence,14.5,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
538958,Combined immunodeficiency due to CD70 deficiency,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,29942301[PMID]
538958,Combined immunodeficiency due to CD70 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29942301[PMID]
48431,Congenital cataracts-facial dysmorphism-neuropathy syndrome,Malformation syndrome,Cases/families,170.0,,Case(s),Worldwide,Validated,20301787[PMID]
48431,Congenital cataracts-facial dysmorphism-neuropathy syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301787[PMID]
538963,Combined immunodeficiency due to ITK deficiency,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,29942301[PMID]
538963,Combined immunodeficiency due to ITK deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29942301[PMID]
48435,Postinfectious vasculitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
48686,Primary effusion lymphoma,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,[EXPERT]
48686,Primary effusion lymphoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
48652,Phelan-McDermid syndrome,Malformation syndrome,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
48652,Phelan-McDermid syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
50809,Talo-patello-scaphoid osteolysis,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,12910489[PMID]
50809,Talo-patello-scaphoid osteolysis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12910489[PMID]
50810,Microlissencephaly-micromelia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,12749064[PMID]
50810,Microlissencephaly-micromelia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12749064[PMID]
50811,Lipodystrophy-intellectual disability-deafness syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,12923870[PMID]
50811,Lipodystrophy-intellectual disability-deafness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12923870[PMID]
50812,Zellweger-like syndrome without peroxisomal anomalies,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,12784304[PMID]
50812,Zellweger-like syndrome without peroxisomal anomalies,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12784304[PMID]
50814,Craniolenticulosutural dysplasia,Malformation syndrome,Cases/families,28.0,,Case(s),Worldwide,Validated,ORPHANET
50814,Craniolenticulosutural dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
50815,Branchiogenic deafness syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,12833414[PMID]
50815,Branchiogenic deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12833414[PMID]
49566,Acquired purpura fulminans,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
49566,Acquired purpura fulminans,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
49827,Thiamine-responsive megaloblastic anemia syndrome,Disease,Cases/families,80.0,,Case(s),Worldwide,Validated,[EXPERT]
49827,Thiamine-responsive megaloblastic anemia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
50251,Pleural mesothelioma,Disease,Point prevalence,3.1,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
50251,Pleural mesothelioma,Disease,Annual incidence,1.9,1-9 / 100 000,Value and class,Europe,Not yet validated,22406029[PMID]
50251,Pleural mesothelioma,Disease,Annual incidence,0.8,1-9 / 1 000 000,Value and class,France,Validated,19569174[PMID]
50945,Blomstrand lethal chondrodysplasia,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,27353973[PMID]
50945,Blomstrand lethal chondrodysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27353973[PMID]
50944,Schöpf-Schulz-Passarge syndrome,Disease,Cases/families,25.0,,Case(s),Worldwide,Validated,ORPHANET
50944,Schöpf-Schulz-Passarge syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
51083,Familial short QT syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,23916535[PMID]_[EXPERT]
51083,Familial short QT syndrome,Disease,Cases/families,80.0,,Family(ies),Worldwide,Validated,[EXPERT]
50839,Cat-scratch disease,Disease,Point prevalence,6.6,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
50918,Kikuchi-Fujimoto disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25500707[PMID]
50918,Kikuchi-Fujimoto disease,Disease,Cases/families,1052.0,,Case(s),Worldwide,Validated,25500707[PMID]
50918,Kikuchi-Fujimoto disease,Disease,Annual incidence,0.278,1-9 / 1 000 000,Value and class,Martinique,Validated,27015112[PMID]
52054,Craniosynostosis-intracranial calcifications syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,14564206[PMID]
52054,Craniosynostosis-intracranial calcifications syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14564206[PMID]
52022,Potocki-Shaffer syndrome,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,23239541[PMID]_15852040[PMID]
52022,Potocki-Shaffer syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23239541[PMID]
52047,Braddock syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,14556254[PMID]
52047,Braddock syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14556254[PMID]
51577,Cobblestone lissencephaly,Clinical group,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,ORPHANET
51577,Cobblestone lissencephaly,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
51608,Generalized arterial calcification of infancy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25392903[PMID]
51608,Generalized arterial calcification of infancy,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,[EXPERT]_25392903[PMID]
51188,Ethylmalonic encephalopathy,Disease,Cases/families,80.0,,Case(s),Worldwide,Validated,28933811[PMID]
51188,Ethylmalonic encephalopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28933811[PMID]
541423,Growth delay-intellectual disability-hepatopathy syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,29052218[PMID]_30431579[PMID]
541423,Growth delay-intellectual disability-hepatopathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29052218[PMID]_30431579[PMID]
51208,Formiminoglutamic aciduria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
51636,WHIM syndrome,Disease,Cases/families,65.0,,Case(s),Worldwide,Validated,23009155[PMID]_24492099[PMID]
51636,WHIM syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
51636,WHIM syndrome,Disease,Prevalence at birth,0.023,<1 / 1 000 000,Value and class,France,Validated,23009155[PMID]_[EXPERT]
51890,Anterior cutaneous nerve entrapment syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
51890,Anterior cutaneous nerve entrapment syndrome,Disease,Annual incidence,55.6,6-9 / 10 000,Value and class,Netherlands,Validated,[EXPERT]_25887961[PMID]_72957[PMID]
542306,GNB5-related intellectual disability-cardiac arrhythmia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
542306,GNB5-related intellectual disability-cardiac arrhythmia syndrome,Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,27523599[PMID]_27677260[PMID]_28697420[PMID]_29368331[PMID]_30631341[PMID]
542301,Combined immunodeficiency due to CARMIL2 deficiency,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,27896283[PMID]_27647349[PMID]_28112205[PMID]_29479355[PMID]
542301,Combined immunodeficiency due to CARMIL2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27896283[PMID]_27647349[PMID]_28112205[PMID]_29479355[PMID]
542310,Leukoencephalopathy with calcifications and cysts,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,27571260[PMID]
542310,Leukoencephalopathy with calcifications and cysts,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27571260[PMID]
42642,PFAPA syndrome,Disease,Cases/families,500.0,,Case(s),Worldwide,Validated,24505122[PMID]_24677969[PMID]
42642,PFAPA syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
42665,Tietz syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,23020089[PMID]
42665,Tietz syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23020089[PMID]
542323,CAR T cell therapy-associated cytokine release syndrome,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
43117,Acute tricyclic antidepressant poisoning,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
542585,Auditory neuropathy-optic atrophy syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,28965846[PMID]
542585,Auditory neuropathy-optic atrophy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28965846[PMID]
43116,Serotonin syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
542592,Necrobiosis lipoidica,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29184811[PMID]
43393,Lambert-Eaton myasthenic syndrome,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Netherlands,Validated,22094130[PMID]_23690300[PMID]
43393,Lambert-Eaton myasthenic syndrome,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
43393,Lambert-Eaton myasthenic syndrome,Disease,Point prevalence,0.35,1-9 / 1 000 000,Value and class,Worldwide,Validated,22094130[PMID]
43119,Acute poisoning by drugs with membrane-stabilizing effect,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
542643,Livedoid vasculopathy,Clinical syndrome,Annual incidence,1.0,1-9 / 100 000,Value and class,United States,Validated,4830097[PMID]_21184847[PMID]
542643,Livedoid vasculopathy,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
42775,PHACE syndrome,Malformation syndrome,Cases/families,300.0,,Case(s),Worldwide,Validated,26564079[PMID]
42775,PHACE syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26564079[PMID]
42738,Severe congenital neutropenia,Clinical group,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
42738,Severe congenital neutropenia,Clinical group,Point prevalence,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
42738,Severe congenital neutropenia,Clinical group,Point prevalence,0.07,<1 / 1 000 000,Value and class,Worldwide,Not yet validated,12555210[PMID]
42738,Severe congenital neutropenia,Clinical group,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Sweden,Validated,22624626[PMID]
42738,Severe congenital neutropenia,Clinical group,Point prevalence,0.0,1-9 / 1 000 000,Class only,Sweden,Not yet validated,22624626[PMID]
42738,Severe congenital neutropenia,Clinical group,Point prevalence,0.6,1-9 / 1 000 000,Value and class,France,Validated,20399414[PMID]
42738,Severe congenital neutropenia,Clinical group,Point prevalence,0.077,<1 / 1 000 000,Value and class,"Iran, Islamic Republic of",Validated,17024564[PMID]
42738,Severe congenital neutropenia,Clinical group,Point prevalence,25.7,1-5 / 10 000,Value and class,China,Validated,34103049[PMID]
43115,Hereditary myopathy with lactic acidosis due to ISCU deficiency,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,20301757[PMID]
43115,Hereditary myopathy with lactic acidosis due to ISCU deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301757[PMID]
45448,Miyoshi myopathy,Disease,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Japan,Validated,[EXPERT]
45448,Miyoshi myopathy,Disease,Point prevalence,0.26,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
45448,Miyoshi myopathy,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
543470,Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,29040572[PMID]
543470,Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29040572[PMID]
45453,Incessant infant ventricular tachycardia,Disease,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
45453,Incessant infant ventricular tachycardia,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
45453,Incessant infant ventricular tachycardia,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,United Kingdom,Validated,23551862[PMID]
45453,Incessant infant ventricular tachycardia,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,United Kingdom,Validated,23551862[PMID]
45452,Idiopathic neonatal atrial flutter,Disease,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_23551862[PMID]
45452,Idiopathic neonatal atrial flutter,Disease,Prevalence at birth,2.1,1-9 / 100 000,Value and class,United Kingdom,Validated,23551862[PMID]
45452,Idiopathic neonatal atrial flutter,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
542657,Isolated hyperchlorhidrosis,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,21035102[PMID]_26911677[PMID]_21184099[PMID]
542657,Isolated hyperchlorhidrosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21035102[PMID]_26911677[PMID]_21184099[PMID]
44890,Gastrointestinal stromal tumor,Disease,Point prevalence,13.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]_23623056[PMID]
44890,Gastrointestinal stromal tumor,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Europe,Not yet validated,21420965[PMID]_23623056[PMID]
44890,Gastrointestinal stromal tumor,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,23177515[PMID]
44890,Gastrointestinal stromal tumor,Disease,Annual incidence,1.9,1-9 / 100 000,Value and class,"Korea, Republic of",Not yet validated,20514305[PMID]
44890,Gastrointestinal stromal tumor,Disease,Point prevalence,14.5,1-5 / 10 000,Value and class,Hong Kong,Not yet validated,16610025[PMID]
44890,Gastrointestinal stromal tumor,Disease,Annual incidence,1.82,1-9 / 100 000,Value and class,Hong Kong,Not yet validated,16610025[PMID]
44890,Gastrointestinal stromal tumor,Disease,Annual incidence,1.5,1-9 / 100 000,Value and class,United States,Not yet validated,11213830[PMID]_23079473[PMID]
44890,Gastrointestinal stromal tumor,Disease,Point prevalence,12.9,1-5 / 10 000,Value and class,Sweden,Validated,15648083[PMID]
45358,Congenital fibrosis of extraocular muscles,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET_9797671[PMID]
45358,Congenital fibrosis of extraocular muscles,Disease,Point prevalence,0.43,1-9 / 1 000 000,Value and class,United Kingdom,Validated,9797671[PMID]
46487,Epidermolysis bullosa acquisita,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,Europe,Not yet validated,7826096[PMID]_19170813[PMID]_7669112[PMID]
46487,Epidermolysis bullosa acquisita,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,France,Not yet validated,7826096[PMID]_23237497[PMID]
46487,Epidermolysis bullosa acquisita,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Germany,Validated,19170813[PMID]_7669112[PMID]
46487,Epidermolysis bullosa acquisita,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Singapore,Validated,12207586[PMID]_23237497[PMID]
46487,Epidermolysis bullosa acquisita,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
46487,Epidermolysis bullosa acquisita,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Serbia,Validated,27767273[PMID]
46487,Epidermolysis bullosa acquisita,Disease,Point prevalence,0.284,1-9 / 1 000 000,Value and class,Germany,Validated,27456755[PMID]
544254,SYNGAP1-related developmental and epileptic encephalopathy,Disease,Cases/families,57.0,,Case(s),Worldwide,Validated,30541864[PMID]
544254,SYNGAP1-related developmental and epileptic encephalopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30541864[PMID]
46488,Linear IgA dermatosis,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Germany,Validated,19170813[PMID]
46488,Linear IgA dermatosis,Disease,Annual incidence,0.069,<1 / 1 000 000,Value and class,Kuwait,Validated,15569006[PMID]
46488,Linear IgA dermatosis,Disease,Annual incidence,0.026,<1 / 1 000 000,Value and class,Singapore,Validated,12207586[PMID]_23237497[PMID]
46488,Linear IgA dermatosis,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Germany,Validated,19170813[PMID]_30252369[PMID]_ORPHANET
46488,Linear IgA dermatosis,Disease,Point prevalence,0.207,1-9 / 1 000 000,Value and class,Kuwait,Validated,15569006[PMID]_30252369[PMID]_ORPHANET
46488,Linear IgA dermatosis,Disease,Point prevalence,0.078,<1 / 1 000 000,Value and class,Singapore,Validated,12207586[PMID]_23237497[PMID]_30252369[PMID]_ORPHANET
46485,Superficial pemphigus,Clinical group,Point prevalence,1.2,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
46486,Mucous membrane pemphigoid,Disease,Annual incidence,0.13,1-9 / 1 000 000,Value and class,France,Validated,7826096[PMID]_23237497[PMID]
46486,Mucous membrane pemphigoid,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,Germany,Validated,19170813[PMID]_23237497[PMID]
46486,Mucous membrane pemphigoid,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
46486,Mucous membrane pemphigoid,Disease,Point prevalence,2.456,1-9 / 100 000,Value and class,Germany,Validated,27456755[PMID]
46348,Paroxysmal extreme pain disorder,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,8778439[PMID]
46348,Paroxysmal extreme pain disorder,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
46484,Oligodendroglial tumor,Clinical group,Annual incidence,0.35,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
46484,Oligodendroglial tumor,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
46484,Oligodendroglial tumor,Clinical group,Annual incidence,0.24,1-9 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
46059,Lathosterolosis,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,24142275[PMID]
46059,Lathosterolosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
46135,Primary central nervous system lymphoma,Disease,Annual incidence,0.44,1-9 / 1 000 000,Value and class,United States,Validated,Central Brain Tumor registry of the United States 2010-2014[REG]_29117289[PMID]
46135,Primary central nervous system lymphoma,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,Sweden,Validated,28983970[PMID]
46724,Cerebral arteriovenous malformation,Morphological anomaly,Point prevalence,6.0,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
46627,Char syndrome,Malformation syndrome,Cases/families,109.0,,Case(s),Worldwide,Validated,[EXPERT]_31012281[PMID]
46627,Char syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
46532,Hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
48372,Nodular regenerative hyperplasia of the liver,Histopathological subtype,Annual incidence,0.34,1-9 / 1 000 000,Value and class,Spain,Validated,2586240[PMID]
48372,Nodular regenerative hyperplasia of the liver,Histopathological subtype,Point prevalence,3.1,1-9 / 100 000,Value and class,Spain,Validated,2586240[PMID]
48372,Nodular regenerative hyperplasia of the liver,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
48162,Lewis-Sumner syndrome,Clinical subtype,Point prevalence,0.9,1-9 / 1 000 000,Value and class,Europe,Not yet validated,19260065[PMID]
544493,Streptococcus pneumoniae-associated hemolytic uremic syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
48104,Pyoderma gangrenosum,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,United States,Validated,ISBN:978-1-60831-581-9[OTHER]
48104,Pyoderma gangrenosum,Disease,Annual incidence,0.91,1-9 / 1 000 000,Value and class,United Kingdom,Validated,22534879[PMID]
48104,Pyoderma gangrenosum,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25213386[PMID]
48104,Pyoderma gangrenosum,Disease,Annual incidence,0.33,1-9 / 1 000 000,Value and class,Spain,Validated,21782147[PMID]
48104,Pyoderma gangrenosum,Disease,Annual incidence,0.74,1-9 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET_21782147[PMID]_22534879[PMID]_ISBN:978-1-60831-581-9[OTHER]
48104,Pyoderma gangrenosum,Disease,Annual incidence,0.517,1-9 / 1 000 000,Value and class,Italy,Validated,29877043[PMID]
544503,RNF13-related severe early-onset epileptic encephalopathy,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,30595371[PMID]
544503,RNF13-related severe early-onset epileptic encephalopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30595371[PMID]
47612,Felty syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
544482,Infection-related hemolytic uremic syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
47159,Proximal renal tubular acidosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
544488,Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,30239107[PMID]_30475435[PMID]
544488,Global developmental delay-alopecia-macrocephaly-facial dysmorphism-structural brain anomalies syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30239107[PMID]_30475435[PMID]
544469,PRUNE1-related neurological syndrome,Malformation syndrome,Cases/families,48.0,,Case(s),Worldwide,Validated,30556349[PMID]
544469,PRUNE1-related neurological syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30556349[PMID]
544472,Atypical hemolytic uremic syndrome with complement gene abnormality,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
47045,Familial cold urticaria,Disease,Annual incidence,0.0,Unknown,Class only,Europe,Not yet validated,24262697[PMID]
47045,Familial cold urticaria,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
544628,Atypical Fanconi syndrome-neonatal hyperinsulinism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24285859[PMID]
544628,Atypical Fanconi syndrome-neonatal hyperinsulinism syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,24285859[PMID]
544602,Congenital myopathy with reduced type 2 muscle fibers,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,30215711[PMID]
544602,Congenital myopathy with reduced type 2 muscle fibers,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30215711[PMID]
48377,Subcorneal pustular dermatosis,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
48377,Subcorneal pustular dermatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
544578,"Congenital primary megaureter, refluxing and obstructed form",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
555402,NAD(P)HX dehydratase deficiency,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,30576410[PMID]
555402,NAD(P)HX dehydratase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30576410[PMID]
555434,Fibrohistiocytic inflammatory pseudotumor of the liver,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_17571078[PMID]
555407,NAD(P)HX epimerase deficiency,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,27616477[PMID]_27122014[PMID]
555407,NAD(P)HX epimerase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27616477[PMID]_27122014[PMID]
68367,Rare inborn errors of metabolism,Category,Prevalence at birth,3.3,1-9 / 100 000,Value and class,Germany,Validated,21689452[PMID]
555437,Lymphoplasmacytic inflammatory pseudotumor of the liver,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_17571078[PMID]
555874,Congenital tricuspid valve dysplasia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
555877,FLNA-related X-linked myxomatous valvular dysplasia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29146485[PMID]
555905,IgA pemphigus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_30085605[PMID]
556030,Early-onset familial hypoaldosteronism,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
556037,Late-onset familial hypoaldosteronism,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
556985,Early-onset calcifying leukoencephalopathy-skeletal dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30982608[PMID]_30982609[PMID]_28383543[PMID]
556985,Early-onset calcifying leukoencephalopathy-skeletal dysplasia,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,30982608[PMID]_30982609[PMID]_28383543[PMID]
556955,Pancreatic agenesis-holoprosencephaly syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,31006513[PMID]_28525974[PMID]
556955,Pancreatic agenesis-holoprosencephaly syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_31006513[PMID]_28525974[PMID]
557064,Neonatal epileptic encephalopathy due to glutaminase deficiency,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,30575854[PMID]
557064,Neonatal epileptic encephalopathy due to glutaminase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30575854[PMID]
557056,Spastic ataxia-dysarthria due to glutaminase deficiency,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,29468182[PMID]_30987386[PMID]
557056,Spastic ataxia-dysarthria due to glutaminase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29468182[PMID]_30987386[PMID]
557003,Oculoskeletodental syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,31034465[PMID]
557003,Oculoskeletodental syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_31034465[PMID]
90065,Acquired aneurysmal subarachnoid hemorrhage,Particular clinical situation in a disease or syndrome,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
90066,Pneumonia caused by Pseudomonas aeruginosa infection,Particular clinical situation in a disease or syndrome,Point prevalence,50.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90068,Cocaine intoxication,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2011[INST]
90061,Non-infectious posterior uveitis,Category,Point prevalence,18.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90062,Acute liver failure,Clinical syndrome,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
519388,Autosomal recessive anterior segment dysgenesis,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,27839872[PMID]_29556725[PMID]
519388,Autosomal recessive anterior segment dysgenesis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27839872[PMID]_29556725[PMID]
90064,Acute peripheral arterial occlusion,Particular clinical situation in a disease or syndrome,Point prevalence,16.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90073,Hepatitis B reinfection following liver transplantation,Particular clinical situation in a disease or syndrome,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2004[INST]
90076,Partial deep dermal and full thickness burns,Particular clinical situation in a disease or syndrome,Point prevalence,10.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90069,Systemic monochloroacetate poisoning,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2004[INST]
90050,Retinopathy of prematurity,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
90045,Hereditary folate malabsorption,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
90045,Hereditary folate malabsorption,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90052,Recurrent hepatitis C virus induced liver disease in liver transplant recipients,Particular clinical situation in a disease or syndrome,Point prevalence,7.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90051,Sepsis in premature infants,Particular clinical situation in a disease or syndrome,Point prevalence,32.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90041,Gaisböck syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90039,Hemoglobin D disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90044,Familial pseudohyperkalemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
90042,Primary familial polycythemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90058,Spinal cord injury,Particular clinical situation in a disease or syndrome,Annual incidence,3.57,1-9 / 100 000,Value and class,Canada,Validated,22337075[PMID]
90058,Spinal cord injury,Particular clinical situation in a disease or syndrome,Point prevalence,32.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90060,Diffuse alveolar hemorrhage,Clinical syndrome,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90059,Sudden sensorineural hearing loss,Particular clinical situation in a disease or syndrome,Point prevalence,40.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
90053,Complications after hematopoietic stem cell transplantation,Particular clinical situation in a disease or syndrome,Point prevalence,0.65,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90056,Moderate and severe traumatic brain injury,Particular clinical situation in a disease or syndrome,Point prevalence,37.8,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90024,"Deafness with labyrinthine aplasia, microtia, and microdontia",Malformation syndrome,Cases/families,56.0,,Case(s),Worldwide,Validated,22993869[PMID]
90024,"Deafness with labyrinthine aplasia, microtia, and microdontia",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22993869[PMID]
90023,Primary immunodeficiency syndrome due to P14/LAMTOR2 deficiency,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,17195838[PMID]
90023,Primary immunodeficiency syndrome due to P14/LAMTOR2 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17195838[PMID]
90003,Inflammatory pseudotumor of the liver,Disease,Cases/families,140.0,,Case(s),Worldwide,Validated,ORPHANET
90003,Inflammatory pseudotumor of the liver,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
90037,Drug-induced autoimmune hemolytic anemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
90038,Shiga toxin-associated hemolytic uremic syndrome,Clinical subtype,Annual incidence,2.1,1-9 / 100 000,Value and class,United States,Validated,ISBN:0123864577[OTHER]
90038,Shiga toxin-associated hemolytic uremic syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
90035,Paroxysmal cold hemoglobinuria,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
90036,Mixed-type autoimmune hemolytic anemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
90031,Non-spherocytic hemolytic anemia due to hexokinase deficiency,Disease,Cases/families,17.0,,Family(ies),Worldwide,Validated,ORPHANET
90031,Non-spherocytic hemolytic anemia due to hexokinase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90033,"Autoimmune hemolytic anemia, warm type",Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
90026,Primary erythromelalgia,Disease,Annual incidence,1.1,1-9 / 100 000,Value and class,United States,Validated,18713229[PMID]
90026,Primary erythromelalgia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90030,Hemolytic anemia due to glutathione reductase deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,947404[PMID]
90030,Hemolytic anemia due to glutathione reductase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_947404[PMID]
89936,X-linked hypophosphatemia,Disease,Point prevalence,1.89,1-9 / 100 000,Value and class,Norway,Validated,PMID: 26543054
89936,X-linked hypophosphatemia,Disease,Point prevalence,1.54,1-9 / 100 000,Value and class,United Kingdom,Validated,PMID: 31730177
89936,X-linked hypophosphatemia,Disease,Point prevalence,1.66,1-9 / 100 000,Value and class,Europe,Validated,PMID: 26543054 ; 31730177
89936,X-linked hypophosphatemia,Disease,Annual incidence,4.5,1-9 / 100 000,Value and class,Worldwide,Validated,34009447[PMID]_ORPHANET
89936,X-linked hypophosphatemia,Disease,Point prevalence,2.14,1-9 / 100 000,Value and class,Worldwide,Validated,34009447[PMID]_ORPHANET
89844,"Lissencephaly syndrome, Norman-Roberts type",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
89843,Dystrophic epidermolysis bullosa pruriginosa,Disease,Cases/families,100.0,,Family(ies),Worldwide,Validated,ORPHANET
89843,Dystrophic epidermolysis bullosa pruriginosa,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
89842,"Autosomal recessive generalized dystrophic epidermolysis bullosa, intermediate form",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90001,X-linked cone dysfunction syndrome with myopia,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
90001,X-linked cone dysfunction syndrome with myopia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90000,Erythema elevatum diutinum,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
89938,Bartter syndrome type 4,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET_[EXPERT]
89937,Autosomal dominant hypophosphatemic rickets,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
89937,Autosomal dominant hypophosphatemic rickets,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90340,Blau syndrome,Disease,Prevalence at birth,0.06,<1 / 1 000 000,Value and class,Denmark,Validated,[EXPERT]
90340,Blau syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
90342,Xeroderma pigmentosum variant,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
90342,Xeroderma pigmentosum variant,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90348,Autosomal dominant cutis laxa,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
90348,Autosomal dominant cutis laxa,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90349,Autosomal recessive cutis laxa type 1,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,ORPHANET
90349,Autosomal recessive cutis laxa type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90350,Autosomal recessive cutis laxa type 2,Clinical group,Cases/families,40.0,,Case(s),Worldwide,Validated,ORPHANET
90350,Autosomal recessive cutis laxa type 2,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90354,Brittle cornea syndrome,Disease,Cases/families,65.0,,Case(s),Worldwide,Validated,14679583[PMID]_17122114[PMID]
90354,Brittle cornea syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90362,Primary intestinal lymphangiectasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90289,Localized scleroderma,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
90301,Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,6997748[PMID]_6587221[PMID]
90301,Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90291,Systemic sclerosis,Disease,Point prevalence,15.4,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
90291,Systemic sclerosis,Disease,Annual incidence,230.0,>1 / 1000,Value and class,Spain,Validated,18794710[PMID]
90291,Systemic sclerosis,Disease,Point prevalence,27.7,1-5 / 10 000,Value and class,Spain,Validated,18794710[PMID]
90291,Systemic sclerosis,Disease,Point prevalence,8.8,1-9 / 100 000,Value and class,United Kingdom,Validated,14872101[PMID]
90291,Systemic sclerosis,Disease,Point prevalence,17.3,1-5 / 10 000,Value and class,France,Validated,ORPHANET_15213329[PMID]_23290691[PMID]_26816302[PMID]
90291,Systemic sclerosis,Disease,Annual incidence,110.0,>1 / 1000,Value and class,Greece,Validated,15846586[PMID]
90291,Systemic sclerosis,Disease,Point prevalence,15.4,1-5 / 10 000,Value and class,Greece,Validated,15846586[PMID]
90291,Systemic sclerosis,Disease,Annual incidence,72.0,6-9 / 10 000,Value and class,Japan,Validated,1796818[PMID]
90291,Systemic sclerosis,Disease,Point prevalence,4.6,1-9 / 100 000,Value and class,Japan,Not yet validated,1796818[PMID]
90291,Systemic sclerosis,Disease,Point prevalence,30.0,1-5 / 10 000,Value and class,United States,Validated,18430269[PMID]
90291,Systemic sclerosis,Disease,Point prevalence,44.3,1-5 / 10 000,Value and class,Canada,Validated,19248123[PMID]
90291,Systemic sclerosis,Disease,Annual incidence,204.0,>1 / 1000,Value and class,Australia,Validated,11456035[PMID]
90291,Systemic sclerosis,Disease,Point prevalence,23.3,1-5 / 10 000,Value and class,Australia,Validated,11456035[PMID]
90291,Systemic sclerosis,Disease,Annual incidence,1.09,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,21388247[PMID]
90291,Systemic sclerosis,Disease,Point prevalence,5.63,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,21388247[PMID]
90291,Systemic sclerosis,Disease,Point prevalence,22.2,1-5 / 10 000,Value and class,Italy,Validated,33596949[PMID]
90291,Systemic sclerosis,Disease,Annual incidence,1.7,1-9 / 100 000,Value and class,Italy,Validated,33596949[PMID]
90308,Klippel-Trénaunay syndrome,Disease,Annual incidence,0.007,<1 / 1 000 000,Value and class,United States,Validated,20301304[PMID]
90308,Klippel-Trénaunay syndrome,Disease,Point prevalence,0.007,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
90280,Chilblain lupus,Disease,Cases/families,70.0,,Case(s),Worldwide,Validated,18543054[PMID]
90280,Chilblain lupus,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18543054[PMID]
90281,Discoid lupus erythematosus,Disease,Annual incidence,3.56,1-9 / 100 000,Value and class,United States,Validated,19289752[PMID]
90281,Discoid lupus erythematosus,Disease,Annual incidence,3.2,1-9 / 100 000,Value and class,Sweden,Validated,21574972[PMID]
90186,Meige disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
90285,Lupus erythematosus panniculitis,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,United States,Validated,19289752[PMID]
90285,Lupus erythematosus panniculitis,Disease,Point prevalence,0.315,1-9 / 1 000 000,Value and class,United States,Validated,9918242[PMID]_19289752[PMID]_30658703[PMID]_ORPHANET
90283,Lupus erythematosus tumidus,Disease,Cases/families,250.0,,Case(s),Worldwide,Validated,21798482[PMID]
90283,Lupus erythematosus tumidus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_21798482[PMID]
90080,Scarring in glaucoma filtration surgical procedures,Particular clinical situation in a disease or syndrome,Point prevalence,22.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90078,Invasive infections due to vancomycin-resistant enterococci,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90103,Charcot-Marie-Tooth disease-deafness-intellectual disability syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,9475604[PMID]
90103,Charcot-Marie-Tooth disease-deafness-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9475604[PMID]
514980,ATP13A2-related parkinsonism,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22388936[PMID]_29112700[PMID]
90081,AIDS wasting syndrome,Particular clinical situation in a disease or syndrome,Point prevalence,20.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency[INST]
90117,"Hereditary motor and sensory neuropathy, Okinawa type",Disease,Cases/families,120.0,,Case(s),Worldwide,Validated,22883144[PMID]
90117,"Hereditary motor and sensory neuropathy, Okinawa type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
90114,Autosomal dominant intermediate Charcot-Marie-Tooth disease,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,6.2,1-9 / 100 000,Value and class,United States,Validated,25142309[PMID]_SEER Surveillance Epidemiology and End Results 1973-2011[INST]
88673,Hepatocellular carcinoma,Clinical group,Point prevalence,15.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2017[INST]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,6.264,1-9 / 100 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,2.106,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,5.129,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,5.212,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,9.266,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,15.0,1-5 / 10 000,Value and class,Greece,Validated,22537432[PMID]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,5.0,1-9 / 100 000,Value and class,Canada,Validated,22537432[PMID]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,5.0,1-9 / 100 000,Value and class,Oceania,Validated,22537432[PMID]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,12.5,1-5 / 10 000,Value and class,Latin America,Validated,22537432[PMID]_18666317[PMID]_ ORPHANET
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,35.0,1-5 / 10 000,Value and class,China,Validated,12095924[PMID]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,29.0,1-5 / 10 000,Value and class,Japan,Validated,12095924[PMID]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,49.0,1-5 / 10 000,Value and class,"Korea, Republic of",Validated,12095924[PMID]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,99.0,6-9 / 10 000,Value and class,Mongolia,Validated,12095924[PMID]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,16.0,1-5 / 10 000,Value and class,Africa,Validated,18666317[PMID]_20616577[PMID]_22537432[PMID]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,3.221,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,5.296,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,2.275,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,1.697,1-9 / 100 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,2.762,1-9 / 100 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,2.979,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,1.487,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,3.382,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,1.278,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,1.045,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,1.933,1-9 / 100 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,1.146,1-9 / 100 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,1.627,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,0.925,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,2.345,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,2.762,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,6.649,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88673,Hepatocellular carcinoma,Clinical group,Annual incidence,1.127,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
88644,"Autosomal recessive ataxia, Beauce type",Disease,Cases/families,57.0,,Case(s),Worldwide,Validated,ORPHANET
88644,"Autosomal recessive ataxia, Beauce type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
88659,Autosomal dominant progressive nephropathy with hypertension,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,10930359 [PMID]
88659,Autosomal dominant progressive nephropathy with hypertension,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10930359 [PMID]
88661,Amelogenesis imperfecta,Disease,Point prevalence,7.1,1-9 / 100 000,Value and class,United States,Validated,13469154[PMID]
88661,Amelogenesis imperfecta,Disease,Point prevalence,90.0,6-9 / 10 000,Value and class,India,Validated,21712629[PMID]
88661,Amelogenesis imperfecta,Disease,Point prevalence,142.0,>1 / 1000,Value and class,Sweden,Validated,3169793[PMID]
88661,Amelogenesis imperfecta,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
88637,Hypomyelination-hypogonadotropic hypogonadism-hypodontia syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29618326[PMID]
88639,Neurodegeneration due to 3-hydroxyisobutyryl-CoA hydrolase deficiency,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,29703962[PMID]
88639,Neurodegeneration due to 3-hydroxyisobutyryl-CoA hydrolase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29703962[PMID]
88642,Congenital insensitivity to pain-anosmia-neuropathic arthropathy,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
88642,Congenital insensitivity to pain-anosmia-neuropathic arthropathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
88643,Obesity-colitis-hypothyroidism-cardiac hypertrophy-developmental delay syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,17163533[PMID]
88643,Obesity-colitis-hypothyroidism-cardiac hypertrophy-developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17163533[PMID]
88635,Vacuolar myopathy with sarcoplasmic reticulum protein aggregates,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,16714317[PMID]
88635,Vacuolar myopathy with sarcoplasmic reticulum protein aggregates,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16714317[PMID]
88621,Ichthyosis-prematurity syndrome,Disease,Cases/families,16.0,,Family(ies),Worldwide,Validated,ORPHANET
88621,Ichthyosis-prematurity syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
88628,Posterior column ataxia-retinitis pigmentosa syndrome,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
88628,Posterior column ataxia-retinitis pigmentosa syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
88629,Tritanopia,Disease,Point prevalence,4.8,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
88630,Terminal osseous dysplasia-pigmentary defects syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26059211[PMID]
88620,Isolated congenital anosmia,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,ORPHANET
88620,Isolated congenital anosmia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
88619,Familial acute necrotizing encephalopathy,Disease,Cases/families,14.0,,Family(ies),Worldwide,Validated,12874403[PMID]_19118815[PMID]_21205700[PMID]
88619,Familial acute necrotizing encephalopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12874403[PMID]_19118815[PMID]_21205700[PMID]
88618,S-adenosylhomocysteine hydrolase deficiency,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,2380820[PMID]_15024124[PMID]
88618,S-adenosylhomocysteine hydrolase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2380820[PMID]_15024124[PMID]
87884,Non-syndromic genetic deafness,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
87876,Sialidosis type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
87876,Sialidosis type 2,Disease,Prevalence at birth,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
87503,Mal de Meleda,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,9887370[PMID]
86923,"Hereditary palmoplantar keratoderma, Gamborg-Nielsen type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
86920,Dermatopathia pigmentosa reticularis,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,27512211[PMID]
86920,Dermatopathia pigmentosa reticularis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27512211[PMID]
86919,Keratosis palmaris et plantaris-clinodactyly syndrome,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
86919,Keratosis palmaris et plantaris-clinodactyly syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
86918,Diffuse palmoplantar keratoderma-acrocyanosis syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,2564235[PMID]_8578969[PMID]
86918,Diffuse palmoplantar keratoderma-acrocyanosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2564235[PMID]_8578969[PMID]
86915,Lymphedema-atrial septal defects-facial changes syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,19533797[PMID]
86915,Lymphedema-atrial septal defects-facial changes syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19533797[PMID]
522077,Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,30107533[PMID]
522077,Infantile hypotonia-oculomotor anomalies-hyperkinetic movements-developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30107533[PMID]
86913,Myoclonic epilepsy in non-progressive encephalopathies,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_25266964[PMID]
86914,Lymphedema-cerebral arteriovenous anomaly-primary pulmonary hypertension syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,5718986[PMID]
86914,Lymphedema-cerebral arteriovenous anomaly-primary pulmonary hypertension syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5718986[PMID]
86909,Myoclonic epilepsy of infancy,Disease,Cases/families,106.0,,Case(s),Worldwide,Validated,ORPHANET
86909,Myoclonic epilepsy of infancy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
521450,LAMA5-related multisystemic syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,28735299[PMID]
521450,LAMA5-related multisystemic syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28735299[PMID]
521445,Microcephaly-facial dysmorphism-ocular anomalies-multiple congenital anomalies syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,28722276[PMID]
521445,Microcephaly-facial dysmorphism-ocular anomalies-multiple congenital anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28722276[PMID]
521438,Congenital vertebral-cardiac-renal anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28792876[PMID]
521438,Congenital vertebral-cardiac-renal anomalies syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,28792876[PMID]
86900,Interdigitating dendritic cell sarcoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
521432,Congenital cataract-severe neonatal hepatopathy-global developmental delay syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27878435[PMID]
521432,Congenital cataract-severe neonatal hepatopathy-global developmental delay syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,27878435[PMID]
86902,Follicular dendritic cell sarcoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
521426,PLAA-associated neurodevelopmental disorder,Malformation syndrome,Cases/families,15.0,,Case(s),Worldwide,Validated,28007986[PMID]_28413018[PMID]
521426,PLAA-associated neurodevelopmental disorder,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28007986[PMID]_28413018[PMID]
86896,Histiocytic sarcoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
521414,Autosomal dominant Charcot-Marie-Tooth disease type 2DD,Disease,Cases/families,51.0,,Case(s),Worldwide,Validated,29499166[PMID]
521414,Autosomal dominant Charcot-Marie-Tooth disease type 2DD,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29499166[PMID]
521258,Xq25 microduplication syndrome,Malformation syndrome,Cases/families,28.0,,Case(s),Worldwide,Validated,26443594[PMID]
521258,Xq25 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26443594[PMID]
521305,Proximal myopathy with focal depletion of mitochondria,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,26782016[PMID]_27169979[PMID]
521305,Proximal myopathy with focal depletion of mitochondria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26782016[PMID]_27169979[PMID]
521308,Frontonasal dysplasia-bifid nose-upper limb anomalies syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,29136349[PMID]
521308,Frontonasal dysplasia-bifid nose-upper limb anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29136349[PMID]
521390,Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,27005418[PMID]
521390,Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27005418[PMID]
521406,Dystonia-parkinsonism-hypermanganesemia syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,29382362[PMID]_29685658[PMID]_27231142[PMID]
521406,Dystonia-parkinsonism-hypermanganesemia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29382362[PMID]_29685658[PMID]_27231142[PMID]
89838,Autosomal recessive generalized epidermolysis bullosa simplex,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,[EXPERT]
89838,Autosomal recessive generalized epidermolysis bullosa simplex,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
521411,Autosomal recessive axonal Charcot-Marie-Tooth disease due to copper metabolism defect,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,29351582[PMID]
521411,Autosomal recessive axonal Charcot-Marie-Tooth disease due to copper metabolism defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29351582[PMID]
521219,Mirizzi syndrome,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29494098[PMID]
88949,MUC1-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
88949,MUC1-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
88949,MUC1-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Point prevalence,0.07,<1 / 1 000 000,Value and class,United States,Validated,31488840[PMID]
88949,MUC1-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Point prevalence,0.4,1-9 / 1 000 000,Value and class,Ireland,Validated,31488840[PMID]
88950,UMOD-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Point prevalence,1.7,1-9 / 1 000 000,Value and class,Austria,Validated,22740033[PMID]
88950,UMOD-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Point prevalence,9.0,1-9 / 1 000 000,Value and class,United Kingdom,Validated,30376835[PMID]
88950,UMOD-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_21868615[PMID]
88991,Rare congenital non-syndromic heart malformation,Category,Prevalence at birth,7.8,1-9 / 100 000,Value and class,Europe,Not yet validated,21321151[PMID]
88991,Rare congenital non-syndromic heart malformation,Category,Prevalence at birth,223.0,>1 / 1000,Value and class,Canada,Validated,23812182[PMID]
88924,Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
88924,Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
88917,X-linked Alport syndrome,Clinical subtype,Prevalence at birth,1.25,1-9 / 100 000,Value and class,Sweden,Validated,16114783[PMID]
88917,X-linked Alport syndrome,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
93256,Fragile X-associated tremor/ataxia syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,United States,Validated,15000674[PMID]_17166801[PMID]_ [EXPERT]
93256,Fragile X-associated tremor/ataxia syndrome,Malformation syndrome,Lifetime Prevalence,6.3,1-9 / 100 000,Value and class,United States,Validated,15000674[PMID]_17166801[PMID]_ [EXPERT]
93256,Fragile X-associated tremor/ataxia syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
528105,Hypohidrosis-electrolyte imbalance-lacrimal gland dysfunction-ichthyosis-xerostomia syndrome,Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,DOI: https://doi.org/10.1053/j.ajkd.2018.08.015[OTHER]
528105,Hypohidrosis-electrolyte imbalance-lacrimal gland dysfunction-ichthyosis-xerostomia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_DOI: https://doi.org/10.1053/j.ajkd.2018.08.015[OTHER]
528091,Hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,26537577[PMID]
528091,Hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26537577[PMID]
528084,Non-specific syndromic intellectual disability,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
93262,Crouzon syndrome-acanthosis nigricans syndrome,Malformation syndrome,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Worldwide,Validated,23986840[PMID]_ISBN:019511843X[OTHER]
93262,Crouzon syndrome-acanthosis nigricans syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
93260,Pfeiffer syndrome type 3,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
93259,Pfeiffer syndrome type 2,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
93258,Pfeiffer syndrome type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
93271,"Short rib-polydactyly syndrome, Verma-Naumoff type",Malformation syndrome,Prevalence at birth,5.2,1-9 / 100 000,Value and class,United Arab Emirates,Validated,12769508[PMID]
93271,"Short rib-polydactyly syndrome, Verma-Naumoff type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,United Arab Emirates,Validated,ORPHANET
93269,"Short rib-polydactyly syndrome, Majewski type",Malformation syndrome,Cases/families,34.0,,Case(s),Worldwide,Validated,20607029[PMID]
93269,"Short rib-polydactyly syndrome, Majewski type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20607029[PMID]
93267,Cloverleaf skull-multiple congenital anomalies syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,12081722[PMID]
93267,Cloverleaf skull-multiple congenital anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12081722[PMID]
93282,"Spondyloepimetaphyseal dysplasia, PAPSS2 type",Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,ORPHANET
93282,"Spondyloepimetaphyseal dysplasia, PAPSS2 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93283,"Spondyloepiphyseal dysplasia, Kimberley type",Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,1978986[PMID]
93283,"Spondyloepiphyseal dysplasia, Kimberley type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93279,Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,7757086[PMID]
93279,Mild spondyloepiphyseal dysplasia due to COL2A1 mutation with early-onset osteoarthritis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7757086[PMID]
93274,Thanatophoric dysplasia type 2,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93108,Renal dysplasia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
93108,Renal dysplasia,Morphological anomaly,Prevalence at birth,43.5,1-5 / 10 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies[REG]_21381187[PMID]
527497,NKX6-2-related autosomal recessive hypomyelinating leukodystrophy,Disease,Cases/families,25.0,,Case(s),Worldwide,Validated,29388673[PMID]_30285346[PMID]
527497,NKX6-2-related autosomal recessive hypomyelinating leukodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29388673[PMID]_30285346[PMID]
93101,Renal hypoplasia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
93110,Posterior urethral valve,Morphological anomaly,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
93110,Posterior urethral valve,Morphological anomaly,Prevalence at birth,4.125,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_19838598[PMID]
93110,Posterior urethral valve,Morphological anomaly,Prevalence at birth,6.4,1-9 / 100 000,Value and class,Australia,Validated,25198372[PMID]
93109,Congenital megacalycosis,Morphological anomaly,Cases/families,25.0,,Case(s),Worldwide,Validated,23252475[PMID]
93109,Congenital megacalycosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23252475[PMID]
527450,Severe myopia-generalized joint laxity-short stature syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,28475863[PMID]
527450,Severe myopia-generalized joint laxity-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28475863[PMID]
91547,Relapsing fever,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93100,"Renal agenesis, unilateral",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
93100,"Renal agenesis, unilateral",Clinical subtype,Prevalence at birth,50.0,1-5 / 10 000,Value and class,Worldwide,Validated,23449343[PMID]
527468,Diaphragmatic hernia-short bowel-asplenia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,28898547[PMID]
527468,Diaphragmatic hernia-short bowel-asplenia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28898547[PMID]
92050,Congenital tufting enteropathy,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,Dr Julie Salomon_Dr Olivier Goulet[EXPERT]
92050,Congenital tufting enteropathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_17448233[PMID]
93160,Hypocalcemic vitamin D-resistant rickets,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93164,Transient pseudohypoaldosteronism,Disease,Cases/families,152.0,,Case(s),Worldwide,Validated,36090572[PMID]
93164,Transient pseudohypoaldosteronism,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,36090572[PMID]_ORPHANET
93114,Autosomal dominant intermediate Charcot-Marie-Tooth disease type E,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,22187985[PMID]_24174593[PMID]
93114,Autosomal dominant intermediate Charcot-Marie-Tooth disease type E,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93111,HNF1B-related autosomal dominant tubulointerstitial kidney disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
93126,Pauci-immune glomerulonephritis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_Dr Laure-Hélène NOEL[EXPERT]
93172,"Renal dysplasia, unilateral",Clinical subtype,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,EUROCAT European surveillance of congenital anomalies[REG]_ORPHANET
93172,"Renal dysplasia, unilateral",Clinical subtype,Prevalence at birth,0.0,1-5 / 10 000,Class only,Europe,Validated,EUROCAT European surveillance of congenital anomalies[REG]_[EXPERT]
93173,"Renal dysplasia, bilateral",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Validated,[EXPERT]
93322,Isolated tibial hemimelia,Morphological anomaly,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,16224672[PMID]
93322,Isolated tibial hemimelia,Morphological anomaly,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET
93321,Isolated radial hemimelia,Morphological anomaly,Prevalence at birth,2.5,1-9 / 100 000,Value and class,Worldwide,Validated,28669420[PMID]_34452798[PMID]_ORPHANET
93321,Isolated radial hemimelia,Morphological anomaly,Point prevalence,2.5,1-9 / 100 000,Class only,Worldwide,Validated,28669420[PMID]_34452798[PMID]_ORPHANET
93320,Isolated ulnar hemimelia,Morphological anomaly,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
93323,Isolated fibular hemimelia,Morphological anomaly,Prevalence at birth,1.1033,1-9 / 100 000,Value and class,Worldwide,Validated,20498623[PMID]_27909861[PMID]
93323,Isolated fibular hemimelia,Morphological anomaly,Point prevalence,1.1033,1-9 / 100 000,Value and class,Worldwide,Validated,20498623[PMID]_27909861[PMID]_ORPHANET
93329,Autosomal recessive omodysplasia,Clinical subtype,Cases/families,23.0,,Case(s),Worldwide,Validated,19481194[PMID]
93329,Autosomal recessive omodysplasia,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93335,Postaxial polydactyly type B,Morphological anomaly,Point prevalence,43.5,1-5 / 10 000,Value and class,Mexico,Validated,31091006[PMID]_ORPHANET
93335,Postaxial polydactyly type B,Morphological anomaly,Prevalence at birth,43.5,1-5 / 10 000,Value and class,Mexico,Validated,31091006[PMID]
93334,Postaxial polydactyly type A,Morphological anomaly,Point prevalence,15.7,1-5 / 10 000,Value and class,Mexico,Validated,31091006[PMID]_ORPHANET
93334,Postaxial polydactyly type A,Morphological anomaly,Prevalence at birth,15.7,1-5 / 10 000,Value and class,Mexico,Validated,31091006[PMID]
93333,Pelviscapular dysplasia,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,19068278[PMID]
93333,Pelviscapular dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19068278[PMID]
93337,Polydactyly of an index finger,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID]
527276,Encephalopathy due to mitochondrial and peroxisomal fission defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17460227[PMID]_26825290[PMID]_26992161[PMID]_26604000[PMID]_27145208[PMID]_30109270[PMID]_27328748[PMID]_26783368[PMID]
93346,"Spondyloepimetaphyseal dysplasia congenita, Strudwick type",Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,[EXPERT]
93346,"Spondyloepimetaphyseal dysplasia congenita, Strudwick type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93347,Anauxetic dysplasia,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,27380734[PMID]
93347,Anauxetic dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27380734[PMID]
93356,"Spondyloepimetaphyseal dysplasia, Missouri type",Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,9258750[PMID]
93356,"Spondyloepimetaphyseal dysplasia, Missouri type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93351,"Spondyloepimetaphyseal dysplasia, Irapa type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6772027[PMID]
93352,"Spondyloepimetaphyseal dysplasia, Shohat type",Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,8357004[PMID]_8074146[PMID]_28263186[PMID]
93352,"Spondyloepimetaphyseal dysplasia, Shohat type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28263186[PMID]
93284,Spondyloepiphyseal dysplasia tarda,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
93296,Achondrogenesis type 2,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93298,Achondrogenesis type 1B,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301689[PMID]
93297,Hypochondrogenesis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93299,Achondrogenesis type 1A,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93302,"Brachyolmia, Maroteaux type",Malformation syndrome,Cases/families,4.0,,Family(ies),Worldwide,Validated,2669482[PMID]_20503319[PMID]
93302,"Brachyolmia, Maroteaux type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2669482[PMID]
93307,Multiple epiphyseal dysplasia type 4,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_18328978[PMID]
93308,Multiple epiphyseal dysplasia type 1,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_18328978[PMID]
93311,Multiple epiphyseal dysplasia type 5,Disease,Cases/families,18.0,,Family(ies),Worldwide,Validated,15948199[PMID]
93311,Multiple epiphyseal dysplasia type 5,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15948199[PMID]
93314,"Spondylometaphyseal dysplasia, Kozlowski type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,[EXPERT]
93315,"Spondylometaphyseal dysplasia, 'corner fracture' type",Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,[EXPERT]
93315,"Spondylometaphyseal dysplasia, 'corner fracture' type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29100092[PMID]
93316,"Spondylometaphyseal dysplasia, Schmidt type",Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,23653587[PMID]_[EXPERT]
93316,"Spondylometaphyseal dysplasia, Schmidt type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93317,"Spondylometaphyseal dysplasia, Sedaghatian type",Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,[EXPERT]
93317,"Spondylometaphyseal dysplasia, Sedaghatian type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
529962,17q24.2 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28465847[PMID]_29696806[PMID]
529962,17q24.2 microdeletion syndrome,Malformation syndrome,Cases/families,19.0,,Case(s),Worldwide,Validated,29696806[PMID]
529864,Secondary erythromelalgia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
529864,Secondary erythromelalgia,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,United States,Validated,18713229[PMID]
529852,Combined hepatocellular carcinoma and cholangiocarcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_23034166[PMID]
90673,Hypothyroidism due to TSH receptor mutations,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90674,Isolated thyroid-stimulating hormone deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
529831,Letrozole toxicity,Particular clinical situation in a disease or syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
529808,Chronic bilirubin encephalopathy,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Canada,Validated,22966025[PMID]_ORPHANET
529808,Chronic bilirubin encephalopathy,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Denmark,Validated,15858962[PMID]_ORPHANET
529808,Chronic bilirubin encephalopathy,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,United States,Validated,15466085[PMID]_ORPHANET
529808,Chronic bilirubin encephalopathy,Clinical syndrome,Prevalence at birth,1.49,1-9 / 100 000,Value and class,Canada,Validated,22966025[PMID]
529808,Chronic bilirubin encephalopathy,Clinical syndrome,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Denmark,Validated,15858962[PMID]
529808,Chronic bilirubin encephalopathy,Clinical syndrome,Prevalence at birth,1.0,1-9 / 100 000,Value and class,United States,Validated,15466085[PMID]
90658,Charcot-Marie-Tooth disease type 1E,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_23224996[PMID]
529799,Acute bilirubin encephalopathy,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,United Kingdom,Validated,32021624[PMID]_ORPHANET
529799,Acute bilirubin encephalopathy,Clinical syndrome,Prevalence at birth,0.87,1-9 / 1 000 000,Value and class,United Kingdom,Validated,17074786[PMID]
90791,Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency,Disease,Cases/families,68.0,,Case(s),Worldwide,Validated,12428206[PMID]_15671104[PMID]_17496421[PMID]_15448795[PMID]_15559435[PMID]
90791,Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90790,Congenital lipoid adrenal hyperplasia due to STAR deficency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
529980,Inflammatory bowel disease-recurrent sinopulmonary infections syndrome,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,25667416[PMID]
529980,Inflammatory bowel disease-recurrent sinopulmonary infections syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25667416[PMID]
529977,Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,30026316[PMID]
529977,Immune dysregulation-inflammatory bowel disease-arthritis-recurrent infections-lymphopenia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30026316[PMID]
529965,Intellectual disability-autism-speech apraxia-craniofacial dysmorphism syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,28866611[PMID]
529965,Intellectual disability-autism-speech apraxia-craniofacial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28866611[PMID]
529970,Male infertility due to acephalic spermatozoa,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27640305[PMID]_30032984[PMID]
90400,Scleromyxedema without monoclonal gammopathy,Clinical subtype,Cases/families,15.0,,Case(s),Worldwide,Validated,ORPHANET
90400,Scleromyxedema without monoclonal gammopathy,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90625,Rare X-linked non-syndromic sensorineural deafness type DFN,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90635,Rare autosomal dominant non-syndromic sensorineural deafness type DFNA,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90636,Rare autosomal recessive non-syndromic sensorineural deafness type DFNB,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
529468,Monoclonal mast cell activation syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_24745674[PMID]
529574,Duane retraction syndrome with congenital deafness,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,27181683[PMID]
529574,Duane retraction syndrome with congenital deafness,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27181683[PMID
90398,Localized lichen myxedematosus with mixed features of different subtypes,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
90398,Localized lichen myxedematosus with mixed features of different subtypes,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90399,Localized lichen myxedematosus with monoclonal gammopathy or systemic symptoms,Clinical subtype,Cases/families,5.0,,Case(s),Worldwide,Validated,22235972[PMID]
90399,Localized lichen myxedematosus with monoclonal gammopathy or systemic symptoms,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90368,Hypotrichosis simplex of the scalp,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90390,Anonychia-onychodystrophy syndrome,Clinical subtype,Cases/families,14.0,,Case(s),Worldwide,Validated,15200512[PMID]
90390,Anonychia-onychodystrophy syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
90652,Otopalatodigital syndrome type 2,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,17431908[PMID]
90652,Otopalatodigital syndrome type 2,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17431908[PMID]
529665,Neurodevelopmental delay-seizures-ophthalmic anomalies-osteopenia-cerebellar atrophy syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,29100095[PMID]
529665,Neurodevelopmental delay-seizures-ophthalmic anomalies-osteopenia-cerebellar atrophy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29100095[PMID]
90647,Jervell and Lange-Nielsen syndrome,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Worldwide,Validated,[EXPERT]
90641,Rare mitochondrial non-syndromic sensorineural deafness,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
91387,Familial thoracic aortic aneurysm and aortic dissection,Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,ORPHANET
91387,Familial thoracic aortic aneurysm and aortic dissection,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
91396,Isolated cryptophthalmia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16352480[PMID]
91396,Isolated cryptophthalmia,Morphological anomaly,Cases/families,30.0,,Case(s),Worldwide,Validated,16352480[PMID]
91378,Hereditary angioedema,Clinical group,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,23662043[PMID]_European Medicines Agency 2018[INST]
91378,Hereditary angioedema,Clinical group,Point prevalence,1.4,1-9 / 100 000,Value and class,Denmark,Validated,19709101[PMID]
91378,Hereditary angioedema,Clinical group,Point prevalence,1.51,1-9 / 100 000,Value and class,Norway,Validated,11202238[PMID]
91378,Hereditary angioedema,Clinical group,Point prevalence,1.09,1-9 / 100 000,Value and class,Spain,Validated,15875532[PMID]
91385,Acquired angioedema,Clinical group,Point prevalence,0.11,1-9 / 1 000 000,Value and class,Denmark,Validated,23921495[PMID]
91385,Acquired angioedema,Clinical group,Cases/families,200.0,,Case(s),Worldwide,Validated,23921495[PMID]
91385,Acquired angioedema,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
91412,Marcus-Gunn syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
91397,Isolated ankyloblepharon filiforme adnatum,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
91411,Congenital ptosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
91355,Sheehan syndrome,Malformation syndrome,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
91355,Sheehan syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
91359,Chronic pneumonitis of infancy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
91496,Snowflake vitreoretinal degeneration,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
91496,Snowflake vitreoretinal degeneration,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
91495,Persistent hyperplastic primary vitreous,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
91494,Macular coloboma-cleft palate-hallux valgus syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,4977272[PMID]
91494,Macular coloboma-cleft palate-hallux valgus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4977272[PMID]
91546,Lyme disease,Disease,Annual incidence,177.5,>1 / 1000,Value and class,Europe,Validated,[EXPERT]
91546,Lyme disease,Disease,Annual incidence,16.6,1-5 / 10 000,Value and class,France,Validated,[EXPERT]
91546,Lyme disease,Disease,Annual incidence,21.9,1-5 / 10 000,Value and class,Worldwide,Not yet validated,emedicine[OTHER]
91546,Lyme disease,Disease,Annual incidence,12.37,1-5 / 10 000,Value and class,Hungary,Validated,23428090[PMID]
91546,Lyme disease,Disease,Annual incidence,36.0,1-5 / 10 000,Value and class,Sweden,Not yet validated,ORPHANET
91546,Lyme disease,Disease,Annual incidence,100.0,>1 / 1000,Value and class,United States,Validated,24045727[PMID]
91546,Lyme disease,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
91500,Tubulointerstitial nephritis and uveitis syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_28709457[PMID]
91498,Familial congenital palsy of trochlear nerve,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,3985833[PMID]
91498,Familial congenital palsy of trochlear nerve,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3985833[PMID]
91481,Ring dermoid of cornea,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
91481,Ring dermoid of cornea,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
91416,Isolated congenital alacrima,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
91414,Pilomatrixoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
91127,Adenovirus infection in immunocompromised patients,Particular clinical situation in a disease or syndrome,Point prevalence,18.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2003[INST]
91130,Cardiomyopathy-hypotonia-lactic acidosis syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,17273968[PMID]
91130,Cardiomyopathy-hypotonia-lactic acidosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17273968[PMID]
91131,DK1-CDG,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,23890587[PMID]
91131,DK1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23890587[PMID]
91132,Ichthyosis-hypotrichosis syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,26596219[PMID]
91132,Ichthyosis-hypotrichosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26596219[PMID]
90793,Congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Point prevalence,7.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Prevalence at birth,7.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,3259306[PMID]_15964450[PMID]
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Prevalence at birth,6.4,1-9 / 100 000,Value and class,France,Validated,22312171[PMID]
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Prevalence at birth,9.2,1-9 / 100 000,Value and class,Italy,Not yet validated,ORPHANET
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Prevalence at birth,8.7,1-9 / 100 000,Value and class,Sweden,Validated,2321478[PMID]
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Prevalence at birth,6.2,1-9 / 100 000,Value and class,United States,Validated,9521938[PMID]_22692165[PMID]
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Prevalence at birth,4.2,1-9 / 100 000,Value and class,New Zealand,Validated,7815200[PMID]
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Prevalence at birth,6.4,1-9 / 100 000,Value and class,Croatia,Validated,19844117[PMID]
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Prevalence at birth,6.2,1-9 / 100 000,Value and class,Estonia,Validated,18204270[PMID]
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Prevalence at birth,4.5,1-9 / 100 000,Value and class,Singapore,Validated,12008686[PMID]
90794,Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency,Disease,Prevalence at birth,6.5,1-9 / 100 000,Value and class,Switzerland,Validated,6967865[PMID]
90795,Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency,Disease,Prevalence at birth,0.75,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
90795,Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency,Disease,Point prevalence,0.47,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
90796,"46,XY difference of sex development due to isolated 17,20-lyase deficiency",Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,22170710[PMID]
90796,"46,XY difference of sex development due to isolated 17,20-lyase deficiency",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22170710[PMID]
90797,Partial androgen insensitivity syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
90970,Primary lipodystrophy,Category,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
91347,TSH-secreting pituitary adenoma,Disease,Point prevalence,0.28,1-9 / 1 000 000,Value and class,Sweden,Validated,23295463[PMID]
91349,Non-functioning pituitary adenoma,Disease,Annual incidence,1.05,1-9 / 100 000,Value and class,Worldwide,Validated,25946030[PMID]_20534753[PMID]_10770176[PMID]
91349,Non-functioning pituitary adenoma,Disease,Annual incidence,2.55,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET_25946030[PMID]_20534753[PMID]_10770176[PMID]
91349,Non-functioning pituitary adenoma,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,ORPHANET_26072284[PMID]
91349,Non-functioning pituitary adenoma,Disease,Annual incidence,4.0,1-9 / 100 000,Value and class,Finland,Validated,20534753[PMID]
91349,Non-functioning pituitary adenoma,Disease,Annual incidence,1.1,1-9 / 100 000,Value and class,Sweden,Validated,10770176[PMID]
91349,Non-functioning pituitary adenoma,Disease,Point prevalence,94.0,6-9 / 10 000,Value and class,Belgium,Validated,16968795[PMID]
91349,Non-functioning pituitary adenoma,Disease,Point prevalence,80.5,6-9 / 10 000,Value and class,Switzerland,Validated,19968031[PMID]
91349,Non-functioning pituitary adenoma,Disease,Point prevalence,77.6,6-9 / 10 000,Value and class,United Kingdom,Validated,19650784[PMID]
91349,Non-functioning pituitary adenoma,Disease,Point prevalence,68.0,6-9 / 10 000,Value and class,Finland,Validated,20534753[PMID]
91350,Pituitary deficiency due to Rathke cleft cysts,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_21951110[PMID]
91136,Acquired monoclonal Ig light chain-associated Fanconi syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,[EXPERT]
91136,Acquired monoclonal Ig light chain-associated Fanconi syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
91135,Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,25151188[PMID]
91135,Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25151188[PMID]
91138,Cryoglobulinemic vasculitis,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,United States,Validated,6996482[PMID]
91138,Cryoglobulinemic vasculitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
91137,Immunotactoid or fibrillary glomerulopathy,Clinical group,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
91139,Simple cryoglobulinemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79396,"Autosomal dominant generalized epidermolysis bullosa simplex, severe form",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
79397,Epidermolysis bullosa simplex with mottled pigmentation,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79394,Congenital ichthyosiform erythroderma,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Spain,Validated,22000705[PMID]
79394,Congenital ichthyosiform erythroderma,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
79395,Keratoderma hereditarium mutilans with ichthyosis,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,24346921[PMID]
79395,Keratoderma hereditarium mutilans with ichthyosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24346921[PMID]
79373,Ectodermal dysplasia syndrome,Category,Point prevalence,0.0,6-9 / 10 000,Class only,Worldwide,Validated,15468153[PMID]
79399,"Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79401,PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement,Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,22854623[PMID]_23774525[PMID]
79401,PLEC-related intermediate epidermolysis bullosa simplex without extracutaneous involvement,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79400,Localized epidermolysis bullosa simplex,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
79403,Junctional epidermolysis bullosa with pyloric atresia,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,20301336[PMID]
79403,Junctional epidermolysis bullosa with pyloric atresia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301336[PMID]
79402,Intermediate generalized junctional epidermolysis bullosa,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79405,Junctional epidermolysis bullosa inversa,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,[EXPERT]
79405,Junctional epidermolysis bullosa inversa,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79404,Severe generalized junctional epidermolysis bullosa,Disease,Prevalence at birth,0.17,1-9 / 1 000 000,Value and class,Worldwide,Validated,ORPHANET
79404,Severe generalized junctional epidermolysis bullosa,Disease,Prevalence at birth,0.04,<1 / 1 000 000,Value and class,United States,Validated,[EXPERT]
79404,Severe generalized junctional epidermolysis bullosa,Disease,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,Netherlands,Validated,21801158[PMID]
79404,Severe generalized junctional epidermolysis bullosa,Disease,Prevalence at birth,0.07,<1 / 1 000 000,Value and class,Italy,Validated,[EXPERT]
79404,Severe generalized junctional epidermolysis bullosa,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
79406,Late-onset junctional epidermolysis bullosa,Disease,Cases/families,37.0,,Case(s),Worldwide,Validated,[EXPERT]_24005051[PMID]
79406,Late-onset junctional epidermolysis bullosa,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79409,Recessive dystrophic epidermolysis bullosa inversa,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
79409,Recessive dystrophic epidermolysis bullosa inversa,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79408,"Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form",Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,United States,Validated,31920360[PMID]
79408,"Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form",Disease,Prevalence at birth,1.3,1-9 / 100 000,Value and class,Europe,Validated,31920360[PMID]
79408,"Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form",Disease,Point prevalence,0.963,1-9 / 1 000 000,Value and class,Europe,Validated,31920360[PMID]_ORPHANET
79408,"Autosomal recessive generalized dystrophic epidermolysis bullosa, severe form",Disease,Point prevalence,0.2222,1-9 / 1 000 000,Value and class,United States,Validated,31920360[PMID]_ORPHANET
79411,Self-improving dystrophic epidermolysis bullosa,Disease,Cases/families,52.0,,Case(s),Worldwide,Validated,ORPHANET
79411,Self-improving dystrophic epidermolysis bullosa,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79410,"Localized dystrophic epidermolysis bullosa, pretibial form",Clinical subtype,Cases/families,40.0,,Family(ies),Worldwide,Validated,ORPHANET
79410,"Localized dystrophic epidermolysis bullosa, pretibial form",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79452,Milroy disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
79452,Milroy disease,Disease,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Israel,Validated,12224079[PMID]
79447,X-linked lethal multiple pterygium syndrome,Malformation syndrome,Cases/families,6.0,,Family(ies),Worldwide,Validated,9916854[PMID]
79447,X-linked lethal multiple pterygium syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9916854[PMID]
79456,Diffuse cutaneous mastocytosis,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,20678092[PMID]
79456,Diffuse cutaneous mastocytosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79457,Maculopapular cutaneous mastocytosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET_25662299[PMID]
79455,Cutaneous mastocytoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79435,Oculocutaneous albinism type 4,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Worldwide,Validated,20301683[PMID]
79434,Oculocutaneous albinism type 1B,Clinical subtype,Point prevalence,1.3,1-9 / 100 000,Value and class,Worldwide,Validated,18463683[PMID]
79433,Oculocutaneous albinism type 3,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,30347088[PMID]_ORPHANET
79433,Oculocutaneous albinism type 3,Disease,Point prevalence,11.7647,1-5 / 10 000,Value and class,Africa,Validated,30347088[PMID]_ORPHANET
79432,Oculocutaneous albinism type 2,Disease,Point prevalence,58.34,6-9 / 10 000,Value and class,Specific population,Validated,12469324[PMID]_ORPHANET_[EXPERT]
79432,Oculocutaneous albinism type 2,Disease,Point prevalence,2.55,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]_20301410[PMID]
79432,Oculocutaneous albinism type 2,Disease,Point prevalence,71.43,6-9 / 10 000,Value and class,"Tanzania, United Republic of",Validated,3978567[PMID]
79432,Oculocutaneous albinism type 2,Disease,Point prevalence,2.78,1-9 / 100 000,Value and class,United States,Validated,2667743[PMID]
79432,Oculocutaneous albinism type 2,Disease,Point prevalence,48.52,1-5 / 10 000,Value and class,Africa,Validated,ORPHANET_7887411[PMID]_3978567[PMID]
79431,Oculocutaneous albinism type 1A,Clinical subtype,Point prevalence,1.3,1-9 / 100 000,Value and class,Worldwide,Validated,18463683[PMID]
79430,Hermansky-Pudlak syndrome,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,ORPHANET
79430,Hermansky-Pudlak syndrome,Disease,Point prevalence,55.0,1-5 / 10 000,Value and class,Puerto rico,Validated,7573033[PMID]
79445,Pseudopseudohypoparathyroidism,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
79444,Pseudohypoparathyroidism type 1C,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
79443,Pseudohypoparathyroidism type 1A,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
79478,Griscelli syndrome type 3,Clinical subtype,Cases/families,13.0,,Case(s),Worldwide,Validated,26337734[PMID]
79478,Griscelli syndrome type 3,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26337734[PMID]
79479,Pemphigus vegetans,Disease,Point prevalence,0.391,1-9 / 1 000 000,Value and class,Germany,Validated,PMID: 27456755
79481,Pemphigus foliaceus,Disease,Point prevalence,1.001,1-9 / 100 000,Value and class,Germany,Validated,27456755[PMID]
79493,Brooke-Spiegler syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,Dr Neil RAJAN[EXPERT]
79493,Brooke-Spiegler syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_Dr Neil RAJAN[EXPERT]
79477,Griscelli syndrome type 2,Clinical subtype,Cases/families,102.0,,Case(s),Worldwide,Validated,26960655[PMID]
79477,Griscelli syndrome type 2,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26960655[PMID]
79476,Griscelli syndrome type 1,Clinical subtype,Cases/families,20.0,,Case(s),Worldwide,Validated,22711375[PMID]
79476,Griscelli syndrome type 1,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22711375[PMID]
79473,Variegate porphyria,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Europe,Not yet validated,23114748[PMID]
79473,Variegate porphyria,Disease,Point prevalence,0.32,1-9 / 1 000 000,Value and class,Europe,Not yet validated,23114748[PMID]
79473,Variegate porphyria,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,France,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Point prevalence,0.48,1-9 / 1 000 000,Value and class,France,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Finland,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Point prevalence,0.24,1-9 / 1 000 000,Value and class,Finland,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Ireland,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Point prevalence,0.64,1-9 / 1 000 000,Value and class,Ireland,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Italy,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Point prevalence,0.24,1-9 / 1 000 000,Value and class,Netherlands,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Point prevalence,0.24,1-9 / 1 000 000,Value and class,Italy,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Netherlands,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Annual incidence,0.007,<1 / 1 000 000,Value and class,Norway,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Point prevalence,0.28,1-9 / 1 000 000,Value and class,Norway,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Annual incidence,0.004,<1 / 1 000 000,Value and class,Spain,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Point prevalence,0.16,1-9 / 1 000 000,Value and class,Spain,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Sweden,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Point prevalence,0.44,1-9 / 1 000 000,Value and class,Sweden,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Annual incidence,0.026,<1 / 1 000 000,Value and class,Switzerland,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Point prevalence,1.04,1-9 / 100 000,Value and class,Switzerland,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,United Kingdom,Validated,23114748[PMID]
79473,Variegate porphyria,Disease,Point prevalence,0.32,1-9 / 1 000 000,Value and class,United Kingdom,Validated,23114748[PMID]
79269,Sanfilippo syndrome type A,Etiological subtype,Point prevalence,0.32,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2014[INST]
79269,Sanfilippo syndrome type A,Etiological subtype,Prevalence at birth,1.16,1-9 / 100 000,Value and class,Netherlands,Validated,10480370[PMID]
79269,Sanfilippo syndrome type A,Etiological subtype,Prevalence at birth,0.88,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
79269,Sanfilippo syndrome type A,Etiological subtype,Prevalence at birth,0.47,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
79269,Sanfilippo syndrome type A,Etiological subtype,Prevalence at birth,1.62,1-9 / 100 000,Value and class,Estonia,Validated,22480138[PMID]
79269,Sanfilippo syndrome type A,Etiological subtype,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
79269,Sanfilippo syndrome type A,Etiological subtype,Prevalence at birth,0.62,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
79269,Sanfilippo syndrome type A,Etiological subtype,Point prevalence,0.052,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
79269,Sanfilippo syndrome type A,Etiological subtype,Prevalence at birth,0.19,1-9 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
79257,GM1 gangliosidosis type 3,Clinical subtype,Cases/families,70.0,,Case(s),Worldwide,Validated,ORPHANET
79257,GM1 gangliosidosis type 3,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79256,GM1 gangliosidosis type 2,Clinical subtype,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
79256,GM1 gangliosidosis type 2,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79255,GM1 gangliosidosis type 1,Clinical subtype,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
79255,GM1 gangliosidosis type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
79254,Classic phenylketonuria,Clinical subtype,Point prevalence,6.0,1-9 / 100 000,Value and class,Worldwide,Validated,32024337[PMID]_ORPHANET
79254,Classic phenylketonuria,Clinical subtype,Point prevalence,6.34,1-9 / 100 000,Value and class,Europe,Validated,32024337[PMID]_ORPHANET
79254,Classic phenylketonuria,Clinical subtype,Prevalence at birth,6.0,1-9 / 100 000,Value and class,Worldwide,Validated,32024337[PMID]
79254,Classic phenylketonuria,Clinical subtype,Prevalence at birth,6.34,1-9 / 100 000,Value and class,Europe,Validated,32024337[PMID]
79259,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib,Clinical subtype,Cases/families,150.0,,Case(s),Worldwide,Validated,23351985[PMID]
79259,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
79259,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib,Clinical subtype,Prevalence at birth,4.1,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]
79259,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib,Clinical subtype,Prevalence at birth,8.0,1-9 / 100 000,Value and class,Specific population,Validated,33239050[PMID]
79258,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia,Clinical subtype,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
79258,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia,Clinical subtype,Prevalence at birth,1.7,1-9 / 100 000,Value and class,Italy,Validated,11953730[PMID]
79258,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79258,Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia,Clinical subtype,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Israel,Validated,33239050[PMID]
79246,Pyruvate dehydrogenase phosphatase deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79253,Mild phenylketonuria,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79240,Glycogen storage disease due to liver and muscle phosphorylase kinase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79241,Biotinidase deficiency,Disease,Prevalence at birth,1.6,1-9 / 100 000,Value and class,Worldwide,Not yet validated,1779651[PMID]
79241,Biotinidase deficiency,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Not yet validated,1779651[PMID]
79241,Biotinidase deficiency,Disease,Prevalence at birth,1.5,1-9 / 100 000,Value and class,United States,Validated,2314964[PMID]
79241,Biotinidase deficiency,Disease,Prevalence at birth,1.6,1-9 / 100 000,Value and class,Brazil,Validated,9713119[PMID]
79241,Biotinidase deficiency,Disease,Point prevalence,1.6,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
79241,Biotinidase deficiency,Disease,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Sweden,Validated,20224900[PMID]
79241,Biotinidase deficiency,Disease,Prevalence at birth,3.2,1-9 / 100 000,Value and class,Italy,Validated,11953730[PMID]_3391228[PMID]
79241,Biotinidase deficiency,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Italy,Validated,11953730[PMID]_3391228[PMID]
79241,Biotinidase deficiency,Disease,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Austria,Validated,11388594[PMID]
79241,Biotinidase deficiency,Disease,Prevalence at birth,5.0,1-9 / 100 000,Value and class,Hungary,Validated,17185019[PMID]
79241,Biotinidase deficiency,Disease,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Turkey,Validated,20333870[PMID]
79241,Biotinidase deficiency,Disease,Point prevalence,0.0069,<1 / 1 000 000,Value and class,China,Validated,34103049[PMID]
79241,Biotinidase deficiency,Disease,Prevalence at birth,11.58,1-5 / 10 000,Value and class,Czech Republic,Validated,31241292[PMID]
79238,Galactose epimerase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79239,Classic galactosemia,Disease,Annual incidence,2.1,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
79239,Classic galactosemia,Disease,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Netherlands,Validated,15841485[PMID]
79239,Classic galactosemia,Disease,Prevalence at birth,2.3,1-9 / 100 000,Value and class,United Kingdom,Validated,8215542[PMID]
79239,Classic galactosemia,Disease,Prevalence at birth,4.3,1-9 / 100 000,Value and class,Ireland,Validated,8215542[PMID]
79239,Classic galactosemia,Disease,Prevalence at birth,0.13,1-9 / 1 000 000,Value and class,Japan,Validated,6468444[PMID]
79239,Classic galactosemia,Disease,Prevalence at birth,0.25,1-9 / 1 000 000,Value and class,China,Validated,10457302[PMID]
79239,Classic galactosemia,Disease,Prevalence at birth,20.8,1-5 / 10 000,Value and class,"Iran, Islamic Republic of",Validated,23113108[PMID]
79239,Classic galactosemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79244,Pyruvate dehydrogenase E2 deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79242,Holocarboxylase synthetase deficiency,Disease,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
79242,Holocarboxylase synthetase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
79243,Pyruvate dehydrogenase E1-alpha deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79298,Diazoxide-resistant focal hyperinsulinism,Clinical group,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
79301,Congenital bile acid synthesis defect type 1,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79293,Familial LCAT deficiency,Clinical subtype,Cases/families,70.0,,Case(s),Worldwide,Validated,[EXPERT]
79293,Familial LCAT deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79292,Fish-eye disease,Clinical subtype,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
79292,Fish-eye disease,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79278,Autosomal erythropoietic protoporphyria,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,Europe,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,0.92,1-9 / 1 000 000,Value and class,Europe,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,France,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,0.46,1-9 / 1 000 000,Value and class,France,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Annual incidence,0.007,<1 / 1 000 000,Value and class,Italy,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,0.62,1-9 / 1 000 000,Value and class,Ireland,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Netherlands,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,0.54,1-9 / 1 000 000,Value and class,Italy,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Annual incidence,0.036,<1 / 1 000 000,Value and class,Norway,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,1.39,1-9 / 100 000,Value and class,Netherlands,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Poland,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,2.77,1-9 / 100 000,Value and class,Norway,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Annual incidence,0.003,<1 / 1 000 000,Value and class,Spain,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Poland,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Sweden,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,0.23,1-9 / 1 000 000,Value and class,Spain,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Annual incidence,0.035,<1 / 1 000 000,Value and class,Switzerland,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,1.39,1-9 / 100 000,Value and class,Sweden,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Annual incidence,0.033,<1 / 1 000 000,Value and class,United Kingdom,Validated,17994169[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,2.7,1-9 / 100 000,Value and class,Switzerland,Validated,23114748[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,2.54,1-9 / 100 000,Value and class,United Kingdom,Validated,17994169[PMID]
79278,Autosomal erythropoietic protoporphyria,Disease,Point prevalence,1.75,1-9 / 100 000,Value and class,Slovenia,Validated,23114748[PMID]
79279,Alpha-N-acetylgalactosaminidase deficiency type 1,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
79279,Alpha-N-acetylgalactosaminidase deficiency type 1,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79280,Alpha-N-acetylgalactosaminidase deficiency type 2,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
79280,Alpha-N-acetylgalactosaminidase deficiency type 2,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79281,Alpha-N-acetylgalactosaminidase deficiency type 3,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
79281,Alpha-N-acetylgalactosaminidase deficiency type 3,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79282,"Methylmalonic acidemia with homocystinuria, type cblC",Clinical subtype,Cases/families,500.0,,Case(s),Worldwide,Validated,ORPHANET
79282,"Methylmalonic acidemia with homocystinuria, type cblC",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
79283,"Methylmalonic acidemia with homocystinuria, type cblD",Clinical subtype,Cases/families,17.0,,Case(s),Worldwide,Validated,ORPHANET
79283,"Methylmalonic acidemia with homocystinuria, type cblD",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79284,Methylmalonic acidemia with homocystinuria type cblF,Clinical subtype,Cases/families,15.0,,Case(s),Worldwide,Validated,ORPHANET
79284,Methylmalonic acidemia with homocystinuria type cblF,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79270,Sanfilippo syndrome type B,Etiological subtype,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency 2013[INST]
79270,Sanfilippo syndrome type B,Etiological subtype,Prevalence at birth,0.42,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
79270,Sanfilippo syndrome type B,Etiological subtype,Prevalence at birth,0.72,1-9 / 1 000 000,Value and class,Portugal,Validated,14685153[PMID]
79270,Sanfilippo syndrome type B,Etiological subtype,Prevalence at birth,0.47,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
79270,Sanfilippo syndrome type B,Etiological subtype,Prevalence at birth,0.02,<1 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
79270,Sanfilippo syndrome type B,Etiological subtype,Prevalence at birth,0.05,<1 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
79270,Sanfilippo syndrome type B,Etiological subtype,Point prevalence,0.014,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
79270,Sanfilippo syndrome type B,Etiological subtype,Prevalence at birth,0.05,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
79271,Sanfilippo syndrome type C,Etiological subtype,Prevalence at birth,0.21,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
79271,Sanfilippo syndrome type C,Etiological subtype,Prevalence at birth,0.12,1-9 / 1 000 000,Value and class,Portugal,Validated,14685153[PMID]
79271,Sanfilippo syndrome type C,Etiological subtype,Prevalence at birth,0.07,<1 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
79271,Sanfilippo syndrome type C,Etiological subtype,Prevalence at birth,0.42,1-9 / 1 000 000,Value and class,Czech Republic,Validated,20490927[PMID]
79271,Sanfilippo syndrome type C,Etiological subtype,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
79271,Sanfilippo syndrome type C,Etiological subtype,Prevalence at birth,0.34,1-9 / 1 000 000,Value and class,Sweden,Validated,25274184[PMID]
79271,Sanfilippo syndrome type C,Etiological subtype,Point prevalence,4.0E-4,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
79271,Sanfilippo syndrome type C,Etiological subtype,Prevalence at birth,0.015,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
79272,Sanfilippo syndrome type D,Etiological subtype,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Netherlands,Validated,10480370[PMID]
79272,Sanfilippo syndrome type D,Etiological subtype,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,Australia,Validated,9918480[PMID]
79273,Hereditary coproporphyria,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
79276,Acute intermittent porphyria,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Europe,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Point prevalence,0.54,1-9 / 1 000 000,Value and class,Europe,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Annual incidence,0.012,<1 / 1 000 000,Value and class,France,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Point prevalence,0.55,1-9 / 1 000 000,Value and class,France,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Annual incidence,0.011,<1 / 1 000 000,Value and class,Italy,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Italy,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Finland,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Point prevalence,0.59,1-9 / 1 000 000,Value and class,Finland,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Annual incidence,0.018,<1 / 1 000 000,Value and class,Netherlands,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Point prevalence,0.81,1-9 / 1 000 000,Value and class,Netherlands,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Norway,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Point prevalence,0.63,1-9 / 1 000 000,Value and class,Norway,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,Poland,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Point prevalence,0.72,1-9 / 1 000 000,Value and class,Poland,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Annual incidence,0.014,<1 / 1 000 000,Value and class,Spain,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Point prevalence,0.63,1-9 / 1 000 000,Value and class,Spain,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Annual incidence,0.051,<1 / 1 000 000,Value and class,Sweden,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Sweden,Validated,12372055[PMID]
79276,Acute intermittent porphyria,Disease,Annual incidence,0.022,<1 / 1 000 000,Value and class,Switzerland,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Point prevalence,0.99,1-9 / 1 000 000,Value and class,Switzerland,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Annual incidence,0.016,<1 / 1 000 000,Value and class,United Kingdom,Validated,23114748[PMID]
79276,Acute intermittent porphyria,Disease,Point prevalence,0.72,1-9 / 1 000 000,Value and class,United Kingdom,Validated,23114748[PMID]
79277,Congenital erythropoietic porphyria,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,ORPHANET
79277,Congenital erythropoietic porphyria,Disease,Annual incidence,0.065,<1 / 1 000 000,Value and class,Europe,Not yet validated,23114748[PMID]
79277,Congenital erythropoietic porphyria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79333,COG7-CDG,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,19577670[PMID]
79333,COG7-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19577670[PMID]
79332,B4GALT1-CDG,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,11930273[PMID]
79332,B4GALT1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11930273[PMID]
79330,MOGS-CDG,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,24716661[PMID]
79330,MOGS-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24716661[PMID]
79329,MGAT2-CDG,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,22105986[PMID]
79329,MGAT2-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22105986[PMID]
79328,ALG9-CDG,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,26453364[PMID]_28122681[PMID]_28932688[PMID)
79328,ALG9-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28122681[PMID]_28932688[PMID]
79327,ALG1-CDG,Disease,Cases/families,57.0,,Case(s),Worldwide,Validated,26931382[PMID]
79327,ALG1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26931382[PMID]
79326,ALG2-CDG,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,12684507[PMID]
79326,ALG2-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12684507[PMID]
79325,ALG8-CDG,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,26066342[PMID]
79325,ALG8-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26066342[PMID]
79324,ALG12-CDG,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,22516080[PMID]
79324,ALG12-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22516080[PMID]
79323,MPDU1-CDG,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,28122681[PMID]_28940310[PMID]
79323,MPDU1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28122681[PMID]_28940310[PMID]
79322,DPM1-CDG,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,27481510[PMID]
79322,DPM1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27481510[PMID]
79321,ALG3-CDG,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,28122681[PMID]
79321,ALG3-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28122681[PMID]
79320,ALG6-CDG,Disease,Cases/families,54.0,,Case(s),Worldwide,Validated,25052310[PMID]
79320,ALG6-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25052310[PMID]
79319,MPI-CDG,Disease,Cases/families,25.0,,Case(s),Worldwide,Validated,19862844[PMID]
79319,MPI-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19862844[PMID]
79318,PMM2-CDG,Disease,Prevalence at birth,1.73,1-9 / 100 000,Value and class,Italy,Validated,11953730[PMID]
79318,PMM2-CDG,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_19862844[PMID]
79318,PMM2-CDG,Disease,Prevalence at birth,0.0,1-9 / 100 000,Class only,Europe,Validated,10854097[PMID]_11953730[PMID]
79314,L-2-hydroxyglutaric aciduria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79314,L-2-hydroxyglutaric aciduria,Disease,Cases/families,140.0,,Case(s),Worldwide,Validated,[EXPERT]
79315,D-2-hydroxyglutaric aciduria,Disease,Cases/families,80.0,,Case(s),Worldwide,Validated,[EXPERT]
79315,D-2-hydroxyglutaric aciduria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79312,Vitamin B12-unresponsive methylmalonic acidemia type mut-,Clinical subtype,Cases/families,450.0,,Case(s),Worldwide,Validated,ORPHANET
79312,Vitamin B12-unresponsive methylmalonic acidemia type mut-,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
79310,Vitamin B12-responsive methylmalonic acidemia type cblA,Clinical subtype,Cases/families,60.0,,Case(s),Worldwide,Validated,ORPHANET
79310,Vitamin B12-responsive methylmalonic acidemia type cblA,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79306,Progressive familial intrahepatic cholestasis type 1,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
79304,Progressive familial intrahepatic cholestasis type 2,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
79305,Progressive familial intrahepatic cholestasis type 3,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
79302,Congenital bile acid synthesis defect type 3,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,9802883[PMID]
79302,Congenital bile acid synthesis defect type 3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9802883[PMID]
79303,Congenital bile acid synthesis defect type 2,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79361,Inherited epidermolysis bullosa,Category,Prevalence at birth,1.9,1-9 / 100 000,Value and class,Europe,Validated,20507631[PMID]
79361,Inherited epidermolysis bullosa,Category,Point prevalence,0.8,1-9 / 1 000 000,Value and class,Europe,Validated,20507631[PMID]
79361,Inherited epidermolysis bullosa,Category,Point prevalence,0.96,1-9 / 1 000 000,Value and class,Croatia,Validated,2359725[PMID]
79361,Inherited epidermolysis bullosa,Category,Prevalence at birth,1.9,1-9 / 100 000,Value and class,United States,Validated,20507631[PMID]
79361,Inherited epidermolysis bullosa,Category,Point prevalence,0.8,1-9 / 1 000 000,Value and class,United States,Validated,20507631[PMID]
79361,Inherited epidermolysis bullosa,Category,Point prevalence,0.59,1-9 / 1 000 000,Value and class,China,Validated,34103049[PMID]
79351,"3-phosphoglycerate dehydrogenase deficiency, infantile/juvenile form",Etiological subtype,Cases/families,15.0,,Case(s),Worldwide,Validated,23564319[PMID]
79351,"3-phosphoglycerate dehydrogenase deficiency, infantile/juvenile form",Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23564319[PMID]
79350,"3-phosphoserine phosphatase deficiency, infantile/juvenile form",Etiological subtype,Cases/families,8.0,,Case(s),Worldwide,Validated,9222972[PMID]_14673469[PMID]
79350,"3-phosphoserine phosphatase deficiency, infantile/juvenile form",Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9222972[PMID]_14673469[PMID]
79347,"Chondrodysplasia punctata, Toriello type",Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,8267015[PMID]_9450859[PMID]
79347,"Chondrodysplasia punctata, Toriello type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8267015[PMID]_9450859[PMID]
79345,Brachytelephalangic chondrodysplasia punctata,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_Dr BAUJAT Geneviève[EXPERT]
85191,Singleton-Merten dysplasia,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,23322711[PMID]_25620203[PMID]
85191,Singleton-Merten dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23322711[PMID]_25620203[PMID]
85188,"Metaphyseal dysplasia, Braun-Tinschert type",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
85193,Idiopathic juvenile osteoporosis,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
85192,Calvarial doughnut lesions-bone fragility syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,ORPHANET
85192,Calvarial doughnut lesions-bone fragility syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85194,Spondylo-ocular syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,11260210[PMID]_16470687[PMID]
85194,Spondylo-ocular syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11260210[PMID]_16470687[PMID]
85197,Genochondromatosis type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
85199,Craniosynostosis-anal anomalies-porokeratosis syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,15924278[PMID]_24095818[PMID]_[EXPERT]
85199,Craniosynostosis-anal anomalies-porokeratosis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85198,Dysspondyloenchondromatosis,Malformation syndrome,Cases/families,16.0,,Case(s),Worldwide,Validated,24357493[PMID]_26250472[PMID]
85198,Dysspondyloenchondromatosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
85198,Dysspondyloenchondromatosis,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24357493[PMID]_26250472[PMID]
85201,Genitopatellar syndrome,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,22265014[PMID]_22265017[PMID]
85201,Genitopatellar syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22265014[PMID]_22265017[PMID]
85203,Acropectoral syndrome,Malformation syndrome,Cases/families,25.0,,Case(s),Worldwide,Validated,22183091[PMID]
85203,Acropectoral syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22183091[PMID]
85202,Keutel syndrome,Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,[EXPERT]
85202,Keutel syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85273,"X-linked intellectual disability, Abidi type",Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,10398233[PMID]
85273,"X-linked intellectual disability, Abidi type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10398233[PMID]
85212,Fetal Gaucher disease,Clinical subtype,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
85212,Fetal Gaucher disease,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85274,Syndromic X-linked intellectual disability 7,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,10573017[PMID]
85274,Syndromic X-linked intellectual disability 7,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10573017[PMID]
85275,Microphthalmia-ankyloblepharon-intellectual disability syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
85276,"X-linked intellectual disability, Armfield type",Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,10398235[PMID]
85276,"X-linked intellectual disability, Armfield type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10398235[PMID]
85277,"X-linked intellectual disability, Cantagrel type",Malformation syndrome,Cases/families,30.0,,Case(s),Worldwide,Validated,27358180[PMID]_27568816[PMID]
85277,"X-linked intellectual disability, Cantagrel type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27358180[PMID]_27568816[PMID]
85278,Christianson syndrome,Malformation syndrome,Point prevalence,1.7241,1-9 / 100 000,Class only,Worldwide,Validated,25044251[PMID]
85279,KDM5C-related syndromic X-linked intellectual disability,Malformation syndrome,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
85279,KDM5C-related syndromic X-linked intellectual disability,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85280,X-linked intellectual disability-cubitus valgus-dysmorphism syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,14556244[PMID]
85280,X-linked intellectual disability-cubitus valgus-dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14556244[PMID]
85282,MEHMO syndrome,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,12032729[PMID]
85282,MEHMO syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12032729[PMID]
85283,"X-linked intellectual disability, Miles-Carpenter type",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,2018061[PMID]
85283,"X-linked intellectual disability, Miles-Carpenter type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2018061[PMID]
85284,BRESEK syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,24090718[PMID]
85284,BRESEK syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85285,"X-linked intellectual disability, Schimke type",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,6538752[PMID]
85285,"X-linked intellectual disability, Schimke type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6538752[PMID]
85286,"X-linked intellectual disability, Shashi type",Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,12605440[PMID]
85286,"X-linked intellectual disability, Shashi type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12605440[PMID]
85287,"X-linked intellectual disability, Siderius type",Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,16199551[PMID]
85287,"X-linked intellectual disability, Siderius type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16199551[PMID]
85288,"X-linked intellectual disability, Stocco Dos Santos type",Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,2063914[PMID]
85288,"X-linked intellectual disability, Stocco Dos Santos type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2063914[PMID]
85293,"X-linked intellectual disability, Cabezas type",Malformation syndrome,Cases/families,24.0,,Family(ies),Worldwide,Validated,25385192[PMID]
85293,"X-linked intellectual disability, Cabezas type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25385192[PMID]
85292,X-linked spinocerebellar ataxia type 4,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,3470628[PMID]
85292,X-linked spinocerebellar ataxia type 4,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85290,"X-linked intellectual disability, Wilson type",Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,1357179[PMID]
85290,"X-linked intellectual disability, Wilson type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1357179[PMID]
85317,X-linked intellectual disability-hypogammaglobulinemia-progressive neurological deterioration syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,10398239[PMID]
85317,X-linked intellectual disability-hypogammaglobulinemia-progressive neurological deterioration syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10398239[PMID]
85297,X-linked spinocerebellar ataxia type 3,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,3614654[PMID]
85297,X-linked spinocerebellar ataxia type 3,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3614654[PMID]
85295,"HSD10 disease, atypical type",Clinical subtype,Cases/families,5.0,,Case(s),Worldwide,Validated,27306202[PMID]
85295,"HSD10 disease, atypical type",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ 27306202[PMID]
85294,X-linked epilepsy-learning disabilities-behavior disorders syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
85321,"Deafness-intellectual disability syndrome, Martin-Probst type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,11073537[PMID]
85321,"Deafness-intellectual disability syndrome, Martin-Probst type",Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,ORPHANET_11073537[PMID]
85320,X-linked intellectual disability-macrocephaly-macroorchidism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9863601[PMID]
85320,X-linked intellectual disability-macrocephaly-macroorchidism syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,9863601[PMID]
85319,X-linked intellectual disability-epilepsy-progressive joint contractures-dysmorphism syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,8574418[PMID]
85319,X-linked intellectual disability-epilepsy-progressive joint contractures-dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8574418[PMID]
85325,"X-linked intellectual disability, Stevenson type",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,9192265[PMID]
85325,"X-linked intellectual disability, Stevenson type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9192265[PMID]
85324,"X-linked intellectual disability, Shrimpton type",Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,10331611[PMID]
85324,"X-linked intellectual disability, Shrimpton type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10331611[PMID]
85323,"X-linked intellectual disability, Seemanova type",Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,8958326[PMID]
85323,"X-linked intellectual disability, Seemanova type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8958326[PMID]
85322,"X-linked intellectual disability, Pai type",Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,9222958[PMID]
85322,"X-linked intellectual disability, Pai type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9222958[PMID]
85329,X-linked intellectual disability-hypotonia-facial dysmorphism-aggressive behavior syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,12599187[PMID]
85329,X-linked intellectual disability-hypotonia-facial dysmorphism-aggressive behavior syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12599187[PMID]
85326,"X-linked intellectual disability, Stoll type",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,1877628[PMID]
85326,"X-linked intellectual disability, Stoll type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1877628[PMID]
85327,X-linked intellectual disability-acromegaly-hyperactivity syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,2018059[PMID]
85327,X-linked intellectual disability-acromegaly-hyperactivity syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2018059[PMID]
85332,X-linked intellectual disability-retinitis pigmentosa syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
85336,"X-linked neurodegenerative syndrome, Hamel type",Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,10051014[PMID]
85336,"X-linked neurodegenerative syndrome, Hamel type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10051014[PMID]
85334,"X-linked neurodegenerative syndrome, Bertini type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1605224[PMID]
85334,"X-linked neurodegenerative syndrome, Bertini type",Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,1605224[PMID]
85335,Fried syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_5054319[PMID]
85335,Fried syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,5054319[PMID]
85410,Oligoarticular juvenile idiopathic arthritis,Disease,Point prevalence,20.5,1-5 / 10 000,Value and class,Europe,Not yet validated,ORPHANET
85414,Systemic-onset juvenile idiopathic arthritis,Disease,Point prevalence,3.1,1-9 / 100 000,Value and class,Worldwide,Validated,24210707[PMID]
85414,Systemic-onset juvenile idiopathic arthritis,Disease,Annual incidence,0.6,1-9 / 1 000 000,Value and class,Worldwide,Validated,24210707[PMID]
85338,X-linked intellectual disability-ataxia-apraxia syndrome,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,1605232[PMID]
85338,X-linked intellectual disability-ataxia-apraxia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1605232[PMID]
85408,Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis,Disease,Point prevalence,8.0,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
85443,AL amyloidosis,Disease,Point prevalence,6.459,1-9 / 100 000,Value and class,Germany,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.127,1-9 / 100 000,Value and class,Worldwide,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.044,1-9 / 100 000,Value and class,Worldwide,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.5311,1-9 / 100 000,Value and class,Europe,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.1177,1-9 / 100 000,Value and class,Europe,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.77,1-9 / 100 000,Value and class,Austria,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.166,1-9 / 100 000,Value and class,Austria,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.54,1-9 / 1 000 000,Value and class,Belgium,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.122,1-9 / 100 000,Value and class,Belgium,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.892,1-9 / 100 000,Value and class,Bulgaria,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.174,1-9 / 100 000,Value and class,Bulgaria,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.801,1-9 / 100 000,Value and class,Croatia,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.156,1-9 / 100 000,Value and class,Croatia,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,4.299,1-9 / 100 000,Value and class,Cyprus,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,0.894,1-9 / 1 000 000,Value and class,Cyprus,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.462,1-9 / 100 000,Value and class,Czech Republic,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.109,1-9 / 100 000,Value and class,Czech Republic,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.568,1-9 / 100 000,Value and class,Denmark,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.124,1-9 / 100 000,Value and class,Denmark,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.51,1-9 / 100 000,Value and class,Estonia,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.107,1-9 / 100 000,Value and class,Estonia,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.885,1-9 / 100 000,Value and class,Finland,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.187,1-9 / 100 000,Value and class,Finland,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.692,1-9 / 100 000,Value and class,France,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.152,1-9 / 100 000,Value and class,France,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.294,1-9 / 100 000,Value and class,Germany,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,6.219,1-9 / 100 000,Value and class,Greece,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.254,1-9 / 100 000,Value and class,Greece,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.418,1-9 / 100 000,Value and class,Hungary,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.088,1-9 / 100 000,Value and class,Hungary,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,4.643,1-9 / 100 000,Value and class,Iceland,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,0.948,1-9 / 1 000 000,Value and class,Iceland,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,4.448,1-9 / 100 000,Value and class,Ireland,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,0.913,1-9 / 1 000 000,Value and class,Ireland,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,6.538,1-9 / 100 000,Value and class,Italy,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.329,1-9 / 100 000,Value and class,Italy,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.71,1-9 / 100 000,Value and class,Latvia,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.123,1-9 / 100 000,Value and class,Latvia,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.809,1-9 / 100 000,Value and class,Liechtenstein,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.174,1-9 / 100 000,Value and class,Liechtenstein,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.61,1-9 / 100 000,Value and class,Lithuania,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.109,1-9 / 100 000,Value and class,Lithuania,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,4.653,1-9 / 100 000,Value and class,Luxembourg,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,0.968,1-9 / 1 000 000,Value and class,Luxembourg,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.641,1-9 / 100 000,Value and class,Malta,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.147,1-9 / 100 000,Value and class,Malta,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.672,1-9 / 100 000,Value and class,Netherlands,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.146,1-9 / 100 000,Value and class,Netherlands,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,4.977,1-9 / 100 000,Value and class,Norway,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.018,1-9 / 100 000,Value and class,Norway,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.134,1-9 / 100 000,Value and class,Poland,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.044,1-9 / 100 000,Value and class,Poland,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,6.216,1-9 / 100 000,Value and class,Portugal,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.25,1-9 / 100 000,Value and class,Portugal,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.537,1-9 / 100 000,Value and class,Romania,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.107,1-9 / 100 000,Value and class,Romania,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,4.76,1-9 / 100 000,Value and class,Slovakia,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,0.968,1-9 / 1 000 000,Value and class,Slovakia,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.756,1-9 / 100 000,Value and class,Slovenia,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.167,1-9 / 100 000,Value and class,Slovenia,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.864,1-9 / 100 000,Value and class,Spain,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.193,1-9 / 100 000,Value and class,Spain,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.667,1-9 / 100 000,Value and class,Sweden,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.141,1-9 / 100 000,Value and class,Sweden,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.316,1-9 / 100 000,Value and class,United Kingdom,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.078,1-9 / 100 000,Value and class,United Kingdom,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,3.222,1-9 / 100 000,Value and class,Brazil,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,0.672,1-9 / 1 000 000,Value and class,Brazil,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,5.215,1-9 / 100 000,Value and class,Canada,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.076,1-9 / 100 000,Value and class,Canada,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,7.108,1-9 / 100 000,Value and class,Japan,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.43,1-9 / 100 000,Value and class,Japan,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,4.569,1-9 / 100 000,Value and class,Russian Federation,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,0.93,1-9 / 1 000 000,Value and class,Russian Federation,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,4.822,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,0.997,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,4.852,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,1.001,1-9 / 100 000,Value and class,"Taiwan, Province of China",Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Point prevalence,4.842,1-9 / 100 000,Value and class,United States,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,0.991,1-9 / 1 000 000,Value and class,United States,Validated,35854312[PMID]
85443,AL amyloidosis,Disease,Annual incidence,6.0,1-9 / 1 000 000,Value and class,Argentina,Validated,31343332[PMID]
85442,Short stature-pituitary and cerebellar defects-small sella turcica syndrome,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,11567216[PMID]_17527005[PMID]_18073311[PMID]
85442,Short stature-pituitary and cerebellar defects-small sella turcica syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11567216[PMID]_17527005[PMID]_18073311[PMID]
85446,Wild type ABeta2M amyloidosis,Disease,Point prevalence,4.5,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2012[INST]
85445,AA amyloidosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
85436,Psoriasis-related juvenile idiopathic arthritis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,24210707[PMID]
85435,Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis,Disease,Point prevalence,4.2,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
85438,Enthesitis-related juvenile idiopathic arthritis,Disease,Point prevalence,5.7,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
85458,Cerebral Amyloid Angiopathy,Disease,Cases/families,350.0,,Case(s),Worldwide,Validated,[EXPERT]
85458,Cerebral Amyloid Angiopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85453,X-linked reticulate pigmentary disorder,Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,ORPHANET
85453,X-linked reticulate pigmentary disorder,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
86788,X-linked severe congenital neutropenia,Disease,Cases/families,45.0,,Case(s),Worldwide,Validated,16804117[PMID]_11242115[PMID]
86788,X-linked severe congenital neutropenia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
86309,DPAGT1-CDG,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,26033833 [PMID]
86309,DPAGT1-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26033833 [PMID]
85448,AGel amyloidosis,Disease,Cases/families,475.0,,Case(s),Worldwide,Validated,9547007[PMID]_17097682[PMID]_14639586[PMID]_20229579[PMID]_22068858[PMID]_2262277[PMID]_10729296[PMID]_[EXPERT]
85448,AGel amyloidosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
85447,ATTRV30M amyloidosis,Clinical subtype,Point prevalence,90.0,6-9 / 10 000,Value and class,Portugal,Validated,8825887[PMID]_24572009[PMID]
85447,ATTRV30M amyloidosis,Clinical subtype,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Japan,Validated,[EXPERT]_23425518[PMID]
85447,ATTRV30M amyloidosis,Clinical subtype,Annual incidence,3.75,1-9 / 100 000,Value and class,Sweden,Not yet validated,8406517[PMID]
85447,ATTRV30M amyloidosis,Clinical subtype,Point prevalence,97.5,6-9 / 10 000,Value and class,Sweden,Not yet validated,8406517[PMID]
85447,ATTRV30M amyloidosis,Clinical subtype,Annual incidence,0.69,1-9 / 1 000 000,Value and class,Cyprus,Validated,19291512[PMID]
85447,ATTRV30M amyloidosis,Clinical subtype,Point prevalence,3.7,1-9 / 100 000,Value and class,Cyprus,Validated,19291512[PMID]
85447,ATTRV30M amyloidosis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
85447,ATTRV30M amyloidosis,Clinical subtype,Point prevalence,3.0,1-9 / 100 000,Value and class,Spain,Validated,3210815[PMID]_12855135[PMID]_24572009[PMID]
85451,ATTRV122I amyloidosis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
85450,Hereditary amyloidosis with primary renal involvement,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
86812,POMT1-related limb-girdle muscular dystrophy R11,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
86813,Helicoid peripapillary chorioretinal degeneration,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
86813,Helicoid peripapillary chorioretinal degeneration,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
86814,Benign adult familial myoclonic epilepsy,Disease,Point prevalence,2.8,1-9 / 100 000,Value and class,Japan,Validated,15508931[PMID]
86814,Benign adult familial myoclonic epilepsy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
86789,Isolated patella aplasia/hypoplasia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11857555[PMID]
86789,Isolated patella aplasia/hypoplasia,Morphological anomaly,Cases/families,5.0,,Family(ies),Worldwide,Validated,11857555[PMID]
86797,Atypical lichen myxedematosus,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
86797,Atypical lichen myxedematosus,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
86820,Familial avascular necrosis of femoral head,Disease,Annual incidence,5.0,1-9 / 100 000,Value and class,United States,Validated,[EXPERT]
86820,Familial avascular necrosis of femoral head,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
86821,Lissencephaly type 3-familial fetal akinesia sequence syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,8779318[PMID]
86821,Lissencephaly type 3-familial fetal akinesia sequence syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8779318[PMID]
86822,Lissencephaly type 3-metacarpal bone dysplasia syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,11170088[PMID]
86822,Lissencephaly type 3-metacarpal bone dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11170088[PMID]
86823,Lissencephaly with cerebellar hypoplasia,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,18521588[PMID]
86816,Congenital analbuminemia,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
86816,Congenital analbuminemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
86817,Hemolytic anemia due to adenylate kinase deficiency,Disease,Cases/families,7.0,,Family(ies),Worldwide,Validated,10233365[PMID]
86817,Hemolytic anemia due to adenylate kinase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10233365[PMID]
86818,Alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,7923864[PMID]_9598718[PMID]
86818,Alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
512034,Large granular lymphocyte leukemia,Clinical group,Annual incidence,0.02,<1 / 1 000 000,Value and class,United States,Validated,27494824[PMID]
86843,Acute panmyelosis with myelofibrosis,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86841,Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86839,Myelodysplastic neoplasm with increased blasts,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
86839,Myelodysplastic neoplasm with increased blasts,Disease,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86836,Refractory cytopenia with multilineage dysplasia,Clinical group,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86834,Juvenile myelomonocytic leukemia,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,European Medicines Agency[INST]
86830,"Chronic myeloproliferative disease, unclassifiable",Disease,Annual incidence,0.53,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86829,Chronic neutrophilic leukemia,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86855,Plasmacytoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
86855,Plasmacytoma,Disease,Annual incidence,0.34,1-9 / 1 000 000,Value and class,United States,Validated,19016727[PMID]_SEER Surveillance Epidemiology and End Results 1992-2004[INST]
512260,Congenital cerebellar ataxia due to RNU12 mutation,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,27863452[PMID]
512260,Congenital cerebellar ataxia due to RNU12 mutation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27863452[PMID]
86854,Splenic marginal zone lymphoma,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,European Medecines Agency 2013[INST]
86852,B-cell prolymphocytic leukemia,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86850,Myeloid sarcoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
86850,Myeloid sarcoma,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86849,Acute basophilic leukemia,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86846,Therapy related acute myeloid leukemia and myelodysplastic syndrome,Category,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86845,Acute myeloid leukaemia with myelodysplasia-related features,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86872,T-cell large granular lymphocyte leukemia,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
86872,T-cell large granular lymphocyte leukemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
86873,Aggressive NK-cell leukemia,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
86870,Blastic plasmacytoid dendritic cell neoplasm,Disease,Point prevalence,12.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2015[INST]
86870,Blastic plasmacytoid dendritic cell neoplasm,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,United States,Validated,36946176[PMID]
86871,T-cell prolymphocytic leukemia,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,[WHO Classification of Tumours ]
86871,T-cell prolymphocytic leukemia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[WHO Classification of Tumours ]
86867,Nodal marginal zone B-cell lymphoma,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,European Medecines Agency 2013[INST]
86864,Heavy chain disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
86864,Heavy chain disease,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86886,Angioimmunoblastic T-cell lymphoma,Disease,Annual incidence,0.05,<1 / 1 000 000,Value and class,United States,Validated,16150940[PMID]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Worldwide,Validated,[EXPERT]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.095,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.041,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.006,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.099,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.037,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.097,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.074,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.038,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.008,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.013,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.055,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.053,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.056,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.092,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.128,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.285,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.124,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.226,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.14,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.135,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86893,Nodular lymphocyte predominant Hodgkin lymphoma,Disease,Annual incidence,0.133,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
86884,Subcutaneous panniculitis-like T-cell lymphoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
86880,Enteropathy-associated T-cell lymphoma,Disease,Annual incidence,0.0111,<1 / 1 000 000,Value and class,United States,Validated,26104061[PMID]
86880,Enteropathy-associated T-cell lymphoma,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Netherlands,Validated,18618372[PMID]
86882,Hepatosplenic T-cell lymphoma,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,United States,Validated,21823196[PMID]
86882,Hepatosplenic T-cell lymphoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
86875,Adult T-cell leukemia/lymphoma,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2014[INST]
86879,Extranodal nasal NK/T cell lymphoma,Disease,Annual incidence,2.25,1-9 / 100 000,Value and class,France,Validated,Institut National du Cancer 2013[INST]
79502,Punctate palmoplantar keratoderma type 2,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,2525006[PMID]
79502,Punctate palmoplantar keratoderma type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2525006[PMID]
79503,Ichthyosis hystrix of Curth-Macklin,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,28405559[PMID]_26538731[PMID]
79503,Ichthyosis hystrix of Curth-Macklin,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28405559[PMID]_26538731[PMID]
79507,Hypotonia-failure to thrive-microcephaly syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,10896305[PMID]
79507,Hypotonia-failure to thrive-microcephaly syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10896305[PMID]
79499,Autosomal dominant deafness-onychodystrophy syndrome,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,[EXPERT]
79499,Autosomal dominant deafness-onychodystrophy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,[EXPERT]
79500,DOORS syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
79500,DOORS syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
79501,Punctate palmoplantar keratoderma type 1,Disease,Cases/families,437.0,,Case(s),Worldwide,Validated,34535911[PMID]_EXPERT
79501,Punctate palmoplantar keratoderma type 1,Disease,Point prevalence,1.17,1-9 / 100 000,Value and class,Croatia,Validated,8349860[PMID]
79501,Punctate palmoplantar keratoderma type 1,Disease,Point prevalence,3.3,1-9 / 100 000,Value and class,Slovenia,Validated,19784524[PMID]
79665,Gardner syndrome,Clinical subtype,Prevalence at birth,9.1,1-9 / 100 000,Value and class,Worldwide,Not yet validated,17517313[PMID]_24858982[PMID]
79651,Mild hyperphenylalaninemia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
79644,Autosomal recessive hyperinsulinism due to Kir6.2 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
83317,Scrub typhus,Disease,Point prevalence,7.2,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,18362409[PMID]
83317,Scrub typhus,Disease,Point prevalence,0.3,1-9 / 1 000 000,Value and class,Japan,Validated,18362409[PMID]
83317,Scrub typhus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83330,Proximal spinal muscular atrophy type 1,Clinical subtype,Annual incidence,0.26,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
83330,Proximal spinal muscular atrophy type 1,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
83315,Murine typhus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83316,Pseudotyphus of California,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83419,Proximal spinal muscular atrophy type 3,Clinical subtype,Prevalence at birth,0.6623,1-9 / 1 000 000,Value and class,Italy,Validated,1483045[PMID]
83419,Proximal spinal muscular atrophy type 3,Clinical subtype,Point prevalence,0.61,1-9 / 1 000 000,Class only,Europe,Validated,28676062[PMID]_ORPHANET
83420,Proximal spinal muscular atrophy type 4,Clinical subtype,Annual incidence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
83420,Proximal spinal muscular atrophy type 4,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
83418,Proximal spinal muscular atrophy type 2,Clinical subtype,Prevalence at birth,2.0,1-9 / 100 000,Value and class,Europe,Validated,10677857[PMID]_1483045[PMID]
83418,Proximal spinal muscular atrophy type 2,Clinical subtype,Point prevalence,2.0322,1-9 / 100 000,Class only,Worldwide,Validated,28676062[PMID]_ORPHANET
83313,Boutonneuse fever,Disease,Point prevalence,24.2,1-5 / 10 000,Value and class,France,Not yet validated,ORPHANET
83313,Boutonneuse fever,Disease,Point prevalence,9.8,1-9 / 100 000,Value and class,Portugal,Not yet validated,ORPHANET
83313,Boutonneuse fever,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
83314,Epidemic typhus,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83311,Rocky Mountain spotted fever,Disease,Annual incidence,0.24,1-9 / 1 000 000,Value and class,United States,Not yet validated,ORPHANET
83311,Rocky Mountain spotted fever,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83312,Rickettsialpox,Disease,Cases/families,800.0,,Case(s),Worldwide,Validated,15577753[PMID]
83312,Rickettsialpox,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
83469,Desmoplastic small round cell tumor,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,15557784[PMID]
83469,Desmoplastic small round cell tumor,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
83469,Desmoplastic small round cell tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
83468,Solitary bone cyst,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83467,Morvan syndrome,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,27698847[PMID]
83467,Morvan syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27698847[PMID]
83465,Narcolepsy type 2,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83465,Narcolepsy type 2,Disease,Point prevalence,20.3,1-5 / 10 000,Value and class,United States,Validated,11902429[PMID]
83476,West-Nile encephalitis,Disease,Point prevalence,0.92,1-9 / 1 000 000,Value and class,United States,Validated,23013055[PMID]_Center for Diseases Control and Prevention 2012[INST]
83476,West-Nile encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83476,West-Nile encephalitis,Disease,Annual incidence,0.036,<1 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
83476,West-Nile encephalitis,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Austria,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
83476,West-Nile encephalitis,Disease,Annual incidence,0.17,1-9 / 1 000 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2012-2015[INST]
83476,West-Nile encephalitis,Disease,Annual incidence,0.66,1-9 / 1 000 000,Value and class,Greece,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
83476,West-Nile encephalitis,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
83476,West-Nile encephalitis,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2011-2013[INST]
83476,West-Nile encephalitis,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Romania,Validated,European Centre for Disease prevention and Control 2011-2015[INST]
83473,Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome,Malformation syndrome,Cases/families,62.0,,Case(s),Worldwide,Validated,27854409[PMID]
83473,Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27854409[PMID]
83472,CAMOS syndrome,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,11391656[PMID]
83472,CAMOS syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11391656[PMID]
83471,T-cell immunodeficiency with thymic aplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83452,Complex regional pain syndrome,Disease,Annual incidence,26.2,1-5 / 10 000,Value and class,Netherlands,Validated,17084977[PMID]_24161450[PMID]
83452,Complex regional pain syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
83451,Florid cemento-osseous dysplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83450,Regional odontodysplasia,Disease,Cases/families,140.0,,Case(s),Worldwide,Validated,ORPHANET
83450,Regional odontodysplasia,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
83463,Microtia,Morphological anomaly,Point prevalence,38.0,1-5 / 10 000,Value and class,Specific population,Validated,16359491[PMID]
83463,Microtia,Morphological anomaly,Prevalence at birth,13.0,1-5 / 10 000,Value and class,Europe,Not yet validated,ORPHANET
83463,Microtia,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
83463,Microtia,Morphological anomaly,Prevalence at birth,15.5,1-5 / 10 000,Value and class,Worldwide,Not yet validated,21656661[PMID]
83463,Microtia,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Worldwide,Not yet validated,21656661[PMID]
83463,Microtia,Morphological anomaly,Prevalence at birth,3.7,1-9 / 100 000,Value and class,France,Validated,8933331[PMID]
83463,Microtia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,France,Validated,8933331[PMID]
83463,Microtia,Morphological anomaly,Prevalence at birth,1.2,1-9 / 100 000,Value and class,Italy,Validated,7666397[PMID]
83463,Microtia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Italy,Not yet validated,7666397[PMID]
83463,Microtia,Morphological anomaly,Prevalence at birth,2.1,1-9 / 100 000,Value and class,Sweden,Validated,8933331[PMID]
83463,Microtia,Morphological anomaly,Point prevalence,0.0,1-9 / 100 000,Class only,Sweden,Validated,8933331[PMID]
83463,Microtia,Morphological anomaly,Prevalence at birth,22.0,1-5 / 10 000,Value and class,United States,Validated,8933331[PMID]_19760683[PMID]
83463,Microtia,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,United States,Validated,8933331[PMID]_19760683[PMID]
83463,Microtia,Morphological anomaly,Prevalence at birth,43.4,1-5 / 10 000,Value and class,Finland,Validated,17548114[PMID]
83463,Microtia,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Finland,Validated,17548114[PMID]
83463,Microtia,Morphological anomaly,Prevalence at birth,174.0,>1 / 1000,Value and class,Ecuador,Validated,3771073[PMID]
83463,Microtia,Morphological anomaly,Prevalence at birth,83.0,6-9 / 10 000,Value and class,Chile,Validated,17186100[PMID]
83461,Congenital primary aphakia,Malformation syndrome,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
83454,Glomuvenous malformation,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83453,Vulvovaginal gingival syndrome,Disease,Cases/families,380.0,,Case(s),Worldwide,Validated,20373919[PMID]
83453,Vulvovaginal gingival syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
514352,Congenital brachyesophagus-intrathoracic stomach-vertebral anomalies syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,27836748[PMID]
514352,Congenital brachyesophagus-intrathoracic stomach-vertebral anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27836748[PMID]
83619,Macrostomia-preauricular tags-external ophthalmoplegia syndrome,Malformation syndrome,Cases/families,9.0,,Case(s),Worldwide,Validated,16854200[PMID]
83619,Macrostomia-preauricular tags-external ophthalmoplegia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16854200[PMID]
83620,Enteric anendocrinosis,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,24134759[PMID]
83620,Enteric anendocrinosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24134759[PMID]
83628,LUMBAR syndrome,Malformation syndrome,Cases/families,54.0,,Case(s),Worldwide,Validated,24259379[PMID]
83628,LUMBAR syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
83601,Steroid-responsive encephalopathy associated with autoimmune thyroiditis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
83616,Rubella panencephalitis,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,9103895[PMID]
83616,Rubella panencephalitis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
83617,Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,16691627[PMID]
83617,Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16691627[PMID]
83594,Eastern equine encephalitis,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,United States,Validated,Center for Diseases Control and Prevention 1989-1996[INST]
83594,Eastern equine encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83595,Colorado tick fever,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83597,Acute disseminated encephalomyelitis,Disease,Annual incidence,0.6,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
83597,Acute disseminated encephalomyelitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
83600,Encephalitis lethargica,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
83482,Mycoplasma encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83483,La Crosse encephalitis,Disease,Annual incidence,1.91,1-9 / 100 000,Value and class,Canada,Validated,Canada Public Health Agency[INST]
83483,La Crosse encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83484,St. Louis encephalitis,Disease,Annual incidence,0.38,1-9 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
83484,St. Louis encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
83593,Western equine encephalitis,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,United States,Validated,Center for Diseases Control and Prevention[INST]
83593,Western equine encephalitis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
84085,Hinman syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
84081,Senior-Boichis syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
84090,Fibronectin glomerulopathy,Disease,Cases/families,16.0,,Family(ies),Worldwide,Validated,ORPHANET
84090,Fibronectin glomerulopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
84064,Syndromic diarrhea,Disease,Cases/families,116.0,,Case(s),Worldwide,Validated,[EXPERT]_29527791[PMID]_29868001[PMID]_30397475[PMID]
84064,Syndromic diarrhea,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]_30397475[PMID]
84064,Syndromic diarrhea,Disease,Prevalence at birth,0.1,1-9 / 1 000 000,Value and class,France,Validated,23302111[PMID]
513436,Autosomal recessive spastic paraplegia type 78,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,28137957[PMID]_29112700[PMID]_27217339[PMID]
513436,Autosomal recessive spastic paraplegia type 78,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29112700[PMID]
83639,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,16767100[PMID]
83639,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16767100[PMID]
83629,Leukoencephalopathy-spondyloepimetaphyseal dysplasia syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,16924009[PMID]_10486082[PMID]_27102849[PMID]
83629,Leukoencephalopathy-spondyloepimetaphyseal dysplasia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16924009[PMID]_10486082[PMID]_27102849[PMID]
513456,Intellectual disability-seizures-abnormal gait-facial dysmorphism syndrome,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,28686853[PMID]
513456,Intellectual disability-seizures-abnormal gait-facial dysmorphism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28686853[PMID]
83642,Microcytic anemia with liver iron overload,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,16439678[PMID]
83642,Microcytic anemia with liver iron overload,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16439678[PMID]
85163,Hypomyelination-congenital cataract syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
85163,Hypomyelination-congenital cataract syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85164,Camptodactyly-tall stature-scoliosis-hearing loss syndrome,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,ORPHANET
85164,Camptodactyly-tall stature-scoliosis-hearing loss syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85146,"Neurogenic scapuloperoneal syndrome, Kaeser type",Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,17439987[PMID]
85146,"Neurogenic scapuloperoneal syndrome, Kaeser type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17439987[PMID]
85162,Facial onset sensory and motor neuronopathy,Disease,Cases/families,47.0,,Case(s),Worldwide,Validated,29781209[PMID]
85162,Facial onset sensory and motor neuronopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29781209[PMID]
85138,Addison disease,Disease,Annual incidence,54.0,1-5 / 10 000,Value and class,Specific population,Validated,12788587[PMID]
85138,Addison disease,Disease,Point prevalence,12.5,1-5 / 10 000,Value and class,Europe,Validated,21164269[PMID]_12788587[PMID]_ [EXPERT]
85138,Addison disease,Disease,Point prevalence,14.0,1-5 / 10 000,Value and class,Norway,Validated,12072049[PMID]
85138,Addison disease,Disease,Point prevalence,9.3,1-9 / 100 000,Value and class,United Kingdom,Validated,919670[PMID]
85128,Bothnia retinal dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_10102298[PMID]
85136,Cystic leukoencephalopathy without megalencephaly,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,[EXPERT]
85136,Cystic leukoencephalopathy without megalencephaly,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85110,Familial encephalopathy with neuroserpin inclusion bodies,Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,18591508[PMID]
85110,Familial encephalopathy with neuroserpin inclusion bodies,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18591508[PMID]
85112,Palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,16227098[PMID]_10733237[PMID]
85112,Palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16227098[PMID]_10733237[PMID]
84132,Desmin-related myopathy with Mallory body-like inclusions,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,PMID: 7224095 & 15122708
84132,Desmin-related myopathy with Mallory body-like inclusions,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET; PMID: 7224095 & 15122708
84142,Isaacs syndrome,Disease,Cases/families,150.0,,Case(s),Worldwide,Validated,[EXPERT]
84142,Isaacs syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
84093,Hereditary thermosensitive neuropathy,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,9191787[PMID]
84093,Hereditary thermosensitive neuropathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9191787[PMID]
85186,Endosteal sclerosis-cerebellar hypoplasia syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,15672385[PMID]
85186,Endosteal sclerosis-cerebellar hypoplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15672385[PMID]
85184,"Craniometadiaphyseal dysplasia, wormian bone type",Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,20684007[PMID]
85184,"Craniometadiaphyseal dysplasia, wormian bone type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20684007[PMID]
85179,Infantile osteopetrosis with neuroaxonal dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
85175,Astley-Kendall dysplasia,Malformation syndrome,Cases/families,5.0,,Case(s),Worldwide,Validated,9643294[PMID]
85175,Astley-Kendall dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9643294[PMID]
85174,Pseudodiastrophic dysplasia,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,26754439[PMID]
85174,Pseudodiastrophic dysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26754439[PMID]
85173,IMAGe syndrome,Malformation syndrome,Cases/families,28.0,,Case(s),Worldwide,Validated,24624461[PMID]
85173,IMAGe syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24624461[PMID]
85172,"Microcephalic osteodysplastic dysplasia, Saul-Wilson type",Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,8074143[PMID]
85172,"Microcephalic osteodysplastic dysplasia, Saul-Wilson type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8074143[PMID]
85170,"Mesomelic dysplasia, Savarirayan type",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
85169,Familial digital arthropathy-brachydactyly,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
85168,Craniofacial conodysplasia,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,7593576[PMID]
85168,Craniofacial conodysplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7593576[PMID]
85167,Spondylometaphyseal dysplasia-cone-rod dystrophy syndrome,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,24387990[PMID]
85167,Spondylometaphyseal dysplasia-cone-rod dystrophy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
85166,"Platyspondylic dysplasia, Torrance type",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
85165,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,10053006[PMID]_18076102[PMID]
85165,Severe achondroplasia-developmental delay-acanthosis nigricans syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10053006[PMID]_18076102[PMID]
603448,Cerebellar hypoplasia-intellectual disability-congenital microcephaly-dystonia-anemia-growth retardation syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,33186543[PMID]_33186545[PMID]_33460484[PMID]
603448,Cerebellar hypoplasia-intellectual disability-congenital microcephaly-dystonia-anemia-growth retardation syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,33186543[PMID]_33186545[PMID]_33460484[PMID]_ORPHANET
603515,Isolated female hypospadias,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,31105404[PMID]
603494,Coloboma-osteopetrosis-microphthalmia-macrocephaly-albinism-deafness syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,27889061[PMID]
603494,Coloboma-osteopetrosis-microphthalmia-macrocephaly-albinism-deafness syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,27889061[PMID]_ORPHANET
603689,KLHL7-related Bohring-Opitz-like syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,29074562[PMID]_31953236[PMID]
603689,KLHL7-related Bohring-Opitz-like syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,29074562[PMID]_31953236[PMID]_ORPHANET
603684,KLHL7-related Bohring-Opitz-like and Crisponi/Cold-induced sweating-like overlap syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,30300710[PMID]_30142437[PMID]
603684,KLHL7-related Bohring-Opitz-like and Crisponi/Cold-induced sweating-like overlap syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30300710[PMID]_30142437[PMID]_ORPHANET
610573,CLCN6-related childhood-onset progressive neurodegeneration-peripheral neuropathy syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,33217309[PMID]
610573,CLCN6-related childhood-onset progressive neurodegeneration-peripheral neuropathy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,33217309[PMID]_ORPHANET
610569,KIAA1109-related early lethal congenital brain malformations-arthrogryposis syndrome,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,29290337[PMID]
610569,KIAA1109-related early lethal congenital brain malformations-arthrogryposis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,29290337[PMID]_ORPHANET
604680,Symptomatic form of X-linked centronuclear myopathy in female carriers,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,28685322[PMID]_34011573[PMID]_ORPHANET
604680,Symptomatic form of X-linked centronuclear myopathy in female carriers,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,28685322[PMID]_34011573[PMID]_ORPHANET
611256,Pontocerebellar hypoplasia type 12,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,30089828[PMID]
611256,Pontocerebellar hypoplasia type 12,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30089828[PMID]_ORPHANET
611237,Parkinsonism with polyneuropathy,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,33141179[PMID]
611237,Parkinsonism with polyneuropathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,33141179[PMID]_ORPHANET
611247,Pontocerebellar hypoplasia type 11,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,28823707[PMID]_28823706[PMID]
611247,Pontocerebellar hypoplasia type 11,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,28823707[PMID]_28823706[PMID]_ORPHANET
611216,Aplastic anemia-intellectual disability-dwarfism syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,33355142[PMID]
611216,Aplastic anemia-intellectual disability-dwarfism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,33355142[PMID]_ORPHANET
611223,EN1-related dorsoventral syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,33568816[PMID]
611223,EN1-related dorsoventral syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,33568816[PMID]_ORPHANET
611201,Oculogastrointestinal-neurodevelopmental syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,32885237[PMID]_33410501[PMID]
611201,Oculogastrointestinal-neurodevelopmental syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,32885237[PMID]_33410501[PMID]_ORPHANET
613267,Pontocerebellar hypoplasia type 13,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,30624672[PMID]_31207318[PMID]
613267,Pontocerebellar hypoplasia type 13,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30624672[PMID]_31207318[PMID]_ORPHANET
98085,"46,XY difference of sex development",Category,Annual incidence,0.06,<1 / 1 000 000,Value and class,Denmark,Validated,27603905[PMID]
98085,"46,XY difference of sex development",Category,Prevalence at birth,6.4,1-9 / 100 000,Value and class,Denmark,Validated,27603905[PMID]
613274,Pontocerebellar hypoplasia type 14,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,33220177[PMID]
613274,Pontocerebellar hypoplasia type 14,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,33220177[PMID]_ORPHANET
98249,Ehlers-Danlos syndrome,Clinical group,Prevalence at birth,0.9,1-9 / 1 000 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2005-2012[REG]
98249,Ehlers-Danlos syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
600668,CCNK-related neurodevelopmental disorder-severe intellectual disability-facial dysmorphism syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,30122539[PMID]
600668,CCNK-related neurodevelopmental disorder-severe intellectual disability-facial dysmorphism syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30122539[PMID]_ORPHANET
600663,NRXN1-related severe neurodevelopmental disorder-motor stereotypies-chronic constipation-sleep-wake cycle disturbance,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,30873608[PMID]
600663,NRXN1-related severe neurodevelopmental disorder-motor stereotypies-chronic constipation-sleep-wake cycle disturbance,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30873608[PMID]_ORPHANET
600691,Combined deficiency of factor VII and factor X,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,28164683[PMID]
600691,Combined deficiency of factor VII and factor X,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,28164683[PMID]_ORPHANET
600731,Clark-Baraitser syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,ORPHANET
600731,Clark-Baraitser syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98287,Histiocytic and dendritic cell tumor,Category,Annual incidence,0.05,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98293,Hodgkin lymphoma,Clinical group,Annual incidence,2.4,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98293,Hodgkin lymphoma,Clinical group,Lifetime Prevalence,46.9,1-5 / 10 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
98293,Hodgkin lymphoma,Clinical group,Annual incidence,2.8,1-9 / 100 000,Value and class,United States,Validated,National Cancer Institute 2008[INST]_22835602[PMID]
98293,Hodgkin lymphoma,Clinical group,Annual incidence,0.25,1-9 / 1 000 000,Value and class,Japan,Not yet validated,emedicine[OTHER]
98293,Hodgkin lymphoma,Clinical group,Annual incidence,0.25,1-9 / 1 000 000,Value and class,China,Not yet validated,emedicine[OTHER]
98292,Mastocytosis,Category,Point prevalence,3.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
98292,Mastocytosis,Category,Point prevalence,9.59,1-9 / 100 000,Value and class,Denmark,Validated,24761987[PMID]
98292,Mastocytosis,Category,Point prevalence,10.0,1-5 / 10 000,Value and class,Worldwide,Validated,[EXPERT]_24745674[PMID]
98274,Myeloproliferative neoplasm,Clinical group,Annual incidence,3.07,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98277,Acute myeloid leukemia with recurrent genetic anomaly,Category,Annual incidence,0.11,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98275,Myelodysplastic/myeloproliferative disease,Clinical group,Annual incidence,0.29,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98267,Genetic non-syndromic obesity,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
98267,Genetic non-syndromic obesity,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
601028,Non-syndromic anorectal malformation with rectovaginal fistula,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601028,Non-syndromic anorectal malformation with rectovaginal fistula,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601033,Non-syndromic anorectal malformation with H-type fistula,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601033,Non-syndromic anorectal malformation with H-type fistula,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601008,Non-syndromic anorectal malformation with anal stenosis,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601008,Non-syndromic anorectal malformation with anal stenosis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601013,Non-syndromic anorectal malformation with pouch colon,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601013,Non-syndromic anorectal malformation with pouch colon,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601018,Non-syndromic anorectal malformation with rectal atresia,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601018,Non-syndromic anorectal malformation with rectal atresia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601023,Non-syndromic anorectal malformation with rectal stenosis,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601023,Non-syndromic anorectal malformation with rectal stenosis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
600984,Non-syndromic anorectal malformation with rectovesical fistula,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
600984,Non-syndromic anorectal malformation with rectovesical fistula,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
600993,Non-syndromic anorectal malformation with vestibular fistula,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
600993,Non-syndromic anorectal malformation with vestibular fistula,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
600998,Non-syndromic cloacal malformation,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
600998,Non-syndromic cloacal malformation,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601002,Non-syndromic anorectal malformation without fistula,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
601002,Non-syndromic anorectal malformation without fistula,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
600961,Non-syndromic anorectal malformation with rectourethral fistula,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
600961,Non-syndromic anorectal malformation with rectourethral fistula,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
600952,Non-syndromic anorectal malformation with perineal fistula,Morphological anomaly,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
600952,Non-syndromic anorectal malformation with perineal fistula,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,16226976[PMID]_31194415[PMID]_ORPHANET
97245,Congenital myopathy,Category,Point prevalence,3.8,1-9 / 100 000,Value and class,United States,Validated,22028225[PMID]
97244,Rigid spine syndrome,Disease,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
97244,Rigid spine syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
97244,Rigid spine syndrome,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
97242,Congenital muscular dystrophy,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET
97242,Congenital muscular dystrophy,Category,Point prevalence,0.563,1-9 / 1 000 000,Value and class,Italy,Validated,25653289[PMID]
97261,GRFoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
97253,Neuroendocrine tumor of pancreas,Category,Annual incidence,0.22,1-9 / 1 000 000,Value and class,United States,Validated,18515795[PMID]_National Cancer Institute[INST]
97253,Neuroendocrine tumor of pancreas,Category,Annual incidence,1.27,1-9 / 100 000,Value and class,Japan,Validated,24499825[PMID]
97253,Neuroendocrine tumor of pancreas,Category,Point prevalence,2.69,1-9 / 100 000,Value and class,Japan,Validated,24499825[PMID]
97253,Neuroendocrine tumor of pancreas,Category,Annual incidence,0.21,1-9 / 1 000 000,Value and class,France,Validated,15016750[PMID]
97253,Neuroendocrine tumor of pancreas,Category,Annual incidence,0.21,1-9 / 1 000 000,Value and class,Europe,Validated,15016750[PMID]
97253,Neuroendocrine tumor of pancreas,Category,Point prevalence,27.5,1-5 / 10 000,Value and class,United States,Validated,23237225[PMID]_[EXPERT]
97253,Neuroendocrine tumor of pancreas,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
97249,Pontocerebellar hypoplasia type 3,Malformation syndrome,Cases/families,3.0,,Family(ies),Worldwide,Validated,[EXPERT]
97249,Pontocerebellar hypoplasia type 3,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
97279,Insulinoma,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Ireland,Validated,2575263[PMID]
97279,Insulinoma,Disease,Annual incidence,0.25,1-9 / 1 000 000,Value and class,Worldwide,Validated,23430217[PMID]
97279,Insulinoma,Disease,Point prevalence,0.56,1-9 / 1 000 000,Value and class,Japan,Validated,24499825[PMID]
97279,Insulinoma,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
97278,PPoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
97285,Thyroid lymphoma,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Not yet validated,23714679[PMID]
97283,Somatostatinoma,Disease,Annual incidence,0.0025,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_17645474[PMID]
97283,Somatostatinoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
97282,VIPoma,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,[EXPERT]
97282,VIPoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
97280,Glucagonoma,Disease,Annual incidence,0.005,<1 / 1 000 000,Value and class,Europe,Validated,9113318[PMID]
97280,Glucagonoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,ORPHANET
97290,Familial papillary thyroid carcinoma with renal papillary neoplasia,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,10843148[PMID]
97286,Carney-Stratakis syndrome,Disease,Cases/families,20.0,,Family(ies),Worldwide,Validated,ORPHANET
97286,Carney-Stratakis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
97292,Cardiogenic shock,Particular clinical situation in a disease or syndrome,Point prevalence,40.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2008[INST]
97335,Osgood-Schlatter disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
97297,Bohring-Opitz syndrome,Malformation syndrome,Cases/families,46.0,,Case(s),Worldwide,Validated,29446906[PMID]
97297,Bohring-Opitz syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
97330,Thoracic outlet syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
97339,Dural sinus malformation,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
97336,Panner disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
97337,Sinding-Larsen-Johansson disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
97341,Persistent placoid maculopathy,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,17471331[PMID]_[EXPERT]
97341,Persistent placoid maculopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
97340,Hunter-McAlpine syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
97340,Hunter-McAlpine syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
97360,Robinow syndrome,Malformation syndrome,Cases/families,200.0,,Case(s),Worldwide,Validated,[EXPERT]
97360,Robinow syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
97355,Caribbean parkinsonism,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
97361,"Renal hypoplasia, unilateral",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
97362,"Renal hypoplasia, bilateral",Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Prevalence at birth,23.2,1-5 / 10 000,Value and class,Worldwide,Validated,19171687[PMID]_[EXPERT]
97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Prevalence at birth,14.8,1-5 / 10 000,Value and class,Europe,Validated,16053904[PMID]_[EXPERT]
97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Prevalence at birth,45.4,1-5 / 10 000,Value and class,United Kingdom,Validated,18278521[PMID]
97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Prevalence at birth,25.0,1-5 / 10 000,Value and class,Japan,Validated,11967035[PMID]
97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Prevalence at birth,108.0,>1 / 1000,Value and class,Saudi Arabia,Validated,12415373[PMID]
97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Prevalence at birth,24.4,1-5 / 10 000,Value and class,Finland,Validated,12532949[PMID]
97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Prevalence at birth,41.0,1-5 / 10 000,Value and class,United States,Validated,7776710[PMID]
97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Prevalence at birth,60.3,6-9 / 10 000,Value and class,Switzerland,Validated,11683078[PMID]
97363,Unilateral multicystic dysplastic kidney,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET_[EXPERT]
97364,Bilateral multicystic dysplastic kidney,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
97548,Right sided atrial isomerism,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,France,Validated,9562017[PMID]_25752370[PMID]_34631807[PMID]_ORPHANET
97548,Right sided atrial isomerism,Malformation syndrome,Prevalence at birth,16.67,1-5 / 10 000,Value and class,France,Validated,8308205[PMID]
97560,Primary membranous glomerulonephritis,Disease,Annual incidence,0.8103,1-9 / 1 000 000,Value and class,Worldwide,Validated,21068142[PMID]_ORPHANET
97560,Primary membranous glomerulonephritis,Disease,Annual incidence,0.9194,1-9 / 1 000 000,Value and class,Europe,Validated,21068142[PMID]_ORPHANET
97560,Primary membranous glomerulonephritis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,21068142[PMID]_34593809[PMID]_ORPHANET
96181,Maternal uniparental disomy of chromosome 6 syndrome,Malformation syndrome,Cases/families,15.0,,Case(s),Worldwide,Validated,27922284[PMID]
96181,Maternal uniparental disomy of chromosome 6 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27922284[PMID]
96178,Ring chromosome 16 syndrome,Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,23705081[PMID]
96178,Ring chromosome 16 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23705081[PMID]
96177,Ring chromosome 15 syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,16267671[PMID]
96177,Ring chromosome 15 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16267671[PMID]
96176,Ring chromosome 13 syndrome,Malformation syndrome,Prevalence at birth,1.72,1-9 / 100 000,Value and class,United Kingdom,Validated,7129419[PMID]
96188,Maternal uniparental disomy of chromosome 22 syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,ISBN:978-3-642-55287-8[OTHER]
96188,Maternal uniparental disomy of chromosome 22 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ISBN:978-3-642-55287-8[OTHER]
96187,Maternal uniparental disomy of chromosome 21 syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,ISBN:978-3-642-55287-8[OTHER]
96187,Maternal uniparental disomy of chromosome 21 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ISBN:978-3-642-55287-8[OTHER]
96186,Maternal uniparental disomy of chromosome 20 syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,26248010[PMID]
96186,Maternal uniparental disomy of chromosome 20 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26248010[PMID]
96184,Temple syndrome due to maternal uniparental disomy of chromosome 14,Etiological subtype,Cases/families,64.0,,Case(s),Worldwide,Validated,28640239[PMID]_24891339[PMID]
96184,Temple syndrome due to maternal uniparental disomy of chromosome 14,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28640239[PMID]_24891339[PMID]
96192,Paternal uniparental disomy of chromosome 7 syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,17935233[PMID]
96192,Paternal uniparental disomy of chromosome 7 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17935233[PMID]
96253,Cushing disease,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency[INST]
96253,Cushing disease,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,Europe,Not yet validated,22710101[PMID]
96264,"49,XXXXY syndrome",Malformation syndrome,Prevalence at birth,0.55,1-9 / 1 000 000,Value and class,Europe,Validated,7567329[PMID]_[EXPERT]_ ORPHANET
96264,"49,XXXXY syndrome",Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
96263,"48,XXXY syndrome",Malformation syndrome,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
96263,"48,XXXY syndrome",Malformation syndrome,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]_ORPHANET
96334,Kagami-Ogata syndrome due to paternal uniparental disomy of chromosome 14,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26377239[PMID]
96334,Kagami-Ogata syndrome due to paternal uniparental disomy of chromosome 14,Etiological subtype,Cases/families,37.0,,Case(s),Worldwide,Validated,26377239[PMID]
97214,Eisenmenger syndrome,Malformation syndrome,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Belgium,Validated,19725436[PMID]
97214,Eisenmenger syndrome,Malformation syndrome,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
97234,Glycogen storage disease due to phosphoglycerate mutase deficiency,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,34237446[PMID]_ORPHANET
97234,Glycogen storage disease due to phosphoglycerate mutase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,34237446[PMID]_ORPHANET
97239,Reducing body myopathy,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,ORPHANET
97239,Reducing body myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
97240,Zebra body myopathy,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
97240,Zebra body myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
97229,Riboflavin transporter deficiency,Malformation syndrome,Cases/families,109.0,,Case(s),Worldwide,Validated,30793323[PMID]_[EXPERT]
97229,Riboflavin transporter deficiency,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30793323[PMID]
97230,Solar urticaria,Disease,Point prevalence,3.1,1-9 / 100 000,Value and class,United Kingdom,Validated,12975156[PMID]_[EXPERT]
97230,Solar urticaria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_30585308[PMID]_27793344[PMID]_[EXPERT]
97232,Fingerprint body myopathy,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
97232,Fingerprint body myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
600194,Factor V Atlanta bleeding disorder,Etiological subtype,Cases/families,1.0,,Case(s),Worldwide,Validated,33773040[PMID]
600194,Factor V Atlanta bleeding disorder,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,33773040[PMID]_ORPHANET
97678,Maternal uniparental disomy of chromosome 13 syndrome,Malformation syndrome,Cases/families,3.0,,Case(s),Worldwide,Validated,ISBN:978-3-642-55287-8[OTHER]
97678,Maternal uniparental disomy of chromosome 13 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_ISBN:978-3-642-55287-8[OTHER]
97593,Pseudohypoparathyroidism,Category,Point prevalence,0.67,1-9 / 1 000 000,Value and class,Italy,Validated,[EXPERT]
97593,Pseudohypoparathyroidism,Category,Point prevalence,0.34,1-9 / 1 000 000,Value and class,Japan,Validated,10695258[PMID]
97593,Pseudohypoparathyroidism,Category,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET_[EXPERT]
97564,Pauci-immune glomerulonephritis without ANCA,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_Dr Laure-Hélène NOEL[EXPERT]
97563,Pauci-immune glomerulonephritis with ANCA,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_Dr Laure-Hélène NOEL[EXPERT]
97685,17q11 microdeletion syndrome,Clinical subtype,Cases/families,170.0,,Case(s),Worldwide,Validated,16467218[PMID]
97685,17q11 microdeletion syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
95707,Idiopathic isolated micropenis,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_21527236[PMID]
95706,Non-syndromic posterior hypospadias,Morphological anomaly,Prevalence at birth,19.25,1-5 / 10 000,Value and class,Europe,Validated,25712311[PMID]_26810252[PMID]
95706,Non-syndromic posterior hypospadias,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
95702,X-linked adrenal hypoplasia congenita,Disease,Point prevalence,8.0,1-9 / 100 000,Value and class,Worldwide,Validated,20301604[PMID]_ORPHANET
95702,X-linked adrenal hypoplasia congenita,Disease,Prevalence at birth,8.0,1-9 / 100 000,Value and class,Worldwide,Validated,20301604[PMID]
95715,Congenital hypothyroidism due to transplacental passage of TSH-binding inhibitory antibodies,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
95716,Familial thyroid dyshormonogenesis,Disease,Annual incidence,2.67,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]_emedicine[OTHER]
95716,Familial thyroid dyshormonogenesis,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
95716,Familial thyroid dyshormonogenesis,Disease,Annual incidence,4.0,1-9 / 100 000,Value and class,Finland,Validated,2919526[PMID]
95713,Athyreosis,Morphological anomaly,Point prevalence,3.5,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
95714,Primary congenital hypothyroidism without thyroid developmental anomaly,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
95711,Congenital hypothyroidism due to developmental anomaly,Category,Point prevalence,21.3,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
95712,Thyroid ectopia,Morphological anomaly,Point prevalence,14.3,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
95613,Pituitary apoplexy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
95700,Familial adrenal hypoplasia with absent pituitary luteinizing hormone,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,2906226[PMID]
95700,Familial adrenal hypoplasia with absent pituitary luteinizing hormone,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2906226[PMID]
95699,Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency,Disease,Prevalence at birth,0.75,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
95699,Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
95626,Acquired arginine vasopressin deficiency,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
95506,Primary hypophysitis,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
95496,Pituitary stalk interruption syndrome,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
95494,"Combined pituitary hormone deficiencies, genetic forms",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
95433,Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,11175288[PMID]_4154794[PMID]
95433,Autosomal recessive spinocerebellar ataxia-blindness-deafness syndrome,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,ORPHANET_11175288[PMID]_4154794[PMID]
95434,Autosomal recessive cerebellar ataxia-movement disorder syndrome,Disease,Cases/families,27.0,,Case(s),Worldwide,Validated,29518282[PMID]_29604224[PMID]_31876103[PMID]
95434,Autosomal recessive cerebellar ataxia-movement disorder syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,29518282[PMID]_29604224[PMID]_31876103[PMID]_ORPHANET
95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Disease,Annual incidence,0.19,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,21162721[PMID]
95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Disease,Annual incidence,0.8,1-9 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,15057820[PMID]
95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Disease,Annual incidence,0.189,1-9 / 1 000 000,Value and class,Germany,Validated,15057820[PMID]
95455,Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum,Disease,Annual incidence,0.19,1-9 / 1 000 000,Value and class,United States,Not yet validated,ORPHANET
95157,Acute hepatic porphyria,Clinical group,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
95159,Hepatoerythropoietic porphyria,Disease,Cases/families,40.0,,Case(s),Worldwide,Validated,[EXPERT]
95159,Hepatoerythropoietic porphyria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
95428,COG8-CDG,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,17331980[PMID]_17220172[PMID]
95428,COG8-CDG,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17331980[PMID]_17220172[PMID]
95427,Secondary short bowel syndrome,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,30725620[PMID]_ORPHANET
95427,Secondary short bowel syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,30725620[PMID]_ORPHANET
95409,Acute adrenal insufficiency,Clinical syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
95432,Primary progressive aphasia,Clinical group,Point prevalence,7.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,24108322[PMID]
95430,Congenital tracheomalacia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
95429,Angioma serpiginosum,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
94091,Mills syndrome,Disease,Point prevalence,0.12,1-9 / 1 000 000,Value and class,United Kingdom,Validated,30631918[PMID]
94093,Neuroleptic malignant syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
94122,"Cerebellar ataxia, Cayman type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
94124,Spinocerebellar ataxia with axonal neuropathy type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12244316[PMID]
94124,Spinocerebellar ataxia with axonal neuropathy type 1,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,12244316[PMID]
94145,Autosomal dominant cerebellar ataxia type I,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
94147,Spinocerebellar ataxia type 7,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Worldwide,Validated,24374739[PMID]
94148,Autosomal dominant cerebellar ataxia type III,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,24225362[PMID]
94064,Deafness-infertility syndrome,Malformation syndrome,Cases/families,3.0,,Family(ies),Worldwide,Validated,26011646[PMID]
94064,Deafness-infertility syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26011646[PMID]
94063,12q14 microdeletion syndrome,Malformation syndrome,Cases/families,22.0,,Case(s),Worldwide,Validated,28407409[PMID]_29501611[PMID]
94063,12q14 microdeletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28407409[PMID]_29501611[PMID]
94066,Severe intellectual disability-epilepsy-anal anomalies-distal phalangeal hypoplasia,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,17351347[PMID]
94066,Severe intellectual disability-epilepsy-anal anomalies-distal phalangeal hypoplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17351347[PMID]
94065,15q24 microdeletion syndrome,Etiological subtype,Cases/families,30.0,,Case(s),Worldwide,Validated,22359776[PMID]
94065,15q24 microdeletion syndrome,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22359776[PMID]
94068,Spondyloepiphyseal dysplasia congenita,Disease,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
94068,Spondyloepiphyseal dysplasia congenita,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
94083,Partington syndrome,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,3177452[PMID]_12376949[PMID]
94083,Partington syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3177452[PMID]_12376949[PMID]
94086,Blue diaper syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
94088,Hereditary renal hypouricemia,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
94087,Cytophagic histiocytic panniculitis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
94087,Cytophagic histiocytic panniculitis,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
94090,Pseudohypoparathyroidism type 2,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
94089,Pseudohypoparathyroidism type 1B,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
96175,Ring chromosome 11 syndrome,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,26576288[PMID]
96175,Ring chromosome 11 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26576288[PMID]
96173,Ring chromosome 9 syndrome,Malformation syndrome,Cases/families,31.0,,Case(s),Worldwide,Validated,25722017[PMID]
96173,Ring chromosome 9 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25722017[PMID]
96172,Ring chromosome 3 syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,11491310[PMID]_27984612[PMID]
96172,Ring chromosome 3 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11491310[PMID]_27984612[PMID]
96171,Ring chromosome 2 syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,25997743[PMID]
96171,Ring chromosome 2 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25997743[PMID]
96170,Emanuel syndrome,Malformation syndrome,Cases/families,350.0,,Case(s),Worldwide,Validated,26076791[PMID]_20301440[PMID]
96170,Emanuel syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26076791[PMID]_20301440[PMID]
96169,Koolen-De Vries syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]_26306646[PMID]
96168,Monosomy 13q34 syndrome,Malformation syndrome,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
96168,Monosomy 13q34 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
96167,Recombinant 8 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
96148,Distal deletion 10q syndrome,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,ORPHANET
96148,Distal deletion 10q syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
96147,Kleefstra syndrome due to 9q34 microdeletion,Etiological subtype,Cases/families,86.0,,Case(s),Worldwide,Validated,22670141[PMID]
96147,Kleefstra syndrome due to 9q34 microdeletion,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
96125,Distal deletion 6p syndrome,Malformation syndrome,Cases/families,35.0,,Case(s),Worldwide,Validated,23686687[PMID]
96125,Distal deletion 6p syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
96121,7q11.23 microduplication syndrome,Malformation syndrome,Cases/families,163.0,,Case(s),Worldwide,Validated,27617154[PMID]
96121,7q11.23 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_27617154[PMID]
96102,Distal duplication 10q syndrome,Malformation syndrome,Cases/families,40.0,,Case(s),Worldwide,Validated,ORPHANET
96102,Distal duplication 10q syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
96095,3q26 microduplication syndrome,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,27549440[PMID]
96095,3q26 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27549440[PMID]
96092,8p inverted duplication/deletion syndrome,Malformation syndrome,Prevalence at birth,3.9,1-9 / 100 000,Value and class,Italy,Validated,11231899[PMID]
96092,8p inverted duplication/deletion syndrome,Malformation syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,[EXPERT]
96092,8p inverted duplication/deletion syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,[EXPERT]_ORPHANET
96078,16p13.3 microduplication syndrome,Malformation syndrome,Cases/families,27.0,,Case(s),Worldwide,Validated,26873618[PMID]
96078,16p13.3 microduplication syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26873618[PMID]
96061,Mosaic trisomy 8 syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
95717,Idiopathic congenital hypothyroidism,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
95719,Thyroid hemiagenesis,Morphological anomaly,Point prevalence,25.0,1-5 / 10 000,Value and class,Worldwide,Not yet validated,19016002[PMID]
95720,Thyroid hypoplasia,Morphological anomaly,Point prevalence,3.5,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
96055,Tetrasomy 21 syndrome,Malformation syndrome,Cases/families,13.0,,Case(s),Worldwide,Validated,18372039[PMID]
96055,Tetrasomy 21 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18372039[PMID]
597623,IRF2BPL-related regressive neurodevelopmental disorder-dystonia-seizures syndrome,Disease,Cases/families,19.0,,Case(s),Worldwide,Validated,31432588[PMID]
597623,IRF2BPL-related regressive neurodevelopmental disorder-dystonia-seizures syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,31432588[PMID]_ORPHANET
597733,Oculocutaneous albinism type 8,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,33100333[PMID]
597733,Oculocutaneous albinism type 8,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,33100333[PMID]
597738,Luscan-Lumish syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,31643139[PMID]_33248444[PMID]
597738,Luscan-Lumish syndrome,Malformation syndrome,Cases/families,11.0,,Case(s),Worldwide,Validated,31643139[PMID]_33248444[PMID]
597887,ALPI-related inflammatory bowel disease,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,29567797[PMID]
597887,ALPI-related inflammatory bowel disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,29567797[PMID]_ORPHANET
93555,Mixed cryoglobulinemia type III,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93554,Mixed cryoglobulinemia type II,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
597939,Euthyroid dysprealbuminemic hyperthyroxinemia,Disease,Cases/families,23.0,,Case(s),Worldwide,Validated,8784093[PMID]_15833783[PMID]_1979335[PMID]_31590893[PMID]
597939,Euthyroid dysprealbuminemic hyperthyroxinemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,8784093[PMID]_15833783[PMID]_1979335[PMID]_31590893[PMID]_ORPHANET
597743,SETD2-related microcephaly-severe intellectual disability-multiple congenital anomalies syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,32710489[PMID]
597743,SETD2-related microcephaly-severe intellectual disability-multiple congenital anomalies syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,32710489[PMID]
597746,Blepharophimosis-intellectual disability syndrome/genitopatellar overlap syndrome,Malformation syndrome,Cases/families,122.0,,Case(s),Worldwide,Validated,32424177[PMID]
597746,Blepharophimosis-intellectual disability syndrome/genitopatellar overlap syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,32424177[PMID]
93552,Pediatric systemic lupus erythematosus,Disease,Point prevalence,1.1,1-9 / 100 000,Value and class,United States,Validated,34825516[PMID]
93552,Pediatric systemic lupus erythematosus,Disease,Annual incidence,0.7,1-9 / 1 000 000,Value and class,United States,Validated,34825516[PMID]
597874,MTHFS-related developmental delay-microcephaly-short stature-epilepsy syndrome,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,30031689[PMID]_31844630[PMID]
597874,MTHFS-related developmental delay-microcephaly-short stature-epilepsy syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30031689[PMID]_31844630[PMID]_ORPHANET
598216,Upper tract urothelial carcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
598216,Upper tract urothelial carcinoma,Disease,Annual incidence,1.5,1-9 / 100 000,Value and class,Worldwide,Validated,28543959[PMID]_32593530[PMID]
598603,Facial dysmorphism-hypertrichosis-epilepsy-intellectual disability/developmental delay-gingival overgrowth syndrome,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,30290154[PMID]_32981868[PMID]
598603,Facial dysmorphism-hypertrichosis-epilepsy-intellectual disability/developmental delay-gingival overgrowth syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30290154[PMID]_32981868[PMID]_ORPHANET
598363,Multisystem inflammatory syndrome in children and adults,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,33640145[PMID]
598363,Multisystem inflammatory syndrome in children and adults,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,33640145[PMID]
93561,ALys amyloidosis,Clinical subtype,Cases/families,7.0,,Family(ies),Worldwide,Validated,21988333[PMID]
93561,ALys amyloidosis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21988333[PMID]
93571,Dense deposit disease,Histopathological subtype,Point prevalence,0.25,1-9 / 1 000 000,Value and class,Worldwide,Validated,20301598[PMID]
597201,TRIM22-related inflammatory bowel disease,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,26836588[PMID]_32463623[PMID]
597201,TRIM22-related inflammatory bowel disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,26836588[PMID]_32463623[PMID]_ORPHANET
93474,Scheie syndrome,Clinical subtype,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Canada,Validated,4250044[PMID]_ORPHANET
93474,Scheie syndrome,Clinical subtype,Point prevalence,0.07,<1 / 1 000 000,Value and class,United Kingdom,Validated,18796143[PMID]_ORPHANET
93474,Scheie syndrome,Clinical subtype,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Canada,Validated,4250044[PMID]
93474,Scheie syndrome,Clinical subtype,Prevalence at birth,0.07,<1 / 1 000 000,Value and class,United Kingdom,Validated,18796143[PMID]
93476,Hurler-Scheie syndrome,Clinical subtype,Prevalence at birth,0.24,1-9 / 1 000 000,Value and class,United Kingdom,Validated,18796143[PMID]
93476,Hurler-Scheie syndrome,Clinical subtype,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
93473,Hurler syndrome,Clinical subtype,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
93473,Hurler syndrome,Clinical subtype,Point prevalence,0.76,1-9 / 1 000 000,Value and class,United Kingdom,Validated,18796143[PMID]
93473,Hurler syndrome,Clinical subtype,Prevalence at birth,0.64,1-9 / 1 000 000,Value and class,Germany,Validated,16435194[PMID]
93473,Hurler syndrome,Clinical subtype,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Denmark,Validated,18681890[PMID]
93473,Hurler syndrome,Clinical subtype,Point prevalence,0.0,1-9 / 1 000 000,Class only,Denmark,Validated,18681890[PMID]
93473,Hurler syndrome,Clinical subtype,Prevalence at birth,1.05,1-9 / 100 000,Value and class,Portugal,Validated,14685153[PMID]
93473,Hurler syndrome,Clinical subtype,Prevalence at birth,0.06,<1 / 1 000 000,Value and class,"Taiwan, Province of China",Validated,19396827[PMID]
93473,Hurler syndrome,Clinical subtype,Prevalence at birth,0.93,1-9 / 1 000 000,Value and class,Australia,Validated,14608657[PMID]
93473,Hurler syndrome,Clinical subtype,Prevalence at birth,0.7,1-9 / 1 000 000,Value and class,Europe,Validated,ORPHANET_16435194[PMID]_14685153[PMID]_18681890[PMID]_18796143[PMID]
93473,Hurler syndrome,Clinical subtype,Point prevalence,0.07,<1 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
93473,Hurler syndrome,Clinical subtype,Prevalence at birth,0.26,1-9 / 1 000 000,Value and class,United States,Validated,34051828[PMID]
93398,Genochondromatosis type 2,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,17632779[PMID]
93398,Genochondromatosis type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17632779[PMID]
599373,STXBP1-related encephalopathy,Disease,Point prevalence,1.0885,1-9 / 100 000,Value and class,Denmark,Validated,26865513[PMID]
599373,STXBP1-related encephalopathy,Disease,Cases/families,282.0,,Case(s),Worldwide,Validated,32643187[PMID]
599373,STXBP1-related encephalopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
93403,Syndactyly type 2,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
599376,Hypomyelination of early myelinating structures,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,26125040[PMID]_33450882[PMID]
599376,Hypomyelination of early myelinating structures,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,26125040[PMID]_33450882[PMID]_ORPHANET
93402,Syndactyly type 1,Morphological anomaly,Prevalence at birth,25.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
93402,Syndactyly type 1,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,[EXPERT]
93405,Syndactyly type 4,Morphological anomaly,Cases/families,4.0,,Case(s),Worldwide,Validated,22448207[PMID]
93405,Syndactyly type 4,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22448207[PMID]
93404,Syndactyly type 3,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
599480,Acquired hemophilia A,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,36331704[PMID]_ORPHANET
599480,Acquired hemophilia A,Disease,Annual incidence,0.1505,1-9 / 1 000 000,Value and class,Europe,Validated,14675412[PMID]_17047148 [PMID]_32937680 [PMID]_36331704 [PMID]_37021783[PMID]
599480,Acquired hemophilia A,Disease,Point prevalence,0.0,Unknown,Class only,United Kingdom,Validated,14675412[PMID]_17047148 [PMID]_ORPHANET
599480,Acquired hemophilia A,Disease,Annual incidence,0.141,1-9 / 100 000,Value and class,United Kingdom,Validated,14675412[PMID]_17047148 [PMID]_ORPHANET
599480,Acquired hemophilia A,Disease,Point prevalence,0.3063,1-9 / 1 000 000,Value and class,Spain,Validated,34521101[PMID]_ORPHANET
599480,Acquired hemophilia A,Disease,Annual incidence,0.0829,<1 / 1 000 000,Value and class,Spain,Validated,34521101[PMID]_ORPHANET
599480,Acquired hemophilia A,Disease,Point prevalence,0.0,Unknown,Class only,Germany,Validated,32937680[PMID]
599480,Acquired hemophilia A,Disease,Annual incidence,0.6,1-9 / 1 000 000,Value and class,Germany,Validated,32937680[PMID]
599480,Acquired hemophilia A,Disease,Point prevalence,0.0,Unknown,Class only,Australia,Validated,20169513[PMID]
599480,Acquired hemophilia A,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Australia,Validated,20169513[PMID]
599480,Acquired hemophilia A,Disease,Point prevalence,0.0,Unknown,Class only,Japan,Validated,28299631[PMID]_36331704[PMID]_ORPHANET
599480,Acquired hemophilia A,Disease,Annual incidence,0.097,<1 / 1 000 000,Value and class,Japan,Validated,28299631[PMID]_36331704[PMID]_ORPHANET
599480,Acquired hemophilia A,Disease,Point prevalence,0.0,Unknown,Class only,Switzerland,Validated,37021783[PMID]
599480,Acquired hemophilia A,Disease,Annual incidence,0.45,1-9 / 1 000 000,Value and class,Switzerland,Validated,37021783[PMID]
599485,Acquired hemophilia B,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
599485,Acquired hemophilia B,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
93406,Syndactyly type 5,Morphological anomaly,Cases/families,10.0,,Case(s),Worldwide,Validated,ORPHANET
93406,Syndactyly type 5,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
599490,Acquired factor V deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,27428013[PMID]_36713339[PMID]_ORPHANET
599490,Acquired factor V deficiency,Disease,Cases/families,200.0,,Case(s),Worldwide,Validated,27428013[PMID]_36713339[PMID]_ORPHANET
599490,Acquired factor V deficiency,Disease,Annual incidence,0.029,<1 / 1 000 000,Value and class,Australia,Validated,15613918[PMID]
599490,Acquired factor V deficiency,Disease,Annual incidence,0.009,<1 / 1 000 000,Value and class,Singapore,Validated,19404538[PMID]
93409,"Brachydactyly-syndactyly, Zhao type",Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,17236141[PMID]
93409,"Brachydactyly-syndactyly, Zhao type",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17236141[PMID]
599495,Acquired factor VII deficiency,Disease,Cases/families,83.0,,Case(s),Worldwide,Validated,36546749[PMID]
599495,Acquired factor VII deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,36546749[PMID]_ORPHANET
599501,Acquired factor X deficiency,Disease,Cases/families,77.0,,Case(s),Worldwide,Validated,37587057[PMID]
599501,Acquired factor X deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,37587057[PMID]_ORPHANET
599507,Acquired factor XI deficiency,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,18519152[PMID]_29027258[PMID]
599507,Acquired factor XI deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,18519152[PMID]_29027258[PMID]_ORPHANET
599513,Acquired factor XIII deficiency,Disease,Cases/families,95.0,,Case(s),Worldwide,Validated,30446212[PMID]
599513,Acquired factor XIII deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30446212[PMID]_ORPHANET
599519,Factor V short isoforms-related bleeding disorder,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,25634741[PMID]_33773040[PMID]
599519,Factor V short isoforms-related bleeding disorder,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,25634741[PMID]_33773040[PMID]_ORPHANET
93420,FGFR3-related chondrodysplasia,Category,Prevalence at birth,8.1,1-9 / 100 000,Value and class,United States,Validated,22461456[PMID]
599579,Factor V Amsterdam bleeding disorder,Etiological subtype,Cases/families,2.0,,Case(s),Worldwide,Validated,25634741[PMID]
599579,Factor V Amsterdam bleeding disorder,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,25634741[PMID]_ORPHANET
93360,"Spondyloepimetaphyseal dysplasia with joint laxity, leptodactylic type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
93358,Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome,Disease,Cases/families,27.0,,Case(s),Worldwide,Validated,26463668[PMID]
93358,Spondyloepimetaphyseal dysplasia-short limb-abnormal calcification syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26463668[PMID]
93357,SPONASTRIME dysplasia,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,18203204[PMID]
93357,SPONASTRIME dysplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18203204[PMID]
599082,CHD3-related developmental delay-speech delay-intellectual disability-abnormalities of vision-facial dysmorphism syndrome,Malformation syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,PMID: 30397230 ;  32483341 ;  34535214
599082,CHD3-related developmental delay-speech delay-intellectual disability-abnormalities of vision-facial dysmorphism syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93372,Familial hypocalciuric hypercalcemia type 1,Etiological subtype,Point prevalence,74.1,6-9 / 10 000,Value and class,United States,Validated,32386559[PMID]
93372,Familial hypocalciuric hypercalcemia type 1,Etiological subtype,Point prevalence,5.5,1-9 / 100 000,Value and class,Worldwide,Validated,21986511[PMID]
93372,Familial hypocalciuric hypercalcemia type 1,Etiological subtype,Point prevalence,1.3,1-9 / 100 000,Value and class,United Kingdom,Validated,11353947[PMID]
93382,Brachydactyly type A6,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,4073128[PMID]
93382,Brachydactyly type A6,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_4073128[PMID]
93383,Brachydactyly type B,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET_18554391[PMID]
93383,Brachydactyly type B,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93387,Brachydactyly type E,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET_18554391[PMID]
93388,Brachydactyly type A1,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_18554391[PMID]
93384,Brachydactyly type C,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET_18554391[PMID]
93396,Brachydactyly type A2,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
93396,Brachydactyly type A2,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_18554391[PMID]
93397,Brachydactyly type A7,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,2714013[PMID]
93397,Brachydactyly type A7,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_2714013[PMID]
93394,Brachydactyly type A4,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_18554391[PMID]
595356,Localized dystrophic epidermolysis bullosa,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,32017015[PMID]_ORPHANET
595356,Localized dystrophic epidermolysis bullosa,Disease,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,32017015[PMID]_ORPHANET
94059,Uremic pruritus,Particular clinical situation in a disease or syndrome,Point prevalence,35.0,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2010[INST]
94058,Neovascular glaucoma,Particular clinical situation in a disease or syndrome,Point prevalence,24.4,1-5 / 10 000,Value and class,Europe,Validated,European Medicines Agency 2003[INST]
94056,Isolated humero-ulnar synostosis,Morphological anomaly,Cases/families,5.0,,Case(s),Worldwide,Validated,ORPHANET
94056,Isolated humero-ulnar synostosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93976,Anotia,Morphological anomaly,Point prevalence,0.03,<1 / 1 000 000,Value and class,Specific population,Validated,16359491[PMID]
93976,Anotia,Morphological anomaly,Prevalence at birth,0.028,<1 / 1 000 000,Value and class,Europe,Not yet validated,ORPHANET
93976,Anotia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
93976,Anotia,Morphological anomaly,Prevalence at birth,0.04,<1 / 1 000 000,Value and class,France,Validated,8933331[PMID]
93976,Anotia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,France,Validated,8933331[PMID]
93976,Anotia,Morphological anomaly,Prevalence at birth,0.03,<1 / 1 000 000,Value and class,Italy,Validated,7666397[PMID]
93976,Anotia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Italy,Not yet validated,7666397[PMID]
93976,Anotia,Morphological anomaly,Prevalence at birth,0.02,<1 / 1 000 000,Value and class,Sweden,Validated,8933331[PMID]
93976,Anotia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Sweden,Validated,8933331[PMID]
93976,Anotia,Morphological anomaly,Prevalence at birth,0.02,<1 / 1 000 000,Value and class,United States,Validated,8933331[PMID]_19760683[PMID]
93976,Anotia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,United States,Validated,8933331[PMID]_19760683[PMID]
93976,Anotia,Morphological anomaly,Prevalence at birth,0.02,<1 / 1 000 000,Value and class,Finland,Validated,17548114[PMID]
93976,Anotia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Finland,Validated,17548114[PMID]
93976,Anotia,Morphological anomaly,Prevalence at birth,0.05,<1 / 1 000 000,Value and class,Chile,Validated,17186100[PMID]
93976,Anotia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Chile,Not yet validated,17186100[PMID]
93932,FG syndrome type 1,Disease,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,17574621[PMID]_ORPHANET
93932,FG syndrome type 1,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,17574621[PMID]_ORPHANET
93930,Bladder exstrophy,Clinical subtype,Prevalence at birth,2.8,1-9 / 100 000,Value and class,Spain,Validated,11251990[PMID]
93930,Bladder exstrophy,Clinical subtype,Prevalence at birth,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
93930,Bladder exstrophy,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
93930,Bladder exstrophy,Clinical subtype,Prevalence at birth,2.8,1-9 / 100 000,Value and class,United States,Not yet validated,8013895[PMID]_15821570[PMID]_17990338[PMID]
93930,Bladder exstrophy,Clinical subtype,Prevalence at birth,3.05,1-9 / 100 000,Value and class,Worldwide,Not yet validated,19878548[PMID]_ORPHANET
93928,Isolated epispadias,Clinical subtype,Prevalence at birth,2.4,1-9 / 100 000,Value and class,Europe,Not yet validated,19878548[PMID]
93928,Isolated epispadias,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,19878548[PMID]
93929,Cloacal exstrophy,Clinical subtype,Prevalence at birth,0.75,1-9 / 1 000 000,Value and class,Europe,Not yet validated,19878548[PMID]
93929,Cloacal exstrophy,Clinical subtype,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,19878548[PMID]
93929,Cloacal exstrophy,Clinical subtype,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,United States,Validated,17990338[PMID]
93929,Cloacal exstrophy,Clinical subtype,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Spain,Validated,11251990[PMID]
93929,Cloacal exstrophy,Clinical subtype,Prevalence at birth,0.54,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,22002951[PMID]
93926,Midline interhemispheric variant of holoprosencephaly,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,31063520[PMID]_ORPHANET
93926,Midline interhemispheric variant of holoprosencephaly,Clinical subtype,Prevalence at birth,0.0,1-9 / 100 000,Class only,Worldwide,Validated,31063520[PMID]_ORPHANET
93926,Midline interhemispheric variant of holoprosencephaly,Clinical subtype,Prevalence at birth,2.778,1-9 / 100 000,Value and class,Romania,Validated,31063520[PMID]
93924,Lobar holoprosencephaly,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
93925,Alobar holoprosencephaly,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
93921,Full schwannomatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET_ISBN:3211695001[OTHER]
93921,Full schwannomatosis,Disease,Annual incidence,0.058,<1 / 1 000 000,Value and class,Finland,Validated,ISBN:3211695001[OTHER]_10636128[PMID]
93953,Familial thyroglossal duct cyst,Morphological anomaly,Cases/families,22.0,,Case(s),Worldwide,Validated,16012840[PMID]_19344886[PMID]_17457484[PMID]
93953,Familial thyroglossal duct cyst,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16012840[PMID]_19344886[PMID]_17457484[PMID]
93952,"X-linked intellectual disability, Hedera type",Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,26467484[PMID]_11782983[PMID]
93952,"X-linked intellectual disability, Hedera type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26467484[PMID]_11782983[PMID]
595133,Perivascular epithelioid cell neoplasm,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
93947,"X-linked intellectual disability, Golabi-Ito-Hall type",Clinical subtype,Cases/families,3.0,,Case(s),Worldwide,Validated,[EXPERT]
93947,"X-linked intellectual disability, Golabi-Ito-Hall type",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93946,Hamel cerebro-palato-cardiac syndrome,Clinical subtype,Cases/families,4.0,,Case(s),Worldwide,Validated,[EXPERT]
93946,Hamel cerebro-palato-cardiac syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93941,Laryngotracheoesophageal cleft type 4,Clinical subtype,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
93941,Laryngotracheoesophageal cleft type 4,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93940,Laryngotracheoesophageal cleft type 3,Clinical subtype,Cases/families,30.0,,Case(s),Worldwide,Validated,[EXPERT]
93940,Laryngotracheoesophageal cleft type 3,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93939,Laryngotracheoesophageal cleft type 2,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93938,Laryngotracheoesophageal cleft type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93616,Hemoglobin H disease,Clinical subtype,Prevalence at birth,8.7,1-9 / 100 000,Value and class,United States,Not yet validated,21167500[PMID]_22766612[PMID]
93616,Hemoglobin H disease,Clinical subtype,Point prevalence,0.1,1-9 / 1 000 000,Value and class,United States,Validated,21167500[PMID]_[EXPERT]
93616,Hemoglobin H disease,Clinical subtype,Annual incidence,1200.0,>1 / 1000,Value and class,South East Asia,Not yet validated,20301608[PMID]_ORPHANET
93622,Dent disease type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93623,Dent disease type 2,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
93672,Juvenile dermatomyositis,Disease,Annual incidence,0.295,1-9 / 1 000 000,Value and class,Worldwide,Validated,12794783[PMID]_7551657[PMID]
93672,Juvenile dermatomyositis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
93685,Unicentric Castleman disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29157611[PMID]
93685,Unicentric Castleman disease,Clinical subtype,Annual incidence,0.0,1-9 / 100 000,Class only,United States,Validated,ORPHANET_25120049[PMID]
93890,Rare developmental defect during embryogenesis,Category,Point prevalence,3.3,1-9 / 100 000,Value and class,France,Validated,22939647[PMID]
93890,Rare developmental defect during embryogenesis,Category,Prevalence at birth,2.42,1-9 / 100 000,Value and class,France,Validated,22939647[PMID]
93591,Infantile nephronophthisis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Validated,European Rare Kidney Diseases Reference Network[EXPERT]
93598,Primary hyperoxaluria type 1,Clinical subtype,Annual incidence,0.015,<1 / 1 000 000,Value and class,Netherlands,Validated,12543880[PMID]
93598,Primary hyperoxaluria type 1,Clinical subtype,Point prevalence,0.29,1-9 / 1 000 000,Value and class,Netherlands,Validated,12543880[PMID]
93598,Primary hyperoxaluria type 1,Clinical subtype,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Switzerland,Validated,8808215[PMID]
93598,Primary hyperoxaluria type 1,Clinical subtype,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Switzerland,Validated,8808215[PMID]
93598,Primary hyperoxaluria type 1,Clinical subtype,Annual incidence,0.83,1-9 / 1 000 000,Value and class,France,Validated,[EXPERT]
93598,Primary hyperoxaluria type 1,Clinical subtype,Point prevalence,0.1,1-9 / 1 000 000,Value and class,France,Validated,8592622[PMID]_[EXPERT]
93583,Congenital thrombotic thrombocytopenic purpura,Clinical subtype,Annual incidence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,[EXPERT]_19847791[PMID]
93583,Congenital thrombotic thrombocytopenic purpura,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,[EXPERT]_ORPHANET
93583,Congenital thrombotic thrombocytopenic purpura,Clinical subtype,Cases/families,123.0,,Case(s),Worldwide,Validated,PMID:30792199
93585,Immune-mediated thrombotic thrombocytopenic purpura,Clinical subtype,Annual incidence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
93585,Immune-mediated thrombotic thrombocytopenic purpura,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
93610,Distal renal tubular acidosis with anemia,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
596759,Combined immunodeficiency due to RELA haploinsufficiency,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,28600438[PMID]_29305315[PMID]
596759,Combined immunodeficiency due to RELA haploinsufficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,28600438[PMID]_29305315[PMID]_ORPHANET
93608,Autosomal dominant distal renal tubular acidosis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
93607,Autosomal recessive proximal renal tubular acidosis,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
596937,Portosinusoidal vascular disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,30957754[PMID]_36606618[PMID]
596937,Portosinusoidal vascular disease,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,30957754[PMID]_36606618[PMID]
596448,IgG4-related systemic disease,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
596448,IgG4-related systemic disease,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
596448,IgG4-related systemic disease,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Japan,Validated,21881964[PMID]_25360299[PMID]_ORPHANET
596448,IgG4-related systemic disease,Disease,Annual incidence,1.026,1-9 / 100 000,Value and class,Japan,Validated,21881964[PMID]_33906357[PMID]_ORPHANET
596448,IgG4-related systemic disease,Disease,Point prevalence,0.576,1-9 / 1 000 000,Value and class,Denmark,Validated,30931680[PMID]
596448,IgG4-related systemic disease,Disease,Annual incidence,0.6885,1-9 / 1 000 000,Value and class,Denmark,Validated,30931680[PMID]
93600,Primary hyperoxaluria type 3,Clinical subtype,Cases/families,50.0,,Case(s),Worldwide,Validated,23167815[PMID]
93600,Primary hyperoxaluria type 3,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
93599,Primary hyperoxaluria type 2,Clinical subtype,Cases/families,10.0,,Case(s),Worldwide,Validated,23167815[PMID]
93599,Primary hyperoxaluria type 2,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
93606,Nephrogenic syndrome of inappropriate antidiuresis,Disease,Cases/families,21.0,,Case(s),Worldwide,Validated,22722264[PMID]_[EXPERT]
93606,Nephrogenic syndrome of inappropriate antidiuresis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
596753,VEXAS syndrome,Disease,Cases/families,37.0,,Case(s),Worldwide,Validated,PMID: 34489099
596753,VEXAS syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
93605,Bartter syndrome type 3,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET_[EXPERT]
99094,Laubry-Pezzi syndrome,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
99063,Shone complex,Malformation syndrome,Cases/families,100.0,,Case(s),Worldwide,Validated,DOI: 10.5530/jcdr.2016.3.8[OTHER]
99063,Shone complex,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_DOI: 10.5530/jcdr.2016.3.8[OTHER]
99125,Congenital total pulmonary venous return anomaly,Morphological anomaly,Prevalence at birth,8.0,1-9 / 100 000,Value and class,United States,Validated,18657826[PMID]
99125,Congenital total pulmonary venous return anomaly,Morphological anomaly,Prevalence at birth,9.0,1-9 / 100 000,Value and class,Worldwide,Validated,12084585[PMID]
99125,Congenital total pulmonary venous return anomaly,Morphological anomaly,Point prevalence,9.0,1-9 / 100 000,Value and class,Worldwide,Validated,12084585[PMID]_ORPHANET
99125,Congenital total pulmonary venous return anomaly,Morphological anomaly,Point prevalence,8.0,1-9 / 100 000,Value and class,United States,Validated,18657826[PMID]_ORPHANET
99095,Congenital Gerbode defect,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
99147,Acquired von Willebrand syndrome,Disease,Cases/families,300.0,,Case(s),Worldwide,Validated,ORPHANET
99147,Acquired von Willebrand syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
592873,Acute transverse myelitis with anti-MOG antibodies,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
592873,Acute transverse myelitis with anti-MOG antibodies,Clinical subtype,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99141,Lymphedema-posterior choanal atresia syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,20826270[PMID] _DOI:10.1016/j.mgene.2017.07.006[OTHER]
99141,Lymphedema-posterior choanal atresia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20826270[PMID]
99329,"48,XYYY syndrome",Malformation syndrome,Cases/families,10.0,,Case(s),Worldwide,Validated,28137251[PMID]
99329,"48,XYYY syndrome",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28137251[PMID]
99330,"49,XYYYY syndrome",Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,28137251[PMID]
99330,"49,XYYYY syndrome",Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28137251[PMID]
99657,"Primary dystonia, DYT2 type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99429,Complete androgen insensitivity syndrome,Disease,Annual incidence,3.0,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
99429,Complete androgen insensitivity syndrome,Disease,Point prevalence,0.83,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,ORPHANET_22698698[PMID]
99642,"Spondyloepimetaphyseal dysplasia, Handigodu type",Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_7886470[PMID]
99642,"Spondyloepimetaphyseal dysplasia, Handigodu type",Disease,Cases/families,234.0,,Case(s),Worldwide,Validated,7886470[PMID]
99646,Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99688,Dermotrichic syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14708109[PMID]
592574,Menke-Hennekam syndrome,Malformation syndrome,Cases/families,27.0,,Case(s),Worldwide,Validated,PMID: 27311832; 29460469; 30892814
592574,Menke-Hennekam syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
592564,GNAO1-related developmental delay-seizures-movement disorder spectrum,Disease,Cases/families,75.0,,Case(s),Worldwide,Validated,PMID: 26060304 ; 29758257 ; 30682224 ; 34122306
592564,GNAO1-related developmental delay-seizures-movement disorder spectrum,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
592570,TRAF7-associated heart defect-digital anomalies-facial dysmorphism-motor and speech delay syndrome,Malformation syndrome,Cases/families,55.0,,Case(s),Worldwide,Validated,PMID: 29961569 ;  32376980 ;  32459067 ;  34088006
592570,TRAF7-associated heart defect-digital anomalies-facial dysmorphism-motor and speech delay syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
99672,Fried's tooth and nail syndrome,Malformation syndrome,Cases/families,12.0,,Case(s),Worldwide,Validated,856958[PMID]_9450885[PMID]
99672,Fried's tooth and nail syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_856958[PMID]_9450885[PMID]
99718,Leber plus disease,Disease,Point prevalence,0.04,<1 / 1 000 000,Value and class,Europe,Validated,ORPHANET
590539,Isolated melanotic schwannoma,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,PMID: 33088497
590539,Isolated melanotic schwannoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,PMID: 33088497
99725,Pituitary gigantism,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]_26187128[PMID]
589821,Congenital-onset Steinert myotonic dystrophy,Clinical subtype,Prevalence at birth,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
589821,Congenital-onset Steinert myotonic dystrophy,Clinical subtype,Prevalence at birth,2.1,1-9 / 100 000,Value and class,Canada,Validated,PMID: 23415617
589821,Congenital-onset Steinert myotonic dystrophy,Clinical subtype,Prevalence at birth,0.94,1-9 / 1 000 000,Value and class,Italy,Validated,PMID: 26882032
589821,Congenital-onset Steinert myotonic dystrophy,Clinical subtype,Prevalence at birth,47.6,1-5 / 10 000,Value and class,United States,Validated,PMID: 33472919
589821,Congenital-onset Steinert myotonic dystrophy,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
589827,Juvenile-onset Steinert myotonic dystrophy,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
589827,Juvenile-onset Steinert myotonic dystrophy,Clinical subtype,Point prevalence,1.64,1-9 / 100 000,Value and class,Italy,Validated,PMID: 26882032
589824,Childhood-onset Steinert myotonic dystrophy,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
589824,Childhood-onset Steinert myotonic dystrophy,Clinical subtype,Point prevalence,1.29,1-9 / 100 000,Value and class,Italy,Validated,26882032[PMID]
589833,Late-onset Steinert myotonic dystrophy,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
589833,Late-onset Steinert myotonic dystrophy,Clinical subtype,Point prevalence,8.14,1-9 / 100 000,Value and class,Italy,Validated,PMID: 26882032
589830,Adult-onset Steinert myotonic dystrophy,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
589830,Adult-onset Steinert myotonic dystrophy,Clinical subtype,Point prevalence,12.54,1-5 / 10 000,Value and class,Italy,Validated,PMID: 26882032
589905,PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome,Disease,Cases/families,35.0,,Case(s),Worldwide,Validated,PMID:27900362 ;  29209020 ; 31167805
589905,PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,PMID:27900362 ; 29209020 ; 31167805
589856,Choanal atresia-athelia-hypothyroidism-delayed puberty-short stature syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,PMID: 34369642
589856,Choanal atresia-athelia-hypothyroidism-delayed puberty-short stature syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,PMID: 34369642
99710,Punctate acrokeratoderma freckle-like pigmentation,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,8338755[PMID]
99710,Punctate acrokeratoderma freckle-like pigmentation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8338755[PMID]
99750,Atypical progressive supranuclear palsy syndrome,Clinical subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
99749,Kostmann syndrome,Disease,Cases/families,45.0,,Case(s),Worldwide,Validated,23351985[PMID]
99749,Kostmann syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
99749,Kostmann syndrome,Disease,Annual incidence,0.0425,<1 / 1 000 000,Value and class,Brazil,Validated,35209917[PMID]
99748,Pontiac fever,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.048,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.091,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.034,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.054,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.011,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.055,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.005,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.046,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.089,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.045,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.032,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.046,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.057,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.035,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.051,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.074,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.088,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.051,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.051,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.093,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.053,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.128,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99757,Embryonal rhabdomyosarcoma,Clinical subtype,Annual incidence,0.126,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.018,<1 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.054,<1 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.03,<1 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.017,<1 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.02,<1 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.009,<1 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.002,<1 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.033,<1 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.085,<1 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.062,<1 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.039,<1 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.005,<1 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.021,<1 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.063,<1 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.035,<1 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.02,<1 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.02,<1 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.029,<1 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.044,<1 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.027,<1 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.045,<1 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.036,<1 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99756,Alveolar rhabdomyosarcoma,Clinical subtype,Annual incidence,0.039,<1 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99734,Myotonia fluctuans,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99731,Isolated sulfite oxidase deficiency,Clinical subtype,Cases/families,50.0,,Case(s),Worldwide,Validated,28933809[PMID]
99731,Isolated sulfite oxidase deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28933809[PMID]
99735,Myotonia permanens,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99736,Acetazolamide-responsive myotonia,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
99741,King-Denborough syndrome,Malformation syndrome,Cases/families,18.0,,Case(s),Worldwide,Validated,12738133[PMID]_18765655[PMID]
99741,King-Denborough syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12738133[PMID]_18765655[PMID]
99742,Amish lethal microcephaly,Malformation syndrome,Prevalence at birth,200.0,>1 / 1000,Value and class,Specific population,Validated,12376931[PMID]
99742,Amish lethal microcephaly,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301539[PMID]
99745,Typhoid,Disease,Annual incidence,3.0,1-9 / 100 000,Value and class,Europe,Validated,15298225[PMID]_[EXPERT]_World Health Organization[INST]
99745,Typhoid,Disease,Annual incidence,274.0,>1 / 1000,Value and class,South East Asia,Validated,15298225[PMID]_World Health Organization[INST]
99745,Typhoid,Disease,Annual incidence,53.0,1-5 / 10 000,Value and class,Latin America,Validated,15298225[PMID]_World Health Organization[INST]
99745,Typhoid,Disease,Annual incidence,50.0,1-5 / 10 000,Value and class,Africa,Validated,15298225[PMID]_World Health Organization[INST]
99745,Typhoid,Disease,Annual incidence,0.0,1-9 / 1 000 000,Class only,North America,Validated,15298225[PMID]_World Health Organization[INST]
99745,Typhoid,Disease,Annual incidence,15.0,1-5 / 10 000,Value and class,Oceania,Validated,15298225[PMID]_World Health Organization[INST]
99745,Typhoid,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,France,Validated,Institut Pasteur[INST]
99745,Typhoid,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98818,Landau-Kleffner syndrome,Disease,Point prevalence,0.4,1-9 / 1 000 000,Value and class,Japan,Validated,23706409[PMID]
98815,Self-limited epilepsy with autonomic seizures,Clinical subtype,Annual incidence,0.8,1-9 / 1 000 000,Value and class,United Kingdom,Validated,DOI:10.1136/archdischild-2016-310863.98[OTHER]
98813,Hypohidrotic ectodermal dysplasia with immunodeficiency,Disease,Prevalence at birth,0.2,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
98813,Hypohidrotic ectodermal dysplasia with immunodeficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98811,Paroxysmal exertion-induced dyskinesia,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,18577546[PMID]
98811,Paroxysmal exertion-induced dyskinesia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98810,Paroxysmal non-kinesigenic dyskinesia,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Worldwide,Validated,19289562[PMID]_[EXPERT]
98809,Paroxysmal kinesigenic dyskinesia,Disease,Point prevalence,0.6,1-9 / 1 000 000,Value and class,Worldwide,Validated,20301633[PMID]
98808,Autosomal dominant dopa-responsive dystonia,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
98807,"Primary dystonia, DYT13 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9120448[PMID]
98807,"Primary dystonia, DYT13 type",Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,9120448[PMID]
98838,Primary mediastinal large B-cell lymphoma,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
98833,Acute myeloblastic leukemia without maturation,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98834,Acute myeloblastic leukemia with maturation,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98831,Acute myeloid leukemia with 11q23 abnormalities,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98832,Acute myeloid leukemia with minimal differentiation,Disease,Annual incidence,0.01,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98829,Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22),Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98827,Unclassified myelodysplastic syndrome,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,WHO Tumour classification
98827,Unclassified myelodysplastic syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,WHO Tumour classification
98826,Myelodysplastic neoplasm with low blasts,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
98823,Chronic myelomonocytic leukemia,Disease,Annual incidence,0.68,1-9 / 1 000 000,Value and class,Worldwide,Validated,30690330[PMID]_32501529[PMID]
98824,Atypical chronic myeloid leukemia,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98851,Mast cell leukemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
98851,Mast cell leukemia,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98848,Indolent systemic mastocytosis,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Validated,ORPHANET
98850,Aggressive systemic mastocytosis,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,[EXPERT]_ORPHANET
98849,Systemic mastocytosis with associated hematologic neoplasm,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,[EXPERT]
98844,"Classic Hodgkin lymphoma, mixed cellularity type",Histopathological subtype,Annual incidence,0.42,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98843,"Classic Hodgkin lymphoma, nodular sclerosis type",Histopathological subtype,Annual incidence,1.28,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98846,"Classic Hodgkin lymphoma, lymphocyte-depleted type",Histopathological subtype,Annual incidence,0.04,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98845,"Classic Hodgkin lymphoma, lymphocyte-rich type",Histopathological subtype,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
98842,Lymphomatoid papulosis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
98841,Anaplastic large cell lymphoma,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2011[INST]
589608,"Linear hypopigmentation and craniofacial asymmetry with acral, ocular and brain anomalies",Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,PMID: 31570889
589608,"Linear hypopigmentation and craniofacial asymmetry with acral, ocular and brain anomalies",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
589595,Mixed phenotype acute leukemia with t(v;11q23.3),Etiological subtype,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumour_ORPHANET
589595,Mixed phenotype acute leukemia with t(v;11q23.3),Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumour_ORPHANET
98868,Southeast Asian ovalocytosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
98869,Congenital dyserythropoietic anemia type I,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,20665989[PMID]_[EXPERT]
98869,Congenital dyserythropoietic anemia type I,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
589618,Dystonia 28,Disease,Cases/families,160.0,,Case(s),Worldwide,Validated,ORPHANET
589618,Dystonia 28,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
98870,Congenital dyserythropoietic anemia type III,Disease,Cases/families,60.0,,Case(s),Worldwide,Validated,23570799[PMID]
98870,Congenital dyserythropoietic anemia type III,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23570799[PMID]
589534,Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2),Etiological subtype,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
589534,Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2),Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
98863,X-linked Emery-Dreifuss muscular dystrophy,Etiological subtype,Point prevalence,0.13,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19767415[PMID]
98863,X-linked Emery-Dreifuss muscular dystrophy,Etiological subtype,Prevalence at birth,1.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,20301609[PMID]_Association Française contre les Myopathies[Patient organisation]
98863,X-linked Emery-Dreifuss muscular dystrophy,Etiological subtype,Point prevalence,1.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,20301609[PMID]_Association Française contre les Myopathies[Patient organisation]
589527,Spinocerebellar ataxia type 45,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,PMID: 29053796 ; 29847346
589527,Spinocerebellar ataxia type 45,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,PMID: 29053796 ; 29847346
589547,"GRIN2B-related developmental delay, intellectual disability and autism spectrum disorder",Disease,Cases/families,98.0,,Case(s),Worldwide,Validated,PMID: 28377535 ; 31085877 ; 34568804 ; 34615535
589547,"GRIN2B-related developmental delay, intellectual disability and autism spectrum disorder",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
589542,Myeloid/lymphoid neoplasm associated with JAK2 rearrangement,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
589542,Myeloid/lymphoid neoplasm associated with JAK2 rearrangement,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
589442,Short stature-skeletal dysplasia-retinal degeneration-intellectual disability-sensorineural hearing loss syndrome,Malformation syndrome,Cases/families,7.0,,Case(s),Worldwide,Validated,PMID: 30488656 ; 31263216
589442,Short stature-skeletal dysplasia-retinal degeneration-intellectual disability-sensorineural hearing loss syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
589435,Spondylometaphyseal dysplasia-corneal dystrophy syndrome,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,PMID: 29122926
589435,Spondylometaphyseal dysplasia-corneal dystrophy syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,PMID: 29122926
589522,Spinocerebellar ataxia type 46,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,PMID: 8595484 ; 29847346
589522,Spinocerebellar ataxia type 46,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,PMID: 8595484 ; 29847346
589515,PUM1-associated developmental disability-ataxia-seizure syndrome,Disease,Cases/families,14.0,,Case(s),Worldwide,Validated,"PMID reference: 29474920, 31859446, 30903679"
589515,PUM1-associated developmental disability-ataxia-seizure syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,"PMID reference: 29474920, 31859446, 30903679"
98856,Charcot-Marie-Tooth disease type 2B1,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98881,Familial dysfibrinogenemia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98879,Hemophilia B,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Europe,Validated,21649801[PMID]_European Medicines Agency 2018[INST]
98879,Hemophilia B,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Albania,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.44,1-9 / 1 000 000,Value and class,Algeria,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.54,1-9 / 1 000 000,Value and class,Argentina,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Armenia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.665,1-9 / 1 000 000,Value and class,Austria,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.16,1-9 / 1 000 000,Value and class,Azerbaijan,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.015,<1 / 1 000 000,Value and class,Bangladesh,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.84,1-9 / 1 000 000,Value and class,Belarus,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.32,1-9 / 100 000,Value and class,Belgium,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.155,1-9 / 100 000,Value and class,Belize,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.045,<1 / 1 000 000,Value and class,Bolivia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.265,1-9 / 1 000 000,Value and class,Bosnia and Herzegovina,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.535,1-9 / 1 000 000,Value and class,Brazil,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.775,1-9 / 1 000 000,Value and class,Bulgaria,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.795,1-9 / 1 000 000,Value and class,Chile,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.405,1-9 / 1 000 000,Value and class,Colombia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.645,1-9 / 1 000 000,Value and class,Costa rica,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.625,1-9 / 100 000,Value and class,Croatia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.49,1-9 / 1 000 000,Value and class,Cuba,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,3.195,1-9 / 100 000,Value and class,Cyprus,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.045,1-9 / 100 000,Value and class,Czech Republic,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.56,1-9 / 100 000,Value and class,Denmark,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.165,1-9 / 1 000 000,Value and class,Dominican Republic,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.25,1-9 / 1 000 000,Value and class,Ecuador,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.955,1-9 / 1 000 000,Value and class,Egypt,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.31,1-9 / 1 000 000,Value and class,El Salvador,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.065,<1 / 1 000 000,Value and class,Eritrea,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.24,1-9 / 1 000 000,Value and class,Estonia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.235,1-9 / 100 000,Value and class,Finland,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Georgia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.885,1-9 / 1 000 000,Value and class,Germany,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.075,1-9 / 100 000,Value and class,Greece,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.075,<1 / 1 000 000,Value and class,Guatemala,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.17,1-9 / 1 000 000,Value and class,Honduras,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,2.115,1-9 / 100 000,Value and class,Hungary,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.695,1-9 / 1 000 000,Value and class,Iceland,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.095,<1 / 1 000 000,Value and class,India,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.01,<1 / 1 000 000,Value and class,Indonesia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.98,1-9 / 1 000 000,Value and class,"Iran, Islamic Republic of",Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.545,1-9 / 1 000 000,Value and class,Iraq,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.06,1-9 / 100 000,Value and class,Italy,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.495,1-9 / 1 000 000,Value and class,"Korea, Republic of",Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.76,1-9 / 1 000 000,Value and class,Latvia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.57,1-9 / 1 000 000,Value and class,Lithuania,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.235,1-9 / 1 000 000,Value and class,Luxembourg,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,3.205,1-9 / 100 000,Value and class,North Macedonia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Malaysia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.77,1-9 / 1 000 000,Value and class,Malta,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.29,1-9 / 1 000 000,Value and class,Mexico,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.37,1-9 / 1 000 000,Value and class,"Moldova, Republic of",Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Mongolia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Morocco,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.065,<1 / 1 000 000,Value and class,Nepal,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.035,1-9 / 100 000,Value and class,Netherlands,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.855,1-9 / 100 000,Value and class,New Zealand,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.005,<1 / 1 000 000,Value and class,Nigeria,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.975,1-9 / 100 000,Value and class,Norway,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.24,1-9 / 1 000 000,Value and class,Pakistan,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.84,1-9 / 1 000 000,Value and class,"Palestinian Territory, occupied",Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.24,1-9 / 1 000 000,Value and class,Peru,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Philippines,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.85,1-9 / 1 000 000,Value and class,Poland,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.93,1-9 / 1 000 000,Value and class,Portugal,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,2.265,1-9 / 100 000,Value and class,Qatar,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.73,1-9 / 1 000 000,Value and class,Russian Federation,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.15,1-9 / 1 000 000,Value and class,Saudi Arabia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.04,<1 / 1 000 000,Value and class,Senegal,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.715,1-9 / 1 000 000,Value and class,Serbia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.045,<1 / 1 000 000,Value and class,Sierra leone,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.545,1-9 / 1 000 000,Value and class,Singapore,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.995,1-9 / 1 000 000,Value and class,Israel,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.32,1-9 / 1 000 000,Value and class,Jamaica,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.745,1-9 / 1 000 000,Value and class,Jordan,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.13,1-9 / 1 000 000,Value and class,Kenya,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.33,1-9 / 1 000 000,Value and class,Lebanon,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.33,1-9 / 1 000 000,Value and class,Nicaragua,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.585,1-9 / 1 000 000,Value and class,Panama,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.375,1-9 / 1 000 000,Value and class,Paraguay,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.76,1-9 / 1 000 000,Value and class,Romania,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.28,1-9 / 100 000,Value and class,Slovakia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.82,1-9 / 1 000 000,Value and class,Slovenia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.525,1-9 / 1 000 000,Value and class,South Africa,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.765,1-9 / 1 000 000,Value and class,Spain,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.065,<1 / 1 000 000,Value and class,Sri Lanka,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.115,1-9 / 1 000 000,Value and class,Sudan,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.85,1-9 / 100 000,Value and class,Sweden,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.375,1-9 / 100 000,Value and class,Switzerland,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.085,<1 / 1 000 000,Value and class,Thailand,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.02,<1 / 1 000 000,Value and class,Togo,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.37,1-9 / 1 000 000,Value and class,Tunisia,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.31,1-9 / 1 000 000,Value and class,Turkey,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.01,<1 / 1 000 000,Value and class,Ukraine,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,2.08,1-9 / 100 000,Value and class,United Kingdom,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.36,1-9 / 1 000 000,Value and class,Uruguay,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.285,1-9 / 1 000 000,Value and class,Uzbekistan,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,1.18,1-9 / 100 000,Value and class,Venezuela,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.14,1-9 / 1 000 000,Value and class,Viet Nam,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Point prevalence,0.35,1-9 / 1 000 000,Value and class,Zimbabwe,Validated,21649801[PMID]
98879,Hemophilia B,Disease,Prevalence at birth,1.665,1-9 / 100 000,Value and class,Worldwide,Validated,20301668[PMID]
98879,Hemophilia B,Disease,Point prevalence,2.44,1-9 / 100 000,Value and class,France,Validated,https://www.francecoag.org/SiteWebPublic/public/stats/stats_page.jsp?stat3=on
98873,Congenital dyserythropoietic anemia type II,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,20665989[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.85,1-9 / 100 000,Value and class,Worldwide,Not yet validated,19845775[PMID]_ORPHANET
98878,Hemophilia A,Disease,Prevalence at birth,11.25,1-5 / 10 000,Value and class,Worldwide,Not yet validated,20301578[PMID]_ORPHANET
98878,Hemophilia A,Disease,Point prevalence,10.5,1-5 / 10 000,Value and class,France,Validated,https://www.francecoag.org/SiteWebPublic/public/stats/stats_page.jsp?stat2=on
98878,Hemophilia A,Disease,Point prevalence,7.0,1-9 / 100 000,Value and class,United States,Validated,20301578[PMID]_19845775[PMID]_ ORPHANET
98878,Hemophilia A,Disease,Point prevalence,8.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
98878,Hemophilia A,Disease,Point prevalence,1.58,1-9 / 100 000,Value and class,Africa,Validated,19845775[PMID]_ORPHANET
98878,Hemophilia A,Disease,Point prevalence,7.6,1-9 / 100 000,Value and class,Albania,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.8,1-9 / 100 000,Value and class,Algeria,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.5,1-9 / 100 000,Value and class,Argentina,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Armenia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,6.8,1-9 / 100 000,Value and class,Australia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.3,1-9 / 100 000,Value and class,Austria,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,8.0,1-9 / 100 000,Value and class,Azerbaijan,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,Bangladesh,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,5.1,1-9 / 100 000,Value and class,Belarus,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,6.0,1-9 / 100 000,Value and class,Belgium,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.2,1-9 / 100 000,Value and class,Belize,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Bolivia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.6,1-9 / 100 000,Value and class,Bosnia and Herzegovina,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.7,1-9 / 100 000,Value and class,Brazil,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,6.8,1-9 / 100 000,Value and class,Bulgaria,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,7.3,1-9 / 100 000,Value and class,Canada,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,5.3,1-9 / 100 000,Value and class,Chile,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.2,1-9 / 1 000 000,Value and class,China,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.6,1-9 / 100 000,Value and class,Colombia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,Costa rica,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,8.5,1-9 / 100 000,Value and class,Croatia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.7,1-9 / 100 000,Value and class,Cuba,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,5.2,1-9 / 100 000,Value and class,Cyprus,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,6.1,1-9 / 100 000,Value and class,Czech Republic,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,6.2,1-9 / 100 000,Value and class,Denmark,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,1.8,1-9 / 100 000,Value and class,Dominican Republic,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.5,1-9 / 100 000,Value and class,Ecuador,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.4,1-9 / 100 000,Value and class,Egypt,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,El Salvador,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.7,1-9 / 1 000 000,Value and class,Eritrea,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.8,1-9 / 100 000,Value and class,Estonia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.6,1-9 / 100 000,Value and class,Finland,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,5.0,1-9 / 100 000,Value and class,Germany,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,6.5,1-9 / 100 000,Value and class,Greece,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Guatemala,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.6,1-9 / 100 000,Value and class,Honduras,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,8.3,1-9 / 100 000,Value and class,Hungary,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,19.3,1-5 / 10 000,Value and class,Iceland,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.7,1-9 / 1 000 000,Value and class,India,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Indonesia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,5.6,1-9 / 100 000,Value and class,"Iran, Islamic Republic of",Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,1.8,1-9 / 100 000,Value and class,Iraq,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,9.2,1-9 / 100 000,Value and class,Ireland,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,5.4,1-9 / 100 000,Value and class,Israel,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.7,1-9 / 100 000,Value and class,Italy,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.6,1-9 / 100 000,Value and class,Jamaica,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.3,1-9 / 100 000,Value and class,Japan,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.5,1-9 / 100 000,Value and class,Jordan,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,1.1,1-9 / 100 000,Value and class,Kenya,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.9,1-9 / 100 000,Value and class,Latvia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Lebanon,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.7,1-9 / 1 000 000,Value and class,Lesotho,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.1,1-9 / 100 000,Value and class,Lithuania,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,5.4,1-9 / 100 000,Value and class,Luxembourg,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,8.1,1-9 / 100 000,Value and class,North Macedonia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.3,1-9 / 100 000,Value and class,Malaysia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.3,1-9 / 100 000,Value and class,Malta,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.2,1-9 / 100 000,Value and class,Mexico,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.7,1-9 / 100 000,Value and class,"Moldova, Republic of",Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,1.4,1-9 / 100 000,Value and class,Mongolia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Morocco,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.6,1-9 / 1 000 000,Value and class,Nepal,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,9.3,1-9 / 100 000,Value and class,Netherlands,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,11.0,1-5 / 10 000,Value and class,New Zealand,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.7,1-9 / 100 000,Value and class,Nicaragua,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.025,<1 / 1 000 000,Value and class,Nigeria,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,6.1,1-9 / 100 000,Value and class,Norway,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.8,1-9 / 1 000 000,Value and class,Pakistan,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.7,1-9 / 100 000,Value and class,"Palestinian Territory, occupied",Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,6.6,1-9 / 100 000,Value and class,Panama,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,1.2,1-9 / 100 000,Value and class,Paraguay,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,1.6,1-9 / 100 000,Value and class,Peru,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.9,1-9 / 1 000 000,Value and class,Philippines,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,5.6,1-9 / 100 000,Value and class,Poland,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.9,1-9 / 100 000,Value and class,Portugal,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,7.9,1-9 / 100 000,Value and class,Qatar,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,6.4,1-9 / 100 000,Value and class,Romania,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.3,1-9 / 100 000,Value and class,Russian Federation,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Saudi Arabia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.8,1-9 / 1 000 000,Value and class,Senegal,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.7,1-9 / 100 000,Value and class,Serbia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Sierra leone,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Singapore,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,8.6,1-9 / 100 000,Value and class,Slovakia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,8.2,1-9 / 100 000,Value and class,Slovenia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.0,1-9 / 100 000,Value and class,South Africa,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.8,1-9 / 100 000,Value and class,Spain,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.6,1-9 / 1 000 000,Value and class,Sri Lanka,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.85,1-9 / 1 000 000,Value and class,Sudan,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,7.7,1-9 / 100 000,Value and class,Sweden,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,7.1,1-9 / 100 000,Value and class,Switzerland,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,1.8,1-9 / 100 000,Value and class,Thailand,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.02,<1 / 1 000 000,Value and class,Togo,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.2,1-9 / 100 000,Value and class,Tunisia,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.1,1-9 / 100 000,Value and class,Turkey,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,0.35,1-9 / 1 000 000,Value and class,Ukraine,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,10.4,1-5 / 10 000,Value and class,United Kingdom,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.9,1-9 / 100 000,Value and class,Uruguay,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,3.8,1-9 / 100 000,Value and class,Uzbekistan,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.9,1-9 / 100 000,Value and class,Venezuela,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Viet Nam,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,2.3,1-9 / 100 000,Value and class,Zimbabwe,Validated,19845775[PMID]
98878,Hemophilia A,Disease,Point prevalence,4.4,1-9 / 100 000,Value and class,Georgia,Validated,19845775[PMID]
98895,Becker muscular dystrophy,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2018[INST]
98895,Becker muscular dystrophy,Disease,Prevalence at birth,2.7,1-9 / 100 000,Value and class,United Kingdom,Validated,1673177[PMID]
98895,Becker muscular dystrophy,Disease,Point prevalence,3.64,1-9 / 100 000,Value and class,United Kingdom,Validated,19767415[PMID]_24780148[PMID]_ORPHANET
98895,Becker muscular dystrophy,Disease,Prevalence at birth,2.5,1-9 / 100 000,Value and class,United States,Validated,12495984[PMID]
98895,Becker muscular dystrophy,Disease,Point prevalence,2.4,1-9 / 100 000,Value and class,United States,Not yet validated,emedicine[OTHER]
98895,Becker muscular dystrophy,Disease,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
98895,Becker muscular dystrophy,Disease,Point prevalence,1.53,1-9 / 100 000,Value and class,Worldwide,Not yet validated,24780148[PMID]
98895,Becker muscular dystrophy,Disease,Point prevalence,2.47,1-9 / 100 000,Value and class,Italy,Validated,10466417[PMID]_24780148[PMID]
98895,Becker muscular dystrophy,Disease,Point prevalence,3.94,1-9 / 100 000,Value and class,Egypt,Validated,16210862[PMID]_24780148[PMID]
98895,Becker muscular dystrophy,Disease,Point prevalence,0.91,1-9 / 1 000 000,Value and class,Japan,Validated,1745328[PMID]_24780148[PMID]_ORPHANET
98895,Becker muscular dystrophy,Disease,Point prevalence,0.07,<1 / 1 000 000,Value and class,South Africa,Validated,7825085[PMID]_24780148[PMID]_ORPHANET
98895,Becker muscular dystrophy,Disease,Point prevalence,1.59,1-9 / 100 000,Value and class,Ireland,Validated,8845721[PMID]_24780148[PMID]
98895,Becker muscular dystrophy,Disease,Point prevalence,1.42,1-9 / 100 000,Value and class,Puerto rico,Validated,DOI:10.3233/JND-160147[OTHER]
98896,Duchenne muscular dystrophy,Disease,Prevalence at birth,9.9,1-9 / 100 000,Value and class,Worldwide,Validated,PMID: 32503598
98896,Duchenne muscular dystrophy,Disease,Point prevalence,4.14,1-9 / 100 000,Value and class,United Kingdom,Validated,19767415[PMID]_24780148[PMID]_ORPHANET
98896,Duchenne muscular dystrophy,Disease,Prevalence at birth,14.0,1-5 / 10 000,Value and class,United States,Validated,12495984[PMID]
98896,Duchenne muscular dystrophy,Disease,Prevalence at birth,12.0,1-5 / 10 000,Value and class,Netherlands,Validated,1733827[PMID]
98896,Duchenne muscular dystrophy,Disease,Prevalence at birth,10.5,1-5 / 10 000,Value and class,Canada,Validated,20080524[PMID]
98896,Duchenne muscular dystrophy,Disease,Prevalence at birth,9.7,1-9 / 100 000,Value and class,United Kingdom,Validated,23340516[PMID]
98896,Duchenne muscular dystrophy,Disease,Prevalence at birth,8.2,1-9 / 100 000,Value and class,Ireland,Validated,8845721[PMID]_24780148[PMID]
98896,Duchenne muscular dystrophy,Disease,Point prevalence,1.7,1-9 / 100 000,Value and class,Italy,Validated,10466417[PMID]_24780148[PMID]
98896,Duchenne muscular dystrophy,Disease,Point prevalence,4.26,1-9 / 100 000,Value and class,Ireland,Validated,8845721[PMID]_24780148[PMID]
98896,Duchenne muscular dystrophy,Disease,Point prevalence,2.8,1-9 / 100 000,Value and class,Worldwide,Validated,PMID: 32503598
98896,Duchenne muscular dystrophy,Disease,Lifetime Prevalence,7.66,1-9 / 100 000,Value and class,Egypt,Validated,16210862[PMID]_24780148[PMID]
98896,Duchenne muscular dystrophy,Disease,Point prevalence,3.56,1-9 / 100 000,Value and class,Japan,Validated,1745328[PMID]_24780148[PMID]_ORPHANET
98896,Duchenne muscular dystrophy,Disease,Point prevalence,0.47,1-9 / 1 000 000,Value and class,South Africa,Validated,7825085[PMID]_24780148[PMID]_ORPHANET
98896,Duchenne muscular dystrophy,Disease,Point prevalence,2.75,1-9 / 100 000,Value and class,Denmark,Validated,14678803[PMID]_24780148[PMID]_ORPHANET
98896,Duchenne muscular dystrophy,Disease,Point prevalence,2.59,1-9 / 100 000,Value and class,Puerto rico,Validated,DOI:10.3233/JND-160147[OTHER]
98902,Amish nemaline myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
98902,Amish nemaline myopathy,Disease,Prevalence at birth,200.0,>1 / 1000,Value and class,Specific population,Validated,10952871[PMID]
98890,Early-onset X-linked optic atrophy,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,16969871[PMID]
98890,Early-onset X-linked optic atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16969871[PMID]
98893,Congenital muscular dystrophy type 1B,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,10677302[PMID]
98893,Congenital muscular dystrophy type 1B,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10677302[PMID]
98892,Periventricular nodular heterotopia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98912,"Late-onset distal myopathy, Markesbery-Griggs type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15668942[PMID]
98912,"Late-onset distal myopathy, Markesbery-Griggs type",Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,15668942[PMID]
98916,Acute inflammatory demyelinating polyradiculoneuropathy,Disease,Point prevalence,3.1,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_European Medicines Agency[INST]
98908,Neutral lipid storage disease with myopathy,Disease,Cases/families,36.0,,Case(s),Worldwide,Validated,26600210[PMID]_28499397[PMID]
98908,Neutral lipid storage disease with myopathy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26600210[PMID]_28499397[PMID]
98907,Neutral lipid storage disease with ichthyosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
98909,Desminopathy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
98933,"Multiple system atrophy, parkinsonian type",Clinical subtype,Point prevalence,2.4,1-9 / 100 000,Value and class,Europe,Not yet validated,ORPHANET
98934,Huntington disease-like 2,Disease,Cases/families,50.0,,Family(ies),Worldwide,Validated,20301701[PMID]_[EXPERT]
98934,Huntington disease-like 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98919,Miller Fisher syndrome,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
98919,Miller Fisher syndrome,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
98920,Spinal muscular atrophy with respiratory distress type 1,Disease,Cases/families,128.0,,Case(s),Worldwide,Validated,26709713[PMID]
98920,Spinal muscular atrophy with respiratory distress type 1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26709713[PMID]
98938,Colobomatous microphthalmia,Malformation syndrome,Prevalence at birth,19.0,1-5 / 10 000,Value and class,United Kingdom,Validated,11826019[PMID]
98938,Colobomatous microphthalmia,Malformation syndrome,Point prevalence,19.0,1-5 / 10 000,Value and class,United Kingdom,Validated,11826019[PMID]_ORPHANET
98949,Complete cryptophthalmia,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16352480[PMID]
98949,Complete cryptophthalmia,Clinical subtype,Cases/families,15.0,,Case(s),Worldwide,Validated,16352480[PMID]
98950,Partial cryptophthalmia,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3099574[PMID]
98948,Congenital symblepharon,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3099574[PMID]
98957,Gelatinous drop-like corneal dystrophy,Disease,Point prevalence,0.33,1-9 / 1 000 000,Value and class,Japan,Validated,[EXPERT]
98957,Gelatinous drop-like corneal dystrophy,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
98955,Lisch epithelial corneal dystrophy,Disease,Cases/families,36.0,,Case(s),Worldwide,Validated,ORPHANET
98955,Lisch epithelial corneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98954,Meesmann corneal dystrophy,Disease,Cases/families,250.0,,Case(s),Worldwide,Validated,ORPHANET
98954,Meesmann corneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98964,Lattice corneal dystrophy type I,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
98963,Granular corneal dystrophy type II,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98962,Granular corneal dystrophy type I,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98961,Reis-Bücklers corneal dystrophy,Disease,Cases/families,81.0,,Case(s),Worldwide,Validated,ORPHANET
98961,Reis-Bücklers corneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98960,Thiel-Behnke corneal dystrophy,Disease,Cases/families,173.0,,Case(s),Worldwide,Validated,ORPHANET
98960,Thiel-Behnke corneal dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
98959,Subepithelial mucinous corneal dystrophy,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,8352693[PMID]_[EXPERT]
98959,Subepithelial mucinous corneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98971,Posterior amorphous corneal dystrophy,Disease,Cases/families,11.0,,Family(ies),Worldwide,Validated,301356[PMID]_2314832[PMID]_1582220[PMID]_7573302[PMID]_8600425[PMID]_17273695[PMID]_17300585[PMID]_11862100[PMID]
98971,Posterior amorphous corneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98972,Central cloudy dystrophy of François,Disease,Cases/families,24.0,,Case(s),Worldwide,Validated,5305046[PMID]_1083619[PMID]_15734014[PMID]_15534129[PMID]_9258229[PMID]_8776559[PMID]_20337272[PMID]
98972,Central cloudy dystrophy of François,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98973,Posterior polymorphous corneal dystrophy,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Czech Republic,Validated,23049806[PMID]
98973,Posterior polymorphous corneal dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98974,Fuchs endothelial corneal dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98967,Schnyder corneal dystrophy,Disease,Cases/families,115.0,,Case(s),Worldwide,Validated,19398911[PMID]
98967,Schnyder corneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98969,Macular corneal dystrophy,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,United States,Not yet validated,21791583[PMID]
98969,Macular corneal dystrophy,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
98970,Fleck corneal dystrophy,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,139144[PMID]_7950337[PMID]_141212[PMID]_14078376[PMID]_10660318[PMID]_19948560[PMID]_22065932[PMID]
98970,Fleck corneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98976,Congenital glaucoma,Disease,Prevalence at birth,2.2,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,2.9,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,6.6,1-9 / 100 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2000-2010[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,2.8,1-9 / 100 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,3.6,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,5.6,1-9 / 100 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,0.8,1-9 / 1 000 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,0.9,1-9 / 1 000 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,6.5,1-9 / 100 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,2.2,1-9 / 100 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,3.0,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2000-2004[REG]
98976,Congenital glaucoma,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
98976,Congenital glaucoma,Disease,Prevalence at birth,1.5,1-9 / 100 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,4.1,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,4.1,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,2.8,1-9 / 100 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98976,Congenital glaucoma,Disease,Prevalence at birth,3.4,1-9 / 100 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2000-2016[REG]
98977,Juvenile glaucoma,Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,United States,Validated,18214788[PMID]
99000,Adult-onset foveomacular vitelliform dystrophy,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
99013,Spastic paraplegia type 7,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99014,X-linked Charcot-Marie-Tooth disease type 5,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_17701900[PMID]_20301731[PMID]
99014,X-linked Charcot-Marie-Tooth disease type 5,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,17701900[PMID]_20301731[PMID]
99015,Spastic paraplegia type 2,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,ORPHANET
99015,Spastic paraplegia type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
585867,Acute myeloid leukemia with t(9;22)(q34.1;q11.2),Disease,Annual incidence,4.0,1-9 / 100 000,Value and class,Worldwide,Validated,PMID: 29340131; 29090343; 31101526
585877,B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality,Etiological subtype,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_WHO Classification of Tumours
585877,B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_WHO Classification of Tumours
585909,B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2),Etiological subtype,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_WHO Classification of Tumours
585909,B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2),Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_WHO Classification of Tumours
585936,B-lymphoblastic leukemia/lymphoma with hyperdiploidy,Etiological subtype,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
585936,B-lymphoblastic leukemia/lymphoma with hyperdiploidy,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
585942,B-lymphoblastic leukemia/lymphoma with hypodiploidy,Etiological subtype,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
585942,B-lymphoblastic leukemia/lymphoma with hypodiploidy,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
585918,B-lymphoblastic leukemia/lymphoma with t(v;11q23.3),Etiological subtype,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
585918,B-lymphoblastic leukemia/lymphoma with t(v;11q23.3),Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
585929,B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1),Etiological subtype,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
585929,B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1),Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
99027,Adult-onset autosomal dominant leukodystrophy,Disease,Cases/families,20.0,,Family(ies),Worldwide,Validated,[EXPERT]
99027,Adult-onset autosomal dominant leukodystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Not yet validated,ORPHANET
585956,B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3),Etiological subtype,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
585956,B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3),Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
585948,B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3),Etiological subtype,Annual incidence,0.0,Unknown,Class only,Western Asia,Validated,WHO Classification of Tumours_ORPHANET
585948,B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3),Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,WHO Classification of Tumours_ORPHANET
586130,Sporadic fatal insomnia,Disease,Cases/families,27.0,,Case(s),Worldwide,Validated,PMID: 30048013
586130,Sporadic fatal insomnia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,PMID: 30048013
99042,Congenitally uncorrected transposition of the great arteries with coarctation,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99050,Abnormal origin of right or left pulmonary artery from the aorta,Morphological anomaly,Cases/families,200.0,,Case(s),Worldwide,Validated,24182510[PMID]
99050,Abnormal origin of right or left pulmonary artery from the aorta,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,[EXPERT]
98606,Syndromic orbital border hypoplasia,Malformation syndrome,Cases/families,2.0,,Family(ies),Worldwide,Validated,14359373[PMID]
98606,Syndromic orbital border hypoplasia,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14359373[PMID]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,8.3,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,2.9,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,9.8,1-9 / 100 000,Value and class,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Austria,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,36.4,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,7.3,1-9 / 100 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-9 / 100 000,Class only,France,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,5.8,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,17.7,1-5 / 10 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,3.6,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,11.0,1-5 / 10 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,25.9,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2005[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2005[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,11.1,1-5 / 10 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,6.4,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,2.4,1-9 / 100 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,13.1,1-5 / 10 000,Value and class,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Croatia,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,14.4,1-5 / 10 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,12.3,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,3.9,1-9 / 100 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-9 / 100 000,Class only,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,12.9,1-5 / 10 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-5 / 10 000,Class only,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,5.2,1-9 / 100 000,Value and class,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Portugal,Validated,EUROCAT European surveillance of congenital anomalies 2008[REG]
98555,Microphthalmia-anophthalmia-coloboma,Category,Prevalence at birth,18.0,1-5 / 10 000,Value and class,United States,Validated,8921488[PMID]_8179669[PMID]_16007635[PMID]_Center for Diseases Control and Prevention 2004-2006[INST]
98555,Microphthalmia-anophthalmia-coloboma,Category,Point prevalence,0.0,1-5 / 10 000,Class only,United States,Validated,8921488[PMID]_8179669[PMID]_16007635[PMID]_Center for Diseases Control and Prevention 2004-2006[INST]
98676,Autosomal recessive isolated optic atrophy,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,14508503[PMID]
98676,Autosomal recessive isolated optic atrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_14508503[PMID]
98673,"Autosomal dominant optic atrophy, classic form",Disease,Point prevalence,2.0,1-9 / 100 000,Value and class,Worldwide,Not yet validated,ORPHANET_20301426[PMID]
98673,"Autosomal dominant optic atrophy, classic form",Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Denmark,Validated,8689476[PMID]
98673,"Autosomal dominant optic atrophy, classic form",Disease,Point prevalence,2.86,1-9 / 100 000,Value and class,United Kingdom,Validated,20417570[PMID]
98673,"Autosomal dominant optic atrophy, classic form",Disease,Point prevalence,83.33,6-9 / 10 000,Value and class,Specific population,Validated,21745197[PMID]
98672,Autosomal dominant optic atrophy,Clinical group,Point prevalence,10.0,1-5 / 10 000,Value and class,Denmark,Validated,22776096[PMID]
98672,Autosomal dominant optic atrophy,Clinical group,Point prevalence,2.5,1-9 / 100 000,Value and class,United Kingdom,Not yet validated,20417570[PMID]_ORPHANET
98672,Autosomal dominant optic atrophy,Clinical group,Point prevalence,3.3,1-9 / 100 000,Value and class,Worldwide,Not yet validated,22776096[PMID]
98672,Autosomal dominant optic atrophy,Clinical group,Point prevalence,83.0,6-9 / 10 000,Value and class,Specific population,Validated,21745197[PMID]
98627,Posterior corneal dystrophy,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
98626,Stromal corneal dystrophy,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
98625,Superficial corneal dystrophy,Category,Point prevalence,13.8,1-5 / 10 000,Value and class,United States,Not yet validated,21791583[PMID]
98625,Superficial corneal dystrophy,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
583856,Isolated splenic vein thrombosis,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
583856,Isolated splenic vein thrombosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
583861,Isolated mesenteric vein thrombosis,Disease,Annual incidence,1.6,1-9 / 100 000,Value and class,Europe,Validated,18720461[PMID]_25917534[PMID]
583861,Isolated mesenteric vein thrombosis,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Finland,Validated,25917534[PMID]
583861,Isolated mesenteric vein thrombosis,Disease,Annual incidence,2.7,1-9 / 100 000,Value and class,Sweden,Validated,18720461[PMID]
583861,Isolated mesenteric vein thrombosis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,18720461[PMID]_25917534[PMID]_ORPHANET
98715,Uveitis,Category,Annual incidence,17.0,1-5 / 10 000,Value and class,Europe,Not yet validated,8407119[PMID]
98715,Uveitis,Category,Point prevalence,38.0,1-5 / 10 000,Value and class,Europe,Not yet validated,8407119[PMID]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,3.3,1-9 / 100 000,Value and class,Europe,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,2.9,1-9 / 100 000,Value and class,Belgium,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,19.8,1-5 / 10 000,Value and class,Denmark,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,2.0,1-9 / 100 000,Value and class,France,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,5.8,1-9 / 100 000,Value and class,Germany,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,3.3,1-9 / 100 000,Value and class,Hungary,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,3.6,1-9 / 100 000,Value and class,Ireland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,1.4,1-9 / 100 000,Value and class,Italy,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,24.1,1-5 / 10 000,Value and class,Malta,Validated,EUROCAT European surveillance of congenital anomalies 2009[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,5.8,1-9 / 100 000,Value and class,Netherlands,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,6.5,1-9 / 100 000,Value and class,Norway,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,0.5,1-9 / 1 000 000,Value and class,Poland,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,12.6,1-5 / 10 000,Value and class,Switzerland,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,3.9,1-9 / 100 000,Value and class,United Kingdom,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,9.5,1-9 / 100 000,Value and class,Ukraine,Validated,EUROCAT European surveillance of congenital anomalies 2011[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,0.6,1-9 / 1 000 000,Value and class,Spain,Validated,EUROCAT European surveillance of congenital anomalies 2010[REG]
98723,Hypoplastic right heart syndrome,Clinical group,Prevalence at birth,1.68,1-9 / 100 000,Value and class,United States,Validated,28009100[PMID]
583097,Congenital infiltrating lipomatosis of the face,Disease,Cases/families,59.0,,Case(s),Worldwide,Validated,PMID: 31280031; 25860506; 28846548
583097,Congenital infiltrating lipomatosis of the face,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,PMID: 31280031; 25860506; 28846548
98791,Alpha-thalassemia-intellectual disability syndrome linked to chromosome 16,Malformation syndrome,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
98791,Alpha-thalassemia-intellectual disability syndrome linked to chromosome 16,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98806,"Primary dystonia, DYT6 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19345147[PMID]_21110056[PMID]
98806,"Primary dystonia, DYT6 type",Disease,Cases/families,53.0,,Case(s),Worldwide,Validated,19345147[PMID]_21110056[PMID]
98805,"Primary dystonia, DYT4 type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21956287[PMID]
98805,"Primary dystonia, DYT4 type",Disease,Cases/families,22.0,,Case(s),Worldwide,Validated,21956287[PMID]
98784,Autosomal dominant nocturnal frontal lobe epilepsy,Disease,Cases/families,100.0,,Family(ies),Worldwide,Validated,20301348[PMID]
98784,Autosomal dominant nocturnal frontal lobe epilepsy,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
98764,Spinocerebellar ataxia type 27A,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,[EXPERT]
98764,Spinocerebellar ataxia type 27A,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98763,Spinocerebellar ataxia type 14,Disease,Cases/families,20.0,,Family(ies),Worldwide,Validated,20301573[PMID]_[EXPERT]
98763,Spinocerebellar ataxia type 14,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98766,Spinocerebellar ataxia type 5,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,25142508[PMID]
98766,Spinocerebellar ataxia type 5,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]_25142508[PMID]
98765,Spinocerebellar ataxia type 4,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98760,Spinocerebellar ataxia type 8,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98759,Spinocerebellar ataxia type 17,Disease,Cases/families,100.0,,Family(ies),Worldwide,Validated,[EXPERT]
98759,Spinocerebellar ataxia type 17,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98759,Spinocerebellar ataxia type 17,Disease,Point prevalence,0.047,<1 / 1 000 000,Value and class,Japan,Validated,12116198[PMID]_[EXPERT]
98759,Spinocerebellar ataxia type 17,Disease,Point prevalence,0.16,1-9 / 1 000 000,Value and class,United Kingdom,Validated,16223509[PMID]_[EXPERT]
98762,Spinocerebellar ataxia type 12,Disease,Cases/families,40.0,,Family(ies),Worldwide,Validated,20301381[PMID]_[EXPERT]
98762,Spinocerebellar ataxia type 12,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98761,Spinocerebellar ataxia type 10,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
98772,Spinocerebellar ataxia type 19/22,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,[EXPERT]
98772,Spinocerebellar ataxia type 19/22,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98771,Spinocerebellar ataxia type 18,Disease,Cases/families,26.0,,Case(s),Worldwide,Validated,[EXPERT]
98771,Spinocerebellar ataxia type 18,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98773,Spinocerebellar ataxia type 21,Disease,Cases/families,35.0,,Case(s),Worldwide,Validated,26813285[PMID]
98773,Spinocerebellar ataxia type 21,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_26813285[PMID]
98768,Spinocerebellar ataxia type 13,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
98768,Spinocerebellar ataxia type 13,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
98767,Spinocerebellar ataxia type 11,Disease,Cases/families,51.0,,Case(s),Worldwide,Validated,21827911[PMID]
98767,Spinocerebellar ataxia type 11,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_21827911[PMID]
98769,Spinocerebellar ataxia type 15/16,Disease,Cases/families,80.0,,Case(s),Worldwide,Validated,Dr Shinsuke FUJIOKA_Dr Nathaniel WHALEY_Dr Zbigniew WSZOLEK[EXPERT]
98769,Spinocerebellar ataxia type 15/16,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_[EXPERT]
580933,Lethal brain and heart developmental defects,Malformation syndrome,Cases/families,4.0,,Case(s),Worldwide,Validated,PMID: 29555651
580933,Lethal brain and heart developmental defects,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,PMID: 29555651
98755,Spinocerebellar ataxia type 1,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Worldwide,Validated,20301363[PMID]_[EXPERT]
98756,Spinocerebellar ataxia type 2,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
98757,Spinocerebellar ataxia type 3,Disease,Point prevalence,1.5,1-9 / 100 000,Value and class,Worldwide,Validated,[EXPERT]
98757,Spinocerebellar ataxia type 3,Disease,Point prevalence,1.0,1-9 / 100 000,Value and class,Portugal,Validated,21635785[PMID]
98757,Spinocerebellar ataxia type 3,Disease,Point prevalence,5.5,1-9 / 100 000,Value and class,Japan,Validated,19169038[PMID]
98758,Spinocerebellar ataxia type 6,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Worldwide,Validated,23331413[PMID]
98758,Spinocerebellar ataxia type 6,Disease,Point prevalence,1.7,1-9 / 100 000,Value and class,Japan,Validated,19169038[PMID]
580572,Intraductal tubulopapillary neoplasm of pancreas,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,28529742[PMID]_26464736[PMID]
98306,Familial partial lipodystrophy,Clinical group,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2016[INST]_29066925[PMID]
576278,SATB2-associated syndrome,Malformation syndrome,Cases/families,171.0,,Case(s),Worldwide,Validated,ORPHANET
576278,SATB2-associated syndrome,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
573253,Split cord malformation type II,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
574957,Mendelian susceptibility to mycobacterial diseases due to partial JAK1 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
574918,Predisposition to severe viral infection due to IRF7 deficiency,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,25814066[PMID]
574918,Predisposition to severe viral infection due to IRF7 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25814066[PMID]
98375,Autoimmune hemolytic anemia,Clinical group,Annual incidence,2.02,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]_ORPHANET
98375,Autoimmune hemolytic anemia,Clinical group,Annual incidence,2.02,1-9 / 100 000,Value and class,United States,Validated,[EXPERT]_ORPHANET
98375,Autoimmune hemolytic anemia,Clinical group,Point prevalence,11.0,1-5 / 10 000,Value and class,Denmark,Validated,20066507[PMID]
98375,Autoimmune hemolytic anemia,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
573278,Split cord malformation,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
98482,Idiopathic inflammatory myopathy,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_30073460[PMID]
572385,Brachydactyly type B1,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
572361,Blepharophimosis-ptosis-epicanthus inversus syndrome type 2,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
98428,Secondary polycythemia,Category,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
572428,Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,29455859[PMID]
572428,Infantile-onset pulmonary alveolar proteinosis-hypogammaglobulinemia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29455859[PMID]
98434,Hereditary combined deficiency of vitamin K-dependent clotting factors,Disease,Cases/families,30.0,,Family(ies),Worldwide,Validated,20630065[PMID]
98434,Hereditary combined deficiency of vitamin K-dependent clotting factors,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20630065[PMID]
572543,RFVT2-related riboflavin transporter deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
572550,RFVT3-related riboflavin transporter deficiency,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
572773,Microcephaly-short stature-limb abnormalities syndrome,Clinical subtype,Cases/families,29.0,,Case(s),Worldwide,Validated,28191891[PMID]_31320746[PMID]
572773,Microcephaly-short stature-limb abnormalities syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28191891[PMID]_31320746[PMID]
572798,WARS2-related combined oxidative phosphorylation defect,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,29783990[PMID]
572798,WARS2-related combined oxidative phosphorylation defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_29783990[PMID]
572761,DONSON-related microcephaly-short stature-limb abnormalities spectrum,Malformation syndrome,Cases/families,51.0,,Case(s),Worldwide,Validated,PMID: 31191207 & EXPERT
572761,DONSON-related microcephaly-short stature-limb abnormalities spectrum,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
572768,Microcephaly-micromelia syndrome,Clinical subtype,Cases/families,32.0,,Case(s),Worldwide,Validated,7468660[PMID]_28630177[PMID]_31191207[PMID]
572768,Microcephaly-micromelia syndrome,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_31191207[PMID]
98523,Non-syndromic pontocerebellar hypoplasia,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
572013,Posterior-predominant lissencephaly-broad flat pons and medulla-midline crossing defects syndrome,Malformation syndrome,Cases/families,8.0,,Case(s),Worldwide,Validated,30471716[PMID]
572013,Posterior-predominant lissencephaly-broad flat pons and medulla-midline crossing defects syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30471716[PMID]
572333,Blepharophimosis-ptosis-epicanthus inversus syndrome plus,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
572354,Blepharophimosis-ptosis-epicanthus inversus syndrome type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
570762,Infective endocarditis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
570762,Infective endocarditis,Disease,Annual incidence,3.38,1-9 / 100 000,Value and class,France,Validated,22492317[PMID]
570762,Infective endocarditis,Disease,Annual incidence,1.8,1-9 / 100 000,Value and class,Denmark,Validated,3433553[PMID]
570762,Infective endocarditis,Disease,Annual incidence,0.0,1-9 / 100 000,Class only,Europe,Validated,ORPHANET_25432123[PMID]
570491,QRSL1-related combined oxidative phosphorylation defect,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_30459337[PMID]
570470,Ricin poisoning,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
570470,Ricin poisoning,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2018[INST]
570438,HHV-8-associated multicentric Castleman disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
570431,Idiopathic multicentric Castleman disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_29157611[PMID]
570431,Idiopathic multicentric Castleman disease,Clinical subtype,Annual incidence,0.0,1-9 / 1 000 000,Class only,United States,Validated,ORPHANET_25120049[PMID]
570422,Galactose mutarotase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
570422,Galactose mutarotase deficiency,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Worldwide,Validated,30451973[PMID]
570422,Galactose mutarotase deficiency,Disease,Annual incidence,1.2,1-9 / 100 000,Value and class,Japan,Validated,30451973[PMID]
570371,Bartter syndrome type 5,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27120771[PMID]
570371,Bartter syndrome type 5,Clinical subtype,Cases/families,15.0,,Case(s),Worldwide,Validated,27120771[PMID]_9630034[PMID]
98497,Genetic peripheral neuropathy,Category,Point prevalence,40.0,1-5 / 10 000,Value and class,Worldwide,Not yet validated,22961002[PMID]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.588,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.517,1-9 / 1 000 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.734,1-9 / 1 000 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.174,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.308,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.464,1-9 / 1 000 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.36,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.574,1-9 / 1 000 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.657,1-9 / 1 000 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.551,1-9 / 1 000 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.724,1-9 / 1 000 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.564,1-9 / 1 000 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.79,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.265,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.277,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.377,1-9 / 1 000 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.788,1-9 / 1 000 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.219,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.743,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.462,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.477,1-9 / 1 000 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.76,1-9 / 1 000 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.626,1-9 / 1 000 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104075,Adenocarcinoma of the small intestine,Disease,Annual incidence,0.679,1-9 / 1 000 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
104008,Short bowel syndrome,Clinical group,Point prevalence,2.0,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2019[INST]
103918,Tropical pancreatitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
103910,Congenital enterocyte heparan sulfate deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,8622507[PMID]
103910,Congenital enterocyte heparan sulfate deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8622507[PMID]
103908,Congenital sodium diarrhea,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,26835907[PMID]
103908,Congenital sodium diarrhea,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,26835907[PMID]_ORPHANET
103909,Trehalase deficiency,Disease,Annual incidence,7700.0,>1 / 1000,Value and class,Greenland,Validated,[EXPERT]
103909,Trehalase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
103907,Chronic diarrhea due to glucoamylase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
102724,Acute myeloid leukemia with t(8;21)(q22;q22) translocation,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
101997,Primary immunodeficiency,Category,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,22288591[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,6.8,1-9 / 100 000,Value and class,Norway,Validated,11202238[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,11.0,1-5 / 10 000,Value and class,France,Validated,28732644[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,3.6,1-9 / 100 000,Value and class,Spain,Validated,22288591[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,2.6,1-9 / 100 000,Value and class,Netherlands,Validated,22288591[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,1.84,1-9 / 100 000,Value and class,United Kingdom,Validated,22288591[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,1.79,1-9 / 100 000,Value and class,Italy,Validated,22288591[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,1.38,1-9 / 100 000,Value and class,Germany,Validated,22288591[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,2.0,1-9 / 100 000,Value and class,Turkey,Validated,22288591[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,1.33,1-9 / 100 000,Value and class,Poland,Validated,22288591[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,5.6,1-9 / 100 000,Value and class,Australia,Not yet validated,17588141[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,4.9,1-9 / 100 000,Value and class,New Zealand,Validated,17588141[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,1.1,1-9 / 100 000,Value and class,"Korea, Republic of",Validated,22787376[PMID]
101997,Primary immunodeficiency,Category,Point prevalence,4.5,1-9 / 100 000,Value and class,Oman,Validated,23268475[PMID]
101685,Rare non-syndromic intellectual disability,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
101685,Rare non-syndromic intellectual disability,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
101959,Chronic primary adrenal insufficiency,Category,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
101959,Chronic primary adrenal insufficiency,Category,Point prevalence,14.0,1-5 / 10 000,Value and class,Europe,Validated,12788587[PMID]_[EXPERT]
101150,Autosomal recessive dopa-responsive dystonia,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,ORPHANET
101150,Autosomal recessive dopa-responsive dystonia,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,ORPHANET
101111,Spinocerebellar ataxia type 25,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,[EXPERT]
101111,Spinocerebellar ataxia type 25,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
101112,Spinocerebellar ataxia type 26,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,15732118[PMID]
101112,Spinocerebellar ataxia type 26,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15732118[PMID]
101109,Spinocerebellar ataxia type 28,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
101110,Spinocerebellar ataxia type 20,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
101110,Spinocerebellar ataxia type 20,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
101108,Spinocerebellar ataxia type 23,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,[EXPERT]
101108,Spinocerebellar ataxia type 23,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
101330,Porphyria cutanea tarda,Disease,Annual incidence,0.6,1-9 / 1 000 000,Value and class,Europe,Validated,19233912[PMID]_9516680[PMID]_[EXPERT]_ORPHANET
101330,Porphyria cutanea tarda,Disease,Point prevalence,4.0,1-9 / 100 000,Value and class,Europe,Validated,[EXPERT]
101330,Porphyria cutanea tarda,Disease,Annual incidence,1.0,1-9 / 100 000,Value and class,Norway,Validated,19233912[PMID]
101330,Porphyria cutanea tarda,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Sweden,Validated,16191856[PMID]
101085,Charcot-Marie-Tooth disease type 1F,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301366[PMID]
101081,Charcot-Marie-Tooth disease type 1A,Disease,Point prevalence,82.37,6-9 / 10 000,Value and class,Norway,Validated,20482598[PMID]_24646194[PMID]
101081,Charcot-Marie-Tooth disease type 1A,Disease,Point prevalence,15.2,1-5 / 10 000,Value and class,United Kingdom,Validated,21984771[PMID]
101081,Charcot-Marie-Tooth disease type 1A,Disease,Point prevalence,0.0,1-5 / 10 000,Class only,Worldwide,Validated,ORPHANET_20301384[PMID]
101082,Charcot-Marie-Tooth disease type 1B,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Worldwide,Validated,ORPHANET_20301384[PMID]
101083,Charcot-Marie-Tooth disease type 1C,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
101077,X-linked Charcot-Marie-Tooth disease type 3,Disease,Cases/families,4.0,,Family(ies),Worldwide,Validated,18458969[PMID]
101077,X-linked Charcot-Marie-Tooth disease type 3,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18458969[PMID]
101078,X-linked Charcot-Marie-Tooth disease type 4,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,23217327[PMID]
101078,X-linked Charcot-Marie-Tooth disease type 4,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23217327[PMID]
101075,X-linked Charcot-Marie-Tooth disease type 1,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,20301548[PMID]
101076,X-linked Charcot-Marie-Tooth disease type 2,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,1557086[PMID]_1674639[PMID]
101076,X-linked Charcot-Marie-Tooth disease type 2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_1557086[PMID]_1674639[PMID]
101102,Charcot-Marie-Tooth disease type 2H,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,11166163[PMID]
101102,Charcot-Marie-Tooth disease type 2H,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11166163[PMID]
101101,Charcot-Marie-Tooth disease type 2B2,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,11112660[PMID]
101101,Charcot-Marie-Tooth disease type 2B2,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11112660[PMID]
101097,Autosomal recessive Charcot-Marie-Tooth disease with hoarseness,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
101041,Familial hypofibrinogenemia,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
101046,Autosomal dominant epilepsy with auditory features,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301709[PMID]
101068,Congenital stromal corneal dystrophy,Disease,Cases/families,6.0,,Family(ies),Worldwide,Validated,24413633[PMID]_20301741[PMID]
101068,Congenital stromal corneal dystrophy,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24413633[PMID]_20301741[PMID]
101009,Autosomal dominant spastic paraplegia type 29,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,16130112[PMID]
101009,Autosomal dominant spastic paraplegia type 29,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16130112[PMID]
101010,Autosomal spastic paraplegia type 30,Disease,Cases/families,3.0,,Family(ies),Worldwide,Validated,22258533[PMID]
101010,Autosomal spastic paraplegia type 30,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22258533[PMID]
101011,Autosomal dominant spastic paraplegia type 31,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
101016,Romano-Ward syndrome,Disease,Point prevalence,40.0,1-5 / 10 000,Value and class,Europe,Validated,[EXPERT]
101039,Female restricted epilepsy with intellectual disability,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,18234694[PMID]_20830798[PMID]
101039,Female restricted epilepsy with intellectual disability,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18234694[PMID]_20830798[PMID]
101028,Transaldolase deficiency,Disease,Cases/families,23.0,,Case(s),Worldwide,Validated,23315216[PMID]
101028,Transaldolase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23315216[PMID]
100984,Autosomal dominant spastic paraplegia type 3,Disease,Point prevalence,0.14,1-9 / 1 000 000,Value and class,Portugal,Validated,23609960[PMID]
100984,Autosomal dominant spastic paraplegia type 3,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,20862796[PMID]_8649538[PMID]_23609960[PMID]
100980,Autosomal dominant pure spastic paraplegia,Clinical group,Point prevalence,4.4,1-9 / 100 000,Value and class,Norway,Not yet validated,22554690[PMID]_ORPHANET
100980,Autosomal dominant pure spastic paraplegia,Clinical group,Point prevalence,0.9,1-9 / 1 000 000,Value and class,Ireland,Validated,22554690[PMID]
100980,Autosomal dominant pure spastic paraplegia,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
100979,Autosomal dominant complex spastic paraplegia,Clinical group,Point prevalence,1.0,1-9 / 100 000,Value and class,Norway,Validated,19339254[PMID]
100979,Autosomal dominant complex spastic paraplegia,Clinical group,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
100978,Cloverleaf skull-asphyxiating thoracic dysplasia syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3499843[PMID]
100991,Autosomal dominant spastic paraplegia type 10,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
100991,Autosomal dominant spastic paraplegia type 10,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
100989,Autosomal dominant spastic paraplegia type 8,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
100989,Autosomal dominant spastic paraplegia type 8,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
100988,Autosomal dominant spastic paraplegia type 6,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
100988,Autosomal dominant spastic paraplegia type 6,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
100986,Autosomal recessive spastic paraplegia type 5A,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
100985,Autosomal dominant spastic paraplegia type 4,Disease,Point prevalence,0.91,1-9 / 1 000 000,Value and class,Portugal,Validated,23609960[PMID]
100999,Autosomal dominant spastic paraplegia type 19,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,12112072[PMID]
100999,Autosomal dominant spastic paraplegia type 19,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12112072[PMID]
101000,Autosomal recessive spastic paraplegia type 20,Disease,Cases/families,36.0,,Case(s),Worldwide,Validated,28679690[PMID]
101000,Autosomal recessive spastic paraplegia type 20,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28679690[PMID]
100997,X-linked spastic paraplegia type 16,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,9254866[PMID]
100997,X-linked spastic paraplegia type 16,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9254866[PMID]
100998,Autosomal dominant spastic paraplegia type 17,Disease,Cases/families,20.0,,Family(ies),Worldwide,Validated,ORPHANET
100998,Autosomal dominant spastic paraplegia type 17,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
100995,Autosomal recessive spastic paraplegia type 14,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,10877981[PMID]
100995,Autosomal recessive spastic paraplegia type 14,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10877981[PMID]
100996,Autosomal recessive spastic paraplegia type 15,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,ORPHANET
100996,Autosomal recessive spastic paraplegia type 15,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
100993,Autosomal dominant spastic paraplegia type 12,Disease,Cases/families,27.0,,Case(s),Worldwide,Validated,22232211[PMID]
100993,Autosomal dominant spastic paraplegia type 12,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22232211[PMID]
100994,Autosomal dominant spastic paraplegia type 13,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,10677329[PMID]
100994,Autosomal dominant spastic paraplegia type 13,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10677329[PMID]
101007,Autosomal recessive spastic paraplegia type 27,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,15455396[PMID]_16511635[PMID]_20301682[PMID]
101007,Autosomal recessive spastic paraplegia type 27,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15455396[PMID]_16511635[PMID]
101008,Autosomal recessive spastic paraplegia type 28,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,27216551[PMID]
101008,Autosomal recessive spastic paraplegia type 28,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27216551[PMID]
101005,Autosomal recessive spastic paraplegia type 25,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,12070243[PMID]
101005,Autosomal recessive spastic paraplegia type 25,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12070243[PMID]
101006,Autosomal recessive spastic paraplegia type 26,Disease,Cases/families,10.0,,Family(ies),Worldwide,Validated,24103911[PMID]_23746551[PMID]_24283893[PMID]
101006,Autosomal recessive spastic paraplegia type 26,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24103911[PMID]_23746551[PMID]_24283893[PMID]
101003,Autosomal recessive spastic paraplegia type 23,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,7294071[PMID]_6264350[PMID]_6886718[PMID]_4061404[PMID]_12868479[PMID]
101003,Autosomal recessive spastic paraplegia type 23,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_7294071[PMID]_6264350[PMID]_6886718[PMID]_4061404[PMID]_12868479[PMID]
101004,Autosomal recessive spastic paraplegia type 24,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,12499481[PMID]
101004,Autosomal recessive spastic paraplegia type 24,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12499481[PMID]
101001,Autosomal recessive spastic paraplegia type 21,Disease,Cases/families,35.0,,Case(s),Worldwide,Validated,6024251[PMID]_6024251[PMID]_14564668[PMID]_24451228[PMID]
101001,Autosomal recessive spastic paraplegia type 21,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_6024251[PMID]_14564668[PMID]_24451228[PMID]
100088,Rare thyroid carcinoma,Category,Annual incidence,3.65,1-9 / 100 000,Value and class,Europe,Not yet validated,22033323[PMID]_23894154[PMID]
100088,Rare thyroid carcinoma,Category,Lifetime Prevalence,61.7,6-9 / 10 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,12.2,1-5 / 10 000,Value and class,United States,Validated,National Cancer Institute 2010[INST]
100088,Rare thyroid carcinoma,Category,Annual incidence,3.1,1-9 / 100 000,Value and class,Worldwide,Validated,World Health Organization 2008[INST]
100088,Rare thyroid carcinoma,Category,Point prevalence,12.7,1-5 / 10 000,Value and class,Worldwide,Validated,World Health Organization 2008[INST]
100088,Rare thyroid carcinoma,Category,Annual incidence,2.733,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,12.86,1-5 / 10 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,7.679,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,3.74,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,2.921,1-9 / 100 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,8.329,1-9 / 100 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,6.382,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,4.803,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,6.375,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,5.526,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,2.45,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,4.563,1-9 / 100 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,7.905,1-9 / 100 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,6.344,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,4.472,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,4.488,1-9 / 100 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,8.628,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,3.991,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,5.649,1-9 / 100 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,5.162,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,6.39,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100088,Rare thyroid carcinoma,Category,Annual incidence,2.373,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
100085,Primary hepatic neuroendocrine carcinoma,Disease,Annual incidence,0.2,1-9 / 1 000 000,Value and class,Worldwide,Validated,8227395[PMID]_24944650[PMID]_ [EXPERT]
100085,Primary hepatic neuroendocrine carcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
100087,Rare thyroid tumor,Category,Annual incidence,3.2,1-9 / 100 000,Value and class,Worldwide,Not yet validated,21513910[PMID]_ORPHANET
100087,Rare thyroid tumor,Category,Annual incidence,5.0,1-9 / 100 000,Value and class,Europe,Not yet validated,21513910[PMID]
100087,Rare thyroid tumor,Category,Annual incidence,5.7,1-9 / 100 000,Value and class,Italy,Not yet validated,23518150[PMID]_ORPHANET
100087,Rare thyroid tumor,Category,Annual incidence,5.35,1-9 / 100 000,Value and class,France,Not yet validated,21513910[PMID]_ORPHANET
100924,Porphyria due to ALA dehydratase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
100973,FRAXE intellectual disability,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
100974,FRAXF syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
100976,Bathing suit ichthyosis,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,[EXPERT]
100976,Bathing suit ichthyosis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
100054,F12-related hereditary angioedema with normal C1Inh,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
100051,Hereditary angioedema type 2,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
100057,Renin-angiotensin-aldosterone system-blocker-induced angioedema,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
100070,Progressive non-fluent aphasia,Disease,Point prevalence,2.5,1-9 / 100 000,Value and class,Europe,Validated,22608668[PMID]_European Medicines Agency 2010[INST]
100070,Progressive non-fluent aphasia,Disease,Annual incidence,0.7,1-9 / 1 000 000,Value and class,Europe,Not yet validated,22608668[PMID]
100073,Neurogenic thoracic outlet syndrome,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
100075,Neuroendocrine tumor of stomach,Disease,Point prevalence,3.2,1-9 / 100 000,Value and class,Europe,Validated,25480460[PMID]
100075,Neuroendocrine tumor of stomach,Disease,Point prevalence,1.7,1-9 / 100 000,Value and class,United States,Validated,25480460[PMID]
100075,Neuroendocrine tumor of stomach,Disease,Point prevalence,0.7,1-9 / 1 000 000,Value and class,United Kingdom,Validated,25480460[PMID]
100075,Neuroendocrine tumor of stomach,Disease,Point prevalence,0.5,1-9 / 1 000 000,Value and class,Japan,Validated,25480460[PMID]
100071,Mosaic trisomy 3 syndrome,Malformation syndrome,Cases/families,6.0,,Case(s),Worldwide,Validated,15386452[PMID]
100071,Mosaic trisomy 3 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15386452[PMID]
100020,Myelodysplastic neoplasm with increased blasts type 2,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
100019,Myelodysplastic neoplasm with increased blasts type 1,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
100022,Extramedullary soft tissue plasmacytoma,Clinical subtype,Annual incidence,0.1,1-9 / 1 000 000,Value and class,United States,Validated,19016727[PMID]_SEER Surveillance Epidemiology and End Results 1992-2004[INST]
100021,Primary plasmacytoma of the bone,Clinical subtype,Annual incidence,0.15,1-9 / 1 000 000,Value and class,United States,Validated,19016727[PMID]_SEER Surveillance Epidemiology and End Results 1992-2004[INST]
100024,Mu-heavy chain disease,Clinical subtype,Cases/families,35.0,,Case(s),Worldwide,Validated,[EXPERT]
100024,Mu-heavy chain disease,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
100026,Gamma-heavy chain disease,Clinical subtype,Cases/families,120.0,,Case(s),Worldwide,Validated,[EXPERT]
100026,Gamma-heavy chain disease,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
100025,Alpha-heavy chain disease,Clinical subtype,Cases/families,400.0,,Case(s),Worldwide,Validated,[EXPERT]
100025,Alpha-heavy chain disease,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
100043,Autosomal dominant intermediate Charcot-Marie-Tooth disease type A,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,11533914[PMID]
100043,Autosomal dominant intermediate Charcot-Marie-Tooth disease type A,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11533914[PMID]
100044,Autosomal dominant intermediate Charcot-Marie-Tooth disease type B,Disease,Cases/families,37.0,,Case(s),Worldwide,Validated,19502294[PMID]
100044,Autosomal dominant intermediate Charcot-Marie-Tooth disease type B,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_19502294[PMID]
100045,Autosomal dominant intermediate Charcot-Marie-Tooth disease type C,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16429158[PMID]_24354524[PMID]
100045,Autosomal dominant intermediate Charcot-Marie-Tooth disease type C,Disease,Cases/families,35.0,,Case(s),Worldwide,Validated,16429158[PMID]_24354524[PMID]
100046,Autosomal dominant intermediate Charcot-Marie-Tooth disease type D,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10406984[PMID]
100046,Autosomal dominant intermediate Charcot-Marie-Tooth disease type D,Disease,Cases/families,12.0,,Case(s),Worldwide,Validated,10406984[PMID]
100050,Hereditary angioedema type 1,Etiological subtype,Point prevalence,1.54,1-9 / 100 000,Value and class,Italy,Validated,25758562[PMID]_[EXPERT]
100050,Hereditary angioedema type 1,Etiological subtype,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
100012,Lissencephaly with cerebellar hypoplasia type B,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,11748497[PMID]
100012,Lissencephaly with cerebellar hypoplasia type B,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11748497[PMID]
100013,Lissencephaly with cerebellar hypoplasia type C,Malformation syndrome,Cases/families,2.0,,Case(s),Worldwide,Validated,10594886[PMID]_11748497[PMID]
100013,Lissencephaly with cerebellar hypoplasia type C,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11748497[PMID]
100008,ACys amyloidosis,Clinical subtype,Cases/families,9.0,,Family(ies),Worldwide,Validated,[EXPERT]
100008,ACys amyloidosis,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
100006,"ABeta amyloidosis, Dutch type",Clinical subtype,Cases/families,250.0,,Case(s),Worldwide,Validated,[EXPERT]
100006,"ABeta amyloidosis, Dutch type",Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
99995,Complex regional pain syndrome type 1,Clinical subtype,Annual incidence,5.46,1-9 / 100 000,Value and class,United States,Validated,12749974[PMID]
99995,Complex regional pain syndrome type 1,Clinical subtype,Point prevalence,20.57,1-5 / 10 000,Value and class,United States,Validated,12749974[PMID]
99994,Complex regional pain syndrome type 2,Clinical subtype,Annual incidence,0.82,1-9 / 1 000 000,Value and class,United States,Validated,12749974[PMID]
99994,Complex regional pain syndrome type 2,Clinical subtype,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
99989,Intermediate DEND syndrome,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99981,Apnea of prematurity,Disease,Point prevalence,8.5,1-9 / 100 000,Value and class,Europe,Validated,European Medicines Agency 2003[INST]
99978,Klatskin tumor,Disease,Annual incidence,1.5,1-9 / 100 000,Value and class,United States,Not yet validated,19638920[PMID]_ORPHANET
99978,Klatskin tumor,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Not yet validated,ORPHANET
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,3.357,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Lifetime Prevalence,5.42,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,5.2,1-9 / 100 000,Value and class,Worldwide,Validated,25320104[PMID]_WHO World Health Organization (GLOBOCAN 2012)[INST]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,2.026,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,3.881,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,0.801,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,2.79,1-9 / 100 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,2.315,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,3.122,1-9 / 100 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,2.325,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,5.069,1-9 / 100 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,4.172,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,2.215,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,3.443,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,2.623,1-9 / 100 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,2.896,1-9 / 100 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,2.922,1-9 / 100 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,1.256,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,1.706,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,1.996,1-9 / 100 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,3.734,1-9 / 100 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,3.866,1-9 / 100 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,3.234,1-9 / 100 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,3.544,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,3.778,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,3.139,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99977,Squamous cell carcinoma of the esophagus,Disease,Annual incidence,4.186,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,3.264,1-9 / 100 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Lifetime Prevalence,5.55,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,0.7,1-9 / 1 000 000,Value and class,Worldwide,Validated,25320104[PMID]_WHO World Health Organization (GLOBOCAN 2012)[INST]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,1.235,1-9 / 100 000,Value and class,Austria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,3.918,1-9 / 100 000,Value and class,Belgium,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,0.364,1-9 / 1 000 000,Value and class,Bulgaria,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,0.485,1-9 / 1 000 000,Value and class,Croatia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,1.28,1-9 / 100 000,Value and class,Czech Republic,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,0.305,1-9 / 1 000 000,Value and class,Estonia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,1.5,1-9 / 100 000,Value and class,Finland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,1.681,1-9 / 100 000,Value and class,France,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,1.636,1-9 / 100 000,Value and class,Germany,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,2.471,1-9 / 100 000,Value and class,Iceland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,3.736,1-9 / 100 000,Value and class,Ireland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,0.947,1-9 / 1 000 000,Value and class,Italy,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,0.39,1-9 / 1 000 000,Value and class,Latvia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,0.526,1-9 / 1 000 000,Value and class,Lithuania,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,1.319,1-9 / 100 000,Value and class,Malta,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,0.315,1-9 / 1 000 000,Value and class,Poland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,0.829,1-9 / 1 000 000,Value and class,Portugal,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,0.578,1-9 / 1 000 000,Value and class,Slovakia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,0.651,1-9 / 1 000 000,Value and class,Slovenia,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,2.612,1-9 / 100 000,Value and class,Switzerland,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,5.196,1-9 / 100 000,Value and class,Netherlands,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,6.592,1-9 / 100 000,Value and class,United Kingdom,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,1.848,1-9 / 100 000,Value and class,Norway,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99976,Adenocarcinoma of the esophagus,Disease,Annual incidence,1.178,1-9 / 100 000,Value and class,Spain,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99971,Well-differentiated liposarcoma,Histopathological subtype,Annual incidence,0.51,1-9 / 1 000 000,Value and class,Europe,Validated,22517534[PMID]_[EXPERT]
99971,Well-differentiated liposarcoma,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99969,Pleomorphic liposarcoma,Histopathological subtype,Annual incidence,0.05,<1 / 1 000 000,Value and class,Europe,Validated,22517534[PMID]_[EXPERT]
99969,Pleomorphic liposarcoma,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99970,Dedifferentiated liposarcoma,Histopathological subtype,Annual incidence,0.27,1-9 / 1 000 000,Value and class,Europe,Validated,22517534[PMID]_[EXPERT]
99970,Dedifferentiated liposarcoma,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99967,Myxoid/round cell liposarcoma,Histopathological subtype,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,22517534[PMID]_[EXPERT]
99967,Myxoid/round cell liposarcoma,Histopathological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99966,Atypical teratoid rhabdoid tumor,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,20737418[PMID]_19707161[PMID]_22988546[PMID]
99966,Atypical teratoid rhabdoid tumor,Disease,Annual incidence,1.38,1-9 / 100 000,Value and class,Austria,Validated,[EXPERT]
643549,Hao-Fountain syndrome,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,26365382[PMID]_30679821[PMID]_35627274[PMID]
643549,Hao-Fountain syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,26365382[PMID]_30679821[PMID]_35627274[PMID]_ORPHANET
99955,Charcot-Marie-Tooth disease type 4B1,Disease,Cases/families,11.0,,Family(ies),Worldwide,Validated,20301641[PMID]_DOI: 10.1016/j.nmd.2015.06.356[OTHER]
99955,Charcot-Marie-Tooth disease type 4B1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_20301641[PMID]_DOI: 10.1016/j.nmd.2015.06.356[OTHER]
99956,Charcot-Marie-Tooth disease type 4B2,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99948,Charcot-Marie-Tooth disease type 4A,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99947,Autosomal dominant Charcot-Marie-Tooth disease type 2A2,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,21715711[PMID]_21715704[PMID]
99950,Charcot-Marie-Tooth disease type 4D,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99949,Charcot-Marie-Tooth disease type 4C,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99952,Charcot-Marie-Tooth disease type 4F,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
99954,Charcot-Marie-Tooth disease type 4H,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,23770104[PMID]_26400421[PMID]
99954,Charcot-Marie-Tooth disease type 4H,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_23770104[PMID]_26400421[PMID]
99953,Charcot-Marie-Tooth disease type 4G,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99953,Charcot-Marie-Tooth disease type 4G,Disease,Point prevalence,10.0,1-5 / 10 000,Value and class,Czech Republic,Validated,26822750[PMID]
99940,Autosomal dominant Charcot-Marie-Tooth disease type 2F,Disease,Cases/families,5.0,,Family(ies),Worldwide,Validated,16087758[PMID]
99940,Autosomal dominant Charcot-Marie-Tooth disease type 2F,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_16087758[PMID]
99939,Autosomal dominant Charcot-Marie-Tooth disease type 2E,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_20301366[PMID]
99941,Autosomal dominant Charcot-Marie-Tooth disease type 2G,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,3022865[PMID]
99941,Autosomal dominant Charcot-Marie-Tooth disease type 2G,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_3022865[PMID]
99944,Autosomal dominant Charcot-Marie-Tooth disease type 2K,Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,18231710[PMID]_19089472[PMID]_20685671[PMID]_21753178[PMID]
99944,Autosomal dominant Charcot-Marie-Tooth disease type 2K,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_18231710[PMID]_19089472[PMID]_20685671[PMID]_21753178[PMID]
99946,Autosomal dominant Charcot-Marie-Tooth disease type 2A1,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,9409358[PMID]
99946,Autosomal dominant Charcot-Marie-Tooth disease type 2A1,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9409358[PMID]
99945,Autosomal dominant Charcot-Marie-Tooth disease type 2L,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,15021985[PMID]
99945,Autosomal dominant Charcot-Marie-Tooth disease type 2L,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15021985[PMID]
99931,Idiopathic pulmonary hemosiderosis,Disease,Annual incidence,0.0425,<1 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
99931,Idiopathic pulmonary hemosiderosis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
99938,Autosomal dominant Charcot-Marie-Tooth disease type 2D,Disease,Cases/families,44.0,,Case(s),Worldwide,Validated,8872480[PMID]_10732809[PMID]_9879677[PMID]_19329989[PMID]
99938,Autosomal dominant Charcot-Marie-Tooth disease type 2D,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_8872480[PMID]_10732809[PMID]_9879677[PMID]_19329989[PMID]
99925,Invasive mole,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99926,Gestational choriocarcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99926,Gestational choriocarcinoma,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99926,Gestational choriocarcinoma,Disease,Lifetime Prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99927,Hydatidiform mole,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99927,Hydatidiform mole,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99928,Placental site trophoblastic tumor,Disease,Annual incidence,0.02,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99928,Placental site trophoblastic tumor,Disease,Lifetime Prevalence,0.86,1-9 / 1 000 000,Value and class,Europe,Validated,22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG]
99928,Placental site trophoblastic tumor,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
99918,Streptococcal toxic-shock syndrome,Etiological subtype,Annual incidence,0.1,1-9 / 1 000 000,Value and class,France,Validated,21976764[PMID]_Dr Lina Gérard[EXPERT]
99918,Streptococcal toxic-shock syndrome,Etiological subtype,Annual incidence,0.2,1-9 / 1 000 000,Value and class,United States,Validated,22534148[PMID]_Dr Lina Gérard[EXPERT]
99918,Streptococcal toxic-shock syndrome,Etiological subtype,Annual incidence,0.33,1-9 / 1 000 000,Value and class,Sweden,Validated,17638193[PMID]_Dr Lina Gérard[EXPERT]
99918,Streptococcal toxic-shock syndrome,Etiological subtype,Annual incidence,0.23,1-9 / 1 000 000,Value and class,Denmark,Validated,15815000[PMID]
99917,"Theca steroid-producing cell malignant tumor of ovary, not further specified",Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99916,Malignant Sertoli-Leydig cell tumor of the ovary,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99915,Malignant granulosa cell tumor of the ovary,Disease,Annual incidence,0.12,1-9 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99919,Staphylococcal toxic-shock syndrome,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99919,Staphylococcal toxic-shock syndrome,Etiological subtype,Annual incidence,0.58,1-9 / 1 000 000,Value and class,United States,Validated,21860665[PMID]_24188357[PMID]
99912,Ovarian dysgerminoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99912,Ovarian dysgerminoma,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99901,Acyl-CoA dehydrogenase 9 deficiency,Disease,Cases/families,23.0,,Case(s),Worldwide,Validated,24158852[PMID]_26669660[PMID]
99901,Acyl-CoA dehydrogenase 9 deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_26669660[PMID]
99905,Streptobacillary rat-bite fever,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99903,Spirillary rat-bite fever,Etiological subtype,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99892,ACTH-dependent Cushing syndrome,Clinical group,Annual incidence,0.55,1-9 / 1 000 000,Value and class,Worldwide,Not yet validated,20829610[PMID]_18226430[PMID]_15903005[PMID]
99892,ACTH-dependent Cushing syndrome,Clinical group,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99898,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25453225[PMID]
99898,Mendelian susceptibility to mycobacterial diseases due to complete IFNgammaR1 deficiency,Disease,Cases/families,31.0,,Case(s),Worldwide,Validated,25453225[PMID]
99879,Familial isolated hyperparathyroidism,Disease,Cases/families,100.0,,Family(ies),Worldwide,Validated,18084346[PMID]
99879,Familial isolated hyperparathyroidism,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET_18084346[PMID]
99880,Hyperparathyroidism-jaw tumor syndrome,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,25511968[PMID]
99880,Hyperparathyroidism-jaw tumor syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_25511968[PMID]
99889,Cushing syndrome due to ectopic ACTH secretion,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99885,Isolated permanent neonatal diabetes mellitus,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Europe,Validated,19499210[PMID]
99885,Isolated permanent neonatal diabetes mellitus,Disease,Point prevalence,0.0,1-9 / 1 000 000,Class only,Europe,Validated,19499210[PMID]_ORPHANET
99885,Isolated permanent neonatal diabetes mellitus,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,United Kingdom,Validated,19499210[PMID]
99885,Isolated permanent neonatal diabetes mellitus,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Poland,Validated,19499210[PMID]
99885,Isolated permanent neonatal diabetes mellitus,Disease,Prevalence at birth,0.38,1-9 / 1 000 000,Value and class,Netherlands,Validated,19499210[PMID]
99885,Isolated permanent neonatal diabetes mellitus,Disease,Prevalence at birth,0.46,1-9 / 1 000 000,Value and class,Slovakia,Validated,17213273[PMID]
99885,Isolated permanent neonatal diabetes mellitus,Disease,Prevalence at birth,0.4,1-9 / 1 000 000,Value and class,United States,Validated,23050777[PMID]
99885,Isolated permanent neonatal diabetes mellitus,Disease,Prevalence at birth,18.0,1-5 / 10 000,Value and class,Oman,Validated,10798084[PMID]
99886,Transient neonatal diabetes mellitus,Disease,Prevalence at birth,0.3,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
99886,Transient neonatal diabetes mellitus,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,ORPHANET
99865,Spermatocytic seminoma,Disease,Annual incidence,0.03,<1 / 1 000 000,Value and class,Europe,Validated,RARECARE surveillance of rare cancers in Europe[REG]
99865,Spermatocytic seminoma,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Not yet validated,ORPHANET
99868,Thymic carcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99867,Thymoma,Disease,Annual incidence,0.14,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]_RARECARE surveillance of rare cancers in Europe 2011[REG]
99867,Thymoma,Disease,Lifetime Prevalence,1.22,1-9 / 100 000,Value and class,Europe,Validated,22033323[PMID]_[EXPERT]_RARECARE surveillance of rare cancers in Europe[REG]
99867,Thymoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99869,Thymic neuroendocrine carcinoma,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99849,Glycogen storage disease due to muscle beta-enolase deficiency,Disease,Cases/families,1.0,,Case(s),Worldwide,Validated,11506403[PMID]
99849,Glycogen storage disease due to muscle beta-enolase deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_11506403[PMID]
99845,Genetic recurrent myoglobinuria,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99846,Autosomal dominant myoglobinuria,Disease,Cases/families,2.0,,Family(ies),Worldwide,Validated,9098484[PMID]
99846,Autosomal dominant myoglobinuria,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_9098484[PMID]
99843,Leukocyte adhesion deficiency type II,Clinical subtype,Cases/families,7.0,,Case(s),Worldwide,Validated,24403049[PMID]
99843,Leukocyte adhesion deficiency type II,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24403049[PMID]
99844,Leukocyte adhesion deficiency type III,Clinical subtype,Cases/families,40.0,,Case(s),Worldwide,Validated,28827066[PMID]
99844,Leukocyte adhesion deficiency type III,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_28827066[PMID]
99853,Ovarioleukodystrophy,Clinical subtype,Cases/families,17.0,,Case(s),Worldwide,Validated,24808023[PMID]_12707859[PMID]_9153528[PMID]
99853,Ovarioleukodystrophy,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_24808023[PMID]_12707859[PMID]_9153528[PMID]
99852,Ravine syndrome,Disease,Cases/families,38.0,,Case(s),Worldwide,Validated,10429812[PMID]
99852,Ravine syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_10429812[PMID]
99832,Resistance to thyrotropin-releasing hormone syndrome,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,19213692[PMID]
99832,Resistance to thyrotropin-releasing hormone syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,19213692[PMID]
99829,Yellow fever,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99829,Yellow fever,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Centre for Disease prevention and Control 2017[INST]
99828,Dengue fever,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99828,Dengue fever,Disease,Annual incidence,714.0,>1 / 1000,Value and class,Worldwide,Validated,22494122[PMID]
99828,Dengue fever,Disease,Annual incidence,0.5,1-9 / 1 000 000,Value and class,Europe,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Point prevalence,0.0,1-9 / 100 000,Class only,Europe,Validated,European Medicines Agency 2015[INST]
99828,Dengue fever,Disease,Annual incidence,1.14,1-9 / 100 000,Value and class,Austria,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.98,1-9 / 1 000 000,Value and class,Belgium,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.033,<1 / 1 000 000,Value and class,Croatia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.58,1-9 / 1 000 000,Value and class,Estonia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.98,1-9 / 1 000 000,Value and class,Finland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.36,1-9 / 1 000 000,Value and class,France,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.96,1-9 / 1 000 000,Value and class,Germany,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.14,1-9 / 1 000 000,Value and class,Hungary,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.32,1-9 / 1 000 000,Value and class,Ireland,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.14,1-9 / 1 000 000,Value and class,Italy,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.34,1-9 / 1 000 000,Value and class,Latvia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.15,1-9 / 1 000 000,Value and class,Lithuania,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,Luxembourg,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Malta,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.1,1-9 / 1 000 000,Value and class,Portugal,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.07,<1 / 1 000 000,Value and class,Slovakia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.22,1-9 / 1 000 000,Value and class,Slovenia,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.26,1-9 / 1 000 000,Value and class,Spain,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,1.7,1-9 / 100 000,Value and class,Sweden,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.72,1-9 / 1 000 000,Value and class,United Kingdom,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,1.26,1-9 / 100 000,Value and class,Norway,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99828,Dengue fever,Disease,Annual incidence,0.0,<1 / 1 000 000,Class only,Greece,Validated,European Centre for Disease prevention and Control 2013-2017[INST]
99827,Crimean-Congo hemorrhagic fever,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99827,Crimean-Congo hemorrhagic fever,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2018[INST]
99842,Leukocyte adhesion deficiency type I,Clinical subtype,Point prevalence,0.1,1-9 / 1 000 000,Value and class,Europe,Validated,[EXPERT]
99812,LIG4 syndrome,Disease,Cases/families,28.0,,Case(s),Worldwide,Validated,27717373[PMID]
99812,LIG4 syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_27717373[PMID]
99824,Lassa fever,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99824,Lassa fever,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Validated,European Medicines Agency 2018[INST]
99825,Nipah virus disease,Disease,Cases/families,556.0,,Case(s),Worldwide,Validated,[EXPERT]_World Health Organization[INST]
99825,Nipah virus disease,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
99826,Marburg hemorrhagic fever,Disease,Cases/families,500.0,,Case(s),Worldwide,Validated,[EXPERT]
99826,Marburg hemorrhagic fever,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
99798,Oligodontia,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99802,Hemimegalencephaly,Malformation syndrome,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
99803,Haddad syndrome,Malformation syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,ORPHANET
99803,Haddad syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
99806,Oculootodental syndrome,Malformation syndrome,Cases/families,1.0,,Family(ies),Worldwide,Validated,12147582[PMID]
99806,Oculootodental syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_12147582[PMID]
99807,PEHO-like syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,8723564[PMID]_12868478[PMID]_12949965[PMID]_15968934[PMID]_22408680[PMID]_12818526[PMID
99807,PEHO-like syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_15968934[PMID]_22408680[PMID]
99810,Familial porencephaly,Etiological subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Europe,Not yet validated,ORPHANET
99789,Dentin dysplasia type I,Clinical subtype,Point prevalence,1.0,1-9 / 100 000,Value and class,Europe,Validated,17452557[PMID]_[EXPERT]
99791,Dentin dysplasia type II,Clinical subtype,Cases/families,19.0,,Family(ies),Worldwide,Validated,10397672[PMID]
99791,Dentin dysplasia type II,Clinical subtype,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
99792,Dentin dysplasia-sclerotic bones syndrome,Disease,Cases/families,1.0,,Family(ies),Worldwide,Validated,264650[PMID]
99792,Dentin dysplasia-sclerotic bones syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_264650[PMID]
99772,Cleft velum,Morphological anomaly,Point prevalence,0.0,1-5 / 10 000,Class only,Europe,Not yet validated,ORPHANET
99771,Bifid uvula,Morphological anomaly,Point prevalence,0.0,Unknown,Class only,Worldwide,Not yet validated,ORPHANET
99776,Mosaic trisomy 9 syndrome,Malformation syndrome,Cases/families,50.0,,Case(s),Worldwide,Validated,22249800[PMID]
99776,Mosaic trisomy 9 syndrome,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET_22249800[PMID]
631073,Autosomal recessive spastic paraplegia type 82,Disease,Cases/families,5.0,,Case(s),Worldwide,Validated,31637422[PMID]
631073,Autosomal recessive spastic paraplegia type 82,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,31637422[PMID]_ORPHANET
631076,Autosomal recessive spastic paraplegia type 83,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,32707086[PMID]_33188300[PMID]_33970200[PMID]
631076,Autosomal recessive spastic paraplegia type 83,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,32707086[PMID]_33188300[PMID]_33970200[PMID]_ORPHANET
631079,Autosomal recessive spastic paraplegia type 84,Disease,Cases/families,2.0,,Case(s),Worldwide,Validated,34415322[PMID]
631079,Autosomal recessive spastic paraplegia type 84,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,34415322[PMID]_ORPHANET
631082,Autosomal recessive spastic paraplegia type 85,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,31636353[PMID]
631082,Autosomal recessive spastic paraplegia type 85,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,31636353[PMID]_ORPHANET
631068,Autosomal dominant spastic paraplegia type 80,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,30929741[PMID]_ 31203368[PMID]
631068,Autosomal dominant spastic paraplegia type 80,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30929741[PMID]_ 31203368[PMID]_ORPHANET
631106,Spinocerebellar ataxia type 49,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,35310830[PMID]
631106,Spinocerebellar ataxia type 49,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,35310830[PMID]_ORPHANET
631103,Spinocerebellar ataxia type 48,Disease,Cases/families,50.0,,Case(s),Worldwide,Validated,34070858[PMID]
631103,Spinocerebellar ataxia type 48,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,34070858[PMID]_ORPHANET
631095,Spinocerebellar ataxia type 44,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,28886343[PMID]
631095,Spinocerebellar ataxia type 44,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,28886343[PMID]_ORPHANET
631088,Autosomal recessive spastic paraplegia type 87,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,35718349[PMID]
631088,Autosomal recessive spastic paraplegia type 87,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,35718349[PMID]_ORPHANET
631085,Autosomal recessive spastic paraplegia type 86,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,34866177[PMID]_34489854[PMID]_34587489[PMID]
631085,Autosomal recessive spastic paraplegia type 86,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,34866177[PMID]_34489854[PMID]_34587489[PMID]_ORPHANET
631248,Mitchell Syndrome,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,32169171[PMID]
631248,Mitchell Syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,32169171[PMID] _ORPHANET
634475,Mosaic NF2-related schwannomatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,35674741[PMID]_ORPHANET
634492,Mosaic schwannomatosis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,29909380[PMID]_ORPHANET
634492,Mosaic schwannomatosis,Disease,Point prevalence,0.7928,1-9 / 1 000 000,Value and class,United Kingdom,Validated,29909380[PMID]
634492,Mosaic schwannomatosis,Disease,Prevalence at birth,1.4502,1-9 / 100 000,Value and class,United Kingdom,Validated,29909380[PMID]
634461,Mosaic neurofibromatosis type 1,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,20301288[PMID]_29215653[PMID]
634461,Mosaic neurofibromatosis type 1,Disease,Point prevalence,24.4618,1-5 / 10 000,Value and class,Finland,Validated,29215653[PMID]_ORPHANET
633228,Isolated proximal femoral focal deficiency,Morphological anomaly,Point prevalence,1.55,1-9 / 100 000,Value and class,Worldwide,Validated,32019581[PMID]_ORPHANET
633228,Isolated proximal femoral focal deficiency,Morphological anomaly,Prevalence at birth,1.55,1-9 / 100 000,Value and class,Worldwide,Validated,32019581[PMID]_ORPHANET
637064,Isolated optic nerve aplasia,Morphological anomaly,Cases/families,3.0,,Case(s),Worldwide,Validated,29676329[PMID]
637064,Isolated optic nerve aplasia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,29676329[PMID]_ORPHANET
637061,Isolated optic nerve hypoplasia,Morphological anomaly,Cases/families,25.0,,Case(s),Worldwide,Validated,24082663[PMID]
637061,Isolated optic nerve hypoplasia,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,24082663[PMID]_ORPHANET
637051,Borna virus encephalitis,Disease,Cases/families,18.0,,Case(s),Worldwide,Validated,31924550[PMID]
637051,Borna virus encephalitis,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,31924550[PMID]_ORPHANET
636945,Invasive candidiasis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,27394927[PMID]_32809459[PMID]_ORPHANET
636945,Invasive candidiasis,Disease,Annual incidence,2.5,1-9 / 100 000,Value and class,France,Validated,27394927[PMID]
636941,Vascular Ehlers-Danlos-polymicrogyria syndrome,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,29499446[PMID]
636941,Vascular Ehlers-Danlos-polymicrogyria syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,29499446[PMID]_ORPHANET
636955,Endemic pemphigus foliaceus,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,34909708[PMID]
636955,Endemic pemphigus foliaceus,Disease,Annual incidence,0.4,1-9 / 1 000 000,Value and class,Tunisia,Validated,34909708[PMID]
636950,Glaucomatocyclitic crisis disease,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,35015437[PMID]_ORPHANET
641829,Neonatal compartment syndrome,Clinical syndrome,Cases/families,60.0,,Case(s),Worldwide,Validated,35415493[PMID]
641829,Neonatal compartment syndrome,Clinical syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,35415493[PMID]_ORPHANET
641496,Childhood-onset schizophrenia,Disease,Annual incidence,0.0,1-5 / 10 000,Class only,Europe,Validated,22906158[PMID]_ORPHANET
641496,Childhood-onset schizophrenia,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,22906158[PMID]_ORPHANET
641390,PsAPASH syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,32942279[PMID]_ORPHANET
641390,PsAPASH syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,32942279[PMID]_ORPHANET
641380,PAPASH syndrome,Disease,Cases/families,20.0,,Case(s),Worldwide,Validated,32942279[PMID]_35034021[PMID]
641380,PAPASH syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,32942279[PMID]_35034021[PMID]_ORPHANET
641385,PASS syndrome,Disease,Cases/families,16.0,,Case(s),Worldwide,Validated,32942279[PMID]_ORPHANET
641385,PASS syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,32942279[PMID]_ORPHANET
641368,Autosomal recessive hyper-IgE syndrome due to ZNF341 deficiency,Disease,Cases/families,61.0,,Case(s),Worldwide,Validated,30264496[PMID]
641368,Autosomal recessive hyper-IgE syndrome due to ZNF341 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30264496[PMID]_ORPHANET
641353,Infantile neurodegeneration-progressive spasticity-intellectual disability-white matter lesions syndrome,Disease,Cases/families,32.0,,Case(s),Worldwide,Validated,35985664[PMID]
641353,Infantile neurodegeneration-progressive spasticity-intellectual disability-white matter lesions syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,35985664[PMID]_ORPHANET
641361,Neurodevelopmental delay-hypotonia-cerebellar ataxia-cardiac conduction defects syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,34089229[PMID]
641361,Neurodevelopmental delay-hypotonia-cerebellar ataxia-cardiac conduction defects syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,34089229[PMID]_ORPHANET
641350,Immunotherapy induced hypophysitis,Disease,Annual incidence,12.8074,1-5 / 10 000,Value and class,Europe,Validated,28702249[PMID]_34430146[PMID]
641350,Immunotherapy induced hypophysitis,Disease,Point prevalence,0.0,Unknown,Class only,Europe,Validated,28702249[PMID]_34430146[PMID]_ORPHANET
642099,"Spondyloepimetaphyseal dysplasia with joint laxity, Beighton type",Disease,Cases/families,30.0,,Case(s),Worldwide,Validated,27245527[PMID]
642099,"Spondyloepimetaphyseal dysplasia with joint laxity, Beighton type",Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,27245527[PMID]_ORPHANET
642085,EXOC6B-related spondyloepimetaphyseal dysplasia with joint laxity,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,36150098[PMID]
642085,EXOC6B-related spondyloepimetaphyseal dysplasia with joint laxity,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,36150098[PMID]_ORPHANET
633004,KDM3B-related intellectual disability-facial dysmorphism-short stature syndrome,Disease,Cases/families,17.0,,Case(s),Worldwide,Validated,30929739[PMID]
633004,KDM3B-related intellectual disability-facial dysmorphism-short stature syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30929739[PMID]_ORPHANET
633014,SLC12A2-related developmental delay-intellectual disability-sensorineural deafness syndrome,Disease,Cases/families,13.0,,Case(s),Worldwide,Validated,34797034[PMID]
633014,SLC12A2-related developmental delay-intellectual disability-sensorineural deafness syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,34797034[PMID]_ORPHANET
633124,Invasive scopulariopsis infection,Disease,Point prevalence,0.05,<1 / 1 000 000,Value and class,Europe,Validated,https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2563
633028,CPE-related Prader-Willi-like syndrome,Disease,Cases/families,8.0,,Case(s),Worldwide,Validated,26120850[PMID]_32936766[PMID]_34383079[PMID]
633028,CPE-related Prader-Willi-like syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,26120850[PMID]_32936766[PMID]_34383079[PMID]_ORPHANET
615970,Chronic intervillositis of unknown etiology,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,32841927[PMID]_ORPHANET
617408,Classic eosinophilic pustular folliculitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,37983361[PMID]_ORPHANET
617304,Amniotic fluid embolism,Disease,Point prevalence,0.0,Unknown,Class only,United Kingdom,Validated,31714909[PMID]_ORPHANET
617294,Twin anemia-polycythemia sequence,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,27068715[PMID]_ORPHANET
617301,Selective intrauterine growth restriction,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,28532678[PMID]_ORPHANET
617297,Twin-reversed arterial perfusion sequence,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,20522408[PMID]_ORPHANET
621758,Fibrosis-neurodegeneration-cerebral angiomatosis syndrome,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,34165204[PMID]
621758,Fibrosis-neurodegeneration-cerebral angiomatosis syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,34165204[PMID]_ORPHANET
620371,Gitelman-like kidney tubulopathy due to mitochondrial DNA mutation,Disease,Cases/families,14.0,,Family(ies),Worldwide,Validated,15498972[PMID]_34607911[PMID]
620371,Gitelman-like kidney tubulopathy due to mitochondrial DNA mutation,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,15498972[PMID]_34607911[PMID]_ORPHANET
620368,EGF-related primary hypomagnesemia with intellectual disability,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,33600043[PMID]
620368,EGF-related primary hypomagnesemia with intellectual disability,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,33600043[PMID]_ORPHANET
620363,Primary hypomagnesemia-generalized seizures-intellectual disability-obesity syndrome,Disease,Cases/families,11.0,,Case(s),Worldwide,Validated,33600043[PMID]
620363,Primary hypomagnesemia-generalized seizures-intellectual disability-obesity syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,33600043[PMID]_ORPHANET
620205,Non-syndromic bicoronal and sagittal craniosynostosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
620212,Non-syndromic pansynostosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
620192,Non-syndromic metopic and sagittal craniosynostosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
620198,Non-syndromic bicoronal and metopic craniosynostosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
620178,Non-syndromic bilambdoid craniosynostosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
620186,Non-syndromic unicoronal and sagittal craniosynostosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
620158,Non-syndromic non-specific multisutural craniosynostosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
620139,Non-syndromic unifrontosphenoidal craniosynostosis,Morphological anomaly,Point prevalence,0.0136,<1 / 1 000 000,Value and class,Worldwide,Validated,29065043[PMID]_ORPHANET
620146,Non-syndromic unisquamosal craniosynostosis,Morphological anomaly,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,ORPHANET
620102,Non-syndromic unicoronal craniosynostosis,Morphological anomaly,Point prevalence,0.1049,1-9 / 1 000 000,Value and class,Worldwide,Validated,35636659[PMID]_38348760[PMID]_ORPHANET
620113,Non-syndromic unilambdoid craniosynostosis,Morphological anomaly,Point prevalence,0.0442,<1 / 1 000 000,Value and class,Worldwide,Validated,35636659[PMID]_ORPHANET
624268,Non-specific autoimmune cerebellar ataxia without characteristic antibodies,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
624199,Non-specific autoimmune brainstem encephalitis with characteristic antibodies,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
624190,Paraneoplastic isolated brainstem encephalitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,34827413[PMID]_ORPHANET
624244,Postinfectious cerebellitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,31515702[PMID]_ORPHANET
624244,Postinfectious cerebellitis,Disease,Annual incidence,0.0,Unknown,Class only,Worldwide,Validated,31515702[PMID]_ORPHANET
624216,Non-specific autoimmune brainstem encephalitis without characteristic antibodies,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
623789,Body integrity dysphoria,Disease,Point prevalence,0.11,1-9 / 1 000 000,Value and class,Worldwide,Validated,25108391[PMID] _34237024[PMID]
623801,Acute flaccid myelitis,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,36268734[PMID]_ORPHANET
623801,Acute flaccid myelitis,Disease,Annual incidence,1.12,1-9 / 100 000,Value and class,Australia,Validated,37817313[PMID]
623801,Acute flaccid myelitis,Disease,Annual incidence,0.06,<1 / 1 000 000,Value and class,Netherlands,Validated,32628734[PMID]
623801,Acute flaccid myelitis,Disease,Annual incidence,0.04,<1 / 1 000 000,Value and class,United States,Validated,36268734[PMID]
624166,Non-specific autoimmune supratentorial encephalitis with characteristic antibodies,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
624178,Non-specific autoimmune supratentorial encephalitis without characteristic antibodies,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,ORPHANET
623615,Autoimmune limbic encephalitis,Disease,Point prevalence,1.7,1-9 / 100 000,Value and class,Europe,Validated,31552550[PMID]_ORPHANET
623615,Autoimmune limbic encephalitis,Disease,Annual incidence,0.25,1-9 / 1 000 000,Value and class,Europe,Validated,31552550[PMID]_ORPHANET
623626,Paraneoplastic cerebellar degeneration,Disease,Point prevalence,0.9553,1-9 / 1 000 000,Value and class,Europe,Validated,31552550[PMID]_32847939[PMID]_ORPHANET
623626,Paraneoplastic cerebellar degeneration,Disease,Annual incidence,0.2225,1-9 / 1 000 000,Value and class,Europe,Validated,31552550[PMID]_32847939[PMID]_ORPHANET
623626,Paraneoplastic cerebellar degeneration,Disease,Point prevalence,0.6869,1-9 / 1 000 000,Value and class,France,Validated,32847939[PMID]_ORPHANET
623626,Paraneoplastic cerebellar degeneration,Disease,Annual incidence,0.16,1-9 / 1 000 000,Value and class,France,Validated,32847939[PMID]_ORPHANET
623626,Paraneoplastic cerebellar degeneration,Disease,Point prevalence,1.2236,1-9 / 100 000,Value and class,Italy,Validated,31552550[PMID]
623626,Paraneoplastic cerebellar degeneration,Disease,Annual incidence,0.285,1-9 / 1 000 000,Value and class,Italy,Validated,31552550[PMID]
622925,X-linked severe syndromic thoracic aortic aneurysm and dissection,Malformation syndrome,Cases/families,32.0,,Case(s),Worldwide,Validated,27632686[PMID]_34807424[PMID]
622925,X-linked severe syndromic thoracic aortic aneurysm and dissection,Malformation syndrome,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,27632686[PMID]_34807424[PMID]_ORPHANET
618891,Chronic neurovisceral acid sphingomyelinase deficiency,Disease,Point prevalence,0.0,Unknown,Class only,Worldwide,Validated,20301544[PMID]_ORPHANET
617910,Conjunctival malignant melanoma,Disease,Cases/families,32.0,,Case(s),Worldwide,Validated,31768361[PMID]
617910,Conjunctival malignant melanoma,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,31768361[PMID]_ORPHANET
617916,Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia,Disease,Cases/families,100.0,,Case(s),Worldwide,Validated,30593169[PMID]
617916,Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,30593169[PMID]_ORPHANET
617919,F12-associated cold autoinflammatory syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,31924766[PMID]
617919,F12-associated cold autoinflammatory syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,31924766[PMID]_ORPHANET
619941,Congenital neutropenia-combined immunodeficiency due to MKL1 deficiency,Disease,Cases/families,3.0,,Case(s),Worldwide,Validated,32128589[PMID]
619941,Congenital neutropenia-combined immunodeficiency due to MKL1 deficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,32128589[PMID]_ORPHANET
619367,SAMD9L-associated autoinflammatory syndrome,Disease,Cases/families,6.0,,Case(s),Worldwide,Validated,31874111[PMID]
619367,SAMD9L-associated autoinflammatory syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,31874111[PMID]_ORPHANET
619953,Familial hyperinflammatory lymphoproliferative immunodeficiency,Disease,Cases/families,7.0,,Case(s),Worldwide,Validated,32646852[PMID]_32647003[PMID]_32766723[PMID]
619953,Familial hyperinflammatory lymphoproliferative immunodeficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,32646852[PMID]_32647003[PMID]_32766723[PMID]_ORPHANET
619948,Early-onset autoimmunity-autoinflammation-immunodeficiency syndrome due to SOCS1 haploinsufficiency,Disease,Cases/families,10.0,,Case(s),Worldwide,Validated,34421895[PMID]
619948,Early-onset autoimmunity-autoinflammation-immunodeficiency syndrome due to SOCS1 haploinsufficiency,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,34421895[PMID]_ORPHANET
619979,Developmental delay-immunodeficiency-leukoencephalopathy-hypohomocysteinemia syndrome,Disease,Cases/families,4.0,,Case(s),Worldwide,Validated,29018201[PMID]
619979,Developmental delay-immunodeficiency-leukoencephalopathy-hypohomocysteinemia syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,29018201[PMID]_ORPHANET
619363,NOCARH syndrome,Disease,Cases/families,15.0,,Case(s),Worldwide,Validated,31271789[PMID]_37741518[PMID]
619363,NOCARH syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,31271789[PMID]_37741518[PMID]_ORPHANET
619233,Hereditary persistence of fetal hemoglobin-intellectual disability syndrome,Disease,Cases/families,9.0,,Case(s),Worldwide,Validated,27453576[PMID]
619233,Hereditary persistence of fetal hemoglobin-intellectual disability syndrome,Disease,Point prevalence,0.0,<1 / 1 000 000,Class only,Worldwide,Validated,27453576[PMID]_ORPHANET
